[
    {
        "instruction":"已知信息：\n'It may be largely a functional (or “dysfunctional”) disorder in many patients but there is some evidence for alterations in pain and sensory processing in the CNS in FMS. The established diagnostic criteria for FMS (American College of Rheumatology Fibromyalgia Diagnostic Criteria (ACR FDC) including Widespread Pain Index (WPI) and Symptom Severity Scale (SSS)) do not emphasise pain intensity exclusively.'可被翻译为：它可能在许多患者中主要是功能性（或“功能障碍性”）障碍，但是有一些证据表明在FMS中CNS中的疼痛和感觉处理改变。 FMS的既定诊断标准（美国风湿病学院纤维肌痛诊断标准（ACRFDC）包括广泛疼痛指数（WPI） 和症状严重程度量表（SSS））并不只强调疼痛强度。\n'6.5.Fibromyalgia Syndrome'可被翻译为：6.5.纤维肌痛综合征\n'6.6.Other specific pain syndromes'可被翻译为：6.6.其他特定疼痛综合征\n'More complex pain syndromes (e.g. Complex Regional Pain Syndrome) with incomplete understanding of the underlying pathophysiological abnormalities and lack of objective diagnostic criteria are beyond the scope of this document although many of the general principles will apply.'可被翻译为：更复杂的疼痛综合征（例如复杂性区域性疼痛综合征）不完全理解潜在病理生理学异常和缺乏 客观诊断标准-超出了本文件的范围，但许多一般原则将适用。\n\n根据上述已知信息，请将'The Fibromyalgia Syndrome (FMS) may be categorized with the soft tissue pain syndromes of unknown aetiology.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"纤维肌痛综合征（FMS）可能归类为具有未知病因的软组织疼痛综合征。"
    },
    {
        "instruction":"已知信息：\n'Patient-rated, reflective, and instantaneous total ocular symptom scores, similar to the symptom scoring system used for nasal symptoms, can be used to support inclusion of relevant information in labeling.'可被翻译为：病人的评分，反射性和瞬 时总的眼部症状评分，类似的症状评分系统用于鼻症状，可以用来支持列入标签 中的相关信息。\n'This may be done with either the criterion of rating “troublesomeness” or severity on a global level, or with defining and rating the symptoms with a validated scale by frequency and severity41 at the time of inclusion.'可被翻译为：这可能可以用整体 “令人厌烦”或严重程度水平评级标准或在入选时用经验证的量表通过频率和严 重程度41来定义和分级症状来实现。\n'Symptom scores: Assessment of symptoms is an acceptable clinical variable although there are no validated scales.'可被翻译为：症状评分：症状的评估是一个可接受的临床变量，尽管尚无经过验证的量表。\n'Among the pain rating scales the Visual analogue scale (VAS), numeric rating scale (NRS) and verbal rating scale (VRS) have been extensively used and validated.'可被翻译为：在疼痛评定量表中，视觉模拟量表（VAS）、数字评定量表（NRS）和口头评定量表（VRS）已被广泛使用和验证。\n\n根据上述已知信息，请将'such as incorporating symbolic visual anchors and\/or age-appropriate text in symptom rating scales.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如在症状评级量表中加入符号视觉标记和\/或与年龄相当的内容。"
    },
    {
        "instruction":"已知信息：\n'Assays that are used in pivotal clinical trials as well as in post-authorisation studies need to be validated.'可被翻译为：需要对关键性临床试验以及授予许可后研究中使用的测定法进行验证。\n'Oversight by the quality unit should provide assurance of appropriate science and risk based assessments.'可被翻译为：质量部门的监督 应为相应的基于科学和风险 的评估提供保证。\n'Accreditation of PGx analytics Not all European Union member states require accreditation by a public authority for performing PGx analytics.'可被翻译为：药物基因组学分析的认证并非所有欧盟成员国均要求由公共主管部门认证才能开展药物基因组学分析。\n'Different trial designs will require different procedures for generating randomisation schedules.'可被翻译为：不同的试验设计需要 不同的程序来生成随机化列表。\n\n根据上述已知信息，请将'Therefore, appropriate oversight is necessary and this may require accreditation in the different member states or be subjected to validation using nationally accepted procedures for predictive biomarker analytics, including intra-laboratory proficiency testing.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"因此，适当的监督是必要的，这可能要求在不同成员国获得认证或遵循预测性生物标志物分析的国别公认程序进行验证，包括实验室能力比对验证。"
    },
    {
        "instruction":"已知信息：\n'The plan may include detailed procedures for executing the statistical analysis of the primary and secondary variables and other data.'可被翻译为：该计划可包括对 主要和次要指标以及其他数据进行统计分析的详细程序。\n'A statistical analysis plan is a document that contains a more technical and detailed elaboration of the principal features of the analysis described in the protocol, and includes detailed procedures for executing the statistical analysis of the primary and secondary variables and other data.'可被翻译为：是指更技术性地和更详细地阐述方案中描述的分析要点的文件，包括对主要和次要指标及其他数据进行统计分析的详细程序。\n'A statistical analysis plan (SAP), describing the planned analysis in detail, should be submitted to the Agency as soon as possible, and certainly prior to the un-blinding of the data.'可被翻译为：应尽快（当然是在数据揭盲之前）向FDA提交统计分析计划 (SAP)，详细 说明所计划的分析。\n'Statistical Analysis Plan A statistical analysis plan is a document that contains a more technical and detailed elaboration of the principal features of the analysis described in the protocol, and includes detailed procedures for executing the statistical analysis of the primary and secondary variables and other data.'可被翻译为：统计分析计划 是指更技术性地和更详细地阐述方案中描述的分析要 点的文件，包括对主要和次要指标及其他数据进行统计分析 的详细程序。\n\n根据上述已知信息，请将'Describing the statistical approach, including a well-developed statistical analysis plan and plans for minimizing and dealing with missing data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"- 描述统计方法，包括开发完善的统计分析计划和最小化及处理缺失数 据的计划。"
    },
    {
        "instruction":"已知信息：\n'Besides aspects like the general product safety and clinical efficacy, there has to be a focus on immunogenicity, particularly on inhibitor development, anaphylactic reactions and thrombogenic effects.'可被翻译为：除了一般产品安全性和临床疗效方面外，还须关注免疫原性，特别是抑制物形成、过敏性反应和血栓形成效应。\n'For biotechnology derived product(s), immunogenicity should be evaluated prospectively.'可被翻译为：对于生物技术产品，应前瞻性评估免疫原性。\n'Autoimmunity: Cross-reactivity to an endogenous counterpart'可被翻译为：自免疫：与内源性蛋白质的交叉反应性\n'Immunogenicity issues should be further addressed in the Risk Management Plan (RMP).'可被翻译为：免疫原性问题应在风险管理计划（RMP）中进一步解决。\n\n根据上述已知信息，请将'In the case of biological medicinal products the risk for immunogenicity should be addressed, in particular the potential cross-reactivity seen in TPO-R agonists with endogenous thrombopoietin.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于生物药品，应该进行免疫原性风险评价,尤其是潜在的血小板生成素受 体激动剂与内源性血小板生成素之间的交叉反应。"
    },
    {
        "instruction":"已知信息：\n'To assist in selecting appropriate patient populations for study and endpoints for evaluation it is suggested that at least one exploratory study is conducted before proceeding to pivotal studies with pre-defined objectives.'可被翻译为：为了帮助选择合适的研究患者群和评估终点，建议在进行有预定目标的关键性研究之前 进行至少一项探索性研究。\n'Pharmacokinetic and dose finding studies in the target population are needed.'可被翻译为：需要在目标人群中进行药代动力学和剂量范围确定研究。\n'Since evolution of bone marrow failure and survival depend on patients’ baseline characteristics, any efficacy or safety conclusion may apply only to patients sharing similar prognostic features. It is, however, also acknowledged that pharmacological activity may vary in relation to, e.g. cytogenetic characteristics. There is thus a need for rather extensive exploratory studies in order to identify the proper target population for confirmatory studies.'可被翻译为：因为骨髓衰竭和存活依赖于患者的基线特性，任何疗效或安全性的结论仅适用于有相同预后特征的患者。但是，也普遍认为许多因素（如细胞遗传学特征）可能会导致药理学活性差异。因此，需要相当广泛的探索性研究来为验证性研究确认合适的目标人群。\n'If not pharmacologically justified, proper analyses of biopsies from accessible tumours (primaries and\/or metastatic lesions), are expected to constitute a pivotal role in studies undertaken to identify the proper target population for confirmatory studies.'可被翻译为：如果药理学上没有合理的理由，则期望对可取组织的肿瘤（原发性和\/或转移性病 变）的正确活检分析在进行确定验证性研究的合适目标人群的研究中起到举足轻重的作用。\n\n根据上述已知信息，请将'There is thus a need for rather extensive exploratory studies in order to identify the proper target population for confirmatory studies.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"因此，需要相当广泛的探索性研究来为验证性研究确认合适的目标人群。"
    },
    {
        "instruction":"已知信息：\n'Aseptic Technique Control: Place one (1) sterile Dacron or cotton swab into sterile water and place back into its sterile transport media solution. Place this negative control into a sterile Whirl- pak® bag.\nNote: This control may not be needed if the sponges and\/or swabs are received premoistened. There is no surface contact for this control.'可被翻译为：无菌技术控制：将一个无菌涤纶或棉签放入无菌水中，并放回其无菌输送培养基溶液中，将此阴性对照放入无菌 Whirl- pak®袋中。\n注：如果海绵和\/或棉签在收到之前就已蘸湿则不需要该控制。该控制没有表面接触。\n'Place the swab (or sponge) back into the carrier container (if it came with one) and place into the additional sterile Whirl-pak® bag. Be sure to break off the handle portion of the sponge applicator stick.'可被翻译为：将棉签（或海绵）重新放回装载容器（如果有）并放置在另一个 Whirl-pak®无菌袋中。确认已将海绵手柄折断去除。\n'RODAC\/Hycheck Sterility Control: Place an unused RODAC plate and\/or Hycheck plate within a sterile Whirl-pak® bag.'可被翻译为：RODAC\/Hycheck 无菌控制：将未使用的 RODAC 碟和\/或 Hycheck 碟放入无菌Whirl- pak®袋中。\n'b. Apply swab (or sponge with handle) to surface (or equipment) being monitored with firm application pressure.'可被翻译为：b. 将棉签（或带有手柄的海绵）用固定压力擦拭被监测表面（或设备）。\n\n根据上述已知信息，请将'Swab\/Sponge Sterility Control: Place an intact unus ed swab (or sponge) unit into a sterile Whirl-pak® bag.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"棉签\/海绵无菌控制：将完整的未使用的棉签（或海绵）单元放入无菌 Whirl-pak®袋中。"
    },
    {
        "instruction":"已知信息：\n'6.Special Cases # Date of Approval Questions Answers 6.1 The ICH E14 Guideline states that in certain cases a conventional thorough QT study might not be feasible.'可被翻译为：6．特殊情况 # 批准日期 问题 解答 6.1 ICH E14 指导原则陈 述，在某些情况中传 统全面 QT 研究可 能不可行。\n'3.1 June 2008 The ICH E14 Guideline emphasizes the importance of assay sensitivity and recommends the use of a positive control. In order to accept a negative thorough QT\/QTc study, assay sensitivity should be established in the study by use of a positive control with a known QT-prolonging effect.'可被翻译为：3.1 2008 年 6 月 ICH E14 指导原则重点强 调了分析灵敏度的重要 性，并推荐使用阳性对照。 为接受结果为阴性的“全 面 QT\/QTc 研究”，应在 研究中使用已知会延长 QT 间期的阳性对照确立 分析灵敏度。\n'Therefore, QT interval data corrected using Bazett’s corrections is no longer warranted in all applications unless there is a compelling reason for a comparison to historical Bazett’s corrected QT data.'可被翻译为：因此，在所有申请中将不再认可经 Bazett 公式校 正的 QT 间期数据，除非为与历史 Bazett 公式校正的 QT 数据进行对 比而必须使用。\n'5.1 The ICH E14 Guideline states (in Section 3.2.3, page 10) that analysis of the relationship between drug concentration and QT\/QTc interval changes is under active investigation.'可被翻译为：5.1 ICH E14指南(第3.2.3 节，第10页)指出，正在 积极研究药物浓度与 QT\/QTc间期变化之间 浓度-反应分析中，整合所有剂量下的所有相关数据以表征一种药物影响\n\n根据上述已知信息，请将'1.5 April 2012 The ICH E14 Guideline states that QT interval corrected by Fridericia’s and Bazett’s correction should be submitted in all applications; is this still necessary?'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.5 2012 年 4 月 依据 ICH E14 指导原则 所述，应在所有申请中， 递交用 Fridericia 公式 和 Bazett 公式校正的 QT 间期；是否仍旧有必 要？"
    },
    {
        "instruction":"已知信息：\n'Quality: The degree to which a set of inherent properties of a product, system or process fulfils requirements. (ICH Q9)'可被翻译为：质量：产品、系统或工艺的一系列固有特性符合要求的程度。（ICH Q9）\n'Quality: The suitability of either a drug substance or a drug product for its intended use. This term includes such attributes as the identity, strength, and purity (ICH Q6A).'可被翻译为：质量（Quality）：指原料药或制剂对预期用途的适用性，包括鉴别、规格和纯度等属性（ICH Q6A）。\n'Quality Risk Management: A systematic process for the assessment, control, communication, and review of risks to the quality of the drug product across the product lifecycle. (ICH Q9)'可被翻译为：质量风险管理： 对产品生命周期中药品质量风险进行评估、控制、沟通和回顾的系统过程。 （ICH Q9）\n'A systematic process for the assessment, control, communication, and review of risks to the quality of the drug product across the product lifecycle. (ICH Q9)'可被翻译为：对产品生命周期中药品质量风险进行评估、控制、沟通和回顾的系统过程。（ICHQ9）\n\n根据上述已知信息，请将'Quality: The degree to which a set of inherent properties of a product, system, or process fulfills requirements (see ICH Q6A definition specifically for quality of drug substance and drug products). (ICH Q9)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"质量： 产品、系统和工艺的一组内在特性满足要求的程度（参见ICHQ6A特别针对原料药和制剂质量的定义）。（ICH Q9）"
    },
    {
        "instruction":"已知信息：\n'The DTD specifies the required structure and format of a particular document.XML is more flexible than SGML and allows for the concept of ‘well-formed’ data – content that meets the basic vocabulary and ‘grammatical’ requirements of XML but does not reference a DTD for a specific set of attributes or list of required elements.XML contains a further concept called a schema.'可被翻译为：DTD 指定了特定文件所需的结构和格式。XML比SGML更灵活，并且允许采纳“格式良好” 数据的内容-满足 XML 的基本词汇和“语法”要求、但不针对一组特定属性或必需元素列表引用元素DTD。XML包含一个称为模式的进一步概念。\n'In addition, XML schemas can be manipulated, stored, and indexed, which is a practical advantage6.'可被翻译为：另外，XML 模式可以被修改、存储和索引，这是一个实际的优点6。\n'SGML\/XML documents that do not follow the rules in their DTDs are categorised as invalid.'可被翻译为：在DTD中不符合其规则的SGML\/XML文件视为无效。\n'5. The clinical trial institution and professional institutions formulate management documents adapting with the work, and perform in accordance with the documents. The management documents shall meet the requirements of the relevant regulations and guidelines, and cover the whole process of the clinical trial.'可被翻译为：5.临床试验机构及专业制定与工作相适应的管理文件，并遵照执行。管理文件符合法规及指导原则等的要求，能够覆盖临床试验的全过程。\n\n根据上述已知信息，请将'In general, DTDs perform well when applied to documents or text-intensive information.XML schema work best for data-intensive information5.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一般而言，DTD 在应用于文件或文本密集型信息时表现良好。XML 模式最适合数据密集型信息5。"
    },
    {
        "instruction":"已知信息：\n'Once the hydration and temperature of the skin has equilibrated (i.e., after 30 min) the skin surface temperature should be measured. The skin surface temperature should be within ±1° of the target temperature (32°) prior to applying the dosage form. The temperature of the receptor solution, or the circulating water bath, or the set point of a dry heat system, or any other component of the system should not be assumed to be the same as the skin surface temperature. Instead, the skin surface temperature should be directly measured (with an infrared thermometer or a thermocouple), and the thermoregulatory mechanism of the VDC system should be adjusted as needed to produce the target temperature of 32° at the skin surface. The stirrers can be run during the duration of the equilibration to speed up temperature stabilization.'可被翻译为：一旦皮肤的水合作用和温度达到平衡(即30分钟后)，应测量皮肤表面温度。在施用剂型之前，皮肤表面温度应在目标温度(32°)的±1°内。受体溶液的温度，或循环水浴的温度，或干热系统的设定点，或系统的任何其他组成部分的温度不应假定与皮肤表面温度相同。而是直接测量皮肤表面温度(使用红外温度计或热电偶)，并根据需要调节VDC系统的热调节机制，使皮肤表面温度达到32°的目标温度。搅拌器可以在平衡期间运行，以加速温度稳定。\n'Skin surface temperature should be measured using an IR thermometer. The temperature of the heating block must be set higher than the desired membrane temperature (e.g., 33° for a 32° skin surface temperature).'可被翻译为：皮肤表面温度应使用红外温度计测量。加热块的温度必须设置高于所需的膜温度(例如，对于32°的皮肤表面温度设为33°)。\n'The system should be appropriately equilibrated under the predefined experimental conditions prior to the beginning of the IVPT run. No air bubbles should be present in the receptor solution (under the membrane) immediately prior and during the experiment; if appropriate, the receptor solution can be degassed. The system temperature (including the membrane surface temperature and the circulating water bath temperature, if applicable) should be stable and well controlled. Frozen biological membranes should be thawed at ambient temperature prior to assembling on the diffusion cells. Once mounted, the skin sections should be allowed to equilibrate to a physiologically relevant state of hydration and temperature (e.g., for 30 min at a membrane surface temperature of 32°).'可被翻译为：在IVPT开始运行之前，系统应在预先确定的实验条件下进行适当的平衡。在实验之前和实验过程中，受体溶液(膜下)中不应出现气泡;如果合适，受体溶液可以脱气。系统温度(包括膜表面温度和循环水浴温度，如适用)应稳定且控制良好。冷冻的生物膜应在室温下解冻，然后组装在扩散池上。一旦安装，皮肤切片应该被允许平衡到生理上相关的水合作用和温度状态(例如，在32°的膜表面温度下30分钟)。\n'The surface of each skin section should be kept constant at 32 ± 1° throughout the length of the study. Temperature fluctuations of the skin surface will affect drug diffusion and may increase experimental variability. The use of a thermoregulated diffusion cell is encouraged to control the temperature of the membrane surface.'可被翻译为：在整个研究过程中，每个皮肤切片的表面应保持在32±1°恒定。皮肤表面的温度波动会影响药物的扩散，并可能增加实验的可变性。鼓励使用具有温控的扩散池来控制膜表面的温度。\n\n根据上述已知信息，请将'Once the hydration and temperature of the skin has equilibrated (e.g., after 30 min) the skin surface temperature should be measured. The skin surface temperature should be within ±1° of the target temperature (32°) prior to applying the dosage form. The temperature of the receptor solution, or the circulating water bath, or the set point of a dry heat system, or any other component of the system should not be assumed to be the same as the skin surface temperature. Instead, the skin surface temperature should be directly measured (with an infrared thermometer or a thermocouple), and the thermoregulatory mechanism of the FDC system should be adjusted as needed to produce the target temperature of 32° at the skin surface.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一旦皮肤的水合作用和温度达到平衡(例如，30分钟后)，应测量皮肤表面温度。在施用剂型之前，皮肤表面温度应在目标温度(32°)的±1°内。受体溶液的温度，或循环水浴的温度，或干热系统的设定点，或系统的任何其他组成部分的温度不应假定与皮肤表面温度相同。相反，应直接测量皮肤表面温度(使用红外温度计或热电偶)，并根据需要调整FDC系统的温度调节机制，使皮肤表面温度达到32°的目标温度。"
    },
    {
        "instruction":"已知信息：\n'Adverse events  Safety, including vital signs, should be assessed in all patients receiving the factor VIII product during  clinical trials.'可被翻译为：5.1. 不良事件 应对临床试验期间所有接受因子 VIII 制品的病人进行包括生命体征在内的安全性评估。\n'Safety aspects of factor IX products include viral safety, immunogenicity and other adverse events.'可被翻译为：因子IX的安全包括病毒安全性、免疫原性和其他不良反应。\n'Safety & Tolerability The safety of a medical product concerns the medical risk to the subject, usually assessed in a clinical trial by laboratory tests (including clinical chemistry and haematology), vital signs, clinical adverse events (diseases, signs and symptoms), and other special safety tests (e.g. ECGs, ophthalmology).'可被翻译为：安全性和耐受性 医疗产品的安全性是指受试者的医学风险，通常在临床 试验中由实验室检查（包括临床生化和血液学）、生命体征、 临床不良事件（疾病、体征和症状），以及其他特殊的安全性 检查（如心电图、眼科检查）等来评价。\n'Furthermore, clinical efficacy of factor IX treatment (e.g. prophylaxis, on demand) should be assessed during a period of a minimum of 50 exposure days by the patients themselves and treating physicians.'可被翻译为：而且，因子IX的临床治疗效果（比如即需预防） 应由患者自己或主治医师在至少50 天的给药期进行评价。\n\n根据上述已知信息，请将'Safety, including vital signs, should be assessed in all patients receiving the factor IX product during clinical trials.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"所有在临床试验期间使用因子 IX 的患者都应该接受安全性评估，包括生命体征。"
    },
    {
        "instruction":"已知信息：\n'The purpose of this guidance is to outline the FDA’s current thinking on the principles of clinical  development relevant to dose-selection and assessment of efficacy and safety to support the  approval of drug products for the treatment of patients with rheumatoid arthritis (RA).'可被翻译为：本指导原则的目的是表述 FDA 目前对支持治疗类风湿性关节炎（RA）患者 的药物批准的临床开发中， 剂量选择以及疗效和安全性评价的考虑。\n'This guidance revises the guidance for industry Clinical Development Programs for Drugs,  Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA), published in  February 1999.2'可被翻译为：本指导原则是 1999年2月发布的《行业指导原则：治疗类风湿性关节炎（RA） 的药物、医疗器械以及生物制品的临床开发》的更新2。\n'After it has been finalized, this guidance will replace the February 1999  guidance and will reflect the current thinking of the FDA on RA drug product development.'可被翻译为：最终定稿后，将取代1999 年 02 月的指导原则， 并反映FDA关于RA药品开发的最新见解。\n'Specifically, this guidance addresses the FDA’s current thinking regarding the overall development program and clinical trial designs to support DAA drugs.'可被翻译为：具体来说，本指导原则阐述了FDA 关于支持DAA药物的整体研发计划和临床试验设计的最新见解。\n\n根据上述已知信息，请将'The  FDA’s current thinking has been influenced by clinical development programs conducted for RA since the 1999 guidance published, and by changes in the standard of care for RA because of  availability of many effective treatments.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"FDA现在的态度，受到自 1999 年版指导原则发表以来的临床项开发项目的影响，以及因为大量有 效的治疗面世， RA标准治疗变化的影响。"
    },
    {
        "instruction":"已知信息：\n'Any safety issues identified from a review of these withdrawals should be addressed in Section 18 of the DSUR as appropriate.'可被翻译为：若在对受试者退出的评估 中发现了任何安全性问题，应根据具体情况在DSUR第18节中 进行说明。\n'Summary of overall safety assessment (based on Section 18 of the DSUR);'可被翻译为：整体安全性评估的总结（以DSUR的第18节为基础）；\n'Significant manufacturing changes This section should include a summary of significant manufacturing or microbiological changes during the reporting period and discuss potential safety issues arising from these changes in Section 18 of the DSUR, if applicable.'可被翻译为：重大生产变更 如适用，本节应概述报告期内的重大生产或微生物变更，并 在DSUR第18节中讨论此类变更引起的潜在安全性问题。\n'• Any new or different safety issues identified;'可被翻译为：任何被确定的新的或不同的安全性问题；\n\n根据上述已知信息，请将'Any safety issues identified from a review of these deaths should be addressed in Section 18 of the DSUR as appropriate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"若在 对受试者死亡进行的评估中发现任何安全性问题，应根据具体情 况在整体安全性评估一节中进行说明。"
    },
    {
        "instruction":"已知信息：\n'6. Any relevant processing operation or event, process parameters and control limits, and the reference number of major equipment used;'可被翻译为：（六）相关生产操作或活动、工艺参数及控制范围，以及所 用主要生产设备的编号；\n'1) A statement of the processing location and the equipment to be used (e.g. operation room's location and reference number, cleanliness level, necessary temperature and humidity requirements, equipment type and reference number);'可被翻译为：1.对生产场所和所用设备的说明（如操作间的位置和编号、洁净度级别、必要的温湿度要求、设备型号和编号等）；\n'1) A statement of the processing location and the equipment to be used (e.g. operation room's location and reference number, cleanliness level, necessary temperature and humidity requirements, equipment type and reference number);'可被翻译为：1.对生产场所和所用设备的说明（如操作间的位置和编号、 洁净度级别、必要的温湿度要求、设备型号和编号等）；\n'8.16 The processing status of major units of equipment should be indicated either on the individual units of equipment or by appropriate documentation, computer control systems, or alternative means.'可被翻译为：8.16 应当在设备主要部件上标明工作状态，或以文件形式、计算机控制形式或其它方式标明主要设备单元的工作状态。\n\n根据上述已知信息，请将'6. Any relevant processing operation or event, process parameters and control limits, and the reference number of major equipment used;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"6.相关生产操作或活动、工艺参数及控制范围，以及所用主要生产设备的编号。"
    },
    {
        "instruction":"已知信息：\n'An immune response to a therapeutic protein representing a counterpart to an endogenous protein may result in cross-reactivity, directed to the endogenous protein in cases where endogenous protein is still produced.'可被翻译为：代表着内源性蛋白对应物的治疗蛋白的免疫应答会导致出现针对内源性蛋白的交叉反应性，如果在内源性蛋白不断合成的情况下。\n'Previous exposure to similar or related proteins can lead to pre-sensitisation that may modify theresponse to the new therapeutic protein, e.g. proteins being used for replacement therapy.'可被翻译为：既往暴露于相似或相关蛋白质会导致预致敏，这可能改变对新治疗蛋白的应答，例如替代治疗所使用的蛋白质。\n'A possible life-threatening clinical consequence of ADA formation against a therapeutic protein is cross-reactivity with an endogenous protein when this protein has a non-redundant role in key physiological functions.'可被翻译为：形成抗治疗蛋白的ADA的潜在危及生命性临床后果是与内源性蛋白的交叉反应性，尤其是当这种蛋白在关键生理学功能中的作用并非多余时。\n'Potential clinical consequences of an unwanted immune response include loss of efficacy of the therapeutic protein, serious acute immune effects such as anaphylaxis, and, for therapeutic proteins used for substitution, cross-reactivity with the endogenous counterpart.'可被翻译为：不良免疫应答的潜在临床后果包括治疗性蛋白失去疗效、严重的急性免疫效应，例如过敏反应，以及对于替代用治疗性蛋白，与内源性蛋白的交叉反应性。\n\n根据上述已知信息，请将'When the therapeutic protein is used for substitution of an endogenous protein (e.g. factor VIII; enzyme replacement) where the patient is deficient of the natural counterpart, the physiological antigen may represent a neo-antigen and the immune system will interpret the therapeutic protein as foreign or non-self.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当在患者缺乏天然因子的情况下将治疗蛋白用于替代内源性蛋白时（例如VIII因子；酶替代疗法），生理性抗原可能代表着某种新抗原，免疫系统会将治疗蛋白判读为异物或非自身蛋白。"
    },
    {
        "instruction":"已知信息：\n'Class 2B elements have a reduced probability of occurrence in the drug product related to their low abundance and low potential to be co-isolated with other materials.'可被翻译为：2B类元素丰度较低并且与其他物料共生的可能性较低，因此出现在药品中的概率较低。\n'3 Class 3 elements with a cutaneous PDE above 500 μg\/day do not have to be included in the risk assessment unless intentionally added (see section 4 of ICH Q3D)'可被翻译为：3 如非有意添加，在风险评估中不需要考虑皮肤给药途径PDE大于500 μg\/day的3类元素 （见ICH Q3D第4章）。\n'Class 3: The elements in this class have relatively low toxicities by the oral route of administration (high PDEs, generally > 500 µg\/day) but may require consideration in the risk assessment for inhalation and parenteral routes.'可被翻译为：3类：此类元素口服给药途径的毒性相对较低（高PDE值，通常>500µg\/天）， 但在吸入和注射给药途径的风险评估中仍需考虑。\n'Class 2 elements are further divided in sub-classes 2A and 2B based on their relative likelihood of occurrence in the drug product.'可被翻译为：根据它们出现在药品中的相对可能性，进一步分成2A和2B亚类。\n\n根据上述已知信息，请将'2 Class 2B elements were excluded from the assessment of oral, parenteral and inhalation products due to the low likelihood that they would be present if not intentionally added (see section 4 of ICH Q3D).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2 如非有意添加，2B类元素出现在药品中的概率较低，在口服、注射和吸入药品评估中不 需要考虑（见ICH Q3D第4章）。"
    },
    {
        "instruction":"已知信息：\n'Prepare a suspension of WEHI-164 cells containing 1x106 cells per millilitre, using assay medium containing 2 µg\/mL of actinomycin D'可被翻译为：使用含2 µg\/mL放线菌素D的试验培养基，制备每ml含1x10 6 个细 胞的WEHI-164细胞悬液。\n'WEHI-164 cells (ATCC), TNF-alpha solution of suitable concentration, assay and culture medium including components and concentrations- Actinomycin D, Tetrazolium salt WST-8'可被翻译为：WEHI-164细胞（ATCC）、适当浓度的TNF-α溶液、试验和培养基质 包括组分和浓度 - 放线菌素D、四唑盐WST-8\n'Cell line: WEHI-164 cells (ATCC)'可被翻译为：细胞系： WEHI-164细胞（ATCC）\n'Immediately following centrifugation of cells, growth medium is removed from cell pellets,and cells are gently resuspended by slow addition of cryopreservation medium that is often precooled for many cell types. The cell suspension is immediately diluted with an appropriate volume of cryopreservation medium based on viable cell count and targeted cell density (typically, cell banks are produced at aviable cell density of approximately 1 × 107 cells\/mL). As mentionedin the previous section, cryopreservation medium is highly hypertonic, and exposure time should be limited. The'可被翻译为：细胞离心后，立即从细胞沉淀中除去培养基，并通过缓慢添加预冷的冻存培养基轻轻重悬细胞。根据活细胞数量和目标细胞浓度（通常，细胞库活细胞密度大约1×107个细胞\/ mL），立即用适当体积的冷冻保存介质稀释细胞悬液。如上一节所述，冷冻储藏介质是高渗的，应限制暴露时间。将最终的细胞悬浮液转移到一个容器中，在小瓶灌装期间可以在其中轻轻混合细胞，促进细胞库的均匀性。\n\n根据上述已知信息，请将'Preparation of a suspension of WEHI-164 cells containing 1x106 cells per millilitre, using assay medium containing 2 µg\/mL of actinomycin D.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"使用含2 µg\/mL放线菌素 D的试验培养基制备含 1x10 6 个细胞\/mL的WEHI- 164细胞悬液。"
    },
    {
        "instruction":"已知信息：\n'In a multicentre trial these considerations apply to the individual centres.'可被翻译为：这些考虑适用于多中心试验的各个中心。\n'In many trials, however, the situation is more complex. One investigator may recruit subjects from several hospitals; one investigator may represent a team of clinicians (subinvestigators) who all recruit subjects from their own clinics at one hospital or at several associated hospitals.'可被翻译为：可 是，很多试验会更复杂一些，例如，一个研究者可能从几家 医院招募受试者；一个研究者可能代表一个临床医生团队 （参与研究者），他们或从一家医院所辖的几个诊所，或从几 家相关的医院招募受试者。\n'5.6.1 The sponsor is responsible for selecting the investigator(s)\/institution(s). Each investigator should be qualified by training and experience and should have adequate resources (see 4.1, 4.2) to properly conduct the trial for which the investigator is selected. If organization of a coordinating committee and\/or selection of coordinating investigator(s) are to be utilized in multicentre trials, their organization and\/or selection are the sponsor's responsibility.'可被翻译为：5.6.1 申办者有责任选择研究者及研究机构。每一个研究者应当是通过培训合格的和有经验的，应当有足够的资源(见4.1， 4.2)正确地实施其被选择来进行的试验。如果在多中心试验中 将组织一个协调委员会组织和\/或选择协调研究者，他们的组织和\/或选择是申办者的责任。\n'For each clinical investigator who is not identified as an employee of the sponsor, one of the following must be submitted (21 CFR § 54.4(a)):'可被翻译为：对于未被鉴别为申办方员工的每名临床研究者， 必须 提交下列项目之一（21 CFR § 54.4（a））：\n\n根据上述已知信息，请将'In the simplest multicentre trial, each investigator will be responsible for the subjects recruited at one hospital, so that ‘centre’ is identified uniquely by either investigator or hospital.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"最简单的多中心试验是每位研究者负责在一家医院招 募受试者，所以，“中心”是由研究者或医院唯一确定的。"
    },
    {
        "instruction":"已知信息：\n'The PBRER may also be accompanied by regional appendices, as needed, to fulfil national and regional requirements.'可被翻译为：根据需要，PBRER还可能伴随区域性附录，以达到国家和区域的要求。\n'Final study reports completed during the reporting interval for the studies mentioned in the paragraph above should also be included in the regional appendix of the report where stipulated by regional requirements.'可被翻译为：在上述段落中提到的研究报告期内完成的最终研究报告也应列入报告中区 域要求规定的区域性附录。\n'The PBRER should contain an evaluation of new information relevant to the medicinal product that became available to the MAH during the reporting interval, in the context of cumulative information by:'可被翻译为：在累积信息的背景下中，PBRER应包含与报告期内MAH可获 得的药品相关新信息的评估，该评估通过以下方式进行：\n'3.7 Summaries of Significant Safety Findings from Clinical Trials during the Reporting Interval This section of the PBRER should provide a brief summary of clinically important emerging efficacy\/effectiveness and safety findings obtained from the MAH’s sponsored clinical trials that became available during the reporting interval of the report.'可被翻译为：3.7 报告期内临床试验重大安全性发现的总结 PBRER的这一章节应简要总结在报告期内从MAH申办的临床试验获得的 临床重要的新发现的有效性\/疗效和安全性结果。\n\n根据上述已知信息，请将'When required for reporting in a PBRER, results of evaluations that are relevant to only one region and that became available during the reporting interval should be provided in regional appendices.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在PBRER中需要报告的情况下，应在区域附录中提供在报告期内获得的 仅与该区域相关的评估结果。"
    },
    {
        "instruction":"已知信息：\n'‒ Sponsors and\/or FDA attendees should summarize important discussion points, agreements, clarifications, and actions items either at the end of the meeting or after the discussion of each question.'可被翻译为：- 申办方和\/或FDA与会者应在会议结束时或在讨论完每个问题的之 后总结重要的讨论点、协议、说明和行动项目。\n'Instead, valuable meeting time should be preserved for a focused discussion of issues identified in the meeting package, particularly those that are still unresolved after FDA’s preliminary responses have been sent to the sponsor or that have been raised in FDA’s responses.'可被翻译为：相反，应保留宝贵的会议时间，以便对会议文件包中确定的问题进行集中讨论，特别是在FDA将初步回复发送给申办方后仍未解决的问题或在FDA回复中提出的问题。\n'‒ FDA project managers should send preliminary responses to sponsor questions before the meeting so that the meeting time can be dedicated to unresolved issues for which more discussion is needed. In the preliminary responses, FDA should provide high-level recommendations for important issues identified during the review of the meeting package, even if questions concerning those issues were not explicitly posed by the sponsor.'可被翻译为：- FDA项目经理应在会前发送对申办方所提问题的初步回复，以便将 与会时间用于需要进行更多讨论的未解决问题。在初步回复中，即 使有关这些议题的问题申办方没有明确提出，FDA也应为在审评会 议文件包期间发现的重要议题提供高级别建议。\n'After the meeting package is submitted but before preliminary responses are sent by the FDA, the sponsor or applicant sends CBER or CDER additional questions or data that are intended for discussion at the meeting and require additional review time.'可被翻译为：. 在提交了会议资料包而在 FDA 发送初步的回复之前， 申办方或申请人给 CBER 或 CDER 发送了额外的问题或数据用于在会议上讨论，需要额外 的评审时间。\n\n根据上述已知信息，请将'During the course of the meeting, sponsors should generally not ask substantive questions that were not included in the meeting package, or present new data or information that was not previously provided to FDA or requested by FDA in their preliminary comments.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在会议期间，申办方通常不应询问未包括在会议文件包或以前未提供给FDA或FDA在其初步意见中未要求的现有新数据或信息中的实质性问题。"
    },
    {
        "instruction":"已知信息：\n'The CV obtained must be less than or equal to a pre-defined acceptable value'可被翻译为：获得的CV必须小于或等于预设的可接受值\n'Rounding off of CI values:'可被翻译为：置信区间有效位数的保留：\n'·90 percent Confidence intervals (CI)'可被翻译为：•90%置信区间\n'If the predose concentration is 5 percent of Cmax value in a subject with predose plasma concentration, you can include the subject’s data without any adjustments in all pharmacokinetic measurements and calculations. We recommend that if the predose value is greater than 5 percent of Cmax, you drop the subject from all BE study evaluations.'可被翻译为：如果给药前血样的浓度小于Cmax的5%，则该受试者的数据可以不经校正而直接参与药代数据测定和计算。如果给药前血样浓度大于Cmax的5%，则建议从BE研究评估中剔除该受试者的数据。\n\n根据上述已知信息，请将'We recommend that applicants not round off CI values; therefore, to pass a CI limit of 80 to 125 percent, the value would be at least 80.00 percent and not more than 125.00 percent.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"建议申请人不要舍去置信区间(CI)的有效位数；因此，要达到80%到125%的标准，CI的数值不得低于80.00%，且不超过125.00%。"
    },
    {
        "instruction":"已知信息：\n'2.The raw liquid should be sub-packaged in advance, under proper conditions, with packaging materials consistent with those to be imported as applied. Small packaging specifications should be selected as far as possible to avoid sample contamination and ensure the proper progress of each test.'可被翻译为：2.原液应提前在适当的条件下分装，包装材料与进口材料一只。应尽量选取小的包装规格，以避免样品的污染，并保证各项实验的进行。\n'11.72 The reserve sample should be stored in the same packaging system in which the API is stored or in one that is equivalent to or more protective than the marketed packaging system. Sufficient quantities should be retained to conduct at least two full compendial analyses or, when there is no pharmacopoeial monograph, two full specification analyses.'可被翻译为：11.72 留样应保存在与原料药保存相同的包装系统中，或保存在与上市包装等同或保护性更好的包装系统中。留样量应至少可供两次按药典标准的全检之用；若无药典标准，则应至少可供两次按质量标 准的全检之用。\n'1) There should be reference samples for each batch. Where a batch is packaged into several distinct packaging operations, at least one reference sample should be taken from each individual packaging operation.'可被翻译为：1.每批药品均应当有留样；如果一批药品分成数次进行包装，则每次包装至少应当保留一件最小市售包装的成品。\n'1) There should be reference samples for each batch. Where a batch is packaged into several distinct packaging operations, at least one reference sample should be taken from each individual packaging operation.'可被翻译为：1.每批药品均应当有留样；如果一批药品分成数次进行包装，则每次包装至少应当保留一件最小市售包装的成品；\n\n根据上述已知信息，请将'2.The sample APIs should be sub- packaged in advance, under proper conditions, with packaging materials consistent with those to be imported as applied. Small packaging specifications should be selected as far as possible to avoid sample contamination and ensure the proper progress of each test.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2.原料药应提前在适当的条件下选用与申报进口包装材料一致的包装材料进行分装后送样，应尽量选取小的包装规格，避免样品污染，保证各项实验的进行。"
    },
    {
        "instruction":"已知信息：\n'The lot release applicant shall immediately take measures such as stopping the sale and use and recalling the defective products, and destroy them under the supervision of the drug regulatory departments in accordance with relevant provisions. The lot release applicant shall report the destruction records to the drug regulatory departments and the corresponding lot release institution simultaneously.'可被翻译为：批签发申请人应当立即采取停止销售、使用，召回缺陷产品等措施，并按照有关规定在药品监督管理部门的监督下予以销毁。批签发申请人将销毁记录同时报药品监督管理部门和相应的批签发机构。\n'Article 25 For any of the following circumstances, the lot release institution shall notify food and drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government in the place where the enterprise is located, order the enterprise to analyze and identify the reasons, propose the recommendations for on-site inspection to the CFDI and simultaneously report to the CFDA :'可被翻译为：第二十五条 有下列情形之一的，批签发机构应当通知企业所在地省、自治区、直辖市食品药品监督管理部门，并责令企业分析查找原因，向核查中心提出现场检查建议，同时报告食品药品监管总局：\n'The lot release applicant shall also report the destruction records to the food and drug regulatory departments and the corresponding lot release institution simultaneously.'可被翻译为：批签发申请人应当将销毁记录同时报食品药品监督管理部门和相应的批签发机构。\n'Article 32 If the product is identified to have any quality or other potential safety issues, involving the batches already marketed or circulated, the lot release institution shall immediately report to the drug regulatory departments of provinces, autonomous regions or municipalities directly under the Central Government where the lot release applicant is located and where the production site is located; if the imported biological product is involved, the lot release institution shall notify the drug regulatory departments of provinces, autonomous regions or municipalities directly under the Central Government where the import port is located. The drug regulatory departments receiving the notification shall immediately notify the lot release applicant.'可被翻译为：第三十二条    在批签发工作中发现企业产品存在质量问题或者其他安全隐患，涉及已上市流通批次的，批签发机构应当立即通报批签发申请人所在地和生产场地所在地省、自治区、直辖市药品监督管理部门；涉及进口生物制品的应当通报进口口岸所在地省、自治区、直辖市药品监督管理部门。接到通报的药品监督管理部门立即通知批签发申请人。\n\n根据上述已知信息，请将'Article 31 Where the product of the enterprise is identified to have serious defects in the lot release, involving the batches that have already been marketed and distributed, the CFDA shall immediately notify the lot release applicant. The lot release applicant shall immediately take such measures as stopping the sales and use and recalling the defective products and destruct them in accordance with relevant regulations and under the supervision of the food and drug regulatory departments of the provinces, autonomous regions and municipalities directly under the Central Government. The lot release applicant shall also report the destruction records to the food and drug regulatory departments and the corresponding lot release institution simultaneously.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十一条 在批签发工作中发现企业产品存在严重缺陷，涉及已上市流通批次的，食品药品监管总局应当立即通知批签发申请人，批签发申请人应当及时采取停止销售、使用、召回缺陷产品等措施，并按照有关规定在省、自治区、直辖市食品药品监督管理部门的监督下予以销毁。批签发申请人应当将销毁记录同时报食品药品监督管理部门和相应的批签发机构。"
    },
    {
        "instruction":"已知信息：\n'Local and systemic toxicities were considered.'可被翻译为：考虑局部和全身毒性。\n'The different dosing regimens and modes of action of these pharmacological entities affect the toxicity and tolerability profiles in different ways, which must be taken into account in the planning of the collection and reporting of safety data.'可被翻译为：这些药物的不同给药方案和作用方式会以不同的方式影响毒性和耐受性，在计划安全性数据的收集和报告时必须考虑这些问题。\n'The safety review for platinum identified limited assessments of platinum salt toxicity for parenteral routes of administration.'可被翻译为：现有的铂的安全性数据对评估铂盐注射途径的毒性有限。\n'Safety Limiting Toxicity'可被翻译为：毒性安全限度\n\n根据上述已知信息，请将'The data was reviewed to identify the safety limiting toxicities based on routes of administration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以给药途径为基础对数据进行总结来确定毒性安全限度。"
    },
    {
        "instruction":"已知信息：\n'Implementation Guide for Electronic Transmission of Individual Case Safety Reports (ICSRs) Data Elements and Message Specification'可被翻译为：个例安全报告个例（ICSRs）电子传输执行指 导原则 数据元素和信息规范元素\n'Electronic Transmission of Individual Case Safety Reports (ICSRs) Implementation Guide Data Elements and Message Specification'可被翻译为：个例安全报告个例（ICSRs）电子传输的执行 指导原则 数据元素和信息规范元素\n'This will facilitate the implementation of the electronic transmission of Individual Case Safety Reports (ICSRs) in the ICH regions.'可被翻译为：这将有助于在ICH地区实施问答个例安全报告（ICSRS）的电子传输。\n'• Guidance for Industry: E2B(R3) Electronic Transmission of Individual Case Safety Reports (ICSRs) Implementation Guide – Data Elements and Message Specification'可被翻译为：• 业界指南：E2B（R3）个别病例安全性报告（ICSR）执行指引的电子传递 - 数 据元素和信息规范\n\n根据上述已知信息，请将'Implementation Guide for Electronic Transmission of Individual Case Safety Reports (ICSRs)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"个例安全报告（ICSR）电子传输执行指导原则"
    },
    {
        "instruction":"已知信息：\n'There may be cases when an impurity is also a metabolite of the drug substance. In such cases the risk assessment that addresses mutagenicity of the metabolite can qualify the impurity.'可被翻译为：某些情况下，某杂质同时也是原料药的代谢产物。此时对代谢产物的致突变风险评估可作为该杂质限度制订的依据。\n'An assessment of potential impurities likely to be present in the final drug substance is carried out to determine if further evaluation of their mutagenic potential is required.'可被翻译为：可能存在于最终的原料药中的潜在杂质应进行评估，以确定是否需要进一步 评估其潜在致突变性。\n'To qualify an alternative assay or a combination of assays for use in risk assessment for regulatory purposes, a comprehensive description of the methodology and findings should be provided, including the following:'可被翻译为：为了对用于监管目的的风险评估的替代试验或组合试 验进行资格验证1，应提供方法学和结果的全面详细描述，包括以下内容：\n'In some cases, the use of statistical process control and trending of process measurements can be useful for continued suitability and capability of processes to provide adequate control on the impurity.'可被翻译为：在某些情况下，使用统计的工艺控制和工艺测量的趋势分析以获得持续适应 性和工艺能力，从而对杂质进行充分控制。\n\n根据上述已知信息，请将'In such cases the risk assessment that addresses mutagenicity of the metabolite can qualify the impurity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在这种情况下，对代谢产物的 致突变风险评估可以界定该杂质。"
    },
    {
        "instruction":"已知信息：\n'The prevalence of constipation in childhood varies with age. The peak incidence of childhood constipation is thought to occur around the time of toilet training (age 2-4 years).'可被翻译为：其发病率随着年龄的增长而变化， 2-4 岁是发病的高峰期（此时，儿童 正经历如厕训练）。\n'The prevalence of constipation in childhood varies with age.'可被翻译为：儿童期内便秘的患病率随年龄变化。\n'The peak incidence of childhood constipation is thought to occur around toilet training (age 2-4 years)76.'可被翻译为：儿童期便秘发病率的 高峰出现在排便习惯训练阶段（2-4 岁） 76 。\n'The definition of childhood functional constipation is based on the “Paris Consensus on Childhood Constipation Terminology (PACCT) Group, and the Rome III criteria , which include both the following: Must include 2 or more of the following criteria for at least 2 months before diagnosis:'可被翻译为：儿童功能性便秘的诊断可参考儿童便秘巴黎共识（PACCT）和罗马 III 标准，包括：必须满足下列至少2项，且诊断前症状持续至少2 个月：\n\n根据上述已知信息，请将'While organic causes for constipation are rare, and usually detected in early childhood, 95% of childhood constipation is thought to be “functional” on the basis of a learned behaviour of interruption of the defecation process with stool-withholding cycles leading to constipation, faecal impaction, and finally overflow faecal incontinence.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"儿童器质性便秘很少见，且 95%的儿童便秘是“功能性”的。由于在排便过程 受干扰、憋大便等行为原因引起粪便嵌塞，最后溢出致大便失禁。"
    },
    {
        "instruction":"已知信息：\n'Sensitivity analyses are recommended to test the robustness of the primary analysis results in the intent-to-treat population and by relaxing the assumed missing data mechanism of the primary analysis.'可被翻译为：建议采用敏感性分析，通过放松主要分析的假定缺失数据机制检验意向治疗人群中主要分析结果的稳健性。\n'Sensitivity analyses will need to be performed to evaluate the impact of different assumptions regarding missing data and, in particular, potentially informative censoring.'可被翻译为：将需要进行灵敏度分析以评估关于缺失数据的不同假设的影响，以及特别是潜在信息删失。\n'Sensitivity analyses can be performed using various methods for imputing missing post-treatment virologic results at 12 weeks of follow-up.'可被翻译为：可以采用多种方法，对输入的12周随访的治疗后病毒学结果进行敏感性分析。\n'The primary analysis will also have to be accompanied by several sensitivity analyses, not all of which should be based on the same assumptions.'可被翻译为：将对主要分析进行几项敏感性分析，这些分析并不基于相同的假设。\n\n根据上述已知信息，请将'Appropriate sensitivity analyses should be performed to demonstrate that the primary analysis is robust to discontinuation and missing data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应该进行一系列敏感性分析，从而证明主要分析对终止和缺失数据不敏感。"
    },
    {
        "instruction":"已知信息：\n'If hypothesis tests are used, statistical adjustments for multiplicity to quantify the type I error are appropriate, but the type II error is usually of more concern.'可被翻译为：如果使用假设检验，对多重性的统计调整以量化I类错 误是合适的，但是II类错误通常更值得关注。\n'When multiplicity is present, the usual frequentist approach to the analysis of clinical trial data may necessitate an adjustment to the type I error.'可被翻译为：当存在多重性时，用于临床试验数据分析常用的频率派 方法可能需要对I类错误进行调整。\n'The probability of type II error is conventionally set at 10% to 20%; it is in the sponsor’s interest to keep this figure as low as feasible especially in the case of trials that are difficult or impossible to repeat.'可被翻译为：II类错误的概率通常设在10%到20%之间， 申办方通常愿意让该值尽可能低，尤其当试验难以或不可能 重复时。\n'Any null hypothesis is rejected if it is rejected at the Type I error level of α = 0.05, and all possible intersections with this null hypothesis are also rejected at this α-level.'可被翻译为：如果在I类错误水平α=0.05被拒绝，则任何零假设被拒绝，这一零假设的可能交集在这一α水平上也被拒绝。\n\n根据上述已知信息，请将'Conventionally the probability of type I error is set at 5% or less or as dictated by any adjustments made necessary for multiplicity considerations; the precise choice may be influenced by the prior plausibility of the hypothesis under test and the desired impact of the results.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通常I类错误概率设 在5%或者更小，或者由多重比较所需要的任何调整来决定； 检验假设的事先合理性以及结果的预期影响可能会影响I类 错误的精确选择。"
    },
    {
        "instruction":"已知信息：\n'Requalification should be performed every 6–12 months, based on equipment usage, risk tolerance, and manufacturers recommendation. Requalification should also be performed if the system is relocated or undergoes a major repair.'可被翻译为：应根据设备使用情况、风险承受能力和制造商建议，每6-12个月进行一次再确认。如果系统重新安置或进行大修，也应进行重新确认。\n'Cleanroom and clean air equipment qualification'可被翻译为：洁净室和洁净空气设备的确认\n'Appropriate requalification consisting of at least the above tests should also be carried out following completion of remedial action implemented to rectify an out of compliance equipment or facility condition or after changes to equipment, facility or processes as appropriate. The significance of a change should be determined through the change management process. Examples of changes to be considered include but are not limited to the following:'可被翻译为：在纠正设备或设施缺陷而采取的整改措施完成后，或设备、设施或工艺的变更后，还应视情况进行上述检测进行适当的再确认。变更的重要性应通过变更管理程序确定。需要考虑的变更案例包括但不限于：\n'After initial qualification and validation, requalification or revalidation should be carried out according to the product quality review.'可被翻译为：首次确认 或验证后，应当根据产品质量回顾分析情况进行再确认或再验 证。\n\n根据上述已知信息，请将'The requalification of cleanrooms and clean air equipment should be carried out periodically following defined procedures. The requalification should include at a minimum the following:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"洁净室和洁净空气设备的再确认应按照规定的程序定期执行。再确认应至少包括以下内容："
    },
    {
        "instruction":"已知信息：\n'‘Visually clean’ may be acceptable for dedicated equipment based on the ability to visually inspect and sufficient supporting data from cleaning studies (e.g., analytical determination to demonstrate cleaning effectiveness) [ICH Q7, Section 12.76].'可被翻译为：基于目视检查的能力，并有充分的清洁研究支持性数据（例如，分析检测来证明清洁有效性）时，对专用设备采用“目测清洁”是可能被接受的【ICHQ7，第12.76章节】。\n'12.76 Cleaning procedures should be monitored at appropriate intervals after validation to ensure that these procedures are effective when used during routine production. Equipment cleanliness can be monitored by analytical testing and visual examination, where feasible. Visual inspection can allow detection of gross contamination concentrated in small areas that could otherwise go undetected by sampling and\/or analysis.'可被翻译为：12.76 验证后的清洁规程应当适时监控，以确保这些规程在日常生产中的有效性。尽可能通过分析测试和目视检查来监控设备的清洁程度。目视检查能够发现那些用取样和\/或分析检测发现不了的、集中在小面积上的严重污染。\n'5.5 June 2015 At product changeover, are both visual examination and analytical testing necessary to verify that equipment is clean?'可被翻译为：5.5 更换品种时，是否需要同时采用目视检查和分析测试来确认设备是清洁的？（2015年6月）\n'5.3 June 2015 Is it expected that equipment cleaning time limits be confirmed in cleaning validation?'可被翻译为：5.3 是否期望在清洁验证时确认设备清洁时限？（2015年6月）\n\n根据上述已知信息，请将'5.1 June 2015 For dedicated equipment, is ‘visually clean’ acceptable for verification of cleaning effectiveness, (i.e., no expectation for specific analytical determination)?'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"5.1对于专用设备，在清洁有效性确认中使用“目测清洁”是否可接受（即无需专属的分析检测）？（2015年6月）"
    },
    {
        "instruction":"已知信息：\n'Provincial drug regulatory departments shall be responsible for the permit and registration of the post-approval change of supervision items for production, and the filing and reporting of the post-approval change of administrative items for registration for the drugs of MAHs within their respective administrative regions in accordance with their responsibilities; and organize the supervision and administration of post-approval changes of drugs in accordance with law.'可被翻译为：省级药品监管部门依职责负责辖区内持有人药品上市后生产监管事项变更的许可、登记和注册管理事项变更的备案、报告等管理工作；依法组织实施对药品上市后变更的监督管理。\n'Each provincial drug regulatory department shall implement the responsibility for supervision over change management of post-approval drugs at its administrative area, by specifying requirements, formulating working documents, and clarifying time limits. The cooperation between drug registration administration and production supervision should be consolidated for mutual support, to ensure the smooth and orderly implementation of change management of post-approval drugs.'可被翻译为：各省级药品监管部门应当落实辖区内药品上市后变更监管责任，细化工作要求，制定工作文件，明确工作时限，药品注册管理和生产监管应当加强配合，互为支撑，确保药品上市后变更监管工作平稳有序开展。\n'Article 14 Where the MAH or drug manufacturer within the territory of China makes internal change on the manufacturing sites, or the MAH within the territory of China makes change on their manufacturers (including change of contract manufacturers, addition of contract manufacturers, change of self-production by MAH to contract manufacturer, and change of contract manufacturing to self-manufacturing), MAH (drug manufacturers) shall conduct study, evaluation and necessary verification in accordance with the requirements in the Provisions for the Supervision and Administration of Drug Manufacture and relevant technical guidelines for changes, and file an application for changing the Drug Manufacturing Certificate with the local provincial drug regulatory department and submit relevant dossiers.'可被翻译为：第十四条 境内持有人或药品生产企业内部变更生产场地、境内持有人变更生产企业（包括变更受托生产企业、增加受托生产企业、持有人自行生产变更为委托生产、委托生产变更为自行生产）的，持有人（药品生产企业）应当按照《药品生产监督管理办法》及相关变更技术指导原则要求进行研究、评估和必要的验证，向所在地省级药品监管部门提出变更《药品生产许可证》申请并提交相关资料。\n'Article 2 In the Provisions, the post-approval changes of drugs include the change of registration administrative items and the change of production supervision items.'可被翻译为：第二条 本办法所指药品上市后变更包括注册管理事项变更和生产监管事项变更。\n\n根据上述已知信息，请将'Article 30 The provincial drug regulatory department in the place where the MAHs and contract manufacturers are located shall strengthen the supervision and administration of post-approval changes of drugs in accordance with the relevant provisions for drug production supervision, supervise and inspect the MAHs' change control system, and urge them to fulfill their responsibilities for change management.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十条 持有人和受托生产企业所在地省级药品监管部门应当按照药品生产监管的有关规定加强对药品上市后变更的监督管理，对持有人变更控制体系进行监督检查，督促其履行变更管理的责任。"
    },
    {
        "instruction":"已知信息：\n'Any one of several data elements is sufficient to define an identifiable patient (e.g. initials, age, and sex) or an identifiable reporter (e.g. initials, address, and qualification).'可被翻译为：几个数据元素中的任意一个即可定义一个身份可识别的患者几个数据元素中的任意一个即可定义一个身份可识别的患者（例如姓名首字母缩写、年龄和性别）或一个身份可识别的报告者（例如姓名首字母缩写、地址和资格）。\n'• one identifiable patient - any one of several data elements is considered sufficient to define an identifiable patient (e.g. initials, age, sex);'可被翻译为：● 一个身份可识别的患者-几个数据元素中认为足以定义可识别的患者的任何一个元素（例如姓名首字母缩写、年龄、性别）；\n'At least one of the data elements in Section D must be populated with a meaningful value or masked to fulfil the criteria ‘one identifiable patient’.'可被翻译为：D 节中至少有一个数据元素必须填写一个有意义的数值或被遮盖元素，以满足“一例可识别的患者”的标准。\n'If only the name of the reporter is known and confidentiality requirements prohibit transmission of the reporter’s full name or initials, the data elements C.2.r.1.2, C.2.r.1.3, and\/or C.2.r.1.4 can be masked and ‘populated’ with a nullFlavor as appropriate, in compliance with confidentiality requirements or reporter request.'可被翻译为：如果仅已知报告者的姓名，且保密性要求禁止传输报告者的全名或姓名首字母缩写，则数据元素元素 C.2.r.1.2，C.2.r.1.3 和（或）C.2.r. 1.4 可根据保密要求或报告者的要求，酌情掩盖和以不完整信息“填写”。\n\n根据上述已知信息，请将'• one identifiable reporter - any one of several data elements is considered sufficient to define an identifiable reporter (e.g. initials, address, qualifications);'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"● 一个身份可识别的报告者-几个数据元素中认为足以定义可识别的报告者的任何一个元素（例如姓名、地址、资质）；"
    },
    {
        "instruction":"已知信息：\n'The toxicity should be graded according to a generally recognised system, e.g. the National Cancer Institute’s (NCI) Common Terminology Criteria for Adverse Events (CTCAE).'可被翻译为：应根据 通常的分级系统，例如美国国家癌症研究所（NCI）的不良事件常用术语标准（CTCAE） 对毒性进行分级。\n'5 Using the grading system for adverse events in cancer trials described in the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE), U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. A Grade 4 adverse event results in need for life-saving urgent intervention; a Grade 3 adverse event results in severe or clinically significant but not immediately life-threatening consequences; hospitalization or prolonged hospitalization needed; disabling; results in limitations on ability to bathe, dress, undress, feed, use toilet, take medications; and a Grade 2 event results in need for moderate, minimal, or local or invasive intervention; results in limitations on age appropriate ability to prepare meals, grocery, and\/or clothes shop, use the telephone, manage money.'可被翻译为：5 采用美国国立癌症研究所的通用不良事件术语标准（CTCAE），U.S.健康与人类服务部门，美国国立卫生 研究院、美国国立癌症研究院描述的分级系统用于癌症试验中的不良事件。4级不良事件是导致需要救生 紧急干预的事件；3级不良事件可导致严重或临床重要但不会立刻危及生命的结果；需要住院或住院期延 长；伤残；导致洗澡、穿衣、脱衣、饮食、上厕所、服药能力受限；和2级事件导致需要中度、最低、或 局部或侵入性干预；导致相应年龄的做饭、在杂货店和\/或服装店购买、使用电话、管理财物的能力受限。\n'National Cancer Institute'可被翻译为：美国国家癌症研究所\n'NCI National Cancer Institute'可被翻译为：NCI 美国国家癌症研究所（National Cancer Institute）\n\n根据上述已知信息，请将'5 The grading system was used for adverse events in cancer trials described in the Common Terminology Criteria for Adverse Events document from the National Cancer Institute (U.S. Department of Health and Human Services’ National Cancer Institute at the National Institutes of Health).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"5采用美国国立癌症研究所的通用不良事件术语标准（CTCAE），U.S.健康与人类服务部门，美国国立卫生 研究院、美国国立癌症研究院描述的分级系统用于癌症试验中的不良事件。"
    },
    {
        "instruction":"已知信息：\n'An immune response to the transgene product might eventually compromise the efficacy of the product and might have an impact on safety.'可被翻译为：对转基因产品的免疫应 答可能最终损害产品的功效， 并对安全性产生影响。\n'Effects of pre-existing immunity against the vector vehicle and\/or vector gene products in the patient may be mimicked by pre-treatment of the animals with the vector.'可被翻译为：可采用载体对动物进行预治疗， 以模拟对载体媒介和\/或载体基因制品的预存免疫性在患者中的作用。\n'Some examples of GT products can include purified nucleic acid (e.g., plasmids and RNA), microorganisms (e.g., viruses, bacteria, fungi) genetically modified to express transgenes (including products that edit the host genome), and ex vivo genetically modified human cells.'可被翻译为：GT产品的举例可包括： 纯化的核酸（例如，质粒和RNA）、表达特定基因（包括编 辑宿主基因组的产品）的基因修饰微生物（例如，病毒、细菌、真菌）、离体基因修饰的人类细胞。\n'It is fully acknowledged that criteria for HSCT (e.g. patient eligibility, HLA matching, conditioning regimen, graft versus host disease prevention, etc) vary between institutions and regions.'可被翻译为：目前完全承认，机构和地区间的异基因造血干细胞 移植标准（例如患者资格、HLA配型、预处理方案、预防移植物抗宿主病等）是有差 异的。\n\n根据上述已知信息，请将'In addition, the occurrence of graft versus host disease in animals can complicate interpretation of BD assessment of genetically modified human T cells.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"此外，动物体内可能出现移植物抗宿主病，会使基因修饰人T细胞的BD分析评价复杂化。"
    },
    {
        "instruction":"已知信息：\n'ICH E2B(R3) Expert Working Group \/ Implementation Working Group ICH E2B(R3) Guideline: Electronic Transmission of Individual Case Safety Reports (ICSRs)'可被翻译为：ICHE2B(R3)专家工作组\/执行工作组 ICH E2B(R3)指南: 个例安全报告的电子传输(ICSRs)\n'The ICH ICSR message allows for the preparation of adverse event\/reaction data sets that can accurately maintain and represent the intended purpose of the E2B(R3) document. Section 3 of this IG lists the exact E2B(R3) data elements and essential components to develop usable and exchangeable ICH ICSR messages.Necessary schemas for the ICH ICSR message are listed in Appendix I (A).'可被翻译为：ICH ICSR消息允许准备不良事件\/反应数据集，可以准确维护和遵守E2B（R3）文件的预期目的。该IG的第3节列出了确切的E2B （R3）数据元素和基本组成元素，以便开发有用且和可交换的ICH ICSR消息。 ICH ICSR 消息的必要模式见附录I（A）。\n'• Guidance for Industry: E2B(R3) Electronic Transmission of Individual Case Safety Reports (ICSRs) Implementation Guide – Data Elements and Message Specification'可被翻译为：• 业界指南：E2B（R3）个别病例安全性报告（ICSR）执行指引的电子传递 - 数 据元素和信息规范\n'FDA adopted that guideline and in February of 2014 published it as FDA Guidance for Industry E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification (ICH E2B(R3) IG).'可被翻译为：FDA采纳了该指南，并于2014年2月将其发布为FDA业界指南E2B（R3）个别病例安全性报告执行指引的电子传递 一数据 元素和信息规范（ICH E2B（R3）IG）。\n\n根据上述已知信息，请将'A. Background The ICH E2B Expert Workgroup (E2B EWG) released the revised, ICH Implementation Guide for the Electronic Transmission of ICSRs: E2B(R3) Data Elements and Message Specification for pharmacovigilance reporting guideline.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A. 背景 ICH E2B专家工作组（E2B EWG）发布了修订版ICH ICSR电子提交执行指引： 药物警戒性报告指南的E2B（R3）数据元素和信息规范。"
    },
    {
        "instruction":"已知信息：\n'An IND sponsor, acting much earlier, must inquire into investigator financial interests and arrangements before the ultimate role of a study in the application is determined (21 CFR § 312.53).'可被翻译为：很早采取行动的 IND 申办方 必须在确定某研究在某项申请中的最终作用时，询问研究者的财务权益和安排 （21 CFR § 312.53）。\n'Given that a reduced-design study will necessarily be a small-size study, the Applicant needs to carefully consider a priori the strength of evidence that may be obtained and how data should be handled in the decision-making procedure.'可被翻译为：考虑到简化设计的研究必然是一个小规模的研究，申请人需要仔细考虑可能获得证据的力度和如何在决策程序中处理数据。\n'FDA discourages investigators from applying a one size fits all approach to study design, irrespective of the design’s suitability in addressing the particular study questions and hypotheses.'可被翻译为：FDA不鼓励研究者对研究设计一刀切，而不考虑研究设计是否适于解决特殊的研究疑问及假设。\n'Study duration also can be affected by other species-specific considerations.'可被翻译为：研究持续时间也可 能受到其他种属特异性因素的影响。\n\n根据上述已知信息，请将'A: The IND sponsor will need to consider the potential role of a particular study based on study size, design, and other considerations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"答：IND 申办方将需要根据研究大小、设计和其他方面的考虑， 考虑某项给定研究的潜在作用。"
    },
    {
        "instruction":"已知信息：\n'important non-clinical safety findings;'可被翻译为：重要的非临床安全性发现；\n'Within the Specification, this section should present non-clinical safety findings that have not been adequately addressed by clinical data, for example:'可被翻译为：在安全性说明中，这一节应当介绍尚未被临床数据充分说明 的非临床安全性发现，例如：\n'Examples of potential risks include: non-clinical safety concerns that have not been observed or resolved in clinical studies; adverse events observed in clinical trials or epidemiological studies for which the magnitude of the difference, compared with the comparator group (placebo or active substance, or unexposed group), on the parameter of interest raises a suspicion of, but is not large enough to suggest, a causal relationship; an event which is known to be associated with other products of the same class or which could be expected to occur based on the properties of the medicinal product.'可被翻译为：潜在风险的示例包括： 在临床研究中尚未观察或解决的非临床安全性 问题； 在临床试验或流行病学研究中观察到的不良事 件与对照组（安慰剂或活性物质或未暴露组） 相比，在所关注的参数方面的差异程度引起怀 疑，但不足以提示因果关系； 已知与相同类别的其它产品相关的或可基于药 品的性质预期会发生的事件。\n'An untoward occurrence for which there is some basis for suspicion of an association with the medicinal product of interest but where this association has not been confirmed. Examples of potential risks include:non-clinical safety concerns that have not been observed or resolved in clinical studies; adverse events observed in clinical trials or epidemiological studies for which the magnitude of the difference, compared with the comparator group (placebo or active substance, or unexposed group), on the parameter of interest raises a suspicion of, but is not large enough to suggest, a causal relationship; an event which is known to be associated with other products of the same class or which could be expected to occur based on the properties of the medicinal product.'可被翻译为：有一定的依据怀疑与所关注的药品有关但是未能确认的不利事件。潜在风险的示例包括：在临床研究中尚未观察或解决的非临床安全性问题；在临床试验或流行病学研究中观察到的不良事件与对照组（安慰剂或活性物质或未暴露组）相比，在所关注的参数方面的差异程度引起怀疑，但不足以提示因果关系；已知与相同类别的其它产品相关的或可基于药 品的性质预期会发生的事件。\n\n根据上述已知信息，请将'Non-clinical safety concerns that have not been observed or resolved in clinical studies;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在临床研究中未发现或未解决的非临床安全性问题；"
    },
    {
        "instruction":"已知信息：\n'CAPA Corrective Action and Preventive Action – System that focuses on investigating, understanding, and correcting discrepancies while attempting to prevent their occurrence'可被翻译为：CAPA 纠正措施和预防措施-用于调查、理解和纠正偏差， 并预防其再次发生的系统。\n'Root cause analysis of procedural, process or equipment failure is performed in such a way that the risk to product is correctly identified and understood so that suitable corrective and preventive actions (CAPA) are implemented.'可被翻译为：对程序、工艺或设备失败进行根本原因分析，正确识别和理解产品风险，从而实施适当的纠正和预防措施（CAPA）\n'Article 252: The manufacturer should establish a corrective actions and preventive actions (CAPA) system, for the investigation of complaints, recalls, deviations, findings of self-inspections or external inspections, process performances and quality monitoring trends, etc, and take corrective actions and preventive actions.'可被翻译为：第二百五十二条 企业应当建立纠正措施和预防措施系统，对投诉、召回、偏差、自检或外部检查结果、工艺性能和质量监测趋势等进行调查并采取纠正和预防措施。\n'CAPA methodology is useful where corrective actions and preventive actions are incorporated into the iterative design and development process.'可被翻译为：将 纠正和预防措施纳入反复的设计和研发过 程时，CAPA方法是有用的。\n\n根据上述已知信息，请将'Prevention mechanisms - trend analysis, detailed investigation, root cause determination, corrective and preventive actions (CAPA) and the need for comprehensive investigational tools.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"预防机制——趋势分析、详细调查、确定根本原因、纠正和预防措施（CAPA）以及对全面调查工具的需求。"
    },
    {
        "instruction":"已知信息：\n'Any therapeutic substances derived from human blood, including whole blood, blood components and plasma-derived medicinal products.'可被翻译为：从人类血液中提取的任何治疗物质，包括全血、血液成分和血浆来源的药品。\n'The liquid part of human blood remaining after separation of the cellular elements from blood collected in a container containing an anticoagulant, or separated by continuous filtration and\/or centrifugation of anticoagulated blood in an apheresis procedure, intended for further manufacturing.'可被翻译为：从含有抗凝剂的容器中收集的血液中分离细胞成分后，或在单采过程中通过抗凝血的连续过滤和\/或离心分离，用于进一步生产的人体血液的液体部分。\n'In laboratory mice, micronuclei can be measured in polychromatic erythrocytes in blood, and mature (normochromatic) erythrocytes can be used when mice are treated continuously for about 4 weeks or more.'可被翻译为：在小鼠上，微核可通过血中的嗜多染红 细胞进行测定，当小鼠连续给药约4周或更长时间时也可采 用成熟红细胞（正染红细胞）进行测定。\n'The collected blood, and its derived plasma or serum, can be used to measure drug concentrations in either liquid or dried form.'可被翻译为：采集的血液及其来源的血浆或血清可在液体或干燥形式下测定药物浓度。\n\n根据上述已知信息，请将'A constituent of blood (erythrocytes, leukocytes, platelets, cryoprecipitate and plasma) that can be prepared by various separation methods and under such conditions that it can be used either directly for therapeutic purposes or for further processing\/manufacturing.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种血液成分(红细胞、白细胞、血小板、低温沉淀和血浆)，可通过各种分离方法制备，并在可直接用于治疗目的或用于进一步加工\/制造的条件下制备。"
    },
    {
        "instruction":"已知信息：\n'A highest dose based on knowledge of probable systemic exposure in the test species and in humans may be an acceptable end-point in testing for carcinogenic potential. Historically, a toxicity end-point1 has been often used to select the top dose level.'可被翻译为：基于受试动物种属和人体可能达到的全身暴露量而确定的最高剂量可以作为潜在致癌性试验可接受的终点。在以往的研究中，经常用毒性终点选择最高剂量。\n'Therefore, a second carcinogenicity study by a route that produces systemic exposure is also generally recommended.'可被翻译为：因此，通常建议通过 产生系统暴露的途径开展第二次致癌性研究。\n'4. Is adequate systemic or local exposure attained in relation to human exposure?'可被翻译为：（4）是否达到了与人体暴露相关的充分的系统暴露或局部暴露？\n'When multiple routes of administration are being evaluated in humans, a single route in the test species can be adequate provided that sufficient systemic exposure is achieved compared to that of all clinical routes and that there is adequate coverage for the metabolites.'可被翻译为：当将 在人体中进行多种给药途径的评估时，如果与所用临床途径相比能达到充足的系 统暴露，并对代谢产物具有足够的覆盖，那么在试验种属中该单一的给药途径可 能是足够的。\n\n根据上述已知信息，请将'The level of animal systemic exposure should be sufficiently great compared to exposure to provide reassurance of an adequate test of carcinogenicity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"动物全身药物暴露量应足够高，以确保充分检测致癌性。"
    },
    {
        "instruction":"已知信息：\n'Inclusion of pharmacogenetic information in the product information and its impact on pharmacovigilance activities will be guided by the overall benefit risk balance in specific genomic subpopulations, magnitude of the genetic \/ genomic biomarker effect and the level of evidence.'可被翻译为：药物信息中是否纳入药物基因组学信息及其对于药物警戒活动的影响将受到特定 基因组亚群总体受益风险情况、基因组学生物标记物影响程度及证据水平的影响。\n'Pharmacogenomics related information should be considered in the product labelling, in case an impact on the benefit-risk balance in a specific genomic subpopulation is identifiable by a genomic BM or set of markers.'可被翻译为：如果特定基因组亚群中的获益-风险平衡的影响可通过基因组学BM或一套标志物识别，应在产品标签中考虑药物基因组学相关信息。\n'to confirm the impact of a genomic BM and optimise benefit-risk balance and risk minimisation measures:'可被翻译为：确认基因组学BM的影响，优化获益风险平衡和风险最小化措施：\n'The impact of the genomic BM findings on labelling guidance will depend on the relevance and importance of the associated clinical consequences.'可被翻译为：基因组学BM结果对标签指导的影响将取决于相关临床后果的相关性和重要性。\n\n根据上述已知信息，请将'Inclusion and positioning of genomic information in the product labelling and therefore impact on clinical use and pharmacovigilance activities will be guided by the overall benefit-risk balance, magnitude of the genomic BM effect in specific genomic subpopulations, and the strength and conclusiveness of evidence.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在产品标签中包含和定位基因组学信息，因此，对临床使用和药物警戒活动的影响将受到总体获益-风险平衡、特定基因组亚群中基因组学BM效应的大小以及证据的强度和决定性指导。"
    },
    {
        "instruction":"已知信息：\n'Reflection Paper on the regulatory guidance for the use of Health-Related Quality of Life (HRQL) measures in the evaluation of medicinal products (CHPM\/EWP\/139391\/04)'可被翻译为：关于新药评价中使用健康相关生活质量（HRQL）量表的监管指导文件的反思（CHPM\/EWP\/139391\/04）\n'More general Health-related quality of life (HRQOL) tools are assessing the patient’s perception of the impact of disease and treatment on daily life, physical, psychological and social functioning and well-being.'可被翻译为：更通用的健康相关生活质量（HRQOL）工具正在评估患者对疾病和治疗对日常生活、身体、心理和社会功能以及健康的影响的看法。\n'Role of pharmacokinetics in the development of medicinal products in the paediatric population (EMEA\/CHMP\/EWP\/147013\/2004\/Corr);'可被翻译为：针对儿童人群的医药产品研发中药代动力学的作用(EMEA\/CHMP\/EWP\/147013\/2004\/Corr);\n'Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population (EMEA\/CHMP\/EWP\/147013\/2004)'可被翻译为：药代动力学在药物的儿科人群开发中的作用指南（EMEA\/CHMP\/EWP\/147013\/2004）；\n\n根据上述已知信息，请将'Reflection Paper on the Regulatory Guidance for the Use of Health-Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products (EMEA\/CHMP\/EWP\/139391\/2004);'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"健康相关的生命质量（HRQoL）测量用于药物评估的法规指南（EMEA\/CHMP\/EWP\/139391\/2004）的读后感；"
    },
    {
        "instruction":"已知信息：\n'ii) Should the toxicity of a metabolite be tested in case it constitutes ≥10% of the initial parent compound concentration in the sediment?'可被翻译为：ii）如果在沉积物中代谢物的含量构成≥10％的初始母体化合物浓度，应检测代 谢物的毒性吗？\n'Yes, results from toxicity tests should be recalculated into standard sediment with an organic carbon content of 10% according to: Please note that the resulting effect concentration from a test is expressed as a dry weight concentration.'可被翻译为：是的，毒性试验的结果应被重新计算为有机碳含量为10%的标准沉积物， 根据公式： 标准沉积物检测标准沉积物 检测请注意，检测得到的效应浓度表示为干重浓度。\n'Thus, if a Koc determined using the HPLC method is within a fac- tor of 2 of the trigger value (10.000 L\/kg) in Tier A and\/or the SimpleTreat model is used in Tier B and\/or calculated sediment risk assessment has been triggered (>10% of substance shifted to sedi- ment at or after 14 days), an indicative value is not acceptable.'可被翻译为：因此，如果使用HPLC方法确定的Koc在A级中的触发值 （10.000L \/ kg）的2倍内，和\/或在B级中使用SimpleTreat模型，和\/或计算的 沉积物风险评价被触发（在14天时或14天之后>10%的物质转移到沉积物）， 则指示值是不可接受的。\n'According to REACH guidance Chapter R.10.5.2.2 (ECHA, 2008), an assessment factor of 100 should be applied to the NOEC from a chronic sediment toxicity test when one chronic sediment test is available.'可被翻译为：根据REACH指南第R.10.5.2.2节（ECHA，2008），当有一个慢性沉积物 检测时，应该对来自慢性沉积物毒性试验的NOEC应用100的评估因子。\n\n根据上述已知信息，请将'(1) the amount of compound (including Non –Extractable Residues = NER) that has shifted to sediment at any time point at or after 14 days – if this is more than 10%, a sediment toxicity test is triggered;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（1）在14天时的任何时间点或者14天之后 转移到沉积物的化合物的量（包括不可提取残渣= NER）- 如果大于10%，则触 发沉积物毒性检测；"
    },
    {
        "instruction":"已知信息：\n'Article 152 The State Food and Drug Administration shall make the review and approval decision within 20 days; where a decision cannot be made within 20 days, another ten days may be extended with the approval of the State Food and Drug Administration head in charge, and the applicant shall be informed of the reason of the time extended.'可被翻译为：第一百五十二条 国家食品药品监督管理局应当在20日内作出审批决定；20日内不能作出决定的，经主管局领导批准，可以延长10日，并应当将延长时限的理由告知申请人。\n'Article 43 The food and drug regulatory department shall make a re-evaluation decision within 30 workdays after accepting the re-evaluation application and inform the applicant. Where the original decision shall be maintained, the food and drug regulatory department shall not accept further application for re-evaluation by the applicant.'可被翻译为：第四十三条 食品药品监督管理部门应当自受理复审申请之日起30个工作日内作出复审决定，并书面通知申请人。维持原决定的，食品药品监督管理部门不再受理申请人再次提出的复审申请。\n'Article 156 If holding any dispute on the unapproval decision made by the State Food and Drug Administration, an applicant may, within 60 days after receiving the decision, fill in the Application Form for Drug Registration Second Review, and submit the application to the State Food and Drug Administration and provide reasons.'可被翻译为：第一百五十六条 申请人对国家食品药品监督管理局作出的不予批准决定有异议的，可以在收到不予批准的通知之日起60日内填写《药品注册复审申请表》，向国家食品药品监督管理局提出复审申请并说明复审理由。\n'Article 158 Where there is any need for technical review in second review, the State Food and Drug Administration shall organize relevant technical personnel to conduct review within the timeline as that for the original application.'可被翻译为：第一百五十八条 复审需要进行技术审查的，国家食品药品监督管理局应当组织有关专业技术人员按照原申请时限进行。\n\n根据上述已知信息，请将'Article 157 The State Food and Drug Administration shall make a second review decision, and notify the applicant the decision within 50 days after receiving an application for second review. Where the original decision is affirmed, the State Food and Drug Administration shall not accept any further application for second review thereof.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百五十七条 国家食品药品监督管理局接到复审申请后，应当在50日内作出复审决定，并通知申请人。维持原决定的，国家食品药品监督管理局不再受理再次的复审申请。"
    },
    {
        "instruction":"已知信息：\n'a: Extrapolated from reported values at 5 mg\/kg (Brouwer): Cmax = ~1.0 µg\/mL from visual inspection of graph, AUC = 4.4 µg∙h\/mL.'可被翻译为：a：从5 mg\/kg的报告值外推得到（Brouwer）：从曲线图目测得到Cmax=~1.0 µg\/mL，AUC=4.4 µg∙h\/mL。\n'Data are also available after a 370 mg\/m2 dose (Bocci): Cmax = 48.41 µg\/mL, AUC = 13.61 µg·h\/mL.'可被翻译为：给药370 mg\/m2后的数 据也可获得（Bocci）：Cmax=48.41 µg\/mL，AUC=13.61 µg·h\/mL。\n'd: Extrapolated to 14.7 mg\/m2 f rom reported value after 30 mg\/m2 methotrexate intravenous single dose (Campbell): Cmax = 4.37 µg\/mL from visual inspection of graph, AUC(0-inf) = 6.69 µg·h\/mL.'可被翻译为：d：单次静脉注射给予甲氨蝶呤30 mg\/m2后报告值外推至14.7 mg\/m2（Campbell）：目测曲线图得Cmax=4.37 µg\/mL，AUC(0-inf)=6.69 µg·h\/mL。\n'a: Actual or extrapolated from reported value after 150 mg\/kg phenytoin oral dose on GD8 in Sprague Dawley rats (Rowland): Cmax = 13.4 µg\/mL, AUC(0-inf) = 205 µg∙h\/mL. PK data are also available on GD17: Cmax = 30.2 µg\/mL, AUC(0-inf) = 906 µg·h\/mL.'可被翻译为：a：Sprague Dawley大鼠于GD8经口给予苯妥英150 mg\/kg后实际值或报告值的外推（Rowland）：Cmax=13.4 µg\/mL，AUC(0-inf)=205 µg∙h\/mL。也可获得 GD17的PK数据：Cmax=30.2 µg\/mL，AUC(0-inf)=906 µg·h\/mL。\n\n根据上述已知信息，请将'Oral data are also available (Campbell): Cmax = 0.50 µg \/mL from visual inspection of graph, AUC(0-inf) = 2.34µg·h\/mL.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"也可获得口 服给药数据（Campbell）：目测曲线图得Cmax=0.50 µg \/mL，AUC(0-inf) = 2.34µg·h\/mL。"
    },
    {
        "instruction":"已知信息：\n'Population pharmacokinetic analysis may be used as a hypothesis-generating tool where the effect of new or unexpected polymorphisms may be indicated (see section 5.1). If relevant information become available during the clinical development program or during pharmacovigilance monitoring, the relative contribution of the metabolism or transport pathway in question to the bioavailability, distribution and\/or metabolism of the medicinal product in vitro and\/or in vivo should be estimated. Further required or recommended pharmacogenetic investigations to be initiated from this point depend conditions as indicated in section 4.1.'可被翻译为：出现新的或非预期的多态性影响时，可能会利用群体药代动力学分析作为产生假设的工具（参见 5.1 节）。如果在临床开发阶段和药物警戒性监测阶段发现了相关的信息，则应对药物体内和体外生物利用度、分布和代谢的关于代谢和转运途径相关的代谢或转运途径的相对作用进行评估。针对遗传药理学研究的进一步要求或建议参见 4.1 节中所述的情况。\n'Population pharmacokinetic analysis may be used as a hypothesis-generating tool w has been identified, this should generally be supported by data on the effect of genotype generated from a conventional pharmacokinetic study, as in such cases a precise estimation of the genotype supportive data indicating that a genotype-based dosing or treatment recommendation apply Phase III has normalised drug exposure in the patient population. The study15\/23 a satisfactory number of patients of each genotype, and enough samples per patient to obtain valid estimates.'可被翻译为：群体药代动力学分析可以用作研究新的或非预期多态性的假设生成工具。如有必要进行基因型依赖性剂量调整，需要有传统药代动力学研究产生的基因型影响数据作为支撑，此时需要对基因型影响进行精确的评价。III期临床试验中关于群体药代动力学分析的零散数据，可以用于支持说明III期研究中所采用的基因型依赖性剂量方案或建议治疗方案已对患者人群中的药物暴露量进行了校正。受试者研究人群应该包含数量充足的各种基因型的患者和足够的生物样本以获取有效的评估数据。\n'If appropriate, the same applies here as described for pharmacokinetic studies. It is acknowledged that in Phase II and III studies, full pharmacokinetic data will not always be available. Still, available pharmacokinetic or population pharmacokinetic data in relation to genotypes should be listed, and standard descriptive statistics for each genetic subpopulation, including mean, standard deviation and range should be provided for the pharmacokinetic parameters.'可被翻译为：对药代动力学研究的原则同样适用于II期和III期研究中不一定能获得完整的药代动力学数据，但应列出与基因型相关的已有药代动力学或群体药代动力学数据，并给出药代动力学参数在各基因亚群中的标准描述性统计数据，包括均值、标准差和范围。\n'In this context it is noticed that also well-planned cohort studies may provide valuable information. Data from elderly patients should be available for pharmacokinetic analyses, e.g. as part of population pharmacokinetic analyses.'可被翻译为：在这种情况下，需要说明的是计划周密的队列研究 也可能提供有价值的信息。 来自老年患者的数据应该是可用于药代动力学分析的，例如作为人群药代动力学分 析的一部分。\n\n根据上述已知信息，请将'Conclusions from a retrospective analysis carried out in response to emerging data may be acceptable for genetic issues related to pharmacokinetics if mechanistically supported by available in vitro or pharmacokinetic information. In this case, DNA should preferably be available from a large proportion of patients in the Phase I, II and III studies. If a new genetic association is discovered in a retrospective analysis, complementary studies, such as in vitro studies or pharmacokinetic studies investigating the mechanism and confirming pharmacokinetic consequences of this finding, will be expected as additional support.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"遗传药理学相关的基因问题，若其机制得到已有的体外或药代动力学信息的支持，则可接受对新产生的数据进行的回顾性分析结论。此种情况下建议从I、II、III期研究较大比例的患者中获取DNA。若在回顾性分析中发现的新的遗传相关性信息，则建议开展补充性研究（例如研究并确证该发现的药代动力学结果的体外或药代动力学研究）提供额外的支持信息。"
    },
    {
        "instruction":"已知信息：\n'Closeness of the agreement between the results of successive measurements of the same measure and under the same conditions of measurement (adapted from ISO).'可被翻译为：在相同的测量条件下，同一测量的连续测量结果之间的一致性(改编自ISO)。\n'measurement uncertainty'可被翻译为：测量的不确定性\n'Uncertainty of the result of a measurement expressed as a standard deviation.'可被翻译为：用标准偏差表示的测量结果的不确定度。\n'Specificity\/selectivity can be verified by demonstrating that the measured result of an analyte is comparable to the measured result of a second, well characterised analytical procedure that ideally applies a different measurement principle.'可被翻译为：专属性\/选择性可通过证明被分析物的测定结果与另一个经充分表征的分析方法测定结果相当来确认，理想情况下该方法应为不同测定原理的方法。\n\n根据上述已知信息，请将'Property of a measurement result whereby the result can be related to a reference through a documented, unbroken chain of calibrations, each contributing to the measurement uncertainty'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"测量结果的特性，即测量结果可以通过记录的、不间断的校准链与参考相关联，每个校准链都对测量不确定度有贡献"
    },
    {
        "instruction":"已知信息：\n'2.3 : QUALITY OVERALL SUMMARY (QOS)'可被翻译为：2.3：质量综述（QOS）\n'The QOS should include sufficient information from each section to provide the Quality reviewer with an overview of Module 3. The QOS should also emphasise critical key parameters of the product and provide, for instance, justification in cases where guidelines were not followed. The QOS should include a discussion of key issues that integrates information from sections in the Quality Module and supporting information from other Modules (e.g. qualification of impurities via toxicological studies discussed under the CTD-S module), including cross-referencing to volume and page number in other Modules.'可被翻译为：质量综述应包括各章节的充分信息，为质量审评员提供模块3的综述。质量综述还应重点强调产品的关键参数，如果存在未遵循指导原则的情况，应提供合理性论证。质量综述还应包括需整合质量模块信息与其他模块信息关键问题的讨论（如，通过CTD- S模块中毒理学研究来确定杂质限度），包括交叉引用其他模块的卷号和页码。\n'THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE: QUALITY QUALITY OVERALL SUMMARY OF MODULE 2 MODULE 3 : QUALITY'可被翻译为：人用药品注册通用技术文档：质量 模块2的质量综述 模块3：质量\n'THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE: QUALITY – M4Q(R1) QUALITY OVERALL SUMMARY OF MODULE 2 MODULE 3 : QUALITY'可被翻译为：人用药品注册通用技术文档： 质量-M4Q（R1） 模块2的质量综述 模块3：质量 （中文翻译公开征求意见稿）\n\n根据上述已知信息，请将'The Quality Overall Summary (QOS) is a summary that follows the scope and the outline of the Body of Data in Module 3. The QOS should not include information, data or justification that was not already included in Module 3 or in other parts of the CTD.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"质量综述（QOS）是对模块3中主体数据的总结。质量综述不应包含未出现在CTD模块3或其他部分的信息或数据。"
    },
    {
        "instruction":"已知信息：\n'The extent of clinical data to be provided has to be judged on a case-by-case basis depending on the anticipated impact of the changes and could vary from a pharmacokinetic trial comparing “pre-change” versus “post-change” product up to the full clinical data set as outlined for a new product.'可被翻译为：所要提供的临床资料的范围，必须根据变更预期产生的影响逐个案例来评估，而且 从比较“变更后”和“变更前”产品的药动学试验数据到概述一个新产品的全面临床数 据可能会有所不同。\n'As more information is obtained during the clinical development, the estimated values of clinical exposures can be refined.'可被翻译为：随着在临床发展过程 中获得的信息越来越多，可对临床暴露量的估计值进行优化。\n'A WoE approach is based on a comprehensive assessment of the totality of data relevant to carcinogenic potential available from public sources and from relevant drug development studies. These factors include, but are not limited to:'可被翻译为：WoE方法是基于对公开来源和相关药物开发研究中获得的与潜在致癌性相关的全部数据的综合评估。这些因素包括但不限于：\n'The robustness evaluation can be submitted as part of development data for an analytical procedure on a case-by-case basis or should be made available upon request.'可被翻译为：耐用性评价可根据具体情况作为分析方法开发数据的一部分提交，或应根据要求提供。\n\n根据上述已知信息，请将'As clinical development progresses, adjustments to the WoE can be made based on all the available data at that time.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"随着临床开发的进展，可以根据当时所有已有资料来调整WoE。"
    },
    {
        "instruction":"已知信息：\n'The active and\/or passive distribution of virus\/vector in the organism.'可被翻译为：病毒\/载体在生物体中的主动及\/或被动分布。\n'The ability of the intended virus\/vector to infect\/transduce, and to replicate in, the chosen animal species\/models.'可被翻译为：预期病毒\/载体感染\/转导以及复制到所选动物物种\/模型的能力。\n'As for any other medicinal products, the effects of co-medications should be investigated on a case by case basis since it can affect infection efficacy of the vector, therapeutic gene expression, biological activity of the expressed proteins and tissue distribution of the vector.'可被翻译为：与其它任何药品联合用药的作用需逐一进行研究， 因为它可能会影响载体的感染效 力、治疗基因的表达、表达蛋白质的生物活性以及载体的组织分布。\n'When selecting the animal 868 model for such vectors, the comparability of the tissue tropism in the selected animal model 869 and human should be discussed and justified.'可被翻译为：为此类载体选择动物模型时，所选动物模型与人类中的组织嗜性 的可比性需要讨论与证明。\n\n根据上述已知信息，请将'The expression and tissue distribution of cellularreceptors for virus\/bacteria in the animal  model that might affect the efficiency of the uptake by the host and the cellular and tissue sequestration of the vector.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"动物模型中病毒\/细菌的细胞受体表达和组织分布，可能会影响宿主摄取的效率以 及载体细胞和组织的隔离。"
    },
    {
        "instruction":"已知信息：\n'For the same reason, it may be more important to study multiple doses of a drug that is significantly more toxic than the other drug in the combination.'可被翻译为：出于相同原因，对联合治疗中毒性 显著高于其他药物的一种药物各种剂量进行研究可能更为重要。\n'In some cases, cumulative dose might be pertinent.'可被翻译为：部分情况下，累积剂量可能比较适宜。\n'c: The dose of 500 mg\/m2 IV bolus was used for comparison although higher doses (e.g., ~1500 mg\/m2\/day CIV) are used.'可被翻译为：c：单次静脉推注给予500 mg\/m2的这个剂量被用于比较，尽管试验中也使用了更高的剂量（例如，~1500 mg\/m2\/天 CIV）。\n'Based on review by Janer, 10 mg\/kg appeared to be the highest dose with no evidence of developmental toxicity.'可被翻译为：基于Janer的综述，10 mg\/kg看起来是最高的未见发育毒性剂量。\n\n根据上述已知信息，请将'Although higher intermittent doses are used for oncology indications, the dose for sickle cell anemia is believed to be more relevant for assessing risk of developmental toxicity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"尽管更高的间歇性给药剂量被用于肿瘤适应症，但认为用于镰状细胞性贫血的剂量与发育毒性风险评估更相关。"
    },
    {
        "instruction":"已知信息：\n'ii. An in vivo assessment of genotoxicity with two different tissues, usually an assay for micronuclei using rodent hematopoietic cells and a second in vivo assay.'可被翻译为：（2）采用两种不同组织进行的体内遗传毒性试验，通 常是一项啮齿类造血细胞微核试验及第二项体内试验。\n'The in vivo lymphocyte assay can be useful in following up indications of clastogenicity, but in general another tissue such as liver is a more informative supplement to the micronucleus assay in hematopoietic cells because exposure to drug and metabolite(s) is often higher in liver.'可被翻译为：体内淋巴细胞试验可用于断裂剂指征的追加，但是，对于造血细胞微核试验，采用其他组织（如肝脏）的试验通常可补充提供更多信息量，因为肝脏中药物和代谢物的暴露通常更高。\n'Some experience is now available for micronucleus induction in the dog and rhesus monkey (Harper et al., 2007; Hotchkiss et al., 2008).'可被翻译为：现已有一些在犬和恒河猴上诱导微核的经验（Harper等， 2007；Hotchkiss等，2008）。\n'Rat blood can be used for micronucleus analysis provided methods are used to ensure analysis of the newly formed reticulocytes (Hayashi et al., 2007; MacGregor et al., 2006), and the sample size is sufficiently large to provide appropriate statistical sensitivity given the lower micronucleus levels in rat blood than in bone marrow (Kissling et al., 2007).'可被翻译为：大鼠血液也可用于微核分析，只要所用方法学可确保能分析新生网织红细胞（Hayashi等,2007；MacGregor等,2006），而且与骨髓相比， 大鼠的血液样本量足够大，可提供合适的统计学灵敏度以确定更低的微核水平（Kissling等，2007）。\n\n根据上述已知信息，请将'6. There is some experience with in vivo assays for micronucleus induction in skin and colon (Hayashi et al., 2007), and DNA damage assays in these tissues can also be an appropriate substitute.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（6）采用皮肤和结肠进行诱导微核的体内试验已有一 些经验（Hayashi等，2007），而且在这些组织中进行DNA 损伤试验也是一种合适的替代方法。"
    },
    {
        "instruction":"已知信息：\n'• CLINICAL PHARMACOLOGY, Pharmacodynamics and Pharmacokinetics: A more detailed discussion of the pharmocodynamic, pharmacokinetic, and pharmacogenomic data summarized in the Pediatric Use subsection should be provided. Relevant pediatric pharmacokinetic and\/or pharmacodynamic study data and dose response information should be included.'可被翻译为：·临床药理学，药效学和药代动力学：应提供儿科用药小节概述的药效学、药代动力学和药物基因组学数据更为详细的讨论。应包括相关的儿科药代动力学和\/或药效学研究数据以及剂量反应信息。\n'In addition, data summarized in the above statement must be discussed in more detail in the appropriate section of labeling. Any significant differences between pediatric and adult responses, a need for specific monitoring, dosing adjustments, and any other information related to the safe and effective use of the drug in pediatric patients must be cited briefly in the Pediatric Use subsection (21 CFR 201.57(c)(9)(iv)(D)(2)), and a more detailed discussion should be included in the appropriate section of 417 labeling.'可被翻译为：另外，上述说明中概述的数据必须在说明书的适当部分进行更为详细的讨论。儿科和成人应答之间任何有意义的差异、特殊监测的需要、剂量调整以及与儿科患者安全和有效使用该药相关的任何其他资料，必须在儿科用药小节简要引述 （21 CFR 201.57（c）（9）（iv）（D）（2）），并且应在说明书的适当部分更为详细地讨论。\n'All data summarized in the Pediatric Use subsection should be discussed in further detail in 297 other labeling sections, as appropriate (21 CFR 201.57(c)(9)(iv)(B)). Appropriate labeling cross-references should be used when pediatric data are summarized in one section of labeling and discussed in more detail in another section of labeling. When a pediatric indication is supported by available data, the pediatric information must be placed in the labeling as required by regulation (21 CFR 201.57(c)(9)(iv)). Recommendations are further described in section III.A., Sufficient Evidence to Support Safety and Effectiveness for a Pediatric Indication.'可被翻译为：儿科用药小节概述的所有数据，当合适时，应在说明书的其他部分进一步详细讨论（21 CFR 201.57（c）（9）（iv）（B））。当儿科数据在说明书某一部分进行概述，在说明书的另一部分进行详细讨论时，应采用适当的交叉参照。当现有数据支持儿科适应症时，根据法规要求说明书中必须有儿科信息（21 CFR 201.57（c）（9）（iv））。更多建议参见第III.A.节“支持儿科适应症安全性和有效性的证据充足”。\n'− When approval for use in a pediatric indication(s) is based on adequate and well- controlled pediatric studies, the following information should be described or summarized briefly:'可被翻译为：− 当用于儿科适应症的批准是基于充分且严格对照的儿科研究时，应简单描述或概述下列信息：\n\n根据上述已知信息，请将'• CLINICAL STUDIES: A more detailed discussion of the pediatric clinical data summarized in the Pediatric Use subsection should be provided.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"·临床研究：应提供儿科用药小节概述的儿科临床数据更为详细的讨论。"
    },
    {
        "instruction":"已知信息：\n'Consequently the large Phase 3 trials often failed to be confirmatory.'可被翻译为：最后大型的III期试验往往未能证实疗效。\n'Another scenario may be where phase 3 trials would be unrealistic to perform against monocomponents, where compelling mechanistic data (e.g. using biomarkers) would suggest an inadequate response to monotherapy.'可被翻译为：另一种方案可能出现在不能对比单药疗法的III期临床试验中，其中引人注目的机理数据（如生物标志物）将提示对单药疗法反应不足。\n'The field of AD research and development witnessed a recent paradigm shift in the diagnostic framework of AD which is now considered a continuum with a long-lasting presymptomatic phase, with evidence of AD neuropathology, which precedes 10-20 years the onset of dementia.'可被翻译为：AD 研发领域见证了 AD 诊断流程的变迁，现在认为 AD 是一个包括长期症状发生前期在内的连续疾病过程，AD 神经病理学证据可出现在痴呆发生前 10-20 年。\n'A primary objective of a phase 2 program should be demonstration of proof of concept of efficacy (i.e., SVR) for DAA-containing regimens that are planned for study in phase 3.'可被翻译为：II期临床试验的主要目的应是证明将要在III期临床试验中计划研究的含 DAA治疗方案的疗效（如SVR）。\n\n根据上述已知信息，请将'Unfortunately the field of AD drug development has witnessed many failures and it is noted that in some cases, exploratory trials did not provide ‘proof of concept’ to inform Phase 3.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"遗憾的是， AD 的药物研发领域遭遇了重重挫折，在一些情况下，探索性试验未能为III期研究提供 “假说验证”的信息。"
    },
    {
        "instruction":"已知信息：\n'D.9.2.r.1b Reported Cause(s) of Death (MedDRA code) User Guidance This data element captures the MedDRA LLT code for the reported cause of death. Conformance Optional, but required if D.9.2.r.1a is populated. Data Type 8N OID 2.16.840.1.113883.6.163 Value Allowed Numeric Business Rule(s)'可被翻译为：D.9.2.r.1b 报告的死因（MedDRA编码） 用户指导原则 该数据元素获取报告的死因的元素MedDRA 低位语代码。 一致性 数据类型 2.16.840.1.113883.6.163 可选，但如果填写了D.9.2.r.1a，则为必填项。 8N OID 允许值 数值 业务规则\n'D.9.4.r.1a MedDRA Version for Autopsy-determined Cause(s) of Death User Guidance This data element captures the MedDRA version for D.9.4.r.1b. Conformance Optional, but required if D.9.4.r.1b is populated. Data Type 4AN OID None Value Allowed Numeric and ‘.‘(dot) Business Rule(s) Only 1 MedDRA version is allowed per ICSR. For MedDRA version 15.1 value allowed is ‘15.1’.'可被翻译为：D.9.4.r.1a 用于尸检确定的死因的MedDRA版本 用户指导原则 一致性 4AN 该数据元素为编码元素D.9.4.r.1b所使用的所使用的MedDRA版本。 可选，但如果填写了D.9.4.r.1b，则为必填项。 数据类型 OID 允许值 无 数值和“.”（点） 业务规则 每个ICSR仅允许1个MedDRA版本。 对于MedDRA版本15.1，容许值为“15.1”。\n'D.10.8.r.6b Indication (MedDRA code) User Guidance This data element captures the MedDRA LLT code for the indication of the medicinal product. Conformance Optional, but required if D.10.8.r.6a is populated. Data Type 8N OID 2.16.840.1.113883.6.163 Value Allowed Numeric Business Rule(s)'可被翻译为：D.10.8.r.6b 适应症（MedDRA编码） 用户指导原则 该数据元素获取药品适应症的MedDRA 低位语代码。 一致性 数据类型 2.16.840.1.113883.6.163 可选，但如果填写了D.10.8.r.6a，则为必填项。 8N OID 允许许值 数值 业务规则\n'D.8.r.6b Indication (MedDRA code) User Guidance This data element captures the MedDRA LLT code for the indication of the medicinal product. Conformance Optional, but required if D.8.r.6a is populated. Data Type 8N OID 2.16.840.1.113883.6.163 Value Allowed Numeric Business Rule(s)'可被翻译为：D.8.r.6b 适应症（MedDRA编码） 用户指导原则 该数据元素获取药品适应症的MedDRA 低位语代码。 一致性 数据类型 2.16.840.1.113883.6.163 可选，但如果填写了D.8.r.6a，则为必填项。 8N OID 允许值 数值 业务规则\n\n根据上述已知信息，请将'D.9.4.r.1b Autopsy-determined Cause(s) of Death (MedDRA code) User Guidance This data element captures the MedDRA LLT code for the autopsy- determined cause of death. Conformance Optional, but required if D.9.4.r.1a is populated. Data Type 8N OID 2.16.840.1.113883.6.163 Value Allowed Numeric Business Rule(s)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"D.9.4.r.1b 尸检-确定的死因（MedDRA编码） 用户指导原则 一致性 该数据元素获取尸检时确定的死因的MedDRA 低位语代码。 可选，但如果填写了D.9.4.r.1a，则为必填项。 数据类型 OID 允许值 8N 2.16.840.1.113883.6.163 数值 业务规则"
    },
    {
        "instruction":"已知信息：\n'If the mechanism of action is well characterized (e.g. conventional NSAIDs or µ agonist opioids) extrapolation of efficacy and safety data from products in the same class is likely to be acceptable on a case by case basis subject to PK \/ PD considerations.'可被翻译为：如果作用机制得到充分表征（例如常规的NSAID或μ受体激动剂阿片类药物），根据PK\/PD考虑因素，在同一类别的产品中有效性和安全性数据的外推可能是可接受的。\n'The extent to which efficacy data can be extrapolated across pain models will depend on the known properties of the drug and others in its class and needs to be considered on a case by case basis.'可被翻译为：在不同疼痛模型中有效性数据可外推的程度将取决于药物和其类别中其他药物的已 知特性，并需要根据具体情况加以考虑。\n'In the case of plasma-derived factor IX products (e.g. manufactured with novel methods) the need for PUP studies will be considered on a case by case basis.'可被翻译为：对于 血浆衍生因子 IX 制品（比如，用新工艺生产的），将逐个情况考虑是否需要 PUP 研 究。\n'In the case of plasma-derived factor VIII products (e.g. manufactured with novel  methods), the need for PUP studies will be considered on a case by case basis.'可被翻译为：对于血浆衍生因子VIII制品（如采用新工艺生产的），根据具体情况考虑是否需要进行PUP研究。\n\n根据上述已知信息，请将'If the mechanism of action is well characterized (e.g. conventional NSAIDs or mu agonist opioids) extrapolation of data from products in the same class can be accepted on a case by case basis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果作用机制得到充分表征（例如常规的NSAID或μ受体激动剂阿片类药物），则可以根据具体情况接受由同一类别的产品的数据推断。"
    },
    {
        "instruction":"已知信息：\n'Therefore, the parameters evaluated by these modalities should correlate with clinically relevant outcomes.'可被翻译为：因此，这 些方法评估的参数应该与临床相关结局关联。\n'During the design of a clinical programme careful attention should be paid to the uniform definition and collection of measurements which will facilitate subsequent interpretation of the series of trials, particularly if they are likely to be combined across trials.'可被翻译为：在设计临床项目中，应认真关 注测量的统一定义和收集，这将有助于随后一系列试验的解 释，特别是如果不同试验之间的测量可能被合并时。\n'3.1.1 Parallel Group Design'可被翻译为：3.1.1 平行组设计\n'At regular intervals'可被翻译为：定期\n\n根据上述已知信息，请将'In consequence clinical outcomes in a parallel group design should be measured at regular intervals to establish a clinically relevant effect.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"因此，在平行组设计中，应定期进行测定从而建立临床相关性的效应。"
    },
    {
        "instruction":"已知信息：\n'Article 12 The term of validity for the Drug Approval License is 5 years. An MAH shall continually ensure the safety, efficacy and quality of the drug during the term of validity and apply for registration renewal 6 months prior to the expiration date.'可被翻译为：第十二条 药品注册证书有效期为五年，药品注册证书有效期内持有人应当持续保证上市药品的安全性、有效性和质量可控性，并在有效期届满前六个月申请药品再注册。\n'Article 125 The State Food and Drug Administration shall deal with import drug re-registration applications, complete the review within six months, and approve the re-registration application if regulations are conformed to, or issue a non-acceptance notice, in which reasons shall be given, if regulations are not conformed to.'可被翻译为：第一百二十五条 进口药品的再注册申请由国家食品药品监督管理局受理，并在6个月内完成审查，符合规定的，予以再注册；不符合规定的，发出不予再注册的通知，并说明理由。\n'Article 19 For a drug patented in China, applicants other than the patentee may submit the application for registration two years prior to the expiry date of the patent. The State Food and Drug Administration shall review the drug application in accordance with the Provisions, and after the expiry date of the patent, check and issue the drug approval number, Import Drug License or a Pharmaceutical Product License if the application conforms with the provisions.'可被翻译为：第十九条 对他人已获得中国专利权的药品，申请人可以在该药品专利期届满前2年内提出注册申请。国家食品药品监督管理局按照本办法予以审查，符合规定的，在专利期满后核发药品批准文号、《进口药品注册证》或者《医药产品注册证》。\n'Where a re-registration application has been rejected, except where the drug approval document is withdrawn due to lawfully defined reasons, the drug approval number, Dug Import License or Pharmaceutical Production Certificate shall be withdrawn on the expiry date.'可被翻译为：对不予再注册的品种，除因法定事由被撤销药品批准证明文件的外，在有效期届满时，注销其药品批准文号、《进口药品注册证》或者《医药产品注册证》。\n\n根据上述已知信息，请将'Article 120 The valid term of a drug approval number, Import Drug License or Pharmaceutical Product License issued by the State Food and Drug Administration is five years. To continue its drug production or importation, the applicant shall submit a re-registration application six months prior to the expiry date.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百二十条 国家食品药品监督管理局核发的药品批准文号、《进口药品注册证》或者《医药产品注册证》的有效期为5年。有效期届满，需要继续生产或者进口的，申请人应当在有效期届满前6个月申请再注册。"
    },
    {
        "instruction":"已知信息：\n'The US EPA (Ref. 9) calculated an oral slope factor of 0.54 \/mg\/kg\/day and a drinking water limit of 0.6 µg\/L at the 1\/100,000 risk level, based on the occurrence of multi-organ tumors in a drinking water study in rats. This drinking water limit equates to a daily dose of ~1 µg\/day for a 50 kg human.'可被翻译为：基于大鼠饮水研究中多器官肿瘤的发生情况，EPA（参考文献9）计算了1\/100,000风险水平下，口服斜率因子为 0.54\/mg\/kg\/天，饮用水限度为0.6μg\/L。这种饮用水限度等同于体重50kg的人1µg\/day的每日剂量。\n'drinking water, potable water'可被翻译为：饮用水\n'Estimates of total dietary intake of vanadium in humans range from 10 to 60 µg\/day.'可被翻译为：人体钒总膳食摄入量预计为10~60 μg\/天。\n'WHO (Ref. 1) reports that the methyl chloride concentration in the air in rural sites is in general below 2.1 µg\/m3 (1.0 ppb) while in urban cities it is equal to 0.27 to 35 µg\/m3 (0.13- 17 ppb), corresponding to approximately 20-700 µg daily intake (human respiratory volume of 20 m3 per day). A wide range of concentrations is reported in rivers, ocean water, ground water and drinking water, with the maximum drinking water level reported at 44 µg\/L in a well sample (Ref. 1).'可被翻译为：WHO（参考文献）报道农村地区空气中甲基氯的浓度一般低于2.1μg\/m3 (1.0 ppb)，而在城市为0.27至35μg\/m3(0.13- 17ppb)，相当于每天约20-700μg的摄入量（人类呼吸量为每天20m3）。据报道，河流、海洋、地下水和饮用水的浓度范围较宽，健康的饮用水最高浓度为44µg\/L。\n\n根据上述已知信息，请将'Intake from drinking water depends on the water source and estimates are up to 140 µg\/day.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"从饮用水摄入的量取决于水源，预计可达140 μg\/天。"
    },
    {
        "instruction":"已知信息：\n'These investigations should include electrocardiography and continuous ambulatory monitoring which may require to be supplemented by some electrophysiological studies.'可被翻译为：此类研究应包括心电图和持续动态监测，且可能需要由某些电生理学检查进行补充。\n'AF has to be documented on two separate occasions by ECG evidence, Holter monitoring, pacemaker or cardiac defibrillator read outs.'可被翻译为：房颤必须由两次分开的心电图证据、Holter监控、起搏器或心脏除 颤器读数证明。\n'This includes robust, high-quality electrocardiogram (ECG) recording and analysis sufficient to support a valid assay for ECG intervals (see ICH E14 and Q&A #1).'可被翻译为：这包括可靠、高质量的心电图（ECG）记录 和分析，足够支持 ECG 间期的有效测定（参见 E14 和问与答#1）。\n'ECG collection at around Tmax is not important for drugs with low fluctuations between peak and trough concentrations.'可被翻译为：对于峰谷浓度之间波动较小的药物，在Tmax前后 采集ECG并不重要。\n\n根据上述已知信息，请将'Additional ECG assessment over and above what is recommended earlier in the Q&A might also be called for (e.g., 24 hour ECG recording, telemetry, multiple trough ECGs through steady state).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"除Q&A中早期推荐的评估外，还可能需要进行额外的 ECG评估（例如 24 小时心电图记录、遥测、稳态时多次谷浓度下 的心电图评估）。"
    },
    {
        "instruction":"已知信息：\n'The duration of therapy should reflect the range that was documented to be effective in each indication.'可被翻译为：. 治疗的持续时间应反映出证明对每个适应症都有效的范围。\n'After completion of treatment, viral RNA should be measured at weeks 4, 12, and 24 of follow up.'可被翻译为：在完成治疗之后，应在随访的第4、12和24周测量病毒RNA。\n'In the three ongoing Phase III 12-week studies, patients now have LFTs measured at 1, 2, 4, 8 and 12 weeks, and 2 weeks post-dosing.'可被翻译为：在3项进行中的、为 期12周的III期研究中，患者在第1、2、4、8和12周以及给药后2周 检测LFT。\n'In ongoing studies 202 and 204, serum creatinine, eGFR, blood urea nitrogen, and urinalysis continue to be monitored at baseline, Weeks 1, 2, 4, 12, 24, and 48.'可被翻译为：正 在进行的202和204研究中，继续在基线和第1、2、4、12、24、 48周监测血肌酐、eGFR、血尿素氮和尿液分析。\n\n根据上述已知信息，请将'Key on-treatment measurements can include weeks 1, 2, 4, 8, 12, and 24, or at the end of therapy.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于 peg-IFN\/RBV加一种DAA治疗方案，治疗过程中的关键测量值可能包括第1、2、 4、8、12和24周或治疗结束时。"
    },
    {
        "instruction":"已知信息：\n'Pharmacogenetics (PGt) is a subset of pharmacogenomics (PGx) and is defined as: The study of variations in DNA sequence as related to drug response.'可被翻译为：遗传药理学（PGt）是药物基因组学（PGx）的分支，被 定义为: 对药物反应相关的DNA序列变化的研究。\n'Pharmacogenetics (a subset of pharmacogenomics (PGx)): the study of variations in DNA sequence as related to drug response (ICH15).'可被翻译为：药物遗传学（药物基因组学（PGx）的子集）：研究DNA序列中与药物反应相关的变异（ICH15）。\n'Pharmacogenomics: the study of variations of DNA and RNA characteristics as related to drug response (ICH15).'可被翻译为：药物基因组学：与药物反应相关的DNA和RNA特征的差异的研究（ICH15）。\n'CIOMs VII (2005): Pharmacogenetics is defined as the study of inter individual variations in DNA sequence related to drug disposition (pharmacokinetics) or drug action (pharmacodynamics) that can influence clinical response.'可被翻译为：CIOMs VII（2005）：药物遗传学的定义为能够影响临 床反应的、与药物处置（药代动力学）或药物作用（药效学）相关的DNA序列中的个体间差异的研究。\n\n根据上述已知信息，请将'Pharmacogenomics (PGx) is defined as: The study of variations of DNA and RNA characteristics as related to drug response.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物基因组学（PGx）被定义为： 对药物反应相关的DNA和RNA特征变化的研究。"
    },
    {
        "instruction":"已知信息：\n'Article 20 Clinical evaluation of medical devices refers to the process that the applicant or filing entity validates whether the products under registration can meet their intended use and indications based on the information of clinical literature, clinical experience data and clinical trials.'可被翻译为：第二十条 医疗器械临床评价是指申请人或者备案人通过临床文献资料、临床经验数据、临床试验等信息对产品是否满足使用要求或者适用范围进行确认的过程。\n'Article 4 In-vitro diagnostic reagent registration refers to the prescribed procedures conducted by the food and drug regulatory department upon an application submitted by the registration applicant to decide whether the medical device to be marketed can be sold based on a comprehensive evaluation of the research and results of its safety and effectiveness.'可被翻译为：第四条 体外诊断试剂注册是食品药品监督管理部门根据注册申请人的申请，依照法定程序，对其拟上市体外诊断试剂的安全性、有效性研究及其结果进行系统评价，以决定是否同意其申请的过程。\n'For the clinical trial of in-vitro diagnostic reagents are not required, the applicant shall evaluate the clinical performance of in-vitro diagnostic reagents through non-clinical trial methods such as evaluation on the clinical samples covering intended use and interference factors as well as comprehensive literatures. The applicant or filing entity shall ensure that the clinical samples for evaluation are traceable.'可被翻译为：无需进行临床试验的体外诊断试剂，申请人或者备案人应当通过对涵盖预期用途及干扰因素的临床样本的评估、综合文献资料等非临床试验的方式对体外诊断试剂的临床性能进行评价。申请人或者备案人应当保证评价所用的临床样本具有可追溯性。\n'The clinical trial of in-vitro diagnostic reagents (including the comparative study made with the marketed products) refers to the systematic study on the clinical performance of in-vitro diagnostic reagents in the corresponding clinical environment.'可被翻译为：体外诊断试剂临床试验（包括与已上市产品进行的比较研究试验）是指在相应的临床环境中，对体外诊断试剂的临床性能进行的系统性研究。\n\n根据上述已知信息，请将'Article 28 Clinical evaluation of in-vitro diagnostic reagents refers to the process that the applicant or filing entity validates whether the products under registration can meet their intended use and indications based on the information of clinical literature, clinical experience data and clinical trials.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十八条 体外诊断试剂临床评价是指申请人或者备案人通过临床文献资料、临床经验数据、临床试验等信息对产品是否满足使用要求或者预期用途进行确认的过程。"
    },
    {
        "instruction":"已知信息：\n'For example complete pain relief might be a reasonable treatment objective for headache, whereas a 30 or 50 percent reduction in pain intensity compared to baseline might be appropriate in other pain conditions. Patients who discontinue the trial prematurely or who require more than a pre-specified amount of rescue medication should generally be defined as non-responders.'可被翻译为：例如，完全疼痛缓解可能是头痛的合理治疗目标，而与基线相比疼痛强度降低30％或50％可能适合于其他疼痛病症。提前退出试验或需要超过预先规定量的抢救药物的患者通常应定义为无反应者。\n'The endpoint refers to an indicator used to assess the clinical trial hypothesis.'可被翻译为：终点，是指用于评估临床试验假设的指标。\n'Assessment of Rescue Medication Use If rescue medications are allowed during the trial, the protocol should document how rescue medication use will be analyzed in the different treatment groups.'可被翻译为：抢救药物使用评估 如果允许抢救药物在试验中使用，那么在试验草案中应说明抢救药物的使用在不 同治疗组中如何分析。\n'If rescue medications are allowed during the trial, the trial protocol should document how rescue medication use will be analyzed in the different treatment groups.'可被翻译为：如果允许抢救药物在试验中使用，那么在试验草案中应说明抢救药物的使用在不同治疗组中如何分析。\n\n根据上述已知信息，请将'Need for rescue medication as indicator of treatment failure may be defined as a trial endpoint in some study designs (e.g. dose requirement, time to rescue or time to non-trial analgesia as appropriate).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"作为治疗失败指示的抢救药物需要可定义为一些研究设计中的试验终点（例如剂量需求、抢救 时间或至非试验镇痛时间，视情况而定）。"
    },
    {
        "instruction":"已知信息：\n'3. Section C: Identification of the Case Safety Report'可被翻译为：3. 第C节：病例安全性报告的鉴别\n'C.1 IDENTIFICATION OF THE CASE SAFETY REPORT'可被翻译为：C.1 安全性报告的识别\n'Individual Case Safety Report.'可被翻译为：个例安全性报告。\n'The following notation will be used to represent C.1.1: <id extension=\"country code-company name-report no\" root=\" 2.16.840.1.113883.3.989.2.1.3.1 \"\/> The following notation will be used to represent C.1.8: <id extension=\"country code-company name-report no\" root=\" 2.16.840.1.113883.3.989.2.1.3.2\"\/> Although the attribute <id> can repeat in the message, but there must be a single instance of the <id> attribute with the root value of ‘2.16.840.1.113883.3.989.2.1.3.2 ‘ for a particular case safety report.'可被翻译为：使用以下符号表示C.1.1： 使用以下符号表示C.1.8： 尽管属性 可以在信息中重复，但是对于特定安全性报告但是对于特定安全性报告，必须有一个 属性的单个实例，其根值为 “2.16.840.1.113883.3.989.2.1.3.2”。\n\n根据上述已知信息，请将'This section corresponds to the root of the case safety report.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"本节对应于安全性报告的根源。"
    },
    {
        "instruction":"已知信息：\n'MAXIMUM FEASIBLE DOSE (MFD) ENDPOINT'可被翻译为：最大可行剂量（MFD）终点\n'Maximum Feasible Dose'可被翻译为：最大可行剂量\n'Maximum Feasible Dose (MFD)'可被翻译为：最大可行剂量（MFD）\n'MFD: Maximum Feasible Dose'可被翻译为：MFD: 最大可行剂量\n\n根据上述已知信息，请将'All regions have used a maximum feasible dose as an appropriate endpoint.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"各 方均以最大可行剂量作为合适的终点。"
    },
    {
        "instruction":"已知信息：\n'The guideline can be used by sponsors to develop a stand-alone document for regions that prefer this approach or to provide guidance on incorporation of elements of the Safety Specification and Pharmacovigilance Plan into the Common Technical Document (CTD).'可被翻译为：本指导原则可被用于指导申办方撰写一份独立的文件（针对有相应法规的地区），或指导申办方将安全性说明和药物警戒计划的要素整合到通用技术文档（CTD）中。\n'It can be a stand-alone document but elements could also be incorporated into the CTD.'可被翻译为：可以将药物警戒计划撰写成一个 独立文件，也可以将其要素整合到 CTD中。\n'A Safety Specification and Pharmacovigilance Plan can also be developed for products already on the market (e.g., new indication or major new safety concern).'可被翻译为：对一个已经上市的产品（如，增加新适应症或出现新的重大安全性问题）也可以制订安全性说明和药物警戒 计划。\n'This is important if the Pharmacovigilance Plan is a separate document from the Safety Specification.'可被翻译为：如果药物警戒计划与安全性说明是分开的独立文件，这个 摘要非常重要。\n\n根据上述已知信息，请将'The Safety Specification can be a stand-alone document, usually in conjunction with the Pharmacovigilance Plan, but elements can also be incorporated into the CTD.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"安全性说明可以是一个与 药物警戒计划关联的独立文件，也可以将其要素结合到 CTD中。"
    },
    {
        "instruction":"已知信息：\n'When the in vivo genotoxicity test is integrated into a multiple administration toxicology study, the doses are generally considered appropriate when the toxicology study meets the criteria for an adequate study to support human clinical trials; this can differ from dose selection criteria in the OECD guideline for the in vivo micronucleus assay.'可被翻译为：当体内遗传毒性试验整合在重复给药毒性试验中时，若该重复给药毒性试验符合支持进行人体临床试验的一个充分试验的标准，则通常认为对于遗传毒性评价剂量是合适的；这与OECD指导原则关于体内微核试验的剂量选择标准有差异。\n'In conclusion, the assessment of the genotoxic potential of a compound should take into account the totality of the findings and acknowledge the intrinsic values and limitations of both in vitro and in vivo tests.'可被翻译为：总之，化合物遗传毒性潜力的评价应综合考虑所有结果，并承认体外和体内试验具有各自的内在价值和局限性。\n'Due to the narrow assay range in many LBAs, study samples may require dilution in order to achieve analyte concentrations within the range of the assay. Dilution linearity should be assessed to confirm: (i) that measured concentrations are not affected by dilution within the calibration range and (ii) that sample concentrations above the ULOQ of a calibration curve are not impacted by hook effect (i.e., a signal suppression caused by high concentrations of the analyte), whereby yielding an erroneous result.'可被翻译为：由于很多LBA的分析范围狭窄，因此研究样品的浓度可能需要稀释后才能处于定量范围内。对稀释线性进行评估，以确定：（i）测量浓度在校准曲线范围内不受稀释的影响，以及（ii）高于校准曲线ULOQ的样品浓度的准确性不受钩状效应（即由高浓度待测物引起的信号抑制）的影响，以免产生错误的结果。\n'c. Drug tolerance of the assay at therapeutic concentrations'可被翻译为：c. 在治疗浓度下检测法对药物的耐受性\n\n根据上述已知信息，请将'To obtain an appropriate toxicity range, a preliminary range-finding assay over a broad range of concentrations is useful, but in the genotoxicity assay it is often critical to use multiple concentrations that are spaced quite closely (less than two fold dilutions). Extra concentrations can be tested but not all concentrations need be evaluated for genotoxicity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为获得合适的毒性范围，在一个较宽的浓度范围内进行初步的范围探索试验是有益的，但是，在遗传毒性试验中，采用剂距非常接近（低于两倍稀释度）的多个浓度进行试验，通常是非常关键的。可对更多、额外的浓度进行试验，但是不必对所有浓度都进行遗传毒性评价。"
    },
    {
        "instruction":"已知信息：\n'If the sponsor submits a protocol for a single-arm trial for an SPA, the sponsor should justify why a concurrently controlled trial is not feasible or cannot be conducted ethically.'可被翻译为：如果申办方请求SPA递 交的是单组试验的方案，申办方应证明为什么同时进行的对照试验不可 行或不能以伦理方式进行。\n'A trial design that is suitable for one estimand might not be suitable for other estimands of potential importance.'可被翻译为：一种适用 于某个估计目标的试验设计，不一定适用于其他具有潜在重要性 的估计目标。\n'i) If the antibacterial spectrum and pharmacokinetics of the test agent permit, the sponsor may choose to conduct at least one randomised and active¬ controlled study in a specific type of infection.'可被翻译为：1）如果试验药物的抗菌谱和药代动力学允许，申办方可以选择进行至少一项针对特定感染类型的随机、活性对照研究。\n'Similar clinical efficacy between the biosimilar and reference medicinal product should be demonstrated in an adequately powered, randomised, parallel group, equivalence clinical trial, preferably double-blind.'可被翻译为：生物类似物和参比药品之间相似的临床有效性应通过充分有力的、随机、平行、等 效性临床研究证明，最好是双盲研究。\n\n根据上述已知信息，请将'There may be instances in which the sponsor considers that it is not feasible to conduct at least one adequately powered randomised and controlled clinical trial to support an indication.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"可能在某些情况下申办方认为执行至少一项有充分把握度的随机、对照临床 试验来支持某个适应症是行不通的。"
    },
    {
        "instruction":"已知信息：\n'For the drugs marketed overseas but not marketed in China, full evaluation should be performed for the clinical study data of the originator drugs according to the basic logic of clinical evaluation and in combination with the actual situation of the drugs, and the clinical trial requirements should be determined according to the evaluation results. For drugs with different R & D backgrounds, the clinical trials required to be carried out should be determined case by case.'可被翻译为：对于境外已上市境内未上市的药品，需结合药品具体情况，按照临床评价的基本逻辑对原研药品的临床研究数据进行充分评价，根据评价结果确定临床试验要求。对于不同研发背景的药品，其所需开展的临床试验应具体问题具体分析。\n'For adding new dosage form (with clinical advantage), new administration route, new usage and dosage approved overseas but not in China for approved indications of drugs marketed in China, and each domestically marketed single drug in a new compound drug marketed overseas but not marketed in China, when the following conditions are met simultaneously, reduction or exemption of clinical trials can be considered according to the evaluation of overseas clinical trial data : ①Data of completed clinical trials of marketed originator drugs indicates that benefits of the drug for Chinese patients outweigh the risks, and there is no significant impact of racial factors compared with data in foreign populations; ②The overseas clinical trial data of new dosage form, new administration route, new usage and dosage or new compound of the drug can be used to fully evaluate its safety and effectiveness.'可被翻译为：对于境内已上市药品增加境外已批准境内未批准的新剂型（有临床优势的）、新给药途径、新用法用量，用于境内已上市药品已批准适应症的情形，以及境外已上市境内未上市新复方药品中各单药均已在境内上市的情形，在同时满足以下条件时，可考虑基于境外临床试验数据评价情况，减或免临床试验：①已上市原研药品完成的临床试验数据显示，该药品用于中国患者的获益大于风险，且与境外人群数据相比未见明显种族因素的影响；②递交的该药物新剂型、新给药途径、新用法用量，或新复方的境外临床试验数据可用于充分评价其安全性和有效性。\n'In the absence of the study and data related to the impact of racial factors in global data, necessary PK, and\/or PD, effectiveness and safety studies should be conducted to support the marketing application of the drug.'可被翻译为：全球数据缺乏种族因素影响相关研究和数据的，应开展必要的PK，和\/或PD，有效性和安全性研究，以支持该药品上市申请。\n'Global data indicated that racial factors had impacts on evaluation of safety and effectiveness, and necessary clinical trials(including dosage exploration) should be conducted to support marketing application of the drug.'可被翻译为：全球数据显示种族因素对安全有效性评价存在影响的，应开展必要的临床试验（包括剂量探索等），以支持该药品的上市申请。\n\n根据上述已知信息，请将'For drugs with no relevant data of Chinese population in the global data, but there is relatively sufficient racial factor related study and analysis data and no significant impact of racial factors is identified, the analysis should be conducted on a case-by case basis: (1) For a drug used for serious or life-threatening diseases and rare diseases for which there is no effective therapeutic means, or a drug with significantly improved effectiveness or safety and other advantages over existing therapeutic means when being used for such diseases, the approval for marketing can be considered on the premise of strict risk control, and post-marketing effectiveness and safety clinical trial should be conducted to support the whole life cycle benefit\/risk evaluation of the drug. (2) For a drug without significant clinical advantages over existing therapeutic means, the clinical trial should be conducted with reference to the requirements of Section \"V (I) 2\".'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于全球数据中没有中国人群相关数据，但有较充分的种族因素相关研究和分析数据且未见明显种族因素影响的药品，应具体问题具体分析：（1）用于严重或危及生命疾病、罕见病且无有效治疗手段的药品，或用于此类疾病且较现有治疗手段具有明显提高疗效或安全性等优势的药品，可考虑在严格风险控制的前提下批准上市，并应开展上市后有效性和安全性临床试验以支持药品全生命周期获益\/风险评估。（2）对于较现有治疗手段未见明显临床优势的药品，应参考“五（一）2”项相关要求进行临床试验。"
    },
    {
        "instruction":"已知信息：\n'Examples of such studies are - Rhabdosphincter volume - Rhabdosphincter thickening - Rhabdosphincter contractility - Integration of the newly formed tissue into surrounding muscle tissue'可被翻译为：这种研究的例子是 -杆状括约肌大小 -杆状括约肌增厚 -杆状括约肌收缩 -将新形成的组织汇合到周围的肌肉组织\n'In addition, some guidance is given on drugs for symptomatic treatment of muscle strength.'可被翻译为：此外，提供了关于肌力对症治疗药物的一些指导。\n'For treatments whose mechanisms of action are expected to improve symptoms of ALS but would not have a beneficial effect on disease progression, trials should aim to demonstrate a beneficial effect on both symptoms (muscle strength) and functioning.'可被翻译为：如果治疗的作用机制支持它们可能会改善ALS的症状但将不会对疾病进展产生有 益作用的预期，试验应旨在证明对症状（肌力）和功能的有益作用。\n'The effect of biopharmaceuticals on EFD should typically be assessed in two species (one rodent and one non-rodent) if both are pharmacologically relevant.'可被翻译为：生物制品对EFD的影响通常应在两种动物种属中（一种啮齿类动物和一种 非啮齿类动物）进行评估，如果这两种种属都是药理学相关种属。\n\n根据上述已知信息，请将'If bulking effect is one of the aims, it should be separated from the regeneration of the muscle tissue and both of these effects should be followed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果膨胀效应是目标之一，应将其从再生的肌肉组织分离，跟进这两种效应。"
    },
    {
        "instruction":"已知信息：\n'Appropriate negative controls should be run concurrently with the sample.'可被翻译为：应同时进行适当的空白控制。\n'Assays should include appropriate controls to ensure adequate sensitivity and specificity.'可被翻译为：应设相应的对照试验，以确保试验具有充分的敏感性和特异性。\n'Negative Controls'可被翻译为：阴性控制\n'These tests are sufficiently well characterized and have sufficient internal controls that repetition of a clearly positive or negative assay is not usually warranted.'可被翻译为：这些试验都经过充分验证且具有充分的内部控制，对明确的阳性或阴性结果试验通常不需要重复。\n\n根据上述已知信息，请将'Negative controls are needed to establish assay baselines and characterize\/validate the assays.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"需要阴性对照来确立检测基线，并且表征\/验证检测方法。"
    },
    {
        "instruction":"已知信息：\n'(5) other circumstances where administrative licensing shall be canceled as stipulated by laws and regulations.'可被翻译为：（五）法律、法规规定应当注销行政许可的其他情形。\n'(4) Cosmetics Manufacturing License is withdrawn or canceled according to law, or the license for production of cosmetics is revoked according to law;'可被翻译为：（四）化妆品生产许可依法被撤回、撤销或者化妆品生产许可证依法被吊销的；\n'(5) Other circumstances where registration renewal shall be disapproved as per laws and administrative regulations.'可被翻译为：（五）法律、行政法规规定的其他不予再注册情形。\n'(8) Other circumstances where the Drug Approval License shall be cancelled according to law.'可被翻译为：（八）其他依法应当注销药品注册证书的情形。\n\n根据上述已知信息，请将'(5) Other circumstances where the cosmetics manufacturing license shall be cancelled as prescribed by laws and regulations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）法律法规规定应当注销化妆品生产许可的其他情形。"
    },
    {
        "instruction":"已知信息：\n'A set of individual animals within a dose group that are assigned to the same endpoint.'可被翻译为：在同一剂量组中被分配至相同 终点指 标的个体动物集合。增强的围产期发育毒性试验 （Enhanced Pre - and Postnatal Development\n'3.9 Allocation of Animals to Study Groups and Endpoint Subsets'可被翻译为：3.9 试验组和终点指标亚组的动物分配\n'The third set of 10 pups\/sex\/dose group (M3\/F3 green lines) could also be assigned to the CNS subset to achieve a total of 16 pups\/sex\/dose group.'可被翻译为：第三列10只幼仔\/性别\/剂量组（绿线的M3\/F3）也可被分配至CNS亚组，以达到总共16只幼仔\/性别\/剂量组。\n'When assigning individual animals to endpoints in definitive studies, it is recommended that litter mates of the same sex not be assigned to the same endpoint to avoid maternal care biases (see Appendix C).'可被翻译为：在确定性试验中，当将个体动物分配至终点指标组时，为了避免母体护理偏差，建议不要将同性别的同窝幼仔分配至同一终点指标组（参见附录C）。\n\n根据上述已知信息，请将'Endpoint Subset: A set of individual animals within a dose group that are assigned to the same endpoint.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"终点指标亚组（Endpoint Subset）：在同一剂量组中被分配至相同终点指标的个体动物集合。"
    },
    {
        "instruction":"已知信息：\n'L. Quick Response Code A Quick Response Code (QR code) is a type of matrix bar code (or two-dimensional bar code) that can be read by a mobile phone.'可被翻译为：L. 快速响应码 快速响应码（QR码）是一种矩阵条码（或二维码），可以通过手机阅读。\n'The most appropriate data element should be used in order to indicate the source of the number and facilitate record retrieval when possible and desirable.'可被翻译为：应使用最合适的数据元素来表明编号来源元素，并在可能和可取的情况下帮助记录检索。\n'For questions on the content of this guidance, contact OCOD at the phone numbers or email address listed above.'可被翻译为：与该指导原则的内容相关的问题，请拨打电话或按上述地址发送电子邮件， 与OCOD联系。\n'17 The address for the Office of Generic Drugs is available at http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ucm119100.htm. The phone and fax numbers (for fatal or life-threatening adverse event reports) are also available at this site.'可被翻译为：17仿制药办公室的地址可以获得如下。我们推荐通过电话、电子邮件或传真进行 7 天通知。如果完成 7 个日历日提交的安全报告，就不需要进行从 0 天算 15 天内的额外提交。http:\/\/www.fda.gov\/AboutFDA\/CentersOffices-\/OfficeofMedicalProductsandTobacco\/CDER\/ucm119100.htm。电话和传真号码（对于死亡或危及生命的不良事件报告）也可以在这个地址获得。\n\n根据上述已知信息，请将'QR codes may provide various bits of information (e.g., Internet address, phone numbers).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"QR 码可以提供各种各样的信息（例如，互联网地址，电话号码）。"
    },
    {
        "instruction":"已知信息：\n'For genotoxic drugs targeting rapidly dividing cells (e.g., nucleoside analogs, alkylating agents, microtubule inhibitors) that have anti-proliferative effects (evident in rapidly growing tissues) and are expected to be consistent across different species, toxicity studies in one rodent species of 3-month duration are considered sufficient for continued clinical development and registration.'可被翻译为：对于具有抗增殖作用（在快速生长组织中很明显）且预期在不同种属间具有一致性的靶向快速分裂细胞的遗传毒性 药物（例如，核苷类似物，烷化剂，微管抑制剂），在一种 啮齿动物中的3个月毒性试验足以支持后续临床开发和注 册。\n'3.4 Duration of Toxicology Studies to Support Continued Clinical Development and Marketing'可被翻译为：3.4 支持后续临床试验和上市的毒理学研究期限\n'These studies are also not considered essential for the purpose of marketing applications for pharmaceuticals that are genotoxic and target rapidly dividing cells (e.g., crypt cells, bone marrow) in general toxicity studies or belong to a class that has been well characterized as causing developmental toxicity.'可被翻译为：对于那些有遗传毒性且在一般毒理学试验中靶向快速分裂细胞（如crypt细胞、骨髓）的药物，或者归属于确定可引起发育毒性的药物类别，这些发育毒性试验在上市时也不是必需的。\n'In certain circumstances, determined case-by-case, alternative approaches can be appropriate (e.g., for genotoxic drugs targeting rapidly dividing cells, a repeat- dose toxicity study in one rodent species might be considered sufficient, provided the rodent is a relevant species).'可被翻译为：根据具体问题具体分析的原则，在某些情况下，采用替代试验方法也是合适的（如靶向快速分裂细胞的遗传毒性药物，如果啮齿类动物是相关动物种属，则在一种啮齿类动物种属开展重复给药毒性试验可能认为是足够的）。\n\n根据上述已知信息，请将'3.4 What general toxicology studies are recommended for continued clinical development, including marketing, for genotoxic drugs targeting rapidly dividing cells?'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3.4 对于靶向快速分裂细胞的遗传毒性药物，推荐何种一般毒理学研究以支持后续的临床开发，包括上市？"
    },
    {
        "instruction":"已知信息：\n'Include a test for the impurity in the specification for a raw material, starting material or intermediate, or as an in-process control, with an acceptance criterion above the acceptable limit of the impurity in the drug substance, using an appropriate analytical procedure coupled with demonstrated understanding of fate and purge and associated process controls that assure the level in the drug substance is below the acceptable limit without the need for any additional testing later in the process.'可被翻译为：在原料、起始物料或中间体的质量标准中对杂质进行检测，或进行过程控制，制订一个高于原料药中该杂质可接受限度的标准，使用合适的分析方法并结合对杂质去向和清除的认知，及相关的工艺控制，保证原料药中的杂质的水平低于可接受限度而无需在后续工艺中再行检测。\n'Include a test for the impurity in the specification for a raw material, starting material or intermediate, or as an in-process control, with an acceptance criterion at or below the acceptable limit using an appropriate analytical procedure.'可被翻译为：在原料、起始物或中间体的质量标准中包含杂质检查项，或作为过程控制项，采用合适的分析方法将杂质控制在可接受限度以内。\n'Option 2 Include a test for the impurity in the specification for a raw material, starting material or intermediate, or as an in-process control, with an acceptance criterion at or below the acceptable limit using an appropriate analytical procedure.'可被翻译为：方法2 在原料、起始物料或中间体的质量标准中包含对杂质的检测，或作为过程控 制，使用合适的分析规程将可接受标准设定在可接受限度以内。\n'8.1 Control of Process Related Impurities There are 4 potential approaches to development of a control strategy for drug substance: Option 1 Include a test for the impurity in the drug substance specification with an acceptance criterion at or below the acceptable limit using an appropriate analytical procedure.'可被翻译为：工艺相关杂质的控制（8.1） 开发原料药控制策略有 4 种可能的方法：方法1 在原料药质量标准中包含对杂质的检测，使用合适的分析规程将可接受标准 设定在可接受限度以内。\n\n根据上述已知信息，请将'Include a test for the impurity in the drug substance specification with an acceptance criterion at or below the acceptable limit using an appropriate analytical procedure.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"原料药质量标准中包含杂质检查项，采用合适的分析方法将杂质控制在可接受限度以内。"
    },
    {
        "instruction":"已知信息：\n'Article 210: Special care should be taken when using cut-labels and when over-printing is carried out off-line, to avoid mixups.'可被翻译为：第二百一十条 使用切割式标签或在包装线以外单独打印 标签，应当采取专门措施，防止混淆。\n'If it is not the case, appropriate operation procedures should be applied to ensure that no mixups or mislabeling can occur.'可被翻译为：未能及时贴签时，应当按照相关的操作规程操作，避免发生混淆或贴错标 签等差错。\n'Care should be taken when interpreting putative statistically significant findings when there is no multiplicity adjustment.'可被翻译为：如果未做多重 性调整，应谨慎解释常规的统计显著性。\n'Article 72 When a public health emergency breaks out, special review and approval for corresponding therapeutic and prophylactic drugs may be carried out based on the decision of NMPA in accordance with the law.'可被翻译为：第七十二条 在发生突发公共卫生事件的威胁时以及突发公共卫生事件发生后，国家药品监督管理局可以依法决定对突发公共卫生事件应急所需防治药品实行特别审批。\n\n根据上述已知信息，请将'Article 210 Special care should be taken when using cut-labels and when over-printing is carried out off-line, to avoid mixups.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二百一十条 使用切割式标签或在包装线以外单独打印标签，应当采取专门措施，防止混淆。"
    },
    {
        "instruction":"已知信息：\n'ICH Q7 does not expect the use of a consultant.'可被翻译为：ICH Q7并未期望企业聘用顾问。\n'ICH Q7 does not apply to Steps prior to the introduction of the API starting material.'可被翻译为：ICH Q7不适用于原料药起始物料之前的步骤。\n'[ICH Q7, Section 2.3] does not specify who is responsible for the issuance of batch production records [ICH Q7, Section 6.5] as long as the issuance process is described in writing and approved by the quality unit [ICH Q7, Section 2.21].'可被翻译为：【ICHQ7，第2.3章节】没有指明应由谁来负责发放批生产记录【ICHQ7，第6.5章节】，仅要求建立书面发放程序，并经质量管理部门批准【ICH Q7，第2.21章节】。\n'While ICH Q7 does not specify the need for time limits between equipment cleaning and use in the next process (clean hold time), [ICH Q7, Section 5.21] does state that written procedures should include instructions for the protection of clean equipment from contamination prior to use and inspection of equipment for cleanliness immediately before use, if practicable.'可被翻译为：尽管ICHQ7并没有说明需要确认设备清洁后到下次使用的最长保存时限（已清洁设备放置时限），【ICHQ7，第5.21章节】明确要求书面程序中应当包含保护已清洁设备在使用前免受污染的方法，以及如果可行使用前检查设备清洁状况的方法。\n\n根据上述已知信息，请将'ICH Q7 does not specify a need for physical and secure segregation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"ICH Q7并未明确要求采用物理和安全隔离。"
    },
    {
        "instruction":"已知信息：\n'Products may be intended for intravenous (IV), intramuscular (IM) or subcutaneous (SC) administration.'可被翻译为：产品可用于静脉内（IV），肌内（IM）或皮下（SC）给药。\n'The medicinal product should be administered via the subcutaneous route.'可被翻译为：本产品由皮下注射给药。\n'We recommend that dose-ranging and confirmatory trials use the to-be-marketed product.'可被翻译为：建 议剂量范围试验和验证性试验使用即将上市产品。\n'We recommend key dose-ranging and efficacy and safety trials use the to-be-marketed formulation.'可被翻译为：建议关键剂量范围，有效性和安全性试验使用即将上市的合成配方。\n\n根据上述已知信息，请将'We recommend using positive statements such as “for intravenous use,” “give by subcutaneous injection,” or “topical use only.”'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"我们推荐使用肯定句，如“静脉使用”， “ 通过皮下注射给药”，”或“仅局部使用”。"
    },
    {
        "instruction":"已知信息：\n'User Guidance This data element captures the date of the last menstrual period of the patient when it is relevant.'可被翻译为：用户指导原则 该数据元素获取患者的末次月经日期元素（如相关）。\n'D.10.3 Last Menstrual Period Date of Parent'可被翻译为：D.10.3母亲末次月经日期\n'• If both the parent and the child\/foetus sustain adverse event(s)\/reaction(s), two separate reports, e.g. one for the parent (mother or father) and one for the child\/foetus, should be provided and should be linked by using the data element C.1.10.r in each report.'可被翻译为：● 如果父母和儿童\/胎儿同时出现不良事件\/反应，则应提供 2 份独立的报告，即一份关于父母即关于（母亲或父亲）的报告、一份关于儿童\/胎儿的报告，并应在每份报告中使用数据元素C.1.10.r将两份报告链接起来。\n'User Guidance This data element captures the full precision date (e.g. day, month, year) for the date of birth of the patient.'可被翻译为：用户指导原则 该数据元素获取患者出生日期的完整精确日期元素（例如年、月、日）。\n\n根据上述已知信息，请将'Imprecise dates can be included (e.g. month and year, or year only).Other information on menopause or conditions related to menopause should be captured in the data element D.7.1.r. If this report is for a child\/foetus, then the mother’s last menstrual period is captured in the data element D.10.3.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"可包括不精确的日期（例如年份和月份或仅年份）。应在数据元素元素D.7.1.r中记录关于更年期或更年期相关疾病的其他信息。如此报告是针对儿童\/胎儿的，应在数据元素D.10.3中记录母亲的末次月经日期。"
    },
    {
        "instruction":"已知信息：\n'If anyone other than the investigator was responsible for evaluation of clinical outcomes (e.g., the sponsor or an external committee to review X-rays or ECG's or to determine whether the patient had a stroke, acute infarction, or sudden death) the person or group should be identified.'可被翻译为：如果有研究者以外的人员负责评估临床结果（例如，申 办方或外部委员审查X光或心电图，或诊断患者是否患有中 风、急性梗死或猝死），应注明该人员或组织。\n'There should be a review of any notable discrepancies between the investigators’ and experts’ opinions.'可被翻译为：如果研究者和专家的意见有明显分歧，应该进行审查。\n'In addition to critical measurements, the tabulation should note whether the patient was included in the efficacy evaluation (and which evaluation, if more than one), provide patient compliance information, if collected, and a reference to the location of the case report form, if included.'可被翻译为：除了关键测量之外，制表 应注意是否将患者纳入疗效评估（如果多于一个，列出有哪 些评估），并提供患者依从性信息（如果收集），以及病例 报告表在报告中的位置（如果包括）。\n'For a controlled study in which critical efficacy measurements or assessments (e.g., blood or urine cultures, pulmonary function tests, angina frequency, or global evaluations) are repeated at intervals, the data listings accompanying the report should include, for each patient, a patient identifier, all measured or observed values of critical measurements, including baseline measurements, with notation of the time during the study (e.g., days on therapy and time of day, if relevant) when the measurements were made, the drug\/dose at the time (if useful, given as mg\/kg), any measurements of compliance, and any concomitant medications at the time of, or close to the time of, measurement or assessment.'可被翻译为：对于每隔一段时间重复进行关键疗效变量测量或评估 （例如血液或尿液培养，肺功能测试，心绞痛频率或整体评估）的对照试验，报告附带的数据列表应包括每位试验患者 的识别码，关键变量的所有测量值或观察值（包括基线测量 值），并标注试验期间的测量时间（例如，治疗日和治疗时 间，如相关），该时间点的药物\/剂量（如需要，以mg \/ kg表 示），任何依从性的评估结果、进行测量和评估时或临近时 间内使用的任何伴随用药。\n\n根据上述已知信息，请将'If any critical measurements or assessments of efficacy or safety outcomes were made by more than one party (e.g., both the investigator and an expert committee may offer an opinion on whether a patient had an acute infarction), overall differences between the ratings should be shown, and each patient having disparate assessments should be identified.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果任何疗效或安全性结果的关键测量或评估是由多 方（例如，研究者和专业委员会可提供关于患者是否发生急 性梗塞的意见）合作完成的，应该显示各方评定尺度的整体 差异，并且应识别具有不同评价结果的个体患者。"
    },
    {
        "instruction":"已知信息：\n'II. Applying for exemption from human bio equivalence tests shall be indicated in the application form. If the exemption cannot be made after evaluation, and the substantial defects cannot be corrected, the applicant will not be required to provide supplementary materials, and the registration application shall be disapproved.'可被翻译为：二、申请豁免进行人体生物等效性试验，须在申请表中注明。经评审不能豁免，实质缺陷不能纠正的，不要求申请人提供补充材料，不予批准注册申请。\n'In order to promote the technical standards of drug registration in line with international standards, upon study, NMPA decided to apply the ICH Guidelines M9 Biopharmaceutics Classification System-based Biowaivers and Q&A document thereof and Q5D Derivation and Characterization of Cell Substrates Used for Production of Biotechnological\/Biological Products. On April 28, 2021, relevant matters were announced as follows:'可被翻译为：为推动药品注册技术标准与国际接轨。经研究，国家药品监督管理局决定适用《M9：基于生物药剂学分类系统的生物等效性豁免》及问答文件和《Q5D：用于生物技术产品及生物制品生产的细胞基质的来源和鉴定》国际人用药品注册技术协调会（ICH）指导原则。在2021年4月28日，就有关事项公告如下：\n'III. In case of inconsistency between the previously issued Guideline for Exemption from Human Bio equivalence Tests and the M9 Guideline, the M9 Guideline shall prevail.'可被翻译为：三、如果先前发布的《人类生物等效性试验豁免指南》与M9指南不一致，应以M9指南为准。\n'According to the NMPA Announcement, in order to well implement the ICH Guideline M9: Bio pharmaceutics Classification System-Based Bio waivers and Q&A Document thereof (hereinafter referred to as M9 Guideline), upon the approval by National Medical Products Administration, the CDE is hereby notifying relevant issues as follows:'可被翻译为：根据国家药监局公告，为落实好ICH指南《M9：基于生物药剂学分类系统的生物等效性豁免》(以下简称《M9指南》)及问答文件，经国家药品监督管理局批准，现就有关问题通知如下:\n\n根据上述已知信息，请将'I. If M9 requirements are met according to the assessment by the applicant, the applicant can directly propose exemption of human bio equivalence test in the drug registration application. NMPA will not issue a separate catalogue of varieties exempted from human bioequivalence test or subject to simplified human bio equivalence test.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一、如果经申报人评估符合M9要求，申报人可直接在药品注册申请中提出免除人体生物等效性试验。国家药监局不会单独发布免人生物等效性试验或简化人生物等效性试验的品种目录。"
    },
    {
        "instruction":"已知信息：\n'Studies in the paediatric population are encouraged.'可被翻译为：鼓励在儿科人群中开展研究。\n'If the product is indicated for children, clinical studies are usually expected to be carried out in this age group.'可被翻译为：如果产品预期应用于儿童，则通常希望在该年龄组中开展临床研究。\n'The recommendations for studies in adults are also valid for studies in paediatric populations.'可被翻译为：通常在成人研究中的建议也适用于在儿童人群中的研究。\n'Allergen immunotherapy The recommendations for studies in adults in Section 4.3.4. are also valid for studies in paediatric populations.'可被翻译为：变应原免疫治疗在第4.3.4.节中对于成人研究的建议同样适用于儿童人群的研究。\n\n根据上述已知信息，请将'As paediatric development usually follows studies in adults, studies in children will be mainly to establish specific questions as applicable to this group of patients.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"儿童试验常在成人试验后进行，对儿童的研究会主要设立适用于这一组患者的具体问题，"
    },
    {
        "instruction":"已知信息：\n'To fully reflect the monitoring of adverse events in relation to China's medical devices in 2019, the National Center for Adverse Drug Reaction Monitoring has compiled and released the Annual Report for National Medical Device Adverse Event Monitoring (2019).'可被翻译为：为全面反映2019年我国医疗器械不良事件监测情况，国家药品不良反应监测中心编撰了《国家医疗器械不良事件监测年度报告（2019年）》。\n'Release of Annual Report for National Medical Device Adverse Event Monitoring (2018)'可被翻译为：国家医疗器械不良事件监测年度报告\n'Annual Report for National Medical Device Adverse Event Monitoring (2019)'可被翻译为：国家医疗器械不良事件监测年度报告（2019年）\n'To fully reflect the status of China's adverse drug reaction (ADR) monitoring in 2019, improve the level of safe drug use, and better ensure drug safety for the public, the National Center for ADR Monitoring has organized the compilation of the Annual Report for National Adverse Drug Reaction Monitoring (2019)'可被翻译为：为全面反映2019年我国药品不良反应监测情况，提高安全用药水平，更好地保障公众用药安全，国家药品不良反应监测中心组织编撰《国家药品不良反应监测年度报告（2019年）》。\n\n根据上述已知信息，请将'To fully reflect the monitoring of adverse events in China's medical devices in 2018,the National Center for Adverse Drug Reaction Monitoring has compiled and released on October 30, 2019 the Annual Report for National Medical Device Adverse Event Monitoring (2018), which is excerpted as follows:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为全面反映2018年我国医疗器械不良事件监测情况，国家药品不良反应监测中心编撰了《国家医疗器械不良事件监测年度报告(2018年)》。"
    },
    {
        "instruction":"已知信息：\n'New treatment options are therefore in demand.'可被翻译为：因此非常需要新的治疗选项。\n'This ultimately supports the development of drugs that are better tailored to patients’ needs.'可被翻译为：从而最终支持研 发更适合患者需求的药物。\n'Therefore, there is a need to develop age-appropriate formulations for bowel cleansing.'可被翻译为：因此需要开发用来进行肠道 清洁的适龄制剂。\n'Therefore, there is a need to develop age- and body-weight appropriate formulations and strengths for bowel cleansing.'可被翻译为：因此，需要开发与儿童的年龄和体重相适的制剂和规格的肠道清洁药物。\n\n根据上述已知信息，请将'Therefore, a need to develop more specific treatments has been recognized.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"因此，需要更加有针对性的治疗药物。"
    },
    {
        "instruction":"已知信息：\n'In vivo or in vitro screening models were used to identify compounds with specific biological activities.'可被翻译为：利用体内或体外筛选模型，确定具有特定生物学活性的化合物。\n'antitumor model'可被翻译为：抗肿瘤模型\n'Artificial infection models for screening antiviral compounds and evaluating antiviral efficacy.'可被翻译为：筛选抗病毒化合物及评价抗病毒药效的人工感染模型。\n'Models for the screening of antimicrobial agents and the evaluation of their efficacy.'可被翻译为：筛选抗菌药物及评价其药效的各种模型。\n\n根据上述已知信息，请将'An in vivo and in vitro model for screening antitumor drugs and evaluating their efficacy.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"筛选抗肿瘤药物及评价其药效的体内外模型。"
    },
    {
        "instruction":"已知信息：\n'Adequate representation of older patients (above 70 years) in the clinical trials should be ensured.'可被翻译为：应确保临床试验中老年患者（70 岁以上）的充分代表性。\n'Therefore, to assess the benefit\/risk balance of a drug that will be used in the geriatric population, these patients should be appropriately represented in clinical trials.'可被翻译为：因为老年患者很可能存在伴随疾病、同时在接受合并 用药，因此要评价一种药物用于老年人群的获益\/风险平衡关系，在临 床试验中则应该适当的纳入老年患者来代表这一群体。\n'The prevalence of most chronic diseases increases with age, so it is not surprising that many older individuals suffer from two or more chronic conditions, a situation named multimorbidity.'可被翻译为：大多数慢性病患病率随年龄而增加，故许多老年个体患有两种或多种慢性病（这种情况称为多病）的情形并不令人惊奇。\n'Currently a large number of new medicinal products are under late clinical development or have recently been marketed.'可被翻译为：目前有很多新药正处于临床开发的后期或者已经在最近上市销售。\n\n根据上述已知信息，请将'Executive summary Older persons are large drugs consumers for a number of chronic diseases, but despite this they have often been excluded from clinical trials.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"执行摘要 因大量慢性病，老年人是药物的大客户；尽管这样，临床试验常将其排除。"
    },
    {
        "instruction":"已知信息：\n'ICH Q10 is not intended to create any new expectations beyond current regulatory requirements.'可被翻译为：ICH Q10无意在现行法规之外增加新的要求。\n'4 April 2009 Will there be certification that the PQS is in accordance with ICH Q10?'可被翻译为：4 2009年4 月 是否有针对PQS 是否符合ICH Q10要求 的认证？\n'To meet the objectives described below, ICH Q10 augments GMPs by describing specific quality system elements and management responsibilities.'可被翻译为：为达到本文中所述的目标，ICHQ10通过阐述明确而具体的质量体系要素和管理职责扩充了GMP。\n'1.5 ICH Q10 Objectives'可被翻译为：1.5 ICH Q10的目标\n\n根据上述已知信息，请将'No. There will not be a specific ICH Q10 certification programme.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"没有。不会有特殊的ICH Q10认证程序。"
    },
    {
        "instruction":"已知信息：\n'If it is not possible to use the identified virus, “relevant” or specific “model” viruses should be used to demonstrate acceptable clearance.'可被翻译为：如果不能使用已鉴定的病毒，应使用相关模型 病毒或特异模型病毒来评估其工艺清除效果是否可被接受。\n'When a “relevant” virus is not available or when it is not well adapted to process evaluation of viral clearance studies (e.g., it cannot be grown in vitro to sufficiently high titers), a specific “model” virus should be used as a substitute.'可被翻译为：如果得不到“相关”病毒，或它不太适用于病毒清除的工艺评价研究（如不能离体培养到足够的滴度）， 应使用特异“模型”病毒代替。\n'6. Process evaluation for “relevant” viruses or specific “model” viruses should be performed.'可被翻译为：6. 应使用相关病毒或特异性病毒完成工艺步骤评估。\n'Such viruses fall into three categories: “relevant” viruses, specific “model” viruses and non-specific “model” viruses.'可被翻译为：这些病毒可分为三类：“相关”病毒、特异“模型”病毒和非特 异“模型”病毒。\n\n根据上述已知信息，请将'If it is not possible to use the identified virus, “relevant” and\/or specific “model” viruses (described later) should be used.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如无法使用该病毒，应使用“相关”和\/或特异模型病毒（后文叙述）。"
    },
    {
        "instruction":"已知信息：\n'13.4 March 2014 Section 3.16.1 of the Guideline states that the PBRER should include a summary of important risks and missing information that are known at the beginning of the reporting interval.'可被翻译为：13.4 2014年3月 指南的章节3.16.1规定，PBRER应包 括对该报告期开始时已知的重要风险 和缺失信息的总结。\n'Section 16.4 of the PBRER (Characterisation of Risks) could be similarly affected.'可被翻译为：PBRER（风险表征）的章节16.4可能 受到同样的影响。\n'Section 16.4: Characterisation of Risks In characterising the risk for Section 16.4 of the PBRER, the MAH should consider whether the risk is important or not.'可被翻译为：章节16.4：风险的表征 在PBRER章节16.4的风险表征中，MAH应考虑风险是否属于重要风险。\n'Section 16.1: Summary of Safety Concerns For a discussion on this topic, please refer to the answer for Question 13.4.'可被翻译为：章节16.1：安全性问题的总结 对于这一课题的讨论，请参见疑问13.4的解答。\n\n根据上述已知信息，请将'If this method is used, all the safety concerns listed in Section 16.1 should be characterised in Section 16.4 of the PBRER, including a description of the important missing information.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果使用这一方法，在章节16.1中列出的所有安全性问题应在PBRER章节16.4中 表征，包括对重要缺失信息进行描述。"
    },
    {
        "instruction":"已知信息：\n'Since the drug product is new, application of this guideline is expected.'可被翻译为：由于制剂 是新创的，所以其申请适 用于本指南。\n'To facilitate clinical development programmes there is a need to allow for some flexibility in requirements while ensuring that each indication sought is supported by sufficient data to enable a sound assessment of the benefit-risk relationship.This revised guideline and the addendum that will follow build upon these principles.'可被翻译为：为了推进临床开发项目，在确保每个目标适应症都有足够 的数据支持进行利益-风险关系的充分评价的同时，允许要求上有一定的灵活性。 本次修订的指南及其附录正是基于这些原则。\n'The use of tumour biomarkers and other dynamic measures of activity is encouraged. In haematological malignancies, disease specific response criteria are unavoidable in many cases and full harmonization has not yet been accomplished for some disease entities. Therefore it is of importance to follow the progress made by international working groups on these issues. Especially if less conservative disease specific response criteria are introduced in new clinical guidelines, a justification with focus on aspects of drug development is expected from the sponsor.'可被翻译为：对于血液学恶性肿瘤而言，在许多情况下疾病特定缓解标准往往无法避免，并且某些病种还未实现完全协调。因此，及时跟进国际工作组在这些问题上取得的进展就显得十分重要。特别是，当在新的临床指导原则中引入更为开放的疾病特定缓解标准时，希望申办者能重点对药物开发方面进行解释。\n'Biological rationale and preliminary data to especially differentiate (disease) prognostic PGBM from predictive PGBM (drug response)'可被翻译为：生物学理论基础和初步的数据，尤其是将预后PGBM与预测性PGBM（药物反应）相区分的数据\n\n根据上述已知信息，请将'Especially if less conservative disease specific response criteria are introduced in new clinical guidelines, a justification with focus on aspects of drug development is expected from the sponsor.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"特别是如果在新的临床指导原则中引入了不太保守的疾病特异 性缓解标准时，期望获得申办方的关于药物开发的理由。"
    },
    {
        "instruction":"已知信息：\n'A chemical that causes the gain or loss of a single or multiple base pairs in a DNA molecule.'可被翻译为：在DNA分子中引起单个或多个碱基对增加或丢失的化学物。\n'In nucleic acid molecules, bases that can be paired with each other by hydrogen bonding.'可被翻译为：在核酸分子中，可以通过氢键相互配对的碱基。\n'A substance that alkalizes the amino, base, hydroxyl, and phosphate groups of DNA or protein molecules in cells.'可被翻译为：能使细胞中脱氧核糖核酸(DNA)或蛋白质分子的氨基、筑基、羟基和磷酸基等起烷化作用的物质。\n'The binding between antigens and antibodies, ligand and receptors and other molecules is a one-to-one relationship, and this one-to-one reaction is called a specific reaction.'可被翻译为：抗原与抗体、配体与受体等分子之间的结合是一对一的关系，这种一对一的反应称特异性反应。\n\n根据上述已知信息，请将'Chemically, the insertion of a molecule between two molecules or groups in a reversible process. When DNA is embedded, many molecules can interact with DNA in living organisms. Take ligand as an example, embedding is a way of binding ligand molecules to DNA. When the size of ligand meets the gap between the base pairs, it is possible to insert it, resulting in the distortion of the DNA substructure. Usually ligands embedded in DNA are polycyclic, aromatic, or planar molecules.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"化学上指在两个分子或基团之间加入一个分子，过程可逆。DNA嵌入时有许多分子可与生物体内的DNA发生交互作用，以配体为例，嵌入是配体分子与DNA的一种结合方式，当配体大小符合碱基对之间的空隙 时，就有可能插入其中，从而造成DNA分 子结构的扭曲变形。通常嵌入DNA的配体 是多环类、芳香类，或是平面分子。"
    },
    {
        "instruction":"已知信息：\n'In most cases, analyses of subpopulation effects in data pooled across studies are more likely than analyses in individual studies to have adequate power to assess differences.'可被翻译为：在大多数情况下，跨研究汇总的数据的亚群效应的分析比个别研究中的分析更有可能具有足够的功效来评价差异。\n'Pooled analyses can be performed on study-level summary data or on subject-level data.'可被翻译为：可以对研究水平总结数据或受试者水平数据进行汇总分析。\n'As noted, the integrated subpopulation analyses should include both individual studies (where subpopulations are large enough for this to be useful) and pooled analyses.'可被翻译为：如上所述，综合亚群分析应包括个别研究（在个别研究中的亚群足够大以使其有用）和汇总分析。\n'To that end, an integrated analysis of the effect of treatment in subpopulations of interest should summarize and compare results across the controlled studies that are described in the ISE, both in individual studies, where there is sufficient subgroup representation, and in pooled analyses.'可被翻译为：为此，感兴趣的亚群的治疗效果的综合分析应该总结并比较ISE中描述的具有足够的亚组代表的个别研究中的以及汇总分析中的对照研究的结果。\n\n根据上述已知信息，请将'Differences among individual studies can affect the validity and interpretability of pooled analyses.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"个别研究之间的差异可影响汇总分析的有效性和可解释性。"
    },
    {
        "instruction":"已知信息：\n'Some potentially useful imaging techniques may not be in routine use (e.g. newly-introduced or experimental diagnostic imaging) and\/or may be difficult to interpret (e.g. chest radiographs in young children).'可被翻译为：一些可能有用的成像技术可能不会被常规性地使用（如新引 进的或者已有的影像诊断学）和\/或可能难以解读（如幼儿的胸片） 。\n'Yet it would be difficult in the current environment to establish a valid non-inferiority margin based on historical data because of the emergence of acute revascularization procedures that might alter the size of the benefits of the thrombolytics.'可被翻译为：然而，在这种情况下，基于历史数据建立一个有价值的非劣效界值也是困难的。因为急性再血管化过程的出现可能会改变使用血栓溶解剂获益的大小。\n'Furthermore, the potential comparator is difficult to be established, since, up to date, non-specific procoagulant agents are not licensed for reversal of the new agents and may be associated with an increased risk of thrombosis.'可被翻译为：此外，由于目前尚未批准逆转新药的非特异性促凝剂并且可能伴随血栓形成风险升高，很难确立潜在的对照药。\n'Transdermal systems that are clear, translucent, or colored to match human skin tones can make it difficult to find the patch on the patient and have led to medication administration errors when patients or caregivers fail to remove old systems and apply more than one system at a time.'可被翻译为：透明、半透明或着色以匹配人类肤色的透皮系统可能使得难以在患者身上找到贴片，当患者或护理人员不能移除旧系统并且同时应用多个系统时，导致用药错误。\n\n根据上述已知信息，请将'Not infrequently, CUS imaging may be technically difficult, or the abnormality is more suggestive of old rather than recent thrombosis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"CUS成像可能产生技术上的困难，或异常更多的提示既往血栓而不是最近形成的血栓，这些情况并不少见。"
    },
    {
        "instruction":"已知信息：\n'TK6 human lymphoblasts.'可被翻译为：TK6人淋巴母细胞。\n'5.4.1.2 Follow-up to an In Vitro Positive Result That is Dependent upon S9 Activation'可被翻译为：5.4.1.2依赖于S9活化的体外试验阳性结果的追加\n'Aniline was positive in the mouse lymphoma L5178Y cell tk assay with and without S9 at quite high concentrations, such as 0.5 to 21 mM (Ref. 9, 10, 11).'可被翻译为：在小鼠淋巴瘤L5178Y细胞Tk基因突变试验中，苯胺在 非常高的浓度下（如0.5-21mM）不论是否加入S9，均呈阳性 （参考文献9-11）。\n'Pig-a assay (blood) \n·For directly acting mutagens (bacterial mutagenicity positive without S9)*'可被翻译为：Pig-a试验（外周血） \n• 检测直接诱变剂对于直接作用的致突 变物（细菌突变试验在非S9代谢活化条 件下结果为阳性时）*\n\n根据上述已知信息，请将'Human lymphoblasts and mouse lymphoma cells, reproducibly with S9, in some cases without S9;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"人淋巴母细胞和小鼠淋巴瘤细胞（有或无代谢活化条件下）中的可重复性；"
    },
    {
        "instruction":"已知信息：\n'Also known as \"local hormone\". An endogenous bioactive substance that is widely present in the body and has strong and extensive pharmacological activity. They do not have a specific production organ or tissue like neurotransmitters, nor do they need to be transported by the blood circulation to a distant target organ to produce effects like hormones, but only act on a variety of local nearby target organs to produce specific physiological or pathological reactions. These substances mainly include histamine, serotonin, prostaglandin, leukotrienes, Substance P, kinin and angiotensin.'可被翻译为：又称\"局部激素”。在体内广泛存在、具有强而广泛的药理活性的内源性生物活性物质。它们不具备神经递质那样的特定的产生器官或组织，也不像激素那样需由血液循环运到远处的靶器官产生作用，而只作用在局部附近的多种靶器官，产生特定的生理或病理反应。这类物质主要包括组胺、5-羟色胺、前列腺素、白三烯、P物质、激肽和血管紧张素等。\n'An endogenous substance that is widely present in the body and has physiological and pharmacological activity. It acts on a variety of target organs of the body and produces specific physiological or pathological reactions.'可被翻译为：体内广泛存在、具有生理、药理活性的内源性物质。作用于机体的多种靶器官，产生特定的生理或病理反应。\n'bioactive substance'可被翻译为：生物活性物质\n'As an alternative to, or in addition to, supplemental nonclinical assessment of endocrine toxicity, inclusion of endocrine endpoints (e.g., hormone levels) in clinical studies can be important to clarify the relevance of adverse endocrine activity identified in nonclinical studies.'可被翻译为：作为内分泌毒性辅助非临床评估的备择或附加途径，在临床研究中纳入内分泌终点（例如，激素水平）在阐明非临床研究中确认的不良 内分泌活性的意义上可能是很重要的。\n\n根据上述已知信息，请将'A highly bioactive substance secreted by endocrine glands or endocrine cells. It acts as a messenger in the body to carry information and regulate physiological processes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由内分泌腺或内分泌细胞分泌的高效生物活性物质。在体内作为信使传递信息，对机体生理过程起调节作用。"
    },
    {
        "instruction":"已知信息：\n'The results of serology performed at centralised laboratories should be used in the primary analysis.'可被翻译为：主要分析应使用由中心实验室进行的血清学研究的结果。\n'During clinical studies it is recommended that the confirmation of identification and susceptibility test results obtained from accredited local laboratories, isolate typing to distinguish relapses from new infections and serological studies should be conducted at designated centralised laboratories with appropriate expertise.'可被翻译为：临床研究中，建议由配备适当的专业人员的中心实验室对从认可的当地实验室获 得的鉴定和药敏试验结果进行确认， 独立分型以区别于新感染的复发， 并进行血清学研究。\n'Appropriate handling and transport to central laboratories may be difficult to establish in multi-centre, multi-national clinical trials.'可被翻译为：多中心、多国临床试验可能难以将样本恰当地处理并运输到中心实验室。\n'Whenever possible the primary methods used for isolation and susceptibility testing of putative pathogens at study site laboratories should be standardised.'可被翻译为：只要有可能，在研究中心的实验室进行的用于假定病原体的分离和药敏试验 的主要方法应该标准化。\n\n根据上述已知信息，请将'Central laboratories with appropriate expertise should be used for the primary conduct of serological studies or for the confirmation of results.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应该主要由有相应专长的中心实验室进行血清学研究或确认结果。"
    },
    {
        "instruction":"已知信息：\n'Table A-1 : Examples of Viruses Which Have Been Used in Viral Clearance Studies'可被翻译为：表A-1：用于病毒清除研究的病毒举例\n'Examples of useful “model” viruses representing a range of physico-chemical structures and examples of viruses which have been used in viral clearance studies are given in Appendix 2 and Table A-1. 2.'可被翻译为：附录2和表A-1例举了代表不同物理化学结构的“模型” 病毒以及已用于病毒清除研究的一些病毒。\n'Process Evaluation Studies of Viral Clearance Viral clearance studies in which “relevant” and\/or specific “model” viruses are used to determine the ability of the manufacturing process to remove and\/or inactivate these viruses.'可被翻译为：病毒清除方法评价研究：用“相关”和\/或特异“模型”病毒确定生产工艺去除和\/或灭活病毒效果的研究。\n'Viral clearance studies in which non-specific “model” viruses are used to assess the robustness of the manufacturing process to remove and\/or inactivate viruses.'可被翻译为：病毒清除工艺鉴定：用非特异“模型”病毒评价生产过程 去除和\/或灭活病毒可靠性的研究。\n\n根据上述已知信息，请将'B. Examples of viruses which have been used in viral clearance studies Several viruses which have been used in viral clearance studies are listed in Table A-1.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"B. 已应用于病毒清除研究的病毒举例 表A-1列举了已用于病毒清除研究的病毒。"
    },
    {
        "instruction":"已知信息：\n'A current pragmatic approach requires at least one year of major parkinsonian motor symptoms before the onset of dementia symptoms appears.'可被翻译为：目前实际的诊断方法是在出现痴呆症状之前，需要具有至少一年以上的帕金森病主要运动症状。\n'As, in general, the course of multiple sclerosis with respect to disability is slow, this may need years of follow-up, e.g. 5 years or even longer.'可被翻译为：因为多发性硬化症复发的致残过程一般是很缓 慢的，这可能需要数年随访，例如5年甚至更长的时间。\n'Several candidate protein-based, neurophysiological and neuroimaging biomarkers for ALS have been identified but until now none has been sufficiently validated for use as a diagnostic or surrogate parameter for clinical outcome (Turner 2009; Bowser 2011).'可被翻译为：已鉴定出数个候选的蛋白水平、神经生理学和神经影像学ALS生物标志物，但到 目前为止仍没有一个可经充分验证来用作临床结局的诊断或替代参数（Turner 2009; Bowser 2011）。\n'There are also considerable differences in aetiology, clinical presentation of signs and symptoms and appropriate outcome measures compared to the adult population.'可被翻译为：在病因学上、临床表现的症状、体征和适当的处理方法与成年人相比也有相当大的差异。\n\n根据上述已知信息，请将'Symptoms are often not recognised until considerable motor function has been lost and the mean delay from presentation to diagnosis is approximately 1 year (Mitchell 2010; Bowser 2011).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"其症状往往要到出现明显的运动功能丧失时才会被辨认出，并且从发病到确诊之 间的平均诊断延迟时间仍有约1年（Mitchell 2010; Bowser 2011）。"
    },
    {
        "instruction":"已知信息：\n'The CFDI and the provincial authority may form separate inspection teams or jointly form an inspection team. In principle, the registration inspection, and the Pre-market GMP inspection should be carried out in the same production period.'可被翻译为：核查中心和省级局可分别组建检查组， 或共同组建一个检查组。原则上注册核查与上市前 GMP 检查选择在同一生产周期内开展。\n'Article 24 The inspection team shall be composed of two or more persons who are qualified as drug inspectors, and the team leader shall assume overall responsibility. According to the specific conditions of the inspected varieties, experts in related fields may participate in the registration inspection. The CDE shall, in principle, send personnel to participate in cause-related inspections initiated by it.'可被翻译为：第二十四条 核查组应当由2名以上具备药品检查员资格的人员组成，实行组长负责制。根据核查品种的具体情况，可有相关领域专家参与注册核查。对药品审评中心启动的有因检查，药品审评中心原则上应当派员参加。\n'Article 6 In accordance with the requirements and functions of laws and regulations, the CFDI and provincial authorities shall form inspection team in accordance with procedures to complete the drug registration inspection and Pre-market GMP inspection.'可被翻译为：第六条 根据法规要求和职能， 核查中心和省级局按程序组建检查组，完成药品注册现场核查和上市前 GMP 检查工作。\n'Article 9 The inspection team shall write registration inspection and Pre-market GMP inspection reports and draw conclusions on registration inspection and Pre-market GMP inspection respectively based on the on-site inspection.'可被翻译为：第九条 检查组依据现场检查情况，分别撰写注册核查、上市前 GMP 检查报告，分别作出注册核查、上市前GMP 检查结论。\n\n根据上述已知信息，请将'If an inspection team is formed together, the inspection team leader and team members should be qualified national GMP inspectors. The inspection team leader shall be determined by the CFDI and the provincial authority through joint discussion.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如共同组建检查组，检查组长和组员均应为国家药品GMP 检查员。检查组长由核查中心和省级局共同协商确定。"
    },
    {
        "instruction":"已知信息：\n'What constitutes an important risk will depend upon several factors, including the impact on the individual, the seriousness of the risk, and the impact on public health.'可被翻译为：是否属于重要风 险将取决于多个因素，包括对个人的影响、风险的严 重性以及对公众健康的影响。\n'With respect to risk, consider its clinical importance, e.g., nature of toxicity, seriousness, frequency, predictability, preventability, reversibility, impact on patients, and whether it arose from off-label use, a new use, or misuse.'可被翻译为：关于风险，请考虑其临床重要性，例如毒性的性质、严重性、频率、 可预测性、可预防性、可逆性、对患者的影响、以及它是否源于标签 外使用、新用途或误用。\n'In assessing the public health impact of individual risks, the MAH should consider the following points that are intended to be illustrative rather than comprehensive: extent of product use (size of treated population), frequency, and health consequences (including consideration of seriousness, preventability, and reversibility).'可被翻译为：在评估个体风险的公众健康影响时，MAH应考虑 以下要点（其目的只是说明而不是综合性的）：产品使用的程度（治疗人群的大小），频率和健康后果（包括严重性、可预防性和可逆性的考虑）。\n'An identified risk or potential risk that could impact on the risk-benefit profile of the product or have implications for public health. What constitutes an important risk will depend upon several factors, including the impact on the individual, the seriousness of the risk, and the impact on public health. Normally, any risk that is likely to be included in the contraindications or warnings and precautions section of the product labelling should be considered important.'可被翻译为：可能会影响产品的风险-利益特征或对公众健康产生影响的已确定风险或潜在风险。是否属于重要风险将取决于多个因素，包括对个人的影响、风险的严重性以及对公众健康的影响。通常，有可能被纳入产品标签中的禁忌，警告和注意事项章节的任何风险都应该被认为是重要的风险。\n\n根据上述已知信息，请将'The following factors should be considered when determining whether or not a risk is important: Medical seriousness of the risk, including the impact on individual patients; Its frequency, predictability, preventability, and reversibility; Potential impact on public health (frequency; size of treated population); and Potential for avoidance of a medical product with a preventive benefit as a result of public perception of risk.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在确定风险是否重要时应考虑以下因素： 风险的医学严重性，包括对个体患者的影响； 其频率、可预测性、可预防性和可逆性； 对公众健康的潜在影响（频率，治疗人群的大小）；和 由于公众对风险的认识，避免使用具有预防作用的医疗产品的可能性。"
    },
    {
        "instruction":"已知信息：\n'This allows assessment of the clinical significance of antibody development, and also whether the antibody effect changes over time, which could occur as a result of increase in titre and\/or isotype switching\/affinity maturation of the antibody response.'可被翻译为：这样才能评估抗体发生的临床意义，以及抗体效应是否随时间变化，这种变化可能是因为滴度变化和\/或抗体反应的同种型变化\/亲和性成熟导致的。\n'While most effort is usually focused on antibody detection and characterisation as this is often related to clinical safety and efficacy, cell-mediated responses are also important and their assessment may be considered by applicants on a case by case basis.'可被翻译为：尽管大多数努力通常着重于抗体检测和表征，因为这通常与临床安全性和疗效有关，但是细胞介导的应答也同样重要，申请人应逐例考虑对其进行评价。\n'8.1. Rationale for sampling schedule and kinetics of the antibody response'可被翻译为：8.1. 抽样计划的依据和抗体应答的动力学\n'Antibody can be measured by using an ELISA or other immunoassay methods. One advantage of this method over the antibody forming cell response is that samples can be collected serially during the study. In monkeys, serial blood collection can be important due to the high inter-animal variability in the kinetics of the response. For these studies, data can be expressed as the sum of the antibody response over several collection dates (e.g., area under the curve).'可被翻译为：可采用ELISA或其它免疫学方法测定抗体。与抗体形成细胞反应相比，该方法的优点之一在于试验中能够连续采集样品。在猴试验中，由于动物间抗体响应动力学存在高度变异，连续采集血样非常重要。对于这些试验，数据可采用不同取样点抗体响应之和（如曲线下面积）表示。\n\n根据上述已知信息，请将'Evaluation of the kinetics of antibody development and the duration as well as the magnitude of the antibody response is important as it may correlate with clinical consequences.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"抗体生成和持续时间的动力学以及抗体应答程度的评价较为重要，因为这与临床后果相关。"
    },
    {
        "instruction":"已知信息：\n'Examples for suitable pain models in the different categories of pain of long duration are discussed in the following.'可被翻译为：在下文中讨论在不同类别的长持续时间疼痛中的合适的疼痛模型示例。\n'The adequacy of the evidence of efficacy will ultimately depend on how compelling the results are when the trials are completed; it is not possible to specify in this guideline the numbers of trials that might be required. Examples of acceptable pain models are given in Table 1.'可被翻译为：有效性证据的充分性最终将取决于试验完成时结果令人信服的程度；在本指南中不可能规定可能需要的试验次数。可接受的疼痛模型的示例在表1中给出。\n'To justify a general indication for the treatment of acute pain, efficacy needs to be demonstrated independently in models of both somatic and visceral pain, or in models of somatic pain and mixed somatic\/visceral pain.'可被翻译为：为了证明治疗急性疼痛的一般适应症是合理的，需要在躯体和内脏疼痛模型中或在躯体疼痛和躯体\/内脏混合疼痛模型中独立证明有效性。\n'5.2.4.Confirmatory efficacy studies (acute and chronic pain)'可被翻译为：5.2.4 确证性有效性研究\n\n根据上述已知信息，请将'Table 1: Examples of pain models appropriate to be used in efficacy studies in acute pain Pain'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"表1：适合用于急性疼痛的有效性研究的疼痛模型示例"
    },
    {
        "instruction":"已知信息：\n'Because bias can occur in subtle or unknown ways and its effect is not measurable directly, it is important to evaluate the robustness of the results and primary conclusions of the trial.'可被翻译为：偏倚常在不知不觉中发生，且难 以直接测量，因而评价试验结果和主要结论的稳健性是重要 的。\n'Unmeasured confounders can affect the study validity.'可被翻译为：未测量的混杂因素可能会影响研究的有效性。\n'The level of improvement to be met should be pre-defined, be clinically meaningful and the results should be statistically significant.).'可被翻译为：需要满足的改善水平应该是预先确定的、具有临床有意义，结果应该具有统计学意义。\n'Analyses excluding patients with missing data or other post-treatment outcomes can be biased because patients who do not complete the trial may differ substantially in both measured and unmeasured ways from patients who remain in the trial.'可被翻译为：排除有缺 失数据或其他治疗后结果的患者分析可能会有失偏颇，因为未完成试验的患者与 仍然留在试验中的患者可能在测量和未测量方式上大相径庭。\n\n根据上述已知信息，请将'However, results might be biased because of unmeasured confounding and small effects can be statistically significant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"但是由于未测量的混杂因素以及较小的效应可能也具有统计学显著性，导致结果有偏倚。"
    },
    {
        "instruction":"已知信息：\n'Relevant data on adverse effects in reproductive organs could be derived from mammalian studies.'可被翻译为：生殖器官的不良反应的相关数据可能来自哺乳动物研究。\n'It is recognized that mating studies are not practical for NHPs. However, when the NHP is the only relevant species, the potential for effects on male and female fertility can be assessed by evaluation of the reproductive tract (organ weights and histopathological evaluation) in repeat dose toxicity studies of at least 3 months duration using sexually mature NHPs. If there is a specific cause for concern based on pharmacological activity or previous findings, specialized assessments such as menstrual cyclicity, sperm count, sperm morphology\/motility, and male or female reproductive hormone levels can be evaluated in a repeat dose toxicity study.'可被翻译为：交配试验对于NHPs并不切合实际。但是，当NHPs是唯一的相关种属时，可以在性成熟的NHPs中进行至少3个月期限的重复给药毒性试验，通过评价生殖系统（器官重量和组织病理学评价）评估对雄性和雌性生育能力的潜在影响。如果根据药理学活性或者既往的发现，存在导致担忧的特别原因，那么可以在重复给药毒性试验中进行专项评估，如评价月经周期、精子数、精子形态\/精子活力、以及雄性或者雌性生殖激素水平。\n'Developmental and reproductive toxicity (DART) studies are recommended to evaluate the potential effects that exposure to the sunscreen active ingredient may have on developing offspring throughout gestation and postnatally until sexual maturation, as well as on the reproductive competence of sexually mature male and female animals.'可被翻译为：建议通过发育和生殖毒性试验（DART）评价整个妊娠过程和出生后至性成熟后过程中暴露于防晒活性成分对幼仔发育的影响，以及对雌性和雄性动物生殖能力的影响。\n'DART: Developmental and Reproductive Toxicity'可被翻译为：DART: 生殖与发育毒性\n\n根据上述已知信息，请将'Repeated–dose toxicity studies with sexually mature animals can provide important information on toxicity to reproductive organs that can affect the design of a DART study.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"采用性成熟动物进行的重复给药毒性试验可提供生殖器官毒性的重要信息， 其可影响DART试验的设计。"
    },
    {
        "instruction":"已知信息：\n'Studies in small study populations, very rare tumours For some truly rare tumours or very narrow indications, whether due to tumour phenotype or restrictions related to target expression, it is simply not possible to recruit a sufficiently large number of patients to conduct reasonably powered, randomised studies in order to detect clearly relevant differences in anti-tumour activity.'可被翻译为：在小规模人群、非常罕见的肿瘤的研究 对于一些真正罕见的肿瘤或者非常窄的适应症（究竟是由于肿瘤表型还是由于与靶 点表达有关的限制所致），为了检测抗肿瘤活性的明显相关性差异根本不可能招募到足 够数量的患者进行合理效力的随机研究。\n'However, it can be difficult to recruit sufficient numbers of patients who are exposed to a drug of interest (such as an orphan drug) or to study very rare outcomes.'可被翻译为：但是，招募足够数量暴露于所要研究药物（如一个孤儿药）的患者或研究非常罕见的结局会有一定难度。\n'If exploratory studies provide a basis for including\/excluding certain patients based on tumour phenotype\/genotype, this will be reflected in the labelling. As a corollary, if patients with tumours not expressing the target for activity are eligible, a restricted labelling may still be appropriate if it has not been demonstrated, e.g. by subgroup analyses, that target expression is irrelevant for anti-tumour activity.'可被翻译为：如果探索性研究基于肿瘤表型\/基因型为纳入\/排除特定的患者提供基础，那么这将 在说明书中显示出来。作为一种推论，如果患有未表现活性靶向的肿瘤的患者符合资格，那么若其未通过亚组分析等证明目标表现与抗肿瘤活性无关，那么受限说明书仍适用。\n'As a corollary, if patients with tumours not expressing the target for activity are eligible, a restricted labelling may still be appropriate if it has not been demonstrated, e.g. by subgroup analyses, that target expression is irrelevant for anti-tumour activity.'可被翻译为：由此类推，如果肿瘤不表达活性靶点的患者是符合条件的，如果还 没有证明（例如通过亚组分析）靶点表达与抗肿瘤活性不相关，那么限制性标签可能仍然是合适的。\n\n根据上述已知信息，请将'For some truly rare tumours or very narrow indications, whether due to tumour phenotype or restrictions related to target expression, it is simply not possible to recruit a sufficiently large number of patients to conduct reasonably powered, randomised studies in order to detect clearly relevant differences in anti-tumour activity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于一些罕见肿瘤或非常有限的适应症，无论是由于肿瘤显型还是相关靶基因的表达限制，几乎就不可能招蓦足够大样本量的患者进行更有说服力的试验，为发现明显相关的抗肿瘤方面的差异应进行随机研究。"
    },
    {
        "instruction":"已知信息：\n'Based on all the above considerations, any exposure to an impurity that is later identified as a mutagen is not necessarily associated with an increased cancer risk for patients already exposed to the impurity.'可被翻译为：基于上述这些原因，任何暴露在一个后来被鉴定 为致突变的杂质下的情况，不一定与已暴露于该杂质的患者的患癌风险增加相关。\n'In addition, in cases where a mutagenic compound is a non-carcinogen in a rodent bioassay, there would be no predicted increase in cancer risk.'可被翻译为：另外，如果致突变化合物在啮齿动物生物测定中显示为非致癌 物，则致癌风险预计不会增加。\n'This guideline does not apply to drug substances and drug products intended for advanced cancer indications as defined in the scope of ICH S9 (Ref. 4). Additionally, there may be some cases where a drug substance intended for other indications is itself genotoxic at therapeutic concentrations and may be expected to be associated with an increased cancer risk. Exposure to a mutagenic impurity in these cases would not significantly add to the cancer risk of the drug substance. Therefore, impurities could be controlled at acceptable levels for non-mutagenic impurities.'可被翻译为：本指导原则不适用于ICH S9（参考文献4）所定义的拟用于晚期癌症适应症的原料药和制剂。另外，某些情况下拟用于其它适应症的原料药本身在治疗浓度下就存在遗传毒性，且预测可能会增加致癌风险。在这些情况下，暴露于致突变杂质不会显著增加原料药的致癌风险。因此，杂质可以按非致突变性杂质进行控制。\n'This guideline does not apply to drug substances and drug products intended for advanced cancer indications as defined in the scope of ICH S9 (Ref. 4). Additionally, there may be some cases where a drug substance intended for other indications is itself genotoxic at therapeutic concentrations and may be expected to be associated with an increased cancer risk. Exposure to a mutagenic impurity in these cases would not significantly add to the cancer risk of the drug substance. Therefore, impurities could be controlled at acceptable levels for non-mutagenic impurities. Assessment of the mutagenic potential of impurities as described in this guideline is not intended for excipients used in existing marketed products, flavoring agents, colorants, and perfumes. Application of this guideline to leachables associated with drug product packaging is not intended, but the safety risk assessment principles outlined in this guideline for limiting potential carcinogenic risk can be used if warranted. The safety risk assessment principles of this guideline can be used if warranted for impurities in excipients that are used for the first time in a drug product and are chemically synthesized.'可被翻译为：本指导原则不适用于ICH S9（参考文献4）所定义的拟用于晚期癌症适应症的原料药和制剂。另外，某些情况下，拟用于其它适应症的原料药本身在治疗浓度下就存在遗传毒性，且预期可能会增加致癌风险。在这些情况下，暴露于致突变杂质不会显著增加原料药的致癌风险。因此，杂质可以按非致突变性杂质进行控制。 本指导原则所述对杂质潜在致突变性的评估不适用于矫味剂、着色剂和香料，以及已上市药物中使用的辅料。本指导原则不适用于药物包材相关的可浸出物，但如有必要，可使用本指导原则中描述的限制潜在致癌风险的安全风险评估原则。如有必要，首次在药品中使用的化学合成辅料中的杂质，可采用本指导原则的安全风险评估原则。\n\n根据上述已知信息，请将'Exposure to a mutagenic impurity in these cases would not significantly add to the cancer risk of the drug substance.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在这些情况下，暴露 在致突变杂质下不会显著增加原料药的癌症风险。"
    },
    {
        "instruction":"已知信息：\n'The cleaning process should be validated to be able to:'可被翻译为：清洁程序应进行验证，确保其能够：\n'The appropriate interval is confirmed during cleaning validation.'可被翻译为：时间间隔应在清洁验证时确认。\n'For example, such evidence may be provided by demonstrating that the cleaning and regeneration procedures do inactivate or remove virus.'可被翻译为：例如，可通过提供证据证实色谱柱经过清洗 和再生过程确实将病毒灭活或清除了。\n'This can be done by first applying appropriate statistical tests (e.g., p values for level of significance of rejection of more than 0.25) to the slopes of the regression lines and zero time intercepts for the individual batches.'可被翻译为：具体做法是：先对每批样品的回归曲线的斜率和截距进行统计检验（如P值＞0.25表示无显著性差异）。\n\n根据上述已知信息，请将'The act of demonstrating that cleaning was done to an acceptable level, for example, between two batches.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"证明清洗已达到可接受水平的行为，例如在两个批次之间。"
    },
    {
        "instruction":"已知信息：\n'It is assumed that the treatment will be an “add-on” to existing PPI therapy.'可被翻译为：假设以后的治疗将是在现有 PPI 治疗的基础上加一个“附加”治疗。\n'In placebo controlled add-on design setting the background treatment becomes of particular relevance.'可被翻译为：在安慰剂对照的附加治疗设计中，设定基础治疗尤为重要。\n'A prospective cohort design is recommended.'可被翻译为：建议采用前瞻性队列设计。\n'Randomised, parallel group, double-blind design is recommended.'可被翻译为：推荐使用随机、平行组、双盲的设计。\n\n根据上述已知信息，请将'For ‘add on’ indication, design with PPI’s as the background treatment is recommended.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于附加的适应症而言，建议把 PPI 设计作为背景治疗。"
    },
    {
        "instruction":"已知信息：\n'(II) Whether the raw materials and auxiliaries, bacterial strains\/seeds, viral strains\/seeds and cells used for production are consistent with those approved by the NMPA;'可被翻译为：（二）生产用原辅材料、菌种、毒种、细胞等是否与国家药品监督管理局批准的一致；\n'(VI) Whether the product package, label and package inserts are consistent with those approved by the CFDA;'可被翻译为：（六）产品包装、标签及说明书是否与食品药品监管总局核准的内容一致；\n'(III) Whether the production process and process control are consistent with those approved by the CFDA and meet the requirements in the ChP;'可被翻译为：（三）生产工艺和过程控制是否与食品药品监管总局批准的一致并符合药典要求；\n'The preparation of a two tiered cell bank and\/or bacterial\/viral seed system is advisable. The source and history of the cells or bacterial or virus seeds used for generation of the respective banks should be described and genetic stability of the parent material demonstrated. All starting materials, including master and working cell banks and viral seeds should be thoroughly characterised and appropriately monitored (e.g. according to the concepts outlined in ICH Q5D). Evidence of freedom from contamination with adventitious agents is essential.'可被翻译为：建议制备两层的细胞库和\/或细菌\/ 病毒种子系统。用于生产各个库的细胞、病毒或病毒种子的来源和历史需阐述，亲缘材料的基因稳定性需证明。所有起始物料，包括主细胞库和工作细胞库以及毒种，需要详细描述特征并适当监测（根据 ICHQ5D 提出的概念）。须证明不存在外来制剂污染。\n\n根据上述已知信息，请将'(II) Whether the raw materials and subsidiary, bacterial strains\/seeds, viral strains\/seeds and cells used for production are consistent with those approved by the CFDA;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）生产用原辅材料、菌种、毒种、细胞等是否与食品药品监管总局批准的一致；"
    },
    {
        "instruction":"已知信息：\n'TLV: Threshold Limit Value: The concentration in air to which it is believed that most workers can be exposed daily without an adverse effect (i.e., effectively, the threshold between safe and dangerous concentrations). The values were established (and are revised annually) by the ACGIH and are time weighted concentrations (TWA) for a 7- or 8-hour workday and 40-hour workweek, and thus related to chronic effects. (IUPAC）'可被翻译为：TLV： 阈值限度值：多数工人能每天暴露而无不良反应的空气中的浓度（即，有效的，安全和危险浓度之间的阈值）。该值由ACGIH确立（且每年进行修订），是以每日工作7或8小时，每周工作40小时计算的时间加权浓度（TWA），其与长期影响有关。（IUPAC）\n'TWA: Time Weighted Average: As defined by ACGIH, time-weighted average concentration for a conventional 8-hour workday and a 40-hour workweek. (IUPAC)'可被翻译为：TWA： 时间加权平均值：如ACGIH定义，以常规的每日工作8小时和每周工作40小时计算的时间加权平均浓度。(IUPAC)\n'Time Weighted Average: As defined by ACGIH, time-weighted average concentration for a conventional 8-hour workday and a 40-hour workweek. (IUPAC)'可被翻译为：时间加权平均值：如 ACGIH 定义，以常规的每日工作 8 小时和每周工作40小时计算的时间加权平均浓度。（IUPAC）\n'chronic threshold concentration'可被翻译为：慢性阈浓度\n\n根据上述已知信息，请将'Threshold Limit Value: The concentration in air to which it is believed that most workers can be exposed daily without an adverse effect (i.e., effectively, the threshold between safe and dangerous concentrations). The values were established (and are revised annually) by the ACGIH and are time_x0002_weighted concentrations (TWA) for a 7- or 8-hour workday and 40-hour workweek, and thus related to chronic effects. (IUPAC）'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"多数工人能每天暴露而无不良反应的空气中的浓度（即，有效的，安全和危险浓度之间的阈值）。该值由 ACGIH 确立（且每年进行修正），是以每日工作7或8小时，每周工作40小时计算的时间加权浓度（TWA），其与长期影响有关。（IUPAC）"
    },
    {
        "instruction":"已知信息：\n'The three-arm placebo- and active-controlled study would aim to demonstrate that the test product is superior to placebo and allow putting results into perspective;'可被翻译为：三臂的安慰剂和活性药物对照研究可以针对性的证明试验药物优于安慰剂并从广泛的角度考虑结果；\n'Three arm studies (study drug – placebo – active comparator (standard of care)) are preferable, particularly if the purpose is establishing non-inferiority of new therapy over the standard therapy.'可被翻译为：三组研究（研究药物–安慰剂–阳性对照药（标准治疗））最为理想，尤其是当研究目的为确立新治疗相比于标准治疗的非劣效性时。\n'When a double blind study is not feasible (for example, some inhalers are difficult to blind), a three arm study comparing the new drug with placebo (blinded comparison) and with an active comparator (unblinded control group comparison) is preferred.'可被翻译为：当双盲研究不可行时（例如，一些吸入剂难以设盲），将新药与安慰剂（盲态比较）和一种阳性对照药（非盲对照组比较）进行比较的三组研究是可取的。\n'Parallel group design including one placebo arm is recommended (see also 6.3.3 and 7.2).'可被翻译为：建议采用包含一个安慰机组的平行组设计（也见6.3.3 和 7.2）。\n\n根据上述已知信息，请将'A possible approach is a 3 arm study comparing the investigational product to placebo and an active comparator (see section 7.2).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一个可能的办法是设计3臂的研究，将研究产品和安慰剂组以及一个活性药物进行比较（见第7.2节）。"
    },
    {
        "instruction":"已知信息：\n'BMD can be correlated to mass-normalized strength parameters, but BMC should be associated with whole bone (extrinsic) mechanical properties.'可被翻译为：BMD可与质量归一化强度参数相关，但BMC应与全骨（外在）机械性质相关。\n'Although bone quality cannot be easily assessed directly, nonclinical studies offer the opportunity to provide indirect information about bone quality through the measurement of bone strength, which is determined by both bone mass and bone quality.'可被翻译为：虽然骨质量不易直接评估，非临床研究提供了通过测量由骨量和骨质量确定的骨强度来提供关于骨质量的间 接信息的机会。\n'Systemic effects of corticosteroids on bone mineral density and the eyes should also be assessed.'可被翻译为：还应评估皮质类固醇对骨密度和眼睛的全身效应。\n'b. Bone mass and density'可被翻译为：b. 骨量和骨密度\n\n根据上述已知信息，请将'An adverse effect on bone quality can be identified by a change in the correlation between bone mass (i.e., bone mineral density (BMD) or bone mineral content (BMC)) and bone strength.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"可以通过骨量（即骨矿物质密度（BMD）或骨矿物质含量（BMC））和骨强度之间的相关性的变化来识别对骨质量的不良影响。"
    },
    {
        "instruction":"已知信息：\n'Stratification may be used to ensure balance of treatments across covariates;'可被翻译为：分层可以用来保证治疗组间协变量的平衡性，\n'Stratification at the stage of randomisation and adjustment for covariates in the analysis may be seen as complementary methods of accounting for covariates.'可被翻译为：在随机化阶段分层和分析时校正协变量可以看作对协变量作出解释的补充方法。\n'This includes the use of covariates not stratified for in the randomisation.'可被翻译为：这包括随机化中不用于分层的协变量。\n'The play of chance may lead to unforeseen imbalances between the treatment groups in terms of baseline measurements not pre-defined as covariates in the planned analysis but having some prognostic importance nevertheless.'可被翻译为：对于计划分析中未被预先定义为协变量但仍然具有某 些预后重要性的基线测量，机会作用可能会导致它们在处理 组间出现无法预料的不均衡。\n\n根据上述已知信息，请将'Stratified randomisation is often used to reduce the likelihood of such imbalances between treatment groups within the levels of specified covariates (generally qualitative covariates or categorised quantitative covariates).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"分层随机化常常用于在指定的协变量（一般为定性协变量或分类定量协变量）水平内减少治疗组间这种不平衡的概率。"
    },
    {
        "instruction":"已知信息：\n'3. Blister Cell Label Material and Readability'可被翻译为：3. 泡罩板标签材料和可读性\n'1. Blister Cell Label'可被翻译为：1.泡罩板的标签\n'Text is difficult to read because of font size or style, insufficient color contrast, or other design elements.'可被翻译为：由字体的大小或风格，色彩对比不足或其他设计元素引起的文本阅读困难。\n'When possible, a non-reflective material should be used to enhance readability  of product information.'可被翻译为：若可能，应使用非反射材料，以便提高产品信息的清晰度。\n\n根据上述已知信息，请将'3.Blister Cell Label Material and Readability Color, type size, and font style should be carefully chosen based on the material used for the blister cell backing.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3. 泡罩板标签材料和可读性 应根据泡罩底板所用材料，仔细选择颜色、字体大小和字型。"
    },
    {
        "instruction":"已知信息：\n'As required by 21 CFR 56.109(g), the IRB must promptly provide the sponsor with a copy of the disclosed information. The sponsor, in turn, provides copies to FDA (21 CFR 312.54(a) and 812.47(a)). See Question 84.'可被翻译为：按照21 CFR 56.109（g）的要求，IRB必须及时向申办方提供披露信息的副本。 申办方然后将副本提供给FDA（21 CFR 312.54（a）和 812.47（a））。参见问题 84。\n'84. What does the sponsor do, upon receiving from the IRB the information that has been publicly disclosed?'可被翻译为：84 从IRB收到信息后，申办方如何处理公开披露的信息？\n'83. What does the IRB do with the information that has been publicly disclosed?'可被翻译为：83 IRB如何处理公开披露的信息？\n'83.What does the IRB do with the information that has been publicly disclosed? Ordinarily, the clinical investigator would provide the information that has been publicly disclosed (e.g., copies of newspaper advertisements, tapes or transcripts of radio and television shows, minutes of community meetings) to the IRB so that the IRB is aware that disclosure has occurred.'可被翻译为：83 IRB如何处理公开披露的信息？ 一般而言，临床研究者应向IRB提供已公开披露的信息（例如，报纸广告副 本，电台和电视秀节目磁带或记录，社区会议纪要），故IRB了解已进行了披露。\n\n根据上述已知信息，请将'84.What does the sponsor do, upon receiving from the IRB the information that has been publicly disclosed? Upon receiving copies of the information that has been publicly disclosed from the IRB, the sponsor must submit the information to FDA, i.e., to the IND\/IDE and to FDA’s Dockets Management at the following address:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"84 从IRB收到信息后，申办方如何处理公开披露的信息？ 从IRB收到已公开披露的信息的副本后，申办方必须按照下列地址将资料递 交给FDA IND\/IDE和备案文件管理处："
    },
    {
        "instruction":"已知信息：\n'Timing might differ for each region.'可被翻译为：各地区的实施时间可以不同。\n'When transmitting across the time zone, use this indicator to ensure no confusion about future dates.'可被翻译为：当跨时区传输时，请使用此指标以确保不与未来日期混淆。\n'Example: 1995 The time (hhmmss) one second before midnight is written as 235959.'可被翻译为：示例：1995 午夜前一秒的时间（hhmmss）写为235959。\n'Through the ICH process, considerable harmonisation has been achieved among the three regions in the technical requirements for the registration of pharmaceuticals for human use.'可被翻译为：通过ICH过程，三个地区的人用药品注册的技术要求获得了很大程度的统 一。\n\n根据上述已知信息，请将'To synchronize this event over the three ICH regions, the MSSO recommends midnight GMT, Sunday to Monday, for the switchover. For example :'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为了在 ICH 各区域同步切换，MSSO 建议切换日期为格林威治标准时间星期日24时（即星期一0 时）。例如："
    },
    {
        "instruction":"已知信息：\n'Safety reporting should be conducted in accordance with ICH E2.'可被翻译为：应按照ICH E2进行安全性报告。\n'Guidance is available on reporting of safety data to appropriate authorities and on the content and timing of safety reports (ICH E2-E2F Pharmacovigilance, and, for interventional clinical trials in particular, ICH E6).'可被翻译为：已有向有关 主管部门报告安全性数据以及安全性报告内容和时间的指 导原则（ICH E2-E2F药物警戒，特别是对于干预性临床试验， ICH E6）。\n'A table is provided as an Annex of this document showing the link between each Q&A and the relevant Sections of ICH Q7 and other ICH Quality guidance.'可被翻译为：本文附录中的表格，列出了每个问答与ICH Q7相应章节，以及于其他ICH质量指南之间的关联。\n'Guidance on non-clinical safety studies is provided in ICH M3 Nonclinical Safety Studies, ICH Safety (S) Guidelines and related Q&A documents, as well as in regional guidance.'可被翻译为：非临床安全性研究指导原则参见ICH M3非临床安全性 研究、ICH安全性（S）指南和相关问答文件以及区域性指导 原则。\n\n根据上述已知信息，请将'Safety data have to be provided in accordance with ICH E11 and other relevant guidance.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"必须根据ICHE11和其他相关指南提供安全性数据。"
    },
    {
        "instruction":"已知信息：\n'Systemic drugs: Products administered by a route that is intended to produce systemic exposure.'可被翻译为：全身用药：给药后会产生系统暴露的药物。\n'The formulation of the pharmaceutical and route(s) of administration intended for humans;'可被翻译为：拟用于人的药物剂型和给药途径；\n'Section 5 provides strategies for determining how to assess photosafety for drugs given by routes intended to produce systemic exposure or by the dermal route using the considerations and tests described in Sections 2, 3 and 4.'可被翻译为：第5部分介绍如何利用第2、3、4部分阐述的考虑因素和试验方法，评估全身给药或皮肤给药途径光安全性的策略。\n'Assess if the elemental impurity is expected to have local effects when administered by the intended route of administration:'可被翻译为：评估以拟定给药途径给药时元素杂质是否会产生局部作用：\n\n根据上述已知信息，请将'Products administered by a route that is intended to produce systemic exposure.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"给药后会产生系统暴露的药物。"
    },
    {
        "instruction":"已知信息：\n'8) To check the maintenance of premises and equipment for the purpose of maintaining a sound operating state;'可被翻译为：8.监督厂房和设备的维护，以保持其良好的运行状态；\n'4) To ensure that the premises and equipment are maintained and serviced to function in a sound operating state;'可被翻译为：4.确保厂房和设备的维护保养，以保持其良好的运行状态；\n'Preventative maintenance - maintaining equipment, utilities and premises (planned and unplanned maintenance) to a standard that will ensure there is no additional risk of contamination.'可被翻译为：预防性维护——按照确保没有额外污染风险的标准，对设备、公用设施和厂房进行维护（包括计划内和计划外维护）。\n'3. Maintenance, cleaning and sanitation of premises and equipment;'可被翻译为：3.厂房和设备的维护、清洁和消毒；\n\n根据上述已知信息，请将'8) To check the maintenance of premises and equipment for the purpose of maintaining a sound operating state;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"8.监督厂房和设备的维护，以保持其良好的运行状态；"
    },
    {
        "instruction":"已知信息：\n'The third-party platform shall strengthen the examination, manage the drug information display, prescription examination, drug sales and delivery, and other behaviors of the online drug sales enterprises settled on the platform, and urge them to strictly perform their legal obligations.'可被翻译为：第三方平台应当加强检查，对入驻平台的药品网络销售企业的药品信息展示、处方审核、药品销售和配送等行为进行管理，督促其严格履行法定义务。\n'Any third-party platform that accepts electronic prescriptions shall verify the conditions of the electronic prescription provider and sign an agreement.'可被翻译为：第三方平台承接电子处方的，应当对电子处方提供单位的情况进行核实，并签订协议。\n'Article 22 The third-party platform shall establish an examination and monitoring system for online drug sales activities. If it is found that the settled online drug sales enterprise has any illegal act, the platform shall stop it promptly and immediately report to the local drug regulatory department at the county level.'可被翻译为：第二十二条 第三方平台应当对药品网络销售活动建立检查监控制度。发现入驻的药品网络销售企业有违法行为的，应当及时制止并立即向所在地县级药品监督管理部门报告。\n'If the drug MAH recalls the drug according to law, the third-party platform and online drug sales enterprises shall cooperate actively.'可被翻译为：药品上市许可持有人依法召回药品的，第三方平台、药品网络销售企业应当积极予以配合。\n\n根据上述已知信息，请将'The third-party platform shall sign an agreement with the online drug sales enterprise to clarify the drug quality and safety responsibilities of both parties.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三方平台应当与药品网络销售企业签订协议，明确双方药品质量安全责任。"
    },
    {
        "instruction":"已知信息：\n'Sensitivity analyses should include events occurring 1 week and 1 month after study drug discontinuation in order to investigate a possible early rebound increase in thromboembolism after treatment cessation.'可被翻译为：为了考察停止治疗后可能的初期反弹性血栓栓塞增加，敏感性分析应该包括停药后 1 周和 1 个月内发生的事件。\n'The evaluation of the primary endpoint should occur when the full treatment effect can be expected to be evident and at the end of the 3 month study period.'可被翻译为：当预期充分治疗效果明显时以及3个月研究结束时应进行主要终点的评价。\n'The analysis to show superiority should include all primary endpoint events occurring through end of study'可被翻译为：显示优效性的分析应包括直至研究结束时发生的所有主要终点事件\n'The analysis to show superiority should include all primary endpoint events occurring through end of study (from each patient’s date of randomization to the estimated date of attainment of the study’s target of primary endpoint events).'可被翻译为：显示优效性的分 析应包括直至研究结束时发生的所有主要终点事件（从每名患者随机日期至达到 主要终点事件的研究目标的估测日期）。\n\n根据上述已知信息，请将'The analysis to show non-inferiority should include the primary endpoint events while taking study drug including a period of 3 days after study drug discontinuation (on-treatment analysis).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"显示非劣效性的分析应包括在研究药物使用期间（包括停用研究药物后 3 天）的主要终点事件（治疗中分析）。"
    },
    {
        "instruction":"已知信息：\n'FDA encourages sponsors to seek early communication with FDA, such as at pre-IND meetings, to discuss an appropriate nonclinical development program for the investigational product. Such discussions can facilitate the timely conduct of clinical trials, and may reduce the use of animals and other drug development resources.'可被翻译为：FDA鼓励申办方尽早寻求与FDA联络，例如在IND会议上，以讨论研究性药品的适当非临床研发计划。此类讨论有助于及时开展临床试验，并且可以减少动物 以及其他药物研发资源的使用。\n'These discussions are also critically important for reaching consensus on the use of an appropriate animal model to support approval under the animal rule.'可被翻译为：这些讨论对于在动物（效应）法规下使用适当的动物 模型支持批准达成共识十分重要。\n'If there is no IND for the product, FDA will assign a pre-IND number so that a meeting to fully inform FDA of the overall development plan for the product can be scheduled (see section III.B.1., Meeting With FDA Before Submission of a Request).'可被翻译为：如果药品没有IND，FDA将分 配一个IND前编号，以便可以安排一次会议充分通知FDA该药品的整体开发计 划（见第III节B.1部分“递交请求前与FDA召开会议”）。\n'1. Meeting With FDA Before Submission of a Request'可被翻译为：1. 递交请求前与FDA召开会议\n\n根据上述已知信息，请将'Discussions with FDA regarding the development of an appropriate animal model should begin early in the product development process so that the meeting before submission of a Request focuses on final consensus on the animal model, not an introduction of this topic.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"与FDA关于开发适当的动物模型的讨论应 在药品开发过程的早期开始，以便“请求”递交前的会议着重于对动物模型的最 终共识，而不是对该议题的介绍。"
    },
    {
        "instruction":"已知信息：\n'National monitoring agencies shall carry out comprehensive analysis on adverse event reports of the medical devices approved by the NMPA to be registered or filed and quarterly reports submitted by all the provinces, autonomous regions and municipalities directly under the central government, and if necessary, propose recommendations on supervisory measures to the NMPA.'可被翻译为：国家监测机构应当对国家药品监督管理局批准注册或者备案的医疗器械的不良事件报告和各省、自治区、直辖市药品监督管理部门的季度报告进行综合分析，必要时向国家药品监督管理局提出监管措施建议。\n'Monitoring agencies designated by the NMPA (hereinafter referred to as national monitoring agencies) shall be responsible for unified management of all the information of medical device adverse events collected and provide feedback of relevant monitoring information of medical device adverse events to relevant monitoring agencies, MAHs, distributing enterprises or user facilities.'可被翻译为：国家药品监督管理局指定的监测机构（以下简称国家监测机构）负责对收集到的医疗器械不良事件信息进行统一管理，并向相关监测机构、持有人、经营企业或者使用单位反馈医疗器械不良事件监测相关信息。\n'Article 24 Provincial monitoring agencies shall yearly carry out Meta-analysis on the medical devices adverse event monitoring information registered or filed within local administrative regions, complete annual summary report, and submit it to local drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government and national monitoring agencies prior to March 15 each year.'可被翻译为：第二十四条  省级监测机构应当按年度对本行政区域内注册或者备案的医疗器械的不良事件监测情况进行汇总分析，形成年度汇总报告，于每年3月15日前报所在地省、自治区、直辖市药品监督管理部门和国家监测机构。\n'Annual Report for National Medical Device Adverse Event Monitoring (2019)'可被翻译为：国家医疗器械不良事件监测年度报告（2019年）\n\n根据上述已知信息，请将'National monitoring agencies shall carry out Meta-analysis on the annual monitoring information of medical device adverse events nationwide, complete annual report and submit it to the NMPA by the end of March each year.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家监测机构应当对全国医疗器械不良事件年度监测情况进行汇总分析，形成年度报告，于每年3月底前报国家药品监督管理局。"
    },
    {
        "instruction":"已知信息：\n'The diagnosis of “acute” recurrent VTE (i.e. during the first 3-6 months of treatment) should be based on the comparison of objective tests compared to baseline test performed for the initial diagnosis of acute VTE.'可被翻译为：VTE“急性”复发（例如在治疗的前 3~6 个月内）的诊断应基于与急性 VTE 最初诊断的基线检查进行客观的比较。\n'A recurrence during the extended treatment should be defined in comparison to this new baseline test.'可被翻译为：应通过与此新的基线检查结果比较来确定扩展治疗期间的复发。\n'It is important to distinguish between initial treatment of VTE (usually 3-6 months), and extended treatment (secondary prevention of recurrences) of VTE (once initial treatment has finished, to indefinite).'可被翻译为：区别VTE的初始治疗（通常为3-6个月）和VTE的扩展治疗（复发的二级预防）（一旦初始治疗结束后，无限期的）是很重要的。\n'After the initial 3 months of study, the extension part of the study may be performed as an open label study if appropriate justification can be provided.'可被翻译为：在最初3个月的研究后，如果可提供合理的依据，则研究的扩展部分可作为一项开放性研究。\n\n根据上述已知信息，请将'The diagnosis of recurrences during an extended study after the initial 3 to 6 months of treatment should be compared to a new baseline test (i.e. CUS for VTE or sCT or VPLS for PE) performed at the end of the initial treatment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在治疗的最初3~6个月后的扩展治疗期间复发的诊断应与在初期治疗结束之后进行的新基线检查（例如用 CUS 诊断 VTE 或 sTE 或用 VPLS 诊断 PE）进行比较。"
    },
    {
        "instruction":"已知信息：\n'NMPA Announcement on Issuing the Guidance for Evaluation of the Safety and Efficacy of Medical Devices Using Nano Materials-Part 1: System Framework'可被翻译为：国家药监局关于发布应用纳米材料的医疗器械安全性和有效性评价指导原则第一部分：体系框架的通告\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on March 10, 2020 the Fundamental Principles for Medical Device Safety and Performance.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定，并于2020年3月10日发布了《医疗器械安全和性能的基本原则》。\n'To strengthen the supervision and guidance of medical device registration and further improve the quality of registration review, the NMPA organized to formulate the Guidance (Revision 2020) for Technical Review of Clinical Evaluation of Equivalent Devices of Medical Magnetic Resonance Imaging Systems which was issued on January 27, 2021.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药监局组织制定了《医用磁共振成像系统同品种临床评价技术审查指导原则（2020年修订版）》，并于2021年1月27日发布。\n'To strengthen the supervision and guidance over medical device registration and further improve the quality of registration review, NMPA organized to formulate and released on May 19, 2020 the Guidelines for Evaluation of Changes in Raw Materials of Passive Medical Devices.'可被翻译为：为加强对医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定并于2020年5月19日发布了《无源医疗器械产品原材料变化评价指南》。\n\n根据上述已知信息，请将'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, the NMPA has organized to formulate the Guidance for Evaluation of the Safety and Efficacy of Medical Devices Using Nano Materials-Part 1: System Framework, which was issued on August 26, 2021.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定了《应用纳米材料的医疗器械安全性和有效性评价指导原则第一部分：体系框架》，并于2021年8月26日发布。"
    },
    {
        "instruction":"已知信息：\n'Article 148 Qualification or validation should be implemented in accordance with a predefined and approved protocol, and be recorded. Upon completion of qualification or validation, a report should be prepared, reviewed and approved. The qualification or validation result and conclusion (including comments and suggestions) should be recorded and archived.'可被翻译为：第一百四十八条 确认或验证应当按照预先确定和批准的方案实施，并有记录。确认或验证工作完成后，应当写出报告，并经审核、批准。确认或验证的结果和结论（包括评价和建议）应当有记录并存档。\n'Article 148: Qualification or validation should be implemented in accordance with a predefined and approved protocol, and be recorded.'可被翻译为：第一百四十八条 确认或验证应当按照预先确定和批准的 方案实施，并有记录。\n'Upon completion of qualification or validation, a report should be prepared, reviewed and approved.'可被翻译为：确认或验证工作完成后，应当写出报告， 并经审核、批准。\n'Article 54 Enterprises shall form validation control documents in accordance with relevant validation management systems, including validation schemes, reports, evaluations, deviation handling and preventive measures, etc.'可被翻译为：第五十四条 企业应当根据相关验证管理制度，形成验证控制文件，包括验证方案、报告、评价、偏差处理和预防措施等。\n\n根据上述已知信息，请将'Article 55 Validation shall be carried out in accordance with the pre-determined and approved scheme; the validation report shall be reviewed and approved. Validation documents shall be archived.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十五条 验证应当按照预先确定和批准的方案实施，验证报告应当经过审核和批准，验证文件应当存档。"
    },
    {
        "instruction":"已知信息：\n'To establish potential benefits, Phase 2 controlled trials in consenting subjects may be needed to explore dose response for safety or biomarkers before an investigation proceeds under 21 CFR 50.24.'可被翻译为：在开展21CFR 50.24研究前，为了确定潜 在的收益，可能需要在能出具知情同意的受试者中开展2期对照试验，探索出安 全响应剂量和生物标志物。\n'In the later stages of premarket development or in postapproval studies or clinical trials, it may be appropriate to use a selective approach to safety data collection for common, non-serious adverse events that have already been well- characterized through data collection in earlier stages.'可被翻译为：在上市前研发或批准后研究或临床试验后期，可采用 选择性方法收集已通过早期数据收集明确特征的常见的非严重不良事件。\n'Lack of Efficacy in Controlled Clinical Trials'可被翻译为：对照临床试验中的缺乏有效性\n'3.13 Lack of Efficacy in Controlled Clinical Trials Data from clinical trials indicating lack of efficacy, or lack of efficacy relative to established therapy(ies), for products intended to treat or prevent serious or life-threatening illnesses (e.g., excess cardiovascular adverse events in a trial of a new anti-platelet drug for acute coronary syndromes) could reflect a significant risk to the treated population and should be summarised in this section.'可被翻译为：3.13 对照临床试验中的缺乏有效性 来自旨在治疗或预防严重或危及生命的疾病的产品的临床试验的表明缺乏 有效性、或相对于现有疗法缺乏有效性的数据（例如，用于急性冠状动脉综合 征的新的抗血小板药物试验中发生的过量心血管不良事件）可能反映了治疗人 群的重大风险，应在本章节中总结。\n\n根据上述已知信息，请将'Later phase controlled trials represent an important means of exploring in an unbiased manner any new potential adverse effects, even if such trials generally lack power in this respect.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"后期阶段的对照试验代表了以无偏的方式探索任何新的 潜在不良反应的重要方法，即使这些试验在这方面通常缺乏 检验效能。"
    },
    {
        "instruction":"已知信息：\n'FDA generally  recommends avoiding color coding in most instances.'可被翻译为：在大多数情况下，FDA一 般不建议使用颜色编码。\n'When a difference is demonstrated it is interpretable without reference to external findings.'可被翻译为：当证明存在差异时，不参考外部发现，该差异 也是可以解释的。\n'When applying  color, sponsors should ensure that the text highlighted by the color has adequate color contrast  against the background color.'可被翻译为：当用颜色来区分是，主办人应该确保突出文字使用的颜色与背景颜色有足够大的差别。\n'b. Color Coding  Color coding is a technique that uses color to designate a specific meaning.'可被翻译为：b. 颜色编码 颜色编码是一种使用颜色来指定特定含义的技术。\n\n根据上述已知信息，请将'Color differentiation is most effective when the color used has no  association with a particular feature and there is no pattern in the application of the color scheme.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当所用颜色不与任何一特征有关联，且色彩设计的应用没有格式时，颜色差异化的方法是最有效的。"
    },
    {
        "instruction":"已知信息：\n'Different preparations of a drug are given the same dose under the same experimental conditions, and there is no statistical difference in the main pharmacokinetic parameters reflecting the rate and degree of absorption.'可被翻译为：一种药物的不同制剂在相同的实验条件下，给予相同剂量，反映其吸收速度和程度的主要药动学参数没有统计学差异。\n'In general the route or routes of administration should be similar to those intended for human usage. One route of substance administration may be acceptable if it can be shown that a similar distribution (kinetic profile) results from different routes (Note 9).'可被翻译为：一般情况下，给药途径应与临床拟用途径相似。若研究表明，不同给药途径的（药物）分布（动力学特点）情况类似，只采用一种给药途径也可以接受（注释 9）。\n'Bioequivalence study refers to a human study, which applies bioavailability study methods with pharmacokinetic parameters as indicators to compare active ingredient absorption rate and extent of the preparations in the same or different dosage forms of a drug in terms of statistical differences under the same experimental condition.'可被翻译为：生物等效性试验，是指用生物利用度研究的方法，以药代动力学参数为指标，比较同一种药物的相同或者不同剂型的制剂，在相同的试验条件下，其活性成份吸收程度和速度有无统计学差异的人体试验。\n'As provided above, the statutory definition of BE, expressed in terms of rate and extent of absorption of the active ingredient or moiety, emphasizes the use of pharmacokinetic endpoints in an accessible biological matrix, such as blood, plasma, and\/or serum, to indicate release of the drug substance from the drug product into the systemic circulation.9 BE frequently relies on pharmacokinetic endpoints such as C max (peak plasma concentration) and AUC (area under the plasma concentration time curve) that are reflective of rate and extent of absorption, respectively.'可被翻译为：按照前述的BE的法定定义，以活性成分或组分的吸收速度和程度来表示，通过测定可获得的生物基质（如血液、血浆、血清）中的活性物质或组分，以测得的药代动力学参数为终点指标，藉此反应原料药由制剂中释放并被吸收进入循环系统。9 通常分别采用的药代动力学终点指标Cmax（血浆峰浓度）和AUC（血浆浓度\/时间曲线下面积）来分别反应吸收的速度和程度。\n\n根据上述已知信息，请将'The rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses....6'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在相似的试验条件下单剂或多剂服用相同摩尔数的治疗组份后，受试制剂的吸收速度和程度与参比制剂相比没有显著差异 6"
    },
    {
        "instruction":"已知信息：\n'Members of the public wishing to examine public disclosure information submitted to the docket may visit the FDA's Dockets Management Branch in person, view the materials on-line (http:\/\/www.regulations.gov\/search\/Regs\/home.html#docketDetail?R=FDA-1995-S-0036), or request a copy by sending a Freedom of Information Act request to FDA at the address shown below (21 CFR 312.130(d) and 812.38): Food and Drug Administration Division of Freedom of Information (HFI-35) 5600 Fishers Lane Rockville, MD 20857 Telephone: (301) 827-6500 B. PUBLIC DISCLOSURE AFTER THE STUDY IS COMPLETED OR TERMINATED'可被翻译为：如公众希望查阅提交到备案文件管理处的公开披露信息，可亲自到FDA备 案文件管理处分支，在线阅读这些材料 （http:\/\/www.regulations.gov\/search\/Regs\/home.html#docketDetail?R=FDA-1995-S- 0036），或者按下列地址向FDA发送信息法自由权请求，索取副本（21 CFR 312.130（d）和 812.38）: 食品药品监督管理局 信息自由室 （HFI-35） 5600 Fishers Lane Rockville，MD 20857 电话：（301）827-6500 B. 研究完成或终止后的公开披露\n'B. PUBLIC DISCLOSURE AFTER THE STUDY IS COMPLETED OR TERMINATED'可被翻译为：B. 研究完成或终止后的公开披露\n'89.Who is responsible for disclosing information about the study after it is completed or terminated?'可被翻译为：89 研究完成或终止后谁负责披露该项研究的信息？\n'Note that sponsors must report to FDA when a study is terminated or discontinued (21 CFR 312.31(a)(2), 812.150(b)(7)), and it is FDA’s expectation that the public also be informed of terminations\/discontinuances.'可被翻译为：注意，在某项研究被终止或中止时，申办方必须上报FDA（21 CFR 312.31（a）（2），812.150 （b）（7）），并且FDA期望也告知公众终止\/中止的情况。\n\n根据上述已知信息，请将'94. Must information that is disclosed after the study is completed or terminated be submitted to FDA’s Public Docket?'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"94 研究完成或终止后披露的信息必须提交至FDA的备案文件管理处 吗？"
    },
    {
        "instruction":"已知信息：\n'Some alterations can only be identified following an appropriate post-treatment period to allow maturation of an organ system and expression of the alteration. Therefore, some assessments can only be meaningfully performed after a certain level of maturity is reached (e.g., learning and memory, immunological function). These assessments can be conducted in post-treatment periods after exposure has covered all developmental windows relevant to the clinical use. This is especially relevant in cases when the JAS dosing duration would cease at an immature age and the animals will continue to mature during the post-treatment period to an age at which an appropriate assessment can be conducted.'可被翻译为：一些改变只有在适当的停药后时期以使器官系统成熟并表达出改变后才能确定。因此，一些评估只有在达到一定程度的成熟后进行才有意义（例如学习和记忆、免疫功能）。这些评估可以在暴露涵盖与临床使用相关的所有发育窗口之后的停药后时期进行。当JAS给药期在未成熟年龄时停止的情况下，这一点尤为重要，动物将在停药后时期继续成熟至可进行合适评估的年龄。\n'If the duration of dosing is not expected to be tolerable in a JAS, it may be possible to achieve the clinically relevant exposure by separating the dosing period into different subgroups (e.g., a 6-week JAS dosing period is split into two subgroups of 3 weeks dosing, each starting at different ages). If subgroups with different dosing periods are used, all subgroups may need to be followed through to maturity to detect late effects. The benefits of this approach should be considered along with the drawbacks, such as substantially increasing the number of animals and difficulties interpreting data at different ages.'可被翻译为：如果在JAS中给药期限预期不可耐受时，通过将给药期限分为不同的亚组，以使能够达到临床相关暴露（例如，将一个6周的JAS给药期分成两个3周给药期的亚组，每个亚组从不同的年龄开始给药）。 如果采用不同给药期的亚组，则所有亚组可能需要继续观察至成年期以检测迟发效应。考虑这种方法的益处时也应同时考虑到其缺点，例如明显增加动物数量以及解释不同年龄的数据的困难。\n'Severity, duration and reversibility should be determined.'可被翻译为：应确定严重程度、持续时间和可逆性。\n'Recovery from pharmacological and toxicological effects with potential adverse clinical impact should be understood when they occur at clinically relevant exposures. This information can be obtained by an understanding that the particular effect observed is generally reversible\/non-reversible or by including a non-dosing period in at least one study, at at least one dose level, to be justified by the sponsor. The purpose of the non-dosing period is to examine reversibility of these effects, not to assess delayed toxicity. The demonstration of complete recovery is not considered essential. The addition of a recovery period just to assess potential for immunogenicity is not required.'可被翻译为：如果在临床相关的暴露水平下出现具有潜在不良临床影响的药理学和毒理学作用，应了解这些作用是否可以恢复。可以通过对观察到的独特作用总体上是否可逆的认识，或者在至少一项试验中设置至少一个剂量水平的非给药期来获取该信息，由申请人证明其合理性。非给药期的目的是检测这些作用的可逆性，而不是评价延迟的毒性。没有必要证明完全恢复，也无需仅为了评价潜在免疫原性而额外设置恢复期。\n\n根据上述已知信息，请将'Whether a post-treatment period is advisable is dependent on the outcome of the WoE assessment and the endpoints to be evaluated in the study. The principles of evaluation of the potential for reversibility in ICH M3 apply. The duration of the post-treatment period should be sufficient to allow the potential recovery of the effect and should take into account the elimination of the pharmaceutical. However, the demonstration of full reversibility is not considered essential. A trend towards reversibility (e.g., decreased incidence and\/or severity) and a scientific assessment that this would eventually progress to full reversibility could be sufficient. Likewise, if irreversibility of a specific effect is well characterised in adult animals, it is generally not necessary to confirm this in a JAS. There are endpoints in a JAS that are not amenable to the classic approach of reversibility assessment, such as the timing of onset of puberty. Additionally, the timing of the post-treatment period in relation to the life stage of the animals should be considered. If the post-treatment period begins prior to maturity, the capacity for recovery can be influenced by the continued growth and development of some organ systems and should be carefully interpreted.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"是否需进行停药后时期评估，取决于WoE评价的结果和试验中所评估的终点指标。ICHM3中的评价潜在的可逆性的原则适用。停药后时期的期限应足以使影响可能恢复，并应考虑到药物的清除。但是，证明完全可逆性并非是必要的。可逆性的趋势（如发生率和\/或严重程度降低）以及对最终将达到完全可逆性的科学评估可能足够。同样，如果某一特定影响的不可逆性在成年动物中已充分表征，则通常没有必要在JAS中证实这一点。JAS的一些终点指标不适用于可逆性评估的经典方法，例如青春期开始的时间。此外，应考虑与动物生命阶段相关的停药后时期的时间选择。如果停药后时期开始于成熟之前，可逆性的能力可能受到某些器官系统持续生长和发育的影响，应谨慎解释。"
    },
    {
        "instruction":"已知信息：\n'In addition to the IOM recommendations, the Secretary of Health and Human Services published a report entitled Bringing Common Sense to Health Care Regulation: Report of the Secretary’s Advisory Committee on Regulatory Reform (November 2002). This report recommended that FDA adopt safe labeling practices for all FDA-regulated products to improve patient safety and decrease preventable adverse drug events.'可被翻译为：除IOM的建议外，公共与卫生服务部部长公布了一份报告，名为“把常识带到医疗监管:监管改革咨询委员会部长报告（2002年11月）”。这份报告建议FDA对于所有FDA监管药品采用安全的标签，以改善患者安全性，并减少可预防的不良事件。\n'8 This effort is also consistent with FDA's May 10, 1999, report to the FDA Commissioner titled Managing the Risks From Medical Product Use, which underscored the importance of providing an adequate risk assessment associated with the use of drug products, including a mandate to reduce medication errors from proprietary name confusion.'可被翻译为：8此项努力与FDA1999年5月10日的报告相一致，报告名称为“药品使用的风险管理”，此报告强调了提供一份关于药品使用的充足的见险评估的重要性，包括采用避免专利商品名的混淆以降低用药错误的一项要求。\n'A. Poor Design of Product Container Labels and Carton Labeling Can Obscure  Critical Safety Information Product container labels and carton labeling should communicate information that is critical to the safe use of a medication from the initial prescription, to procurement, preparation and  dispensing of the product to the time it is given to the patient.'可被翻译为：A. 容器标签和纸盒标识的不良设计会掩盖关键的安全信息从最初的处方，到药品的采购，制备和分发，到给患者用药，药品的容器标签 和纸盒标识都应该传达关键的安全用药信息。\n'USP, The United States Pharmacopeia'可被翻译为：美国药典\n\n根据上述已知信息，请将'13Recommendations to the Safe Medication Use Expert Committee by the Health Literacy and Prescription Container Labeling Advisory Panel, May and November 2009, United States Pharmacopia (USP), posted April 2010.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"13健康素养和处方容器标签顾问组对安全药物使用专家委员会的建议，2009年5月和11月，美国药典 （USP），2010年4月发表。"
    },
    {
        "instruction":"已知信息：\n'Evaluations should be carried out at the end of the study, but data also can be collected at interim time points.'可被翻译为：评价应在研究结束时进行，但数据也可在中间时间点收集。\n'Even in studies without planned interim analyses, special attention should be paid to any ongoing monitoring of unblinded data to avoid inappropriate access.'可被翻译为：即 使在没有计划期中分析的研究中，也应特别注意对非盲态数 据的任何持续监测，以避免不适当的访问。\n'The frequency and nature of any planned interim analysis, any specified circumstances in which the study would be terminated and any statistical adjustments to be employed because of interim analyses should be described.'可被翻译为：应描述 期中分析进行的频率和性质、试验被终止的任何特定情况以 及由于期中分析所采用的任何统计学调整。\n'Therefore, if a study includes one or more interim analyses, the planned statistical analysis should not be changed after an interim analysis that involves unblinding.'可被翻译为：因此，如果一项研究包括一项或多项期中分析，则不应 在涉及揭盲的期中分析完成后更改所计划的统计分析计划。\n\n根据上述已知信息，请将'In studies with planned interim analyses, special attention should be given to which individuals have access to the data and results.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在有计划期中 分析的研究中，应特别注意哪些人可以访问数据和结果。"
    },
    {
        "instruction":"已知信息：\n'Daily Dose: The total mass of drug product that is consumed by a patient on a daily basis.'可被翻译为：日剂量： 患者每天使用的药品总量。\n'The quantity of a medicine given per administration, or per day.'可被翻译为：每次或每天的用药数量。\n'ZB3579 is currently being investigated for the treatment of adults with GERD as its primary indication.'可被翻译为：目前，正在研究的ZB3579的主要适应症为成人GERD。\n'FEV1 measurements, adjusted for baseline and measured over time should be used as the primary endpoint in studies in adult patients with asthma.'可被翻译为：FEV1测定（按基线进行调整并随时间进行测定）应作为成人哮喘患者研究中的主要终点。\n\n根据上述已知信息，请将'The average daily adult dosage of a drug product at the time it is used to treat its primary clinical indication.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品用于治疗其主要临床适应证时的成人平均日用量。"
    },
    {
        "instruction":"已知信息：\n'Article 1 The Provisions are formulated for the purposes of ensuring the safety, efficacy and quality of drugs and regulating drug registration in accordance with the Drug Administration Law of the People's Republic of China (hereinafter referred to as the Drug Administration Law), Administrative Permission Law of the People's Republic of China (hereinafter referred to as Administrative Permission Law) and the Regulations for Implementation of the Drug Administration Law of the People's Republic of China (hereinafter referred to as the Regulations for Implementation of the Drug Administration Law).'可被翻译为：第一条 为保证药品的安全、有效和质量可控，规范药品注册行为，根据《中华人民共和国药品管理法》（以下简称《药品管理法》）、《中华人民共和国行政许可法》（以下简称《行政许可法》）、《中华人民共和国药品管理法实施条例》（以下简称《药品管理法实施条例》），制定本办法。\n'Article 1 The Provisions is formulated in accordance with the Drug Administration Law of the People's Republic of China, Regulations for Implementation of the Drug Administration Law of the People's Republic of China and Regulations for Supervision and Administration of Medical Devices, etc., with a view to strengthening the supervision and inspection of drugs and medical devices and reinforcing the prevention and control of safety risks.'可被翻译为：第一条 为加强药品和医疗器械监督检查，强化安全风险防控，根据《中华人民共和国药品管理法》、《中华人民共和国药品管理法实施条例》、《医疗器械监督管理条例》等有关法律法规，制定本办法。\n'Article 1 These provisions of Good Manufacturing Practice (GMP) for Drugs, in accordance with the Drug Administration Law of the People's Republic of China and the Regulations for Implementation of the Drug Administration Law of the People's Republic of China, are enacted to regulate the manufacturing and quality management of Drugs.'可被翻译为：第一条 为规范药品生产质量管理，根据《中华人民共和国药品管理法》、《中华人民共和国药品管理法实施条例》，制定本规范。\n'Article 1: These provisions of Good Manufacturing Practice (GMP) for Drugs, in accordance with the Drug Administration Law of the People's Republic of China and the Regulations for Implementation of the Drug Administration Law of the People's Republic of China, are enacted to regulate the manufacturing and quality management of Drugs.'可被翻译为：第一条 为规范药品生产质量管理，根据《中华人民共和国 药品管理法》、《中华人民共和国药品管理法实施条例》，制定 本规范。\n\n根据上述已知信息，请将'Article 1 The Provisions are enacted with a view to regulating drug insert sheets and labels in accordance with the Drug Administration Law of the People's Republic of China and the Regulations for Implementation of the Drug Administration Law of the People's Republic of China.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一条 为规范药品说明书和标签的管理，根据《中华人民共和国药品管理法》和《中华人民共和国药品管理法实施条例》制定本规定。"
    },
    {
        "instruction":"已知信息：\n'As described in Chapter 4 of ICH Q14, QRM can be used to evaluate the impact of prospective changes for analytical procedures.'可被翻译为：如ICH Q14第4章所述，QRM可用于评价分析方法预期变更的影响。\n'• How QRM and the adherence to associated criteria for relevant performance characteristics and\/or the subsequent execution of a bridging study can ensure the post-change quality of the measured result and help to justify the respective reporting categories for ECs and the post approval change management of analytical procedures.'可被翻译为：QRM和遵守相关性能特征的有关标准和\/或后续执行桥接研究 如何确保变更后测量结果的质量，并有助于证明分析方法ECs 的相应报告类别和批准后变更管理的合理性。\n'When implementing the change, and consistent with Appendix 2, an MAH should consider the impact of the planned change, whether concurrent changes are planned, and if the originally proposed reporting category should be revised.'可被翻译为：在实施变更时（与附录2保持一致），MAH应考虑计划内变更的影响、是否计划同步变更以及是否修订最初拟定的报告类别。\n'• Bridging strategy for changes to analytical procedures'可被翻译为：• 分析方法变更的桥接策略\n\n根据上述已知信息，请将'When initiating changes to analytical procedures, QRM can be used to evaluate the impact of the changes and reconfirm that the originally agreed reporting category is still appropriate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当启动分析方法的变更时，QRM可用于评价变更的影响，以及用于重新确认最初商定的报告类别仍然适当。"
    },
    {
        "instruction":"已知信息：\n'At least one dose should be administered during early organogenesis to evaluate potential direct embryotoxic effects of the components of the vaccine formulation and to maintain a high antibody response throughout the remainder of gestation.'可被翻译为：在器官发生期早期至少应有一次给药，以评估疫苗制剂组分潜在的直接胚胎 毒性作用，并在妊娠期的其余时间内维持高抗体应答。\n'When developing vaccines to be given during pregnancy, a justification should be provided for the specific study design, based upon its intended use (e.g., protecting the mother during pregnancy or protecting the child early postnatally).'可被翻译为：当正在开发的疫苗拟用于妊娠期间时，应基于其拟定用途（例如，在妊娠 期间保护母亲或在出生后早期保护儿童）提供该特异性试验设计的合理性。\n'The most probable option can be equated to a combination of studies for effects on\n- Fertility and early embryonic development\n- Pre- and postnatal development, including maternal function\n- Embryo-fetal development'可被翻译为：最常选用的研究设计应该相当于对下述各阶段影响的联合研究：\n-生育力和早期胚胎发育\n-围产期发育，包括母体的功能\n-胚胎-胎仔发育\n'If a pre- and postnatal study is separated into two studies, one covering the embryonic period the other the fetal period, parturition, and lactation, postnatal evaluation of offspring is required in both studies.'可被翻译为：若把出生前和出生后的试验分为两段进行，一段应涉及胚胎期，另一段应涉及胎仔期、分娩期和哺乳期，而两段试验中均需对出生后子代进行评价。\n\n根据上述已知信息，请将'The vaccination regimen should maximize maternal antibody titers and\/or immune response throughout the embryonic, fetal, and early postnatal periods.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"疫苗接种方案应使在整个胚胎、胎仔和出生后早期阶段尽可能提高母体抗体 滴度和\/或免疫应答。"
    },
    {
        "instruction":"已知信息：\n'VTE-related death'可被翻译为：VTE相关死亡\n'VTE-related death:'可被翻译为：与 VTE 相关的死亡：\n'Cardiovascular death: death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, and death due to other cardiovascular causes.'可被翻译为：心血管死亡：急性心肌梗死造成的死亡、心源性猝死，心脏衰竭导致的死亡、卒 中死亡和其他心血管疾病导致的死亡。\n'Arterial and venous thromboembolic events including myocardial infarction, stroke, deep venous thrombosis and pulmonary embolism have been associated with the use of immunoglobulins.'可被翻译为：已知使用免疫球蛋白会造成动脉和静脉血栓栓塞事件，包括心肌梗塞、中风、深静脉血栓和肺栓塞。\n\n根据上述已知信息，请将'Venous thromboembolism (VTE) is the third leading cause of death due to circulatory diseases, only behind of myocardial infarction and stroke [1].'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"静脉血栓栓塞（VTE）是由于循环系统疾病致死的第三位诱因，仅次于心肌梗死和中风[1]。"
    },
    {
        "instruction":"已知信息：\n'In synchronising the DLPs for the DSUR and PBRER, the period covered by the next DSUR should be no longer than one year.'可被翻译为：在同步DSUR和PBRER的DLP时，下一个DSUR所覆盖的时间段不 得超过一年。\n'The data lock point of the DSUR should be the last day of the one-year reporting period.'可被翻译为：数据锁定点应是DSUR一年报告周期的最后一天。\n'The DSUR should be submitted to all concerned regulatory authorities no later than 60 calendar days after the DSUR data lock point.'可被翻译为：DSUR应当在其数据锁定点后60个日历日内递交至所有相 关的监管机构。\n'Periodicity and DSUR Data Lock Point'可被翻译为：报告周期及DSUR数据锁定点\n\n根据上述已知信息，请将'In synchronising the data lock points for the DSUR and PSUR, the period covered by the next DSUR should be no longer than one year.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"两份报告数据锁定点同步后，下一次DSUR 递交周期不应超过一年。"
    },
    {
        "instruction":"已知信息：\n'It should relate to the information elements required in a submission.'可被翻译为：它应该与 申报文件中所需的信息要素有关。\n'It also can include a brief summary of  completed or planned studies and clinical trials or data that the sponsor or applicant  intends to discuss at the meeting, the general nature of the critical questions to be asked, and where the meeting fits in overall development plans.'可被翻译为：还应简单总结申办方或申请人计划在会议上讨论的已完成或计划研究及临床试验或数据，将要提出的关键问题的大致性质，以及会议在总体研发计划 中处于什么位置。\n'If a sponsor submits additional questions, unsolicited revisions to the protocol, or a lengthy or complex response to an FDA question, or amends original submission materials with new information for any reason, FDA ordinarily will not respond to the original questions and will consider the original SPA submission withdrawn.'可被翻译为：如果申办方递交额外的问题、未经过请求的对方案的修订、或对FDA问题的冗长 或复杂的回应，或出于任何原因用新信息修改原始递交材料，FDA通常不会回 应原始问题，并将认为原始SPA递交内容已被撤消。\n'If appropriate, the regulatory submission would include an updated control strategy.'可被翻译为：适当时，法规申报资料应包括更新的控制策略。\n\n根据上述已知信息，请将'The summary, which usually comprises the first page of the submission, should list the objectives of the submission, and include any questions the sponsor would like addressed in writing.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"概要通常位于提案的第一页，应列出提案的目的，并包括申办方希望以书面形式提出的任何问题。"
    },
    {
        "instruction":"已知信息：\n'This section should not serve to provide analyses or conclusions based on the data presented.'可被翻译为：本章节不提供基于所展示的数据进行的分析或结论。\n'In general, sparing use should be made of unplanned analyses.'可被翻译为：一般而言，应少用计划外分析。\n'9.7 STATISTICAL METHODS PLANNED IN THE PROTOCOL AND DETERMINATION OF SAMPLE SIZE 9.7.1 Statistical and Analytical Plans The statistical analyses planned in the protocol and any changes made before outcome results were available should be described.'可被翻译为：9.7 研究方案中计划的统计方法和样本量的确定 9.7.1 统计分析计划 应描述研究方案中计划的统计分析方法和获得试验结 果之前的任何修改。\n'When extensive statistical analyses have been performed by the applicant, it is essential to consider the extent to which the analyses were planned prior to the availability of data and, if they were not, how bias was avoided in choosing the particular analysis used as a basis for conclusions. This is particularly important in the case of any subgroup analyses, because if such analyses are not preplanned they will ordinarily not provide an adequate basis for definitive conclusions.'可被翻译为：如果申请人进行了额外的统计学分析， 首要考虑该分析是否是在数据获得之前计划开展的，如果在数据获得后 进行的结论支持性分析，需要说明避免偏倚的方法。在进行任何亚组分 析时这点特别重要，因为如果未预先计划此类分析，通常不能为确证性 结论提供充分依据。\n\n根据上述已知信息，请将'In this section emphasis should be on which analyses, comparisons and statistical tests were planned, not on which ones were actually used.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在本章节中，应侧重于计划进行哪些分 析、比较和统计学检验，而不是实际使用哪些。"
    },
    {
        "instruction":"已知信息：\n'A sponsor intending to demonstrate effectiveness by means of a trial showing non- inferiority of the test drug to a standard agent needs to address the issue of the assay sensitivity of the trial, as discussed in section 1.5.'可被翻译为：申办者如果想利用一个相对于标准治疗 药物的非劣效性试验来说明试验药物的有效性，就应如1.5 中所讨论的那样，解决试验检测灵敏度问题。\n'When an active control trial is used to show efficacy by demonstrating non-inferiority, there is the special consideration of assay sensitivity, which is considered above in section 1.5.'可被翻译为：当活性对照试验是用于说明试验药物的非劣 效性时，那么就应该特别考虑在1.5讨论过的检测灵敏度。\n'1.5.1 Assay Sensitivity in Non-inferiority or Equivalence Trials'可被翻译为：1.5.1 非劣效\/等效性试验的检测灵敏度\n'It then discusses the critical design and interpretation issues associated with the use of an active control trial to demonstrate efficacy by showing non-inferiority or equivalence to the control (Section 1.5).'可被翻译为：之后探讨了使用活性对照试验（通过表 明相对于对照组非劣效或等效来证实有效性）的关键设计和 问题阐述 (参阅1.5)。\n\n根据上述已知信息，请将'See section 1.5 for discussion of the problem of assay sensitivity and the ability of the trial to support an efficacy conclusion in non-inferiority or equivalence trials.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.5中讨论了非劣效性或等效性试验中检测灵敏度的问 题以及试验对得出有效性结论的能力。"
    },
    {
        "instruction":"已知信息：\n'\"Significance\" tests (inferential statistics) can be used only as a support for the interpretation of results. The interpretation itself must be based on biological plausibility. It is unwise to assume that a difference from control values is not biologically relevant simply because it is not \"statistically significant\". To a lesser extent it can be unwise to assume that a \"statistically significant\" difference must be biologically relevant. Particularly for low frequency events (e.g. embryonic death, malformations) with one sided distributions, the statistical power of studies is low. Confidence intervals for relevant quantities can indicate the likely size of the effect. When using statistical procedures, experimental units of comparison should be considered: the litter, not the individual conceptus, the mating pair, when both sexes are treated, the mating pair of the parent generation in a two generation study.'可被翻译为：“显著性”检验（为推理性统计方法）只是被用于帮助解释结果。结果解释本身必须以生物学的合理性为依据。仅仅因为没有“统计学意义”而认为与对照组结果的差别没有生物学意义的推论是轻率的。从某种程度上讲，认为有“统计学意义”的差别一定有生物学意义也是不慎重的。特别是对那些呈偏态分布的低发生率的事件（例如胚胎死亡、畸形），统计学在研究中所占权重很低。相关各变量的可信区间可提示可能的作用大小。应用统计学程序时，应考虑组间比较所采用的指标单位：采用窝而不是胎仔个体为单位，若亲代两种性别动物均给药处理，则用交配对（也即两代研究中亲代的配对）为单位。\n'The guideline suggests selection of 1 male and 1 female per litter on the evidence that it is feasible to conduct behavioral and other functional tests on the same F1 individuals that will be used for assessment of reproductive function. This has the advantage of allowing cross referencing of performance in different tests at the individual level. It is recognised, however, that some laboratories prefer to select separate sets of animals for behavior testing and for assessment of reproductive function. Which is the most suitable for an individual laboratory will depend upon the combination of tests used and the resources available.'可被翻译为：本指导原则建议每窝中选择一只雌鼠和一只雄鼠进行试验，这样便于在同一 F1 子代个体中评价生殖功能和进行行为及其他功能测试。这样有利于实现在个体水平相互对照比较不同测试的成果。尽管如此，在一些实验室中，人们更愿意选择不同的子代动物来测试行为和生殖功能。对于某个实验室来说，什么是最合适的取决于所选用的试验组合和已有的资源。\n'Note 23 (5.) Inferential statistics'可被翻译为：注释 23（5.）推理性统计\n'Cesarean, fetal and postnatal data summary statistics should be calculated using the litter as the unit of analysis.'可被翻译为：剖宫产、胎仔和出生后数据的汇总统计应以窝为分析单位来计算。\n\n根据上述已知信息，请将'When employing inferential statistics (determination of statistical significance) the mating pair or litter, not the foetus or neonate, should be used as the basic unit of comparison. The tests used should be justified (Note 23).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当采用推理性统计方法（判断统计学意义）时，应该以交配（动物）对或窝作为组间比较的基本单位，而不是用胎仔或幼仔个体。应说明检验方法的合理性（注释 23）。"
    },
    {
        "instruction":"已知信息：\n'IMATINIB CAS No.: 152459-95-5 (220127-57-1 as mesilate) Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAEL Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Notes 30 mg\/kg oral GD6-15 (FDA, United States, p. 69) Cmax = 3.57 μg\/mLa AUC = 39.28 μg∙h\/mLa 100 mg\/kg oral GD6-15 (FDA, United States, p. 69) Cmax = 12.14 µg\/mLb AUC = 142.55 µg∙h\/mLb exencephaly and\/or protruding tongue, encephalocele, absent frontal or parietal bones; increased post- implantation loss, decreased live fetuses 60 mg\/kg oral GD7-19 (FDA, United States, p. 72) Cmax = 53.06 µg\/mLc AUC = 699.8 µg∙h\/mLc'可被翻译为：伊马替尼 CAS号：152459-95-5（甲磺酸盐：220127-57-1） 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAEL 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 注释 30 mg\/kg 经口 GD6-15（美国 FDA，p. 69） Cmax=3.57 μg\/mLa AUC=39.28 μg∙h\/mLa 100 mg\/kg 经口 GD6-15（美国 FDA，p. 69） Cmax=12.14 µg\/mLb AUC=142.55 µg∙h\/mLb 露脑和\/或舌头突出，脑 膨出，额骨或顶骨缺 失；着床后丢失增加， 活胎数减少 60 mg\/kg 经口 GD7-19 （美国FDA，p. 72） Cmax=53.06 µg\/mLc AUC=699.8 µg∙h\/mLc\n'Pazopanib CAS No.: 444731-52-6 Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAEL Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Notes 1 mg\/kg oral GD6- 17 (FDA, United States, p. 218) Cmax = 3.47 μg\/mLa AUC = 0.028 μg∙h\/mLa 3 mg\/kg oral GD6- 17 (FDA, United States, p.218) Cmax = 10.4 µg\/mLa AUC = 0.083 µg∙h\/mLa malformations in the great vessels, missing innominate artery 3 mg\/kg oral GD7-19 (FDA, United States, p. 225) Cmax = 0.130 µg\/mLb AUC(0-t) = 0.517 µg∙h\/mLc 10 mg\/kg oral GD7- 19 (FDA, United States, p. 225) Cmax = 1.063 µg\/mLd AUC(0-t) = 1.723 µg∙h\/mLd increased post- implantation loss'可被翻译为：帕唑帕尼 CAS号：444731-52-6 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAEL 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 注释 1 mg\/kg 经口 GD6-17（美国 FDA，p. 218） Cmax=3.47 μg\/mLa AUC=0.028 μg∙h\/mLa 3 mg\/kg 经口 GD6-17（美国 FDA，p.218） Cmax=10.4 µg\/mLa AUC=0.083 µg∙h\/mLa 大血管畸形，无名动 脉缺失 3 mg\/kg 经口GD7- 19（美国FDA，p. 225） Cmax = 0.130 µg\/mLb AUC(0-t)=0.517 µg∙h\/mLc 10 mg\/kg经口GD7- 19（美国FDA， p. 225） Cmax=1.063 µg\/mLd AUC(0-t)=1.723 µg∙h\/mLd 着床后丢失增 加\n'Ribavirin CAS No.: 36791-04-5 Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAEL Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Notes 0.3 mg\/kg oral GD6-15 (FDA, United States, p. 64) Cmax = 3.8 ng\/mLa AUC = 8.28 ng∙h\/mLa 1.0 mg\/kg oral GD6-15 (FDA, United States, p. 64) Cmax = 12.7 ng\/mLa AUC = 27.6 ng∙h\/mLa hydrocephaly, retinal folds, diaphragmic hernia, displaced adrenal, displaced oesophagus, vascular defects; extra vertabra, scoliosis, fused ribs and vertebrae, split sternum, ectrodactyly, malrotated hind limbs; increased post- implantation loss 0.3 mg\/kg oral GD6-18 (FDA, United States, p. 68) No rabbit PK data found 1.0 mg\/kg oral GD6-18 (FDA, United States, p. 68)'可被翻译为：利巴韦林 CAS号：36791-04-5 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAEL 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 注释 0.3 mg\/kg 经口 GD6-15（美国 FDA，p. 64） Cmax=3.8 ng\/mLa AUC=8.28 ng∙h\/mLa 1.0 mg\/kg 经口 GD6-15（美国 FDA，p. 64） Cmax=12.7 ng\/mLa AUC=27.6 ng∙h\/mLa 脑积水，视网膜襞， 膈疝，肾上腺移位， 食道移位，血管缺 陷；移行椎，脊柱侧 凸，肋骨和椎骨融 合，胸骨分裂，缺趾 畸形，后肢旋转不 良；着床后丢失增加 0.3 mg\/kg 经口 GD6-18（美国 FDA，p. 68） 未发现兔PK数 据 1.0 mg\/kg 经口 GD6-18（美国 FDA，p. 68）\n'IBRUTINIB CAS No.: 936563-96-1 Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAEL Dose Cmax AUC Rabbit LOAELa Dose Cmax AUC Rabbit Findingsb Notes 40 mg\/kg oral GD6-17 (FDA, United States, p. 126) Cmax = 1.31 μg\/mLc AUC(0-24h) = 5.348 μg∙h\/mLc 80 mg\/kg oral GD6-17 (FDA, United States, p. 126) Cmax = 2.627 µg\/mLd AUC(0-24h) = 13.729 µg∙h\/mLd malformations including dextrocardia, retroesophageal aortic arch, persistent truncus arteriosus, right-sided aortic arch, and interrupted aortic arch;'可被翻译为：依鲁替尼 CAS 号：936563-96-1 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAEL 剂量 Cmax AUC 兔LOAELa 剂量 Cmax AUC 兔 发现b 注释 40 mg\/kg 经口 GD6-17 （美国FDA， p. 126） Cmax=1.31 μg\/mLc AUC(0-24h)=5.348 μg∙h\/mLc 80 mg\/kg 经口 GD6-17 （美国FDA， p. 126） Cmax=2.627 µg\/mLd AUC(0-24h)=13.729 µg∙h\/mLd 畸形包括右位心、食管后 主动脉弓、永存动脉干、 右位主动脉弓、主动脉弓 中断；\n\n根据上述已知信息，请将'TACROLIMUS CAS No.: 104987-11-3 Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAEL Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Notes 1.0 mg\/kg oral GD7-17 (FDA, United States, p. 18) Cmax = 2.9 ng\/mLa AUC(0-inf) = 10.9 ng∙h\/mLa 3.2 mg\/kg oral GD7-17 (FDA, United States, p. 18) Cmax = 20 ng\/mLb AUC(0-inf) = 68.9 ng∙h\/mLb slight increase in post implantation loss (late resorptions) 0.32 mg\/kg oral GD6-18 (FDA, United States, p. 19) Cmax = 0.93 ng\/mLc AUC = 17.6 µg∙h\/mLc 1.0 mg\/kg oral GD6-18 (FDA, United States, p. 19) Cmax = 2.9 ng\/mLc AUC = 55 ng∙h\/mLc ventricular hypoplasia, interventricular septal defect, bulbous aortic arch and stenosis of arch and ductus arteriosus, omphalocele, gallbladder agenesis, skeletal malformations;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"他克莫司 CAS号：104987-11-3 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAEL 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 注释 1.0 mg\/kg经口 GD7-17（美国 FDA，p. 18） Cmax=2.9 ng\/mLa AUC(0-inf)=10.9 ng∙h\/mLa 3.2 mg\/kg 经口 GD7-17（美国 FDA，p. 18） Cmax=20 ng\/mLb AUC(0-inf)=68.9 ng∙h\/mLb 着床后丢失轻微 增加（晚期吸 收） 0.32 mg\/kg 经口 GD6-18（美国 FDA，p. 19） Cmax=0.93 ng\/mLc AUC=17.6 µg∙h\/mLc 1.0 mg\/kg 经口 GD6-18（美国 FDA，p. 19） Cmax=2.9 ng\/mLc AUC=55 ng∙h\/mLc 心室发育不良，室间 隔缺损，球茎主动脉 弓和动脉弓和导管狭 窄，脐膨出，胆囊发 育不全，骨骼畸形；"
    },
    {
        "instruction":"已知信息：\n'The approach taken in this document is an ideal scenario to discuss key points applicable to various stages of drug\/biomarker co-development, whilst it is acknowledged that biomarker discovery may occur at any stage of drug development prior as well as after initial marketing authorization is granted for the medicinal product.'可被翻译为：本原则所讨论的是理想状况，讨论适用于药物\/生物标记物共同研发的各个阶段的关键点，但生物标志物的发现可能发生在药物开发的任何阶段，有 可能是研发开始阶段，也有可能是药品获得首次上市许可后。\n'This might be possible to accomplish through the judicious use of biomarkers in all phases of clinical drug development.'可被翻译为：在药物临床开发的 各个阶段，合理地使用生物标志物可能会实现这个目标。\n'It could be recommended as an integrated part of the drug development programme.'可被翻译为：因此，可以认为这是药物开发项目不可分割的一部分。\n'While serum biomarkers or other sources of biological samples might be informative, tumour samples are expected to constitute an integral part of the biomarker exercise, if not otherwise justified.'可被翻译为：尽管血清生物标志物或其他来源的生物学样本可 能是有用的，但是如果没有其他理由，还是希望用肿瘤样本构建生物标志物应用的完整 部分。\n\n根据上述已知信息，请将'It is therefore advised that identification and inclusion of biomarkers is incorporated as an integral part of the drug development programme.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"因此建议将发现和纳入生物标志物作为药物开发计划的一部分。"
    },
    {
        "instruction":"已知信息：\n'4) To approve specifications, sampling instructions, testing methods and other quality management procedures;'可被翻译为：4.批准质量标准、取样方法、检验方法和其他质量管理的操 作规程；\n'4.2.4.1 Preparation of Quality Control Samples'可被翻译为：4.2.4.1 质控样品的配制\n'Article 250: Any deviation from manufacturing process, material reconciliation, specifications, testing methods and operation procedures etc. should be recorded, and promptly reported to the person in charge and the quality management department with a clear description. Full investigation for major deviations should be carried out by the quality management department in conjunction with other departments, and a report should be filed.'可被翻译为：第二百五十条 任何偏离生产工艺、物料平衡限度、质量标准、检验方法、操作规程等的情况均应当有记录，并立即报告主管人员及质量管理部门，应当有清楚的说明，重大偏差应当由质量管理部门会同其他部门进行彻底调查，并有调查报告。\n'4) Other testing methods requested by regulations for validation.'可被翻译为：4.法规规定的其他需要验证的检验方法。\n\n根据上述已知信息，请将'4) To approve specifications, sampling instructions, testing methods and other quality management procedures;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4.批准质量标准、取样方法、检验方法和其他质量管理的操 作规程；"
    },
    {
        "instruction":"已知信息：\n'If the quantity is below 20,000 vials (including), take 1 product for sampling; if the quantity is below 50,000 vials (including), take 2 products for sampling; if the quantity is below 100,000 vials (including), take 3 products for sampling; if the quantity is more than 100,000 vials, take additional 1 product for sampling for every additional 100,000 vials, and the odd less than 100,000 shall be counted as 100,000.'可被翻译为：2万支（瓶）以下（含2万支），抽样1件；5万支（瓶）以下（含5万支），抽样2件；10万支（瓶）以下（含10万支），抽样3件；10万支（瓶）以上，每增加10万支（瓶）加抽1件，不足10万支（瓶）以10万支（瓶）计。\n'Take 1 product for sampling for every 20,000 boxes (vials), and the odd less than 20,000 boxes (vials) shall be counted as 20,000.'可被翻译为：每2万盒（瓶），抽样一件，不足2万盒（瓶）的按2万盒（瓶）计。\n'If the quantity is less than 10, take 1 product for sampling; if the quantity is 11 to 50, take additional 1 product for sampling for every additional 10, and the odd less than 10 shall be counted as 10; if the quantity is 51 to 100, take additional 1 product for sampling for every additional 20, and the odd less than 20 shall be counted as 20; if the quantity is more than 101, take additional 1 product for sampling for every additional 50, and the odd less than 50 shall be counted as 50; if the quantity is more than 1001, take additional 1 product for sampling for every additional 100, and the odd less than 100 shall be counted as 100;'可被翻译为：10件以内，抽样1件；11件－50件，每增加10件加抽1件，不足10件者以10件计；51件－100件，每增加20件加抽1件，不足20件者以20件计；101件以上，每增加50件加抽1件，不足50件者以50件计；1001件以上，每增加100件加抽1件，不足100件者以100件计；\n'2. If the products within one package are 5 kg (including) to 10 kg, take 1 product for sampling for every 100 kg, and the odd less than 100 kg shall be counted as 100 kg;'可被翻译为：2．药品包装为5－10公斤的（含5公斤），每100公斤抽样1件，不足100公斤者以100公斤计；\n\n根据上述已知信息，请将'If the injection is 100 ml to 1000 ml (including), take 1 product for sampling for every 10,000 vials, and the odd less than 10,000 vials shall be counted as 10,000. If the injection (including dialysate) is more than 1000 ml, take 1 product for sampling for every 5,000 vials (bags), and the odd less than 5,000 vials (bags)shall be counted as 5,000.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"100－1000毫升（含1000毫升）的注射液，每1万瓶抽样1件，不足1万瓶的按1万瓶计。1000毫升以上的注射液（含透析液），每5000瓶（袋）抽样1件，不足5000瓶（袋）的按5000瓶计。"
    },
    {
        "instruction":"已知信息：\n'The guideline also describes submission of analytical procedure development and related lifecycle information in the Common Technical Document (CTD) format (ICH M4Q, The Common Technical Document for the Registration of Pharmaceuticals for Human Use).'可被翻译为：本指导原则还说明了在通用技术文档（CTD）格式（ICHM4Q人用药物注册通用技术文档）中分析方法开发和相关生命周期信息的提交。\n'3. SUBMISSION OF PHARMACEUTICAL DEVELOPMENT AND RELATED INFORMATION IN COMMON TECHNICAL DOCUMENTS (CTD) FORMAT'可被翻译为：3.在通用技术文件（CTD）中提交的药品研发及相关信息\n'This guideline is intended to provide guidance on the contents of Section 3.2.P.2 (Pharmaceutical Development) for drug products as defined in the scope of Module 3 of the Common Technical Document (ICH guideline M4). The guideline does not apply to contents of submissions for drug products during the clinical research stages of drug development. However, the principles in this guideline are important to consider during those stages as well. This guideline might also be appropriate for other types of products. To determine the applicability of this guideline to a particular type of product, applicants can consult with the appropriate regulatory authorities.'可被翻译为：本指导原则是为CTD（ICH M4）模块3中所定义的制 剂在药品研发章节（3.2.P.2）中所申报内容提供指导。本原则不适用于指导药品研发中临床研究阶段的申报内容，但是其中的一些基本原则在该阶段也是非常值得考虑的。本原则也可能适用于其他类型的产品，申报者可以咨询相关管理机构来确定是否适用。\n'SUBMISSION OF PHARMACEUTICAL DEVELOPMENT AND RELATED INFORMATION IN COMMON TECHNICAL DOCUMENTS (CTD) FORMAT'可被翻译为：在通用技术文件（CTD）中提交的药品研发及相信息\n\n根据上述已知信息，请将'This guideline describes the suggested contents for the 3.2.P.2 (Pharmaceutical Development) section of a regulatory submission in the ICH M4 Common Technical Document (CTD) format.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"本指导原则介绍了在ICH M4通用技术文件（CTD）中药品研发章节（3.2.P.2）中应注册申报的内容。"
    },
    {
        "instruction":"已知信息：\n'We also recommend that you provide logarithmic transformation for measures used for BE demonstration.'可被翻译为：同时建议提供BE研究测定方法的对数转换。\n'If data transformation (e.g. logarithmic) is performed, a rationale should be provided.'可被翻译为：若进行数据转换（如对数转换），应提供转换理由。\n'Log Dow values should be determined as described above (and then ion-corrected) or log Dow should be determined as a function of pH covering an environmentally relevant pH-range (at least at 3 pH values ranging from pH 5 to 9) e.g. by measuring the lipophilicity profile (log D as function of pH).'可被翻译为：应该如上所述（然后经离子校正）确定Log DOW值，或者log DOW应该被确定为pH的函数，覆盖环境相关的pH范围（至少在pH 5至9的3个pH值），例如，通过测量亲脂性特征（log D作为pH的函数）。\n'The considerations provided here are for models using latent variables that are mathematically related to directly measured variables.'可被翻译为：本章涉及的考虑因素适用于使用潜变量（在数学上 与直接测定的变量相关）的模型。\n\n根据上述已知信息，请将'The measured data can be mathematically transformed if necessary (e.g., through the use of a log function).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如有必要，可对测量数据进行数学转换（例如，通过使用对数函数）。"
    },
    {
        "instruction":"已知信息：\n'For the post-marketing investigation, PTPs (>150 EDs) regardless of their age can be included provided that the pre-authorisation study in children <12 years is finished.'可被翻译为：在上市后研究中，只要完成对12岁以下儿童的上市前研究，就可以招募任何年龄的 PTPs（ED 大于 150 天）。\n'Subsequently, when PK and  efficacy\/safety data from  PTPs ≥12 years for at least  50 EDs are available, the clinical trial(s) in  children  0-<12 years can be initiated.'可被翻译为：随后，在从年龄≥12 岁的 20 个 PTP 获得关于至少50ED 的药动学和疗效\/安全性数据后，对 0-<12 岁儿童的临床研究才可以开始。\n'A separate progress study report should be provided to the relevant Competent  Authority(ies) 2 years after marketing authorisation to allow for evaluation of recruitment status,  progress and the adherence to timelines. The post-marketing investigation should be completed within 4 years.'可被翻译为：上市后2年需向有关管理部门提交独立的进展研究情况，从而允许对招募状态、进展和时效性作出评价。上市后研究要在4年内完成。\n'A separate progress study report should be provided to the relevant Competent Authority(ies) 2 years after marketing authorisation to allow for evaluation of recruitment status, progress and the adherence to timelines.'可被翻译为：在得到上市许可后的2年内，需向有关部门提交一份独立的研究进展报告，用来评价招募状态、发展和依时性。\n\n根据上述已知信息，请将'PTPs of every age group could be included, provided that trial in children is completed (PK and efficacy and safety) and report is submitted and evaluated by the relevant Competent Authority(ies).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"可以入组每个年龄组的PTP，条件是完成儿童试验（药动学参数、疗效和安全性）并递交报告供相关主管部门评估。"
    },
    {
        "instruction":"已知信息：\n'It also addresses additional considerations for drug products developed as drug-device combination products.'可被翻译为：也讨论了药物-医疗器械联用产品开发的其他考虑。\n'The finished medicinal product may be combined with a medical device or active implantable medical device.'可被翻译为：最终药品可能与一种医疗器械或活动的可移植医疗器械联合使用。\n'Users of medical devices shall use medical devices following the instructions.'可被翻译为：医疗器械的使用者应当按照说明书使用医疗器械。\n'(9) Precautions for medical device discarding or disposal. For products that need to be disposed after use, disposal methods shall be provided.'可被翻译为：（九）医疗器械废弃处理时应当注意的事项，产品使用后需要处理的，应当注明相应的处理方法；\n\n根据上述已知信息，请将'(6) For a product needs to be installed or used in combination with other medical devices, requirements, use methods and precautions of the combining medical devices shall be provided.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（六）产品需要同其他医疗器械一起安装或者联合使用时，应当注明联合使用器械的要求、使用方法、注意事项；"
    },
    {
        "instruction":"已知信息：\n'1.53 Sponsor An individual, company, institution, or organization which takes responsibility for the initiation, management, and\/or financing of a clinical trial.'可被翻译为：1.53 申办者 发起一项临床试验的，并对该试验的管理和财务负责的个 人、公司、机构或组织。\n'A: Parties that provide “material support” are considered sponsors of the covered clinical study.'可被翻译为：答：提供“重要支持的 ”各方被认为是涵盖临床研究的申办方。\n'A: The financial information a clinical investigator provides to his\/her institution is based on the institution’s requirements, which may not be sufficient to meet FDA’s regulations.'可被翻译为：答：临床研究者向其所在机构提供的财务信息的依据是其机构的要求， 这些要求可能不足以符合 FDA 的法规规定。\n'To satisfy the requirements in part 54, if the CRO provides material support for a covered study, financial information on clinical investigators' financial interests in and arrangements with the CRO is to be collected.'可被翻译为：为了符合第 54 部分的要求，如果 CRO 对于一项涵盖的研究提供了重要支持，那么将需 要收集临床研究者在该 CRO 中财务权益和安排的财务信息。\n\n根据上述已知信息，请将'The sponsor refers to the institution or organization that launches, manages and provides financial support for the clinical trial.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"申办者，是指临床试验的发起、管理和提供财务支持的机构或者组织。"
    },
    {
        "instruction":"已知信息：\n'4 June 2009 What approaches can be taken in the event of on-line\/in- line\/at-line testing or monitoring equipment breakdown?'可被翻译为：4 2009年6 月 当在线检测或者 监测设备出现故障时， 可以采取哪些措施？\n'A control strategy can include different elements. For example, one element of the control strategy could rely on end-product testing, whereas another could depend on real-time release testing. The rationale for using these alternative approaches should be described in the submission.'可被翻译为：控制策略中可包括不同的要素。例如，控制策略的一个要素可以依赖于成品检验，另一个要素可以依赖于实时放行检验。在申报资料中应描述使用这些不同方法的理由。\n'6.2 Submission of Control Strategy Information The information provided on the control strategy should include detailed descriptions of the individual elements of the control strategy plus, when appropriate, a summary of the overall drug substance control strategy.'可被翻译为：6.2 控制策略信息的申报 所提供的控制策略方面的信息应包括对控制策略单个 要素的详细描述，在适当的时候，还要加上原料药控制策略的整体总结。\n'Approaches to Developing a Control Strategy'可被翻译为：控制策略的开发方法\n\n根据上述已知信息，请将'The control strategy provided in the application should include a proposal for use of alternative testing or monitoring approaches in cases of equipment failure.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"注册申报资料中提供的控制策略应包括设备故障时可 采用的替代检测或者监测方法的建议。"
    },
    {
        "instruction":"已知信息：\n'A set of data used to give an independent assessment of the performance of the calibration model. (ICH Q2)'可被翻译为：用于对校正模型的性能进行独立评估的一组数据。（ICH Q2）\n'MULTIVARIATE GLOSSARY CALIBRATION SET A set of data with matched known characteristics and measured analytical results. (ICH Q14)'可被翻译为：多变量术语表（MULTIVARIATE GLOSSARY） 校正集（CALIBRATION SET） 一组已知特征和分析检测结果相匹配的数据。（ICH Q14）\n'• In the second phase, model validation, a validation set with independent samples is used for validation of the model.'可被翻译为：在第二阶段，模型验证，使用独立样本组成的验证集对模型进行验证。\n'Independent samples are samples not included in the calibration set of a multivariate model.'可被翻译为：独立样本是指未包含在多变量模型校正集中的样品。\n\n根据上述已知信息，请将'VALIDATION SET A set of data used to give an independent assessment of the performance of the calibration model. (ICH Q2)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"验证集（VALIDATION SET） 用于对校正模型的性能进行独立评估的一组数据。（ICH Q2）"
    },
    {
        "instruction":"已知信息：\n'D - Patient Characteristics D.1 - Patient (name or initials) D.1.1.1 - Patient Medical Record Number(s) and the Source(s) of the Record Number (GP Medical Record Number) D.1.1.2 - Patient Medical Record Number(s) and the Source(s) of the Record Number (Specialist Record Number) D.1.1.3 - Patient Medical Record Number(s) and the Source(s) of the Record Number (Hospital Record Number) D.1.1.4 - Patient Medical Record Number(s) and the Source(s) of the Record Number (Investigation Number) D.3 - Body Weight (kg) D.4 - Height (cm) D.5 - Sex D.6 - Last Menstrual Period Date D.7.2 - Text for Relevant Medical History and Concurrent Conditions (not including reaction \/ event) D.7.3 - Concomitant Therapies D.9.1 - Date of Death D.9.3 - Was Autopsy Done? D - Patient Characteristics D.2.1 - Date of Birth D.2.2a - Age at Time of Onset of Reaction \/ Event (number) D.2.2b - Age at Time of Onset of Reaction \/ Event (unit) D.2.2.1a - Gestation Period When Reaction \/ Event Was Observed in the Foetus (number) D.2.2.1b - Gestation Period When Reaction \/ Event Was Observed in the Foetus (unit) D.2.3 - Patient Age Group (as per reporter) D.2 - Age Information D.8.r.1 - Name of Drug as Reported D.8.r.2a - MPID Version Date \/ Number D.8.r.2b - Medicinal Product Identifier (MPID) D.8.r.3a - PhPID Version Date \/ Number D.8.r.3b - Pharmaceutical Product Identifier (PhPID) D.8.r.4 - Start Date D.8.r.5 - End Date D.8.r.6a - MedDRA Version for Indication D.8.r.6b - Indication (MedDRA code) D.8.r.7a - MedDRA Version for Reaction D.8.r.7b - Reaction (MedDRA code) D.8.r - Relevant Past Drug History (repeat as necessary) D.7.1.r.1a - MedDRA Version for Medical History D.7.1.r.1b - Medical history (disease \/ surgical procedure \/ etc.) (MedDRA code) D.7.1.r.2 - Start Date D.7.1.r.3 - Continuing D.7.1.r.4 - End Date D.7.1.r.5 - Comments D.7.1.r.6 - Family History D.7.1.r - Structured Information on Relevant Medical History (repeat as necessary) 0 ... 1 0 ... n 0 ... n 1 ... 1 D.9.2.r.1a - MedDRA Version for Reported Cause(s) of Death D.9.2.r.1b - Reported Cause(s) of Death (MedDRA code) D.9.2.r.2 - Reported Cause(s) of Death (free text) D.9.2.r - Reported Cause(s) of Death (repeat as necessary) 0 ... n Continued on Next Page'可被翻译为：D -患者特征 1„1 D -患者特征 D.1 -患者（姓名或姓名首字母缩写） D.1.1.1 -患者医疗记录编号和记录编号的来源（GP医疗记录编号） D.1.1.2 -患者医疗记录编号和记录编号的来源（专家记录编号） D.1.1.3 -患者医疗记录编号和记录编号的来源（医院记录编号） D.1.1.4 -患者医疗记录编号和记录编号的来源（研究编号） D.3 -体重（kg） D.4 -身高（cm） D.5 -性别 D.6 -末次月经日期 D.7.2 -相关病史及并发疾病的文本说明（不包括反应\/事件） D.7.3 -合并治疗 D.9.1 -死亡日期 D.9.3 -是否进行尸检？ D.2 -年龄信息 0 „ 1 0 „ n 0 „ n 0 „ n D.2.1 -出生日期 D.2.2a -反应\/事件发生时的年龄（数） D.2.2b -反应\/事件发生时的年龄（单位） D.2.2.1a -当胎儿的反应当胎儿的反应\/事件被观察到时的妊娠期（数） D.2.2.1b -当胎儿的反应当胎儿的反应\/事件被观察到时的妊娠期（单位） D.2.3 -患者年龄段年龄段（按报告者） D.7.1.r -相关病史的结构化信息（必要时重复） D.7.1.r.1a -用于病史的 MedDRA 版本 D.7.1.r.1b -病史（疾病\/外科手术\/等）（MedDRA编码） D.7.1.r.2 -开始日期 D.7.1.r.3 -持续时间 D.7.1.r.4 -结束日期 D.7.1.r.5 -评论 D.7.1.r.6 -家族史 D.8.r -相关既往用药史（必要时重复） D.8.r.1 -报告所用药物的名称 D.8.r.2a - MPID 版本日期\/编号 D.8.r.2b -药品标识符（MPID） D.8.r.3a - PhPID 版本日期\/编号 D.8.r.3b -药剂标识符（PhPID） D.8.r.4 -开始日期 D.8.r.5 -结束日期 D.8.r.6a -针对适应症的 MedDRA版本 D.8.r.6b -适应症（MedDRA编码） D.8.r.7a -针对反应的 MedDRA版本 D.8.r.7b -反应（MedDRA编码） D.9.2.r -报告的死因（必要时重复） D.9.2.r.1a -用于报告死因的 MedDRA版本 D.9.2.r.1b -报告的死因（MedDRA编码） D.9.2.r.2 -报告的死因（自定义文本） 接下页\n'D.10.7.2 Text for Relevant Medical History and Concurrent Conditions of Parent'可被翻译为：D.10.7.2相关病史及并发疾病的文本说明\n'D.10.7.1.r Structured Information of Parent (MedDRA code) (repeat as necessary)'可被翻译为：D.10.7.1.r父母的结构化信息（必要时重复）\n'Table 2: E2B (R3) data elements and MedDRA OIDs Element id Element Name OID Reference D.7.1.r.1b Medical History (disease \/ surgical procedure \/ etc.) (MedDRA code) 2.16.840.1.113883.6.163 D.8.r.6b Indication (MedDRA code) 2.16.840.1.113883.6.163 D.8.r.7b Reaction (MedDRA code) 2.16.840.1.113883.6.163 D.9.2.r.1b Reported Cause(s) of Death (MedDRA code) 2.16.840.1.113883.6.163 D.9.4.r.1b Autopsy-determined Cause(s) of Death (MedDRA code) 2.16.840.1.113883.6.163 D.10.7.1.r.1b Medical History (disease \/ surgical procedure \/ etc.) (MedDRA code) 2.16.840.1.113883.6.163 D.10.8.r.6b Indication (MedDRA code) 2.16.840.1.113883.6.163 D.10.8.r.7b Reactions (MedDRA code) 2.16.840.1.113883.6.163 E.i.2.1b Reactions \/ Event (MedDRA code) 2.16.840.1.113883.6.163 F.r.2.2b Test Name (MedDRA code) 2.16.840.1.113883.6.163 G.k.7.r.2b Indication (MedDRA code) 2.16.840.1.113883.6.163 H.3.r.1b Sender's Diagnosis \/ Syndrome and \/ or Reclassification of Reaction \/ Event (MedDRA code) 2.16.840.1.113883.6.163'可被翻译为：表2：E2B（R3）数据元素和元素MedDRA OID 元素元素ID 元素名称元素 D.7.1.r.1b OID 文献参考文献参考 病史（疾病\/外科手术\/等）（MedDRA编码） 2.16.840.1.113883.6.163 D.8.r.6b 适应症（MedDRA编码） D.8.r.7b 2.16.840.1.113883.6.163 反应（MedDRA编码） D.9.2.r.1b 2.16.840.1.113883.6.163 报告的死因（MedDRA编码） D.9.4.r.1b 2.16.840.1.113883.6.163 尸检确定的死因（MedDRA编码） D.10.7.1.r.1b 2.16.840.1.113883.6.163 病史（疾病\/外科手术\/等）（MedDRA编码） 2.16.840.1.113883.6.163 D.10.8.r.6b 适应症（MedDRA编码） D.10.8.r.7b 2.16.840.1.113883.6.163 反应（MedDRA编码） E.i.2.1b 2.16.840.1.113883.6.163 反应\/事件（MedDRA编码） F.r.2.2b 2.16.840.1.113883.6.163 检测名称检测（MedDRA编码） G.k.7.r.2b 2.16.840.1.113883.6.163 适应症（MedDRA编码） 2.16.840.1.113883.6.163 H.3.r.1b 发送者的诊断\/综合征和（或）对不良反应\/事件的重新分类（MedDRA编码） 2.16.840.1.113883.6.163\n\n根据上述已知信息，请将'D - Patient Characteristics Continued from Previous Page D.10.1 - Parent Identification D.10.2.1 - Date of Birth of Parent D.10.2.2 - Age of Parent D.10.2.2a - Age of Parent (number) D.10.2.2b - Age of Parent (unit) D.10.3 - Last Menstrual Period Date of Parent D.10.4 - Body Weight (kg) of Parent D.10.5 - Height (cm) of Parent D.10.6 - Sex of Parent D.10 - For a Parent-Child \/ Foetus Report, Information Concerning the Parent D.10.7.2 - Text for Relevant Medical History and Concurrent Conditions of Parent D.10.7 - Relevant Medical History and Concurrent Conditions of Parent 0 ... 1 0 ... 1 D.10.7.1.r.1a - MedDRA Version for Medical History D.10.7.1.r.1b - Medical History (disease \/ surgical procedure\/ etc.) (MedDRA code) D.10.7.1.r.2 - Start Date D.10.7.1.r.3 - Continuing D.10.7.1.r.4 - End Date D.10.7.1.r.5 - Comments D.10.7.1.r - Structured Information of Parent (repeat as necessary) 0 ... n D.10.8.r.1 - Name of Drug as Reported D.10.8.r.2a - MPID Version Date \/ Number D.10.8.r.2b - Medicinal Product Identifier (MPID) D.10.8.r.3a - PhPID Version Date \/ Number D.10.8.r.3b - Pharmaceutical Product Identifier (PhPID) D.10.8.r.4 - Start Date D.10.8.r.5 - End Date D.10.8.r.6a - MedDRA Version for Indication D.10.8.r.6b - Indication (MedDRA code) D.10.8.r.7a - MedDRA Version for Reaction D.10.8.r.7b - Reactions (MedDRA code) D.10.8.r - Relevant Past Drug History of Parent (repeat as necessary) 0 ... n D.9.4.r.1a - MedDRA Version for Autopsy-determined Cause(s) of Death D.9.4.r.1b - Autopsy-determined Cause(s) of Death (MedDRA code) D.9.4.r.2 - Autopsy-determined Cause(s) of Death (free text) D.9.4.r - Autopsy-determined Cause(s) of Death (repeat as necessary) 0 ... n'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"D -患者特征 续上页 D.9.4.r -尸检-确定的死因（必要时重复） 0„n D.9.4.r.1a -用于尸检确定的死因的 MedDRA版本 D.9.4.r.1b -尸检-确定的死因（MedDRA编码） D.9.4.r.2 -尸检-确定的死因（自定义文本） D.10 -父母-儿童\/胎儿的报告，关于父母的信息 0„1 D.10.1 -研究识别 D.10.2.1 -父母的出生日期 D.10.2.2 -父母的年龄 D.10.2.2a -父母的年龄（数） D.10.2.2b -父母的年龄（单位） D.10.3 –母亲末次月经日期 D.10.4 -父母的体重（kg） D.10.5 -父母的身高（cm） D.10.6 -父母的性别 0„1 D.10.7.2 -相关病史及并发疾病的文本说明 D.10.7 -父母的相关病史及并发疾病 D.10.7.1.r -父母的结构化信息（必要时重复） 0„n D.10.7.1.r.1a -用于编码病史的 MedDRA版本 D.10.7.1.r.1b -病史（疾病\/外科手术\/等）（MedDRA编码） D.10.7.1.r.2 -开始日期 D.10.7.1.r.3 -持续时间 D.10.7.1.r.4 -结束日期 D.10.7.1.r.5 -评论 D.10.8.r -父母的相关既往药物史（必要时重复） 0„n D.10.8.r.1 -报告所用药物的名称 D.10.8.r.2a - MPID 版本日期\/编号 D.10.8.r.2b -药品标识符（MPID） D.10.8.r.3a - PhPID 版本日期\/编号 D.10.8.r.3b –药物制剂标识符（PhPID） D.10.8.r.4 -开始日期 D.10.8.r.5 -结束日期 D.10.8.r.6a -针对适应症的 MedDRA版本 D.10.8.r.6b -适应症（MedDRA编码） D.10.8.r.7a -针对反应的 MedDRA版本 D.10.8.r.7b -反应（MedDRA编码）"
    },
    {
        "instruction":"已知信息：\n'The process should be evaluated to establish appropriate controls for impurities as they progress through multiple process operations.'可被翻译为：由于杂质通过多个工艺步骤产生，因此应当通过评价工艺来建立合适的杂质控制策略。\n'This testing should be performed at an appropriate point in the manufacturing process.'可被翻译为：应在适当的生产工艺点进 行该项检测。\n'12.60 Systems and processes should be periodically evaluated to verify that they are still operating in a valid manner. Where no significant changes have been made to the system or process, and a quality review confirms that the system or process is consistently producing material meeting its specifications, there is normally no need for revalidation.'可被翻译为：12.60 应当对系统或工艺进行定期评估，以确认它们仍能有效地运作。当系统或工艺未发生显著性变化，且质量回顾表明系统或工艺在持续稳定地生产符合质量标准的物料，通常不需要进行再验证。\n'Manufacturing process performance, including the effectiveness of the control strategy, should be periodically evaluated.'可被翻译为：生产工艺性能，包括控制策略的有效性，应定期进行评估。\n\n根据上述已知信息，请将'The manufacturing process should be periodically evaluated under the firm's quality system to verify removal of the solvent.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"生产过程应该在公司的质量体系下被定期评估以核实溶剂的去除情况。"
    },
    {
        "instruction":"已知信息：\n'[In addition to the text below, include any additional product specific precautions and warnings (e.g. those relating to excipients present in the product).] [Product specific for products containing fructose\/sorbitol]<This medicinal product contains {xx} mg of <sorbitol><fructose> per ml as an excipient.'可被翻译为：[除了以下内容，还要包括任何附加的产品特有注意事项和预防措施（比如：有 关本产品辅料的注意事项）。] [含果糖\/山梨糖醇产品的产品特性]<每毫升此药品含有{ XX }毫克<果糖> <山 梨醇>作为辅料。\n'For acute renal failure see below.> [Product specific for products containing sucrose:] <This medicinal product contains {XX} mg of sucrose per ml as an excipient.'可被翻译为：> [含果糖产品的产品特性：]<毎毫升此药品含有{XX}mg果糖作为辅料。\n'For acute renal failure see below.> [Product specific for products containing glucose:] <This medicinal product contains {XX} mg of glucose per ml as an excipient.'可被翻译为：急性肾衰竭情况见下文。> [含葡萄糖产品的产品特性：]<毎毫升此药品含有{XX}mg葡萄糖作为辅料。\n'For containers holding a volume of less than 1 mL, the strength per fraction of a milliliter should be the only expression  of strength. For example: 12.5 mg\/0.625 mL or 12.5 mg per 0.625 mL 4. Expression of Strength for Dry Powder Products  Dry powder products should express the strength in terms of the total amount of drug per vial as follows: XX mg\/vial or XX mg per vial Instructions for reconstituting the product and the resultant concentration should be included on the vial, if space permits.'可被翻译为：就容器容纳低于1 mL 的容量 来讲，每毫升一部分的规格应是唯一的规格表示方式，例如： 12.5 mg\/0.625 mL 或 0.625 mL 含12.5 mg 4. 干粉剂产品规格的表示 干粉剂产品应以每小瓶药物总量表示规格，如： XX mg\/瓶 或 每瓶XX mg 如果空隙允许，在小药瓶上应包括产品复溶的方法及其终浓度说明。\n\n根据上述已知信息，请将'[Product specific for products containing maltose:] <This medicinal product contains {xx} mg of maltose per ml as an excipient.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"[含麦芽糖产品的产品特性：]<每毫升此药品含有{ XX }mg<麦芽糖>作为辅料。"
    },
    {
        "instruction":"已知信息：\n'Clinical comparability regarding efficacy between the similar and the reference biological medicinal product should be demonstrated in an adequately powered, randomised, parallel group clinical trial.'可被翻译为：应通过充分有力的随机、平行临床试验证明生物类似物和参比生物药品的有效性存在临床可比性。\n'Clinical trials designed to demonstrate efficacy of a new drug by showing that it is similar in efficacy to a standard agent have been called \"equivalence\" trials.'可被翻译为：旨在通过显示一个新药同一个标准治疗药物的有效性 相似来证明其有效性的临床试验称为“等效性试验”。\n'Comparative in vivo studies of pharmacodynamic effects would not be anticipated to be sensitive enough to detect differences not identified by in vitro assays, and are not required as part of the comparability exercise.'可被翻译为：比较性的体内研究的药效动力学效果不会敏感到能检测出体外检定未发现的差异，也不会要求作为可比性研究的一部分。\n'Extrapolation of clinical efficacy and safety in confirmed RRMS to the other indications of the reference medicinal product in MS is possible on the basis of the totality of the evidence provided from the comparability exercise.'可被翻译为：根据可比性研究提供的全部证据，参比药品在确诊RRMS患者中的临床有效性和安 全性可以外延到在MS患者中的其他适应症。\n\n根据上述已知信息，请将'A comparative clinical efficacy trial will usually be required as part of the comparability exercise.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"临床疗效的比较试验通常作为可比性工作的一部分。"
    },
    {
        "instruction":"已知信息：\n'Article 73 Prescriptions dispensed by pharmacists or other drug professionals who are qualified in accordance with the law shall be checked, and no drugs listed in the prescriptions may be changed or substituted without authorization. The pharmacists shall refuse to dispense incompatible or over-dosage prescriptions and prescriptions may be dispensed only after the prescribing physician makes corrections or re-signs the order.'可被翻译为：第七十三条 依法经过资格认定的药师或者其他药学技术人员调配处方，应当进行核对，对处方所列药品不得擅自更改或者代用。对有配伍禁忌或者超剂量的处方，应当拒绝调配；必要时，经处方医师更正或者重新签字，方可调配。\n'Article 58 Drug distributors shall retail drugs properly and include an accurate description of dosage and administration and precautions. Prescriptions for dispensing shall be checked, and no drugs listed in the prescription may be changed or substituted without authorization. Requests to dispense incompatible or over-dosage prescriptions and prescriptions may be dispensed only after the prescribing physician makes corrections or re-signs the order.'可被翻译为：第五十八条 药品经营企业零售药品应当准确无误，并正确说明用法、用量和注意事项；调配处方应当经过核对，对处方所列药品不得擅自更改或者代用。对有配伍禁忌或者超剂量的处方，应当拒绝调配；必要时，经处方医师更正或者重新签字，方可调配。\n'Drugs that can be purchased, dispensed and used only on the prescription of a medical practitioner or assistant medical practitioner.'可被翻译为：凭执业医师和执业助理医师处方方可购买、调配和使用的药品。\n'(III) Those distributing Prepared Slices shall have equipment for storing such drugs and prescription dispensing;'可被翻译为：（三）经营中药饮片的，有存放饮片和处方调配的设备；\n\n根据上述已知信息，请将'(I) Prescription can be dispensed only after being audited by licensed pharmacists. The drugs listed in the prescription shall not be altered or substituted without authorization. The dispensing of prescriptions with incompatibility or overdose shall be refused; however, those may be dispensed after being corrected or re-signed by the prescriber. After the dispensing of prescription, the drugs can be sold only after being checked;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）处方经执业药师审核后方可调配；对处方所列药品不得擅自更改或者代用，对有配伍禁忌或者超剂量的处方，应当拒绝调配，但经处方医师更正或者重新签字确认的，可以调配；调配处方后经过核对方可销售。"
    },
    {
        "instruction":"已知信息：\n'There is no data currently available to support a MRD level below the 10 -4 threshold would provide  added clinical benefit.'可被翻译为：目前，尚无数据表明低于 10-4阀值的MRD水平会产生额外的临床利益。\n'At this present point in time, left ventricular remodelling has not been proven as a surrogate endpoint for medium to long term outcome.'可被翻译为：当前时间点，左心室重构尚未被证明是中长期结局的替代性终点。\n'Current evidence suggests that an MRD level ≥ 10 -2 is associated to a median PFS of about 2 years, whereas a MRD level < 10 -4 predicts a median PFS of around 6 years.'可被翻译为：目前的证据表明，MRD 水平≥10-2 的患者的中位PFS 大约 2 年，而 MRD 水平<10-4的患者的预测中位PFS 大约为 6 年。\n'Although a tissue concentration threshold below which the risk for phototoxic reactions would be negligible is scientifically plausible, there are currently no data to delineate such generic thresholds for all compounds.'可被翻译为：虽然低于组织浓度阈值时，光毒性反应的风险弱化有其科学合理性，但目前并没有界定所有化合物的通用阈值。\n\n根据上述已知信息，请将'There is no prospective data currently available to support that a further reduction of MRD level below the 10 -4 threshold would provide added clinical benefit.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"目前，尚无前瞻性的数据表明MRD 低于 10-4 阀值会产生额外的临床利益。"
    },
    {
        "instruction":"已知信息：\n'The design of the formal stability studies for the drug product should be based on knowledge of the behavior and properties of the drug substance and from stability studies on the drug substance and on experience gained from clinical formulation studies.'可被翻译为：制剂正式稳定性研究的设计应根据对原料药性质和特点的了解、原料药的稳定性试验和从临床处方研究中获得的结果而定。\n'Studies undertaken to elucidate the intrinsic stability of the drug substance.'可被翻译为：为了揭示原料药内在稳定性而进行的研究，它是开发研究的一部分。\n'A thorough knowledge of the chemistry associated with the drug substance manufacturing process, and of the drug product manufacturing process, along with an understanding of the overall stability of the drug substance and drug product is fundamental to developing the appropriate controls.'可被翻译为：全面理解原料 药生产工艺相关的化学信息、制剂生产工艺以及原料药和制剂的整体稳定性，是 建立适当的控制策略的基础。\n'Drug substance and drug product stability protocols.'可被翻译为：原料药和药物产品稳定性方案。\n\n根据上述已知信息，请将'The scope and design of such stability studies are informed by the knowledge and experience of the drug product and drug substance acquired since authorisation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过药品或原料药上市后获得的知识和经验来确定此类型稳定性研究的规模和设计。"
    },
    {
        "instruction":"已知信息：\n'The non- clinical assessment usually includes toxicology, carcinogenicity, immunogenicity, pharmacology, pharmacokinetics, and other evaluations to support clinical studies (and may encompass evidence generated in in vivo and in vitro models, and by modelling and simulation).'可被翻译为：非临床评估通常包括毒理学、致癌性、免疫原性、药 理学、药代动力学和其他用于支持临床研究的评估（并且可 能包括利用体内和体外模型以及通过建模与模拟）。\n'In vitro non-clinical studies should be performed with an appropriate number of batches of product representative of that intended to be used in the clinical trial. These studies should include relevant assays on:'可被翻译为：体外非临床研究应使用临床试验所用的适量且有代表性批次的药物进行研究。这些研究应该包括对以下关试验：\n'Non-clinical studies should be performed before initiating clinical trials. In vitro studies should be conducted first and a decision then made as to the extent of what, if any, in vivo work will be required.'可被翻译为：非临床研究应在开始于临床试验之前。体外研究应当首先开展然后做出推断，如有，则是否需要体内试验。\n'Comparative clinical studies between the biosimilar and reference medicinal product should always be conducted. The number and type of studies might vary according to the reference product and should be justified based on a sound scientific rationale. A stepwise approach is normally recommended 1“Safety” in this context does not usually refer to a complete repeated dose toxicity study, but rather an in-life evaluation of safety parameters such as clinical signs, body weight and vital functions. throughout the development programme, and the extent and nature of the clinical programme depends on the level of evidence obtained in the previous step(s). During the clinical development programme, patients are normally enrolled commensurate with the level of evidence obtained from preceding steps which support comparability.'可被翻译为：生物仿制药和参考药物之间应进行临床比较研究。研究的数量和类型根据参考药物有所不同，而且需要合理的科学依据加以证明。一般在整个研发计划中建议采用循序渐进的方法，临床方案的范围和性质取决于在前面的试验步骤中所获得的证据水平。在临床研究项目中，入组的患者通常与前期的试验步骤中获得的证据水平是相当的，且具有可比性。\n\n根据上述已知信息，请将'The extent and nature of the non- clinical in vivo studies and clinical studies to be performed depend on the level of evidence obtained in the previous step(s) including the robustness of the physicochemical, biological and non-clinical in vitro data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"非临床体内研究和临床研究的开展程度和性质取决于前一步获得的证据，包括理 化、生物学和非临床体外数据的稳健性。"
    },
    {
        "instruction":"已知信息：\n'Studies aiming at the proof of efficacy must have a confirmatory statistical approach.'可被翻译为：旨在证明有效性的研究必须有确证性的统计方法。\n'These proposals will be given due consideration according to the strength of the supportive evidence.'可被翻译为：将根据支持证据的强度对这些提议给予 适当考虑。\n'These plots can show individual study p-values and confidence intervals.'可被翻译为：这些图可以显示个体研究的p值和置信区间。\n'The credibility of regional, pooled subpop- ulation, or subgroup findings should take into consideration biological plausibility, inter- nal consistency (e.g., similar patterns of regional variability observed for other secondary endpoints) and\/or external consistency (e.g., similar patterns observed in another clinical trial of the same drug), the strength of evidence, the clinical relevance, and the statistical uncertainty.'可被翻译为：区域、合并亚群，或亚组结果的可信度应考虑生物学上 的合理性、内部一致性（例如，观察到的其它次要终点的区域差异 的相似模式）和\/或外部一致性（例如，同一种药物在其它临床试 验中观察到的相似模式）、证据强度、临床相关性、以及统计学不 确定性。\n\n根据上述已知信息，请将'Support for the proposed claim should be described in terms of the strength of statistical evidence, including consistency of findings, individual study strength, p-values, and confidence intervals.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应根据统计证据的强度来描述对提出的申请的支持，包括结果的一致性、个体研究强度、p值和置信区间。"
    },
    {
        "instruction":"已知信息：\n'Unless the target for activity is expressed only in these rare conditions, Sponsors are in general advised to undertake studies in these small patient groups in parallel to or when benefit – risk is established in indications allowing a more comprehensive evaluation, especially with respect to safety.'可被翻译为：除非 靶点活性的表达仅见于这些罕见的情况，通常建议申办方平行或者在允许进行更全面评 估的适应症中确定了获益-风险时在这些小规模患者人群进行研究，特别是关于安全性的。\n'Some possible target indications comprise very small groups of patients, so small that “exceptional circumstances” might apply.'可被翻译为：一些可能的靶向适应症所包括的患者群体非常小，小到可能是“特殊情况”。\n'Studies in small study populations, very rare tumours For some truly rare tumours or very narrow indications, whether due to tumour phenotype or restrictions related to target expression, it is simply not possible to recruit a sufficiently large number of patients to conduct reasonably powered, randomised studies in order to detect clearly relevant differences in anti-tumour activity.'可被翻译为：在小规模人群、非常罕见的肿瘤的研究 对于一些真正罕见的肿瘤或者非常窄的适应症（究竟是由于肿瘤表型还是由于与靶 点表达有关的限制所致），为了检测抗肿瘤活性的明显相关性差异根本不可能招募到足 够数量的患者进行合理效力的随机研究。\n'7.6.6. Studies in small study populations, very rare tumours'可被翻译为：小样本人群罕见肿瘤的研究\n\n根据上述已知信息，请将'Some possible target indications comprise very small groups of patients, so small that “exceptional circumstances” might apply. Unless the target for activity is expressed only in these rare conditions, Sponsors are in general advised to undertake studies in these small patient groups in parallel to or when benefit – risk is established in indications allowing a more comprehensive evaluation, especially with respect to safety.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"某些潜在目标适应症包括非常小组的患者，小到可以适用“例外情况”。除非在这些 少数情况下表现出目标活性，否则当在适应症确定获益-风险并允许开展与安全 有关的更为全面的评估时，一般建议申办者在这些患者小组中展开研究。"
    },
    {
        "instruction":"已知信息：\n'If a drug product is intended for use in both sexes, the applicant should include similar proportions of males and females in the study.'可被翻译为：·如果药物拟用于两种性别，那么研究入选的男性和女性应占相似的比例。\n'In contrast, substantial reduction in exposure to parent drug with time (e.g., ≥ 50% reduction from initial exposure) can disqualify the study (unless a blood sample taken in the first few days is available).'可被翻译为：与之相反，母体化合物随给药时间增加而 暴露量明显减少（如比起始暴露量减少≥50%），使得该试验不合适（除非可获得开始给药后较短几天内的血样）。\n'Study Animals\/ dose group Duration\/ Exposure Controls Doses Most sensitive tumor site\/sex TD50 (mg\/kg\/d)'可被翻译为：研究项目 动物\/剂量组 时间\/暴 露 对照组 剂量 最敏感的肿 瘤发生部位\/ 性别 TD50 （mg\/kg\/ 天）\n'It is not settled whether and how often there are sex differences in response to QT-prolonging drugs not explained by exposure alone.'可被翻译为：这并未解决对 QT 延长药物的应答是否有性别差异以及 多长时间出现一次性别差异的问题（并不能仅通过暴露量解释说明）。\n\n根据上述已知信息，请将'If this is seen in one sex, generally the sex with reduced exposure would not be scored at the end of the study, unless there is enhanced exposure to a metabolite of interest.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果这种现象发生于单性别，通常在试验结束时不对暴露量减少的该性别进行评价，除非该性别中令人关注的代谢物的暴露量增加。"
    },
    {
        "instruction":"已知信息：\n'Data are still limited, however.'可被翻译为：但是数据仍然有限。\n'So far limited data are available.'可被翻译为：到目前为止，只有有限的数据是可用的。\n'Although a TLV is available for tin (2 mg\/m3; US DoL, 2013), there is insufficient data to set a MRL (ATSDR 2005; EU SCOEL 2003).'可被翻译为：虽然 可用锡的TLV值（2 mg\/m3）[5]，但据此设定MRL值仍不充分[3,6]。\n'In some cases, only a limited number of patients or centers may be willing to participate in studies.'可被翻译为：在有些 情况下，可能只有有限的病人或中心愿意参加研究。\n\n根据上述已知信息，请将'Some human data are available but only in a limited number of subjects (ATSDR, 2003).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"仅在有限的几 个项目提供了一些人类数据[4]。"
    },
    {
        "instruction":"已知信息：\n'All operations, including filling and labeling, which a bulk product has to undergo in order to become a finished product. Aseptic filling, filling of products for terminal sterilization, and etc., are not regarded as packaging.'可被翻译为：待包装产品变成成品所需的所有操作步骤，包括分装、贴签等。但无菌生产工艺中产品的无菌灌装，以及最终灭菌产品的灌装等不视为包装。\n'1. Packaging: All operations, including filling and labeling, which a bulk product has to undergo in order to become a finished product.'可被翻译为：（一）包装 待包装产品变成成品所需的所有操作步骤，包括分装、贴签 等。\n'All operations, including filling and labelling, that a bulk product has to undergo in order to become a finished product.'可被翻译为：散装产品为成为成品而必须经历的所有操作，包括灌装和贴标。\n'If a sterile bulk solution is not filled immediately into the final product containers, the sterile filtration should, unless justified, be repeated immediately before filling in containers.'可被翻译为：无菌待包装溶液未立即灌装到最终产品容器中的，除有正当理由外，在灌 装至容器里之前应立即重复无菌过滤。\n\n根据上述已知信息，请将'1.All operations, including filling and labelling, that a bulk product has to undergo in order to become a finished product. Sterile filling would not normally be regarded as part of packaging, the bulk product being the filled, but not the finally packaged, primary container.\n2.All operations, including filling and labelling, that a bulk product has to undergo in order to become a finished product. Filling of a sterile product under aseptic conditions or a product intended to be terminally sterilized, would not normally be regarded as part of packaging.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.散装产品为成为成品而必须经历的所有操作，包括灌装和贴标签。无菌灌装通常不被视为包装的一部分，散装产品是被灌装的，但不是最终包装的主要容器。\n2.散装产品为成为成品而必须经历的所有操作，包括灌装和贴标签。在无菌条件下灌装无菌产品或打算最终灭菌的产品，通常不被视为包装的一部分。"
    },
    {
        "instruction":"已知信息：\n'Irrespective of the type of trials used for exploration, it is important to collect information on the performance of the biomarker(s) for predictability and clinical validity. Clinical validity of a marker is a  complex interplay of sensitivity and specificity (of the test\/ marker) and the penetrance of the genomic  abnormality or mutation. The developmental studies in addition to hypothesis generation, should aim  to indicate whether further evaluation of the GBM is feasible and worthwhile. In this aspect they would serve equivalent to phase-II clinical studies but are likely influenced by the limitations of the exploratory data sets (in cohort or single arm studies). It is expected that some form of validation of the data generated in these studies will be available and it is necessary to perform this on data not  used for generation of the GBM itself. The process should gather information relating to the predictive performance of the GBM(s) and this should include positive and negative predictive values that are  evaluated further at the confirmatory stage.'可被翻译为：不考虑用以外推的试验类型，有必要收集生物标记物在预测性和临床有效性方面的性能信息。标记物的临床有效性受到敏感性、特异性（试验\/标记物）和基因组异常或突变的显率的复杂相互作用。产生假设的开发研究，目的应该是表明GBM的进一步评估是否可行和有意义。从这一点而言此类研究等同于II期临床研究，但有可能受探索性数据集的限制的影响（队列或单组研究）。可以预料，对这些试验产生的数据进行某些形式的确证是可行的，有必要针对不用于产生GBM本身的一些数据开展此种确证。在确证阶段应收集有关该GBM的预测性能的信息，应包括进一步的评估的阳性和阴性预测值。\n'While GBMS may be used to indicate many facets of a disease, two important roles are identified. In the context of this paper, the GBMs of interest are those that provide clues towards response (safety or efficacy or metabolic) to a particular therapeutic intervention, especially drug therapy (Predictive markers) or those that indicate disease prognosis (Prognostic Markers) that may not have an intrinsic relation to specific intervention, either drug therapy or otherwise. Some markers may play both roles.'可被翻译为：基因生物标记物可用于预测疾病的多个方面，但有两点作用最为重要。本文中的相关基因生物标记物包括可为对特定的治疗干预（特别是药物治疗）的反应（安全性、疗效或代谢）提供信息的标记物（预测性标记物），或与特定干预无内在关联的疾病预后标记物（无论是药物治疗或其他因素）（预后标记物）。某些标记物可能同时起到上述两种作用。\n'Predictive genomic biomarkers may be binary (e.g. gene mutations) or be described by classifiers (e.g. gene expression levels, loss of heterozygosity).'可被翻译为：预测性基因组生物标志物可能是二元的（例如基因突变）或通过分类特征来描述（例如基因表达水平、杂合性的丧失）。\n'A gene that controls the expression of one or more other genes. A gene that codes for proteins. In cases where genes encode micrornas, they also work at the RNA level.'可被翻译为：控制一个或多个其他基因表达的基因。能编码蛋白质。在基因编码微小RNA情况下，也可作用在RNA水平上。\n\n根据上述已知信息，请将'For the purposes of drug development, predictive GBMs occupy the highest area of interest. These should be pre-treatment characteristics that enable to determine whether a particular subject is a good candidate for treatment with a test agent. Commonly these tend to be binary or depend on classifiers (see section 3.2). Of note, these GBMs, in their simplest form could be a gene or point mutation. Alternatively, they could be based on expression levels of many genes where expression profiles of these genes are combined and evaluated in a predefined fashion. If the relationship between different genes or their expression levels are not predefined, but cut off points are generated using ROCs from one trial, then confirmation in a second trial would be expected. Evaluation of clinical utility of such predictive markers is facilitated by pivotal trials conducted in defined patient populations, selected and grouped based on the marker(s).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"预测性基因生物标记物在药物研中是最为重要的领域，这些预测性基因生物标记物应当包括某些治疗前特征，以判定某一受试者是否适合接受这一受试药物。通常来说这些预测性基因生物标记物采用两分法或按特定的分类程序来分类（见3.2章）。需注意这些基因生物标记物最简单的形式可能是一个基因或一个点突变，或者可能基于许多基因的表达水平，其表达模式以一种既定的方式进行结合和评估。如果这些不同的基因或者表达水平的关系不是预先确定，而是按照一项试验中的受试者工作特征来确定相关临界值的，则需要另外一项试验来确认这种关系。通过在一些根据标记物选择和分组的明确患者人群中进行关键性临床试验有助于对这类预测性标记物的临床使用情况进行评估。"
    },
    {
        "instruction":"已知信息：\n'For example, user confusion and dosing errors can occur if product strength is expressed on the label in percentage, but the directions for dosage and administration of the drug are expressed in milligrams.'可被翻译为：如果标签上用表示产品规格，而在用法用量的说明中以mg表示能发生用药者混淆和给药错误。\n'Developing a product strength that is incongruent with the dosage and administration of the product complicates the calculation, preparation, and administration of a dose and has led to medication dosing errors.'可被翻译为：开发与产品的剂量和给药不一致的产 品规格使得剂量的计算、制备和给药复杂化并且导致用药错误。\n'The similarity of the product code numbers has led to selecting and dispensing of the wrong strength and wrong drug. The middle digits are traditionally used by healthcare providers to check the correct product, strength, and formulation.'可被翻译为：药品编码号的相似性导致了选择和分 发错误的规格和错误的药物。医护人员习惯使用中间的位数检查产品，规格及配方是否正确。\n'E. Avoid Look-alike Container Labels and Carton Labeling  Look-alike container labels and carton labeling have frequently contributed to product selection  errors leading to the dispensing and administration of the wrong drug, wrong strength and\/or  wrong dose.'可被翻译为：E.避免使用外形相似的容器标签和纸盒标识 。 外观相似的容器标签和纸盒标识经常导致药品选择错误，从而又导致分发和配 给了错误的药品，错误的规格和\/或错误的剂量。\n\n根据上述已知信息，请将'If the product strength is not clearly displayed on the container label, or is expressed in units of measure that are incongruent with those used in the dosing instructions, the wrong strength can be selected or the wrong dose administered (i.e., over- or under-dosing).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果产品的规格在容器标签 上显示地不清楚，或表述用的计量单位与计量说明上所使用的计量单位不一致，就 有可能会导致选择和配给错误的剂量（即，用药过量或用药不足）。"
    },
    {
        "instruction":"已知信息：\n'If models of just central neuropathic pain or of just peripheral neuropathic pain are studied, 569 the indication will normally be restricted accordingly. Suitable central neuropathic models include spinal cord injury and post-stroke pain.'可被翻译为：如果研究仅仅中枢神经性疼痛或仅仅周围神经性疼痛的模型，通常会相应地限制适应症。合适的中枢神经病模型包括脊髓损伤和中风后疼痛。\n'Suitable peripheral neuropathic models include post herpetic neuralgia, diabetic painful neuropathy and trigeminal neuralgia.'可被翻译为：合适的外周神经病模型包括带状疱疹后神经痛、疼痛性糖尿病性神经病和三叉神经痛。\n'Central mechanisms may be involved in both peripheral and central neuropathic pain, but peripheral mechanisms are not generally involved in central neuropathic pain.'可被翻译为：中枢机制可能参与外周和中枢神经性疼痛，但外周机制通常不参与中枢神经性疼痛。\n'To justify a general indication for the treatment of neuropathic pain, efficacy needs to be demonstrated independently in models of both central and peripheral neuropathic pain.'可被翻译为：为了证明治疗神经性疼痛的一般适应症是合理的，需要单独证明在中枢和周围神经性疼痛中的有效性。\n\n根据上述已知信息，请将'Examples of central neuropathic pain are post-stroke or spinal cord injury neuropathic pain, while diabetic peripheral neuropathy (DPNP) or post-herpetic neuralgia (PHN) are common peripheral neuropathic pain conditions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"中枢神经性疼痛的示例是中风后或脊髓损伤神经性疼痛，而糖尿病痛性周围神经病变 （DPNP）或带状疱疹后神经痛（PHN）是常见的外周神经性疼痛病症。"
    },
    {
        "instruction":"已知信息：\n'The role and responsibility of the trial statistician (see Glossary), in collaboration with other clinical trial professionals, is to ensure that statistical principles are applied appropriately in clinical trials supporting drug development.'可被翻译为：试验统计 师（见词汇表）在与其他临床试验专家合作时，其作用和职 责是确保在支持药物研发的临床试验中恰当地应用统计学 原则。\n'The protocol and subsequent amendments should be approved by the responsible personnel, including the trial statistician.'可被翻译为：方案及后续修 订应获得包括试验统计师在内的责任人员的批准。\n'The integrated full report of a study should not be derived by simply joining a separate clinical and statistical report.'可被翻译为：一项研究的 综合性完整报告不应是临床报告和统计报告的简单合并。\n'1.34 Investigator A person responsible for the conduct of the clinical trial at a trial site. If a trial is conducted by a team of individuals at a trial site, the investigator is the responsible leader of the team and may be called the principal investigator. See also Subinvestigator.'可被翻译为：1.34 研究者 负责在一个试验单位实施临床试验的人。如果在一个试验单位是由一组人员实施试验，研究者指这个组的负责人，也称为主要研究者。见次级研究人员。\n\n根据上述已知信息，请将'To this end the trial statistician should be a member of the team responsible for the clinical study report, and should approve the clinical report.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为此，试验统计师应是负责临床研究报告的小组成 员之一，还应批准临床报告。"
    },
    {
        "instruction":"已知信息：\n'> <This medicinal product is authorised in the Member States of the EEA under the following names:>'可被翻译为：<本药品以下列名称在EEA的成员国中获批。\n'User Guidance This repeatable data element should be populated with the study registration number as assigned in a reporting region, e.g. EudraCT number for reporting in the European Economic Area (EEA). Refer to regional implementation guides for details.'可被翻译为：用户指导原则 该可重复数据元素应该填写报告地区中分配的研究注册编号元素，例如：在欧洲经济区（EEA）报告的EudraCT号码。详细信息请参见地区实施指导原则。\n'G.k.2.1 Medicinal Product Unique Identifier \/ Pharmaceutical Product Unique Identifier'可被翻译为：G.k.2.1 药品独特标识符\/医药产品标识符\n'6.51 These records should be numbered with a unique batch or identification number, dated and signed when issued. In continuous production, the product code together with the date and time can serve as the unique identifier until the final number is allocated.'可被翻译为：6.51 批生产记录在发放时应当有唯一的批号或编号，应记录发放日期并签名。连续生产情况下，在最终批号确定之前，产品代码、日期和时间可以共同作为唯一的识别编号。\n\n根据上述已知信息，请将'11 The EudraCT number is the unique identifier for trials authorised in the European Economic Area.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"11 EudraCT编号是欧洲经济区内获准的临床试验的唯一识别码。"
    },
    {
        "instruction":"已知信息：\n'As discussed in Section IV, FDA recommends that potential ANDA applicants follow a tier-based approach to efficiently compare the abuse deterrence of T product to R product.'可被翻译为：如章节IV中所讨论的，FDA建议潜在ANDA申请者按照基于层次的方法，它可以有效地对比T产品与R产品之间的防止滥用的措施。\n'FDA recommends that potential ANDA applicants follow a tier-based approach to efficiently compare a T product to its R product and limit the number of tests required for evaluating the abuse deterrence of T product.'可被翻译为：FDA建议潜在ANDA申请者遵循基于层次的方法，它可以 有效地对比T产品及其R产品，并限制评估T产品的防止滥用的措施所需的检验 数量。\n'The evaluation of the abuse deterrence of T product should be based on the potential applicant’s best understanding of the abuse deterrence of R product, the potential routes of abuse, and specific measures meaningful to the evaluation of abuse by those routes.'可被翻译为：对T产品的防止滥用的措施评估应基于潜在 申请者对R产品的防止滥用的措施、可能的滥用途径、以及对通过这些途径滥用 的评估有意义的特定措施的最大理解。\n'Statistically compare the abuse deterrence of T versus R products.'可被翻译为：从统计学角度对比T和R产品的防止滥用的措施。\n\n根据上述已知信息，请将'In order to adequately compare R and T products, a potential ANDA applicant should identify the R product’s abuse deterrence for all routes of abuse using the tier-based approach described in this guidance.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为了充分地对比R产品与T产品，潜在ANDA申请者应采用在本指南描述的基于层次的方法，鉴定R产品在所 有滥用途径方面的防止滥用的措施。"
    },
    {
        "instruction":"已知信息：\n'The evaluation of response is performed according to RECIST criteria when soft-tissue metastases are detectable.'可被翻译为：如果检测出软组织转移，需要根据 RECIST 标准评价治疗反应。\n'In most cases supportive evidence of efficacy and safety of the experimental compound is expected from studies conducted in the metastatic setting.'可被翻译为：在大部分情况下，预期关于试验性药物的疗效和安全性的支持性证据来自于用于转移性疾病的研究。\n'The protocol should define methods to be used to exclude distant metastases. Digital rectal examination is still considered the most appropriate method to assess local progression. If studies cannot be conducted under proper double blind conditions, examination by two independent urologists is recommended. Response criteria are otherwise similar to those for metastatic disease presented below.'可被翻译为：方案应该定义出用于排除远端转移的方法。直肠指检仍然被认为是最适合评估局部进展的方法。如果研究无法在双盲情况下进行，建议由两个独立的泌尿科医生进行检查。其它疗效标准与下文描述的远端转移瘤的标准类似。\n'Therapy for metastatic disease'可被翻译为：远端转移瘤的治疗\n\n根据上述已知信息，请将'Response criteria are otherwise similar to those for metastatic disease presented below.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"其它疗效标准与下文描述的远端转移瘤的标准类似。"
    },
    {
        "instruction":"已知信息：\n'So, primary outcomes should focus on renal specific endpoints.'可被翻译为：因此，主要终点应关注肾脏特定的终点。\n'The primary endpoint should be well defined in the protocol with a justification of the clinical relevance and the validity of the measurement procedures.'可被翻译为：方案中应该对主要终点进行明确设定。研究主要终点须有临床依据，而且测量过程经验证后确认有效。\n'Partial response, defined as a clinically meaningful improvement or stabilisation of GFR without full recovery to normal or baseline values.'可被翻译为：部分缓解，其定义为GFR出现有临床意义的改善或稳定，但没有完全恢复到正常水平或基线值。\n'such as active urinary sediment, proteinuria and renal function, including clinically relevant change in serum creatinine and GFR values'可被翻译为：如活动性尿沉渣，蛋白尿，和肾功能包括血清肌酐和GFR检查值出现有临床意义的变化。\n\n根据上述已知信息，请将'It is expected that primary endpoints should be contextualised by reference to clinically meaningful values for major\/complete response, such as normalisation\/return to baseline of measured GFR or proteinuria of <0.5 g\/24-h.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"预期主要终点应参考主要\/完全肾脏缓解的有临床意义的数值，如GFR恢复正常或恢复到基线水平，或 24 小时尿蛋白低于 0.5 g。"
    },
    {
        "instruction":"已知信息：\n'In general, a multi-regional study should be designed with sufficient numbers of subjects so that there is adequate power to have a reasonable likelihood of showing an effect in each region of interest.'可被翻译为：通常，多地区研究应包括足够数量的受试者以便具有足够的把握度来合理地证明药物在每个申报地区的有效性。\n'Assuming the new region finds the studies in the first region pertinent, the regulatory authority of the new region will likely require a controlled study in its own region to establish efficacy (and\/or to address other issues).'可被翻译为：假设发现新地区认为其研究结果与原地区具有相关性，则新地区的监管机构可能会要求在本地区进行对照临床研究，以确定药物的有效性（和\/或解决其它问题）。\n'Although MRCTs may generally become the preferred option for investigating a new drug for which regulatory submission is planned in multiple regions, the potential for regional differences to impact the interpretability of study results should be carefully considered. 2.'可被翻译为：尽管MRCT通常可作为计划在多个区 域监管递交的新药研究首要选择，但应仔细考虑区域差异 影响研究结果可解释性的可能性。\n'6. In light of diverse regional practices, ensuring high quality of study design and conduct in accordance with ICH E6 in all regions is of paramount importance to ensure the study results are interpretable.'可被翻译为：6. 鉴于不同的区域实践，确保在所有区域按照ICH E6要求进 行高质量的研究设计以及实施，对确保研究结果的可解释 性至关重要。\n\n根据上述已知信息，请将'The results of a study are often used in regulatory submissions in multiple regions, and the design should also consider the relevance of the study results for regions other than the one(s) in which the study is conducted.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一项研究的结果通常用于多个地区的监管 申请，设计还应考虑研究结果与进行研究地区以外地区的相 关性。"
    },
    {
        "instruction":"已知信息：\n'Different IRBs may consider more or less community consultation necessary, depending on the unique circumstances of a particular study and the community.'可被翻译为：不同的IRB可能认为需要开展更多或更少的社区咨询，取决于特定研究和社区的独特环境。\n'There are inevitably questions of how “representative” community representatives are, and how to interpret the views of the various communities involved in the research, particularly if they differ, and what constitutes an appropriate response.'可被翻译为：对于社区代表的 “代表性”如何，以及如何解读参与该项研究的不同社区的意见，尤其是在 它们不同时，和如何进行适当的回应，都不可避免的存在疑问。\n'In conducting community consultation activities, sponsors and clinical investigators should ensure that representatives from the community(ies) involved in the research have an opportunity to participate in the consultation process.'可被翻译为：在开展社区咨询活动时，申办方和临床研究者应确保参与该项研究的社区代表具有参与该咨询过程的机会。\n'59. What information should be included in community consultation? The content and extent of community consultation activities (see below) may vary depending on what is known about the product and what is known about the risks posed by the study.'可被翻译为：59 社区咨询时应包括哪些信息？ 社区咨询活动的内容和范围（见以下说明）可能依对该产品的了解和该项研究风险的了解而不同。\n\n根据上述已知信息，请将'The types and number of representatives who participate in community consultation activities may vary by study or even across sites within the same study.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"参与社区咨询活动的代表的类型和数量可以因研 究而不同，甚至同一项研究不同中心也可以不同。"
    },
    {
        "instruction":"已知信息：\n'Data should be gathered so as to enable evaluation of the clinical causes of reduction in mortality (such as arrhythmias, stroke, myocardial infarction, non-cardiovascular, etc.).'可被翻译为：应集中数据，从而能够评估死亡率下降的临床诱因（如心律失常、中风、心肌梗塞、非心血管性等）。\n'Survival  Efforts should be made to define the specific mode of cardiac death occurring in the studies (e.g. sudden cardiac death, pump failure, acute coronary events).'可被翻译为：生存率 应尽量明确研究中发生的心源性死亡的具体模式（如心源性猝死、泵功能衰竭、急性冠状动脉事件）。\n'Cardiovascular death: death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, and death due to other cardiovascular causes.'可被翻译为：心血管死亡：急性心肌梗死造成的死亡、心源性猝死，心脏衰竭导致的死亡、卒 中死亡和其他心血管疾病导致的死亡。\n'Death which cannot be attributed to a documented cause and for which DVT \/ PE cannot be ruled out (sudden unexplained death).'可被翻译为：不能归因于记录的死亡，并且不能排除 DVT\/ PE（不明原因猝死）。\n\n根据上述已知信息，请将'It is important to include sudden death (or death due to arrhythmia when documented) in evaluating mortality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"评估死亡率的时候应把猝死（或有证明的心律失常导致的死亡）包括在内，这是非常重要的，"
    },
    {
        "instruction":"已知信息：\n'defined as the rate of patients experiencing at least one major bleeding and\/or a clinically relevant non-major bleeding.'可被翻译为：定义为至少出现一次严重出血和\/或临床相关非严重出血的患者比例。\n'defined as the rate of patients experiencing at least one clinically relevant non-major bleeding or other non-major bleeding.'可被翻译为：定义为至少出现一次临床相关非严重出血或其他非严重出血的患者比例。\n'- Total bleeding: defined as the rate of patients experiencing at least one major bleeding, clinically relevant non-major bleeding or other non-major bleeding.'可被翻译为：- 总出血：定义为至少出现一次严重出血、临床相关非严重出血或其他非 严重出血的患者比例。\n'- Non-major bleeding: defined as the rate of patients experiencing at least one clinically relevant non-major bleeding or other non-major bleeding.'可被翻译为：- 非严重出血：定义为至少出现一次临床相关非严重出血或其他非严重出血的患者比例。\n\n根据上述已知信息，请将'defined as the rate of patients experiencing at least one major bleeding, clinically relevant non-major bleeding or other non-major bleeding.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"定义为至少出现一次严重出血、临床相关非严重出血或其他非严重出血的患者比例。"
    },
    {
        "instruction":"已知信息：\n'5) A description of the packaging operation, including any significant subsidiary operations, any precaution for equipment to be used and checks on packaging materials prior to use;'可被翻译为：5.包装操作步骤的说明，包括重要的辅助性操作和所用设备 的注意事项、包装材料使用前的核对；\n'7. Details of the packaging operations carried out, including reference numbers to equipment and the packaging lines used;'可被翻译为：7.包装操作的详细情况，包括所用设备及包装生产线的编号。\n'Any materials employed in the packaging of a drug, including immediate packaging materials, container in direct contact with drugs, and printed packaging materials, but excluding any outer packaging materials used for transportation or shipment.'可被翻译为：药品包装所用的材料，包括与药品直接接触的包装材料和容器、印刷包装材料，但不包括发运用的外包装材料。\n'2.Packaging materials: Any materials employed in the packaging of a drug, including immediate packaging materials, container in direct contact with drugs, and printed packaging materials, but excluding any outer packaging materials used for transportation or shipment.'可被翻译为：（二）包装材料 药品包装所用的材料，包括与药品直接接触的包装材料和容器、印刷包装材料，但不包括发运用的外包装材料。\n\n根据上述已知信息，请将'5) A description of the packaging operation, including any significant subsidiary operations, any precaution for equipment to be used and checks on packaging materials prior to use;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"5.包装操作步骤的说明，包括重要的辅助性操作和所用设备 的注意事项、包装材料使用前的核对；"
    },
    {
        "instruction":"已知信息：\n'1. All processing of swabs must be aseptically performed within a HEPA Filtered II Biological Safety Cabinet (BSC) or HEPA Filtered Laminar Flow Hood (LFH) with an air classification at the same rating or better than that from which the swab was collected'可被翻译为：1.拭子处理必须在 HEPA 过滤 II 级生物安全柜（BSC）或 HEPA 过滤层流罩（LFH）内无菌操作，其中的空气级别应该等于或优于擦拭取样点。\n'Carefully disinfect exterior of each swab container and place into the sanitized BSC\/LFH and allow to air dry.'可被翻译为：仔细对每个拭子容器外部消毒，将其放入灭菌后的 BSC\/LFH，晾干。\n'Sterile 70% ethanol (ETOH) or Isopropyl Alcohol (IPA)'可被翻译为：无菌 70%乙醇（ETOH）或异丙醇（IPA）\n'Repeat disinfection procedure using appropriate disinfectant\/sporicidal immediately prior to placing product primary containers in a working certified laminar flow hood. Allow all disinfected containers to completely air dry in the laminar flow hood prior to opening for analysis. Alternatively, if conducting the testing in an isolator, place the disinfected items into the isolator and proceed with the local procedures for the proper decontamination of the interior of the isolator.'可被翻译为：使用适当的消毒剂\/杀孢子重复消毒程序，然后立即在将产品内包容器放入经过认证的工作层流罩中。在打开进行分析之前，让所有已消毒的容器在层流罩中完全晾干。或者，如果在隔离器中进行测试，则将已消毒的物品放入隔离器中，并按照当地程序对隔离器内部进行适当的净化。\n\n根据上述已知信息，请将'2. All surfaces within the BSC or LFH must be thoroughly disinfected with a sporicidal disinfectant followed by filter sterile 70% ethanol or IPA prior to placing swabs under the hood and beginning analysis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2.将拭子放进层流罩开始分析之前，BSC 或 LFH 的所有表面必须用杀孢子剂和过滤器无菌 70%乙醇或 IPA 彻底消毒"
    },
    {
        "instruction":"已知信息：\n'human serum albumin chiral stationary phase'可被翻译为：人血清白蛋白手性固定相\n'A chiral stationary phase of protein prepared by N, v-dissuccinimide binding pepsin to aminopropyl silica gel.'可被翻译为：由N,V-二琥珀酰亚胺酯将胃蛋白酶结合在胺丙基硅胶上制备的一种蛋白质手性固定相。\n'Also known as \"C8 column two, a commonly used high performance liquid chromatography bonded silica gel filler, is a chemically bonded silica gel stationary phase.'可被翻译为：又称“C8柱二一种常用的高效液相色谱键合硅胶填料，是一种化学键合硅胶固定相。\n'Using silica gel as stationary phase, the chromatography of liquid-solid adsorption separation was carried out in the column.'可被翻译为：以硅胶作为固定相，在柱中进行液-固吸附分离的色谱法。\n\n根据上述已知信息，请将'A protein chiral stationary phase covalently bonded by human serum albumin to a diol activated silica gel support using silica gel as a carrier. Used in protein analysis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以硅胶为载体，由人血清白蛋白与双醇激活硅胶担体共价键合的一种蛋白质手性固定相。用于蛋白质分析。"
    },
    {
        "instruction":"已知信息：\n'Article 26 Before CFDI implements registration inspection, it shall formulate an inspection protocol in accordance with the Key Points and Determination Principles of Drug Registration Inspection, based on the risk principle, and in combination with the inspection objects and inspection concerns (if any) proposed by CDE. The content of the inspection protocol includes: the basic information of the inspected institution, the type of inspection, the purpose of the inspection, the basis of the inspection, the time of the on-site inspection, the content of the inspection, the members of the inspection team, etc.'可被翻译为：第二十六条 核查中心实施注册核查前，根据《药品注册核查要点与判定原则》,基于风险原则，并结合药品审评中心提出的核查对象和核查关注点(如有),制定核查方案。核查方案内容包括：被核查单位基本情况、核查品种、核查目的、核查依据、现场核查时间、核查内容、核查组成员等。\n'The principles, procedures, timelines and requirements for initiating drug registration inspection shall be formulated and issued by the CDE; the principles, procedures, timelines and requirements for implementing drug registration inspection shall be formulated and issued by the CFDI.'可被翻译为：药品注册核查启动的原则、程序、时限和要求，由药品审评中心制定公布；药品注册核查实施的原则、程序、时限和要求，由药品核查中心制定公布。\n'Key Points and Determination Principles of Drug Registration Inspection'可被翻译为：药品注册核查要点与判定原则\n'Article 30 The inspection team shall conduct on-site inspection in accordance with the requirements of the inspection protocol and the main points of the inspection, and record the inspection time, location, inspection content, and problems found in detail. When necessary, the inspection team can adjust the inspection implementation protocol based on the on-site inspection situation and the risk principle. For adjustments such as extending or shortening the inspection time, increasing, or reducing the inspection objects, etc., it needs to be reported to CFDI for approval before implementation.'可被翻译为：第三十条 核查组应当按照核查方案的要求，根据核查要点，实施现场核查，详细记录核查时间、地点、核查内容、发现的问题。必要时，核查组可以根据现场核查的情况，基于风险原则，调整核查实施方案。对于延长或者缩短核查时间、增加或者减少核查对象等调整情况，需报核查中心批准后执行。\n\n根据上述已知信息，请将'Article 22 In accordance with the Key Points and Determination Principles of Drug Registration Inspection, based on the risk principle, and combined with the inspection objects and inspection concerns (if any) proposed by CDE, CFDI determines the inspection location and formulates an inspection plan in combination with the inspection resources, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十二条 核查中心根据《药品注册核查要点与判定原则》,基于风险原则，并结合药品审评中心提出的核查对象和核查关注点(如有),确定核查地点，结合核查资源等，制定核查计划。"
    },
    {
        "instruction":"已知信息：\n'2.2.10.Statements\/Labeling A storage statement should be established for the labeling in accordance with relevant national\/regional requirements.'可被翻译为：2.2.10 说明\/标签 应按照相应的国家\/地区的要求，在标签上说明贮藏条件。\n'Such labelling should be in accordance with relevant national\/regional requirements.'可被翻译为：这种标签应符合当地有关国家\/地区的规定。\n'The formal labeling requirements for photolabile drug substances and drug products are established by national\/regional requirements.'可被翻译为：光敏性原料药和制剂的正式标签要求是根据国家\/地区的要求制定的。\n'The stability of freeze-dried products after their reconstitution should be demonstrated for the conditions and the maximum storage period specified on containers, packages, and\/or package inserts. Such labelling should be in accordance with relevant national\/regional requirements.'可被翻译为：在容器、包装和\/或使用说明书上应注明冻干制品溶解后的稳定性，其中应包括溶解后的贮藏条件和最长贮藏期，这些标签均应符合当地有关国家\/地区规定。\n\n根据上述已知信息，请将'A storage statement should be established for the labeling in accordance with relevant national\/regional requirements.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应按照相应的国家\/地区的要求，在标签上说明贮藏条件。"
    },
    {
        "instruction":"已知信息：\n'A1 For the purpose of this document, microsampling is a method to collect a very small amount of blood (typically ≤50 µL) that is generally used to measure concentrations of a drug and\/or its metabolites, and subsequently calculate the appropriate TK parameters.'可被翻译为：回答1：在本文件中，微量采样是采集极少量血液（通常≤50μL） 的一种方法，通常用于测定药物和\/或其代谢物的浓度以及后续计 算合适的毒代动力学参数。\n'Alternatively, sparse sampling* can be used in conjunction with microsampling, if scientifically justified. *Sparse sampling in TK studies usually involves the collection of a few blood samples at specified timepoints from each animal in a treatment group.'可被翻译为：*毒代动力学研究中的稀疏采样通常涉及在特定时间点从治疗组中的每个动物采集少量血液样本。\n'It is referred into deep somatic tissues, to the skin and to other 113 visceral organs.'可被翻译为：内脏疼痛涉及深躯体 组织、皮肤和其他内脏器官。\n'The following methods can be used to determine the permeability of a drug substance from the GI tract: (1) in vivo intestinal perfusion studies in humans; (2) in vivo or in situ intestinal perfusion studies using suitable animal models; (3) in vitro permeation studies using excised human or animal intestinal tissues; or (4) in vitro permeation studies across a monolayer of cultured epithelial cells.'可被翻译为：可采用以下方法测定药物在胃肠道中的渗透性：（1）人体体内肠道灌注研究；（2）使用合适的动物模型进行体内或原位肠道灌注研究；（3）离体人或动物肠道组织的体外渗透性研究；（4）单层人工培养上皮细胞的离体渗透性研究。\n\n根据上述已知信息，请将'A microbiosampling technique that combines push-pull perfusion and dialysis techniques. It can be used on anesthetized or awake organisms and is especially suitable for in vivo biochemical studies of deep tissues and vital organs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将推挽灌流和透析技术结合起来的一种微量生物采样技术。可在麻醉或清醒的生物体上使用，尤其适合于深部组织和重要器官的活体生化研究。"
    },
    {
        "instruction":"已知信息：\n'Different phrases are used to describe the expectation for evaluation of suppliers of materials [ICH Q7, Sections 7.11, 7.12, 7.31], including traders, if any. [ICH Q7, Section 7.12] states that all materials are purchased against a specification and from suppliers approved by the quality unit [ICH Q7, Section 7.31].'可被翻译为：【ICHQ7，第7.11、7.12和7.31章节】从不同方面对物料供应商评估作出了要求，包括贸易商，如适用。【ICHQ7，第7.12章节】要求物料应当按标准从经质量管理部门批准的供应商处采购【ICHQ7，第7.31章节】。\n'11) To assess and approve material suppliers;'可被翻译为：11.评估和批准物料供应商；\n'7.4 June 2015 Are on-site audits required in the evaluation of suppliers?'可被翻译为：7.4 对供应商进行评估时是否需要进行现场审计？\n'11.1 June 2015 What is expected in terms of impurities for APIs extracted from herbal or animal tissue origin [ICH Q7, Section 11.2]?'可被翻译为：11.1 从植物或动物组织提取的原料药，其杂质有哪些要求【ICHQ7，第11.2章节】？\n\n根据上述已知信息，请将'7.2 June 2015 What is expected in terms of evaluation of suppliers of materials?'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"7.2 关于物料供应商评估的具体要求是什么？"
    },
    {
        "instruction":"已知信息：\n'The investigators should describe the reasons for their choices of study design, selection of databases, and analysis plan as they pertain to the hypotheses.'可被翻译为：研究者应该描述选择这样的研究设计、对数据库的选择及分析计划的原因，因为他们都与假设有关。\n'Investigators should predefine aspects of the study related to the design, analysis, conduct, and reporting of the study and articulate them in the study protocol and final reports, along with a science-based rationale for the scientific study choices pertaining to these aspects of the study; more information regarding these aspects is provided in sections IV, V, and VI of this guidance.'可被翻译为：研究者应预先定义与研究的设计、分析、执行和报告有关的方面，将其整理形成研究方案和最终报告，附上与研究的这些方面有关的科学研究选择的科学依据；关于这些方面的更多信息在本指导原则的章节IV、V和VI中提供。\n'Investigators should also discuss the limitations of the database and the study design, and the impact of those limitations on generalizability.'可被翻译为：研究者还应讨论数据库及研究设计的局限性， 以及这些局限性对结论概括性的影响。\n'5. Deviations from study protocol, SOPs or other operational instructions should be recorded, and evaluated in a timely manner, and reported truthfully in the final report.'可被翻译为：5.试验方案、SOP  或其他试验操作文件的偏离应及时记录、评估并如实反映在总结报告中。\n\n根据上述已知信息，请将'Investigators should discuss their rationale for selecting a particular study design in the study protocol and final report.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究者应该在研究方案和最终报告中 讨论选择某种特殊的研究设计的依据。"
    },
    {
        "instruction":"已知信息：\n'On the basis of 26 studies, it has been estimated that the prevalence of constipation is about two 688 times higher in women than in men89.'可被翻译为：根据已实施的 26 项研究，估计女性便秘的发病率比男性高两倍89 。但通常 来说，之前慢性特发性便秘的临床试验中招募的患者主要为女性，约占 80%以上。\n'Constipation more frequently affects women, older people, and patients with a low socioeconomic status.'可被翻译为：便秘更常影响女性、老年人和社会经济地位较低的患者。\n'It occurs about two to three times more commonly in women than in men, although this gender difference disappears in later life as the overall prevalence increases.'可被翻译为：尽管由于总的发病率上升，性别因素在晚年没有差异，但一般来说女性发病率是男性的2-3倍。\n'Frailty prevalence increases with age, with a non-linear pattern, is higher in women than in men, but frail women have a better survival than frail men (6).'可被翻译为：虚弱发病率随年龄增加，二者不是线性模式，女性虚弱发病率高于男性，但虚弱的女性生存情况优于虚弱的男性（6）.\n\n根据上述已知信息，请将'On the basis of 26 studies, it has been estimated that the prevalence of constipation is about two times higher in women than in men.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"基于26项研究，得出女性便秘的患病率高于男性两倍。"
    },
    {
        "instruction":"已知信息：\n'Methods exist that may mitigate some of these challenges and should be considered during the design phase.'可被翻译为：有些方法可能减轻上述某些挑战，应在设计阶 段予以考虑。\n'Special populations, like children and elderly, should be considered when developing a GTMP.'可被翻译为：开发基因治疗药品时应考虑到特殊人群， 如儿童与老年人。\n'Consideration should be given to the quality and quantity of relevant data characterising the pharmacokinetics of the drug when designing the blood sampling protocol.'可被翻译为：在制定血液采集方案时应该考虑药物的药物代谢动力学特征相关数据的质量和数量。长时间间隔的 血液采样可能无法提供足够的信息。\n'When designing such vectors, applicants should take into account that epigenetics could interfere with the efficacy and safety of the final GTMP.'可被翻译为：设计这类载体时，申请人需要考虑表观遗传学对最终基因治疗药品的有效性和安全性产生的影响。\n\n根据上述已知信息，请将'Consideration should be given to such barriers when designing the GTMP.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"设计基因治疗药品时需要考虑到这些障碍。"
    },
    {
        "instruction":"已知信息：\n'When terminal sterilisation by heat is 304 not possible, the application of an alternative method of terminal sterilisation, sterilising filtration 305 and\/or aseptic processing may be considered.'可被翻译为：无法使用热法终端灭菌的，可以考虑应用终端灭菌 的替代方法、除菌过滤和\/或无菌生产工艺。\n'In case of medicinal products containing highly sensitive active substances, (e.g. proteins or heat labile  biological substance), where it is well known that terminal sterilisation is not possible, a justification  based on a scientific rationale is generally acceptable and further justification of the choice of aseptic   processing discussed later in section 4.3 may not be needed.'可被翻译为：药品含高度敏感的活性物质的（如蛋白质或热不稳定的生物物质），众所 周知其无法使用终端灭菌，基于科学理据的解释一般是可接受的，可能不需要 下面第4.3节所讨论的无菌生产工艺选择的进一步依据。\n'A change in shelf-life or storage conditions caused by a terminal sterilisation process is not in itself a  reason to allow aseptic processing, unless the new storage condition or shelf-life would cause problems  in the use of the product.  Aseptic processing cannot be accepted based solely on an increase in impurity levels upon terminal sterilisation without further justification.'可被翻译为：终端灭菌工艺引起的货架期或贮存条件的变化其本身不能成为采用无菌生 产工艺的理由，除非新的贮存条件或货架期会导致产品使用问题。 在不提供进一步证据的情况下，无菌生产工艺是不会仅基于终端灭菌后杂 质水平升高而被认可的。\n'Sterilisation  by  radiation  is  used  mainly  for  the  sterilisation  of heat  sensitive  materials  and  products. Ultraviolet  irradiation  is  not  an   acceptable  method   of  sterilisation.   Guidance  regarding   ionising  radiation sterilisation can be found within Annex 12.'可被翻译为：辐照灭菌主要用于热敏感物料和产品的灭菌。紫外线照射不是可接受的灭菌方法。关于电离辐照灭菌的指导见附录 12。\n\n根据上述已知信息，请将'The choice to use a heat-labile packaging material cannot in itself be the sole reason for not using aterminal sterilisation process and alternative materials could be examined; for instance, polypropylene is not as sensitive to heat as polyethylene and could allow terminal sterilisation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"选择使用热不稳定包装材料本身并不能作为不使用终端灭菌工艺的唯一理 由，可以考察替代材料；例如，聚丙烯对热不如聚乙烯那么敏感，可以进行终 端灭菌。"
    },
    {
        "instruction":"已知信息：\n'Where the review and comparison identify any gaps or differences, appropriate action should be taken. This may include the adaptation of existing equipment or acquisition of new equipment. Any modification or adaptation of existing equipment to become capable of reproducing the process being transferred should be documented.'可被翻译为：如果审核和比较中发现有任何差距与差异，则应采取恰当措施。措施可包括对现有设备进行改造，或采购新设备。对现有设备的任何改造或调整均使得其能够生产准备转移的工艺的情况均应有记录。\n'A review and a side-by-side comparison of equipment and instruments, as well as process steps and parameters of the SU and RU should be carried out in terms of their working principle, capacity, make and models to ensure they are capable of appropriately performing the required processes and methods.'可被翻译为：应对SU和RU的设备与仪器的工作原理、能力、厂商和型号进行审核和一对一比较，确保其能够恰当执行所需工艺和方法。\n'Article 241: Operation procedures should be established to define the request, assessment, review, approval and implementation of changes in starting materials, packaging materials, specifications, testing methods, operation procedures, premises, facilities, equipment, instruments, manufacturing process and computer software.'可被翻译为：第二百四十一条 应当建立操作规程，规定原辅料、包装材料、质量标准、检验方法、操作规程、厂房、设施、设备、仪器、 生产工艺和计算机软件变更的申请、评估、审核、批准和实施。\n'Article 241 Operation procedures should be established to define the request, assessment, review, approval and implementation of changes in starting materials, packaging materials, specifications, testing methods, operation procedures, premises, facilities, equipment, instruments, manufacturing process and computer software. The quality management department should assign a designated person to take charge of the change control.'可被翻译为：第二百四十一条 应当建立操作规程，规定原辅料、包装材料、质量标准、检验方法、操作规程、厂房、设施、设备、仪器、生产工艺和计算机软件变更的申请、评估、审核、批准和实施。质量管理部门应当指定专人负责变更控制。\n\n根据上述已知信息，请将'a parallel comparison of premises, equipment, instruments, materials, procedures, and methods for transfer under consideration;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"转移涉及的设施、设备、仪器、物料、程序与方法的平行比较；"
    },
    {
        "instruction":"已知信息：\n'The ultimate aim of developing new therapies, e.g., in patients with high grade lymphoma, germ cell tumours or in the adjuvant setting, is to improve cure rate and survival or to relevantly decrease toxicity without loss of efficacy. Nevertheless, in some cases and due to the complexity of administered therapies, e.g. in AML, the impact of a relevantly active experimental compound on these endpoints may be hard to demonstrate.'可被翻译为：在患有高恶性淋巴瘤、生殖细胞肿瘤或在佐药设置中制定新的疗法的最终目的是为了提高治愈率和生存率或在不损失疗效的情况下相应地减少毒性。然而，在某些情况下，由于服药疗法的复杂性，如在急性髓系白血病(AML)中，相对活性试验化合物对这些终点 的影响可能难以界定。\n'Irrespective of the choice of primary endpoint OS or PFS, ORR and rate of tumour stabilisation for, e.g. 3 or 6 months should be reported. Especially in the palliative setting, HRQoL\/PRO using generally accepted instruments might be informative (Appendix 2)'可被翻译为：不论是否选择主要终点 OS 或 PFS，应报告 3 个月或 6 个月的 ORR 和肿瘤稳定率。特 别是在缓和设置中，使用通用仪器的 HRQoL\/PRQ 一般可传递出某些信息（附录 2）\n'(Neo)adjuvant therapy In the adjuvant setting, the ultimate aim is to increase cure rate.'可被翻译为：（新）辅助治疗 辅助治疗的最终目的是提高治愈率。\n'7.5.2. (Neo)adjuvant therapy In the adjuvant setting, the ultimate aim is to increase cure rate.'可被翻译为：7.5.2. （新）辅助疗法\n\n根据上述已知信息，请将'Especially in the palliative setting, HRQoL\/PRO using generally accepted instruments might be informative (Appendix 2) 7.2. Treatment administered with curative intent The ultimate aim of developing new therapies, e.g., in patients with high grade lymphoma, germ cell tumours or in the adjuvant setting, is to improve cure rate and survival or to relevantly decrease toxicity without loss of efficacy.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"特别是在姑息性治疗，使用广泛公认仪器的HRQoL\/PRO可能是有用的（附录2） 7.2 以治愈为目的给予治疗 开发新的治疗方法（例如在高分级的淋巴瘤、生殖细胞肿瘤患者或辅助性治疗）的 最终目的是提高治愈率和生存率或相对降低毒性而不损失疗效。"
    },
    {
        "instruction":"已知信息：\n'A plasma exposure (AUC) ratio for high dose selection in the absence of dose limiting toxicity or other criteria as outlined in ICH S1C(R2) has not been globally accepted as a dose-setting criterion in the rasH2-Tg mouse model. A retrospective evaluation of available data from 53 compounds tested in this model determined that detection of compound-related tumors emerged in all cases within a systemic rodent-to-human exposure ratio up to 50-fold (15). Based on this analysis, it was concluded that a 50-fold plasma exposure ratio (rodent:human) is an adequate criterion for high dose selection. Therefore, all criteria for selection of the high dose as specified in S1C(R2) for 2-year rodent carcinogenicity studies are applicable to rasH2-Tg mice, including a plasma exposure ratio, except that the plasma exposure ratio will be 50-fold in rasH2-Tg mice rather than 25-fold as for 2-year studies conducted in standard strains of rodents.'可被翻译为：在rasH2-Tg小鼠模型中，ICH S1C(R2)中列出的在剂量限制性毒性或其他标准不适用时，采用血浆暴露量（AUC）比值选择高剂量尚未被全球接受。对该模型中测试的53种化合物的已有数据的回顾性分析确定，在所有案例中，化合物相关的肿瘤检测均出现在啮齿类动物与人体系统暴露量比50倍的范围内（15）。基于此分析，得出的结论是50倍的血浆暴露量比值（啮齿类动物:人）足以作为高剂量选择的标准。因此，S1C(R2)中规定的2年啮齿类动物致癌性试验高剂量选择的所有标准均适用于rasH2-Tg小鼠致癌性试验，包括血浆暴露量比值，但rasH2-Tg小鼠暴露量比值要求为50倍，而不是在标准品系啮齿类动物2年试验中的25倍。\n'3. CLARIFICATION ON CRITERIA FOR HIGH DOSE SELECTION BASED ON EXPOSURE FOR RASH2-TG MOUSE CARCINOGENICITY STUDIES'可被翻译为：3. 澄清rasH2-Tg小鼠致癌性试验中基于暴露量的高剂量选 择标准\n'However, for the present, and based on an analysis of a database of carcinogenicity studies performed at the MTD, the selection of a high dose for carcinogenicity studies which represents a 25- to-1 exposure ratio of rodent to human plasma AUC of parent compound and\/or metabolites is considered pragmatic (Note 3).'可被翻译为：然而，目前基于对采用MTD选择高剂量开展的致癌性试验数据库的分析，按照人血浆中原形药物和／或代谢物 AUC 25倍选择啮齿类动物致癌性试验的高剂量被认为是实用的 （参见注释3）。\n'In the absence of confounding maternal toxicity, the selection of a high dose for EFD and PPND studies that represents a > 25-fold exposure ratio to human plasma exposure of total parent compound at the intended maximal therapeutic dose is therefore considered pragmatic and reasonably sufficient for detecting outcomes relevant for human risk assessment.'可被翻译为：因此，在没有 母体毒性干扰的情况下，以拟用最大治疗剂量下总原形化合物人血浆暴露量 的>25倍暴露比的剂量，作为EFD和PPND试验的高剂量选择，被认为是实用 的且足以检测与人类风险评估相关的结果。\n\n根据上述已知信息，请将'In addition, an exposure ratio endpoint based on animal to human plasma Area Under the Curve (AUC) for high dose selection in 2-year rodent studies as per ICH S1C(R2) has not been globally accepted for use in the rasH2-Tg mouse study. Therefore, a comprehensive analysis was conducted to assess exposures and outcomes in rasH2-Tg mouse studies from available information (15). As described in Section 3, the results of this analysis indicate that a 50-fold plasma AUC exposure ratio (rodent:human) is an adequate criterion for high dose selection.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"此外，按照ICH S1C(R2)，在2年啮齿类动物试验中基于动物与人血浆的曲线下面积（AUC）的暴露量比值终点选择高剂量的方法，尚未被全球接受用于rasH2-Tg小鼠试验中。因此，应用现有信息对rasH2-Tg小鼠试验中的血浆暴露量和试验结果进行了全面分析（15）。如第3章节所述，分析结果显示，50倍的血浆AUC暴露比值（啮齿类动物：人）足以作为标准用于高剂量的选择。"
    },
    {
        "instruction":"已知信息：\n'The drug is dissolved in the molten carrier, and the drug is mainly dispersed in the molecular state in the homogeneous system formed by the solid dispersion.'可被翻译为：药物溶解于熔融的载体中，药物主要以分子状态分散在固体分散体中所形成的均相体系。\n'The phenomenon of the formation of new phase precipitation between the drug and the material under certain conditions.'可被翻译为：药物与材料在一定条件下形成新相析出的现象。\n'The process by which an electrolyte forms freely moving cationic ions in an aqueous solution or molten state.'可被翻译为：电解质在水溶液或熔融状态下生成自由移动阴阳离子的过程。\n'A dispersion system formed in a highly dispersed solid carrier (or substrate).'可被翻译为：固体药物高度分散在固体载体（或基质）中形成的分散体系。\n\n根据上述已知信息，请将'The drug is dispersed in a molten transparent amorphous carrier, which cools abruptly to obtain a solid solution in a brittle and transparent state.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物分散于熔融的透明状无定形载体中，骤然冷却，得到质脆透明状态的固体溶液。"
    },
    {
        "instruction":"已知信息：\n'10) Dates and signatures of the persons who verified the testing and the calculations.'可被翻译为：10.检验、计算复核人员的签名和日期。\n'9) Dates and signatures of the persons who performed the testing;'可被翻译为：9.检验人员的签名和日期；\n'Persons who use electronic signatures based upon use of identification codes in combination with passwords shall employ controls to ensure their security and integrity. Such controls shall include:'可被翻译为：同时使用识别码和密码的电子签名应给予管理以确保其安全性和完整性，管理内容应包括：\n'8) Dates of testing;'可被翻译为：8.检验日期；\n\n根据上述已知信息，请将'10) Dates and signatures of the persons who verified the testing and the calculations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"10.检验、计算复核人员的签名和日期。"
    },
    {
        "instruction":"已知信息：\n'For confirmatory trials, an acceptable primary end point is time to need for radical therapy, or proportion of patients in need for such therapy at a predefined point in time. Until now, however, there is no consensus as regards criteria defining need for radical therapy. Clinical guidelines developed by European Urology Association (EAU), National Cancer Comprehensive Network (NCCN) and National Institute for health and clinical excellence (NICE) suggest several options. This unfortunate situation is acknowledged; nevertheless clear criteria defining need for radical therapy should be in place in study protocols, especially if the study cannot be conducted under double-blind conditions. Independent adjudication is recommended.'可被翻译为：对于验证性试验，可接受的主要终点是至需要进行放疗的时间，或是在某个预定时间需要进行放疗的患者比例。然而，直到现在尚无统一的需进行放疗的标准。欧洲泌尿科学会（EAU）、美国国家综合癌症网络（NCCN）、英国卫生质量标准署（NICE）开发的临床指南中提出了多种选择。大家都认识到了这种尴尬的现状；然而，在研究方案中应定义出需进行放疗的明确标准，尤其是如果该研究不能按双盲进行的情况下。建议采用独立的裁决程序。\n'Studies are hampered by a lack of consensus on the criteria that constitute an exacerbation and the criteria that should determine the need for specific antibacterial therapy in addition to other treatment modalities.'可被翻译为：缺乏关于加重的标准以及除其它治疗模式之外还需特定抗菌治疗的标准的共识都阻碍了研究。\n'This unfortunate situation is acknowledged; nevertheless clear criteria defining need for radical therapy should be in place in study protocols, especially if the study cannot be conducted under double-blind conditions.'可被翻译为：大家都认识到了这种尴尬的现状；然而，在研究方案中应定义出需进行放疗的明确标准，尤其是如果该研究不能按双盲进行的情况下。\n'However, until now, there has been no harmonisation of the organisation of the registration documents.'可被翻译为：但是，到目前为止，在申报资料的组织方面尚未协调一致。\n\n根据上述已知信息，请将'Until now, however, there is no consensus as regards criteria defining need for radical therapy.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"然而，直到现在尚无统一的需进行放疗的标准。"
    },
    {
        "instruction":"已知信息：\n'PDE: Permitted Daily Exposure: The maximum acceptable intake of elemental impurity in pharmaceutical products per day.'可被翻译为：PDE： 每日允许暴露量：药品中元素杂质每天可接受的最大摄入量。\n'Taking into account the modifying factors (F1-F5 as discussed in Appendix 1), the oral PDE is calculated as below. PDE = 20 mg\/kg x 50 kg \/ (12 x 10 x 5 x 1 x 10) = 167 µg\/day A factor 10 was chosen for F5 because the LOAEL was used to set the PDE as few toxicological endpoints were examined.'可被翻译为：以调整因子（F1-F5参见附录1）计算口服PDE值如下： PDE=20 mg\/kg×50 kg\/（12×10×5×1×10）=167 µg\/天 由于没有毒性终点，采用LOAEL值设定PDE值，故F5=10。\n'No regulatory limits have been published, for example by US EPA, WHO, or Agency for Toxic Substances & Disease Registry (ATSDR).'可被翻译为：无已发表的法规限度，例如EPA、WHO或美国有毒物质与疾病登记局（ATSDR）发布的限度数据。\n'Following inhalation exposure there is evidence for an increased risk of lung cancer (ATSDR, 2007; IARC, 2012; EU EFSA, 2009; WHO, 2011; US EPA, 2010).'可被翻译为：有证据表明吸入 暴露可增加患肺癌的风险[1,4~7]。\n\n根据上述已知信息，请将'The oral PDE is based on the chronic effects of arsenic to skin and sets the limit at 15 µg\/day based on Agency for Toxic Substances and Disease Registry (ATSDR) MRL and US EPA limit of 0.0003 mg\/kg\/day (ATSDR, 2007; US EPA 2007; EU EFSA, 2009).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"口服PDE值是以砷对皮肤的长期效应为基础，并基于有毒物质和疾病登记处（ATSDR）的MRL值以及US EPA0.0003 mg\/kg\/天的限度，确定其限度为15 μg\/天[4,5,8]。"
    },
    {
        "instruction":"已知信息：\n'Through the ICH process, considerable harmonisation has been achieved among the three regions in the technical requirements for the registration of pharmaceuticals for human use.'可被翻译为：通过ICH过程，三个地区的人用药品注册的技术要求获得了很大程度的统 一。\n'ICH International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals fro Human Use'可被翻译为：ICH人用药品注册技术要求国际协调会\n'9 See the ICH guidance for industry E4 Dose-Response Information to Support Drug Registration.'可被翻译为：9 参见ICH行业指南E4 支持药品注册的剂量反应信息。\n'ICH Q10 demonstrates industry and regulatory authorities’ support of an effective pharmaceutical quality system to enhance the quality and availability of medicines around the world in the interest of public health.'可被翻译为：ICH Q10表明了工业界和监管机构从公众健康利益出发， 为提高全球药品质量和可及性，对建立有效药品质量体系的共同支持。\n\n根据上述已知信息，请将'The ICH brings together regulatory authorities and the pharmaceutical industry to harmonise scientific and technical aspects of drug registration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"ICH将监管机构与制药行业连接在一起，以协调药物注册在科学和技术方面的问题。"
    },
    {
        "instruction":"已知信息：\n'For more information about the use of subinvestigators, see the guidance for industry Investigator Responsibilities — Protecting the Rights, Safety, and Welfare of Study Subjects.'可被翻译为：关于使用助理研究者的更多信息，请参见行业指南研究者职责-保护研究受试者的权利、安全性和福利。\n'Guidance for Industry and Investigators'可被翻译为：行业和研究者指导原则\n'Guidance for industry Investigator Responsibilities — Protecting the Rights, Safety, and Welfareof Study Subjects\nGuidance for industry Nonclinical Safety Evaluation of Drug or Biologic Combinations'可被翻译为：行业指导原则研究者职责-保护研究受试者的权利、安全性和福利行业指导原则\n药品 或者生物制品组合的非临床安全性评价\n'For more information, see the information sheet guidance for sponsors, clinical investigators, and IRBs Frequently Asked Questions — Statement of Investigator (Form FDA 1572), section VII., 31-33, and the guidance for industry Investigator Responsibilities — Protecting the Rights, Safety, and Welfare of Study Subjects, section III.'可被翻译为：更多信息，请参见申办方、临床研究者和 IRB 指南常见问题-研究者声明第 VII 部分 31-33 的信息表（表格 FDA 1572）和行业指南研究者职责-保护研究受试者的 权利、安全性和福利，第 III 节。\n\n根据上述已知信息，请将'See the guidance for industry Investigator Responsibilities – Protecting the Rights, Safety, and Welfare of Study Subjects.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"见行业指导原则研究者职责–保护研究受试者的权利、安全和福利。"
    },
    {
        "instruction":"已知信息：\n'A Safety Specification and Pharmacovigilance Plan can also be developed for products already on the market (e.g., new indication or major new safety concern).'可被翻译为：对一个已经上市的产品（如，增加新适应症或出现新的重大安全性问题）也可以制订安全性说明和药物警戒 计划。\n'The ICH E2C(R2) Guideline1 introduced new concepts linked to an evolution of the traditional Periodic Safety Update Report (PSUR) from an interval safety report to a cumulative benefit-risk report.'可被翻译为：ICH E2C（R2）指南1引入了与传统的定期安全性更新报告（PSUR）的进展相关的新概念，从一个时间段的安全性报告发展为累 积的利益-风险报告。\n'Where the reference product information is the Company Core Data Sheet (CCDS), the reference safety information is the Company Core Safety Information (CCSI).'可被翻译为：参考产品信息为公司核心数据表 （CCDS）时，参考安全性信息为公司核心安全性信 息（CCSI）。\n'company core safety information (ccsi)'可被翻译为：公司核心安全性信息(CCSI)\n\n根据上述已知信息，请将'These proposals incorporate the original ICH E2C concept of reference safety information (e.g., Company Core Safety Information* [CCSI]), with the addition of the approved indications for the product.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这些提议包含对参考安全性信息的原始ICH E2C 概念（如公司核心安全信息* [CCSI]），并添加了已批准的产品适应症。"
    },
    {
        "instruction":"已知信息：\n'Not less than a 2.0 log reduction from the initial count at 14 days, and no increase from the 14-day count at 28 days.'可被翻译为：14天取样点计数比初始计数不少于2.0个对数，并且在28天取样点的 计数从14天后不增加。\n'Not less than 1.0 log reduction from the initial calculated count at 7 days, not less than 3.0 log reduction from the initial count at 14 days, and no increase from the 14-day count at 28 days.'可被翻译为：7天取样点计数比初始计数减少不少于1.0个对数，14天取样点计数比 初始计数不少于3.0个对数，并且在28天取样点的计数从14天后不增 加。\n'No increase from the initial calculated count at 14 and 28 days.'可被翻译为：在14和28天取样点的计数从初始计数开始没有增加。\n'No increase from the initial calculated count at 7, 14, and 28 days.'可被翻译为：在7，14和28天取样点的计数从初始计数开始没有增加。\n\n根据上述已知信息，请将'Not less than a 1.0 log reduction from the initial count at 14 days, and no increase from the 14-day count at 28 days.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"14天取样点计数比初始计数不少于1.0个对数，并且在28天取样点的 计数从14天后不增加。"
    },
    {
        "instruction":"已知信息：\n'For example, if the test agent is expected to be active against MDR Gram-negative aerobes\/facultative anaerobes it could be studied for efficacy in HAP\/VAP or IAI since many of the patients will be infected by organisms of relevant genera\/species.'可被翻译为：例如，如果预期试验药物对MDR 革兰氏阴性需氧菌\/兼性厌氧菌有活性， 可以研究用于治疗HAP\/ VAP或IAI的疗效，因为许多这些患者将被相关属种的 生物体感染。\n'i) If the antibacterial spectrum and pharmacokinetics of the test agent permit, the sponsor may choose to conduct at least one randomised and active¬ controlled study in a specific type of infection.'可被翻译为：1）如果试验药物的抗菌谱和药代动力学允许，申办方可以选择进行至少一项针对特定感染类型的随机、活性对照研究。\n'A convincing demonstration of efficacy in VAP could support an indication that includes HAP but not vice versa.'可被翻译为：用 于VAP的令人信服的疗效证据可以同时支持HAP适应症，但反过来不行。\n'In some cases it could be acceptable to conduct only a non-randomised study and make use of external control data to assist in interpreting the efficacy observed against the MDR pathogens of interest.'可被翻译为：在一些情况下，可以接受仅进行一项非随机研究，并使用外部对照数据来帮助解读所观察到的用于所研究的MDR病原体的疗效。\n\n根据上述已知信息，请将'If the test agent is expected to be active against MDR Gram- positive pathogens such as glycopeptide-resistant staphylococci it could be studied for efficacy in HAP\/VAP or SSTI.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果预期试验药物对MDR革兰氏阳性病原体（例如糖肽类药物耐药的葡萄球菌）有效，可以研究用于治疗 HAP\/VAP或SSTI的疗效。"
    },
    {
        "instruction":"已知信息：\n'Important similarities and differences among studies should also be presented (e.g., design, population, dose, duration, endpoints).'可被翻译为：还应介绍研究之间的重要相似性和差异（例如设计、人群、剂量、持续时间、 终点）。\n'Differences in responses among studies should be described.'可被翻译为：应该描述研究之间的反应差异。\n'If there are important differences in the benefit-risk profiles among populations within an indication, benefit-risk evaluation should be presented by population, if possible.'可被翻译为：如果适应症中的人群 之间的利益 - 风险特征存在重大差异，则尽可能由按人群展示利益 - 风险评 估。\n'When there are important differences among trials in dose, route of administration, or patient population, these differences can be noted in the tables, or separate tables can be considered;'可被翻译为：如果试验的剂量、给药途径或患者人群方面存在重要差 异，应在表格中说明这些差异，亦可单独列表说明；\n\n根据上述已知信息，请将'If there are important differences in outcome among studies of generally similar design, these differences should be displayed and discussed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果设计大致类似的研究间结果存在重要差异，应当显示和讨论这些差异。"
    },
    {
        "instruction":"已知信息：\n'Article 31: The manufacturer should have management on the employee's health and establish health archives.'可被翻译为：第三十一条 企业应当对人员健康进行管理，并建立健康档 案。\n'Personnel engaged in manufacturing who is in direct contact with drugs should receive medical examination before being assigned to work, and the examination should be carried out at least annually afterward.'可被翻译为：直接接触药品的生产人员上岗前应当接受健康检查，以后每 年至少进行一次健康检查。\n'(2) failing to carry out health examination of personnel in direct contact with drugs each year and establish health achieves; or'可被翻译为：（二）未按照规定每年对直接接触药品的工作人员进行健康检查并建立健康档案；\n'Article 30 Drug MAHs and manufacturers shall conduct health examination each year for those personnel in direct contact with drugs and file their health information. The persons suffering infectious diseases or other diseases that may contaminate drugs shall not engage in any manufacturing activity in direct contact with drugs.'可被翻译为：第三十条 药品上市许可持有人、药品生产企业应当每年对直接接触药品的工作人员进行健康检查并建立健康档案，避免患有传染病或者其他可能污染药品疾病的人员从事直接接触药品的生产活动。\n\n根据上述已知信息，请将'Article 31 The manufacturer should have management on the employee's health and establish health archives. Personnel engaged in manufacturing who is in direct contact with drugs should receive medical examination before being assigned to work, and the examination should be carried out at least annually afterward.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十一条 企业应当对人员健康进行管理，并建立健康档案。直接接触药品的生产人员上岗前应当接受健康检查，以后每年至少进行一次健康检查。"
    },
    {
        "instruction":"已知信息：\n'An applicant seeking approval for fludeoxyglucose F 18 injection, ammonia N 13 injection, or sodium fluoride F 18 injection may submit an NDA or an ANDA, depending whether or not the specific drug product is the same as an already approved drug formulation and the indications for which approval is sought.'可被翻译为：寻求F 18 脱氧葡萄糖注射液、N 13 氨注射液和F 18 氟化钠注射液许可的申请人可提交NDA或ANDA，这取决于特定药品是否与批准的药物剂型相同以及需申报的适应症。\n'• In a notice in the Federal Register in March 2000 (the PET Safety and Effectiveness Notice),6 FDA presented its findings of safety and effectiveness for the PET drugs studied for certain indications and described the types of applications that can be submitted for fludeoxyglucose F 18 injection, ammonia N 13 injection, and sodium fluoride F 18 injection used in PET imaging (see Section III). These findings fulfill the requirement to develop appropriate approval procedures for these PET drugs.'可被翻译为：● 在2000年3月联FDA 展示了用于特定适应症的PET药物安全性和有效性的结果，并描述了可能提交的PET成像用F 18 脱氧葡萄糖注射液、N 13 氨注射液和F 18 氟 化钠注射液的应用类型（见第III节）。这些结果满足为这些PET药物建立适用的审批程序的要求。\n'As with fludeoxyglucose F 18 injection, if FDA approves other applications for sodium fluoride F 18 injection or ammonia N 13 injection submitted in accordance with the PET Safety and Effectiveness Notice, it is possible that these products could become alternative RLDs.'可被翻译为：与F 18 脱氧葡萄糖注射液相似的，如果FDA批准根据PET安全性和有效 性通告提交的F18氟化钠注射液或N 13 氨注射液的其他申请，则这些药品可成为替代RLD。\n'Within an NDA for ammonia N 13 injection, sodium fluoride F 18 or fludeoxyglucose F 18 injection (neurologic indication):'可被翻译为：在N 13 氨注射液、F 18 氟化钠注射液和F 18 脱氧葡萄糖注射液（神经学 适应症）的NDA内：\n\n根据上述已知信息，请将'This guidance is intended to assist applicants in preparing new drug applications (NDAs) or abbreviated new drug applications (ANDAs) for fludeoxyglucose F 18 injection, ammonia N 13 injection, and sodium fluoride F 18 injection used in PET imaging for the indications cited in Section III (below). FDA approval of an NDA or ANDA will make it possible to market these PET drugs for clinical use according to the requirements of the Federal Food, Drug, and Cosmetic Act (the Act).3'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"本指导原则旨在辅助申请人撰写第III节（下文）中引用适应症的PET成像中使用的F 18 脱氧葡萄糖注射液、N 13 氨注射液和F18氟化钠注射液的新药申请（NDA）或简略新药申请（ANDA）。根据联邦食品、药品和化妆品法案（法案），FDA批准的NDA或ANDA将使这些PET药物上市用于临床应用成为可能。3"
    },
    {
        "instruction":"已知信息：\n'Alleviation of symptoms related to cytopenia is an acceptable aim of treatment in patients with MDS. In most cases this means reduction of anaemia-related symptoms. Due to prevalent co- morbidities in this elderly population, symptom scales, even if properly validated, may be too insensitive to capture also relevant differences between treatment groups especially as transfusion of red blood cells must be individualised due to e.g. concomitant cardiovascular disorders. Loss of need for transfusion for a defined period of time (in combination with improved haemoglobin levels) is therefore considered an acceptable outcome measure.'可被翻译为：对于MDS患者，减轻与血细胞减少相关的症状是一个可接受的治疗目的。大多数情况下这是指减少贫血相关症状。由于在老年患者群中，并存疾病相当普遍，症状量表即使经过正确验证，也对捕捉治疗组之间的相关差异太不敏感，特别是红细胞输血必须个体化时（如由于伴随心血管疾病）。因此在规定时限内不再需要输血（伴有血红蛋白水平提高）也被认为是一个可接受的结局测量指标。\n'Many patients with MDS are asymptomatic at the time of diagnosis, but eventually develop symptomatic anaemia, thrombocytopenia and neutropenia alone or in combination.'可被翻译为：很多MDS 患者在诊断时没有症状，但是最终会发展成有症状的贫血，单纯的血小板减少和单纯的嗜中性白血球减少症或者是两者结合。\n'The aim is to develop dosing recommendations that will ensure that the patients will obtain treatment that is effective and safe.'可被翻译为：目的是制定可确保患者获得有效和安全治疗的给药建议。\n'Urodynamic studies aim to reproduce patient symptoms in a monitored setting.'可被翻译为：尿动力学研究的目的是采用监测设备重现患者的症状。\n\n根据上述已知信息，请将'Alleviation of symptoms related to cytopenia is an acceptable aim of treatment in patients with MDS.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于MDS 患者，减轻与血细胞减少相关的症状是一个可接受的治疗目的。"
    },
    {
        "instruction":"已知信息：\n'E. Potential for Delay of FDA Response Occasionally, FDA divisions determine that input obtained from advisory committee review or consultants (internal, including internal regulatory meetings, or external) is critical to the review of an SPA submission.'可被翻译为：E. FDA回应延迟的可能性 有时，FDA部门决定，从咨询委员会审核或顾问（内部，包括内部监管会议， 或者外部）得到的意见对于SPA递交内容的审核至关重要。\n'Sufficient information should be provided in the meeting request to ensure that all relevant disciplines and offices can participate, permit detailed discussion of the relevant issues, and facilitate subsequent FDA review of an SPA submission.'可被翻译为：应在会议请求中提供充分的信息，以确保所有相关学科和办公室都能参与， 允许相关问题的详细讨论，并促进随后FDA对SPA递交内容的审核。\n'SPA reviews may not always be completed within 45 days, as further described in section VI.E., Potential for Delay of FDA Response.'可被翻译为：SPA审核可能不总是在45天内完成的，进一 步描述见第VI节E部分“FDA回应延迟的可能性”。\n'D. FDA Response to Sponsor Under PDUFA V (90 percent of SPAs) and BsUFA (80 to 90 percent of SPAs) goals, FDA committed to sending an SPA Letter (see sections VIII., Documentation, and VI.E., Potential for Delay of FDA Response) to the sponsor within 45 calendar days of receipt of the SPA submission.'可被翻译为：D. FDA给申办方的回应 在PDUFA V（90%的SPA）和BsUFA（80%到90%的SPA）目标下，FDA 承诺在收到SPA递交内容后45个日历日内给申办方发送SPA函（见第VIII节 “文件”和第VI.E.节“FDA回应延迟的可能性”）。\n\n根据上述已知信息，请将'The need for consultation during an SPA review (e.g., by special government employees or by a different FDA office or center), described in section VI.E., Potential for Delay of FDA Response, also should be considered and discussed at the meeting.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在SPA审核期间（例如，由特殊政府雇员或不同的FDA办公室或中心）进 行磋商的需要描述在第VI.E.节“FDA回应延迟的可能性”中，也应该在会上进行考虑和讨论。"
    },
    {
        "instruction":"已知信息：\n'Although biotechnological\/biological products may be subject to significant losses of activity, physicochemical changes, or degradation during storage, international and national regulations have provided little guidance with respect to distinct release and end of shelf-life specifications.'可被翻译为：虽然生物技术产品\/生物制品在贮藏期内易于发生明显的活性降低、物理化学变化或降解，但国际和国家法规很少有指导原则提供放行标准和有效期末质量标准的区别。\n'Recommendations for maximum acceptable losses of activity, limits for physicochemical changes, or degradation during the proposed shelf- life have not been developed for individual types or groups of biotechnological\/biological products but are considered on a case-by-case basis.'可被翻译为：目前， 对生物技术产品\/生物制品在有效期限内的活性降低、理化变化或降解产物，尚未分门别类地提出最大可接受降低值或变化范围的建议，应随不同制品的情况而定。\n'For biotechnological\/biological products some degradation products may be active.'可被翻译为：对于生物技术产品\/生物制品而言，有些降解产物可能具有活性。\n'Potential degradation products in the drug substance and drug product are those that may be reasonably expected to form during long term storage conditions.'可被翻译为：原料药和制剂中潜在的降解产物是在长期存贮条件下预期可能会形成的杂 质。\n\n根据上述已知信息，请将'This takes into account the fact that degradation of biotechnological\/biological products may not be governed by the same factors during different intervals of a long storage period.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"另外，还应考虑到在较长贮藏期内的不同时段，生物技术产品\/生物制品的降解可能受不同因素的影响。"
    },
    {
        "instruction":"已知信息：\n'User Guidance This data element captures the sender’s organisation name (e.g. company name or regulatory authority name).'可被翻译为：用户指导原则 此数据元素获取发送者的机构名称（例如：公司名称或监管机构名称）。\n'User Guidance This data element captures the sender’s given name.'可被翻译为：用户指导原则 根据该数据元素获取发送者的给定名。\n'User Guidance This data element captures the sender’s title.'可被翻译为：用户指导原则 根据该数据元素获取发送者的职称。\n'User Guidance This data element captures the sender's city.'可被翻译为：用户指导原则 根据该数据元素获取发送者所在城市。\n\n根据上述已知信息，请将'User Guidance This data element captures the type of sender organisation or individual.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用户指导原则 根据该数据元素获取发送者的机构或个体的类型。"
    },
    {
        "instruction":"已知信息：\n'In most instances, PTs relating to diseases or signs and symptoms are assigned to the prime manifestation site SOC. So, for PT Dyspnoea, the primary SOC is SOC Respiratory, thoracic and mediastinal disorders. However, there are exceptions for three types of terms:'可被翻译为：在大多数情况下，PT 的主 SOC 是有关疾病、症状和体征的主要发病部位。所以，PT 呼吸困难的主 SOC 是 SOC 呼吸系统、胸及纵隔疾病。但是有以下三种例外术语：\n'This section explains the concept of the primary System Organ Class (SOC) allocation in MedDRA and why the primary SOC should not be individually selected by MedDRA users. To do so undermines one of the main goals in using MedDRA as a regulatory standard.'可被翻译为：本节介绍 MedDRA 主 SOC 分配的概念，以及为什么用户不应该擅自选择或更改 MedDRA 的主SOC分配。否则将破坏使用 MedDRA 作为监管标准的主要目的。\n'Periodic Benefit-Risk Evaluation Report (PBRER) 31 Table 7 – Numbers of Adverse Drug Reactions by Term from Post-Marketing Sources Spontaneous, including regulatory authority and literature Non-interventional post-marketing study and reports from other solicited sources* Serious Non-serious Total Spontaneous Serious Interval Cumulative Interval Cumulative Cumulative Interval Cumulative SOC 1 MedDRA PT MedDRA PT MedDRA PT SOC 2 MedDRA PT MedDRA PT MedDRA PT MedDRA PT *This does not include interventional clinical trials.'可被翻译为：表7 来自上市后使用经验的药物不良反应的数量 自发报告，包括监管机构和文献 非干预性上市后研究 以及来自其它征集来 源的报告* 严重 非严重 总自发报 告 严重 时间段 累积 时间段 累积 累积 时间段 累积 SOC1 MedDRA PT MedDRA PT MedDRA PT SOC2 MedDRA PT MedDRA PT MedDRA PT MedDRA PT *这并不包括干预性临床试验\n'The Medical Dictionary for Regulatory Activities (MedDRA) version 12.1 has been used for the coding of adverse events. The line listings and the summary tabulations are arranged alphabetically by primary System Organ Class (SOC) and Preferred Term (PT) level.'可被翻译为：采用监管活动医学词典（MedDRA）第12.1版编码不良事件，行 列表和汇总表按系统器官分类（SOC）和首选语（PT）级别的字母 顺序排序。\n\n根据上述已知信息，请将'MedDRA is a multi-axial terminology meaning that a Preferred Term (PT) may be linked to more than one SOC. For example, PT Dyspnoea has a link to both SOC Respiratory, thoracic and mediastinal disorders (its organ system of manifestation) and to SOC Cardiac disorders (because of its connection to heart disease). Each PT is assigned a primary SOC to avoid “double counting” while retrieving information from all SOCs (i.e., a cumulative SOC-by-SOC data output). The other SOCs to which a multi-axial PT is linked are called “secondary” SOCs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"MedDRA是一种多轴性术语，每个首选语（PT）可与一个以上的SOC 相连。例如，PT 呼吸困难链接到两个 SOC：SOC 呼吸系统、胸及纵隔疾病（其发病器官系统）和 SOC心脏器官疾病（因为其与心脏疾病有关）。每个 PT 被分配一个主 SOC，从而在用所有 的SOC（即累计各个 SOC 数据输出）检索信息时，可避免“双重计算”。多轴 PT 链接的 其他 SOC 被称为“次” SOC。"
    },
    {
        "instruction":"已知信息：\n'Wherever meaningful urodynamic measures are available, these can be used to support clinical findings.'可被翻译为：只要任何有意义的尿动态测量数据是可用的，这些都可以用来支持临床研究结果。\n'Urodynamic studies may be useful at several stages of product development for products for urge, mixed or stress incontinence.'可被翻译为：在治疗混合性尿失禁、压力性尿失禁和急迫性尿失禁尿的药物的临床研究的不同阶段，尿动力学研究是非常重要的。\n'In children with NDO, detrusor overactivity as demonstrated by urodynamic evaluation is necessary to establish the baseline and as an inclusion criterion.'可被翻译为：在NDO患者中，尿流动力学评价所示的逼尿肌反射亢进有必要建立基线并作为入选标准。\n'6.1. Urodynamic and structural studies'可被翻译为：6.1.尿动力学及结构研究\n\n根据上述已知信息，请将'Urodynamic studies are also considered useful as supportive parameters in the evaluation of the study outcome, e.g. where patients with clinical improvement can be demonstrated to have improved urodynamic parameters.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"尿动力学检查也是有用的评估研究结局的支持性参数，例如患者临床改善可证明尿流动力学参数改善。"
    },
    {
        "instruction":"已知信息：\n'Under certain circumstances, the FDA may terminate an IND. If an IND is terminated, the sponsor-investigator must end all clinical investigations conducted under the IND, notify the IRB, and recall or otherwise provide for the disposition of all unused supplies of the drug. A termination action may be based on deficiencies in the IND or in the conduct of an investigation under an IND.'可被翻译为：在有些情况下，FDA可以终止IND。如果IND被终止，申办方-研究者必须结束 根据IND实施的所有临床研究，通知IRB ，并召回所有未使用的药物供应 或者提供所有未使用药物供应的处置措施。终止行动可能是基于IND中的缺陷或者根据IND实施研究中的缺陷。\n'Subjects requiring radiation therapy while enrolled in a trial of a novel agent or combination of agents should normally be withdrawn from study therapy.'可被翻译为：当招募患者参加新药剂或多种药剂结合试验时，通常会将需要接受放射治疗的患者排除在研究治疗之外。\n'A sponsor-investigator can request that an IND be placed on inactive status if no subjects are entered into clinical trials for a period of 2 years or more under an IND, or if all investigations under an IND remain on clinical hold for 1 year or more.'可被翻译为：申办方-研究者可以申请将 IND 置于暂停状态（inactive status），如果在 2 年或者 2 年以上的时间内没有受试者入组 IND 临床试验，或者如果所有根据 IND 进行的研究保持临床暂停超过 1 年。\n'After the initial IND is submitted and is in effect, a sponsor-investigator must make changes to the IND as needed to ensure that the clinical investigations are conducted according to protocols included in the application.'可被翻译为：在首次 IND 提交并且生效之后，申办方-研究者必须根据需要对 IND 进行变更，从而保证临床研究按照申请中包含的方案实施。\n\n根据上述已知信息，请将'If an IND is withdrawn, all clinical trials conducted\tunder the IND must be ended.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果 IND 被撤回，必须结束所有根据 IND 实施的临床试验。"
    },
    {
        "instruction":"已知信息：\n'Real-time diagnostics - implement routine diagnostics to confirm model performance in real-time'可被翻译为：实时诊断-实施常规诊断， 以实时确认模型性能。\n'real-time (long-term) stability studies'可被翻译为：实时(长期)稳定性研究\n'Diagnostics: Methods used to assess the performance of a statistical model and\/or evaluate the fit of the method or model to the data.'可被翻译为：诊断法：用于评估一个统计模型的性能和\/或评估该方法或模型是否适合于数据的方法。\n'When propensity score modeling is used, investigators should present diagnostics of the propensity score model to allow for an assessment of its performance and fit.'可被翻译为：在使用倾 向评分模型时，研究者应该展示倾向评分模型的诊断法以评估该模型的性能及适当性。\n\n根据上述已知信息，请将'Real-time diagnostics - implement initial diagnostics to confirm model performance in real-time'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"实时诊断-实施初始诊 断，以实时确认模型性 能。"
    },
    {
        "instruction":"已知信息：\n'Differences in the epidemiology in the different regions should be discussed (because the epidemiology of the indication(s) may vary across regions), if this information is available.'可被翻译为：如果有资料，应当讨论不同地区在流行病学方面的差异 （因为适应症的流行病学可能因地区而异））。\n'Studies in specific subgroups may be conducted.'可被翻译为：可开展特定亚组中的研究。\n'The types and number of representatives who participate in community consultation activities may vary by study or even across sites within the same study.'可被翻译为：参与社区咨询活动的代表的类型和数量可以因研 究而不同，甚至同一项研究不同中心也可以不同。\n'Such analyses may provide important insights, or lead to hypotheses for examination in future studies.'可被翻译为：这样的分析可以提供重要的见解，或产生在未来研究中要检测的假设。\n\n根据上述已知信息，请将'Even so, reporting of symptoms may vary by region and may lead to differences in the types of subjects included in the studies.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"即便如此，症状报告可能因地而异，而且可能导致纳入研 究的受试者类型存在差异。"
    },
    {
        "instruction":"已知信息：\n'Ibuprofen CAS No.: 15687-27-1 Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAELc Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Human Dose Cmax AUC Margins NOAEL\/Human LOAEL\/Human Notes 180 mg\/kg oral GD1-20 [Adams] Cmax = 205 µg\/mLa AUC = 597 µg∙h\/mLa oral GD1-20: No LOAEL idenitifed [Adams] oral GD9-10: 300 mg\/kg [Cappon 2003]b at 300 mg\/kg Cmax = 341 µg\/mLa AUC = 995 µg∙h\/mLa GD1-20: None GD9-10: ventricular septal defects 60 mg\/kg oral GD1-29 [Adams] Cmax = 26.6 µg\/mLd AUC(0-inf) = 80.5 µg∙h\/mLd 500 mg\/kg oral GD9-11 [Cappon 2003]b Cmax = 222 µg\/mLd AUC(0-inf) = 671 µg∙h\/mLd No LOAEL identified None Maximum dose is 800 mg QID, 3200 mg\/day (13.3 mg\/kg\/dose, 53 mg\/kg\/day) [US label] Cmax = 59 µg\/mLe AUC = 839 µg∙h\/mLe'可被翻译为：布洛芬 CAS 号：15687-27-1 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAELc 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 人剂量 Cmax AUC 暴露倍数 NOAEL\/人 LOAEL\/人 注释 180 mg\/kg 经口 GD1-20 [Adams] Cmax = 205 µg\/mLa AUC = 597 µg∙h\/mLa 经口GD1-20: 未确定 LOAEL [Adams] 经口GD9-10: 300 mg\/kg [Cappon 2003]b 300 mg\/kg时 Cmax=341 µg\/mLa AUC=995 µg∙h\/mLa GD1-20: 无 GD9-10: 室间隔缺 损 60 mg\/kg 经口 GD1-29 [Adams] Cmax=26.6 µg\/mLd AUC(0-inf)=80.5 µg∙h\/mLd 500 mg\/kg 经口 GD9-11 [Cappon 2003]b Cmax=222 µg\/mLd AUC(0-inf)=671 µg∙h\/mLd 未确定 LOAEL 无 最大剂量为800 mg QID，3200 mg\/天 (13.3 mg\/kg\/次, 53 mg\/kg\/天) [美国说明书] Cmax=59 µg\/mLe AUC=839 µg∙h\/mLe\n'CAS No.: 50-78-2 Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAEL Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Human Dose Cmax AUC Margins NOAEL\/Human LOAEL\/Human Notes 125 mg\/kg oral GD6-17 (n=20 Sprague Dawley) [Gupta]a aspirin Cmax = ~25 µg\/mLb AUC = 6.6 – 25.3 µg∙h\/mLb salicylate Cmax = 132 µg\/mLc AUC = 8333 µg∙h\/mLd 200 mg\/kg oral GD7-17 (n=20 Sprague Dawley) [Nakatsuka]e aspirin Cmax = ~40 µg\/mLb AUC = 10.5 – 40.5 µg∙h\/mLb salicylate Cmax = 211 µg\/mLc AUC = 13,333 µg∙h\/mLd Nakatsuka (200 mg\/kg):'可被翻译为：CAS号：50-78-2 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAEL 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 人剂量 Cmax AUC 暴露倍数 NOAEL\/人 LOAEL\/人 注释 125 mg\/kg 经口 GD6-17 (n=20 SD) [Gupta]a 阿司匹林 Cmax = ~25 µg\/mLb AUC = 6.6 - 25.3 µg∙h\/mLb 水杨酸 Cmax = 132 µg\/mLc AUC = 8333 µg∙h\/mLd 200 mg\/kg 经口 GD7-17 (n=20 SD) [Nakatsuka]e 阿司匹林 Cmax = ~40 µg\/mLb AUC = 10.5 - 40.5 µg∙h\/mLb 水杨酸 Cmax = 211 µg\/mLc AUC = 13,333 µg∙h\/mLd Nakatsuka (200 mg\/kg):\n'Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAEL Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Human Dose Cmax AUC Margins NOAEL\/Human LOAEL\/Human Notes AUC = 6.5 (49.1\/7.52) a: Extrapolated from reported value after 500 mg\/kg isotretinoin oral single dose in Wistar rats (Tembe): Cmax = 9.07 µg\/mL, AUC(0-10h) = 47.9 µg·h\/mL.'可被翻译为：大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAEL 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 人剂量 Cmax AUC 暴露倍数 NOAEL\/人 LOAEL\/人 注释 AUC=6.5 (49.1\/7.52) a：Wistar大鼠单次经口给予异维甲酸500 mg\/kg后报告值的外推（Tembe）：Cmax=9.07 µg\/mL，AUC(0-10h)=47.9 µg·h\/mL。\n'5-FLUOROURACIL CAS No.: 51-21-8 Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAEL Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Human Dose Cmax AUC Margins NOAEL\/Huma LOAEL\/Human Notes 10 mg\/kg single dose IP GD9 [Wilson]'可被翻译为：5-氟尿嘧啶 CAS号：51-21-8 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAEL 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 人剂量 Cmax AUC 暴露倍数 NOAEL\/人 LOAEL\/人 注释 10 mg\/kg 单次IP给药 GD9 [Wilson]\n\n根据上述已知信息，请将'NOAEL: rat Cmax = 3.4 (205\/59.7) AUC = 0.7 (597\/839) rabbitc 60 mg\/kg NOAEL Cmax = 0.5 (26.6\/59) AUC = 0.1 (80.5\/839) 500 mg\/kg NOAEL Cmax = 3.8 (222\/59) AUC = 0.8 (671\/839) LOAEL: rat Cmax = 5.8 (341\/59)Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAELc Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Human Dose Cmax AUC Margins NOAEL\/Human LOAEL\/Human Notes AUC = 1.2 (995\/839) rabbit no LOAEL a: Extrapolated from reported value after 25 mg\/kg ibuprofen (suspension) single oral dose in Sprague Dawley rats (You): Cmax = 28.4 µg\/mL, AUC(0-inf)= 4971.3 µg·min\/mL (82.9 µg∙h\/mL).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NOAEL:大鼠 Cmax=3.4 (205\/59.7) AUC=0.7 (597\/839) 兔c 60 mg\/kg NOAEL Cmax=0.5 (26.6\/59) AUC=0.1 (80.5\/839) 500 mg\/kg NOAEL Cmax=3.8 (222\/59) AUC=0.8 (671\/839) LOAEL: 大鼠 Cmax = 5.8 (341\/59) AUC = 1.2 (995\/839)大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAELc 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 人剂量 Cmax AUC 暴露倍数 NOAEL\/人 LOAEL\/人 注释 兔 无LOAEL a：Sprague Dawley大鼠单次经口给予布洛芬25 mg\/kg（混悬液）后报告值的外推（You）：Cmax=28.4 µg\/mL，AUC(0-inf)=4971.3 µg·min\/mL（82.9 µg∙h\/mL）。"
    },
    {
        "instruction":"已知信息：\n'The core safety information contained within the CCDS is referred to as the CCSI.'可被翻译为：CCDS 中包含的核心安全信息被称为CCSI。\n'All relevant safety information contained in the reference product information (e.g., CCDS) prepared by the MAH and which the MAH requires to be listed in all countries where the company markets the drug, except when the local regulatory authority specifically requires a modification. It is a subset of information contained within the MAH’s reference product information for the PBRER. Where the reference product information is the Company Core Data Sheet (CCDS), the reference safety information is the Company Core Safety Information (CCSI).'可被翻译为：参考产品信息（CCDS）中包含的由 MAH 编写并要求在公司销售该药物的所有国家\/区域列出的所有相关的安全性信息，除非当地监管机构具体要求修改。它是 MAH用于 PBRER 的参考产品信息中包含的信息的一个子集。参考产品信息为公司核心数据表（CCDS）时，参考安全性信息为公司核心安全性信息（CCSI）。\n'company core safety information (ccsi)'可被翻译为：公司核心安全性信息(CCSI)\n'This reference product information may be the Company Core Data Sheet* (CCDS) or another document proposed by the MAH (see Section 2.4).'可被翻译为：该参考 产品信息可能是公司核心数据表*（CCDS）或MAH提出的其它文件（见章节 2.4）。\n\n根据上述已知信息，请将'Where the reference product information is the Company Core Data Sheet (CCDS), the reference safety information is the Company Core Safety Information (CCSI).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"参考产品信息为公司核心数据表 （CCDS）时，参考安全性信息为公司核心安全性信 息（CCSI）。"
    },
    {
        "instruction":"已知信息：\n'In the case of OTC sunscreen active ingredients, FDA balances the important role that broad spectrum sunscreens with a sun protection factor (SPF) value of 15 or higher play in decreasing the risk of skin cancer and early skin aging caused by the sun, if used as directed with other sun protection measures; the benefits, with the public health importance of providing an adequate safety margin for OTC sunscreen active ingredients and finished sunscreen products, versus the risks. When determining the specific testing and other data needed to adequately demonstrate that an OTC sunscreen active ingredient is safe, FDA considers both the circumstances under which OTC sunscreen products are intended to be used by consumers and current scientific knowledge and assessment technology. To ensure full discussion of the kinds of data needed to address sunscreen safety, FDA held a 2- 112 day meeting of the Nonprescription Drugs Advisory Committee on September 4-5, 2014, at which FDA presented much of the same approach that is recommended in this guidance.'可被翻译为：在含有OTC防晒活性成分的情况下，FDA权衡了其重要作用、获益与风险，如按照说明与其他防晒措施一起使用，防晒指数（SPF）值为15或以上的广谱防晒药品在降低皮肤癌风险和早期皮肤老化方面可发挥重要作用，应该提供一种为对公众健康具有重要作用的OTC防晒活性成分和防晒成品的安全限度。当确定特定检测和充分证明一种OTC防晒活性成分安全性所需的其他数据时，FDA认为当OTC防晒药品需要同时满足用于消费者和最新科学理论和评价技术的两种条件。为了确保充分讨论了证明防晒药品安全性所需的数据，FDA在2014年9月4-5日举办了一个为期2天非处方药品咨询委员会会议，会议中FDA也提出了多数与本指导原则推荐相同的方法。\n'FDA’s OTC drug regulations generally identify the types of effectiveness information that sponsors should submit as evidence that a drug product containing an active ingredient or other OTC drug condition could be GRASE for use as labeled (21 CFR 330.10(a)(2)) and the standard by which effectiveness is to be judged, which requires controlled clinical investigations to support effectiveness (21 CFR 330.10(a)(4)(ii)). When applying these regulations to each potential sunscreen active ingredient, FDA requests evidence from at least two adequate and well-controlled SPF studies showing that the active ingredient effectively prevents sunburn, because sunburn prevention is the minimum indication for an OTC sunscreen product.'可被翻译为：FDA的OTC药品法规通常规定了由申办方提交的有效性数据的类型，这类数据用于证明一种含有一种活性成分的药品或者其他OTC药物可以标识其 GRASE（21 CFR 330.10（a）（2））， 同时法规也规定了评价有效的标准，以及需要进行临床对照试验验证其有效性的标准（21 CFR 330.10（a）（4）（ii））。 当这些规定用于证明一种可能的防晒活性成分时，FDA要求至少两个充分且良好控制的SPF对照试验证明其活性成分可有效防止晒伤，因为防晒伤是OTC防晒产品的最低适应症。\n'FDA requires these sunburn only products to bear a prominent warning stating: “Skin Cancer\/Skin Aging Alert: Spending time in the sun increases your risk of skin cancer and early skin aging.'可被翻译为：FDA要求这些仅防晒伤的产品突出标识警告说明： “皮肤癌\/皮肤老化警告： 晒太阳增加了您皮肤癌和皮肤老化的风险。\n'This product has been shown only to help prevent sunburn, not skin cancer or early skin aging” (21 CFR 201.327(d)(2)).'可被翻译为：本品仅有助于防止晒伤，并不能防止皮肤癌和皮肤老化”（21 CFR 201.327（d）（2））\n\n根据上述已知信息，请将'31 FDA strongly encourages manufacturers to develop OTC sunscreen products that provide broad spectrum protection and have an SPF value of 15 or higher because of the deleterious health effects that may result if consumers increase their overall sun exposure through use of sunscreen products that help prevent sunburn, but do not provide sufficient protection to help reduce the risk of skin cancer and early skin aging caused by the sun.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"31FDA强烈建议生产商研发具有广谱防辐射和SPF值在15或者更高的OTC防晒产品，原因是如果消费者使用了防止晒伤的防晒产品而增加其全身的日光暴露，而这些产品不能提供充分保护以降低日光导致的皮肤癌和皮肤提前老化的风险，这种情况就会有害于健康。"
    },
    {
        "instruction":"已知信息：\n'6) Testing process, including preparation of reference solution, operation of individual tests, necessary data of environment temperature and humidity;'可被翻译为：6.检验过程，包括对照品溶液的配制、各项具体的检验操作、 必要的环境温湿度；\n'Reference solution and test solution preparation'可被翻译为：标准溶液和供试品溶液的制备\n'1) A statement of the processing location and the equipment to be used (e.g. operation room's location and reference number, cleanliness level, necessary temperature and humidity requirements, equipment type and reference number);'可被翻译为：1.对生产场所和所用设备的说明（如操作间的位置和编号、洁净度级别、必要的温湿度要求、设备型号和编号等）；\n'1) A statement of the processing location and the equipment to be used (e.g. operation room's location and reference number, cleanliness level, necessary temperature and humidity requirements, equipment type and reference number);'可被翻译为：1.对生产场所和所用设备的说明（如操作间的位置和编号、 洁净度级别、必要的温湿度要求、设备型号和编号等）；\n\n根据上述已知信息，请将'6) Testing process, including preparation of reference solution, operation of individual tests, necessary data of environment temperature and humidity;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"6.检验过程，包括对照品溶液的配制、各项具体的检验操作、 必要的环境温湿度；"
    },
    {
        "instruction":"已知信息：\n'• Important identified risks;'可被翻译为：重要的已确认风险；\n'important identified risk'可被翻译为：重要的已确定风险，重要的潜在风险\n'This section summarises the important identified or potential risks that have been recognised during the conduct of the ZB3579 clinical trial programme.'可被翻译为：本章节总结了在执行ZB3579临床试验项目过程中已经认识到 的重要已确认或潜在风险。\n'APPENDIX C2: Tabular Format 19 Summary of Important Risks This section summarises the important identified or potential risks that have been recognised during the conduct of the Drug Z clinical development programme.'可被翻译为：附录C2：表格形式 19 重要风险总结 本节总结了药物Z临床研发计划中重要的已确认或潜在的 风险。\n\n根据上述已知信息，请将'The following have been recognised as important potential risks during the reporting period:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"下列各项已被确认为报告周期内的重要潜 在风险："
    },
    {
        "instruction":"已知信息：\n'Studies with long-term follow-up or with comparisons to other treatment options or standards of care may provide important information on safety and efficacy.'可被翻译为：研究中有长期随访，或有与其他治疗方案或标准治疗的比较，则可能提供有关安全性和有效性的重要信息。\n'Assessment of efficacy in some domains may require long-term controlled clinical trial data.'可被翻译为：某些方面的疗效评价可能需要长期对照的临床试验数据。\n'Generally, the control (comparison) groups that are recognised are placebo concurrent control, no treatment concurrent control, active treatment concurrent control, dose comparison concurrent control, and historical control.'可被翻译为：通常设定的对照（比较）组包括安慰剂并行对照、非治 疗并行对照、阳性治疗并行对照、剂量比较并行对照和历史 对照。\n'To optimize the regimen with respect to dose and treatment duration in phase 3 trials, drug efficacy data from phase 1 and phase 2 studies can be combined in a single model to predict SVR in the planned trials.'可被翻译为：为了在III期试验中优化针对剂量和疗程的方案，可以将来自I期和II期研究的 药物疗效数据合并在单个模型中，以预测计划试验中的SVR。\n\n根据上述已知信息，请将'However, safety and efficacy data can be derived from dose or treatment duration comparison or single-arm, historical control trials.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"然而，安全性和有效性 数据可能来自剂量或疗程比较或单组历史对照试验。"
    },
    {
        "instruction":"已知信息：\n'If the product strength is not clearly displayed on the container label, or is expressed in units of measure that are incongruent with those used in the dosing instructions, the wrong strength can be selected or the wrong dose administered (i.e., over- or under-dosing).'可被翻译为：如果产品的规格在容器标签 上显示地不清楚，或表述用的计量单位与计量说明上所使用的计量单位不一致，就 有可能会导致选择和配给错误的剂量（即，用药过量或用药不足）。\n'Check for consistency between the drug product strength and dosing. Developing a product strength or expressing the strength in a manner that is incongruent with the dosage and administration of the product complicates the calculation of dosage and has led to dosing errors. For example, the strength may be expressed on the label in percentage, but the dosage and administration of the drug is described in milligrams. Another example of this type of problem would include a product with a usual dosage of 300 mg when the product is only available as a 100 mg vial. If 3 vials are needed to make up the full dose rather than a single vial, the product may be prone to dosing and administration errors. Multiple units (e.g., tablets, capsules, vials, syringes) required to achieve a usual single dose have led to dosing errors because of users making miscalculations or forgetting how many units have already been administered.'可被翻译为：检查药品规格和剂量的一致性。曾因开发的药品规格或表达的药品规格，与药品的剂量和用法用量不一致，使用剂量计算变得复杂化，而导致剂量错误。例如，说明书中药品规格按百分比表示，但药品的剂量和用法用量是按毫克来描述。这类问题的另一个例子为，一个药品的常用剂量是300mg，但只有每瓶100ml的包装。如果每次服用全部剂量需要3瓶，而不是1瓶时，则很容易发生剂量和用法用量的错误。服用多个单位（如，片、胶囊、瓶、注射器）才达到全部剂量，已经导致剂量错误，因为用药者可以计算错误或每次忘记服用了几个单位的药物。\n'Scores that produce doses that are incongruent with the dosage and administration of a drug have led to medication dosing errors and should be avoided.'可被翻译为：产生与药物的剂量和给药不一致的剂量的刻 痕可导致用药错误，应该避免。\n'Excessive hardness of tablets has led to medication administration errors.'可被翻译为：片剂的硬度过高会导致用药错误。\n\n根据上述已知信息，请将'Developing a product strength that is incongruent with the dosage and administration of the product complicates the calculation, preparation, and administration of a dose and has led to medication dosing errors.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"开发与产品的剂量和给药不一致的产 品规格使得剂量的计算、制备和给药复杂化并且导致用药错误。"
    },
    {
        "instruction":"已知信息：\n'DECISION FLOW CHART FOR PHOTOSTABILITY TESTING OF DRUG PRODUCTS \nSTART \nDIRECTLY EXPOSED \nACCEPTANCE CHANGE \nYES \nFORMULATION CHANGE? \nNO \nIMMEDIATE PACK CHANGE? \nNO \nYES \nYES \nIMMEDIATE PACK \nACCEPTANCE CHANGE? \nMARKETING PACK \nACCEPTANCE CHANGE \nMARKETING PACK CHANGE? \nREDESIGN PACKAGE OR REFORMULATION \nNO \nTEST END \nYES \nTEST END \nYES \nTEST END \nNO \nNO'可被翻译为：制剂光稳定性试验决策流程图 \n测试开始 \n直接暴露在光线下 \n可接受的改变 \n是 \n制剂成分改变？ \n否 \n内包装发生改变？ \n否 \n是 \n是 \n内包装 \n可接受的改变 \n上市销售时的包装 \n可接受的改变 \n上市销售时的包装发生改变 \n重新设计包装或者重新研究制剂组成 \n否 \n测试结束 \n是 \n测试结束 \n是 \n测试结束 \n否 \n否\n'At the end of the exposure period, the samples should be examined for any changes in physical properties (e.g., appearance, clarity or color of solution, dissolution\/disintegration for dosage forms such as capsules, etc.) and for assay and degradants by a method suitably validated for products likely to arise from photochemical degradation processes.'可被翻译为：光暴露试验一结束，应立即检查样品物理性质（如外观、溶液的澄清度或颜色、固体制剂如胶囊剂等的溶出度\/崩解时限）的所有变化，并进行含量和降解产物的测定。所用方法应经过相应的方法学验证，证实其适用于检测光化学降解过 程中所产生的物质。\n'Photostability testing should be conducted on at least one primary batch of the drug product if appropriate. The standard conditions for photostability testing are described in ICH Q1B.'可被翻译为：如必要，至少应用一批注册批样品进行光稳定性试验，其标准条件在ICH Q1B项下有专述。\n'Batch release is the final decision to release the product to the market regardless whether RTR testing or end product testing is employed.'可被翻译为：无论是否进行实时放行检测或最终产品检验，批放行都 是产品上市前放行的最终决策。\n\n根据上述已知信息，请将'The extent of drug product testing should be established by assessing whether or not acceptable change has occurred at the end of the light exposure testing as described in the Decision Flow Chart for Photostability Testing of Drug Products.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"制剂测试范围应依据“制剂光稳定性决策流程图”，通过评估光暴露试验结束时是否产生了可接受的变化来进行设计。"
    },
    {
        "instruction":"已知信息：\n'This Appendix is based extensively on section 505(b) of the Act and regulations in 21 CFR part 314. As a result, this section contains extensive mandatory language. This mandatory language is used whenever FDA regulations require the submission of certain information. Unlike other guidance documents in which mandatory language is typically accompanied by the related cite, to make the guidance more user friendly and less cumbersome, we do not cite each regulation each time we discuss a requirement.'可被翻译为：这个附录大多是基于法案第505(b)条和21 CFR部分314中的条例。因此，这个部分含有广泛的强制性语言。当FDA法规要求提交特定资料时使用这种强制性语言。与其他指导原则文件不同（其中强制性语言通常附带相关引用，以使指导原则更加用户友好和不那么繁琐），每次进行要求讨论时我们没有列举各项规章制度。\n'Because this guidance discusses in great detail what must be submitted in an NDA (particularly a 505(b)(2) NDA) or an ANDA (505(j)), the guidance differs from most guidances in that it contains extensive mandatory language, especially in the Appendices. This mandatory language is used whenever the Act and\/or FDA regulations require the submission of certain information. Unlike other documents in which mandatory language is accompanied by the related cite, to make the guidance more user friendly and less cumbersome, we do not cite each regulation each time we discuss a requirement.'可被翻译为：因为本指导原则非常详细的讨论了NDA（尤其是5059(b)(2)NDA）或ANDA （505(j)）必须提交的内容，所以本指导原则不同于大部分指导原则，其中包含广泛的强制语言，尤其是附录中。当法案和\/或FDA法规要求提交某些信息时使用这种强制性语言。与其他文件不同（其中强制性语言附带相关引用，以使指导原则更加用户友好和不那么繁琐），每次进行要求讨论时我们没有列举各项规章制度。\n'See section 506(c) of the FD&C Act; 21 CFR part 314, subpart H.'可被翻译为：参见FD&C Act的506(c)部分；21 CFR第314部分，第H分部分。\n'In 21 CFR 1271.10, the regulations identify the criteria for regulation solely under section 361 of the PHS Act and 21 CFR Part 1271.'可被翻译为：在21 CFR 1271.10中，条例根据PHS法案第361部分和21CFR第1271部分确定了唯一的标准。\n\n根据上述已知信息，请将'This section of the guidance is based largely on section 505(j) of the Act and regulations in 21 CFR part 314, subpart C. As a result, this section contains extensive mandatory language. This mandatory language is used whenever the Act and\/or FDA regulations require the submission of certain information. Unlike other guidance documents in which mandatory language is typically accompanied by the related cite, to make the guidance more user friendly and less cumbersome, we do not cite each regulation each time we discuss a requirement.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这部分的指导原则大多是基于法案第505(j)条和21 CFR部分314，子部分C 中的法规。因此，这个部分含有广泛的强制性语言。当FDA法规要求提交特定资料时使用这种强制性语言。不同于其他指导原则文件（其中强制性语言通常附带相关引用，以使指导原则更加用户友好和不那么繁琐），每次进行要求讨论时我们没有列举各项规章制度。"
    },
    {
        "instruction":"已知信息：\n'Successful electronic transmission of ICSRs relies on standard common data elements and syntactical definition of the electronic message.'可被翻译为：ICSR 电子传输的成功依赖于电子信息的标准通用数据元素和语法定义。\n'This IG is also intended to support the implementation of software and tools for creating, editing, sending and receiving electronic ICSR messages.'可被翻译为：该IG还可用于支持创建、编辑、发送和接收电子ICSR消息的软件和工具的安装。\n'User Guidance This data element contains the message identifier (also called the Message Wrapper).It is a unique tracking identifier assigned to a specific ICH ICSR message transmitted by the sender. One ICH ICSR message contains one and only one ICSR.'可被翻译为：用户指导原则 该数据元素包含信息标识符元素（也称为信息包装）。是分配给由发送者传输的特定ICH ICSR消息的唯一跟踪标识符。一个ICH ICSR消息包含一个且仅有一个ICSR。\n'ACK.B.r.2 Local Report Number User Guidance This data element captures the number assigned to the ICH ICSR message by the organisation that received the ICH ICSR.'可被翻译为：ACK.B.r.2本地报告编号 用户指导原则 该数据元素记录由接收ICH ICSR的机构分配给每个ICH ICSR消息的编号消 息。\n\n根据上述已知信息，请将'The message standard from which this guidance is derived is fully capable of conveying a comprehensive ICSR.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"本指导原则所依据的信息标准完全有能力传输全面的所依据的 ICSR消息。"
    },
    {
        "instruction":"已知信息：\n'Article 36 Cosmetics for children shall comply with requirements for quality and safety of cosmetics for children in laws, regulations, mandatory national standards, technical specifications, and Good Manufacturing Practice for Cosmetics, etc., and shall be indicated on the product label as specified by the NMPA.'可被翻译为：第三十六条 供儿童使用的化妆品应当符合法律、法规、强制性国家标准、技术规范以及化妆品生产质量管理规范等关于儿童化妆品质量安全的要求，并按照国家药品监督管理局的规定在产品标签上进行标注。\n'Article 26 If the registrant or the filing entity of cosmetics entrusts manufacturing of cosmetics, it shall entrust one that has obtained the manufacturing license for the relevant cosmetics, and shall supervise the whole manufacturing process of the entrusted enterprise, and be responsible for quality and safety of the cosmetics entrusted with manufacturing. The contract manufacturer shall have the corresponding manufacturing conditions, and organize manufacturing in accordance with the laws, regulations, mandatory national standards, technical specifications and contractual agreements, be responsible for the manufacturing and be supervised by the entrusting party.'可被翻译为：第二十六条 化妆品注册人、备案人委托生产化妆品的，应当委托取得相应化妆品生产许可的生产企业生产，并对其生产活动全过程进行监督，对委托生产的化妆品的质量安全负责。受托生产企业应当具备相应的生产条件，并依照法律、法规、强制性国家标准、技术规范和合同约定组织生产，对生产活动负责，接受委托方的监督。\n'Article 15 The Cosmetics Manufacturing License shall be indicated with the license number, the manufacturer’s name, domicile, manufacturing address, unified social credit identifier, legal representative or responsible person, the manufacturing licensed items, expiry date, issuing authority and date of issuance, etc.'可被翻译为：第十五条 化妆品生产许可证应当载明许可证编号、生产企业名称、住所、生产地址、统一社会信用代码、法定代表人或者负责人、生产许可项目、有效期、发证机关、发证日期等。\n'(4) having technicians who are suited to the varieties, quantity and manufacturing licensed items, etc. of the cosmetics manufactured;'可被翻译为：（四）有与生产的化妆品品种、数量和生产许可项目等相适应的技术人员；\n\n根据上述已知信息，请将'For those who have the manufacturing conditions of children's skin care and eye care cosmetics shall be specially indicated in the manufacturing licensed items.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"具备儿童护肤类、眼部护肤类化妆品生产条件的，应当在生产许可项目中特别标注。"
    },
    {
        "instruction":"已知信息：\n'C. Placebo-controlled trials enrolling outpatients with ABECB-COPD:'可被翻译为：C ABECB-COPD门诊患者的安慰剂对照试验\n'22 See References, section B., Clinical trials evaluating hospitalized patients with ABECB-COPD.'可被翻译为：22 见参考文献章节B评估ABECB-COPD住院患者的临床试验\n'21 See References, section A., Treatment guidelines and reviews of ABECB-COPD.'可被翻译为：21 见参考文献章节A治疗指导方针和ABECB-COPD的审核\n'6 See References, section D., Publications that provide definitions for COPD and ABECB-COPD.'可被翻译为：6 见参考D部分“提供COPD和ABECB-COPD定义的发表文章”。\n\n根据上述已知信息，请将'24 See References, section C., Placebo-controlled trials enrolling outpatients with ABECB-COPD.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"24 见参考文献章节CABECB-COPD门诊患者的安慰剂对照试验"
    },
    {
        "instruction":"已知信息：\n'Article 59 Highly active materials or products and printed packaging materials should be stored in safe and secure areas.'可被翻译为：第五十九条 高活性的物料或产品以及印刷包装材料应当贮存于安全的区域。\n'Article 124: Printed packaging materials should be properly stored in specific area so as to exclude unauthorized access.'可被翻译为：第一百二十四条 印刷包装材料应当设置专门区域妥善存 放，未经批准人员不得进入。\n'Article 124 Printed packaging materials should be properly stored in specific area so as to exclude unauthorized access. Cut labels and other loose printed packaging materials should be stored and transported in separate closed containers so as to avoid mixups.'可被翻译为：第一百二十四条 印刷包装材料应当设置专门区域妥善存放，未经批准人员不得进入。切割式标签或其他散装印刷包装材料应当分别置于密闭容器内储运，以防混淆。\n'Article 131 Each packaging container of rejected materials, intermediate, bulk and finished products should be clearly marked, and properly stored in restricted areas.'可被翻译为：第一百三十一条 不合格的物料、中间产品、待包装产品和成品的每个包装容器上均应当有清晰醒目的标志，并在隔离区内妥善保存。\n\n根据上述已知信息，请将'Article 59: Highly active materials or products and printed packaging materials should be stored in safe and secure areas.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十九条 高活性的物料或产品以及印刷包装材料应当 贮存于安全的区域。"
    },
    {
        "instruction":"已知信息：\n'If there are important differences in the benefit-risk profiles among populations within an indication, benefit-risk evaluation should be presented by population, if possible.'可被翻译为：如果适应症中的人群 之间的利益 - 风险特征存在重大差异，则尽可能由按人群展示利益 - 风险评 估。\n'Section 18.2 (Benefit-Risk Analysis Evaluation) Although the evaluation of benefit should be limited to approved use (see Section 17 of the Guideline), the overall benefit-risk evaluation should take into account the risks associated with all uses of the product.'可被翻译为：章节8.2（利益-风险分析评估） 尽管利益评估仅限于已批准的使用（见指南的章节17），但总体利益-风险评估 应考虑到与该产品的所有使用相关的风险。\n'Benefit-Risk Analysis Evaluation'可被翻译为：利益-风险分析评估\n'The demonstrated safety profile will be essential for the benefit-risk balance in a defined patient population.'可被翻译为：经证明的安全性特征对于特定患者人群的获益风险平衡将是必不可少的。\n\n根据上述已知信息，请将'3.18.2 Benefit-Risk Analysis Evaluation A benefit-risk profile is specific to an indication and population.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3.18.2 利益-风险分析评估 利益-风险特征是根据适应症和人群特定的。"
    },
    {
        "instruction":"已知信息：\n'After a new drug is approved, the effectiveness and safety of the new drug are reconfirmed through an investigation conducted during the first four to six years of marketing.'可被翻译为：新药获得批准后，在上市的头4〜6年内，进行的有关新药有效性和安全性的调查，对新药的有效性和安全性进行再确认。\n'6 Interim data and study reports can be submitted in your IND annual report, for FDA review, if guidance is desired.'可被翻译为：6 如果需要指导原则，可在您的IND年度报告中提交期中数据和研究报告供FDA评审。\n'8.3.10 MONITORING VISIT REPORTS To document site visits by, and findings of, the monitor X'可被翻译为：8.3.10 监察随访报告 记录监察员的现 场访问及结论 X\n'For example, in a non inferiority study comparing a new TPO-R agonist versus an approved TPO-R agonist a study duration of approximate one year, including 6 months treatment plus up to 6 months follow up may be acceptable.'可被翻译为：例如,对一个 新的血小板生成素受体激动剂药物与已获批血小板生成素受体激动剂药物进行 比较的非劣效性研究大约需要一年时间。其中包括6个月治疗和6个月随访，这 是可以接受的。\n\n根据上述已知信息，请将'4 apparently unconfounded reports within 6 months of approval; plausible time to onset. targeted follow up of reports with site visit to one hospital.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在批准后 6个月内 发生了4 例明显无 混杂因素 的报告； 至事件发 生的时间 合理 对一家医 院进行研 究中心访 视得出的 定向随访 报告。"
    },
    {
        "instruction":"已知信息：\n'immobilized enzyme'可被翻译为：固定化酶\n'enzymatic synthesis'可被翻译为：酶合成\n'(i)drug-metabolising enzymes (cytochrome P450 enzymes, (CYPs), phase II enzymes),'可被翻译为：（i）药物代谢酶（细胞色素P450酶、（CYP）、II相酶），\n'A non-protein component of an enzyme required for its activity. It can promote the activation of enzymes and reactants, and can be divided into coenzymes and coenzymes.'可被翻译为：一种酶的活性所需要的一种非蛋白质成分。能促进酶及反应物进入活化状态，分辅基和辅酶。\n\n根据上述已知信息，请将'Enzymes made by physically or chemically binding enzymes to water-insoluble macromolecular carriers or by embedding enzymes in microcapsules of water-insoluble gels or semi-permeable membranes. The general stability of the enzyme after immobilization is increased, it is easy to be separated from the reaction system, and it is easy to control and can be used repeatedly.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用物理的或化学的方法使酶与水不溶性大分子载体结合或把酶包埋在水不溶性凝胶或半透膜的微囊体中制成的酶。酶固定化后一般稳定性增加，易从反应系统中分离，且易于控制，能反复多次使用。"
    },
    {
        "instruction":"已知信息：\n'There are several terminologies and controlled vocabularies that are used to describe or code information within an ICSR.'可被翻译为：存在数个术语和受控词汇，用于描述或编码 ICSR中的信息。\n'3.2 Code Sets, Terminologies and Vocabularies for E2B(R3)'可被翻译为：3.2 E2B（R3）的代码集、术语和词汇\n'Some of these terminologies or code sets are general and are used by many applications, such as units for mass or time, or country codes.'可被翻译为：这些术语或代码集中的一些术语为通用术语，已被许多应用程序使用，例如用于质量或时间的单位或国家代码。\n'Although the technical specifications for the code sets (e.g. Data Types) are provided in Section 3.4, these are current as of printing this IG.'可被翻译为：尽管第 3.4 节提供了代码集的技术规范（例如：数据类型），但这仅在此版本 IG 发布时有效。\n\n根据上述已知信息，请将'This section will address the code sets, terminologies and vocabularies used in this IG.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"本节将介绍该 IG 中使用的代码集、术语和词汇。"
    },
    {
        "instruction":"已知信息：\n'At entry, the investigator should evaluate the patient by performing an appropriate history and physical examination. The following information should be recorded on the case report form during the entry examination.'可被翻译为：入组时，研究者应考察患者的病史并进行体格检查，进而评估患者。入组检查过程中记录在病例报告表中的信息应包括以下：\n'Each patient should have daily on-therapy assessments of signs and symptoms using a well- defined and reliable PRO instrument. Regardless of how the assessment is conducted (e.g., using an interviewer-administered PRO, interactive voice response via telephone, or electronic capture using a mobile device), the questioning of patients should be performed in a valid, reproducible, and structured way to minimize the potential for inconsistencies in the assessment.16 The ability to detect differences between therapies for a time-to-improvement endpoint may be increased if assessments are done more often (e.g., twice daily). Therapy should be continued as described in the protocol regardless of whether symptoms have improved. Investigators should attempt to allow a minimum of 72 hours on therapy with the trial drug therapy before classifying a patient as a clinical failure; accordingly, investigators may wish to include a 48- to 72-hour visit to ensure there is no substantial clinical worsening at this time.'可被翻译为：应采用定义良好且可靠的PRO量表在治疗过程中每天对每位患者进行症状评估。不管如何进行评估（例如，采用访谈者使用的PRO、通过电话进行交互式语音应答或用移动装置进行电子记录），都应以一种有效、可重现且有结构的方式对患者提问，从而减量减少评估过程中可能存在的不一致。16 如果增加评估的 频率（例如，每日两次），则可能更有把握检测到治疗组之间“至症状改善的时间” 这一终点的差异。不论症状是否改善，都应按方案中的规定继续进行治疗；研究者在将一名患者分类为“临床失败”之前应尽量让患者接受至少72小时的试验药物治疗。因此，研究者可能希望纳入一个48到72小时的访视来确保此时没有明显的临床恶化。\n'All signs and symptoms that may be present in patients with ABECB-COPD should be captured on the case report form (symptoms and patient-reported signs should be captured by a PRO instrument), as should current tobacco use.'可被翻译为：正如对当前烟草使用情况的记录一样，应在病例报告表中记录所有可能出现 在ABECB-COPD患者中的症状与体征（症状和患者报告的体征应通过PRO量 表记录）：\n'This information should be noted in the protocol case report forms and captured in the electronic dataset.'可被翻译为：这个信息应该在方案病例报告表中注 明，并采集在电子数据集中。\n\n根据上述已知信息，请将'Investigators should document findings from on-therapy office visits on the case report form (e.g., history, physical examination, and laboratory test results). If the investigator contacts the patient by telephone or by another interactive technology, documentation of the specific questions asked, how they were asked, and the responses given should be captured on the case report form. If a well-defined and reliable diary is used to capture patient symptoms during this visit, this information also should be recorded on the case report form.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究者应在病例报告表中记录从治疗过程中诊室访视得来的结果（例如，病史，体格检查和实验室检查结果）。如果研究者通过电话或通过其他交互式技术联系患者，则应在病例报告中记录具体的提问、提问的方式和回答。用良好定义且可靠的日记在这次访视中记录患者症状，也应在病例报告表中记录该信息。"
    },
    {
        "instruction":"已知信息：\n'The difference in outcome between the active treatment and placebo groups is the measure of treatment effect under the conditions of the trial.'可被翻译为：试验组与 安慰剂组之间结果的差异用来评价在该试验条件下所研究 药物的有效性。\n'Evidence of efficacy could be based on significant differences in pair-wise comparisons between dosage groups or between dosage groups and placebo, or on evidence of a significant positive trend with increasing dose, even if no two groups are significantly different.'可被翻译为：药物有效性的证明可以基于配对 比较研究中各剂量组之间或各剂量组与安慰剂之间的显著 性差异，或者即使两组间无显著差异，但有效性有随剂量增 加而显著增加的趋势。\n'In a randomized withdrawal trial, subjects receiving a test treatment for a specified time are randomly assigned to continued treatment with the test treatment or to placebo (i.e., withdrawal of active therapy).'可被翻译为：在随机撤药研究中，接受研究药物一段时间治疗的对象 被随机分配到继续使用受试药物治疗或使用安慰剂(即停用 有效药物)治疗。\n'·Placebo-controlled trial with a background of best available nonantimicrobial therapy — All patients receive the best available nonantimicrobial therapy and are randomized to receive, in addition, an investigational antibacterial drug or matching placebo. To demonstrate efficacy, the group receiving the investigational antibacterial drug should demonstrate superiority to the control group receiving matching placebo. A three-arm trial with the experimental treatment group, an active comparator group, and a placebo-controlled group permits the demonstration of superiority to placebo and also can provide risk-benefit information relative to an approved comparator.'可被翻译为：·以最佳可用的非抗菌治疗为背景的安慰剂对照试验—所有的患者接受最佳可用的非抗菌治疗并在此基础上随机接受一种研究性抗菌药或匹配的安慰剂。为了证明疗效，接受研究性抗菌药的患者组应证明相对于安慰剂组的优效性。由研究性治疗组、活性对照组和安慰剂对照组组成的三组试验可证明相对于安慰剂的优效性，也可提供相对于批准参比剂的获益风险信息。\n\n根据上述已知信息，请将'Any difference that emerges between the group receiving continued treatment and the group randomized to placebo would demonstrate the effect of the active treatment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"继续治疗的试验组与随机接受安慰剂的试验组之间出现 的任何差异都可以证明活性治疗的效应。"
    },
    {
        "instruction":"已知信息：\n'If an approach documenting assay sensitivity, without confirmative documentation of non-inferiority is chosen, and especially if specific claims in relation to marketed products are intended, the focus of the evaluations should lie on the potential advantages of the investigational compound in other domains (e.g. documenting better safety, ease of administration or administration schedule).'可被翻译为：如果选择了一种旨在证明检测灵敏度，而不验证非劣效性的方法，尤其是对于与已上市药品有关的特定适应症，那么评价的焦点应为研究药物在其他方面的潜在优势（如安全性更好，或更方便服用，服用时间更灵活等）。\n'These types of investigations, some of which may be beyond the typical scope of a development program for a specific product, might nevertheless be important for guiding patient selection and providing an appropriate context in which to evaluate the risk-benefit of a particular product.'可被翻译为：这些调查方式，某些可能超出特定药物研发项目的标准范围，却可能对引导患者选择， 提供合适评估特定药物风险-疗效环境来说很重要。\n'Especially problematic container closure systems include those that are (1) incongruent with the intended dosage and administration of the product or are (2) atypical for similar products marketed with a different type of container closure.'可被翻译为：特别是，有问题的容 器密闭系统包括（1）与产品的预期剂量和给药不一致或（2）对于用不同类型 的容器密封件上市的类似产品不典型。\n'9.5.1 Efficacy and Safety Measurements Assessed and Flow Chart The specific efficacy and safety variables to be assessed and laboratory tests to be conducted, their schedule (days of study, time of day, relation to meals, and the timing of critical measures in relation to test drug administration, e.g., just prior to next dose, two hours after dose), the methods for measuring them, and the persons responsible for the measurements should be described.'可被翻译为：9.5.1 评估的疗效和安全性指标和流程图 应对将要评估的具体疗效和安全性变量、将要开展的实 验室检查，其时间表（研究日、每日时间、与饮食的关系、 以及关键测量与试验药物给药之间的时间关系，例如下一次 给药之前，给药后2小时）、测量方法和负责测量的人员进 行描述。\n\n根据上述已知信息，请将'If such an approach is chosen, especially if specific claims in relation to marketed products are intended, the focus of the evaluations should lie on the potential advantages of the investigational compound in other domains (e.g. documenting better safety, ease of administration or administration schedule).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果选择这种方法，尤其是如果拟定与已上市药品相关的特殊主张， 那么评估的重点应放在该受试化合物是否在其他方面有潜在的优势（如 证实有更 好的安全性，便于给药或较简便的给药计划）。"
    },
    {
        "instruction":"已知信息：\n'For biotechnology derived product(s), immunogenicity should be evaluated prospectively.'可被翻译为：对于生物技术产品，应前瞻性评估免疫原性。\n'In general, immunogenicity should be investigated prior to marketing authorisation and substantiated  with post-marketing studies.'可被翻译为：一般而言，免疫原性应该在上市前研究，上市后加以证实。\n'If this is the case, immunogenicity should be included in the RMP as either a potential or identified risk.'可被翻译为：如果构成潜在风险，应将免疫原性作为一种潜在或已确认的风险纳入风险管理计划中。\n'However some sensitivity analyses should be pre-planned to establish whether the conclusions drawn from the primary analysis are robust.'可被翻译为：但某些灵敏度分析应当事先计划，以确定从主要分析中得到的结论是否稳健。\n\n根据上述已知信息，请将'The potential for immunogenicity should be fully evaluated based on the available evidence with appropriate conclusions drawn on whether or not a product may pose such a  (potential) risk.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"基于现有证据，对免疫原性风险进行充分评价，并且得出适当结论“产品是否构成此类潜在风险”。"
    },
    {
        "instruction":"已知信息：\n'For the inclusion of patients with typical symptomatology while on PPI therapy into clinical trials, it is therefore considered likewise acceptable that patients are included on the basis of a non-response or insufficient response to PPIs and to standard dose or to double-dose PPI.'可被翻译为：临床研究仅要求纳入正在接受 PPI 治疗且具有典型症状的患者， 因此认为纳 入对标准剂量或双倍剂量的 PPI 治疗无效或效果不佳的患者也同样是可以接受的。\n'As long as there is a reasonable representation of the above sub-groups of patients in the main therapeutic study\/es, a separate study is not considered necessary.'可被翻译为：如果主要治疗研究中合理代表了上述亚组患者，则无需进行单独研究。\n'The inclusion of all age ranges between 0 and 18 years is considered to be necessary and clinical trials should usually be conducted double-blind and placebo-controlled.'可被翻译为：0 岁到 18 岁的儿童都要包含， 而且要采用双盲和安慰剂对照涉及。\n'The inclusion of all age ranges (in sufficient numbers) between 0 and 18 years is considered to be necessary and clinical trials should usually be conducted double-blind and placebo-controlled.'可被翻译为：其年龄范围应覆盖0～18岁之间的所有年龄段（足够数量），通常应采用双盲、安慰剂对照的方法。\n\n根据上述已知信息，请将'It is not considered necessary that all patients take the same PPI for the inclusion into such trials, as reasonable homogeneity of such a population can be assumed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"认为没有必要让所有纳入这些研究的患者服用相同的PPI，因为可以假定这个人群具有合理的同质性。"
    },
    {
        "instruction":"已知信息：\n'The clinical trial in children should begin with the investigation of pharmacokinetics (incremental recovery, in vivo half-life, AUC and clearance) in 10 patients of each age cohort.'可被翻译为：从各年龄组选出10名患者，从药动学研究（增量回收率、体内半衰期、AUC和清除率）开始开展儿童临床试验。\n'The clinical trial in PUPs should be started when data are available from 10 patients participating in the children trial <12 years with 50 ED each, including a minimum of 5 patients <6 years, and when pharmacokinetic investigations in children <12 years are completed.'可被翻译为：当获得 10 名参与<12 岁儿童试验并分别接受 50 天给药的患者（至少5名<6岁）的数据而且完成<12岁儿童的药动学研究时才能开始PUP 的临床试验。\n'Within the application for marketing authorisation, pharmacokinetic data (incremental recovery, in vivo  half-life, AUC and clearance) as well as the completed efficacy and safety trial in 50 children ( to 0 <12 y) followed for  EDs should be submitted.'可被翻译为：在申请上市时，须递交 50 名儿童（0 至 12 岁）服药 50 天后的药动学参数（增量回收率、体内半衰期、药时曲线下面积和清除率）以及完整的疗效及安全性试验资料。\n'Within the application for marketing authorisation, pharmacokinetic data (incremental recovery, in vivo half-life, AUC and clearance) as well as the completed efficacy and safety trial in 20 children (0 to <12y) followed for 50 EDs should be submitted.'可被翻译为：在上市许可申请时，需要提交 20 名儿童（0-12 岁）在50天ED内的药动学数据（增量回收率、体内半衰期、AUC和清除率）以及完整的疗效和安全性试验。\n\n根据上述已知信息，请将'The clinical trial in children should begin with the investigation of pharmacokinetics (incremental  recovery, in vivo half-life, AUC and clearance) in 12 patients of each age cohort.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"儿童临床试验应该从药动学研究（增量回收率、体内半衰期、药时曲线下面积和清除率）开始，每组选出 12 名患者进行研究。"
    },
    {
        "instruction":"已知信息：\n'The rationale as to why the study must be conducted using an exception from informed consent;'可被翻译为：必须采用知情同意豁免开展该项研究的依据；\n'The IRB must also find and document that the requirements for exception from informed consent for emergency research detailed in 21 CFR 50.24 have been met. (See Appendix A for the text of 21 CFR 50.24.) In addition, the IRB must find that the study meets the relevant requirements of 21 CFR Parts 50 and 56.'可被翻译为：IRB还必须确定并用文件证明，符合21 CFR 50.24中所列 举的紧急临床研究豁免知情同意的相关规定。（21 CFR 50.24正文参见附录A）此 外，IRB必须确定，该项研究符合 21 CFR第50和56部分的相关要求。\n'Studies involving an exception from the informed consent requirements may proceed only after a sponsor has submitted an IND or IDE9 and received prior written authorization from FDA10 and IRB approval (i.e., the IRB must find and document that specific conditions in the regulations have been met11). (See Appendix A for the text of 21 CFR 50.24.)'可被翻译为：涉及知情同意要求豁免的研究只有在申办方提交了IND或IDE9并事先收到FDA10和IRB书面批准后才可进行（即，IRB必须确定并用文件证明，符合这些法规中的特定要求11 )（21 CFR 50.24正文参见 附录A）\n'97. These studies involve an exception from informed consent requirements. Why must an informed consent document be prepared?'可被翻译为：97 研究涉及知情同意要求的豁免，为何还必须准备一份知情同意文件？\n\n根据上述已知信息，请将'7. What must the IRB find and document in order for a study involving an exception from informed consent to proceed?'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"7 IRB必须确定并用文件证明哪些信息，才可开展一项涉及豁免知情同意的研究？"
    },
    {
        "instruction":"已知信息：\n'Early engagement with regulatory authorities to understand local\/regional requirements and expectations is encouraged and will facilitate the ability to design quality into the study.'可被翻译为：鼓励监管机构早期介入，以了解当地\/地区的要求和期 望，并有助于促进将质量设计融入研究中的能力。\n'Early discussion with regulators in regions where endpoints, control groups, inclusion criteria or diagnostic criteria might differ should be considered part of planning clinical studies to meet an individual region’s requirements.'可被翻译为：在早期与该地区监管者就研究终点、对照组、入选标准或诊断标准可能存在的差异进行讨论，应被认为是临床研究计划的一部分，以满足新地区监管要求。\n'Patient consultation early in the study design process can contribute to this approach and ultimately help to identify the critical to quality factors.'可被翻译为：在研究设计过 程中尽早与患者沟通有助于这种方法，并最终有助于确定关 键质量因素。\n'These detailed discussions are especially important if the trial has elements with which there is little past experience (e.g., novel eligibility criteria or efficacy endpoints) or has complex design or analytic features (e.g., noninferiority, bioequivalence, adaptive designs, multiplicity considerations).'可被翻译为：如果试验 在某些方面（例如，新的合格性标准或功效终点）的以往经验较少或者设计或分 析特征（例如，非劣效性、生物等效性、适应性设计、多样性考虑）复杂，则对 这些详细的讨论尤为重要。\n\n根据上述已知信息，请将'Early engagement with regulatory authorities is encouraged, particularly when a study has novel elements considered critical to quality (e.g., defining patient populations, procedures, or endpoints).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"鼓励尽早与监管机构沟通，尤其是当一项研究出现可能 影响质量的新关键要素（例如：确定患者人群、程序或终点） 时。"
    },
    {
        "instruction":"已知信息：\n'A stratified randomization may be needed to account for factors that may significantly influence the primary outcome (e.g. CHADS2 score, study centre, etc).'可被翻译为：对于可显著影响主要结局的因素（例如CHADS2评分，研究中心等）可能需要分层随机。\n'Factors on which randomisation has been stratified should be accounted for later in the analysis.'可被翻译为：应当在后续的分析中对分层随机化的因素加以 考虑。\n'Subgroup analyses are strongly encouraged according to index event (together with stratified randomization in trials recruiting both types of index VTE, DVT and\/or PE, see section 6.1) and are encouraged to illustrate outcome in relation to:'可被翻译为：强烈建议根据指标事件进行亚组分析（连同招募两种类型指标 VTE（DVT 和\/或PE）的临床试验中分层随机，见第6.1节）并且鼓励阐明与以下情相关的结局：\n'In multicentre trials randomisation might be stratified by centre, country and\/or region.'可被翻译为：在多中心试验中，随机化可以根据中心、国家和\/或地区进行分层。\n\n根据上述已知信息，请将'Stratified randomisation may be needed to account for factors that may significantly influence the primary outcome (e.g. index DVT or PE, study centre, etc).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于可显著影响主要结局的因素（如指数DVT或PE，研究中心等）可能需要采用分层随机。"
    },
    {
        "instruction":"已知信息：\n'E.i.1.2 Reaction \/ Event as Reported by the Primary Source for Translation'可被翻译为：E.i.1.2主要来源用于翻译报告的反应\/事件\n'E.i.1.2 Reaction \/ Event as Reported by the Primary Source for Translation User Guidance This data element captures the original reporter's words and\/or short phrases used to describe the reaction\/event should be provided in an English translation for international transmission. Conformance Optional Data Type 250AN OID None Value Allowed Free text Business Rule(s)'可被翻译为：E.i.1.2 主要来源用于翻译报告的反应\/事件 用户指导原则 可选择 该数据元素获取的原始报告者的词语和元素和（或）短句用于描述应提供用于国际传播的英文翻译的反应\/事件。 一致性 数据类型 250AN OID 允许值 无 自定义文本 业务规则\n'E.i.1 Reaction \/ Event as Reported by the Primary Source'可被翻译为：E.i.1主要来源报告的反应\/事件\n'The information related to the outcome of the reaction(s)\/event(s) is noted in E.i.7 - Outcome of Reaction \/ Event at the Time of Last Observation.'可被翻译为：与反应\/事件的结果相关的信息在E.i.7中-在最后一次观察时的反应\/事件的结果。\n\n根据上述已知信息，请将'E.i - Reaction(s)\/Event(s) (repeat as necessary) 1 ... n E - Reaction(s)\/Event(s) E.i.1.1a - Reaction \/ Event as Reported by the Primary Source in Native Language E.i.1.1b - Reaction \/ Event as Reported by the Primary Source Language E.i.1.2 - Reaction \/ Event as Reported by the Primary Source for Translation E.i.2.1a - MedDRA Version for Reaction \/ Event E.i.2.1b - Reaction \/ Event (MedDRA code) E.i.3.1 - Term Highlighted by the Reporter E.i.3.2 - Seriousness Criteria at Event Level E.i.3.2a - Results in Death E.i.3.2b - Life Threatening E.i.3.2c - Caused \/ Prolonged Hospitalisation E.i.3.2d - Disabling \/ Incapacitating E.i.3.2e - Congenital Anomaly \/ Birth Defect E.i.3.2f - Other Medically Important Condition E.i.4 - Date of Start of Reaction \/ Event E.i.5 - Date of End of Reaction \/ Event E.i.6a - Duration of Reaction \/ Event E.i.6b - Duration of Reaction \/ Event (duration unit) E.i.7 - Outcome of Reaction \/ Event at the Time of Last Observation E.i.8 - Medical Confirmation by Healthcare Professional E.i.9 - Identification of the Country Where the Reaction \/ Event Occurred'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"E -反应\/事件 1„n E.i -反应\/事件（必要时重复） E.i.1.1 -主要来源使用母语报告的反应\/事件 E.i.1.1b -主要来源语言报告的反应\/事件 E.i.1.2 -主要来源用于翻译报告的反应\/事件 E.i.2.1a -用于反应\/事件的MedDRA版本 E.i.2.1b ––MedDRA术语中的反应\/事件编码 E.I.3.1 -由报告者强调的术语 E.i.3.2 -事件层面的严重性标准 E.i.3.2a -导致死亡 E.i.3.2b -危及生命 E.i.3.2c -导致\/延长住院 E.i.3.2d –残疾\/功能丧失–残疾功能丧失 AESCONG -先天性异常或出生缺陷 E.i.3.2f -其他重要医学事件其他重要医学事件 E.i.4 -反应\/事件开始日期 E.i.5 -反应\/事件结束日期 E.i.6a -反应\/事件持续时间 E.i.6b -反应\/事件持续时间（持续时间单位） E.i.7 -末次观察时反应\/事件的结果 E.i.8 -医疗保健专业人士的医学确认 E.i.9 -发生反应\/事件的国家识别"
    },
    {
        "instruction":"已知信息：\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on March 5, 2020 the Guidelines for Technical Review of the Registration of Colloidal Gold Immunochromatographic Analyzers, Guidelines for Technical Review of the Registration of Follicle stimulating Hormone Detection Reagents, Guidelines for Technical Review of the Registration of Creatinine Detection Reagents, Guidelines for Technical Review of the Registration of Antinuclear Antibody Detection Reagents, Guidelines for Technical Review of the Registration of Antithyroid Peroxidase Antibody Assay Reagents, Guidelines for Technical Review of the Registration of Glycated Albumin Assay Reagents, and the Guidelines for Technical Review of the Registration of Total Bile Acid Assay Reagents.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定并于2020年3月5日发布了《胶体金免疫层析分析仪注册技术审查指导原则》《促卵泡生成素检测试剂注册技术审查指导原则》《肌酐检测试剂注册技术审查指导原则》《抗核抗体检测试剂注册技术审查指导原则》《抗甲状腺过氧化物酶抗体测定试剂注册技术审查指导原则》《糖化白蛋白测定试剂注册技术审查指导原则》和《总胆汁酸测定试剂注册技术审查指导原则》。\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on January 18, 2021 the Guidelines for Technical Review of the Registration of Mycoplasma Pneumoniae IgM\/IgG Antibody Detection Reagents, Guidelines for Technical Review of the Registration of Cryptococcus Capsular Polysaccharide Antigen Detection Reagents, and Guidelines for Technical Review of the Registration of Hereditary Hearing Loss Gene Mutation Detection Reagents.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定了《肺炎支原体IgM\/IgG抗体检测试剂注册技术审查指导原则》《隐球菌荚膜多糖抗原检测试剂注册技术审查指导原则》和《遗传性耳聋相关基因突变检测试剂注册技术审查指导原则》，于2021年1月18日予以发布。\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on March 10, 2020 the Guidelines for Technical Review of the Registration of EB Virus Nucleic Acid Detection Reagents, Guidelines for Technical Review of the Registration of HBV e Antigen, e Antibody Detection Reagents, Guidelines for Technical Review of the Registration of Thalassemia-Related Gene Detection Reagents, and Guidelines for Technical Review of the Registration of HBV-Resistant Gene Mutation Detection Reagents.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局于2020年3月10日组织制定并发布了《EB病毒核酸检测试剂注册技术审查指导原则》《乙型肝炎病毒e抗原、e抗体检测试剂注册技术审查指导原则》《地中海贫血相关基因检测试剂注册技术审查指导原则》《乙型肝炎病毒耐药相关的基因突变检测试剂注册技术审查指导原则》。\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on November 15, 2019 the Guidelines for Technical Review of the Registration of Human Chromosome Abnormality Detection Reagents Based on Cytofluorometric In Situ Hybridization, Guidelines for Technical Review of the Registration of Multiple Nucleic Acids Detection Reagents for Respiratory Virus, Guidelines for Technical Review of the Registration of Nucleic Acid-Based Detection Reagents for Staphylococcus Aureus and Methicillin-Resistant Staphylococcus Aureus, Guidelines for Technical Review of the Registration of Detection Reagents for Chlamydia Trachomatis and \/ or Neisseria Gonorrhoeae Nucleic Acids, and Guidelines for Technical Review of the Registration of Amino Acid, Carnitine, and Succinyl acetone.'可被翻译为：为加强对医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定并于2019年11月15日发布了《基于细胞荧光原位杂交法的人类染色体异常检测试剂注册技术审查指导原则》《呼吸道病毒多重核酸检测试剂注册技术审查指导原则》《基于核酸检测方法的金黄色葡萄球菌和耐甲氧西林金黄色葡萄球菌检测试剂注册技术审查指导原则》《沙眼衣原体和\/或淋病奈瑟菌核酸检测试剂注册技术审查指导原则》和《氨基酸、肉碱及琥珀酰丙酮检测试剂注册技术审查指导原则》。\n\n根据上述已知信息，请将'To strengthen the supervision and guidance over medical device product registration and further improve the quality of registration review, NMPA has organized the formulation of and released on October 29, 2019 the Guidelines for Technical Review of the Registration of Assay Reagents for Aspartate Aminotransferase, Guidelines for Technical Review of the Registration of Total Cholesterol Assay Reagents, Guidelines for the Technical Review of Registration of Uric Acid Determination Reagents, and Guidelines for Technical Review of the Registration of Urea Determination Reagents.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局于2019年10月29日组织制定并发布了《天门冬氨酸氨基转移酶测定试剂注册技术审查指导原则》《总胆固醇测定试剂注册技术审查指导原则》《尿酸测定试剂注册技术审查指导原则》和《尿素测定试剂注册技术审查指导原则》。"
    },
    {
        "instruction":"已知信息：\n'Parent Element Parent Value Child Element Child Value C.1.5 Date of Most Recent Information for This Report February 2nd G.k.2 Drug Identification k=1 ‘QuitSmoking’ G.k.8 Action(s) Taken with Drug k=1 'drug withdrawn’ G.k.4.r Dosage and Relevant Information k=1, r=1 January 1st: 0.5mg daily, orally, x 7 days k=1, r=2 January 8th: 1mg daily, orally, x 7 days k=1, r=3 January 15th -29th:1mg twice daily, orally (stopped) G.k.9.'可被翻译为：父母要素 父母值 孩子要素 孩子值 C.1.5本报告最新资料的日期 2月2日 G.k.2药物识别 k=1 ‘戒烟 G.k.8 针对药物采取的措施 k=1 '停用药物 G.k.4.r 剂量及相关信 息 k=1, 1月1日: 0.5mg\/日, 口服 7 日 r=1 k=1, 1月8日: 1mg \/日, 口服7 日 r=2 k=1, 1月15-29日:1mg 每日两次, 口服 (已停用) r=3 G.k.9.\n'G - Drug(s) Information G.k - Drug(s) Information G.k.2.3.r.1 - Substance\/ Specified Substance Name G.k.2.3.r.2a - Substance\/Specified Substance TermID Version Date \/ Number G.k.2.3.r.2b - Substance\/Specified Substance TermID G.k.2.3.r.3 - Strength (number) G.k.2.3.r.4 - Strength (unit) G.k.2.3.r - Substance\/Specified Substance Identifier and Strength (repeat as necessary) G.k.4.r.1a - Dose (number) G.k.4.r.1b - Dose (unit) G.k.4.r.2 - Number of Units in the Interval G.k.4.r.3 - Definition of the Time Interval Unit G.k.4.r.4 - Date and Time of Start of Drug G.k.4.r.5 - Date and Time of Last Administration G.k.4.r.6a - Duration of Drug Administration (number) G.k.4.r.6b - Duration of Drug Administration (unit) G.k.4.r.7 - Batch \/ Lot Number G.k.4.r.8 - Dosage Text G.k.4.r.9.1 - Pharmaceutical Dose Form (free text) G.k.4.r.9.2a - Pharmaceutical Dose Form TermID Version Date \/ Number G.k.4.r.9.2b - Pharmaceutical Dose Form TermID G.k.4.r.10.1 - Route of Administration (free text) G.k.4.r.10.2a - Route of Administration TermID Version Date \/ Number G.k.4.r.10.2b - Route of Administration TermID G.k.4.r.11.1 - Parent Route of Administration (free text) G.k.4.r.11.2a - Parent Route of Administration TermID Version Date \/ Number G.k.4.r.11.2b - Parent Route of Administration TermID G.k.4.r - Dosage Information (repeat as necessary) 0 ... n 0 ... n 1 ... n Continued on Next Page G.k.1 - Characterisation of Drug Role G.k.2.1.1a - MPID Version Date \/ Number G.k.2.1.1b - Medicinal Product Identifier (MPID) G.k.2.1.2a - PhPID Version Date \/ Number G.k.2.1.2b - Pharmaceutical Product Identifier (PhPID) G.k.2.2 - Medicinal Product Name as Reported by the Primary Source G.k.2.4 - Identification of the Country Where the Drug Was Obtained G.k.2.5 - Investigational Product Blinded G.k.3.1 - Authorisation \/ Application Number G.k.3.2 - Country of Authorisation \/ Application G.k.3.3 - Name of Holder \/ Applicant G.k.5a - Cumulative Dose to First Reaction (number) G.k.5b - Cumulative Dose to First Reaction (unit) G.k.6a - Gestation Period at Time of Exposure (number) G.k.6b - Gestation Period at Time of Exposure (unit) G.k.8 - Action(s) Taken with Drug G.k.11 - Additional Information on Drug (free text)'可被翻译为：G -药物信息 1„n G.k -药物信息 G.k.1 -药物特征 G.k.2.1.1a - MPID版本日期\/编号 G.k.2.1.1b -药品标识符（MPID） G.k.2.1.2a - PhPID版本日期\/编号 G.k.2.1.2b –药物制剂标识符（PhPID） G.k.2.2 -主要来源报告的药品名称 G.k.2.4 –药品获得国的确认–药品获得国的确认 G.k.5.5 -设盲的试验用产品 G.k.3.1 –上市许可–上市许可\/申请编号 G.k.3.2 –上市许可–上市许可\/申请国家 G.k.3.3 -持有人\/申请人姓名 G.k.5a -首次发生反应的累积剂量（数值数值） G.k.5b -首次发生反应的累积剂量（单位） G.k.6a -暴露时的妊娠期（数值数值） G.kbbb -暴露时的妊娠期（单位） G.k.8 -针对药物采取的措施 G.k.11 -药物的附加信息（自定义文本） G.k.2.3.r -物质\/指定物质标识符和规格（必要时重复） 0„n G.k.2.3.r.1 -物质\/指定物质名称 G.k.2.3.r.2a -物质\/指定物质TermID版本日期\/编号 G.k.2.3.r.2b -物质\/指定物质术语ID G.k.2.3.r.3 -规格（数值数值） G.k.2.3.r.4 -规格（单位） G.k.4.r -剂量信息（必要时重复） 0„n G.k.4.r.1a -剂量（数） G.k.4.r.1b -剂量（单位） G.k.4.r.2 -间隔单位数 G.k.4.r.3 -时间间隔单位的定义 G.k.4.r.4 -开始用药的日期和时间 G.k.4.r.5 -末次给药的日期和时间 G.k.4.r.6a -给药持续时间（数值数值） G.k.4.r.6b -给药持续时间（单位） G.k.4.r.7 -批次\/批号 G.k.4.r.8 -剂量文本 G.k.4.r.9.1 -药物剂量表（自定义文本） G.k.4.r.9.2a -药物剂型术语ID版本日期\/编号 G.k.4.r.9.2b -药物剂型术语ID G.k.4.r.10.1 -给药途径（自定义文本） G.k.4.r.10.2a -给药途径术语ID版本日期\/编号 G.k.4.r.10.2b -给药途径术`语ID G.k.4.r.11.1 -主要给药途径（自定义文本） G.k.4.r.11.2a -主要给药途径术语ID版本日期\/编号 G.k.4.r.11.2b -主要给药途径术语ID 接下页\n'For Cmax, an accumulation factor of 1.3 was applied that was estimated from the equation: accumulation = 1\/(1 – e–k∙tau), where k = 0.693\/t½ with t½ = 2.0 hours and tau = 4 hours (i.e., 1\/(1 – e–1.386) = 1\/(1 – 0.25) = 1\/0.75 = 1.3).'可被翻译为：对于Cmax，使用从以 下方程式中估算的蓄积因子为1.3：蓄积=1\/(1–e–k∙tau)，其k=0.693\/t½，t½=2.0小时，tau=4小时（即，1\/(1–e–1.386)=1\/(1–0.25)=1\/0.75=1.3）。\n'For Cmax, an accumulation factor of 3.2 was applied that was estimated from the equation: accumulation = 1\/(1 – e–k∙tau), where k = 0.693\/t½ with t½ = 14.924 hours and tau = 8 hours (i.e., 1\/(1 – e–0.372) = 1\/(1 – 0.690) = 1\/0.31 = 3.2).'可被翻译为：对于Cmax，蓄积因子采用3.2，该值按下列方程式估算而得：蓄积=1\/(1–e–k∙tau)，k=0.693\/t½， t½=14.924 小时，tau=8 小时（即，1\/(1–e–0.372)=1\/(1–0.690)=1\/0.31=3.2）。\n\n根据上述已知信息，请将'Parent Element Parent Value Child Element Child Value C.1.5 Date of Most Recent Information for This Report March 15th G.k.2 Drug Identification k=1 ‘QuitSmoking’ G.k.8 Action(s) Taken with Drug k=1 ‘Unknown’ G.k.4.r Dosage and Relevant Information k=1, r=1 January 1st: 0.5mg daily, orally, x 7 days duration k=1, r=2 January 8th: 1mg daily, orally, x 7 days duration k=1, r=3 January 15th -29th: 1mg twice daily, orally (stopped) k=1, r=4 February 13th: unknown, unknown G.k.9.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"父母要素 父母值 孩子要素 孩子值 C.1.5本报告最新资料的日期 3月15日 G.k.2药物识别 k=1 ‘戒烟 G.k.8 针对药物采取的措施 k=1 '未知 G.k.4.r 剂量及相关信息 k=1, 1月1日: 0.5mg\/日, 连续口服 7 日 r=1 k=1, 1月8日: 1mg \/日, 连续口服7 日 r=2 k=1, 1月15-29日:1mg 每日两次, 口服 (已停用) r=3 k=1, 2月13日，未知，未知 r=4 G.k.9."
    },
    {
        "instruction":"已知信息：\n'This part does not apply to records required to be established or maintained by subpart O of part 1 of this chapter. Records that satisfy the requirements of subpart O of part 1 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.'可被翻译为：本部分不适用于根据本章第1部分的O部分要求建立或维护的记录。符合本章第1部分的O部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。\n'This part does not apply to records required to be established or maintained by subpart L of part 1 of this chapter. Records that satisfy the requirements of subpart L of part 1 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.'可被翻译为：本部分不适用于根据本章第1部分的L部分要求建立或维护的记录。符合本章第1部分的L部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。\n'This part does not apply to records required to be established or maintained by 1.326 through 1.368 of this chapter. Records that satisfy the requirements of part 1, subpart J of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.'可被翻译为：本条例不适用于1.326-1.368要求建立或维护的记录。符合J节1部分的要求，以及其他相应法定条款或法规条例的记录应遵循本条例的要求。\n'This part does not apply to records required to be established or maintained by part 507 of this chapter. Records that satisfy the requirements of part 507 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.'可被翻译为：本部分不适用于根据本章第507部分要求建立或维护的记录。符合本章第507部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。\n\n根据上述已知信息，请将'This part does not apply to records required to be established or maintained by subpart M of part 1 of this chapter. Records that satisfy the requirements of subpart M of part 1 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"本部分不适用于根据本章第1部分的M部分要求建立或维护的记录。符合本章第1部分的M部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。"
    },
    {
        "instruction":"已知信息：\n'5.4.2 Follow-up to a Positive In Vivo Micronucleus Assay'可被翻译为：5.4.2 对体内微核试验阳性结果的追加\n'This is typically a cytogenetic assay, and the micronucleus assay in vivo is called for when following up potential for chromosome loss.'可被翻译为：代表性的是一个细胞遗传学试验，而且，当为染色体丢失潜力进行追加试验时要求进行体内微核试验。\n'Positive results reported in the mouse lymphoma L5178Y cell tk assay (Ref. 3) are small increases, associated with substantial cytotoxicity, and do not meet the current criteria for a positive assay using the “global evaluation factor” (Ref. 4).'可被翻译为：在小鼠淋巴瘤L5178Y细胞Tk基因突变试验（参考文 献3）中报道的阳性结果是略有增加，这与较高的细胞毒性有关；使用“总体评估因子”（参考文献4）评价认为其结果不符合现行标准而未呈阳性。\n'In vivo, glycidol was positive in a mouse micronucleus assay by oral gavage in male and female P16Ink4a\/p19Arf haploinsufficient mice.'可被翻译为：环氧丙醇灌胃给予雄性和雌性P16Ink4a \/ p19Arf 单基因突变的小鼠，体内微核试验结果呈阳性。\n\n根据上述已知信息，请将'In vivo, positive results were seen in the micronucleus assay (Ref. 3).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"体内微核试验显示阳性结果（参考文献3）。"
    },
    {
        "instruction":"已知信息：\n'With increasing knowledge about the various pathophysiologies of pain, however, other approaches of classifying different pain conditions or target populations might in future come to the fore with the challenge of the development of disease modifying therapies.'可被翻译为：然而，随着关于疼痛的各种病理生理学的知识的增加，分类不同的疼痛病症或目标人群的其他方法可能在未来变得突出，伴随着病情改变治疗的发展的挑战。\n'Thus, unless maladaptive characteristics are clearly shown, these pain models are not regarded as appropriate to support a chronic pain indication. Patients with long-standing nociceptive pain without prominent maladaptive features do however form an appropriate patient population for trials to characterise maintenance of efficacy for medicinal products intended primarily for the treatment of acute pain.'可被翻译为：因此，除非明确显示适应不良的特征，否则这些疼痛模型不被认为适合于支持慢性疼痛适应症。 然而，具有长期伤害性疼痛但没有突出的适应不良特征的患者形成适当的患者人群用于试验， 以表征主要用于治疗急性疼痛的药品的有效性维持。\n'At present the contribution of nociceptive and neuropathic components in patients with chronic pain is not routinely evaluated in general clinical practice.'可被翻译为：目前，在慢性疼痛患者中伤害性和神经性组分的贡献在一般临床实践中不进行常规评价。\n'The following general principles can be stated for the data requirements to support different types of indications in chronic pain:'可被翻译为：对于支持慢性疼痛中不同类型适应症的数据要求，可以规定以下一般原则：\n\n根据上述已知信息，请将'Distinguishing these patients from maladaptive chronic pain, in whom the underlying pathophysiology is different, can be difficult and is currently uncommon in general clinical practice. Recommendations on how to address these challenges are outlined in the following chapters.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"区分这些患者与适应不良的慢性疼痛患者（其中潜在的病理生理学是不同的）可能是 困难的，并且目前在一般的临床实践中是不常见的。 关于如何应对这些挑战的建议在以下章节中概述。"
    },
    {
        "instruction":"已知信息：\n'V. Requirements for clinical trials'可被翻译为：五、临床试验要求\n'5.5.6 The sponsor, or other owners of the data, should retain all of the sponsor- specific essential documents pertaining to the trial (see 8. Essential Documents for the Conduct of a Clinical Trial).'可被翻译为：5.5.6 申办者或数据的其他拥有者应当保留申办者方的有关 试验的所有基本文件(见8.实施临床试验的基本文件)。\n'(1) Before the trial, confirm that the clinical trial institution has appropriate conditions, where the staffing and training meets requirements, laboratory equipment is complete and works properly, there are sufficient subjects as expected and the investigators involved are familiar with the trial requirements.'可被翻译为：（一）在试验前确认临床试验机构已具有适当的条件，包括人员配备与培训符合要求，实验室设备齐全、工作情况良好，预期有足够数量的受试者，参与研究人员熟悉试验要求。\n'Article 60 The clinical trial institutions shall properly keep the clinical trial records and basic documents as per the agreement with the sponsor.'可被翻译为：第六十条 临床试验机构应当按照与申办者的约定妥善保存临床试验记录和基本文件。\n\n根据上述已知信息，请将'(5) The requirements of the sponsor and clinical trial institutions for the trial training plan and training records;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）申办者和临床试验机构对试验培训的计划与培训记录要求；"
    },
    {
        "instruction":"已知信息：\n'In this document, the blind review (see Glossary) of data refers to the checking of data during the period of time between trial completion (the last observation on the last subject) and the breaking of the blind.'可被翻译为：本文件中，数据的盲态审核（见词汇表）是指在试验完 成（对最后一位受试者的最后一次观察）到揭盲之间的这段 时间内对数据的检查。\n'The checking and assessment of data during the period of time between trial completion (the last observation on the last subject) and the breaking of the blind, for the purpose of finalising the planned analysis.'可被翻译为：是指在试验完成（最后一位受试者的最后一次观察）到揭盲这段时间内对数据的检查和评价，旨在最终确定分析计划。\n'Particular attention should be paid to any differences between the planned analysis and the actual analysis as described in the protocol, protocol amendments or the updated statistical analysis plan based on a blind review of data.'可被翻译为：应特 别注意在方案、方案修订以及基于数据盲态审核更新的统计 分析计划中所描述的计划分析与实际分析之间的任何差异。\n'During the planning phase of a trial the principal features of the analysis should have been specified in the protocol as described in Section 5.'可被翻译为：如第5章节所述，在试验的计划阶段，分析的主要特征 应在方案中确定。\n\n根据上述已知信息，请将'When the conduct of the trial is over and the data are assembled and available for preliminary inspection, it is valuable to carry out the blind review of the planned analysis also described in Section 5.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当试验结束而且数据经整理可供初步检查 时，如第5章节提到的按计划进行盲态审核是有价值的。"
    },
    {
        "instruction":"已知信息：\n'As discussed in the relevant guideline (see section 3), for demonstrating clinical similarity of a biosimilar and reference product, magnetic resonance imaging of disease lesions in RMS may be sufficient.'可被翻译为：正如相关指南所讨论的（参见第3节），为了证明生物仿制药和对照产品的临床相似性，RMS 疾病病变的磁共振成像可能是足够的。\n'MRI activity and clinical relapses should be compared between these categories for both the biosimilar and reference product.'可被翻译为：应对生物类似物和参比制剂的 这些类别的MRI活性和临床复发情况进行比较。\n'Magnetic resonance imaging (MRI) is a useful tool for monitoring CNS lesions in MS.'可被翻译为：磁共振成像（MRI）是一种非常有用的监测MS中CNS病变的工具。\n'6.5. Magnetic Resonance Imaging'可被翻译为：6.5. 磁共振成像\n\n根据上述已知信息，请将'For demonstrating clinical similarity of a biosimilar and reference product, magnetic resonance imaging of disease lesions in RMS may be sufficient (see Pharmacodynamics).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用复发性多发性硬化症患者病变部位的核磁共振成像证明生物类似物和参比制剂间的临床相似性就足够了（见药效学）。"
    },
    {
        "instruction":"已知信息：\n'For this purpose, the investigators have to collect data regarding symptoms duration.'可被翻译为：为此，研究者需收集症状持续时间 的数据。\n'Study observations should use timing and methodology similar to those used in the control patients.'可被翻译为：研究观查 在时间选择和方法学上应与在对照病例中使用的相似。\n'Patients displaying “alarm symptoms” additionally to the “typical” GORD symptoms may be included based on endoscopic exclusion of malignancy.'可被翻译为：除有“典型”GORD 症状外 还表现出 “警示症状 ”的患者则应接受内窥镜检查排除恶性肿瘤后方可入选。\n'In this document, the former case is referred to as an interventional study and the latter case is referred to as an observational study.'可被翻译为：在本文件中，前一种情况称为干预性研究，后一种情况称为观察性研究。\n\n根据上述已知信息，请将'Typical symptoms can be quantified during an 8-24 hour observational study.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在一项为时 8 到 24 小时的观察性研究中可以对典型症状进行量化。"
    },
    {
        "instruction":"已知信息：\n'See the guidances for industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products and INDs for Phase 2 and Phase 3 Studies: Chemistry, Manufacturing, and Controls Information.'可被翻译为：请参见行业指南I期研究药物，包括经充分鉴定的治疗性生物技术来源产品，研究新药申请（IND）的内容和格式，和 II 期和III 期研究的IND：化学、生产和控制信息。\n'This rationale, particularly for phase 1 trials, is best supported by in vitro and available animal data, as described in the guidance for industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products.'可被翻译为：这种理论依据，尤其是对于I期试验，最好是通过体外和已有的动物数据来支持，如行业指导原则I期研究药物的研究新药申请（IND）的内容和格式，包括经充分鉴定的治疗性生物技术制品中所述。\n'Guidance for FDA reviewers and sponsors Content and Review of Chemistry, Manufacturing,\tand Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug\tApplications (INDs)\nGuidance for industry Botanical Drug Products'可被翻译为：FDA审评员和申办方指导原则人类体细胞疗法研究新药申请（IND）的化学、生产和控制（CMC）信息的内容和审查\n植物药的行业指导原则\n'B. Investigational New Drug Applications (INDs)'可被翻译为：B. 新药临床试验申请（IND）\n\n根据上述已知信息，请将'Guidance for industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"行业指导原则I期研究药物的研究新药申请（IND）的内容和格式，包括经充分鉴定的治疗性生物技术制品"
    },
    {
        "instruction":"已知信息：\n'Also known as \"the ratio of [enantiomer] to good\". The ratio of the strength of biological activity between the more active enantiomer (superior enantiomer) and the less active enantiomer (inferior enantiomer).'可被翻译为：又称\"［对映］异构体优劣比”。较高活性对映体（优对映体）与较低活性对映体（劣对映体）间生物活性强度的比值。\n'In a mixture of two enantiomers (El and E2), where the amount of E1 is assumed to be greater than E2, the percentage of enantiomer E1 excess is called the enantiomer excess of E1.'可被翻译为：在两个对映体（El和E2）的混合物中，假定E1的量大于E2,则对映体E1过量的百分数称为E1的对映体过量。\n'http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/document_listing\/document_listing_ 000319.jsp&mid=WC0b01ac0580022bb0.'可被翻译为：http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/document_listing\/do cument_listing_000319.jsp&mid=WC0b01ac0580022bb0.\n'If the drug substance is a racemate or some other mixture of enantiomers, additional justification should be made for the choice of the analyte [racemate or enantiomer(s)].'可被翻译为：如果药物是消旋体或对映异构体的混合物，应对分析物（消旋体或对映异构体）的选择进行附加说明。\n\n根据上述已知信息，请将'The ratio of the specific curl of a sample containing an enantiomer mixture to the specific curl of a pure mono-isomer.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"含有对映体混合物的样品比旋度与纯单-异构体的比旋度的比值。"
    },
    {
        "instruction":"已知信息：\n'A substance of established quality and purity, as shown by comparison to a primary reference standard, used as a reference standard for routine laboratory analysis.'可被翻译为：经与标准品\/对照品比对，符合质量和纯度要求的物质，供实验室日常分析使用。\n'Reference Standard: A well-characterised substance of known purity and identity used to prepare calibration and quality control samples.'可被翻译为：对照标准品：用于制备校正标样和质控样品的具有已知纯度和特性的物质。\n'The characteristic quantity value of the standard substance shall be measured by accurate and reliable method or by method directly compared with the first class standard substance, and the standard substance whose measurement accuracy meets the needs shall be measured. In the laboratory, it usually refers to the working reference material (standard material) used as a control after comparison with the primary reference material.'可被翻译为：采用准确、可靠的方法或直接与一级标准物质相比较的方法，测量标准物质的特性量值，测量准确度满足需要的标准物质。在实验室中通常是指与一级标准物质比对后作为对照使用的工作对照品（标准品）。\n'It is important that the reference standard is well characterised and the quality (e.g., purity, identity) of the reference standard and the suitability of the IS is ensured, as the quality will affect the outcome of the analysis and, therefore, the study data. The reference standard used during validation and study sample analysis should be obtained from an authentic and traceable source. The reference standard should be identical to the analyte. If this is not possible, an established form (e.g., salt or hydrate) of known quality should be used.'可被翻译为：对照标准品具有良好性质至关重要，其质量会影响分析结果，从而影响研究数据，因此要确保其质量（纯度、鉴别）和内标的适用性。方法验证和研究样品分析过程中使用的对照标准品的来源应可靠并可追溯，并且其化学形式应与待测物相同。如果无法获得与待测物相同的对照标准品，也可以使用质量可控的其他化学形式的物质（例如盐或水合物）。\n\n根据上述已知信息，请将'A substance of established quality and purity, as shown by comparison to a primary reference standard, used as a reference standard for routine laboratory analysis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过与一级标准品的比对表明具有确定的质量和纯度的物质，作为日常实验室分析的标准品之用。"
    },
    {
        "instruction":"已知信息：\n'Therefore characterisation of flow rate dependency in the range of flows\/pressure drops in the patient populations in whom the DPI is to be used should be presented.'可被翻译为：因此，必须表示出使用DPI的患者人群在流量\/压力差范围中的流速依赖性特征。\n'Transport is driven by a partial-pressure gradient.'可被翻译为：渗透是通过分压梯度来完成的。\n'pressurized container'可被翻译为：压力容器\n'deposition'可被翻译为：沉积\n\n根据上述已知信息，请将'In comparison to pressurized and non-pressurized MDIs, the deposition characteristics of DPIs are more flow dependant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"与压力和非压力MDI相比，DPI的沉积特征一般具有很强的流量依赖性。"
    },
    {
        "instruction":"已知信息：\n'Based on a scientific evaluation, the parenteral and inhalation PDEs may be a more appropriate starting point.'可被翻译为：通过科学评估，注射和吸入途径的PDE值更适合作为启动点。\n'Therefore, the inhalation PDE is equal to the oral PDE.'可被翻译为：因此，吸入途径的PDE值和口服PDE值一致。\n'Based on high bioavailability, and that a study by the intraperitoneal route was used to set the oral PDE, the parenteral PDE is equal to the oral PDE.'可被翻译为：基于较高的生物利用度， 采用肌内注射的研究建立口服PDE 值，注射途径的 PDE 等同于口服 PDE 值。\n'Therefore, the parenteral PDE is equal to the oral PDE.'可被翻译为：因此，注射途径的PDE值和口服PDE值一致。\n\n根据上述已知信息，请将'For this reason, the inhalation PDE is set at the parenteral PDE.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"因此，按注射PDE值设定吸入PDE值。"
    },
    {
        "instruction":"已知信息：\n'8 We recognize that treatment guidelines suggest a stratification of patients in which those with more severe ABECB-COPD should receive treatment with an antibacterial drug. A reliable and well-defined magnitude of the treatment effect for patients with more severe ABECB-COPD has not been established.'可被翻译为：8 我们认识到治疗指导方针建议对患者进行分层，而其中ABECB-COPD更加严重的患者应接受抗菌药物治疗。尚未对ABECB-COPD更加严重的患者确定可靠且定义良好的治疗作用。\n'Since these public discussions were held, publications of reviews and treatment guidelines of ABECB-COPD have suggested a stratified approach in which antibacterial drugs are recommended for patients with ABECB-COPD characterized as moderate or severe, but not for patients with ABECB-COPD characterized as mild. This guidance discusses the trial design issues listed above as well as a different stratification for ABECB-COPD based on inpatient versus outpatient treatment (see Appendix A).'可被翻译为：自这些公共讨论举办以来，审查的出版物与ABECB-COPD治疗指导方针建议采用分层的方式推荐中度或重度ABECB-COPD患者使用抗菌药物，而对轻度患者不建议使用。该指南讨论了上述的试验设计问题和基于住院患者与门诊患者 治疗的不同ABECB-COPD分层（见附件A）。\n'·Patient history and characteristics. The following patient demographic characteristics should be used for a better chance of selecting patients more likely to have ABECB- COPD:'可被翻译为：患者病史与特征。应采用以下患者人口统计学特征提高ABECB-COPD 患者的选择机率：\n'The diagnosis of an acute exacerbation presents additional concerns. A diagnosis of ABECB- COPD reflects a change in patient symptoms from their usual baseline; for a trial to demonstrate efficacy of antimicrobial therapy to be effective, patients who have a true change in symptoms should be selected. Because symptoms and signs as reported by the patient are critical to the diagnosis and clinical management of COPD and ABECB-COPD, a well-defined and reliable patient-reported outcome (PRO) instrument should be used in clinical trials for the treatment of ABECB-COPD.9'可被翻译为：急性加重的诊断本身存在着其他问题。ABECB-COPD的诊断反映了患者症状较之于其基线的变化；对于证明抗菌治疗有效的试验而言，应选择症状发生真 实改变的患者。根据患者报告的症状和体征对诊断和临床管理COPD和ABECB-COPD至关重要，因此应在治疗ABECB-COPD的临床试验中使用一种定义良好且可靠的患者报告结局（PRO）的量表。9\n\n根据上述已知信息，请将'Antimicrobials with clinically significant toxicity may not be appropriate for study of ABECB- COPD unless the treatment goal is directed at a more seriously ill patient portion of the ABECB- COPD population.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"具有临床显著毒性的抗菌药可能不适合研究ABECB-COPD，除非治疗目标是针对ABECB-COPD人群中病情更加严重的患者。"
    },
    {
        "instruction":"已知信息：\n'Endogenous insulin can usually be sufficiently suppressed by clamping blood glucose levels below the subject’s fasting glucose (see below).'可被翻译为：受试者空腹血糖以下的钳夹血糖水平一般能抑制内源性胰岛素（如下）。\n'Clamp studies including either healthy subjects or patients with T1DM are considered appropriate for comparison of insulins with a short or intermediate duration of action,'可被翻译为：健康受试者或者I型糖尿病患者的钳夹试验都适于比较短效或中效胰岛素，\n'If a background insulin is given during the trial (e.g. an approved prandial or basal insulin in addition to the test insulin), the type and regimen of the background insulin should not be changed during the evaluation period.'可被翻译为：如果试验中给予注射背景性胰岛素（如受试胰岛素以外的一个批准的餐时或基础胰岛素），其类型和用法在评估期间不能改变。\n'Methods for suppressing endogenous insulin or adjusting measured insulin serum concentrations for estimated endogenous insulin may be considered (see below).'可被翻译为：可以考虑采取抑制内源性胰岛素或者为其调整胰岛素血清浓度测量值的方法（见下）。\n\n根据上述已知信息，请将'For evaluation of prandial insulins, the insulin bolus is expected to adequately suppress endogenous insulin for the duration of the clamp.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为了评估餐前胰岛素，在钳夹过程中胰岛素剂量应足够压制内源性胰岛素。"
    },
    {
        "instruction":"已知信息：\n'This reason for a blank element is referred to as the ‘flavor’ of the null value.'可被翻译为：空白元素的原因称为空值的元素“flavor”。\n'However, in certain cases it is important to understand if a data element is null because it is not applicable or because it is unknown or because it is ‘protected’ by privacy legislation.'可被翻译为：但是，重要的是需要了解，在某些情况下，数据元素是否由于不适用、或者未知、或者受隐私法“保护”而为空元素。\n'Value Allowed Free text Business Rule(s) ACK.B.r.3 ICSR Message ACK Receiver User Guidance This data element identifies the organisation that submitted the ICH ICSR message (creator of ICH ICSR message).'可被翻译为：ICH ICSR执行指导原则 2016年11月10日 -150- 允许值 自定义文本 业务规则 ACK.B.r.3 ICSR消息R消息ACK接收者 用户指导原则 该数据元素标识提交ICH ICSR消息的机构（ICH ICSR消息的创建者）。\n'In ICSR message, this data element is represented in HL7 IVL_PQ data type which is a composite data type with multiple attributes.'可被翻译为：在ICSR信息中，这一数据元素在HL7 IVL_PQ数据类型中表示，一种具有 多重属性的复合数据类型。\n\n根据上述已知信息，请将'In those cases, provisions for expressing a null value are included in the message for a data element to indicate the absence of data and reason.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在这些情况下，在数据元素的信息中纳入用于表示空值的规定元素，以说明不存在的数据及其原因。"
    },
    {
        "instruction":"已知信息：\n'This Appendix does not apply to drug products intended for mucosal administration (oral, nasal, vaginal), topical ophthalmic, rectal, or subcutaneous and subdermal routes of administration.'可被翻译为：本附录不适用于粘膜给药（口腔、鼻腔、阴道）、局部眼科用药、直肠给药、表皮下和真皮下给药的药品。\n'This guidance does not pertain to labeling for nonprescription drug products.4'可被翻译为：本指导原则并不适用于非处方药品的说明书4\n'Assessing Adhesion with Transdermal Delivery Systems and Topical Patches for ANDAs Draft Guidance for Industry'可被翻译为：ANDA所需的透皮递药系统和外用 贴剂黏附力评估 行业指南草案\n'While the recommendations in this guidance apply to both topical patches and TDS, the single term “TDS” will be used exclusively hereafter in reference to both TDS and topical patches.'可被翻译为：尽管本指南中的建议适用于外用贴剂和TDS， 但在后文中完全使用单一术语“TDS”来表示TDS和外用贴剂。\n\n根据上述已知信息，请将'This guidance does not address drug products that are administered via ophthalmic, otic, nasal, inhalation, oral, or injection-based routes, or that are transdermal or topical delivery systems (including products known as patches, topical patches, or extended-release films).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"本指南不适用于通过眼、耳、鼻、吸入、口服或注射途径的药品，亦不适用于经皮或局部给药系统（包括贴剂、局部贴剂或缓释膜剂）。"
    },
    {
        "instruction":"已知信息：\n'Often there are retrospective genomic analyses in many studies and clinical trials.'可被翻译为：许多研究和临床试验中也开展了回顾性基因组分析。\n'The questions to be addressed in the studies may relate to the identification and\/or characterisation of genomic BMs, and their impact on patient selection, dose selection, and choice of concomitant medications.'可被翻译为：研究中要解决的问题可涉及基因组学BM的识别和\/或表征，以及它们对患者选择、剂量选择和伴 随药物选择的影响。\n'Studies evaluated to define the predictive values of the genomic biomarker included both retrospective case-control studies and prospective clinical trials. Carriers of the HLA-B*5701 allele are at significantly increased risk of serious hypersensitivity reactions when exposed to the anti-retroviral agent abacavir (Mallal et al 2008).'可被翻译为：评估和确定基因组学生物标记物预测值的研究主要包括回顾性病例对照试验 和前瞻性临床试验。 HLA-B*5701等位基因携带者暴露于抗逆转录药物阿巴卡韦时，其严重过敏反应的 发生风险显著增加(Mallal et al 2008)。\n'Major types of these designs are cross- sectional studies, case-control studies, and cohort studies (both retrospective and prospective)12,15.'可被翻译为：这些设计的主要类型是横断面研究，病例对照研究 和队列研究（回顾性的和前瞻性的） [12,15] 。\n\n根据上述已知信息，请将'Studies demonstrating the predictive values of the genomic BM included both retrospective case- control studies and prospective clinical trials.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"例子包括HLA等位基因和与阿巴卡韦、卡马西平和别嘌呤醇的特异性反应。"
    },
    {
        "instruction":"已知信息：\n'The properties listed in items below can lead to changes in the behavior of the liposome drug product, including leakage of the drug from the liposomes.'可被翻译为：下面所列举的特性能导致脂质体药品表现的改变，包括药物成分的泄漏。\n'The physical stability of liposome drug products can be affected by a number of factors (e.g., the liposome integrity, the size distribution of the lipid vesicles, unsaturation of the fatty acid groups). Some liposomes are susceptible to fusion (i.e., irreversible coalition of smaller liposomes to form larger liposomes), aggregation (i.e., reversible conglomeration or pooling of two or more liposomes without fusion), and leakage of the contained drug substance during storage.'可被翻译为：脂质体药品的物理稳定性可受多个因素影响（如，脂质体的完整性，脂质囊泡的粒度分布，脂肪酸的不饱和度）。某些脂质体容易聚合（即较小的脂质体不可逆地聚集成较大的脂质体）、聚集（即两个或两个以上的脂质体可逆地非聚合性结团或淤积）和包载药物在存储中泄漏。\n'Stability testing should include tests to assess liposome size distribution and integrity. You should evaluate the chemical stability of the lipid components in the liposome as well as the chemical stability of the contained drug substance.'可被翻译为：稳定性试验应纳入脂质体的粒度分布和完整性测试。应当同时研究脂质体中脂质成分的稳定性和所包载药物的稳定性。\n'For example, drug encapsulation efficiency (defined as percentage of drug contained inside liposomes compared with total amount of drug) and liposome drug loading (defined as the percentage of drug contained which is then compared with the amount of the lipid used, which is the drug-to-128 lipid ratio).'可被翻译为：例如，药物包封率（定义为包封在脂质体内部的药量与总药量的比值）和脂 质体载药率（定义为含药量与脂质量的百分比，也就是药物-脂质的比例）。\n\n根据上述已知信息，请将'Fusion, aggregation, or leakage can be affected by the lipid components in the liposome or by the contained drug substance.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"聚集、聚合和泄漏都可能受脂质成 分或包载药物的影响。"
    },
    {
        "instruction":"已知信息：\n'It is crucial to have identical diagnostic procedures between active and placebo groups in order to avoid sampling bias. Additionally, long observation periods are needed as both the induction period and the latency period to detect a prostate cancer are long. Even small differences in management between the treatment groups may harbour confounding factors of importance.'可被翻译为：为了避免样本引起的偏倚，活性治疗组与安慰剂组之间的诊断程序相同至关重要。此外，需要较长的观察期，因为能检测出前列腺癌的诱导期和潜伏期都很长。即使治疗组之间的管理的微小差异也可能是重要的混杂因素。\n'There is thus a risk related to the detection of indolent tumours and a challenge to identify clinical significant prostate cancer of importance to treat.'可被翻译为：因此，存在一定的风险去检测这种无痛性肿瘤，发现临床重大的前列腺癌比治疗更具有挑战性。\n'A longer period might be needed for induction of complete renal remission, i.e. 1 year.'可被翻译为：诱导治疗是否获得完全缓解则需要更长的时间，即一年。\n'Prostate cancer is diagnosed on histopathology of core biopsies, but the likelihood to detect a cancer is dependent on number of biopsies, the prostate volume and the cancer location (anterior cancer and cancer located near the urethra is difficult to biopsy using transrectal technique).'可被翻译为：通过核心活检样本的组织病理学结果可以诊断前列腺癌，但是能否检测到癌症的可能性依赖于活检样本的数量、前列腺的体积以及癌症位置（位置靠前的癌症和靠近尿道的癌症很难通过经直肠技术取得活检样本）。\n\n根据上述已知信息，请将'Additionally, long observation periods are needed as both the induction period and the latency period to detect a prostate cancer are long.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"此外，需要较长的观察期，因为能检测出前列腺癌的诱导期和潜伏期都很长。"
    },
    {
        "instruction":"已知信息：\n'In the process of the review and approval of a new drug, the registration classification and technical requirements thereof shall not be changed, even though the preparations of the same active ingredients applied for by domestic manufacturers are approved for marketing in China.'可被翻译为：在新药审批期间，其注册分类和技术要求不因国内药品生产企业申报的相同活性成份的制剂在我国获准上市而发生变化。\n'(1) Drugs with the same active ingredients, indications, dosage forms and strengths as non-prescription drugs that have been marketed within the territory of the People's Republic of China;'可被翻译为：（一）境内已有相同活性成分、适应症（或者功能主治）、剂型、规格的非处方药上市的药品；\n'(3) The review timeline for independent applications of generic products of domestically marketed chemical active drug ingredients is 200 days.'可被翻译为：（三）单独申报仿制境内已上市化学原料药的审评时限为二百日；\n'(2) For rare disease drugs with urgent clinical needs that have been marketed overseas but not marketed within the territory of the People’s Republic of China, the review timeline is 70 days;'可被翻译为：（二）临床急需的境外已上市境内未上市的罕见病药品，审评时限为七十日；\n\n根据上述已知信息，请将'For the generic chemical active drug ingredients already used in marketed drug products within the territory of the People’s Republic of China, separated review and approval may be applied.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"仿制境内已上市药品所用的化学原料药的，可以申请单独审评审批。"
    },
    {
        "instruction":"已知信息：\n'The need for statistical adjustment because of such analyses should be addressed.'可被翻译为：应该说明由于这种分析而进行统计调整的需要。\n'Pre-trial deliberations should identify those covariates and factors expected to have an important influence on the primary variable(s), and should consider how to account for these in the analysis in order to improve precision and to compensate for any lack of balance between treatment groups.'可被翻译为：应通过试验前的缜密考虑，确定这些协变量以及 预期对主要指标有重要影响的因素，并考虑在分析中如何处 理，以提高精度和补偿处理组之间的任何不平衡。\n'A diagram showing the relationship between the entire sample and any other analysis groups should be provided.'可被翻译为：应提供一个描述总体样品与其他分析组之间关系的图 表。\n'A description should be given of any intentions to use baseline data to improve precision or to adjust estimates for potential baseline differences, for example by means of analysis of covariance.'可被翻译为：应当说明使用 基线数据以提高精度或以潜在基线差异校正估计值的任何 意图，例如，使用协方差分析进行校正。\n\n根据上述已知信息，请将'and to specify ‘how to account for them in the analysis in order to improve precision and to compensate for any lack of balance between groups’.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"并说明“如何在分析中对其进行解释以提高精度、弥补组间不平衡的情况”。"
    },
    {
        "instruction":"已知信息：\n'The combined use of the active substances should improve the benefit\/risk by either increasing or adding therapeutic efficacy, or by improving safety with the FDC in comparison to the use of the single active substance.'可被翻译为：相对于单用活性物质而言，应通过增强或增加疗效或者通过改善FDC的安全性来提高联用活性物质的获益\/风险。\n'Justification of the pharmacological and medical rationale for the combination.'可被翻译为：复方制剂的药理学和医学基本原理的正当性。\n'Analytical performance criteria should be defined and justified in a pragmatic way so as to be proportionate to the stage of development and to risks and benefits of its intended use (\"fit-for-purpose\").'可被翻译为：不同研发阶段都应指定明确的判定标准，且与预定用途的收益与风险比相适应（目的导向）。\n'When two substrates are present in the cell at the same time, the readily available substrate and its decomposition products inhibit the synthesis of enzymes that are not readily available.'可被翻译为：细胞内同时存在两种底物时，易利用底物及其分解产物会阻遏难利用底物分解酶系合成的过程。\n\n根据上述已知信息，请将'It should be justified that the benefits of starting two drugs at the same time outweighs its disadvantages (unnecessary treatment, safety issues).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"同时开始使用两种药物的优点大于其缺点（不必要的治疗、安全问题）应该是合理的。"
    },
    {
        "instruction":"已知信息：\n'Adequate PK comparisons between subpopulations known to be associated with differences in PK will allow for decisions with respect to the need for pharmacodynamic studies and dose-response studies in different regions and\/or subpop- ulations.'可被翻译为：在已知有PK差异的 亚群中进行充分的PK比较，将有助于确定是否需要在不同区域和\/ 或亚群实施药效动力学研究与剂量-反应关系研究。\n'On occasion there may be need for specific studies in these older groups including PK and dose Guideline on response.'可被翻译为：有时可能需要在这些老年人群中进行特殊研究，包括PK和剂量反应。\n'MRCTs conducted according to the present guideline will allow investigation of treat- ment effects including safety evaluations in the overall population as well as investiga- tions of the potential impact of intrinsic and extrinsic factors (described as ethnic factors in the ICH E5 guideline) on the treatment effect.'可被翻译为：根据本指导原则实施的MRCT可用于研究处理效应，包括对总 人群进行安全性评价，以及研究内在和外在因素（在ICH E5指导原 则中描述为种族因素）对处理效应的潜在影响。\n'Studies to evaluate the effects of intrinsic (such as renal impairment and hepatic impairment) and extrinsic (such as food effect and drug interactions) factors on pharmacokinetics and pharmacodynamics, and exposure-response could be conducted either with the individual drugs or the combination.'可被翻译为：可对单个药物或联合治疗开展研究以评估内在（如肾损害和肝损害）和外在（如食物影响和药 物相互作用）因素对药代动力学、药效学和暴露-效应的影响。\n\n根据上述已知信息，请将'These could include a PK-PD or dose-response study conducted in a particular ethnic population or studies conducted for a broader population, that would allow further evaluation of the impact of intrinsic and extrinsic factors on dose-response.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"其中可包括在某一特定种族人群 或更广泛人群中的PK-PD或剂量-反应关系研究，这有助于进一步 评估内在和外在因素对剂量-反应关系的影响。"
    },
    {
        "instruction":"已知信息：\n'A trial using any of the control types may demonstrate efficacy of the test treatment by showing that it is superior to the control (placebo, no treatment, low dose of test drug, active drug).'可被翻译为：采用任何类型对照的研究，可能通过显示试验治疗优于 对照(安慰剂、无治疗对照、低剂量试验药物、活性药物)来证明试验治疗的有效性。\n'When a new treatment shows an advantage over an active control, the study is readily interpreted as showing efficacy, just as any other superiority trial is, assuming that the active control is not actually harmful.'可被翻译为：当一个新治疗显示其优于活性对照，且假设活性对照确 实无害时，该研究就可以像其他优效性试验一样，推断出新 治疗的有效性。\n'• Active control seeking to show superiority of test drug to active control (see 2.4)'可被翻译为：活性对照，目的在于表明实验药物比活性 对照优效（见2.4）\n'Where superiority to an active treatment is shown, active control studies are readily interpretable regarding evidence of efficacy.'可被翻译为：当活性对照研究显示出试验治疗优效于活性治疗时，更 易于解读为有效性的证据。\n\n根据上述已知信息，请将'Such a result, however -- superiority in the trial of the test agent to the control -- is interpretable as true superiority of the test treatment to the control treatment only when the active control is used in appropriate patients at an appropriate dose and schedule (see section 1.4.3).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"然而，试验中试验药物所表 现的相对于对照药物的优效性，只有当活性对照药物在最佳 的给药剂量和给药方案下、用于合适的病人时才能判断为真 正的优效(见1.4.3)。"
    },
    {
        "instruction":"已知信息：\n'Depending on the nature of information available at the time of writing, the MAH may be able to use information across multiple documents.'可被翻译为：根据撰写时可获得的信息的性质，MAH或许能使用多个文档中的信息。\n'If a report is submitted to multiple INDs, each IND safety report should identify all INDs to which the report is submitted.'可被翻译为：如果一个报告被提交给多个IND，则每个IND安全性报告都应说明报告提交的所有IND。\n'4. Other IND Submissions Where there is a combination IND and INDs for one or more individual drugs, sponsors should consider whether the information in a planned IND submission is relevant to only one IND or to multiple INDs.'可被翻译为：4. 其他IND提交 。当已有联合治疗IND和一种或多种单一药物IND时，申办方应考虑在计划 IND提交中的信息是否仅与一个IND或与多个IND相关。\n'If a reportable adverse event occurs in a study of one of the individual drugs in the combination, the report should be submitted to the IND for that individual drug and to the IND for the combination.'可被翻译为：如果在联合治疗其中一种药物的研究中发生了可报告的不良事件，则该报告应提交给该单 个药物的IND及联合治疗的IND。\n\n根据上述已知信息，请将'Where information is relevant to more than one IND, the information can be submitted in its entirety to each IND or can be submitted to one IND and cross-referenced in the other INDs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"若信息与多个IND相关，可将信息全部提交给每个IND或可提交给一个IND而在其他IND中交叉参照。"
    },
    {
        "instruction":"已知信息：\n'fluorescence immunoassay'可被翻译为：荧光免疫分析\n'A detection technique that combines the high sensitivity of chemiluminescence reactions with the high specificity of immune reactions for the determination of ultramicroscopical substances.'可被翻译为：结合化学发光反应的高度灵敏度和免疫反应的高度专一性，用于测定超微量物质的一种检测技术。\n'The invention relates to a fluorescence analysis method which uses a micellar solution to increase the solubility, sensitization and temperature of a fluorescent substance to improve the sensitivity of fluorescence analysis.'可被翻译为：一种利用胶束溶液对荧光物质有增溶、增敏和增温的作用，提高荧光分析灵敏度的荧光分析方法。\n'When evaluating the performance of the BM, prospective studies are required and the sensitivity and specificity of the testing method should be presented.'可被翻译为：当评估BM的性能时，需要前瞻性研究，并且应该呈现检测方法的灵敏度和特异性。\n\n根据上述已知信息，请将'An immunoassay method that combines the specificity of an immune response with the sensitivity of a fluorescence technique.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将免疫反应的特异性与荧光技术的灵敏度相结合的一种免疫分析方法。"
    },
    {
        "instruction":"已知信息：\n'Detailed “at a glance” requirements for clinical trials for factor IX products are found in Annexes I to III.'可被翻译为：附录 I 至 III 为因 子 IX 产品的临床试验具体要求的“一览表”。\n'EMA\/CHMP\/BPWP\/\/ rev  \/ Please refer to Annex I ‘Overview on clinical trial concept’ and Annex II ‘Clinical trials for factor VIII  products: new products’.  ...'可被翻译为：参见附录 I “临床试验概念综述”和附录 II“因子 VIII 制品临床试验：新制品”。\n'Annex II – Clinical trials with factor VIII products: new products'可被翻译为：附录II因子VIII的临床试验：新药\n'Guidance on the conduct of clinical trials for factor VIII products is given in the “Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products” (EMA\/CHMP\/BPWP\/144533\/2009) which should be considered in connection with the core SmPC.'可被翻译为：进行因子VIII临床试验的指导 原则已在“重组及人血浆衍生因子VIII临床研究指导原则” （EMA\/CHMP\/BPWP\/144533\/2009）中给出，核心SmPC应结合该临床研究指导原 则加以考虑。\n\n根据上述已知信息，请将'Detailed “at a glance” requirements for clinical trials  for factor VIII products are found in Annexes I to III.  .'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"因子VIII 制品临床试验的详细“一览”要求可参见附录 I 到 III。"
    },
    {
        "instruction":"已知信息：\n'Each year, sponsors and FDA engage in thousands of formal and informal communications, including meetings and teleconferences, during the IND phase of drug development. Because these communications are often opportunities to share information and provide critical advice  (e.g., trial design, dose selection, nonclinical study requirements, manufacturing and facility issues), it is important that interactions be conducted efficiently and consistently, with clear, concise, and timely communication.'可被翻译为：在药物开发的IND阶段，申办方和FDA每年都会进行成千上万次正式和非正式沟通，包括会议和电话会议。因为这些沟通往往是分享信息和提供关键建议（例如，试验设计、剂量选择、非临床研究的要求、生产和设备问题）的时机，因此进行有效且一致的相互交流以及清晰、简明且及时的沟通至关重要。\n'Effective and timely communication between FDA and sponsors promotes understanding of mutual goals and is invaluable to the drug development process. Central to this is the ability to communicate clearly, both orally and in writing, inside and outside the formal meeting format.'可被翻译为：FDA和申办方之间的有效且及时的沟通可促进对相互目标的理解，对药物的开发过程至关重要。这一点的核心是能够在正式会议内外以口头和书面形式进行清楚地沟通。\n'‒ Sponsors are encouraged to request feedback via formal meetings with FDA at the major drug development milestones described above.'可被翻译为：- 鼓励申办方在上述重大药物开发里程碑时经由正式会议向FDA请求反馈。\n'Feedback to sponsors via the formal meeting process is provided in three main formats: face-to-face meetings, teleconferences, and WRO responses.'可被翻译为：通过正式会议流程向申办方提供的反馈包括三种主要形式：面对面会议、电 话会议和WRO回复。\n\n根据上述已知信息，请将'Communications that involve sharing results and information at critical milestones during drug development or are necessary for a stalled development program to proceed are best addressed in formal meetings between FDA and sponsors (e.g., face-to-face meeting, teleconference, or written response only (WRO)). Timelines for FDA sending feedback to sponsors via the formal meeting process are described in Prescription Drug User Fee Act (PDUFA) and Biosimilar User Fee Act (BsUFA) agreements and in FDA’s formal meetings guidances.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"涉及在药物开发期间在关键里程碑分享结果和信息的沟通或者终止开发计划所需进行的沟通最好在FDA与申办方之间的正式会议（例如，面对面会议、电话会议或仅书面答复（WRO））中进行。FDA通过正式会议流程向申办方发送反馈时间限详见处方药用户付费法案（PDUFA）和生物仿制药用户付费法案（BsUFA）协议以及FDA的正式会议指导原则。"
    },
    {
        "instruction":"已知信息：\n'The latter gives rise to missing data to be addressed in the statistical analysis.'可被翻译为：后者导致缺失数据，需在统计分析中加以解决。\n'This is particularly useful for laboratory data, which otherwise can be difficult to summarise appropriately.'可被翻译为：这对于实验室数据尤其 有用，否则可能难以适当地进行汇总。\n'If the method of susceptibility testing employed by the central laboratory or by local laboratories changes during the clinical development programme the sponsor should provide assurance that the change does not affect the results reported or should arrange for re-testing of isolates by a single method.'可被翻译为：如果在临床开发项目期间， 中央实验室或当地实验室采用的药敏试验方法有 变更， 申办方应确保该变更不影响报告的结果，或应通过单一的方法复检该分离体。\n'During the co-development of the drug and of the PGBM assay the use of a central laboratory facilities is the preferred option in order to ensure consistency in the results observed.'可被翻译为：在共同开发药物和PGBM过程中，建议使用中心实验室以确保观测结果一致性。\n\n根据上述已知信息，请将'The central laboratory results should be supplemented by local laboratory results to fill in missing data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"中心实验室的结果应该由当地实验室的检测结果进行补 充，以填补缺失数据。"
    },
    {
        "instruction":"已知信息：\n'See the guidance for industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims.'可被翻译为：详见产业指南患者报告的结果测量：使用医疗产品研发来支持标签要求。\n'5 See the guidance for industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims.'可被翻译为：5详见产业指南患者报告的结果测量：使用医疗产品研发来支持标签要求。\n'16 When interviews are used they should be standardized; in addition, symptoms recorded from the patient should be recorded without interpretation by the interviewer. See the guidance for industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims.'可被翻译为：16如果要进行访谈，则应采用标准的访谈；另外，访谈者对根据患者访谈记录的症状不做任何解释。见行业指南患者报告的结局指标：为支持标签声明而在医学产品研发中的应用\n'Type of COA: Patient-reported outcome (PRO) instrument The Center for Drug Evaluation and Research (CDER) has determined that the E-RS:COPD is qualified for exploratory use as a PRO instrument to measure respiratory symptoms in patients with stable COPD in the context of use described below.'可被翻译为：COA类型：患者自报结果（PRO）工具 药物评估与研究中心（CDER）确定了E-RS：COPD作为一种PRO工具是探索 性使用的合适病种，稳定性COPD患者可依据后面描述进行呼吸症状的监测。\n\n根据上述已知信息，请将'12 The use of a well-defined and reliable PRO instrument can yield greater assurance that symptoms are being measured in a consistent manner across patients. For more information regarding the development of PRO measures, see the guidance for industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"12采用定义良好且可靠的PRO量表更能保证以始终一致的方式测量患者的症状。有关PRO指标研发的更多 信息，见行业指南患者报告的结局指标：为支持标签说明而在医学产品研发中的使用"
    },
    {
        "instruction":"已知信息：\n'Changes in organ system, biochemistry, immune function, etc.'可被翻译为：器官系统、生化、免疫等功能的变化。\n'Manifestations of the disease that are the result of long-standing pathophysiologic processes may be less responsive than those that are the result of acute processes. Estimating the amount of effect on the drug target that may provide clinically meaningful effects.'可被翻译为：因长期存在的病理生理学过程所致的疾病表现的反应性弱于因急性过程所致的疾病表现。估算对药物靶标产生多大的效应量才能提供具有临床意义的效应。\n'B) Modification of the natural course of the disease.'可被翻译为：B) 疾病自然病程的修正。\n'Lupus nephritis is the most common severe systemic manifestation of SLE affecting up to 50% of adult patients during the course of their disease.'可被翻译为：狼疮性肾炎是SLE最常见的重度全身表现，在SLE疾病进程中有一半以上的成年患者发病。\n\n根据上述已知信息，请将'The relative contribution of these processes changes during the course of the disease.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这些过程的相对贡献在病程中不断改变。"
    },
    {
        "instruction":"已知信息：\n'HEPA filter - High efficiency particulate air filter specified in accordance with a relevant international standard.'可被翻译为：HEPA 过滤器：符合相关国际标准的高效空气过滤器。\n'High efficiency particulate air filter.'可被翻译为：高效微粒空气过滤器。\n'high efficiency particulate air filter'可被翻译为：高效微粒空气过滤器\n'11.Compressed air systems—sterile process air, microbial particulate filtration (0.2 µm, hydrophobic), condensate causing blockage and microbial growth, routine point-of-use sampling, maintenance, filter integrity test'可被翻译为：11.压缩空气系统—无菌工艺空气，微生物颗粒过滤（0.2 µm，疏水），冷凝物引起堵塞和微生物生长，常规使用点取样、维护、过滤器完整性测试\n\n根据上述已知信息，请将'1.High-efficiency particulate air filter.\n2.A high-efficiency particulate air filter specified in accordance with a relevant international standard.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.高效微粒空气过滤器。\n2.按照相关国际标准指定的高效微粒空气过滤器。"
    },
    {
        "instruction":"已知信息：\n'The applicant or filing entity may conduct product research and development with reference to the relevant technical guidelines, and may also adopt different test methods or technical means while it is required to describe their reasonableness.'可被翻译为：申请人或者备案人可以参考相关技术指导原则进行产品研制，也可以采用不同的实验方法或者技术手段，但应当说明其合理性。\n'The applicant may elect to use proven acceptable ranges or design space for different aspects of the manufacturing process.'可被翻译为：申请人可以根据生产工艺的各种不同情况，选择采用已 证明的可接受的控制范围的方式，或者设计空间的方式。\n'Risk Assessment: Linking Material Attributes and Process Parameters to Drug Product CQAs'可被翻译为：风险评估：联接物料特性及工艺参数与药品CQA\n'2.3 Risk Assessment: Linking Material Attributes and Process Parameters to Drug Product CQAs'可被翻译为：2.3 风险评估：联接物料特性及工艺参数与药品CQA\n\n根据上述已知信息，请将'No, the applicant will need to justify the choice of material attributes and parameters for multivariate experimentation based on risk assessment and desired operational flexibility.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"没有必要，申请者需要根据风险评估和所设计的操作灵 活性，确证选择哪些物料属性和工艺参数进行多变量试验。"
    },
    {
        "instruction":"已知信息：\n'3T3 NRU-PT: In vitro 3T3 Neutral Red Uptake Phototoxicity Test.'可被翻译为：3T3 NRU-PT：体外3T3中性红摄取光毒性试验。\n'In vitro 3T3 Neutral Red Uptake Phototoxicity Test.'可被翻译为：体外3T3中性红摄取光毒性试验。\n'If the drug developer chooses an in vitro approach, the 3T3 NRU-PT is currently the most widely used assay and in many cases could be considered as an initial test for phototoxicity.'可被翻译为：如果药物研发者选择一种体外方法，则3T3 NRU-PT是目前应用最广泛的试验，而且在很多情况下用于 光毒性的初步检测。\n'Note 4 A survey of pharmaceutical companies indicated that the 3T3 NRU-PT, as described in Organisation for Economic Co-operation and Development, Test Guideline (OECD TG) 432, generates a high percentage of positive results (approximately 50%), the majority of which do not correlate with phototoxicity responses in animals or humans (Ref. 9).'可被翻译为：注释4．如OECD TG432所述，制药公司的一项调查显 示3T3 NRU-PT试验中产生了高比例的阳性结果（约50％），其中大部分与动物或人体光毒性反应无关（参考文献9）。\n\n根据上述已知信息，请将'The most widely used in vitro assay for phototoxicity is the 3T3 Neutral Red Uptake Phototoxicity Test (3T3 NRU-PT) for which an Organisation for Economic Co-operation and Development (OECD) guideline (Ref. 6) is available. This is currently considered the most appropriate in vitro screen for soluble compounds.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应用最广泛的体外试验是3T3中性红摄取光毒性试验 （3T3 NRU-PT），参见经济合作与发展组织（OECD）指导原则（参考文献6），目前认为是可溶性化合物最合适的体外筛选方法。"
    },
    {
        "instruction":"已知信息：\n'Modifications to a fully validated analytical method may be evaluated by partial validation. Partial validation can range from as little as one accuracy an d precision determination to a nearly full validation (Refer to Section 6.1). The items in a partial validation should be determined according to the extent and nature of the changes made to the method.'可被翻译为：对经完整验证的分析方法的修改可以通过部分验证进行评估。部分验证的内容应根据方法变更的范围和性质来确定，验证内容可从仅一项准确度和精密度验证到几乎完整验证（参见第6.1节）。\n'At least 2 QC levels should fall within the range of concentrations measured in study samples. If the calibration curve range is changed, the bioanalytical method should be revalidated (partial validation) to verify the response function and to ensure accuracy and precision.'可被翻译为：至少2个质控样品浓度水平应在研究样品的浓度范围内。如果校准曲线范围被调整，则应重新验证生物分析方法（部分验证），以验证响应函数并确保准确度和精密度。\n'The parameters of the partial validations should meet the full validation criteria. If these criteria are not satisfied, additional investigation and validation is warranted.'可被翻译为：如果检测到的参数满足完整验证标准，则部分验证可以被接受。如果不满足这些标准，则需要额外的调查和验证。\n'This can be documented either as a partial validation or as a note to the bioanalytical report.'可被翻译为：上述可作为部分验证 或作为生物分析报告的注释加以记录。\n\n根据上述已知信息，请将'Partial validations evaluate modifications to already fully validated bioanalytical methods. Partial validation can range from as little as one within-run accuracy and precision determination, to a nearly full validation. If stability is established at one facility it does not necessarily need to be repeated at another facility.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"部分验证旨在评价对已经完整验证的生物分析方法的修改。部分验证的范围可由少至一个批内准确度和精密度的测定，到接近于完整验证。如果在一个场所建立了稳定性，则不必在另一个场所重复验证。"
    },
    {
        "instruction":"已知信息：\n'Guideline on the evaluation of anticancer medicinal products in man - EMA\/CHMP\/205\/95\/Rev.'可被翻译为：人类中的抗癌药品评价指导原则-EMA\/CHMP\/205\/95\/Rev.\n'Guideline on the evaluation of anticancer medicinal products in man (CHMP\/EWP\/205\/95)'可被翻译为：人用抗癌药品评价指南（CHMP\/ EWP\/ 205\/95）\n'DFS is considered to be an appropriate primary endpoint in adjuvant studies (EMA\/CHMP\/205\/95\/Rev.4).'可被翻译为：DFS 在辅助治疗研究中被认为是一个适当的主要终点（EMA\/CHMP\/205\/95\/Rev.4）。\n'Guideline on the evaluation of anticancer medicinal  products in man'可被翻译为：人体抗癌药物评价指南\n\n根据上述已知信息，请将'Guideline on the evaluation of anticancer medicinal products in man - EMA\/CHMP\/205\/95\/Rev.4'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"人体抗癌药品的评估指南 - EMA \/CHMP \/205\/95 \/ 修订4"
    },
    {
        "instruction":"已知信息：\n'In general, a parallel group design that includes the test drug at one or more doses, and one or more control treatments (placebo and\/or active comparator) is appropriate although the use of other study designs may be acceptable depending on the objective of the trial.'可被翻译为：一般来说,虽然还可以采用其他研究设计，但平行分组试验可能更合适试验 目的要求。平行分组试验设计中会考查药物的一个或多个剂量,同时还有一个或 多个对照治疗(安慰剂和\/或活性药物对照)。\n'Choice of comparator (monotherapy trials) In general a randomised controlled parallel group trial is the most appropriate design for confirmatory evidence of efficacy in pain trials.'可被翻译为：对照药物的选择（单药治疗试验）一般来说，随机对照平行组试验是疼痛试验中有效性的确证性证据最合适的设计。\n'In general a randomised controlled parallel group trial is the most appropriate design for confirmatory evidence of efficacy in pain trials.'可被翻译为：一般来说，随机对照平行组试验是疼痛试验中有效性的确证性证据最合适的设计。\n'Short term confirmatory efficacy trials  The preferred design for demonstrating short-term efficacy is a randomised, double-blind, parallel group trial.'可被翻译为：短期验证性有效性试验 用于证明短期有效性的首选设计是随机、双盲、平行组试验。\n\n根据上述已知信息，请将'Parallel group design In situations where extrapolation of efficacy is not possible, the parallel group design provides the most robust evidence for efficacy and safety and is the preferred design.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"平行组设计 在不可能进行疗效外推的情况下，平行组设计提供了最可靠的有效性和安全性证据。"
    },
    {
        "instruction":"已知信息：\n'Following completion of the clinical investigation, the IRB must find and document that sufficient information, including the demographic characteristics of the research population and the study results, will be disclosed to the community(ies) and to other researchers (21 CFR 50.24(a)(7)(iii)).'可被翻译为：临床研究完成后，IRB必须确认并且用文件证明，向社区和其他研究者披露 了充分信息，包括该研究人群的人口统计学特征和研究结果（21 CFR 50.24（a） （7）（iii））。\n'(iii) Public disclosure of sufficient information following completion of the clinical investigation to apprise the community and researchers of the study, including the demographic characteristics of the research population, and its results;'可被翻译为：iii. 该项研究完成后，必须向该研究的社区和其他研究者披露充分的信 息，包括该研究人群的人口统计学特征及其结果；\n'Following completion of the study, the sponsor prepares information to apprise researchers and the community(ies) about the study, including demographic characteristics of the research population, and the study’s results (21 CFR 50.24(a)(7)(iii)).'可被翻译为：研究完成后，申办方准备信息，评估研究者和这项研究的社区，包括研究人 群的人口统计学特征和研究结果（21 CFR 50.24（a）（7）（iii））。\n'The goal of public disclosure after the study is completed is to ensure that the communities, the public, and scientific researchers are aware of the study’s results.'可被翻译为：研究完成后公开披露的目标是确保社区、公众和科学研究者知道到该项研究 的结果。\n\n根据上述已知信息，请将'After the study is completed, the IRB reviews the plans for disclosure of sufficient information to apprise the community and researchers of the study, including the demographic characteristics of the research population and its results.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在研究完成后，IRB会审评将充足信息告知给社区和研究者的公开披露计划， 包括研究人群的人口统计学特征及其结果。"
    },
    {
        "instruction":"已知信息：\n'Double blind, parallel group, randomised trial design is recommended.'可被翻译为：建议选择双盲、平行组、随机试验设计。\n'Confirmatory trials: Design The most appropriate design for confirmatory trials is considered to be a prospective, double-blind randomized, controlled, parallel group clinical trial.'可被翻译为：验证性试验： 设计认为最适用的验证试验设计为前瞻性、双盲、随机、对照、平行组临床试验。\n'Randomised, parallel group, double-blind design is recommended.'可被翻译为：推荐使用随机、平行组、双盲的设计。\n'Placebo controlled, randomised, double blind and parallel group design is recommended.'可被翻译为：建议采用安慰剂对照、随机、双盲、平行组设计。\n\n根据上述已知信息，请将'Design For confirmatory trials a prospective, double-blind randomised, controlled, parallel group clinical trial is recommended.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"设计建议验证性试验采用双盲、随机、对照、平行的临床试验。"
    },
    {
        "instruction":"已知信息：\n'Article 48 Production areas should be effectively ventilated, with air control facilities (including temperature, humidity and filtration) appropriate to the products handled, the operations undertaken within them and the external environment, to ensure that the production environment is in accordance with the requirements.'可被翻译为：第四十八条 应当根据药品品种、生产操作要求及外部环境状况等配置空调净化系统，使生产区有效通风，并有温度、湿度控制和空气净化过滤，保证药品的生产环境符合要求。\n'Article 42: Lighting, temperature, humidity and ventilation should be appropriate and such that they do not adversely affect, directly or indirectly, either the product quality during their manufacture and storage, or the accurate functioning of equipment.'可被翻译为：第四十二条 厂房应当有适当的照明、温度、湿度和通风， 确保生产和贮存的产品质量以及相关设备性能不会直接或间接 地受到影响。\n'Provide assurance that cleanrooms and clean air equipment continue to provide an environment of appropriate air cleanliness, in accordance with design and regulatory requirements.'可被翻译为：根据设计和法规要求，保证洁净室和洁净空气设备持续提供适当空气洁净度的环境。\n'production environment'可被翻译为：生产环境\n\n根据上述已知信息，请将'Article 48: Production areas should be effectively ventilated, with air control facilities (including temperature, humidity and filtration) appropriate to the products handled, the operations undertaken within them and the external environment, to ensure that the production environment is in accordance with the requirements.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十八条 应当根据药品品种、生产操作要求及外部环境 状况等配置空调净化系统，使生产区有效通风，并有温度、湿度 控制和空气净化过滤，保证药品的生产环境符合要求。"
    },
    {
        "instruction":"已知信息：\n'Article 71 The design, selection, installation, adaption and maintenance of equipment should be suitable for its intended use, minimize the risk of contamination, cross-contamination, mixups or errors, and facilitate operation, cleaning, maintenance, as well as disinfection or sterilization if necessary.'可被翻译为：第七十一条 设备的设计、选型、安装、改造和维护必须符合预定用途，应当尽可能降低产生污染、交叉污染、混淆和差错的风险，便于操作、清洁、维护，以及必要时进行的消毒或灭菌。\n'Article 71: The design, selection, installation, adaption and maintenance of equipment should be suitable for its intended use, minimize the risk of contamination, cross-contamination, mixups or errors, and facilitate operation, cleaning, maintenance, as well as disinfection or sterilization if necessary.'可被翻译为：第七十一条 设备的设计、选型、安装、改造和维护必须符 合预定用途，应当尽可能降低产生污染、交叉污染、混淆和差错 的风险，便于操作、清洁、维护，以及必要时进行的消毒或灭菌。\n'Where unplanned maintenance of equipment critical to the sterility of the product is to be carried out, an assessment of the potential impact to the sterility of the product should be performed and recorded.'可被翻译为：当要进行对产品无菌性至关重要的设备计划外维护时，应评估并记录对产品无菌性的潜在影响。\n'Article 72: Procedures for the use, cleaning, maintenance and repair of the equipment should be established, and their operation records should be retained.'可被翻译为：第七十二条 应当建立设备使用、清洁、维护和维修的操作 规程，并保存相应的操作记录。\n\n根据上述已知信息，请将'As far as practicable, equipment, fittings and services should be designed and installed so that operations, maintenance, and repairs can be performed outside the cleanroom. If maintenance has to be performed in the cleanroom, and the required standards of cleanliness and\/or asepsis cannot be maintained, then precautions such as restricting access to the work area to specified personnel, generation of clearly defined work protocols and maintenance procedures should be considered. Additional cleaning, disinfection and environmental monitoring should also be considered. If sterilisation of equipment is required, it should be carried out, wherever possible, after complete reassembly.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"设备及辅助装置和服务的设计和安装方式，应尽可能地使操作、维护和维修在洁净室外进行。如果必须在洁净室中进行维护，并且无法维持所要求的洁净和\/或无菌标准，则应当考虑预防措施，例如限制指定人员进入工作区，建立明确的工作方案和维护程序。还应考虑额外的清洁、消毒和环境监测。如果需要对设备进行灭菌，应尽可能在重新组装完成后灭菌。"
    },
    {
        "instruction":"已知信息：\n'(V) Summary of batch production and testing records signed by the  Qualified Person of the drug manufacturer and affixed with the seal of the enterprise;'可被翻译为：（五）药品生产企业质量受权人签字并加盖企业公章的批生产及检定记录摘要；\n'7. A record of the results obtained from in-process controls and the signatures of the person(s) carrying them out;'可被翻译为：7.中间控制结果的记录以及操作人员的签名。\n'Summary of batch production and testing records of biological products refers to a document summarizing the testing results on all production processes and critical quality control links of a certain batch of biological products. Such document shall be reviewed and determined by the quality management department and Qualified Person of the enterprise.'可被翻译为：生物制品批生产及检定记录摘要，是指概述某一批生物制品全部生产工艺流程和质量控制关键环节检验结果的文件。该文件应当由企业质量管理部门和质量受权人审核确定。\n'Summary of batch production and testing records of biological products refers to a document summarizing the testing results on all production processes and critical quality control links of a certain batch of biological products. Such document shall be reviewed and determined by the quality management department and the qualified person of the enterprise.'可被翻译为：生物制品批生产及检验记录摘要，是指概述某一批生物制品全部生产工艺流程和质量控制关键环节检验结果的文件。该文件应当由企业质量管理部门和质量受权人审核确定。\n\n根据上述已知信息，请将'(V)  Summary of batch production and testing records signed by the qualified person and affixed with the seal of the enterprise;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）质量受权人签字并加盖企业公章的批生产及检验记录摘要；"
    },
    {
        "instruction":"已知信息：\n'Based on the recommendation above, and with reference to the conditions set forth in this annex, the pharmacopoeial texts referenced in Section 2.1 of this annex can be considered interchangeable. However, FDA might request that a company demonstrate that the chosen method is acceptable and suitable for a specific material or product, irrespective of the origin of the method.'可被翻译为：基于上述建议，并结合本附录的相关规定，可认为本附录第2.1节中相关药典文本具有同等效力。但是，不论该方法源自何处，FDA都可能会要求企业证明其所选方法的合理性并适用于某一特定的物料或产品的质量控制。\n'The ICH Steering Committee, based on the evaluation by the Q4B Expert Working Group (EWG), recommends that the official pharmacopoeial texts, the Section in Ph.Eur. 2.2.31. Electrophoresis entitled Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE), JP General Information 23. SDS-Polyacrylamide Gel Electrophoresis, and USP <1056> Biotechnology-derived Articles – Polyacrylamide Gel Electrophoresis, can be used as interchangeable in the ICH regions.'可被翻译为：经Q4B专家工作组（EWG）审核，ICH指导委员会建议，欧洲药典附录2.2.31（十二烷基 硫酸钠-聚丙烯酰胺凝胶电泳（SDS-PAGE））、日本药典一般信息23（SDS-聚丙烯酰胺凝胶 电泳）和美国药典附录<1056>（生物技术相关文件 - 聚丙烯酰胺凝胶电泳），中各自规定的 分析方法在ICH区域中具有同等效力。\n'2.1 Analytical Procedures The ICH Steering Committee, based on the evaluation by the Q4B Expert Working Group (EWG), recommends that the official pharmacopoeial texts, Ph.Eur. 20414 Sulphated Ash, JP 2.44 Residue on Ignition Test, and USP <281> Residue on Ignition can be used as interchangeable in the ICH regions given the following:'可被翻译为：2.1 分析方法 经Q4B专家工作组（EWG）审核，ICH指导委员会建议，欧洲药典附录20414（硫酸灰 分）、日本药典附录2.44（炽灼残渣检查法）和美国药典附录281（炽灼残渣）中各自规定的 分析方法在ICH区域中具有同等效力。\n'The working documents received from the PDG or one or more pharmacopoeial sources (USP, Ph. Eur., or JP) that contain the proposed pharmacopoeial text and any other support documents provided for Q4B evaluation.'可被翻译为：从药典讨论组或一个或多个药典机构(美国药典、欧洲药典或日本药典)获 得的工作文件(包含推荐采纳的药典文本和任何其他用于 Q4B 评价的支持性文 件)的过程。\n\n根据上述已知信息，请将'Where such status is indicated, any of the official texts from JP, EP, or USP can be substituted one for the other (appropriately referenced) in the ICH regions for purposes of the pharmaceutical registration\/approval process. Using any of the interchangeable methods, an analyst will reach the same accept or reject decisions irrespective of which PDG pharmacopeia is used.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这种情况是指，就药品的注册\/审批程序而言，在 ICH 区域内，来自日本药典、欧洲药典或美国药典的特定文本均可互相替代(在恰当引用的前提下)。对于任何可互相替代的方法，分析人员均可得出相同的可接受或不可接受的结论。 而无需考虑该文本是来自哪一个具体的 PDG 成员国药典。"
    },
    {
        "instruction":"已知信息：\n'Data elements beginning with ACK.B contain information relating to each ICSR message within the received batch. This B section contains information related to each ICSR message within a batch, including any errors detected within the message.'可被翻译为：以ACK.B开头的数据元素包含与接收到的批次中的每份ICSR消息相关的信息元素消息。B 节包含与批次内的每份ICSR相关的信息，包括该消息内检测到的任何错误消息。\n'ACK.A.1 ICSR Batch Number User Guidance This data element identifies the transaction (that is the batch) that is being acknowledged.'可被翻译为：ACK.A.1 ICSR批号 用户指导原则 该数据元素标识正在确认的交易元素（批处理）。\n'4.2 ICH ICSR Acknowledgement Message The Acknowledgement header contains core transactional information related to the receipt of the batch transmission. The data elements used for the ICH ICSR Acknowledgement are described below.'可被翻译为：4.2 ICH ICSR确认消息确认消息 确认页眉包含与批量传输接收相关的核心交易信息。用于ICH ICSR确认的数据元素如下所述。\n'1. ICSR Batch and Message Wrapper Information'可被翻译为：1. ICSR 批和信息包装信息\n\n根据上述已知信息，请将'Data elements beginning with ACK.A contain technical information relating to batch received. This A section provides information to identify the batch being acknowledged as well as providing summary data on receipt and parsing. In particular, the information provided is for the entire batch rather than for any specific ICSR message in that batch.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以 ACK.A 开头的数据元素包含与收到的批次相关的技术信息元素。本节提供了识别确认的批次信息，并提供收到和解析的摘要数据。尤其是，所提供的信息是针对整个批次而非该批次中的任何特定ICSR消息消息。"
    },
    {
        "instruction":"已知信息：\n'Article 31 In one of the following circumstances, the medical device manufacturer shall be warned and ordered to rectify the situation within a time limit; if it fails to rectify within the time limit, a fine of not more than 30,000 Yuan shall be imposed:'可被翻译为：第三十一条 医疗器械生产企业有下列情形之一的，予以警告，责令限期改正；逾期未改正的，处3万元以下罚款：\n'Article 30 In one of the following circumstances, the medical device manufacturer shall be warned and ordered to rectify the situation within a time limit, and a fine of not more than 30,000 Yuan shall be imposed concurrently:'可被翻译为：第三十条 医疗器械生产企业有下列情形之一的，予以警告，责令限期改正，并处3万元以下罚款：\n'Article 35 Drug manufacturers shall be warned, ordered to rectify the situation within a time limit in any of the following circumstances. If they fail to rectify within the time limit, they shall be fined not more than 20,000 Yuan:'可被翻译为：第三十五条 药品生产企业有下列情形之一的，予以警告，责令限期改正；逾期未改正的，处2万元以下罚款：\n'Article 32 A medical device distributor or using unit that violates the Provisions of the Paragraph 1, Article 7 of these Provisions shall be ordered to stop the sale and use of defective medical devices, and a fine of not less than 5,000 Yuan but not more than 30,000 Yuan shall be imposed concurrently; for those who have caused serious consequences, the former license issuing department shall revoke their Medical Device Distribution License.'可被翻译为：第三十二条 医疗器械经营企业、使用单位违反本办法第七条第一款规定的，责令停止销售、使用存在缺陷的医疗器械，并处5000元以上3万元以下罚款；造成严重后果的，由原发证部门吊销《医疗器械经营许可证》。\n\n根据上述已知信息，请将'Article 33 A medical device distributor or using unit that refuses to cooperate in relevant medical device defect investigation or refuses to assist the medical device manufacturer in recalling the medical device shall be warned and ordered to rectify the situation within a time limit; if it fails to do so within the time limit, a fine of not more than 30,000 Yuan shall be imposed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十三条 医疗器械经营企业、使用单位拒绝配合有关医疗器械缺陷调查、拒绝协助医疗器械生产企业召回医疗器械的，予以警告，责令限期改正；逾期拒不改正的，处3万元以下罚款。"
    },
    {
        "instruction":"已知信息：\n'If the system is flushed or integrity tested in-situ with a fluid other than the product, appropriate actions are taken to avoid any deleterious effect on product quality.'可被翻译为：如果使用产品之外的其他液体冲洗系统或进行在线完整性测试，应釆取适当措施避以免对产品质量的任何有害影响。\n'4.24 Drains should be of adequate size and should be provided with an air break or a suitable device to prevent back-siphonage, when appropriate.'可被翻译为：4.24 排水设施应当大小适宜，应当视情况安装空气隔断或适宜的防止倒灌的装置。\n'Leak tests on the steriliser should be carried out periodically (normally weekly) when a vacuum phase is part of the cycle or the system is returned, post-sterilisation, to a pressure lower than the environment surrounding the steriliser.'可被翻译为：当真空阶段是循环的一部分，或系统在灭菌后返回到低于灭菌柜环境的压力时，灭菌柜应定期（通常为每周）进行泄漏测试。\n'Gases and vacuum systems'可被翻译为：气体和真空系统\n\n根据上述已知信息，请将'Where backflow from vacuum or pressure systems poses a potential risk to the product, there should be mechanism(s) to prevent backflow when the vacuum or pressure system is shut off.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果真空或压力系统的回流会对产品造成潜在风险，应采取措施阻止真空系统或压力系统关闭时产生的回流。"
    },
    {
        "instruction":"已知信息：\n'3.6 (008) November 2014 Use of HL7 nullFlavors requires implementation of very specific business rules for parsing – not necessarily as part of ICSR file validation.'可被翻译为：3.6 (008) 2014年11月 使用HL7 nullFlavors需要实施非常具体的业务 规则来进行解析--不一定是ICSR文件验证的一 部分。\n'For further information, please see the standard ISO \/ HL7 27953- 2. Not all nullFlavors are valid for all data types (e.g. PINF and NINF for non-numeric data elements).'可被翻译为：更多信息，请参见标准 ISO\/HL7 27953-2。并非所有不完整信息均对所有数据类型有效（例如：非数字数据元素的元素PINF和NINF）。\n'o nullFlavors: ICH ICSR uses the following codes from the HL7 Messaging Standard to categorise exceptions.'可被翻译为：○ 不完整信息：ICH ICSR 使用 HL7 信息传递标准中的以下代码对异常结果进行分类。\n'In ICSR message, this data element is represented in HL7 IVL_PQ data type which is a composite data type with multiple attributes.'可被翻译为：在ICSR信息中，这一数据元素在HL7 IVL_PQ数据类型中表示，一种具有 多重属性的复合数据类型。\n\n根据上述已知信息，请将'ICSR file validation is checking appropriate HL7 nullFlavors by data element (datatype).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"ICSR文件验证正在按照数据元素(数据 类型)检查适当的HL7 nullFlavors。"
    },
    {
        "instruction":"已知信息：\n'Usually, a criterion based on bowel movement frequency – however, with additional features, such as spontaneity and completeness (CSBM), and potential additional other features such as normal consistency (BSFS 3-4) can be used, comparing the change from baseline to the end of treatment.'可被翻译为：通常，纳入标准应该基于排便次数和一些附加的症状如自发性和完整性（CSBM），以及潜在的其他特征如标准稠度（BSFS 3-4） 等，比较在治疗结束时相比于基线的变化。\n'The latter may be chosen in patients with urgency without incontinence.'可被翻译为：后者可能会在尿急但未尿失禁的患者中选择。\n'In case a non-inferiority study is conducted the choice of the non-inferiority margin should not be based on the difference of (any) active bowel cleansing medication to placebo but on a clinically acceptable difference of the endpoint used.'可被翻译为：对于非劣效性研究，非劣界值的选择不应该基于（任何）阳性清肠类药物与安慰剂的差异，而应该是所用终点的临床可接受差异。\n'Later, the total frequency was restricted to so called “spontaneous bowel movements” (SBMs), or “complete spontaneous bowel movements” (CSBMs).'可被翻译为：后来，总次数被限于所谓的“自发排便”（SBM）或“完全自发排便”（CSBM）。\n\n根据上述已知信息，请将'In the meantime, until such an instrument is available, the use of a primary endpoint based on CSBMs will be considered to be acceptable because it incorporates spontaneity (without intake of any “rescue” medication (or any other laxative, including enema or suppository) within 24 hours before the bowel movement), as well as completeness, of the bowel movement.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"与此同时，在这样的工具完善之前，使用基于 CSBM的主要终点将被认为是可以接受的，因为它包含自发（排便之前的24小时之内未服用任何“救援”药物（或任何其他的泻药，包括灌肠剂或栓剂））以及良好的排便。"
    },
    {
        "instruction":"已知信息：\n'No relevant data on parenteral exposure to cobalt compounds were found.'可被翻译为：没有发现钴化物注射途径相关的数据。\n'Despite its being ubiquitous in the body, an essential biological role for vanadium in humans has not been established.'可被翻译为：尽管其在体内无处不在，但钒在人体中的重要生 物学作用尚未明确。\n'Cobalt is essential in the human body because it is an integral component of Vitamin B12 and functions as a co-enzyme for several enzymes critical in the synthesis of hemoglobin and the prevention of pernicious anemia.'可被翻译为：钴是维生素B12的组成部分，是合成血红蛋白的多种酶的辅酶且具有预防恶性贫血的作用，因此，钴是人体必需的元素。\n'The oral bioavailability of cobalt and inorganic cobalt compounds ranges from 18-97% (ATSDR, 2004).'可被翻译为：钴及其无机钴化合物的口服生物利用 度为18~97%[1]。\n\n根据上述已知信息，请将'No essential biological function of inorganic cobalt in the human body has been identified.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"已经证实无机钴在人体内没有重要的生物功能。"
    },
    {
        "instruction":"已知信息：\n'Article 72 Where, in violation of the Provisions, a registration alteration of permission items for a medical device is not performed according to law, punishments shall be imposed according to the situation concerning not obtaining a medical device registration certificate in the Regulations on Supervision and Administration of Medical Devices.'可被翻译为：第七十二条 违反本办法规定，未依法办理医疗器械注册许可事项变更的，按照《医疗器械监督管理条例》有关未取得医疗器械注册证的情形予以处罚。\n'Article 29 If a medical device manufacturer violates Article 24 of these Provisions and refuses to recall the medical devices, the Provisions of Article 66 of the Regulations on Supervision and Administration of Medical Devices shall apply.'可被翻译为：第二十九条 医疗器械生产企业违反本办法第二十四条规定，拒绝召回医疗器械的，依据《医疗器械监督管理条例》第六十六条的规定进行处理。\n'Article 75 If failing to handle Class I medical device manufacturing or filing change as stipulated in these Provisions, it shall be handled in accordance with provisions in Article 84 of the Regulations on Supervision and Administration of Medical Devices.'可被翻译为：第七十五条  未按照本办法规定办理第一类医疗器械生产备案变更的，依照医疗器械监督管理条例第八十四条的规定处理。\n'Article 1 These Provisions are formulated in accordance with the Regulations on Supervision and Administration of Medical Devices for the purpose of strengthening supervision and administration of medical device manufacturing, regulating the manufacturing activities of medical devices, and ensuring the safety and effectiveness of medical devices.'可被翻译为：第一条  为了加强医疗器械生产监督管理，规范医疗器械生产活动，保证医疗器械安全、有效，根据《医疗器械监督管理条例》，制定本办法。\n\n根据上述已知信息，请将'Article 77 For violation of provisions in Article 15(2) and Article 42(3) of these Provisions, where, the manufacturing conditions are changed, and the product safety and effectiveness might be affected, but the manufacturer performs manufacturing without making report as stipulated, it shall be punished in accordance with provisions in Article 88 of the Regulations on Supervision and Administration for Medical Devices.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十七条  违反本办法第十五条第二款、第四十二条第三款的规定，生产条件变化，可能影响产品安全、有效，未按照规定报告即生产的，依照医疗器械监督管理条例第八十八条的规定处罚。"
    },
    {
        "instruction":"已知信息：\n'The China Cancer Immunotherapy Workshop has been successfully held for five consecutive years with rising social attention and influence. The Workshop has provided an important academic exchange platform for Chinese and foreign drug regulatory authorities, academia and industry, promoting the exchange of professional knowledge and experience in the field of cancer immunotherapy. It has played a positive role in promoting international exchanges and cooperation in the field of drug regulation and enhancing innovation and development in the field of cancer immunotherapy.'可被翻译为：中国肿瘤免疫治疗会议已连续成功举办了5届，社会关注度和影响力不断扩大，会议为中外药品监管机构、学术界、企业界搭建了一个重要学术交流平台，促进了肿瘤免疫治疗领域的专业知识和经验交流，为推动我国药品监管领域的国际交流合作和肿瘤免疫治疗领域创新发展发挥了积极的作用。\n'In the Workshop, Dr. Ronald Levy, who is the Member of US National Academy of Sciences, Member of US National Academy of Medicine, professor of Stanford University, was specially invited to deliver a keynote speech entitled In Situ Therapeutic Vaccination and share the experience and views on clinical research progress. Prof.Lieping Chen of Yale University, Prof. Xuetao Cao of Nankai University, Prof.Yilong Wu, Prof. Jun Zhu and other famous experts also shared their latest achievements in the field of cancer immunotherapy and put forward their views from the perspective of clinical research and patient needs.'可被翻译为：本次会议特别邀请了美国国家科学院院士、美国国家医学院院士、斯坦福大学罗纳德•莱维(Ronald Levy)教授，发表了题为“原位治疗性疫苗”的主旨演讲，分享了原位治疗性疫苗临床研究进展等方面的经验与看法。耶鲁大学陈列平教授、南开大学校长曹雪涛院士、我国著名肿瘤领域专家吴一龙教授、朱军教授等也分享了肿瘤免疫治疗领域的最新成果，从临床研究和患者需求的角度提出了观点和经验。\n'Focusing on the hot issues in the field of cancer immunotherapy, the Workshop setup 7 topics including Immune Resistance and Combination Therapy, Emerging New Immunotherapy, Perspective from Biopharma Industry, Clinical Update on Checkpoint Inhibitors, Clinical Update on Cellular Therapy and Regulatory Considerations.'可被翻译为：会议围绕肿瘤免疫治疗领域热点问题设置了免疫耐药和联合疗法、肿瘤免疫新型疗法、生物制药界视角-研发者说、检查点抑制剂的临床治疗进展、细胞疗法的临床进展、监管考量等7个专题。\n'2019 China Cancer Immunotherapy Workshop Successfully Held'可被翻译为：2019中国肿瘤免疫治疗会议成功举办\n\n根据上述已知信息，请将'More than 50 Chinese and foreign leading experts in the field of cancer immunotherapy, including US FDA, EMA, CDE, CAHON delivered speeches on the current status and hot topics of cancer immunotherapy and interactively communicated with the participants.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"美国FDA、欧盟药品监管机构、国家药品监督管理局药品审评中心、美国华裔血液及肿瘤专家学会等50余位中外肿瘤免疫治疗学术界顶尖专家针对当前肿瘤免疫治疗的现状和热点进行演讲，并与参会代表进行互动交流。国内外学术机构代表、从事肿瘤免疫治疗临床研究的专家学者和生物制药企业代表参加了会议。"
    },
    {
        "instruction":"已知信息：\n'Human drug products'可被翻译为：人用药品\n'Method of administration'可被翻译为：给药方法\n'Investigational drug(s) – mode(s) of action, therapeutic class(es), dose(s), route(s) of administration, formulation(s);'可被翻译为：试验药－作用机制、治疗分类、剂量、给药途径及剂型；\n'Investigational drug(s) – mode(s) of action, therapeutic class(es), indication(s), dose(s), route(s) of administration, formulation(s);'可被翻译为：试验药－作用机制、治疗分类、适应症、剂量、给药途径、 剂型；\n\n根据上述已知信息，请将'The formulation of the pharmaceutical and route(s) of administration intended for humans;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"拟用于人的药物剂型和给药途径；"
    },
    {
        "instruction":"已知信息：\n'The importance and requirements of assay characteristics depends on the use of the assay.'可被翻译为：测定法特征的重要性和要求取决于测定法的使用。\n'The influence of such matrix components on assay results should be considered and measured.'可被翻译为：应考虑和测定此类基质成分对检测结果的影响。\n'Usually a single concentration of biological is chosen for the assay and dilutions of each sample assessed for their inhibitory effect on the assay response.'可被翻译为：通常，选择单一浓度的生物制品进行检测，评价每份样本的稀释液对应答的抑制作用。\n'o EC: The impact of PSD of API on blend homogeneity and dissolution was well understood.'可被翻译为：o EC：已知API的PSD对混合均匀性和溶出度具有影响。\n\n根据上述已知信息，请将'The effect of sample type and composition on assay performance should be well understood.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应充分理解样本类型和组成对检测法性能的影响。"
    },
    {
        "instruction":"已知信息：\n'The most important risks associated with an increased bleeding are age (> 75 years), low weight, conditions of hypocoagulabilityand renal insufficiency.'可被翻译为：出血增加最重要的风险是年龄（>75 岁）、体重偏轻、血液凝固性过低和肾损伤。\n'Particular attention should be paid to the appropriate determination of pharmacokinetics in older patients, as potential increased exposure and\/or decreased elimination may pose elderly patients at particularly increased risk of major bleeding, particularly haemorrhagic stroke.'可被翻译为：由于暴露量可能增加或者消除减少可能造成老年患者严重出血的风险增加，尤其是出血性脑卒，应特别注意老年患者药代动力学的适当测定。\n'The estimation of bleeding risk is rendered difficult since many of the known factors that increase bleeding risk overlap with stroke risk factors [7].'可被翻译为：因 为许多已知可增加出血风险的因素会与卒中风险因素叠加，使得出血风险的评估 变得困难[7]。\n'Caution should be exercised in prescribing and infusing IVIg in obese patients and in patients with pre-existing risk factors for thrombotic events (such as advanced age, hypertension, diabetes mellitus and a history of vascular disease or thrombotic episodes, patients with acquired or inherited thrombophilic disorders, patients with prolonged periods of immobilisation, severely hypovolaemic patients, patients with diseases which increase blood viscosity).'可被翻译为：在为肥胖患者及已存在血栓风险因素（如老龄、高血压、糖尿病及有血管疾病或血栓病史，获得性或遗传 性易栓症，长期卧床患者，严重低血容量患者以及患有使血液粘度升高的疾病）的 患者开处方及输注IVIg时需要谨慎。\n\n根据上述已知信息，请将'Additional factors may increase the risk (e.g., advanced age, lifestyle factors, concomitant medications, congenital or acquired bleeding disorders) and should be evaluated before the appropriate management is determined.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"高龄、生活方式、药物、遗传及获得性出血疾病等因素可增加出血风险。在制定原发性免疫性血小板减少症管理方案时，应充分考虑上述因素的影响。"
    },
    {
        "instruction":"已知信息：\n'A type of intravenous infusion. Clinical according to the needs of special conditions, the injection containing essential nutrients - amino acids, fats, carbohydrates, vitamins, trace elements, etc., is directly injected into the vein administration method.'可被翻译为：静脉输液的一种。临床针对特殊病情需要，将含有人体必需的营养素--氨基酸、脂肪、碳水化合物、维生素、微量元素等的注射液直接注射入静脉的给药方法。\n'infusion'可被翻译为：输液\n'The invention relates to a REDOX titration method, which is a method of directly titrating a reducing substance in an acidic medium with the apatite as the standard solution.'可被翻译为：一种氧化还原滴定法，是以溟酸盐为标准溶液，在酸性介质中直接滴定还原性物质的方法。\n'(8) Blood vessels recovered with an organ, as defined in 42 CFR 121.2 that are intended for use in organ transplantation and labeled “For use in organ transplantation only.”'可被翻译为：（8）42 CFR 121.2中规 定的从器官中获得的血管，这些被用于器官移植，并标有“仅用于器官移植”。\n\n根据上述已知信息，请将'A method of standard infusion of an organ with artificial blood or nutrient solution.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将器官进行人工血液或营养液标准灌注的方法。"
    },
    {
        "instruction":"已知信息：\n'3. Computerized systems (or equipment and instruments interface to a computer) applied to data acquisition, transmission, storage, processing, archiving, etc., should be validated properly, and the corresponding validation plans, records and reports should be maintained; when hardware or software replaced, upgraded or patched, the system should be evaluated and relevant evaluation reports should be kept; if an additional validation needed after evaluation, the relevant validation plans, records and reports should be kept;'可被翻译为：3.用于研究数据采集、传输、储存、处理、归档等的计算 机化系统(或者包含有计算机系统的设备和仪器)应经过验证，并保留相应的验证计划、记录和报告；系统更换硬件、软件或者系统升级、安装补丁后，应进行系统评估并保留有相关评估报告；评估结果需进行验证的，应保留相应的验证计划、记录和报告；\n'5.43 Computerized systems should have sufficient controls to prevent unauthorized access or changes to data. There should be controls to prevent omissions in data (e.g. system turned off and data not captured). There should be a record of any data change made, the previous entry, who made the change, and when the change was made.'可被翻译为：5.43 计算机化系统应有足够的控制以防止未经许可的人员访问或更改数据。应有控制措施防止数据遗失（如系统关机导致数据未采集）。应当记录任何数据更改、原始值、更改人和更改时间。\n'2. All original records should be recorded truthfully, promptly, accurately, completely and traceably, and the results should be consistent with those in the application dossiers; the changes made in the records should not obscure the original entry, and the person who made the change should sign and date with the reason for change;'可被翻译为：2.各项原始记录应真实、及时、准确、完整、可追溯，且 结果与申报资料一致；记录修改不得覆盖原有数据痕迹，并标注修改人、修改日期和修改理由；\n'A documented software verification and validation task to determine the extent of verification and validation analysis and testing that must be repeated when changes are made to any previously examined software component or system.'可被翻译为：一项文档化的软件验证和确认任务，用于确定在对任何先前检查过的软件组件或系统进行更改时必须重复的验证和验证分析和测试的程度。\n\n根据上述已知信息，请将'5.47 Changes to the computerized system should be made according to a change procedure and should be formally authorized, documented and tested. Records should be kept of all changes, including modifications and enhancements made to the hardware, software and any other critical component of the system. These records should demonstrate that the system is maintained in a validated state.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"5.47 计算机化系统的变更应当根据变更规程执行，并经过正式批准、记录和测试，所有变更应当被记录，包括对系统的软硬件和其它任何关键部件的修改和升级。记录应证明系统处于验证状态。"
    },
    {
        "instruction":"已知信息：\n'FDA generally expects that applicants will be able to provide this information.'可被翻译为：FDA 一般期望申请人将能够提供这些信息。\n'FDA reviews IND submissions and takes regulatory actions (e.g., clinical hold) as appropriate.'可被翻译为：FDA 会审评IND提案并酌情采取监管措施（例如临床试验暂停）。\n'If the sponsor-investigator is studying an FDA-approved prescription or nonprescription drug, even if an IND is required, some of the information needed for an IND submission can be found in the FDA-approved labeling.'可被翻译为：如果申办方-研究者 研究FDA已经批准的处方药或者非处方药， 即使需要IND，IND提交所需的部分信息可以在FDA批准的说明书中找到。\n'IV. CERTAIN INFORMATION REQUIRED FOR AN IND SUBMISSION'可被翻译为：IV. IND 提交所需的特定信息\n\n根据上述已知信息，请将'After all the needed information has been acquired, the IND is ready for submission to the FDA.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在获得所有必需的信息之后，IND 准备提交给 FDA。"
    },
    {
        "instruction":"已知信息：\n'The definition includes studies to support safety labeling changes where individual investigators make a significant contribution to the safety information.'可被翻译为：该定义包括用于支持安全性标签变更， 其中个别研究者对于安全 性信息作出了重要贡献的研究。\n'G.3. Q: The definition of a covered clinical study includes “any study in which a single investigator makes a significant contribution to the demonstration of safety.”'可被翻译为：G.3. 问：一项涵盖的临床研究的定义中包括“其中单一研究者对安全性的证明具 有重要贡献的任何研究 ”。\n'If each investigator makes a significant contribution to the study and, therefore, to a demonstration of safety, such studies would be considered covered clinical studies and subject to financial disclosure.'可被翻译为：如果每名研究者均对研究， 以及因此对于安全性的证明具有重要贡献，那么 这样的研究将被认为是涵盖的临床研究并需进行财务披露。\n'G.1.Q: Disclosure of financial interests and arrangements is required only for covered clinical studies, specifically, those studies relied upon to provide support for the effectiveness of a product or in which a single investigator makes a significant contribution to the demonstration of safety (21 CFR §§ 54.2(e) and 54.3).'可被翻译为：G.1. 问：仅涵盖的临床研究， 具体而言， 那些被依赖于提供某种产品有效性的支 持或其中单一研究者对安全性的证明具有重要贡献的研究，才被要求进行财务 权益和安排的披露（21 CFR §§ 54.2（e ）和 54.3）。\n\n根据上述已知信息，请将'A: Examples of commonly conducted studies in which a single investigator makes a significant contribution to the demonstration of safety would be studies that are designed to address a particular safety concern.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"答：常开展的其中单一研究者对安全性的证明具有重要贡献的研究示例将是 被设计用以考察特定的安全性顾虑的研究。"
    },
    {
        "instruction":"已知信息：\n'Ordinarily, a drug should be contraindicated on the basis of an anticipated adverse reaction if the risk of the adverse reaction in the clinical situation to which the contraindication will apply, based on both likelihood and severity of the adverse reaction, outweighs any potential benefit to any patient:'可被翻译为：当根据不良反应的可能性和严重性且用于禁忌的临床状态下的不良反应风险超过了对任何患者的任何可能益处时，通常可根据可预知的不良反应来禁用药物：\n'For observed adverse reactions, the following would ordinarily be reason to contraindicate a drug:'可被翻译为：对于已观察到的不良反应，禁用药物的通常理由如下：\n'There are circumstances in which an adverse reaction that has not been observed with a drug can nonetheless be anticipated to occur. The WARNINGS AND PRECAUTIONS section should include serious or otherwise clinically significant adverse reactions (as observed in section II.A) that are anticipated to occur with a drug if:'可被翻译为：可预知没有观察到的药品不良反应的出现。警告和预防措施部分应包括下列可预知出现的严重的或其他有临床意义（如章节II.A所述）的药物不良反应，条件是：\n'2. Anticipated Adverse Reactions'可被翻译为：2.可预知的不良反应\n\n根据上述已知信息，请将'Adverse reactions that are anticipated to occur when a drug is used in a specific clinical situation can be the basis for a contraindication.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在特定临床状态下使用药物时，可预知发生的不良反应可作为禁忌的根据。"
    },
    {
        "instruction":"已知信息：\n'A10: Under current FDA regulations, for all expanded access uses including individual patient access uses, investigators are required to ensure that IRB review and approval is obtained consistent with 21 CFR part 56 (21 CFR 312.305(c)(4)).'可被翻译为：A10：按照现行FDA法规，对于所有扩展使用权用药，包括个体患者使用 权用药，要求研究者保证按照21 CFR 56部分（21 CFR 312.305(c)(4)）获得IRB 的审评和批准。\n'Q10: Is Institutional Review Board (IRB) review and approval required for individual patient access uses?'可被翻译为：Q10：个体患者使用权用药需要机构审查委员会（IRB）审评并批准吗？\n'The concerns are primarily about IRB review of individual patient expanded access programs in settings in which IRB review is not readily accessible (e.g., healthcare settings that do not have IRBs).'可被翻译为：这些担忧主要在于，在IRB审评不容易获得的条件下（例如：在没有 IRB的医疗保健条件下）对个体患者扩展使用权项目进行IRB审评。\n'Q21: May treatment with 2 drugs be requested and authorized under a single access program (under a single access IND or protocol) or may an individual patient participate in more than 1 access program (e.g., be enrolled in 2 different treatment INDs)? A21: Yes, a single access program may involve treatment with more than 1 investigational drug, and a patient may be enrolled in more than 1 access program.'可被翻译为：Q21：在一个使用权项目下（在一个使用权IND或方案下）能否要求并授权含2 种药物的治疗，或者个体患者能否参加多项使用权项目（例如：参加2项不同 的治疗IND）？ A21：可以。一项使用权项目可以包括含一种以上研究药物的治疗，一例患 者可以参加多项使用权项目。\n\n根据上述已知信息，请将'FDA is aware of concerns that this requirement for full IRB review may deter individual patient access to investigational drugs for treatment use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"FDA知道这种完全的IRB审评要求可能阻止个体患者对治疗用研究药物的 使用权。"
    },
    {
        "instruction":"已知信息：\n'When initiating changes to analytical procedures, QRM can be used to evaluate the impact of the changes and reconfirm that the originally agreed reporting category is still appropriate.'可被翻译为：当启动分析方法的变更时，QRM可用于评价变更的影响，以及用于重新确认最初商定的报告类别仍然适当。\n'• Adherence to the performance characteristics and criteria after a change of analytical procedure control strategy elements'可被翻译为：• 分析方法控制策略要素发生变更之后符合性 能特征和标准\n'Submitting the outcomes of the risk assessments to regulatory authorities when ECs are proposed can help to justify reporting categories for future changes to analytical procedures.'可被翻译为：在提出ECs时，向监管机构提交风 险评估结果有助于证明未来分析方法变更报告类别的合理性。\n'The applicant should not implement the new analytical procedure using the predefined reporting category unless adherence to the performance characteristics and associated criteria defined in the ATP are demonstrated during the bridging studies.'可被翻译为：除非在桥接研究期间证明符合ATP中定义的性能特征和相关标准，申请人不得按照预先设定的报告类别实施新的分析方法。\n\n根据上述已知信息，请将'• How QRM and the adherence to associated criteria for relevant performance characteristics and\/or the subsequent execution of a bridging study can ensure the post-change quality of the measured result and help to justify the respective reporting categories for ECs and the post approval change management of analytical procedures.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"QRM和遵守相关性能特征的有关标准和\/或后续执行桥接研究 如何确保变更后测量结果的质量，并有助于证明分析方法ECs 的相应报告类别和批准后变更管理的合理性。"
    },
    {
        "instruction":"已知信息：\n'For ICH ICSR messages, this schema defines the Name of Holder \/ Applicant (G.k.3.3).'可被翻译为：对于ICH ICSR消息，该模式定义了持有人\/申请人姓名（G.k.3.3）。\n'For ICH ICSR messages, this schema defines all of data elements in N.1 section.'可被翻译为：对于ICH ICSR消息，该模式定义了N.1一节中的所有数据元素。\n'For ICH ICSR messages, this schema defines the Batch \/ Lot Number (G.k.4.r.7).'可被翻译为：对于ICH ICSR消息，此模式定义批次\/批号（G.k.4.r.7）。\n'For ICH ICSR messages, this schema defines root element.'可被翻译为：对于ICH ICSR消息，此模式定义根元素。\n\n根据上述已知信息，请将'For ICH ICSR messages, this schema defines Authorisation \/ Application Number (G.k.3.1).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于ICH ICSR消息，此模式定义授权\/申请编号（G.k.3.1）。"
    },
    {
        "instruction":"已知信息：\n'For the evaluation of genomic BM related to PK (e.g. polymorphisms in drug metabolising enzymes, such as CYP2D6, or transporters such as SLCO1B1) or PD, the clinical variables may include level of drug concentrations, in addition to lack of efficacy or particular toxicity.'可被翻译为：PK（例如药物代谢酶的多态性，如CYP2D6或转运蛋白如SLCO1B1）和PD 的基因组BM检测的临床变量应包括药物浓度水平、缺乏疗效及特殊毒性。\n'These genomic variations may relate to drug disposition (pharmacokinetics, PK) or drug action (pharmacodynamics, PD) or to individual’s susceptibility. Consequently, there may be subsets of patients with a different benefit\/risk profile.'可被翻译为：这些基因组差异可能会影响药物体内分布（药物代谢动力学，PK）、药物效应（药物效应动力学，PD）或患者的耐受性，从而导致患者亚群受益\/风险的差异。\n'The potential differences regarding the PK\/PD related clinical variables and genomic BMs in different ethnic populations should be considered.'可被翻译为：应考虑在不同种族人群中PK \/ PD相关临床变量和基因组学BM的潜在差异。\n'For the evaluation of genomic BMs related to idiosyncratic reactions, it is essential to identify and precisely define the clinical variables of the respective reaction.'可被翻译为：对于与特异反应有关的基因组学BM的评价，必须识别和精确定义相应反应的临床变量。\n\n根据上述已知信息，请将'For the evaluation of genomic BMs related to PK or PD, the clinical variables may include level of drug concentrations, particular toxicity or lack of efficacy.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于与PK或PD相关的基因组学BM的评估，临床变量可以包括药物浓度水平、特定毒性或缺乏疗效。"
    },
    {
        "instruction":"已知信息：\n'Data to support a rationale for the combination should be provided prior to starting the clinical study.'可被翻译为：在开始临床研究之前，应提供支持联合用药合理性的数据。\n'3.5 Section 3.5 of ICH S9 states that pharmaceuticals planned for use in combination should be well studied individually in toxicology evaluations. How are these nonclinical data considered “well studied individually in toxicology evaluations” to support a combination study? If needed, when would a dedicated toxicology study be recommended?'可被翻译为：3.5 ICH S9的3.5节章节指出，计划联合使用的药物应分别进行良 的毒理学评价。怎样的非临床数据可被认为是“分别的良好的毒理学评价”以支持药物联合应用研究？ 如果需要，推荐何时需进行专门的毒理学研究？\n'A scientific rationale should be provided to justify a combination clinical study. Data demonstrating increased anti-tumor activity by combined pharmaceuticals in pharmacology studies (e.g., animal tumor models, in vitro or in vivo studies based on mechanistic understanding of target biology) should be provided to support rationale for the combination, if feasible. This data could be from in-house studies or the scientific literature.'可被翻译为：应对药物联合应用临床试验进行科学合理性的判断。如果可行，为支持药物联合应用的合理性，应提供在药理学研究（例如动物肿瘤模型，基于靶点生物学机理的体外或体内研究）中证明药物联合应用可提高抗肿瘤活性的数据。这些数据可以来自内部研究或科学文献。\n'“Well-studied individually” means a toxicological evaluation sufficient to support clinical studies of the individual pharmaceutical alone. If sufficient clinical data (e.g., a completed Phase I or a monotherapy phase within Phase I) are available with the individual pharmaceuticals, additional nonclinical toxicology data may not be warranted. A rationale to support the combination should be provided, which can include in vitro or in vivo pharmacology data or a literature assessment. \nIf there is no or very limited human safety data for one of the combination components, a nonclinical pharmacology study of the combination should be considered, in addition to the toxicology studies with the single agents. \nFor pharmaceuticals that are pharmacologically inactive in animal species, assessment of combination can be based on relevant in vitro tests and\/or a mechanistic understanding of target biology. \nIf the available clinical and nonclinical data are insufficient to establish a safe starting dose of the combination, a dedicated toxicology study may be needed with the combination to establish a safe starting dose in humans.'可被翻译为：“分别的良好的研究”是指足以支持每个药物单独进行临床试验的毒理学评估。如果单药已有足够的临床资料（例如完成的I期试验或I期试验中的单药治疗），则可能不需要额外的非临床毒理学数据。应提供支持药物联合应用合理性的证明，可以包括体内或体外药理学数据或文献评估。 \n如果药物联合应用中的一种药物没有或仅有非常有限的人体安全性数据，则在单一药物毒理学研究之外，应考虑药物联合应用的非临床药理学研究。 \n对于在动物种属中无药理学活性的药物，药物联合应用评价可以基于相关的体外试验和\/或靶点生物学机理的理解。 \n如果已有的临床和非临床数据不足以设定药物联合应用的安全起始剂量，可能需要针对药物联合应用人体安全起始剂量进行专门的毒理学研究。\n\n根据上述已知信息，请将'3.6 Section 3.5 of ICH S9 states that data to support a rationale for the combination should be provided prior to starting the clinical study. What are “data to support a rationale for the combination study”?'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3.6 ICH S9的3.5章节指出，支持药 物联合应用合理性的数据应在开始临床试验前完成。怎样的数据算是“支持药物联合应用合理性的数据” ?"
    },
    {
        "instruction":"已知信息：\n'The assessment of duration of response may vary depending of the objectives of the study, especially if the study drug is intended as a short term treatment, such as to cover a period of increased risk (e.g. surgery), or for continuous therapy.'可被翻译为：评估反应持续时间可根据研究目的不同而变化，尤其是该研究药物拟用于短期治疗，比如用于一段高风险时期（如外伤）或连续治疗。\n'The duration of these studies is - among other criteria - dependent upon the (primary) targetvariable(s) and the extent of clinical information they are aiming at.'可被翻译为：这些研究的持续时间是–在其他标准之中–取决于（主要）目标变量及其所指向的临床信息的范围。\n'As for adults, the choice of study design would depend on the objectives of the trial.'可被翻译为：对于成年人，试验研究设计的选择取决于试验目的。\n'The choice of the primary and secondary endpoints will also ultimately depend on the objectives of the trial.'可被翻译为：根据研究目的最终确定主要终点和次要终点。\n\n根据上述已知信息，请将'The duration of a confirmatory clinical study will also depend on the nature of the experimental drug and the objectives of the trial.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"验证性临床研究的期限还取决于实验药物的性质和试验目标。"
    },
    {
        "instruction":"已知信息：\n'It could include information that supports or refutes previously identified safety issues, as well as evidence of new safety signals.'可被翻译为：可以包括支持或否定已确认的安全性 问题的信息，以及新的安全性信号的证据。\n'For each, the evidence supporting the interaction and possible mechanism should be summarised, and the potential health risks posed for the different indications and in the different populations should be discussed.'可被翻译为：对于每种情况，应当概述支持相互作用和可能机制的证据，并且讨论对不同适应症和不同人群的潜在健康风险。\n'These AEs\/ADRs should usually call for further evaluation as part of the Pharmacovigilance Plan (e.g., frequency in normal conditions of use, severity, outcome, at-risk groups, etc.).'可被翻译为：作为药物警戒计划的一部分，通常要求对 这些AEs\/ADRs作更进一步评价（如，在正常使用条件下的频度， 严重程度，转归，高风险的人群，等等）。\n'These can include exposure margins, biological plausibility, evidence of a dose-response relationship, potential for reversibility, the potential for confounding parental toxicity, and evidence for cross-species concordance.'可被翻译为：这些因素可包括暴露 倍数、生物学合理性、剂量-反应关系证据、潜在可逆性、母体毒性混杂的可能性 以及种属间一致性证据。\n\n根据上述已知信息，请将'This information should include evidence bearing on a causal relationship, severity, seriousness, frequency, reversibility and at-risk groups, if available.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果可能，这些信息应包括关于因果关系、严重程度、严重性、频度、可逆性和高风险人群的证据。"
    },
    {
        "instruction":"已知信息：\n'Having one reference source of information that can be applied across the three ICH regions would facilitate a practical, efficient, and consistent approach to the benefit-risk evaluation and make the PBRER a unique report accepted in all countries and regions.'可被翻译为：拥有可以在三个 ICH区域应用的一个参考信息来源将有助于对利益-风险评估采用实用、有效和 一致的方法，并使PBRER成为所有国家和区域接受的独特报告。\n'All relevant safety information contained in the CCDS prepared by the MAH and which the MAH requires to be listed in all countries where the company markets the drug, except when the local regulatory authority specifically requires a modification. It is the reference information by which listed and unlisted are determined for the purposes of periodic reporting for marketed products, but not by which expected ad unexpected are determined for expedited reporting.'可被翻译为：CCDS 中包含的由 MAH 编写并要求在公司销售该药物的所有国家\/区域列出的所有相关的安全性信息，除非当地监管机构具体要求修改。在已上市产品的定期报告中通过已列入和未列入该参考信息来判断，但不能通过预期和非预期来判断是否需要加速报告。\n'In order to facilitate the assessment of benefit and benefit-risk by indication in the evaluation sections of the PBRER, the reference product information document should list all approved indications in ICH countries or regions.'可被翻译为：为了 方便利益和利益-风险的评估，参考产品信息文件应列出ICH国家或区域的所有 已批准适应症。\n'All adventitious agent safety evaluation information could be in one document or multiple documents and within one or multiple adventitious agent safety evaluation sections (i.e., each section covering a different drug substance and\/or drug product “component”).'可被翻译为：所有外源因子的安 全性评估信息可以放置在一个文件或多个文件中，并且放置在一个或多个外源 因子的安全性评估章节中（即每个章节涵盖一种不同的活性成分和\/或制剂的 “组成”）。\n\n根据上述已知信息，请将'It is generally impractical for Marketing Authorisation Holders (MAHs) to have one reference information source that: Encompasses all parameters that contribute towards the benefit-risk evaluation, (i.e., benefit, efficacy\/effectiveness, indication(s) and safety information); Is common to all ICH regions; and Addresses all circumstances, (e.g., generics, products licensed in one country only).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"销售许可证持有人（MAHs）通常具有以下一种参考信 息来源： 包括有助于利益-风险评估的所有参数（即利益，有效性\/疗效，适应症 和安全性信息）； 所有ICH区域都很常见；并且 所有情况（例如，仿制药，仅在一个国家许可的产品）的解决结果。"
    },
    {
        "instruction":"已知信息：\n'Changes in organ weight, gross organ pathology, clinical chemistry, and histopathology can all be indicative of particular endocrine effects.'可被翻译为：器官重量、大体器官病理、临床生化和组织病理的改变可提示特定的内分泌作用。\n'Although the goal of these studies is to assess the drugs’ carcinogenic potential, organ changes assessed by histopathology also give information about potential endocrine effects.'可被翻译为：尽管这些研究的目标是评估药物的致癌性，但通过组织病理评估的器官改变也可提供关于潜在内分泌影响的信息。\n'Gross pathology Lymphoid organs \/ tissues'可被翻译为：大体病理学 淋巴器官\/组织\n'Such an approach should include a comprehensive histopathological examination of the reproductive organs from both male and female animals (Note 1).'可被翻译为：这种方法应包括对雌性和雄性动物的 生殖器官进行详细全面的组织病理学检查（注释1）。\n\n根据上述已知信息，请将'Organs typically collected for gross and histopathological evaluation include endocrine-sensitive organs such as the thyroid gland, adrenal glands, reproductive organs, and pituitary gland.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通常采集用于大体评估和组织病理学评估的器官包括内分泌敏感器官，例如 甲状腺、肾上腺、生殖器官和垂体。"
    },
    {
        "instruction":"已知信息：\n'Article 70 Where a medical device registration certificate is falsified, altered, bought or sold, leased or lent, punishments shall be made according to Paragraph 2, Article 64 of the Regulations on Supervision and Administration of Medical Devices.'可被翻译为：第七十条 伪造、变造、买卖、出租、出借医疗器械注册证的，按照《医疗器械监督管理条例》第六十四条第二款的规定予以处罚。\n'Article 79 Where a medical device registration certificate is obtained by providing spurious documents or by other deception means, punishments shall be imposed according to Paragraph 1, Article 64 of the Regulations on Supervision and Administration of Medical Devices.'可被翻译为：第七十九条 提供虚假资料或者采取其他欺骗手段取得医疗器械注册证的，按照《医疗器械监督管理条例》第六十四条第一款的规定予以处罚。\n'Article 69 Where a medical device registration certificate is obtained by providing spurious documents or by other deception means, punishments shall be imposed according to Paragraph 1, Article 64 of the Regulations on Supervision and Administration of Medical Devices.'可被翻译为：第六十九条 提供虚假资料或者采取其他欺骗手段取得医疗器械注册证的，按照《医疗器械监督管理条例》第六十四条第一款的规定予以处罚。\n'Where a filing is done by providing spurious documents, punishments shall be imposed according to Paragraph 2, Article 65 of the Regulations on Supervision and Administration of Medical Devices.'可被翻译为：备案时提供虚假资料的，按照《医疗器械监督管理条例》第六十五条第二款的规定予以处罚。\n\n根据上述已知信息，请将'Article 80 Where a medical device registration certificate is falsified, altered, bought or sold, leased or lent, punishments shall be made according to Paragraph 2, Article 64 of the Regulations on Supervision and Administration of Medical Devices.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十条 伪造、变造、买卖、出租、出借医疗器械注册证的，按照《医疗器械监督管理条例》第六十四条第二款的规定予以处罚。"
    },
    {
        "instruction":"已知信息：\n'Associated disorders such as depression, anxiety and sleep disturbances may have an additional impact. Better characterisation of the mechanisms predominant in each individual patient and the tailoring of specific therapies accordingly, could in principle result in greater therapeutic success than has been achieved to date in the treatment of chronic pain.'可被翻译为：相关疾病（如抑郁、焦虑和睡眠障碍）可能有额外的影响。 因此，在每个个体患者中的主要机制的更好表征和相应地调整特定治疗原则上可导致比到目前为止在治疗慢性疼痛中所获得的治疗成功更大的治疗成功。\n'A potential effect not only on pain perception but also on mood may need to be considered when withdrawing treatments such as tricyclics or anticonvulsants.'可被翻译为：当退出治疗（例如三环类药物或抗惊厥药）时，可能需要考虑不仅对疼痛知觉而且对情绪的潜在影响。\n'Chronic pain disorders such as chronic low back pain (CLBP) are frequently associated with anxiety, depression, sleep disturbances, fatigue and may have an impact on physical and social functioning.'可被翻译为：慢性疼痛疾病，如慢性下背痛（CLBP），通常与焦虑、抑郁、睡眠障碍、疲劳 相关，并且可能对身体和社会功能产生影响。\n'Concomitant therapy Treatments that might modulate the perception of pain or patients’ response to pain, either directly or by interacting with the investigational products should generally be avoided during the trial.'可被翻译为：伴随治疗在试验过程中一般应避免可能调节疼痛感知或患者对疼痛反应的治疗（直接或通过与试验用药\n\n根据上述已知信息，请将'Mood changes, anxiety and sleep disturbance may change pain perception and might affect efficacy assessments.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"情绪变化、焦虑和睡眠障碍可能会改变疼痛感觉，并可能会影响有效性评估。"
    },
    {
        "instruction":"已知信息：\n'The use of natural or synthetic polymer material as the membrane shell, solid or liquid drugs as the core of the capsule wrapped into the drug store-like micro capsule.'可被翻译为：利用天然或合成的高分子材料为膜壳，将固体或液体药物作为囊心物包裹而成的药库型微小胶囊。\n'The process by which microcapsules and microspheres are prepared.'可被翻译为：制备微囊和微球的过程。\n'A solid or liquid substance encased in a microcapsule.'可被翻译为：微囊中被包裹的固态或液态物质。\n'The natural or synthetic polymer material that forms the wall of the capsule.'可被翻译为：构成囊壁的天然或合成的高分子材料。\n\n根据上述已知信息，请将'The process by which a solid or liquid drug (capsule substance) is encased in a natural or synthetic polymer material (capsule material) to form a microcapsule.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将固态或液态药物（囊心物）包裹在天然的或合成的高分子材料（囊材）中形成微囊的过程。"
    },
    {
        "instruction":"已知信息：\n'amino acid composition analyzer'可被翻译为：氨基酸组成分析仪\n'An analytical process for determining the sequence of amino acids at the ends of a protein polypeptide chain.'可被翻译为：测定蛋白质的多肽链的两端氨基酸排列顺序的分析法。\n'amino acid composition'可被翻译为：氨基酸组成\n'amino acid'可被翻译为：氨基酸\n\n根据上述已知信息，请将'An instrument that automatically determines the amino acid composition of a sample of amino acid mixtures, peptides, or proteins.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"自动测定氨基酸混合物、多肽或蛋白质样品中氨基酸组成的一种仪器。"
    },
    {
        "instruction":"已知信息：\n'Regulatory approaches for a specific product or manufacturing facility should be commensurate with the level of product and process understanding, the results of quality risk management, and the effectiveness of the pharmaceutical quality system.'可被翻译为：针对特定产品或生产企业的监管方法应与对产品和工艺的理解程度、质量风险管理的结果以及药品质量体系的有效性相适应。\n'The benefits are: Facilitated robustness of the manufacturing process, through facilitation of continual improvement through science and risk-based post approval change processes; Consistency in the global pharmaceutical environment across regions; Enable transparency of systems, processes, organisational and management responsibility; Clearer understanding of the application of a Quality System throughout product lifecycle; Further reducing risk of product failure and incidence of complaints and recalls thereby providing greater assurance of pharmaceutical product consistency and availability (supply) to the patient; Better process performance; Opportunity to increase understanding between industry and regulators and more optimal use of industry and regulatory resources. Enhance manufacturer’s and regulators’ confidence in product quality; Increased compliance with GMPs, which builds confidence in the regulators and may result in shorter inspections.'可被翻译为：益处有：通过科学的和以风险为基础的批准后变更程序，促进 持续改进，保持生产工艺的稳健性； 在全球性的药品环境中，保持各个区域的一致性；能够使体系、程序、组织和管理责任透明化；更清楚的理解质量体系在整个产品生命周期中的应 用；进一步减少不合格产品的风险和投诉及召回的发生 率，从而更好的保证药品质量的一致性和对患者的可及性 （供应）；更好的工艺性能；提供更多的企业与监管部门之间相互了解的机会，更 加优化地利用企业和监管部门资源。增强制造商和监管者对 产品质量的信心；提高GMP的依从性，从而树立监管者的信心，有可能 缩短检查周期。\n'ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management'可被翻译为：ICH Q12 药品生命周期管理的技术和监管考虑\n'The ranking of parameters from the quality risk assessment can be used to communicate with regulators regarding a lifecycle management approach to assure continual improvement throughout the product lifecycle.'可被翻译为：从质量风险评估得到的参数分级可以被用于与监管者交流 沟通，可以看作一种生命周期的管理方法来确保产品生命周 期中的持续改进。\n\n根据上述已知信息，请将'A harmonised approach regarding technical and regulatory considerations for lifecycle management will benefit patients, industry, and regulatory authorities by promoting innovation and continual improvement in the pharmaceutical sector, strengthening quality assurance and improving supply of medicinal products.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"协调统一的生命周期管理的技术和法 规考虑将促进制药行业的创新及持续改进、加强质量保证和改善药 品供应，从而使患者、行业和监管机构从中受益。"
    },
    {
        "instruction":"已知信息：\n'Appropriate environmental controls such as air exposure plates should be used in accordance with local quality procedures.'可被翻译为：应根据本地质量程序使用例如空气暴露碟进行适当的环境控制。\n'Cleanrooms and clean air equipment such as unidirectional airflow units (UDAFs), RABS and isolators, used for the manufacture of sterile products, should be qualified according to the required characteristics of the environment. Each manufacturing operation requires an appropriate environmental cleanliness level in the operational state in order to minimize the risk of contamination of the product or materials being handled. Appropriate cleanliness levels in the “at rest” and “operational” states should be maintained.'可被翻译为：用于无菌产品生产的洁净室和洁净空气设备，如单向流单元（UDAF）、RABS 和隔离器，应根据所要求的环境特性进行确认。每个生产操作都要求在动态条件下达到适当的环境洁净度水平，最大程度降低所处理的产品或物料的污染风险。应维持“静态”和“动态”下的适当洁净度水平。\n'Temperature, relative humidity and other specific characteristics.'可被翻译为：温度、相对湿度和其它具体特性。\n'1) A statement of the processing location and the equipment to be used (e.g. operation room's location and reference number, cleanliness level, necessary temperature and humidity requirements, equipment type and reference number);'可被翻译为：1.对生产场所和所用设备的说明（如操作间的位置和编号、洁净度级别、必要的温湿度要求、设备型号和编号等）；\n\n根据上述已知信息，请将'Other characteristics, such as temperature and relative humidity, should be controlled within ranges that align with product\/processing\/personnel requirements and support maintenance of defined cleanliness standards (e.g. grade A or B).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"温度和相对湿度等检测项目应控制在符合产品\/工艺\/人员要求的范围内，并应能够用于维护规定的洁净标准（例如 A 级或 B 级）。"
    },
    {
        "instruction":"已知信息：\n'If there are active metabolites, the increase in total active moiety (sum of clinically relevant active entities, taking into account the potency and unbound exposure to each active entity) should guide the dosing recommendation.'可被翻译为：如果存在活性代谢物，则总活性部分（临床相关活性实体的总和，考虑到每个活性实体的效能和非结合暴露水平）的增加应当指导给药意见。\n'If the pharmacokinetics of active metabolites has been investigated, the data should be presented in a similar way as for an active drug. If both parent and metabolite are active, the sum of the exposure of pharmacological equivalents should be presented as well.'可被翻译为：若已对活性代谢产物的药代动力学特征进行了研究，则应采用与活性药物相似的方法给出数据。如果原型药与代谢产物均具有活性，则还应给出各药理等值成分的暴露量总和。\n'In this guideline, the term drug generally refers to a pharmacologically active parent compound but, although not mentioned in every subsection of the document, the effect of renal impairment on the exposure to clinically relevant active metabolites should always be considered.'可被翻译为：在本指南中，术语“药物”通常是指药理学活性的母体化合物，但是尽管在肾功能下降患者药品的药代动力学评估指南文献的每个小节中没有提及，应始终考虑肾损伤对临床相关活性代谢物暴露的影响。\n'Clinically relevant active metabolites, or major active metabolites, are defined as pharmacologically active metabolites estimated to contribute significantly to the total target pharmacodynamic activity, i.e. to an extent that alteration of the exposure to the metabolites might affect overall efficacy and safety.'可被翻译为：临床相关活性代谢物或主要活性代谢物是指估测会对总体靶向药效学活性产生显著作用的药理活性代谢物，显著的程度为代谢物暴露水平的改变可能影响整体疗效和安全性。\n\n根据上述已知信息，请将'If the parent drug is pharmacologically active and there are in vivo relevant active metabolites, the exposure of these metabolites should be taken into account when proposing dose adjustments. When relevant, the active moiety can be used to develop dose adjustment (see also section 6.1). However, increased exposure of the separate substances must also be considered. The exposure of all relevant active substances should, as far as possible, be within a well tolerated range after dose adjustment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果原型药具有药理活性且体内存在相关的活性代谢产物，则应在拟进行剂量调整时将此类代谢产物的暴露考虑在内。适当情况下可将该活性成分用于制定剂量调整方案（参见 6.1 节）。但是单一成分的暴露水平增加必须考虑在内。剂量调整后所有相关活性成分的暴露水平尽可能保持在可接受的范围内。"
    },
    {
        "instruction":"已知信息：\n'Contact information is provided below.'可被翻译为：联系信息在下文中给出。\n'The messages should include an expected return time and contact information for other staff that may be able to assist in the interim, particularly for time-sensitive communications (e.g., notification of clinical hold).'可被翻译为：这些留言应包括可能能够暂时获得协助的其他工作人员的预期返回时间和联系信息，特别是对于时效性沟通（例如临床试验暂停通知）。\n'H. Use of Out-of-Office Messages by FDA and Sponsors'可被翻译为：H. FDA和申办方的外出留言使用\n'A brief description of the information specific for the region, as provided under “3.2.R” should be included, where appropriate.'可被翻译为：应提供“3.2.R”中特定的区域性信息的简述（如适用）。\n\n根据上述已知信息，请将'This contact information should be included in out-of-office messages, whenever appropriate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在适当时，此联系信息应包括在外出留言中。"
    },
    {
        "instruction":"已知信息：\n'The QRD product information template with explanatory notes (QRD annotated template1) and the convention to be followed for QRD templates2 provide general guidance on format and text and should be read in conjunction with the core SmPC and the Guideline on summary of product characteristics3 .'可被翻译为：带有注释的QRD产品信息模板（QRD注释模板1）和QRD模板2所遵循的协定会提供关于格式和文字的普通指导，二者应结合核心SmPC和产品特性概要3指导原则来阅读。\n'The QRD product information template with explanatory notes (‘QRD annotated template’) and the convention to be followed for QRD templates provide general guidance on format and text and should be read in conjunction with the core SmPC and the Guideline on summary of product characteristics.'可被翻译为：应遵循SmPC指南和QRD模板。带有注释的QRD产品信息模板（QRD注释模板）和QRD 模板应遵循的协定 提供了关于格式和文本的通用指南，并且应结合核心SmPC 和产品特性概要指导原则 解读。\n'The QRD product information template with explanatory notes ( QRD annotated template’) and the convention to be followed for QRD templates provide general guidance on format and text and should be read in conjunction with the core SmPC and the Guideline on summary of product characteristics.'可被翻译为：带注释的QRD产品信息模板（‘QRD注释模板’）以及QRD模板所遵循的约定对格式和文本给出了指导，二者应结合核心SmPC和产品特性概要指南指导原则\n'The QRD product information template with explanatory notes (′QRD annotated template’) and the convention to be followed for QRD templates provide general guidance on format and text and should be read in conjunction with the core SmPC and the Guideline on summary of product characteristics.'可被翻译为：有注解的QRD产品信息模板（QRD注解模板）及其所遵循的协定提供了关于格式和文本的基本指导原则而且应结合核心SmPC及 产品特性总结指导原则\n\n根据上述已知信息，请将'This core SmPC should be read in conjunction with the QRD product template with explanatory notes (′QRD annotated template’)1 and the convention to be followed for QRD templates2 which provide general guidance on format and text for SmPC, labelling and package leaflet, and with the Guideline on summary of product characteristics3 which provides general principles of presenting information on medicinal products.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"本核心SmPC应结合QRD产品模板和关于提供药物制剂提交资料一般原则 的产品特征概要指南3来理解，其中QRD产品模板含附注（‘QRD注释模板’）1和 QRD模板2应遵循的可提供关于SmPC、标签和包装说明书格式和文本一般指导原 则的约定。"
    },
    {
        "instruction":"已知信息：\n'Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Urinary Incontinence'可被翻译为：药物治疗尿失禁的临床研究指导原则\n'The guidance is relevant to the development of medicinal products that are indicated for the treatment of the different forms of urinary incontinence in adult females, adult males and in the paediatric population.'可被翻译为：该指南关系到治疗不同类型尿失禁的药品的开发，包括成年女性、成年男性和儿科人群中的用药。\n'Keywords Urinary incontinence, EMA, CHMP, Guideline'可被翻译为：关键词 尿失禁、人用药品委员会、EMA、指导原则\n'Pharmacokinetic\/pharmacodynamic (PK\/PD) analyses may be used to select dose regimens for clinical studies and to support interpretive criteria for in-vitro susceptibility testing.'可被翻译为：药代动力学\/药效学（PK\/PD）研究可用于选择临床试验的给药方案，并为 体外药敏试验提供解释性的标准。\n\n根据上述已知信息，请将'This guideline considers pharmacodynamic and clinical data required to support indications, dose regimens and durations of therapy for the treatment of urinary incontinence (UI).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这条指导原则涉及了支持适应症所需的药效学和临床数据、治疗尿失禁的剂量方案和持续时间。"
    },
    {
        "instruction":"已知信息：\n'The drug MAH shall, if it entrusts a qualified drug manufacturer to manufacture drugs, assess the quality assurance capability and risk management capability of contracted accepting company, in accordance with the requirements in the guidelines for the quality agreement of contracted drug manufacturing formulated by the NMPA, sign a quality agreement and an entrustment agreement, and supervise its performance of obligations agreed in the agreements.'可被翻译为：药品上市许可持有人委托符合条件的药品生产企业生产药品的，应当对受托方的质量保证能力和风险管理能力进行评估，根据国家药品监督管理局制定的药品委托生产质量协议指南要求，与其签订质量协议以及委托协议，监督受托方履行有关协议约定的义务。\n'6. If the holder entrusts the production of a preparation, it shall sign with a qualified pharmaceutical manufacturer an entrustment agreement and a quality assurance agreement, the contents of which shall comply with the relevant laws and regulations. After NMPA releases the guidelines for the quality agreement on drug consignment production, both parties to the consignment shall complete and sign the entrustment agreement and quality agreement as required.'可被翻译为：6.持有人委托生产制剂的，应当与符合条件的药品生产企业签订委托协议和质量协议，委托协议和质量协议的内容应当符合有关法律法规规定。国家药监局发布药品委托生产质量协议指南后，委托双方应当按照要求对委托协议和质量协议进行完善和补充签订。\n'(9) supervision of the contract manufacturer, performance of the entrustment manufacturing quality agreement, design conversion and change control of the products entrusted for manufacturing, and manufacturing and release of the products entrusted for manufacturing, etc.;'可被翻译为：（九）对受托生产企业的监督情况，委托生产质量协议的履行、委托生产产品的设计转换和变更控制、委托生产产品的生产放行等情况；\n'MAHs that manufacture their own drug products shall obtain a Drug Manufacturing Certificate in accordance with provisions of this Law. Where a drug is contracted out, the MAH shall entrust a qualified drug manufacturer. The MAH and the contract manufacture shall sign agreements on entrustment quality and shall comply with their obligations under the agreements.'可被翻译为：药品上市许可持有人自行生产药品的，应当依照本法规定取得药品生产许可证；委托生产的，应当委托符合条件的药品生产企业。药品上市许可持有人和受托生产企业应当签订委托协议和质量协议，并严格履行协议约定的义务。\n\n根据上述已知信息，请将'(4) their quality agreements and entrustment agreements for entrusted drug manufacturing;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）药品委托生产质量协议及委托协议；"
    },
    {
        "instruction":"已知信息：\n'(V) The package, label and package insert of drugs shall comply with relevant provisions;'可被翻译为：（五）药品包装、标签、说明书符合有关规定；\n'Article 123: When the version of a printed packaging material is changed, actions should be taken to ensure that the correct version is used for production.'可被翻译为：第一百二十三条 印刷包装材料的版本变更时，应当采取措 施，确保产品所用印刷包装材料的版本正确无误。\n'V. Provincial drug regulatory departments shall urge the drug marketing authorization holders of the product within their respective jurisdiction to revise the package inserts, change the labels and package inserts as required and impose severe punishment in accordance with law if violations of laws and regulations happen.'可被翻译为：五、省级药品监督管理部门应当督促行政区域内本品的药品上市许可持有人按要求做好相应说明书修订和标签、说明书更换工作，对违法违规行为依法严厉查处。\n'Article 20 Where the change management category of circumstances of change has been specified in laws, regulations or technical guidelines, MAHs shall generally determine the change management category in accordance with relevant provisions.'可被翻译为：第二十条 变更情形在法律、法规或技术指导原则中已明确变更管理类别的，持有人一般应当根据有关规定确定变更管理类别。\n\n根据上述已知信息，请将'Article 18 The change management of package inserts and labels shall be carried out in accordance with relevant regulations and technical requirements.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十八条 药品说明书和标签的变更管理按照相关规定和技术要求进行。"
    },
    {
        "instruction":"已知信息：\n'This may increase the ability of the study to detect true drug effects.'可被翻译为：这样可以增加研究检测药物真实有效性的 能力。\n'If the inactive drug in a combination contributes to the activity of the combination only by increasing the systemic concentrations of the active drug, human pharmacokinetic data  may provide adequate evidence to support the contribution of the inactive drug. A confirmatory study of the combination would usually be needed to provide evidence of effectiveness for the combination (see section V.D).'可被翻译为：如果非活性药物仅通过增加活性药物的全身浓度来对联合治疗的活性作出贡献， 人体药代动力学数据或许可以提供足够的证据来支持非活性药物的贡献。通常需要开展联合治疗的确证性研究以提供联合治疗的有效性证据（见V.D节）。\n'The inactive precursor of an enzyme. The ability to change from inactive to catalytically active enzyme precursors by limited proteolysis.'可被翻译为：酶的无活性前体。通过有限蛋白水解能够由无活性变成具有催化活性的酶前体。\n'A substance that changes an enzyme from inactive to active or increases its activity.'可被翻译为：使酶从无活性变为有活性或使酶活性增加的物质。\n\n根据上述已知信息，请将'Attainment of such a response would support the expectation that the study could have distinguished the active drug from an inactive drug.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如一项研究采用该治疗反应，则说明该研究可 以区分有效药物和无效药物。"
    },
    {
        "instruction":"已知信息：\n'Although CBER or CDER will make the final determination as to the meeting type (i.e., Biosimilar Initial Advisory meeting, or BPD Type 1, 2, 3, or 4 meeting), the sponsor or applicant should provide its meeting type assessment as it relates to the product’s development.'可被翻译为：虽然 CBER 或 CDER 将最终确定会议的类型（即生物仿制启动咨询会议、 BPD 1 型、 2 型、 3 型或 4 型会议），申办方或申请人应提供其会议类型的评估结果，因为这涉及到产品的 研发。\n'5.BPD Type 4 meeting: A BPD Type 4 meeting is a meeting to discuss the format and content of a biosimilar biological product application or supplement to be submitted under section 351(k) of the PHS Act.'可被翻译为：5. BPD 4 型会议： BPD 4 型会议是讨论即将根据 PHS 法第 351(k)节提交的生物 类似药申请或补充材料的格式和内容的会议。\n'The Center (i.e., CBER or CDER) may determine that a different meeting type is more  appropriate and it may grant a meeting of a different type than requested (e.g., if a sponsor or  applicant requests a Biosimilar Initial Advisory meeting for a product, but the Center determines  that a BPD Type 3 meeting is more appropriate, the FDA may grant a BPD Type 3 meeting  instead of a Biosimilar Initial Advisory meeting).'可被翻译为：中心（即 CBER 或 CDER）可能 判定另一个会议类型更为恰当， 批准的会议类型 与所申请的有所不同（例如若申办方或申请人申请某产品的生物仿制启动咨询会 议， 但中心确定 BPD 3 型会议更为恰当，FDA 可能批准 BPD 3 型会议， 而非生 物仿制启动咨询会议）。\n'The CBER or CDER division director or designee who receives a meeting request will determine whether to hold the  meeting and will respond to the sponsor or applicant by granting or denying the meeting within  14 calendar days of receipt of the request and meeting package for a BPD Type 1 meeting, andwithin 21 calendar days of receipt of the request and meeting package for a Biosimilar Initial 298 Advisory meeting or a BPD Type 2, 3, or 4 meeting.'可被翻译为：收到会议申请的 CBER 或 CDER 主管或指定人员将确定是否举行会议， 在收到 BPD1 型会议申请及会议资 料包后 14 个自然日内，在收到生物仿制启动咨询会议或 BPD 2 型、 3 型或 4 型 会议申请及会议资料包后 21个自然日内，回复申办方或申请人批准还是拒绝会议。\n\n根据上述已知信息，请将'7.Meeting type being requested (i.e., Biosimilar Initial Advisory meeting, BPD Type 1, 2, 3, or 4 meeting). The rationale for requesting the meeting type should be included.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"7. 所申请的会议类型（即生物仿制启动咨询会议、 BPD 1 型、 2 型、 3 型或 4 型会议）应包括申请该会议类型的理论依据。"
    },
    {
        "instruction":"已知信息：\n'Intravenous use.'可被翻译为：静脉给药。\n'For intravenous use.'可被翻译为：静脉注射用。\n'In order to ensure the special quality requirements and safety of intravenous infusion, the traditional distribution of intravenous infusion distributed in nursing stations in each ward was changed to the centralized management of the pharmacy and the distribution of intravenous infusion room. Infusion of cytotoxic drugs and parenteral nutrition is the focus of centralized preparation.'可被翻译为：为保证静脉输液用药的特殊质量要求和安全，将传统分散于各病区护理站配置输液的方式，改为集中到药房管理的、输液配置室中配置的管理方式。细胞毒类药物和肠外营养输液是集中配制的重点。\n'Packaging products in such containers can lead to incorrect routes or methods of administration (e.g., a prefilled syringe may lead to intravenous push rather than intravenous infusion because a prefilled syringe is typically used for direct administration).'可被翻译为：这种 容器中的包装产品可能导致不正确的给药途径或方法（例如，预灌装注射 器可能导致静脉推注而不是静脉内输注，因为预灌装注射器通常用于直接 给药）。\n\n根据上述已知信息，请将'In order to protect patients' veins in intravenous infusion, avoid the pain of repeated puncture and maintain a smooth venous channel at any time, so as to facilitate first aid and drug administration, the drug administration method is designed for patients with long-term infusion, old age, weakness and vascular puncture difficulties. The commonly used intravenous indentation needle is retained in the peripheral vein or central vein. The intravenous indwelling needle consists of two parts: the needle and the heparin cap.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在静脉输液中为保护患者静脉，避免反复穿刺的痛苦和随时保持畅通的静脉通道，便于急救和给药，所以对长期输液、年老、衰弱、血管穿刺困难的患者而设计的给药方法。常用静脉留置针保留于外周静脉或中央静脉。静脉留置针由针头部与肝素帽两部分组成。"
    },
    {
        "instruction":"已知信息：\n'In metrology absorptiometry, a data processing method used for multi-component analysis.'可被翻译为：在计量学吸光光度法中，对多组分分析时采用的一种数据处理方法。\n'A discipline developed in the middle of the 20th century, all equations and functions in the linear programming model are linear, and it is a method to solve the multi-variable optimal decision. It is a problem to solve or plan the linear objective function optimization of an object under various interrelated multi-variable constraints. In the metrology absorptiometry, it is a data processing method used for multi-component analysis.'可被翻译为：20世纪中期发展起来的学科,线性规划模式中的所有方程式及函数都是线性的，是解决多变量最优决策的方法，是在各种相互关联的多变量约束条件下，解决或规划一个对象的线性目标函数最优的问题。在计量学吸光光度法中，是用于多组分分析的一种数据处理方法。\n'A stoichiometric data processing method used in the analysis and detection of multi-component systems by metrological absorbance spectrophotometry.'可被翻译为：在计量学吸光光度法分析检测多组分体系时，采用的一种化学计量学数据处理方法。\n'The application of multivariate statistical techniques to analyse complex process data with potentially correlated variables. (Ph. Eur.)'可被翻译为：应用多变量统计技术分析具有潜在相关变量的复杂工艺数据。\n\n根据上述已知信息，请将'A new method of multivariate statistical data analysis, first proposed by the Swedish econometrician H. Wolde in 1966, is the regression modeling method of multivariate variables to multi-independent variables. In metrology absorptiometry, it is a data processing method for multi-component analysis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由瑞典经济计量学家沃尔德（H.Wold）于1966年首次提出的一种新型多元统计数据分析方法，是多因变量对多自变量的回归建模方法。在计量学吸光光度法中，是一种用于多组分分析的数据处理方法。"
    },
    {
        "instruction":"已知信息：\n'As an alternative to the traditional process validation, continuous process verification (ICH Q8) can be utilised in process validation protocols for the initial commercial production and also for manufacturing process changes for the continual improvement throughout the remainder of the product lifecycle.'可被翻译为：作为传统工艺验证的替代方法，持续的工艺确认（ICH Q8）可以用于最初的商业化生产的工艺验证方案中，同样也 可用于产品生命周期剩余阶段的生产工艺变更中，以进行持 续的改进。\n'Continuous Process Verification: An alternative approach to process validation in which manufacturing process performance is continuously monitored and evaluated.'可被翻译为：持续工艺确认（Continuous Process Verification）：工艺验证的另一种方法，持续监控和评价生产工艺性能。\n'Continual improvement and successful process validation, or continuous process verification, call for an appropriate and effective control strategy.'可被翻译为：持续的改进和成功的工艺验证，或连 续的工艺确认，需要适宜和有效的控制策略。\n'It facilitates continual improvement of process performance and product quality throughout the product lifecycle.'可被翻译为：在整个产品生命周期内，它能促进工艺性能和产品质量的持续改进。\n\n根据上述已知信息，请将'As an alternative to the traditional process validation, continuous process verification [see definition in ICH Q8(R2) glossary] can be utilised in process validation protocols for the initial commercial production and for manufacturing process changes for the continual improvement throughout the remainder of the product lifecycle.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"作为传统的工艺验证方法的一种替代选择，持续工艺确认（见 ICH Q8（R2）术语）可以被应用于最初的商业生产和此后在 产品整个生命周期中进行的持续改进的工艺验证方案中。"
    },
    {
        "instruction":"已知信息：\n'Article 92 The Center for Drug Evaluation of the State Food and Drug Administration shall make a general opinion based on the technical review opinions and sample testing results, and report the general opinion together with relevant documents to the State Food and Drug Administration. The State Food and Drug Administration shall make a review and approval decision based on the general opinion. Where the regulations are conformed to, a Clinical Trial Approval shall be issued; where the regulations are not conformed to, a Disapproval Notice shall be issued with reasons.'可被翻译为：第九十二条 国家食品药品监督管理局药品审评中心依据技术审评意见和样品检验结果等，形成综合意见，连同相关资料报送国家食品药品监督管理局，国家食品药品监督管理局依据综合意见，做出审批决定。符合规定的，发给《药物临床试验批件》；不符合规定的，发给《审批意见通知件》，并说明理由。\n'Article 65 The Center for Drug Evaluation of the State Food and Drug Administration shall make a general opinion based on the technical review opinions, production site inspection reports and sample testing results, and report the general opinion together with relevant documents to the State Food and Drug Administration. The State Food and Drug Administration shall make a review and approval decision based on the general opinion. Where the regulations are conformed to, a New Drug Certificate shall be issued; if the applicant already has a Drug Manufacturing Certificate and possesses the production conditions, a drug approval number shall be issued at the same time; where the regulations are not conformed to, a Disapproval Notice shall be issued with reasons.'可被翻译为：第六十五条 国家食品药品监督管理局药品审评中心依据技术审评意见、样品生产现场检查报告和样品检验结果，形成综合意见，连同有关资料报送国家食品药品监督管理局。国家食品药品监督管理局依据综合意见，作出审批决定。符合规定的，发给新药证书，申请人已持有《药品生产许可证》并具备生产条件的，同时发给药品批准文号；不符合规定的，发给《审批意见通知件》，并说明理由。\n'Where the regulations are conformed to as reviewed, the Center for Drug Evaluation of the State Food and Drug Administration shall notice the applicant to apply for production site inspection and inform the Center for Drug Certification of the State Food and Drug Administration. Where the regulations are not conformed to as reviewed, the Center for Drug Evaluation of the State Food and Drug Administration shall report the review opinions and relevant documents to the State Food and Drug Administration; the State Food and Drug Administration shall make a disapproval decision to the application based on the technical review opinions, and issue a Disapproval Notice with reasons.'可被翻译为：经审评符合规定的，国家食品药品监督管理局药品审评中心通知申请人申请生产现场检查，并告知国家食品药品监督管理局药品认证管理中心；经审评不符合规定的，国家食品药品监督管理局药品审评中心将审评意见和有关资料报送国家食品药品监督管理局，国家食品药品监督管理局依据技术审评意见，作出不予批准的决定，发给《审批意见通知件》，并说明理由。\n'Article 100 The State Food and Drug Administration shall review the submitted documents. Where the regulations are conformed to, it shall issue an Approval for Supplementary Drug Application and a drug approval number; where the regulations are not conformed to, it shall issue a Disapproval Notice with reasons.'可被翻译为：第一百条 国家食品药品监督管理局对报送的资料进行审查，符合规定的，发给《药品补充申请批件》和药品批准文号；不符合规定的，发给《审批意见通知件》，并说明理由。\n\n根据上述已知信息，请将'Article 81 The Center for Drug Evaluation of the State Food and Drug Administration shall make a general opinion based on the technical review opinions, production site inspection reports and sample testing results, and report the general opinion together with relevant documents to the State Food and Drug Administration. The State Food and Drug Administration shall make a review and approval decision based on the general opinion. Where the regulations are conformed to, it shall issue a drug approval number or a Drug Clinical Trial Approval; where the regulations are not conformed to, it shall issue a Disapproval Notice with reasons.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十一条 国家食品药品监督管理局药品审评中心依据技术审评意见、样品生产现场检查报告和样品检验结果，形成综合意见，连同相关资料报送国家食品药品监督管理局，国家食品药品监督管理局依据综合意见，做出审批决定。符合规定的，发给药品批准文号或者《药物临床试验批件》；不符合规定的，发给《审批意见通知件》，并说明理由。"
    },
    {
        "instruction":"已知信息：\n'Article 161 Records should be kept in a neat fashion without tearing up or uncontrolled alteration. Any alteration made to the entry on a document should be signed and dated; the alteration should permit the reading of the original information. Where appropriate, the reason for the alteration should be recorded. When transcription is needed, the original record should not be destroyed, and be kept as attachment of the transcribed record instead.'可被翻译为：第一百六十一条 记录应当保持清洁，不得撕毁和任意涂改。记录填写的任何更改都应当签注姓名和日期，并使原有信息仍清晰可辨，必要时，应当说明更改的理由。记录如需重新誊写，则原有记录不得销毁，应当作为重新誊写记录的附件保存。\n'Regardless of the documentation format (i.e., paper or electronic), records should be contemporaneous with the event and subsequent alterations should not obscure the original data. The basis for changing or reprocessing data should be documented with sufficient detail, and the original record should be maintained.'可被翻译为：无论资料的格式如何（即纸质或电子文档），记录都应与事件同步进行，后续更改不应使原始数据模糊。变更或重新处理数据的依据应有足够细节的记录，并应保存原始记录。\n'Article 52 The medical device registration alteration document shall be used in conjunction with the original medical device registration certificate and its period of validity shall be the same with that of the original registration certificate. After obtaining the registration alteration document, the registrant shall alter the product technical requirements, instructions and labels by himself.'可被翻译为：第五十二条 医疗器械注册变更文件与原医疗器械注册证合并使用，其有效期与该注册证相同。取得注册变更文件后，注册人应当根据变更内容自行修改产品技术要求、说明书和标签。\n'Article 62 The medical device registration alteration document shall be used in conjunction with the original medical device registration certificate and its period of validity shall be the same with that of the original registration certificate. After obtaining the registration alteration document, the registrant shall alter the product technical requirements, instructions and labels by himself.'可被翻译为：第六十二条 医疗器械注册变更文件与原医疗器械注册证合并使用，其有效期与该注册证相同。取得注册变更文件后，注册人应当根据变更内容自行修改产品技术要求、说明书和标签。\n\n根据上述已知信息，请将'Any alteration made to the entry on a document should be signed and dated; the alteration should permit the reading of the original information. Where appropriate, the reason for the alteration should be recorded.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"记录填写的任何更改都应当签注姓名和日期，并使原有信息 仍清晰可辨，必要时，应当说明更改的理由。"
    },
    {
        "instruction":"已知信息：\n'Special precautions for disposal <and other handling>'可被翻译为：处置和<和其它处理>的特别注意事项\n'Guidance regarding the special requirements of utilities such as water, gas and vacuum.'可被翻译为：关于水、气、真空等公用设施的特殊要求的指导。\n'Regulatory considerations (e.g. legal basis of the marketing authorisation application or other considerations, for example conditional approval) should be decided on a case by case basis.'可被翻译为：法规考虑（如上市授权申请或其它考虑[例如条件性批准]的法律依据）应逐个决定。\n'In case of surgery different data are to be collected (surgical protocol) (e.g. type of surgery (planned or emergency); documentation of complications; mode of administration, consumption)'可被翻译为：在实施手术的情况中，须收集不同数据（手术类型（计划或紧急）；记录并发症；给药模式、消耗量）\n\n根据上述已知信息，请将'emergency planning considerations (e.g. in case of gas or dust release, spillage, f ire and firewater run-off)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应急计划考量（例如，如果气体或粉尘逸出、溅出、失火和消防用水用尽）"
    },
    {
        "instruction":"已知信息：\n'Pharmacoepidemiologic safety studies conducted on preventative therapeutics, such as vaccines, present issues that call for special considerations in study design.'可被翻译为：在预防性治疗（如疫苗）方面进行的药物流行病学安全性研究在研究设计上有需要特别考虑的问题。\n'Additional data on use against target pathogens could be obtained by means of prospective uncontrolled studies, registries and\/or other types of observational studies depending on the research questions.'可被翻译为：关于对抗靶病原体的额外数据可以通过前瞻性非对照研究、登记研究和 \/或其它类型 的观察性研究来获得，研究类型依赖于所探察的问题。\n'• To identify an unexpected serious risk when available data indicates the potential for a serious risk'可被翻译为：·当已有数据提示存在严重风险的可能性时，确认非预期的严重风险\n'• To assess signals of serious risk related to the use of the drug'可被翻译为：·评价与药物使用有关的严重风险信号\n\n根据上述已知信息，请将'• Studies and clinical trials conducted with vaccines, such as surveillance and observational pharmacoepidemiologic studies when data do not suggest a serious risk or signals of serious risk related to the use of the vaccine and when available data do not indicate the potential for serious risk, such as:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"·当数据不能提示与疫苗使用有关的严重风险或严重风险信号以及当现有数据不能表明严重风险的可能性时，针对疫苗实施的研究和临床试验，例如监测和观察药物流行病学研究，例如："
    },
    {
        "instruction":"已知信息：\n'Exploratory analyses may be carried out to improve the understanding of covariates not included in the primary analysis, and to help the sponsor with the ongoing development of the drug.'可被翻译为：可以通过探索性分析来提高对于未纳入主要分析的协变量的理解，从而有助于申办方开发药物。\n'As more information is known about the drug, clinical studies may expand in size and duration, may include more diverse study populations, and may include more secondary endpoints in addition to the primary measures of efficacy.'可被翻译为：随着获取的药物信息的增加，临床研 究的规模得以扩大，持续时间延长，研究人群更加多样化， 除主要有效性指标外，还可能纳入更多次要终点。\n'Alternatively, subgroup analyses might offer similar insights.'可被翻译为：另外，亚组分析可能会有类似的作用。\n'stratification factors of major importance for prognosis might provide insights as well as similar analyses with respect to PFS.'可被翻译为：按照至关重要的预后分层因素开展的分析可提供无进展生存期相关的见解及相似分析。\n\n根据上述已知信息，请将'However, such covariates (e.g. duration of treatment) might be included in secondary (exploratory) analyses and might offer the sponsor useful insights during the drug development process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"然而，这类协变量（如疗程）可能会包括在次要（探索性）分析中，并可能会给申办方在药物开发过程中带来帮助。"
    },
    {
        "instruction":"已知信息：\n'Communications before the meeting between sponsors or applicants and the FDA, including preliminary responses, can serve as a foundation for discussion or can be the final meeting responses.'可被翻译为：申办方或申请人与FDA的会前 沟通，可以作为讨论的基础， 也可以作为最终的会议回应。\n'The FDA may communicate these  preliminary responses to the sponsor or applicant.'可被翻译为：FDA可能将这些初步回应传达给申办方或申请人。\n'After the meeting package is submitted but before preliminary responses are sent by the FDA, the sponsor or applicant sends CBER or CDER additional questions or data that are intended for discussion at the meeting and require additional review time.'可被翻译为：. 在提交了会议资料包而在 FDA 发送初步的回复之前， 申办方或申请人给 CBER 或 CDER 发送了额外的问题或数据用于在会议上讨论，需要额外 的评审时间。\n'‒ Meeting facilitators should keep the discussion focused on the questions posed by the sponsor in the meeting package, as well as relevant FDA preliminary responses, taking into account the total time available for discussion of the questions.'可被翻译为：- 会议召集人应将讨论重点放在申办方在会议文件包中提出的问题 以及相关的FDA初步回复上，同时还要考虑讨论问题的总时间。\n\n根据上述已知信息，请将'A preliminary response should not be construed as final unless there is agreement between the sponsor or applicant and the FDA that  the response constitutes the FDA’s final response and additional discussion is not necessary. Preliminary responses communicated by the FDA are not intended to generate the submission of  a new meeting agenda and new questions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在申办方或申请人与 FDA一致认为初步回应构成了FDA的最终会议回应而不需要额外的讨论之前，不 应将初步回应视为最终回应。FDA传达初步回应的目的不是让他们提交新的会议 程序或新的问题。"
    },
    {
        "instruction":"已知信息：\n'31 See the Federal Register notice “Improving Patient Safety by Enhancing the Container Labeling for Parenteral Infusion Drug Products; Public Meeting,” November 28, 2006 (71 FR 68819).'可被翻译为：31见《联邦登记通知》，“通过加强输液药品的容器标签管理提高患者的安全性；公开会议，”2006年11月 28日（71 FR 68819）。\n'FDA receives many reports of confusion and errors involving large-volume parenteral products. These reports cite similarity of the containers, lack of prominence of important information on the label, and label clutter.'可被翻译为：FDA 收到许多涉及大容量注射产品混淆和错误的报告。这些报告涉及容器相 似、标签重要信息明显不足和标签混乱。\n'The following information is considered label clutter and should not be included on the large volume parenteral container label or presented, as appropriate, in the prescribing information:'可被翻译为：下列资料属标签混乱，而且不应包括在大容量注射剂容器标签上或出现在专业 说明书中：\n'In June 2010, FDA held a public  workshop and opened a public docket to receive comments on these topics.10'可被翻译为：2010年6月，FDA举行公众研讨 会，打开公共留言表接收有关这些话题的评论10\n\n根据上述已知信息，请将'These concerns were addressed at a joint public meeting held by FDA, ISMP, and USP in 2007.31 Based on the information and recommendations presented at the public meeting, FDA considers the following information to be essential for the container label of large volume parenterals:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这些问题在2007年由美国食品药品监督 局， 美国医疗安全协会和美国药典联合召开的公开会议上进行了讨论31  。基于公开 会议上提出的信息和建议，FDA 认为在大容量注射剂容器的标签，下列资料是必 要的："
    },
    {
        "instruction":"已知信息：\n'This characteristic can be a disease (disease registry) or a specific exposure (drug registry).'可被翻译为：这种特征可以是 一种疾病（疾病登记）或一个具体的暴露（药物登记）。\n'In a case-control study, cases of disease (or events) are identified.'可被翻译为：在病例-对照研究中，先确定患病（或发生关注的事件）的患者作为病例组。\n'15. Registry ICH E2E A registry is a list of patients presenting with the same characteristic(s).'可被翻译为：15. 注册登记项目 ICH E2E 注册登记项目是相同特征患者的名单。\n'The registry should preferably be an established disease-based (rather than product-based) clinical registry and allow collection of long-term data from a sufficient number of patients treated with different medicinal products.'可被翻译为：登记应首选一种基于既定疾病（而不是基于药品）的临床登记，并且允许从足量接受治疗的患者中收集长期数据。\n\n根据上述已知信息，请将'A disease registry might also be used as a base for a case-control study comparing the drug exposure of cases identified from the registry and controls selected from either patients with another condition within the registry, or patients outside the registry.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"疾病登记也可以 用作病例-对照研究的基础，比如将登记表中患有某种特定疾病 的一组患者作为病例组，登记表中（或登记表外）不患有该疾 病但具有可比性的一组个体作为对照组，比较两组暴露的差异。"
    },
    {
        "instruction":"已知信息：\n'Take 1 product for sampling for every 20,000 boxes (vials), and the odd less than 20,000 boxes (vials) shall be counted as 20,000.'可被翻译为：每2万盒（瓶），抽样一件，不足2万盒（瓶）的按2万盒（瓶）计。\n'If the quantity is less than 10, take 1 product for sampling; if the quantity is 11 to 50, take additional 1 product for sampling for every additional 10, and the odd less than 10 shall be counted as 10; if the quantity is 51 to 100, take additional 1 product for sampling for every additional 20, and the odd less than 20 shall be counted as 20; if the quantity is more than 101, take additional 1 product for sampling for every additional 50, and the odd less than 50 shall be counted as 50; if the quantity is more than 1001, take additional 1 product for sampling for every additional 100, and the odd less than 100 shall be counted as 100;'可被翻译为：10件以内，抽样1件；11件－50件，每增加10件加抽1件，不足10件者以10件计；51件－100件，每增加20件加抽1件，不足20件者以20件计；101件以上，每增加50件加抽1件，不足50件者以50件计；1001件以上，每增加100件加抽1件，不足100件者以100件计；\n'If the injection is 100 ml to 1000 ml (including), take 1 product for sampling for every 10,000 vials, and the odd less than 10,000 vials shall be counted as 10,000. If the injection (including dialysate) is more than 1000 ml, take 1 product for sampling for every 5,000 vials (bags), and the odd less than 5,000 vials (bags)shall be counted as 5,000.'可被翻译为：100－1000毫升（含1000毫升）的注射液，每1万瓶抽样1件，不足1万瓶的按1万瓶计。1000毫升以上的注射液（含透析液），每5000瓶（袋）抽样1件，不足5000瓶（袋）的按5000瓶计。\n'3. If the products within one package are 1 (including) to 5 kg, take 1 product for sampling for every 50 kg, and the odd less than 50 kg shall be counted as 50 kg;'可被翻译为：3.药品包装为1－5公斤的（含1公斤），每50公斤抽样1件，不足50公斤者以50公斤计；\n\n根据上述已知信息，请将'If the quantity is below 20,000 vials (including), take 1 product for sampling; if the quantity is below 50,000 vials (including), take 2 products for sampling; if the quantity is below 100,000 vials (including), take 3 products for sampling; if the quantity is more than 100,000 vials, take additional 1 product for sampling for every additional 100,000 vials, and the odd less than 100,000 shall be counted as 100,000.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2万支（瓶）以下（含2万支），抽样1件；5万支（瓶）以下（含5万支），抽样2件；10万支（瓶）以下（含10万支），抽样3件；10万支（瓶）以上，每增加10万支（瓶）加抽1件，不足10万支（瓶）以10万支（瓶）计。"
    },
    {
        "instruction":"已知信息：\n'When there are important differences among trials in dose, route of administration, or patient population, these differences can be noted in the tables, or separate tables can be considered;'可被翻译为：如果试验的剂量、给药途径或患者人群方面存在重要差 异，应在表格中说明这些差异，亦可单独列表说明；\n'Separate tables can be provided by indication, formulation, and study population, if appropriate.'可被翻译为：在适当情况下，可分别按照适应症、剂型和研 究人群制作表格。\n'The MAH can use tables, graphs, and\/or narrative descriptions to communicate this information.'可被翻译为：MAH可以使用表格、 图形和\/或叙述性描述来传达此信息。\n'So that it is possible to analyse and evaluate the data in these tables, it is important to identify each patient having each adverse event.'可被翻译为：因此，可在 这些列表中分析和评估数据，确定每位患者和每例不良事件 的对应关系很重要。\n\n根据上述已知信息，请将'Important differences among trials in dose, routes of administration, or patient populations can be noted in the tables, if applicable, or separate tables can be considered.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"剂量、给药途径或患者群的试验之间的重要差异可以在表格中注明， 如果适用，或者考虑单独的表格。"
    },
    {
        "instruction":"已知信息：\n'However, for this manufacturing process, it is also known that all of the significant impurities in the drug substance (other than opposite enantiomer) arise from Steps 4, 5, and 6. Steps 2 and 3 have no impact on the drug substance impurity profile, and the only impact from Step 1 is with regard to the enantiomeric impurity.'可被翻译为：然而，对于这个生产过程，我们还知道原料药中的所有 重要杂质（除对映异构体外）皆在步骤4、5和6中产生，步骤2和步骤3对原料药的杂质谱无影响，步骤1对原料药的 唯一影响就是对映异构体杂质。\n'In the case of Example 4, application of the ICH Q11 principles includes control of the enantiomer in the specification of the proposed starting material D, in combination with the understanding that the steps immediately prior to D do not introduce other impurities that impact the impurity profile of the drug substance. The applicant should provide information in the application on the upstream process to justify the proposed starting material including control strategy of the impurity that persists.'可被翻译为：在例4中应用的ICH Q11原则包括在所选起始原料D的质量标准中对映异构体杂质的控制，以及对D之前的步骤不影响原料药杂质谱的认知。申请人在申请中应该提供起始原料上游工艺中对持续存在杂质的控制策略。\n'In accordance with the principle that manufacturing steps that impact the drug substance impurity profile should normally be included in the manufacturing process described in Section 3.2.S.2.2 of the application, it could be concluded that Step 1 should be described in 3.2.S.2.2, and that A should be considered the starting material.'可被翻译为：通常影响原料药杂质谱的生产步骤应被包含在申 报资料的3.2.S.2.2部分中所述的生产过程中，按照这一原则， 可能得到的结论是步骤1应在3.2.S.2.2部分中进行工艺描述，而化合A应被考虑作为起始原料。\n'A small amount of the opposite enantiomer of compound B is also formed in Step 1.'可被翻译为：在第一步反应中还会生成少量化合物B的对 映异构体。\n\n根据上述已知信息，请将'Furthermore, it is also known that the stereocentre first formed in Step 1 is stable to the manufacturing conditions in all of the steps that follow (i.e., no racemisation occurs or is ever likely to occur), and that a suitable analytical procedure exists for measuring the amount of the opposite enantiomer in compound D. Therefore, provided compound D is in accordance with most of the other general principles described in Section 5.1.1, it would be reasonable to propose D as the starting material instead of A in accordance with the principle that early steps in the manufacturing process tend to have a lower potential to impact drug substance quality than later steps.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"此外，我们还知道在第一步 中最早形成的手性中心在所有后续步骤的生产条件下稳定 （例如：未发生过消旋化或不太可能发生消旋化），而且还有 合适的分析方法来测定化合物D中对映异构体的量。因此， 如果化合物D符合大部分5.1.1部分中所述的一般原则，那 么，根据生产过程的前期步骤往往较后期步骤对原料药的质 量影响更小这一原则，提议化合物D取代化合物A作为起 始原料应是合理的。"
    },
    {
        "instruction":"已知信息：\n'Analyte: A specific chemical moiety being measured, including an intact drug, a biomolecule or its derivative or a metabolite in a biological matrix.'可被翻译为：待测物：特定的被测化学组分，包括原形药物、生物分子或其衍生物，或在生物基质中的代谢物。\n'A substance that is present in the matrix that may affect the quantification of an analyte.'可被翻译为：在基质中存在的可能影响待测物定量的物质。\n'The basis for the moiety used for comparison (parent drug or metabolite) should be justified.'可被翻译为：用作比较的部分（原形药或代谢产物）的基础应证明其合理 性。\n'The stability of a pharmaceutical preparation in vitro. Including physical, chemical, and biological'可被翻译为：药物制剂在体外的稳定性。包括物理、化学、生物\n\n根据上述已知信息，请将'A specific chemical moiety being measured, including an intact drug, a biomolecule or its derivative or a metabolite in a biological matrix.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"特定的被测化学组分，包括原形药物、生物分子或其衍生物，或在生物基质中的代谢物。"
    },
    {
        "instruction":"已知信息：\n'To further protect drug safety for the people, on March 17, 2020, NMPA issued an Announcement with decisions made to revise the Entries of [contraindications], [adverse reactions] and [precautions] on the package inserts of nicotinic acid injections (including nicotinic acid injection and nicotinic acid for injection).'可被翻译为：进一步保障公众用药安全，2020年3月17日，国家药监局发布公告决定对烟酸注射剂（包括烟酸注射液、注射用烟酸）说明书【不良反应】、【禁忌】、【注意事项】项进行修订。\n'Announcement of NMPA on Revising the Package Inserts of triamcinolone injection'可被翻译为：国家药监局关于修订曲安奈德注射剂说明书的公告\n'Announcement of NMPA on Revising the Package Inserts of Drugs Containing Pipemidic Acid'可被翻译为：国家药监局关于修订含吡哌酸药品说明书的公告\n'Announcement of NMPA on Revising the Package Inserts of Probucol'可被翻译为：国家药监局关于修订普罗布考说明书的公告\n\n根据上述已知信息，请将'Announcement of NMPA on Revising the Package Inserts of Nicotinic Acid Injections'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于修订烟酸注射剂说明书的公告"
    },
    {
        "instruction":"已知信息：\n'As patients with acute VTE may be heterogeneous regarding risk factors for recurrence, it is recommended that the intended treatment duration should be decided according to objective criteria pre-specified in the protocol depending on the baseline risk for recurrent VTE.'可被翻译为：因为急性VTE患者在复发风险因素方面不同，建议根据在方案中预先规定的客观标准决定计划的治疗持续时间，客观标准与复方 VTE 的基线风险相关。\n'It is important to distinguish between initial treatment of VTE (usually 3-6 months), and extended treatment (secondary prevention of recurrences) of VTE (once initial treatment has finished, to indefinite).'可被翻译为：区别VTE的初始治疗（通常为3-6个月）和VTE的扩展治疗（复发的二级预防）（一旦初始治疗结束后，无限期的）是很重要的。\n'The time point for primary evaluation must be related to the presence of non-transient risk factors for recurrent VTE in the population under study.'可被翻译为：初期评价的时间点必须与试验研究人群中复发VTE的非短暂性风险因素的出现相关。\n'Factors that should be taken into consideration related to the initial VTE event and risk factors for recurrence include:'可被翻译为：应考虑一些初始 VTE 事件和复发风险因素相关的因素：\n\n根据上述已知信息，请将'In addition, the duration of therapy should be adapted to the risk for VTE recurrence in the patient population under study.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"此外，治疗的持续时间应根据研究患者人群的VTE复发风险进行调整。"
    },
    {
        "instruction":"已知信息：\n'Pre-existing antibodies'可被翻译为：既存抗体\n'Pre-existing antibodies may also be found in treatment-naïve patients.'可被翻译为：既存抗体也可见于未曾接受治疗的患者。\n'Monoclonal antibodies'可被翻译为：单克隆抗体 .\n'Biopharmaceuticals (e.g., recombinant proteins and monoclonal antibodies) are typically selected based upon their high specificity for their human target receptor\/antigen.'可被翻译为：生物药物（例如，重组蛋白和单克隆抗体）通常基于其对其人类靶受体\/抗原的高特异性来选择。\n\n根据上述已知信息，请将'Pre-existing antibodies against a variety of protein therapeutics (e.g. monoclonal antibodies, fusion proteins) are frequently encountered, especially in the context of autoimmune diseases.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"经常会遇到抗多种蛋白治疗药的既存抗体（例如单克隆抗体、融合蛋白），尤其是在自免疫疾病的背景下。"
    },
    {
        "instruction":"已知信息：\n'Insoluble solid drug A heterogeneous liquid preparation formed in the form of particles dispersed in a liquid medium.'可被翻译为：难溶性固体药物以微粒的形式分散于液体介质中形成的非均相液体制剂。\n'Method for preparing a suspension by dispersing an insoluble solid drug in an appropriate medium.'可被翻译为：将难溶性固体药物分散在适当介质中制备混悬剂的方法。\n'A liquid sol with a solid as a dispersing phase, that is, a dispersing system formed by an insoluble solid dispersed in a liquid. The linear size of solid particles is above 0.1pm.'可被翻译为：以固体为分散相的液溶胶，即由不溶性的固体分散在液体中所形成的分散物系。固体粒子的线性大小在0.1pm以上。\n'A heterogeneous liquid formed by dispersing droplets of one of two liquids that are insoluble to each other.'可被翻译为：互不相溶的两种液体中的一种液体，以微滴形式分散于另一种液体中形成的非均相液体。\n\n根据上述已知信息，请将'Insoluble solid drug A non-uniform liquid preparation formed by dispersing in a dispersing medium in a granular state.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"难溶性固体药物以微粒状态分散于分散介质中形成的非均匀的液体制剂。"
    },
    {
        "instruction":"已知信息：\n'The assessment of duration of response may vary depending of the objectives of the study, especially if the study drug is intended as a short term treatment, such as to cover a period of increased risk (e.g. surgery), or for continuous therapy.'可被翻译为：评估反应持续时间可根据研究目的不同而变化，尤其是该研究药物拟用于短期治疗，比如用于一段高风险时期（如外伤）或连续治疗。\n'Studies of short duration, the duration depending on the mechanism of action of the drug and the selected endpoints, may be sufficient.'可被翻译为：短期临床试验可能是足够的，研究时间根据药物的作用机制和所选择的终点而定。\n'Although study treatment duration is expected to be at least six months, a shorter duration for the placebo arm may be acceptable.'可被翻译为：虽然预期研究治疗时间应至少持续6个月，但对于安慰剂组治疗时间短一点，也是可以接受的。\n'Efficacy endpoints For products developed for symptomatic treatment, muscle strength and function are considered the most important endpoints and should show consistency in effects.'可被翻译为：有效性终点 对于开发成对症治疗的药物，肌力和功能应作为最重要的终点并且应显示出一致的 效应。\n\n根据上述已知信息，请将'Study duration Study duration for medicinal products with an effect only on symptomatic improvement (e.g. muscle strength and related function) may in principle be of shorter duration than for products with potential disease-modifying effects.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究持续时间 原则上，仅具有症状改善作用（如肌力和相关功能）的药物与具有潜在疾病修饰作 用的药物相比，研究持续时间可能要短一些。"
    },
    {
        "instruction":"已知信息：\n'2. In case of laboratory animals used in a study, there should be proper animal facilities for carrying out the study with the corresponding approval documentation for the use of laboratory animals; records of environmental monitoring of animal facilities and handling of unexpected events in the course of the study should be retained completely;'可被翻译为：2.涉及实验动物研究的，应具备符合研究要求的动物设 施，具有相应的实验动物使用许可证明；应完整保存研究期间动物设施环境控制数据及异常情况处理等记录；\n'(1) The source of the test system used in the study should be clear and compliant with the related regulation, and the relevant supporting documentation for acquisition and characterization of the test system should be kept completely; documentation for assessing suitability of the test system should be kept completely.'可被翻译为：（一）研究所需实验系统的来源应清晰合规，应完整保存 实验系统购入(转入)、质量鉴定等相关证明性文件；应完整保留适用性评估资料。\n'laboratory animals'可被翻译为：实验动物\n'2. Test systems other than laboratory animals'可被翻译为：2.实验动物以外的其他实验系统\n\n根据上述已知信息，请将'(1) The source of laboratory animals used in the study should be clear and compliant with the related regulations. Suppliers should have corresponding qualification as required for manufacture or supply of laboratory animals; the guarantee certificate or other relevant documentation for the quality of laboratory animals should be maintained completely;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）研究所需实验动物的来源应清晰合规。实验动物供 应商应具有相应的资质证明；应完整保留实验动物合格证及其他相关证明性文件；"
    },
    {
        "instruction":"已知信息：\n'No-Observed-Adverse-Effect Level: Greatest concentration or amount of a substance, found by experiment or observation, that causes no detectable adverse alteration of morphology, functional capacity, growth, development, or life span of the target organism under defined conditions of exposure.'可被翻译为：在特定暴露条件下，通过实验或观察发现的不会导致目标生物体的形态、功能、生长、发育、或寿命发生可被观测到副作用的物质最大量或浓度。\n'NOAEL: No-Observed-Adverse-Effect Level: Greatest concentration or amount of a substance, found by experiment or observation, that causes no detectable adverse alteration of morphology, functional capacity, growth, development, or life span of the target organism under defined conditions of exposure.'可被翻译为：NOAEL: 未见不良反应剂量：在特定暴露条件下，通过实验或观察发现的不会导致目 标生物体的形态、功能、生长、发育、或寿命发生可被观察到不良反应的物质最 大量或浓度。\n'The highest dose of substance at which there are no biologically significant increases in frequency or severity of any effects in the exposed humans or animals.'可被翻译为：暴露于某种物质的人体或动物其反应频率或严重性在生物学上无显著增加的最高物质剂量。\n'Lowest-Observed-Effect Level: The lowest dose of substance in a study or group of studies that produces biologically significant increases in frequency or severity of any effects in the exposed humans or animals.'可被翻译为：在一项或一组研究中，在人或动物体上任何生物学效应的频率或严重程度显著增加的最低暴露量。\n\n根据上述已知信息，请将'NOEL: No-Observed-Effect Level: The highest dose of substance at which there are no biologically significant increases in frequency or severity of any effects in the exposed humans or animals.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NOEL: 未见反应剂量：在人或动物体上未见任何生物学效应的频率或严重程度显著 增加的最高暴露量。"
    },
    {
        "instruction":"已知信息：\n'In situations  of single cases of AEs, unless a strong pharmacological rationale exists, additional information making  a causal relationship plausible should be present, such as positive dechallenge and rechallenge.'可被翻译为：在仅有1例不良事件的情况下，除非有强大的药理 学基础理论，应列出使因果关系合理的其它信息，例如去激发和再激发阳性。\n'The approach chosen should be justified and depends among others on the mechanism of action, on the availability of suitable biomarkers for efficacy as confirmed by the adult trials and on the existence of a valid pharmacokinetic target exposure.'可被翻译为：所选择的方法应当合理而且取决于作用机制、通过趁人试验所确认的有效性标志物以及是否存在有效的药代动力学靶向暴露。\n'Irrespective of design, e.g. BA vs. A or  BA vs. CA, it may not be possible to define causality in relation to the individual drugs.'可被翻译为：不论设计是什么（例如是BA与A还是BA与CA）， 均不可能确定与单个药物的因果关系。\n'The main objective is thus to define dose-limiting toxicities and the dose to bring forward into further trials.'可被翻译为：因此，主要目的是确定剂量限制毒性和进行进一步临床试验的剂量。\n\n根据上述已知信息，请将'These attempts  should not overshadow the main objective, i.e. to define causality of AEs in relation to the regimens  under study.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"试图确定与单个药物的因果关系不应该遮蔽主要 目的——即确定不良事件与研究的治疗方案相关的因果关系。"
    },
    {
        "instruction":"已知信息：\n'Similarly, there is a wide range of study designs and data sources to address these objectives.'可被翻译为：同样，可通过广泛的研 究设计和数据来源达到这些目的。\n'Along with the breadth of study designs, there are multiple sources of data that studies may employ.'可被翻译为：随着研究设计的广度，研究还可使用多种数据来源。\n'As for adults, the choice of study design would depend on the objectives of the trial.'可被翻译为：对于成年人，试验研究设计的选择取决于试验目的。\n'D. Sensitivity Analyses FDA recommends the use of sensitivity analyses to determine the impact of various study decisions relating to design, exposure definition and outcome definition, and of deficiencies in the data source(s) selected.'可被翻译为：D. 灵敏性分析 FDA建议采用灵敏性分析来确定与设计、暴露的定义、结局的定义、以及所 选择的数据来源的缺陷有关的不同研究决定产生的影响。\n\n根据上述已知信息，请将'Study objectives impact the choice of study design and data sources, which in turn impact the strength of a study to support regulatory decisions and clinical practice.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究目的影响研究设计和数据来源的选择，进而影响研 究支持监管决策和临床实践的力度。"
    },
    {
        "instruction":"已知信息：\n'(4) not informing the applicant at once of all the contents needed to be supplemented or corrected, where the drug application dossier submitted is incomplete or not conformed with the required format;'可被翻译为：（四）申请人提交的申报资料不齐全、不符合法定形式，不一次告知申请人必须补正的全部内容的；\n'If the application dossiers are incomplete or nonconforming to the prescribed form, the lot release institution shall inform the lot release applicant of all contents to be supplemented and corrected and the time limit for supplementation in writing all at once within 5 days. Where the lot release institution fails to notify the applicant within the time limit, it shall be regarded as acceptance as of the date of receipt of application dossiers and samples.'可被翻译为：申请资料不齐全或者不符合规定形式的，批签发机构应当在5日内一次性书面告知批签发申请人需要补正的全部内容及资料补正时限。逾期不告知的，自收到申请资料和样品之日起即为受理。\n'If the application dossiers are incomplete or nonconforming to the prescribed form, the lot release institution shall inform the lot release applicant of all contents to be supplemented and corrected and the time limit for supplementation in writing all at once within 5 days. Where the lot release institution fails to notify the applicant within the time limit, it shall be regarded as acceptance as of the date of receipt of application dossiers.'可被翻译为：申请资料不齐全或者不符合规定形式的，批签发机构应当在5日内一次性书面告知批签发申请人需要补正的全部内容及资料补正时限。逾期不告知的，自收到申请资料之日起即为受理。\n'Article 9 Provincial drug regulatory department shall conduct preliminary review on the normalization and completeness of application dossiers upon the receipt of application dossiers for first importation of crude drugs. Where application dossiers have errors which can be corrected on site, the applicant shall be allowed for error correction on site; where application dossiers are incomplete or does not comply with the defined format, the applicant shall be informed on-site or within 5 days of what to be supplemented or corrected all at once; if the applicant is not informed within the regulatory timeline, the application is regarded as accepted on the date the dossiers are received.'可被翻译为：第九条 省级药品监督管理部门收到首次进口药材申报资料后，应当对申报资料的规范性、完整性进行形式审查。申报资料存在可以当场更正的错误的，应当允许申请人当场更正；申报资料不齐全或者不符合法定形式的，应当当场或者5日内一次告知申请人需要补正的全部内容，逾期不告知的，自收到申报资料之日起即为受理。\n\n根据上述已知信息，请将'(IV) Not informing the lot release applicant at once of all the content needed to be supplemented or corrected, where the application dossiers and samples submitted are incomplete or not conforming with the prescribed format;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）批签发申请人提交的申请资料、样品不齐全、不符合法定形式，不一次告知批签发申请人必须补正的全部内容的；"
    },
    {
        "instruction":"已知信息：\n'6 The definition of clinical data for user fee purposes is provided in the guidance for industry Submitting Separate Marketing Applications and Clinical Data for Purposes of Assessing User Fees. The guidance is available on the FDA Drugs guidance Web page at http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm. Contact CDER’s User Fee Staff for questions concerning the definition of clinical data for user fee purposes.'可被翻译为：6需评估使用者费用的“临床数据”的定义见行业指南“单独销售许可申请以及需评估使用者费用的临床数据的提交”。该指南可见FDA药物指南网页http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm. 关于需评估使用者费用的的临床数据的定义的疑问，请联系CDER中负责使用者费用的工作人员。\n'Based on the information gathered, FDA determined that it was appropriate to require the submission of certain financial information with marketing applications that, in part, rely on clinical data.'可被翻译为：基于收集的信息， FDA确定，对于部分依赖于临床数据的 上市申请，要求它们提交某些财务信息是适宜的。\n'We anticipate that few cardiovascular outcome claim supplements will require the payment of user fees because they will not need clinical data for approval.6'可被翻译为：我们预期极少有心血管结局声明补遗需要支付使用者费用，因为它们不需要临床数据获得批准。6\n'•User Fees'可被翻译为：● 使用者费用\n\n根据上述已知信息，请将'We anticipate that applications will be submitted and user fees assessed consistent with FDA’s user fee bundling policy (see Guidance for Industry, Submitting Separate Marketing Applications and Clinical Data for Purposes of Assessing User Fees).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"我们预计申请将提交且评估的使用费符合FDA的 使用费捆绑政策（参见行业指南，提交用于评估使用费的独立上市申请和临床数据）。"
    },
    {
        "instruction":"已知信息：\n'If the elements that are being used to identify the reporter are known to the sender but cannot be transmitted due to data privacy requirements, then those data elements should be left blank with nullFlavor = MSK.'可被翻译为：如果已知发送者的姓名首字母缩写，但由于数据隐私要求而无法发送，则不应填写该数据元素，且不完整信息=MSK。\n'Business Rule(s) If the initials are known to the sender but cannot be transmitted due to data privacy requirements, this data element should be left blank with nullFlavor = MSK.'可被翻译为：业务规则 如果发送者已知姓名首字母缩写，但由于数据隐私要求而无法发送，则不应填写该数据元素元素，且不完整信息=MSK。\n'The order of the tags indicate the order of the names. <name> <prefix>C.2.r.1.1<\/prefix> <!--C.2.r.1.1: Reporter's Title #1 --> <given>C.2.r.1.2<\/given> <!--C.2.r.1.2: Reporter's Given Name #1 --> <given>C.2.r.1.3<\/given> <!--C.2.r.1.3: Reporter's Middle Name #1 --> <family>C.2.r.1.4<\/family> <!--C.2.r.1.4: Reporter's Family Name #1 --> <\/name>'可被翻译为：标签的顺序表明了名字的顺序。 C.2.r.1.1 C.2.r.1.2 C.2.r.1.3 C.2.r.1.4\n'C.2 - Primary Source(s) of Information C.2.r.1.1 - Reporter’s Title C.2.r.1.2 - Reporter’s Given Name C.2.r.1.3 - Reporter’s Middle Name C.2.r.1.4 - Reporter’s Family Name C.2.r.2.1 - Reporter’s Organisation C.2.r.2.2 - Reporter’s Department C.2.r.2.3 - Reporter’s Street Address C.2.r.2.4 - Reporter’s City C.2.r.2.5 - Reporter’s State or Province C.2.r.2.6 - Reporter’s Postcode C.2.r.2.7 - Reporter’s Telephone C.2.r.3 - Reporter’s Country Code C.2.r.4 - Qualification C.2.r.5 - Primary Source for Regulatory Purposes C.2.r - Primary Source(s) (repeat as necessary) 1 ... n'可被翻译为：C.2 -信息的主要来源 1„n C.2.r -主要来源（必要时重复） C.2.r.1.1 -报告者的职称 C.2.r.1.2 -报告者的给定名 C.2.r.1.3 -报告者的中中间名字 C.2.r.1.4 -报告者的姓氏 C.2.r.2.1 -报告者所在机构 C.2.r.2.2 -报告者所在部门 C.2.r.2.3 -报告者的街道地址 C.2.r.2.4 -报告者所在城市 C.2.r.2.5 -报告者所在州或省 C.2.r.2.6 -报告者所在地区的邮政编码 C.2.r.2.7 -报告者的电话号码 C.2.r.3 -报告者的国家代码 C.2.r.4 -资格 C.2.r.5 -用于监管目的的主要来源\n\n根据上述已知信息，请将'If only the name of the reporter is known and confidentiality requirements prohibit transmission of the reporter’s full name or initials, the data elements C.2.r.1.2, C.2.r.1.3, and\/or C.2.r.1.4 can be masked and ‘populated’ with a nullFlavor as appropriate, in compliance with confidentiality requirements or reporter request.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果仅已知报告者的姓名，且保密性要求禁止传输报告者的全名或姓名首字母缩写，则数据元素元素 C.2.r.1.2，C.2.r.1.3 和（或）C.2.r. 1.4 可根据保密要求或报告者的要求，酌情掩盖和以不完整信息“填写”。"
    },
    {
        "instruction":"已知信息：\n'For better comprehension of the M4 references within the text, please see below the document change history for M4 guideline.'可被翻译为：为了更全面地了解文本的M4参考文件，请参阅下下文M4指导原则的文件变更历史。\n'For better comprehension of the M4S references within the text, please see below the document change history for M4S guideline.'可被翻译为：为了更全面地了解文本中的M4S参考文件，请参阅下文M4S指导原则的文件变更历史。\n'For better comprehension of the E5 references within the text, please see below the document change history for E5 guideline.'可被翻译为：为更好地了解正文内的参考文献，请参见以下E5指导原则文件修订历史。\n'M4E Q&As \nDocument History \nFirst Codification \nHistory \nDate \nNew Codification \nNovember 2005 \nM4E Q&As \nApproval by the Steering Committee.'可被翻译为：M4E问答 \n文件历史 \n首次编码 \n历史 \n日期 \n新编码 \n2005年11月 \nM4E问答 \n指导委员会批准。\n\n根据上述已知信息，请将'For better comprehension of the M4E references within the text, please see below the document change history for M4E guideline.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为了更全面地了解文本中M4E参考文件，请参阅下文M4E指导原则的文件变更历史。"
    },
    {
        "instruction":"已知信息：\n'A class of fatty acids essential for the maintenance of life that cannot be synthesized in the body or at an insufficient rate of synthesis and must be ingested from the outside world.'可被翻译为：一类维持生命活动所必需的体内不能合成或合成速度不能满足需要而必需从外界摄取的脂肪酸。\n'A variety of organic molecules with molecular weights of tens of thousands of daltons or larger that are the principal active components of living organisms. Including proteins, nucleic acids, lipids, and sugars.'可被翻译为：生物体内主要活性成分的各种分子量达到上万道尔顿或更大的有机分子。包括蛋白质、核酸、脂质、糖类。\n'Any of several organic substances of small molecular weight that are loosely bound to enzyme proteins and are essential for catalytic activity.'可被翻译为：某些为催化活性所必需的、与酶蛋白疏松结合的小分子量的有机物质。\n'Any substance that, in trace amounts, raises the body temperature of endotherms.'可被翻译为：微量即能引起恒温动物体温升高的物质的总称。\n\n根据上述已知信息，请将'Any of a class of organic substances found in very small amounts in the body that are essential for the maintenance of human life. It is an important active substance for maintaining human health.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一类在体内含量极微的维持人体生命所必需的有机物质。是保持人体健康的重要活性物质。"
    },
    {
        "instruction":"已知信息：\n'The IND must include, as part of the waiver request:\nA sufficient explanation why compliance with the complete requirements of 21 CFR312.23(a)(7) is unnecessary or cannot be achieved;\nInformation that will satisfy the purpose of the requirement by helping to ensure that the investigational drug will have the proper identity, strength, quality, and purity; or\nOther information justifying a waiver.\nInformation that is relevant to whether the investigational drug will have the proper identity, strength, quality, and purity may include, for example, information indicating whether the investigational drug has been licensed by a regulatory authority that has similar scientific and regulatory standards as the FDA (e.g., International Conference on Harmonisation (ICH)\tcountries). \nThis should include, to the extent possible, summary approval information and\tcurrent product labeling made public by the foreign regulatory authority.'可被翻译为：IND 必须包括，作为豁免申请的一部分：\n充分解释为什么不需要或者为什么不能达到符合 21 CFR 312.23（a）（7）的全部要求 ；\n通过帮助保证研究药物具有正确的标识、规格、质量和纯度，让信息满足要求的目的；或者\n证明豁免的其他信息。\n与研究药物是否具有正确的标识、规格、质量和纯度有关的信息可能包括，例如，表明研究药物是否已经被具有和FDA类似的科学和监管标准的监管机构（例如，国际协调会议（ICH）国家）许可的信息。\n这部分信息应该尽可能地包括国外监管机构公开的批准信息概述和现行的产品说明书。\n'An IND must include sufficient CMC information to ensure the proper identity, strength, quality, and purity of the investigational drug. The amount of CMC information that should be provided\twill vary with the phase of the investigation, the proposed duration of the investigation, the\tdosage form, and the amount of information otherwise available.  In all cases, the sponsor-investigator must include the following information in the IND: The label for the immediate packaging of the investigational drug, which must contain the statement “Caution: New Drug — Limited by Federal (or United States) law to investigational use” (§ 312.6(a)) An environmental assessment under 21 CFR 25.40 or a statement requesting a categorical exclusion from an environmental assessment under provisions provided for in 21 CFR 25.31(e) (§ 312.23(a)(7)(iv)(e))'可被翻译为：IND 必须包含足够的 CMC 信息，从而保证研究药物的正确鉴别、规格、质量和纯度。 应该提供的 CMC 信息数量因研究阶段、推荐的研究持续时间、剂型和其他可用信息 的数量而不同。不管在什么样的情况下，申办方-研究者必须在 IND 中包括下列信息：研究药物直接接触包装的说明书，该说明书必须包含声明“警告：新药-联邦（或者美国）法律限制研究使用”（§312.6（a））根据 21 CFR 25.40 所作的环境声明或者根据 21 CFR 25.31（e）中提供的规定 申请明确从环境声明中排除的声明（§312.23（a）（7）（iv）（e））\n'However, the FDA recognizes that in\tmany such cases the sponsor-investigator will not be able to obtain all of the CMC information required by 21 CFR 312.23(a)(7). In these circumstances, the sponsor-investigator can request that the FDA waive the requirement for complete CMC information on the investigational drug\t(21 CFR 312.10).'可被翻译为：但是，FDA 认为在大多数这样的情况下申办方-研究者可能无法获得 21 CFR 312.23（a）（7）要求的所有 CMC 信息。在这样的情况下，申办方-研究者可以申请 FDA 豁免完整的研究药物 CMC 信息的要求（21 CFR 312.10）。\n'The purpose of the investigator brochure is to provide the investigator with information (clinical and nonclinical) about the investigational drug that is relevant to the study of the drug in human subjects. The investigator brochure should include the information that is important for the investigator, who is administering the drug to human subjects, to know and understand. The investigator brochure is required to include information about the following (see 21 CFR 312.23(a)(5)):'可被翻译为：研究者手册的目的是为研究者提供与受试者药物研究相关的研究用药物的信息（临床和非临床的）。研究者手册应该包括对于给予受试者药物的研究者来说需要知道和了解的重要信息。研究者手册需要包括的信息如下（21 CFR312.23（a）（5））：\n\n根据上述已知信息，请将'In addition to the waiver request, the sponsor-investigator should include in the IND as much of\tthe CMC information required by 21 CFR 312.23(a)(7) as is available. This should include, at a\tminimum, the following:\nThe name of the manufacturer or supplier of the investigational drug.\nAn English version of the investigational drug’s labeling, including the package insert. \nInformation on the conditions and containers that will be used to transport the drug product to the U.S. clinical site(s) and information on the relabeling and repackaging operations that will be used to relabel the drug product vials for investigational use. \nThis should include information on how exposure of the drug product to light and temperature conditions outside of the recommended storage conditions will be prevented. A risk assessment on the affect the relabeling operations may have on drug product stability should also be included.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"除了豁免申请之外，申办方-研究者应该在 IND 包括尽可能多的 21 CFR312.23（a） （7）要求的可用 CMC 信息。这部分信息至少应该包括下列内容：\n研究药物生产商或者供应商的名称。\n研究药物的英文版说明书，包括包装说明书。\n用来将药品运送到美国临床研究中心的条件和容器的有关信息，和将被用来重新贴签研究用药品瓶子的重新贴签和重新包装的信息。\n这部分信息应该包括如何预防药品暴露于推荐储存条件以外的光照和温度条件的信息，还应该包括重新贴签操作可能会影响药品稳定性的风险评估。"
    },
    {
        "instruction":"已知信息：\n'The IRB that is responsible for finding and documenting that community consultation and public disclosure will take place (as required by 21 CFR 50.24(a)(7)) should be knowledgeable about local conditions in order to evaluate the community consultation and public disclosure plans.'可被翻译为：IRB按照此规章审评研究，为了评价社区咨询和公开披露计划，其必须了解当地条件（21 CFR 50.24（a）（7））。\n'If the criteria under 21 CFR 50.24 and 56.111 (and Part 50, Subpart D for pediatric research) are satisfied, the IRB reviews the community consultation plan to ensure that it is designed to reach the communities identified in the investigational plan, will adequately inform the communities about the risks and expected benefits of the research, and will provide an opportunity for community members to express their views and ask questions about the proposed research.'可被翻译为：如果符合21 CFR 50.24和56.111（以及针对儿童研究的50部分，D分部分） 的标准，IRB会审评社区咨询计划，确保其设计上能够达到该项研究计划所 指定的这些社区，并充分告知社区该项研究的风险和预期收益，并将向社区 成员提供一个表达其意见和对有关提议研究提出问题的机会。\n'Before a clinical study may be initiated, the IRB must find and document that consultation has occurred with representatives of the community(ies) in which the research will be conducted and from which research subjects may be drawn (21 CFR 50.24(a)(7)(i) and 21 CFR 56.115(a)).'可被翻译为：在启动一项临床研究之前，IRB必须确定并证明，已与将要开展该项研究并 从中招募研究受试者的社区代表进行了咨询活动（21 CFR 50.24（a）（7）（i）和 21 CFR 56.115（a））。\n'66.What is the IRB’s role in the community consultation process? In order to approve the research, the IRB must find and document that community consultation will be provided (including, where appropriate, consultation carried out by the IRB; 21 CFR 50.24(a)(7)(i)).'可被翻译为：） 66 IRB在社区咨询过程中的作用是什么？ 批准研究前提是IRB必须能确定并用文件证明将进行社区咨询（根据情况包 括，由IRB进行的咨询；21 CFR 50.24（a）（7）（i））。\n\n根据上述已知信息，请将'In order to find and document that community consultation has occurred, as required in 21 CFR 50.24(a)(7)(i), the IRB should determine whether meaningful feedback was secured from the community(ies).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"按照21 CFR 50.24（a）（7）（i）的要求，为了确定并用文件证明已经进行了 社区咨询，IRB应当评估采用的方法，并决定来自社区的有意义反馈是否可信。"
    },
    {
        "instruction":"已知信息：\n'For the purpose of this document, this term is defined in the same way as in the IAEA\/WHO guideline on good manufacturing practices for radiopharmaceutical products (3), as any pharmaceutical product that, when ready for use, contains one or more radionuclides (radioactive isotopes) included for medicinal purposes.'可被翻译为：就本文件而言，该术语的定义与国际原子能机构\/WHO《放射性药品良好生产规范》指南中的定义相同(3)，即在准备使用时含有一种或多种用于医疗目的的放射性核素(放射性同位素)的任何药品。\n'good manufacturing practices for radiopharmaceutical products'可被翻译为：放射性药品良好生产规范\n'The evaluation of documentary evidence by a competent regulatory authority recognized by the national regulatory authority, for compliance with the required good practices (good manufacturing practices (GMP), good laboratory practices and good clinical practices) in support of marketing authorization and other regulatory decisions. Desk assessment may be performed in support of a new marketing authorization, or for routine GMP inspection (including in the frame of specified product(s) life-cycle management as required).'可被翻译为：由国家监管机构认可的主管监管机构对文件证据的评估，以证明符合所需的良好规范(良好生产规范(GMP)、良好实验室规范和良好临床规范)，以支持上市许可和其他监管决定。案头评估可用于支持新的上市许可，或用于常规GMP检查(包括在所要求的指定产品生命周期管理框架内)。\n'Good practices of national regulatory authorities in implementing the collaborative registration procedures for medical products (Annex 6, 53rd report, 2019)'可被翻译为：国家监管部门实施医疗产品协同注册程序的良好做法(2019年第53次报告附件6)\n\n根据上述已知信息，请将'For the purpose of this document, these terms are defined in the same way as in the IAEA\/WHO guideline on good manufacturing practices for radiopharmaceutical products (3). They refer to all the procedures carried out as per instructions from marketing authorization holders that involve addition of radionuclide solution approved by regulatory authorities to an approved cold kit.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"就本文件而言，这些术语的定义与原子能机构\/WHO放射性药品良好生产规范指南(3)中的定义相同。它们是指按照上市许可持有人的指示执行的所有程序，这些程序涉及将经监管机构批准的放射性核素溶液添加到经批准的冷试剂盒中。"
    },
    {
        "instruction":"已知信息：\n'‒ Sponsors are encouraged to request feedback via formal meetings with FDA at the major drug development milestones described above.'可被翻译为：- 鼓励申办方在上述重大药物开发里程碑时经由正式会议向FDA请求反馈。\n'Because sponsors are ultimately responsible for managing the overall development program for their proposed drug, sponsors should closely monitor for advances in the field and\/or changes in FDA guidance, and inquire if those changes may necessitate changes in prior FDA recommendations for their development program.'可被翻译为：由于申办方最终负责管理其拟议药物的总体开发计划，申办方应密切监测该领域的进展和\/或 FDA指导原则的变化，并询问这些变化是否可能需要对以前FDA建议的开发计划进行更改。\n'FDA recommends that sponsors consult with FDA on the appropriateness of codevelopment before initiation of clinical development of a combination.'可被翻译为：FDA建议申办方在启动联合治疗方案的临床开发前咨询FDA关于共同开发的适宜性。\n'Sponsors are encouraged to consult with the Division of Bone, Reproductive, and Urologic Products regarding the design of the nonclinical bone quality studies as early in development as possible.'可被翻译为：鼓励申办者在开发中尽早咨询骨骼、生殖系统和泌尿系统产品处关于非临床骨质量研究的设计。\n\n根据上述已知信息，请将'Sponsors also are encouraged to consult FDA as needed throughout the development process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"还鼓励申办方在开发过程全程根据需要咨询FDA。"
    },
    {
        "instruction":"已知信息：\n'In vitro cell age Measure of time between thaw of the MCB vial(s) to harvest of the production vessel measured by elapsed chronological time, by population doubling level of the cells, or by passage level of the cells when subcultivated by a defined procedure for dilution of the culture.'可被翻译为：体外细胞传代周期 指从MCB小瓶细胞融化至生产容器收获的这段时间，它可以用培养所耗的时间来表示，或用细胞数的倍增水平来表示，当细胞采用规定的步骤稀释培养物进行传代培养时，也可用细胞的传代次数来表示。\n'In Vitro Cell Age A measure of the period between thawing of the MCB vial(s) and harvest of the production vessel measured by elapsed chronological time in culture, population doubling level of the cells or passage level of the cells when subcultivated by a defined procedure for dilution of the culture.'可被翻译为：体外胞龄（细胞年龄）：指细胞在体外培养过程中，从 MCB复苏开始到生产反应器收获时所经历的时间。可以采 用细胞群体倍增水平或细胞传代水平表示。若以细胞传代水 平表示，其传代培养程序应已预先预定。\n'A WCB is derived from one or more containers of the MCB.'可被翻译为：WCB来源于一支或多支MCB。\n'in vitro cell age'可被翻译为：体外细胞代次\n\n根据上述已知信息，请将'The starting point of reference for estimates of in vitro cell age during manufacturing should be the thawing of one or more containers of the MCB.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在生产中体外细胞的寿命应从解冻一个或多个容器MCB开始算起。"
    },
    {
        "instruction":"已知信息：\n'Supportive treatment <in <adults> <{age category}> > where standard surgical techniques are insufficient (see section 5.1): - for improvement of haemostasis [Product specific depending on whether specific clinical studies have been undertaken:] <(to include application through a flexible endoscope to stop bleeding)> - as a tissue glue to promote adhesion\/sealing, or as suture support: <In vascular surgery.>'可被翻译为：标准外科技术不充分时<针对<成人> <{年龄组别}> > 的支持性疗法（参见 第5.1节）： - 用于改善止血 [产品特有信息，视是否已开展了具体临床研究而定：] <（列入通过可弯曲式内窥镜应用止血）> - 作为一种组织胶以促进粘合\/封闭，或作为缝合支持： <血管外科。>\n'[Product specific for products containing tranexamic acid:]<Products containing tranexamic acid should not be used in neurosurgery or surgical procedures where contact with cerebro-spinal fluid or dura mater can occur (e.g. otologic, rhinologic, ophthalmic and vertebral surgery) due to the risk of cerebral neurological toxicity (such as oedema and seizure).> 4.4 Special warnings and precautions for use For epilesional use only.'可被翻译为：[含氨甲环酸产品的产品特有信息：]<神经外科手术和可能发生与脑脊髓液 或硬膜接触的外科手术（如：耳科、鼻科、眼科和脊椎手术）由于存在脑神经毒 性风险（例如水肿和发作），不应使用含氨甲环酸的产品。> 4.4 特殊警告和使用注意事项 仅用于损伤面上。\n'For example:] <Clinical studies demonstrating haemostasis and suture support were conducted in {x} patients in {specify type} surgery.>'可被翻译为：例如：] <在{说明类型}手术中，针对{x}例患者开展了旨在证明止血和缝合支持的临 床研究。>\n'1-2. Pericardium is intended to be used as a wound covering for dura mater defects.'可被翻译为：1-2. 心包可以用来覆盖硬脑膜伤口缺陷。\n\n根据上述已知信息，请将'<For tissue adhesion\/sealing and suture support in neurosurgery and surgical procedures where contact with cerebro-spinal fluid or dura mater can occur, e.g. otologic, rhinologic, ophthalmic and vertebral surgery.> <{In other indications, specify}>>'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"<在神经外科和可能接触脑脊髓液或硬膜的外科手术（如：耳科、鼻科、眼科和 脊椎手术）中用于组织粘合\/封闭和缝合支持。> <{其他适应症，请说明}>>"
    },
    {
        "instruction":"已知信息：\n'Although the potential problem is largely unexplored and only a few data are available , this should in future be addressed in respective drug-drug interaction studies based on the mechanism of action of the compound, and potentially in in-vitro experiments which could help to determine adequate test substances.'可被翻译为：尽管有很多未知的潜在问题却仅有少数可参考的资料，但是，仍应在将来根据药物的作 用机制在相应的药物-药物相互作用研究中进行探索，体外试验可能会有助于确定合适的受试物。\n'The proposed mechanism of action of a new compound should be described and discussed in relation to results obtained in non-clinical investigations, e.g. in vitro and\/or animal models, although it is acknowledged that their availability may still be limited.'可被翻译为：应描述新化合物的拟定作用机制，并与在非临床研究（如体外或动物模型）中获得 的结果联系起来讨论，尽管这些结果的可用性仍是有限的。\n'Drug-drug interaction data if the metabolism profiles suggest an interaction potential between drugs in the combination regimen'可被翻译为：如果代谢曲线提示联合方案中的药物间有可能产生相互作用，还需提供药物-药物相互作用数据\n'4.3.2 Drug-drug interaction studies'可被翻译为：4.3.2 药－药相互作用研究\n\n根据上述已知信息，请将'Although the potential problem is largely unexplored and only a few data are available58,59, this should in future be addressed in respective drug-drug interaction studies based on the mechanism of action of the compound, and potentially on in-vitro experiments which could help to determine adequate test substances60.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"虽然大多半潜在问题未被考察， 且仅有少量数据58,59 ，,但这应在未来基于 化合物作用机制的各项药物之间相互作用的研究中得以解决，体外研究可能有助于确定适当的受试药物。"
    },
    {
        "instruction":"已知信息：\n'Treatment administered with the intent to achieve long-term disease control Typical conditions include early lines of therapy in advanced breast cancer, colorectal cancer, low- grade lymphomas and the chronic leukaemias for which established reference therapies are available and next-line treatment options are likely to be meaningfully efficacious.'可被翻译为：以实现疾病长期控制为目的的治疗 典型情况包括晚期乳腺癌、大肠癌、低分级淋巴瘤和慢性白血病的早期线治疗，有 已建立的参考疗法，而且下一线治疗方案可能是明显有效的。\n'This might be of relevance for the activity of next-line therapies.'可被翻译为：这可能与下一线治疗的活性有 关。\n'For established areas of adjuvant therapy, e.g. breast and colorectal cancer, and if benefit- risk is considered favourable for the experimental regimen based on DFS and available safety and survival data, including PFS on next-line therapy following recurrence of the disease, mature survival data may be reported post-licensing.'可被翻译为：对于辅助疗法已确定的领域，如乳腺癌和大肠癌，并且如果获益-风险被视为有利于基于 DFS 和可用的安全和生存数据（包括在疾病复发后下一线疗法的 PFS）的试验方案， 可在药品上市后报告成熟生存数据。\n'- Locally advanced breast cancer'可被翻译为：局部晚期乳腺癌\n\n根据上述已知信息，请将'Typical conditions include early lines of therapy in advanced breast cancer, colorectal cancer, low- grade lymphomas and the chronic leukaemias for which established reference therapies are available and next-line treatment options are likely to be meaningfully efficacious.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一般情况包括在晚期乳腺癌、大肠癌、低恶性度淋巴癌以及慢性白血病中的早期线疗法。可为这些疾病提供已确定的参照疗法，并且下一线治疗方案将可能实际产生疗效。"
    },
    {
        "instruction":"已知信息：\n'The population to be studied should be chosen to support the study objectives and is defined through the inclusion and exclusion criteria for the study.'可被翻译为：应选择支持研究目的的研究人群，并通过研究的入组和 排除标准进行定义。\n'The selection to be used may vary with the aim of the study but should be scientifically justified in each case.'可被翻译为：不同的研究不同的情况下根据研究目的的不同研究终点的选择会有所不同。\n'9.3 SELECTION OF STUDY POPULATION 9.3.1 Inclusion Criteria The patient population and the selection criteria used to enter the patients into the study should be described, and the suitability of the population for the purposes of the study discussed.'可被翻译为：9.3 研究人群的选择 9.3.1 入选标准 应描述患者数量和用于筛选患者的研究入选标准，并讨 论研究人群是否适用于本研究的目的。\n'D. Selection of Study Population Investigators should use explicit inclusion and exclusion criteria for the selection of the study population and provide an appropriate explanation in the protocol for the criteria selected.'可被翻译为：D. 研究人群的选择 关于研究人群的选择，研究者应简述入选和排除标准，并在方案中适当地阐 明所选择的标准。\n\n根据上述已知信息，请将'Any matching on selection criteria or adjustments made to account for population differences should be specified prior to selection of the control and performance of the study.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"任何选择标准的匹 配或者由于人群差异所做的调整都应在选择对照和进行研 究之前说明。"
    },
    {
        "instruction":"已知信息：\n'Bias here (and as used in ICH E9) means the systematic tendency of any aspects of the design, conduct, analysis, and interpretation of the results of clinical trials to make the estimate of a treatment effect deviate from its true value.'可被翻译为：这里 所说的偏倚(以及在E9使用的偏倚)，是指在临床试验的设 计、实施、分析和结果的解释方面出现的系统倾向，从而使 对治疗结果的估计偏离它的真实值。\n'Bias (Statistical & Operational) The systematic tendency of any factors associated with the design, conduct, analysis and evaluation of the results of a clinical trial to make the estimate of a treatment effect deviate from its true value.'可被翻译为：偏倚（统计的和操作的） 是指与临床试验的设计、实施、分析和结果评价有关的 任何因素导致的处理效应估计值偏离其真实值的系统趋势。\n'The systematic tendency of any factors associated with the design, conduct, analysis and evaluation of the results of a clinical trial to make the estimate of a treatment effect deviate from its true value. Bias introduced through deviations in conduct is referred to as 'operational' bias. The other sources of bias listed above are referred to as 'statistical'.'可被翻译为：是指与临床试验的设计、实施、分析和结果评价有关的任何因素导致的处理效应估计值偏离其真实值的系统趋势。由实施偏离所引入的偏倚称为“操作”偏倚，而上述其他来源的偏倚称为“统计”偏倚。\n'The interpretation of statistical measures of uncertainty of the treatment effect and treatment comparisons should involve consideration of the potential contribution of bias to the p-value, confidence interval, or inference. Because the predominant approaches to the design and analysis of clinical trials have been based on frequentist statistical methods, the guidance largely refers to the use of frequentist methods (see Glossary) when discussing hypothesis testing and\/or confidence intervals.'可被翻译为：在对处理效应和处理间比较的不确定 性的统计测量进行解释时，应考虑偏倚对P值、置信区间或 推断的潜在影响。 由于临床试验设计和分析的主要方法基于频率派统计 方法，因此在讨论假设检验和\/或置信区间时，本指南主要使用频率派方法（见词汇表）。\n\n根据上述已知信息，请将'As used in this guidance, the term 'bias' describes the systematic tendency of any factors associated with the design, conduct, analysis and interpretation of the results of clinical trials to make the estimate of a treatment effect (see Glossary) deviate from its true value.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这里的术语“偏倚”是指与临床试验设计、实 施、分析和结果解释有关的任何因素所导致的处理效应（见 词汇表）的估计值与真实值偏离的系统性趋势。"
    },
    {
        "instruction":"已知信息：\n'The Article 4 of the CNDA Announcement on the Direct Reporting of Adverse Reactions by Marketing Authorization Holders (No. 66 of 2018) stipulates that holders should regularly evaluate the ADR Monitoring data, clinical research, literature, etc. Clinical safety literature evaluation of marketed drugs, as one of the major methods for post- marketing clinical research, refers to the process of collection, as systematic and comprehensive as possible, of relevant clinical safety research literatures for specific marketed drugs within a certain time frame; the systematic screening, data extraction, quality evaluation, induction and collation of literature; and thence the qualitative or quantitative comprehensive analysis and evaluation, leading to the formation of evaluation reports. The basic elements of literature evaluation include the general process, methodological points, and written norms of evaluation report.'可被翻译为：国家药品监督管理局《关于药品上市许可持有人直接报告不良反应事宜的公告》（2018年第66号）第四款规定，持有人应当定期对药品不良反应监测数据、临床研究、文献等资料进行评价。上市药品临床安全性文献评价作为药品上市后临床研究的主要方法之一，是指尽可能全面系统地收集一定时间范围内、特定上市药品的临床安全性研究相关文献，在对文献资料进行系统筛选、资料提取、质量评价和归纳整理的基础上，进行定性或定量综合分析评价，并形成评价报告的过程。基本要素包括文献评价的一般流程、方法学要点以及评价报告撰写规范。\n'5.2 Cumulative and Interval Patient Exposure from Marketing Experience E2E and E2F (cumulative only) 6 Data in Summary Tabulations 6.1 Reference Information 6.2 Cumulative Summary Tabulations of Serious Adverse Events from Clinical Trials E2F 6.3 Cumulative and Interval Summary Tabulations from Post-Marketing Data Sources 7 Summaries of Significant Findings from Clinical Trials during the Reporting Period 7.1 Completed Clinical Trials E2F 7.2 Ongoing Clinical Trials E2F 7.3 Long-Term Follow-up E2F 7.4 Other Therapeutic Use of Medicinal Product E2F 7.5 New Safety Data Related to Combination Therapies E2F 8 Findings from Non-Interventional Studies E2F 9 Information from Other Clinical Trials and Sources E2F 10 Non-Clinical Data E2F 11 Literature E2F 12 Other Periodic Reports 13 Lack of Efficacy in Controlled Clinical Trials E2F 14 Late-Breaking Information E2F, if reports cover same period and submitted at same time 15 Overview of Signals: New, Ongoing, or Closed 16 Signal and Risk Evaluation 16.1 Summary of Safety Concerns 16.2 Signal Evaluation'可被翻译为：5.2 上市后使用经验中的累积和时间段患者暴露 量 E2E 和 E2F (累积) 6 总结表中的数据 6.1 参考信息 6.2 来自临床试验的严重不良事件的累积总结表 E2F 6.3 来自上市后数据来源的累积和时间段总结表 7 报告期内来自临床试验的重大发现的总结 7.1 已完成的临床试验 E2F 7.2 正在进行中的临床试验 E2F 7.3 长期随访 E2F 7.4 药品的其它治疗用途 E2F 7.5 与联合治疗有关的新安全性数据 E2F 8 来自非干预性研究的发现 E2F 9 来自其它临床试验和来源的信息 E2F 10 非临床数据 E2F 11 文献 E2F 12 其它定期报告 13 在对照临床试验中缺乏有效性 E2F 14 新出现的信息 E2F，如果报告覆盖的时间段相同 并且同时提交 15 信号总览：新出现的，正在进行中，或关闭 16 信号和风险评估 16.1 安全性问题总结 16.2 信号评估\n'Where two SAEs for the same trial subject code to the same MedDRA PT, they have been counted as one event at the PT level in the tabulation.'可被翻译为：当两个SAE具有同一个受试者编码以 及同一个MedDRA PT时，在表格的PT级别记录为一次事件。\n'MedDRA is a multi-axial terminology meaning that a Preferred Term (PT) may be linked to more than one SOC. For example, PT Dyspnoea has a link to both SOC Respiratory, thoracic and mediastinal disorders (its organ system of manifestation) and to SOC Cardiac disorders (because of its connection to heart disease). Each PT is assigned a primary SOC to avoid “double counting” while retrieving information from all SOCs (i.e., a cumulative SOC-by-SOC data output). The other SOCs to which a multi-axial PT is linked are called “secondary” SOCs.'可被翻译为：MedDRA是一种多轴性术语，每个首选语（PT）可与一个以上的SOC 相连。例如，PT 呼吸困难链接到两个 SOC：SOC 呼吸系统、胸及纵隔疾病（其发病器官系统）和 SOC心脏器官疾病（因为其与心脏疾病有关）。每个 PT 被分配一个主 SOC，从而在用所有 的SOC（即累计各个 SOC 数据输出）检索信息时，可避免“双重计算”。多轴 PT 链接的 其他 SOC 被称为“次” SOC。\n\n根据上述已知信息，请将'Periodic Benefit-Risk Evaluation Report (PBRER) 31 Table 7 – Numbers of Adverse Drug Reactions by Term from Post-Marketing Sources Spontaneous, including regulatory authority and literature Non-interventional post-marketing study and reports from other solicited sources* Serious Non-serious Total Spontaneous Serious Interval Cumulative Interval Cumulative Cumulative Interval Cumulative SOC 1 MedDRA PT MedDRA PT MedDRA PT SOC 2 MedDRA PT MedDRA PT MedDRA PT MedDRA PT *This does not include interventional clinical trials.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"表7 来自上市后使用经验的药物不良反应的数量 自发报告，包括监管机构和文献 非干预性上市后研究 以及来自其它征集来 源的报告* 严重 非严重 总自发报 告 严重 时间段 累积 时间段 累积 累积 时间段 累积 SOC1 MedDRA PT MedDRA PT MedDRA PT SOC2 MedDRA PT MedDRA PT MedDRA PT MedDRA PT *这并不包括干预性临床试验"
    },
    {
        "instruction":"已知信息：\n'liquid-solid extraction'可被翻译为：液固萃取\n'Sample collected directly from the material.'可被翻译为：直接从物料中采集的样品。\n'Infrared sample processing method in which a solid sample is ground into fine powder, mixed with liquid paraffin oil to form a paste, and then sandwiched between two Windows for determination.'可被翻译为：将固体样品研成细末，与液体石蜡油混合成糊状，然后夹在两窗片之间进行测定的红外样品处理方法。\n'• Extraction of the sample from the dried matrix'可被翻译为：·从干基质中提取样品\n\n根据上述已知信息，请将'The method of extracting the measured component directly from the solid powder sample with extraction solvent.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用提取溶剂直接从固体粉末样品中萃取被测组分的方法。"
    },
    {
        "instruction":"已知信息：\n'3.4 Duration of Toxicology Studies to Support Continued Clinical Development and Marketing'可被翻译为：3.4 支持后续临床试验和上市的毒理学研究期限\n'Arising from the extensive analysis and review of the above mentioned data in non- rodents and based upon the achievements of ICH1 for testing in rodents, and so as to avoid duplication and follow a single development plan for chronic toxicity testing of new medicinal products, the following studies are considered acceptable for submission in the 3 Regions: 1) Rodents: a study of 6 months duration; 2) Non-rodents: a study of nine months duration. 2'可被翻译为：非啮齿类动物试验数据的全面回顾和分析，以及第一届ICH会议在啮齿类动物试验方面已达成的共识，也避免重复试验，并遵循新药慢性毒性试验的单一的开发计划，ICH三方监管机构可接受以下的慢性毒性试验的申报： 1） 啮齿类动物： 期限为6个月的试验； 2） 非啮齿类动物： 期限为9个月的试验。\n'However, for chronic toxicity testing in non-rodents, there were different approaches to the duration of testing.'可被翻译为：但是，非啮齿类动物慢性毒性试验的期限仍存在不同的方 法。\n'Each of the regulatory authorities in EU, Japan and US undertook a review to determine whether a single duration for chronic toxicity testing in non-rodents could be identified.'可被翻译为：欧盟、日本和美国各方监管机构分别进行了评价，以决定能否确定一个非啮齿类动物慢性毒性试验期限。\n\n根据上述已知信息，请将'4.GUIDANCE ON DURATION OF CHRONIC TOXICITY TESTING FOR TRIPARTITE DEVELOPMENT PLAN'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4.ICH三方开发计划的慢性毒性试验期限的指导原则"
    },
    {
        "instruction":"已知信息：\n'No, there is no need to run the qualification batches at the outer limits of the design space during process validation studies at commercial scale. The design space must be sufficiently explored earlier during development studies (for scale up see also Chapter 2.1 Design Space Question 2; for life cycle approach see Chapter 1.1 for general clarification Question 3).'可被翻译为：否，在商业规模工艺验证研究中没有必要对设计空间的 外限进行验证。设计空间必须在开发研究的早期进行充分研 究（关于放大规模请参见章节2.1设计空间问题2；关于生 命周期法请参见章节1.1一般声明问题3）。\n'Design Space Versus Proven Acceptable Ranges'可被翻译为：设计空间与证明的可接受范围的比较\n'The number of proposed validation batches should be based on the variability of the process, the complexity of the process\/product, process knowledge gained during development, supportive data at commercial scale during the technology transfer and the overall experience of the MAH.'可被翻译为：拟定的验证批的数量应根据工艺变异性、工艺\/产品的复杂性、 开发过程中获得的工艺知识、技术转移期间商业规模的支持性数据 以及MAH的整体经验确定。\n'Manufacturing data and process knowledge can be used to support a design space for existing products. Relevant information should be utilised from e.g., commercial scale manufacturing, process improvement, CAPA and development data.'可被翻译为：生产数据和对工艺的认知可用于支持现有产 品的设计空间研究，应利用来自诸如商业化规模的生产、工 艺改进、CAPA和研发数据中的相关信息。\n\n根据上述已知信息，请将'9 Nov. 2010 Should the outer limits of the Design Space be evaluated during process validation studies at the commercial scale?'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"9 2010年 11月 是否应在商业规 模工艺验证研究中对 设计空间的外限进行 评价？"
    },
    {
        "instruction":"已知信息：\n'The labeling should describe the disease severity of patients enrolled in the clinical trials.'可被翻译为：该标签说明应描述在临床试验入组的患者的疾病严重度。\n'For this purpose, trial subjects must be constituted by patients with disease that is well characterized according to relevant biomarkers.'可被翻译为：由于这个目的，试验的受试者必须是已充分了解该病的相关生物标志物的患者。\n'd) ERA, as defined by ILAR criteria.'可被翻译为：d）ERA，如ILAR标准所定义。\n'6.9.2 The number of subjects planned to be enrolled. In multicentre trials, the numbers of enrolled subjects projected for each trial site should be specified. Reason for choice of sample size, including reflections on (or calculations of) the power of the trial and clinical justification.'可被翻译为：6.9.2 计划招募的对象数目。如为多中心试验，应当说明每个试验点计划招募的对象数。样本大小的选择理由，包括试验的把握度计算和临床方面的理由。\n\n根据上述已知信息，请将'The ILAR category of each patient enrolled into trials needs to be defined as this is important for cross- trial comparisons.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"需要限定入组试验的每例患者的ILAR类别，因为这对交叉试验比较很重要。"
    },
    {
        "instruction":"已知信息：\n'Article 141 The National Institute for the Control of Pharmaceutical and Biological Products shall be responsible for the overall technical evaluation of the characterized reference standards in respect of the data of source material selection, preparation methods, testing methods and results, accuracy of value assignment, traceability, stability, filling and packaging conditions, etc. and shall conclude whether or not the candidate materials can be used as national reference standards.'可被翻译为：第一百四十一条 中国药品生物制品检定所负责对标定的标准物质从原材料选择、制备方法、标定方法、标定结果、定值准确性、量值溯源、稳定性及分装与包装条件等资料进行全面技术审核，并作出可否作为国家药品标准物质的结论。\n'Article 140 The National Institute for the Control of Pharmaceutical and Biological Products shall be responsible for the characterization of national reference standards.'可被翻译为：第一百四十条 中国药品生物制品检定所负责标定国家药品标准物质。\n'Article 21 The National Institute for the Control of Pharmaceutical and Biological Products shall be responsible for guiding and coordinating the port testing for drugs to be imported. The biological reference standard and chemical reference substance required for port testing shall be reviewed and characterized by the National Institute for the Control of Pharmaceutical and Biological Products.'可被翻译为：第二十一条 中国药品生物制品检定所负责进口药品口岸检验工作的指导和协调。口岸检验所需标准品、对照品由中国药品生物制品检定所负责审核、标定。\n'(2) The mandatory standard(s) of in-vitro diagnostic reagents have been revised or national standard products and reference products have been established, and the in-vitro diagnostic reagent fails to meet the requirements of the new standards.'可被翻译为：（二）体外诊断试剂强制性标准已经修订或者有新的国家标准品、参考品，该体外诊断试剂不能达到新要求的；\n\n根据上述已知信息，请将'Article 25 For the products with national standard products and reference products, it is required to use national standard products and reference materials for registration testing. National Institutes for Food and Drug Control is responsible for organizing the preparation and calibration of national standard products and reference materials.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十五条 有国家标准品、参考品的产品应当使用国家标准品、参考品进行注册检验。中国食品药品检定研究院负责组织国家标准品、参考品的制备和标定工作。"
    },
    {
        "instruction":"已知信息：\n'It is recognized that the clinical characteristics of patients with prodromal\/MCI due to AD may overlap with those at the milder end of the AD dementia spectrum and that, despite all efforts for criteria harmonization, operationally defined stages of disease are not clearly demarcated.'可被翻译为：已经认识到前驱期\/AD 所致 MCI 患者的临床特征可能有所重叠，在 AD 痴呆谱系的较轻端，尽管为了统一标准付诸努力，但尚未能明确界定可行的疾病阶段定义。\n'It is not known whether progression to symptomatic AD will occur.'可被翻译为：并不知道是否会进展为有症状的 AD。\n'Both diagnostic criteria use a similar terminology to define three stages in the Alzheimer disease continuum: preclinical AD, MCI due to AD (National Institute of Aging-Alzheimer’s Association Criteria, NIA-AA) or prodromal AD (International Working Group, IWG) and AD dementia.'可被翻译为：这两项诊断标准均采用了相似的术语将阿尔茨海默病的连续过程定义为三个阶段：临床前 AD，AD 所致 MDI（美国国立老龄化研究所-阿尔茨海默病学会，NIA-AA）或前驱期 AD（国际工作组，IWG）以及 AD 痴呆。\n'Efficacy endpoints in Prodromal AD\/MCI due to AD'可被翻译为：前驱期AD\/AD 所致MCI 的有效性终点\n\n根据上述已知信息，请将'Any recommendation of diagnostic criteria particularly for prodromal AD\/ MCI due to AD is still kept open and all efforts should be focused in detecting a population or homogeneous groups of patients with a defined rate of progression to AD dementia.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于前驱期AD\/AD 所致MCI 诊断标准的任何建议仍保持开放的态度，将致力于建立进展为 AD 痴呆的速度已知的人群或统一的群组。"
    },
    {
        "instruction":"已知信息：\n'The information is usually provided in the Posology or Warning\/Precautions sections of the label and in other sections as relevant.'可被翻译为：信息通常在标签的“剂量学”或“警告\/注意事项”部分以及其他相关部分提供。\n'Where all the above-mentioned information may not be covered completely in the label due to the limits of its position or size, the label shall at least contain name, model, specifications, manufacturing date, service life or expiration date of the product, and a sentence of \"Refer to instructions for other details\" shall be clearly indicated in the label.'可被翻译为：医疗器械标签因位置或者大小受限而无法全部标明上述内容的，至少应当标注产品名称、型号、规格、生产日期和使用期限或者失效日期，并在标签中明确“其他内容详见说明书”。\n'Sampling should be performed by adequately trained personnel [ICH Q7, Section 3.10] and be appropriately documented as per [ICH Q7, Section 6.52].'可被翻译为：取样应该由经过充分培训的人员执行【ICH Q7，第3.10章节】，并应按【ICHQ7，第6.52章节】进行适当记录。\n'21. ANNEX: Q&AS LINKED TO THE RESPECTIVE SECTIONS OF ICH Q7'可被翻译为：21.附录：问答涉及的ICH Q7章节\n\n根据上述已知信息，请将'The new label should contain information as per [ICH Q7, Sections 9.42, 9.43].'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"新的标签应包括【ICHQ7，第9.42和9.43章节】中要求的信息。"
    },
    {
        "instruction":"已知信息：\n'Example: Mother suffers from pre-eclampsia and the child has no adverse reaction. Only one ICSR should be completed for the mother, with the adverse event\/reaction of pre-eclampsia. No events\/reactions are reported for the child, therefore a linked ICSR for the child is not applicable.'可被翻译为：例如：母亲患有先兆子痫，婴儿未发生不良反应。应完成一份关于母亲的 ICSR （含先兆子痫的不良事件\/反应）。婴儿未被报告不良事件\/反应，因此无需提供一份链接的婴儿报告。\n'• If both the parent and the child\/foetus sustain adverse event(s)\/reaction(s), two separate reports, e.g. one for the parent (mother or father) and one for the child\/foetus, should be provided and should be linked by using the data element C.1.10.r in each report.'可被翻译为：● 如果父母和儿童\/胎儿同时出现不良事件\/反应，则应提供 2 份独立的报告，即一份关于父母即关于（母亲或父亲）的报告、一份关于儿童\/胎儿的报告，并应在每份报告中使用数据元素C.1.10.r将两份报告链接起来。\n'Example: A report of foetal distress, where the mother delivered via a Caesarean section. There will be one ICSR for the baby, with the adverse event\/reaction of foetal distress. The Caesarean section should not be considered an adverse event\/reaction for the mother. The mother’s characteristics, should be captured in Section D with the Caesarean section as relevant medical history (D.10.7).'可被翻译为：示例：胎儿窘迫的报告，母亲通过剖腹产分娩。仅需提供一份婴儿的仅需提供一份婴儿的 ICSR（包含胎儿窘迫的不良事件\/反应）。剖宫产不应视为母亲的不良事件\/ 反应。母亲的特征应在D节中记录，且剖腹产作为相关病史（D.10.7）。\n'In the case of a parent-child\/foetus report, the dosage section applies to the known parental dose. For example, if the mother took the drug(s) suspected of causing adverse reaction(s) in a nursing infant, then the dosage information (G.k.4.r.1 to G.k.4.r.11.2) relates to how the mother took the medication(s). If the mother is the source of the suspect drug(s) then the dosage information reflects how the mother ingested or was administered the drug(s). If a father is the source of the suspect drug(s) then the additional information on drug (G.k.10) is provided. The case narrative (H.1) should describe the entire case, including the father’s information.'可被翻译为：在父母-儿童\/胎儿报告的情况中，剂量部分适用于已知的父母所用剂量。例如，如果怀疑母亲服用的药物在哺乳婴儿中引起不良反应，则剂量信息（G.k.4.r.1 至 G.k.4.r.11.2）与母亲如何服用药物相关。如果母亲为疑似药物的来源，则剂量信息反映母亲如何服药或服药方式。如果父亲为疑似药物的来源，则提供有关药物的其他信息（G.k.10）。病例叙述（H.1）应描述整个病例，包括父亲的信息。\n\n根据上述已知信息，请将'Example: Mother suffers from pre-eclampsia and, at parturition, the baby had a low birth weight and club foot. Two linked ICSRs should be submitted: The mother’s report should have the adverse event\/reaction of pre-eclampsia; the report for the baby should have event\/reaction terms for low birth weight and club foot. The term pre- eclampsia would only apply to the mother’s case. The data element C.1.10.r should be completed for both cases (e.g. the mother’s and baby’s).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"例如：母亲患有先兆子痫，分娩时婴儿的出生体重不足且患畸形足。应提交 2 个相关联的 ICSR：母亲的报告应包含先兆子痫的不良事件\/反应；婴儿的报告应包含低出生体重和畸形足的事件\/反应。先兆子痫术语仅适用于母亲的病例。应为 2份病例（即母亲和婴儿）完成数据元素C.1.10.r。"
    },
    {
        "instruction":"已知信息：\n'The specifications for excipients should be provided.'可被翻译为：应提供辅料的质量标准。\n'List of excipients'可被翻译为：辅料列表\n'4.LIST OF ABBREVIATIONS AND DEFINITION OF TERMS A list of the abbreviations, and lists and definitions of specialised or unusual terms or measurements units used in the report should be provided.'可被翻译为：4. 缩略语和术语定义表 应提供一份缩略语表，以及在报告中使用的专门或不 常见的术语或测量单位的列表和定义。\n'The product name used by the reporter should always be provided.'可被翻译为：应始终提供报告者使用的产品名称。\n\n根据上述已知信息，请将'A list of excipients used, the amount used, and their intended functions should be provided.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应列表体现所用辅料及其用量和预期功能。"
    },
    {
        "instruction":"已知信息：\n'{(Invented) name} contains approximately {x} IU ({y}IU\/{z}ml) of human coagulation factor VIII <(rDNA), {INN}> <after reconstitution>.'可被翻译为：<复原后>{（发明的）名称}包含约{x}IU({y}IU\/{z}ml)人类凝血因子VIII<(rDNA), {INN}>。\n'Human coagulation factor VIII is defined by the Ph. Eur. Monograph (0275) and human coagulation factor VIII (rDNA) by the Ph. Eur. Monograph (1643).'可被翻译为：人类凝血因子VIII和人类凝血因子VIII（rDNA）分别由欧洲药典专论（0275）和欧洲药典专 论（1643）定义。\n'The specific activity of {(Invented) name} is approximately {x} IU\/mg protein. <{INN} (human coagulation factor VIII (rDNA)) is a protein that has {x} amino acids [include any product specific modification].'可被翻译为：{（发明的）名称}的比活度为大约{x} IU\/mg 蛋白质。 <{INN}（人类凝血因子VIII (rDNA)）是一种含有{x}个氨基酸[包括任何药品特 有修饰]的蛋白质。\n'<No interactions of human coagulation factor VIII <(rDNA)> products with other medicinal products have been reported.'可被翻译为：<尚未有人类凝血因子VIII <(rDNA)>产品与其他药品相互作用的报道。\n\n根据上述已知信息，请将'Each {container} contains nominally {x} [as per labelled content] IU human coagulation factor VIII <(rDNA), {INN}>.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"每个容器内名义上含{x}[根据标示含量] IU人类凝血因子VIII<(rDNA),{INN}>。"
    },
    {
        "instruction":"已知信息：\n'It is noted that the test for HLA-B*1502 is most useful in certain Asian populations, e.g. Han Chinese and Thai patients, due to high NPV as well as a relatively high frequency of this allele in these populations.'可被翻译为：应当注意，HLA-B *1502的检测在某些亚洲人群（例如汉族和泰国）患者中是最有用的，这是由于高NPV以及这些人群中该等位基因的频率相对较高。\n'It is noted that the test for HLA-B*1502 is most useful in certain Asian populations (e.g. Han Chinese and Thai patients) due to high NPV as well as a relatively high frequency of this allele in these populations.'可被翻译为：研究发现HLA-B*1502检测在特定亚洲人群中(例 如，汉族和泰国患者)非常重要，因为这类群体NPV较高，且携带上述等位基因的概率 较高。\n'On the other side, almost no patients without the HLA-B*5701 allele will develop this adverse reaction, i.e. high negative predictive value (NPV) of 96% or 100%.'可被翻译为：另一方面，无HLA-B*5701等位基因的患者几乎不会发生这种不良反应，即96%或100%的高阴性预测值（NPV）。\n'On the other side, almost no patients who do not have the HLA-B*5701 allele will develop the adverse reaction (high negative predictive value, NPV, of 96% or 100%).'可被翻译为：相比而言， 未携带HLA-B*5701等位基因的患者几乎无人发生此类不良反应（高负预测值（ NPV） 96% 或 100%）。\n\n根据上述已知信息，请将'In certain ethnic groups of South East Asian origin (Han Chinese, Thai and Malays), HLA-B*15:02 is an important predisposing allele with a negative predictive value of 100%.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在东南亚裔的特定种族组中（汉 族人、泰国人和马来人），HLA-B*15:02是一种重要的诱病等位基因，阴性预测 值为100%。"
    },
    {
        "instruction":"已知信息：\n'For specific dosing techniques to apply the product to the membrane, refer to In Vitro Release Test (IVRT), Experimental Design, Dose.'可被翻译为：有关将产品应用于膜上的具体给药技术，请参阅体外释放试验(IVRT)，实验设计，剂量\n'For specific dosing techniques to apply the product to the skin, refer to the In Vitro Permeation Test, Experimental Design, Dose. Set the pump to the flow rate to be used for testing and align the outflow sample tubes (which should all be the same length) with the first set of vials or test tubes.'可被翻译为：有关将产品涂抹在皮肤上的具体剂量技术，请参阅体外渗透试验，实验设计，剂量。将泵设置为用于测试的流量，并将流出样管(应全部相同长度)与第一组小瓶或试管对齐。\n'The following test procedures apply to Direct Inoculation and Membrane Filtration:'可被翻译为：以下测试程序适用于直接接种和膜过滤法：\n'However, if the in vitro permeation of the active ingredient from the specific final formulation is greater than the value obtained from in vitro permeation testing of the standard 510 control formulation for that active ingredient, the formulation would not be considered GRASE.'可被翻译为：然而，某种含有活性成分的最终制剂在体外渗透试验中的结果大于对照制剂的结果，这个最终制剂不会认定为GRASE。\n\n根据上述已知信息，请将'For specific dosing techniques to apply the product to the membrane, refer to In Vitro Permeation Test, Experimental Design, Dose.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将产品应用于膜的具体给药技术，请参见体外渗透试验，实验设计，剂量"
    },
    {
        "instruction":"已知信息：\n'The perspectives of pharmacoeconomic evaluation and research mainly include the social perspective, the patient perspective, the medical institution perspective and the insurance perspective. Different research perspectives need to measure different ranges of costs and outputs.'可被翻译为：药物经济学评价和研究的视角，主要包括社会角度、患者角度、医疗机构角度和保险方角度。不同的研究角度需要测量的成本和产出范围不同。\n'On the basis of health economics, the application of modern economic means, combined with epidemiology, decision science, statistics and other disciplines of research results, comprehensive analysis of the cost-benefit or effect of different drug treatment programs and utility evaluation of their economic differences.'可被翻译为：以卫生经济学为基础，应用现代经济学手段，结合流行病学、决策学、统计学等学科研究成果，全方位地分析不同药物治疗方案的成本效益或效果及效用评价其经济上差别的一门学科。\n'Patient-reported outcomes and health related quality of life measures may be useful for the evaluation of treatment.'可被翻译为：患者报告的结果和健康相关的生活质量测量可能对治疗的评价有用。\n'Such data should be published by a reliable and independent source, e.g., a peer- reviewed scientific journal or the World Health Organization (WHO) (e.g., the International Agency for Research on Can- cer (IARC)).'可被翻译为：此类数据应由可靠和独立的来源，例如，同行评审的科学杂志或世界卫生组织 （WHO）发布（例如，国际癌症研究机构（IARC）））。\n\n根据上述已知信息，请将'An international organization dedicated to research on issues related to pharmacoeconomics, health outcomes evaluation, and public policy.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"致力于在药物经济学、健康产出评估和公共政策相关问题的研究的国际组织。"
    },
    {
        "instruction":"已知信息：\n'Data indicating that pharmacologically related compounds have similar effects in the two regions can be quite useful. 3'可被翻译为：用数据证明作用机制类似的化合物在两个地区 的药理作用相似是非常重要的。\n'Note that assessment of human exposure should take into consideration possible exposure to multiple drugs containing the same active agent (e.g., over-the-counter monograph active ingredients) or exposure to multiple agents having similar endocrine effects.'可被翻译为：请注意，评估人体暴露量时应考虑到可能存在多种含有相同活性成分的药物暴露（例如，非处方专论活性成分）或存在具有相似分泌作用的药物暴露。\n'It should be clear, if not defined in the study protocol, when, (relative to study unblinding), and how inclusion\/exclusion criteria for the data sets analysed were developed.'可被翻译为：如果在研究方案中没有定义，应该明确何时（相对于试验破 盲）以及如何制定分析数据集的入选\/排除标准。\n'For these compounds, the body surface area adjusted dose ratio was employed as a surrogate for the relative systemic exposure ratio.'可被翻译为：对于这些化合物，采用以体表面积调整 的剂量比值作为相对系统暴露量比值的替代指标。\n\n根据上述已知信息，请将'When 123 compounds in the expanded FDA database were analysed by this approach, a similar distribution of relative systemic exposures was observed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当以这一方法对FDA扩充数据库中的123个化合物 进行分析时，观察到一个类似的相对系统暴露量分布。"
    },
    {
        "instruction":"已知信息：\n'The description of an estimand should reflect the clinical question of interest in respect of these intercurrent events, and this addendum introduces strategies to reflect different questions of interest that might be posed.'可被翻译为：估计目标的描述应该反映出与这 些伴发事件相关的临床问题，并且本增补介绍了反映不同临床问 题的策略。\n'The construction of an estimand should consider what is of clinical relevance for the particular treatment in the particular therapeutic setting.'可被翻译为：构建一个估计目标，应该考虑在特定医疗环境下特定治疗的 临床相关性。\n'Precise specifications of treatment, population and variable are likely to address many of the intercurrent events considered in sponsor and regulator discussions of the clinical question of interest.'可被翻译为：其他伴发事件: 在申办方与监管机构关于相关临床问题的交 流中，治疗、人群和变量的精确说明有助于解决一些伴发事件。\n'A.3.1. Intercurrent Events to be Reflected in the Clinical Question of Interest Intercurrent events are events occurring after treatment initiation that affect either the interpretation or the existence of the measurements associated with the clinical question of interest.'可被翻译为：A.3.1. 临床问题中反映的伴发事件 伴发事件是指治疗开始后发生的事件，可影响与临床问题相 关的观测结果的解读或存在。\n\n根据上述已知信息，请将'The description of an estimand involves precise specifications of certain attributes, which should be developed based not only on clinical considerations but also on how intercurrent events are reflected in the clinical question of interest.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"估计目标的描述涉及特定属性的精确说明，这些属性不仅应 基于临床考虑而制定，还应基于所关注的临床问题中如何反映伴 发事件。"
    },
    {
        "instruction":"已知信息：\n'In most patients pain levels vary throughout the day, so that in chronic pain conditions twice daily (morning \/ evening) assessments are recommended.'可被翻译为：在大多数患者中，疼痛水平一整天都在变化着，因此在慢性疼痛情况下，建议每天两次（早上\/晚上）评估。\n'All of them have certain applicabilities and limitations. According to its duration pain can be described as acute or chronic.'可被翻译为：所有这些都有一定的适用性和局限性。根据疼痛持续时间疼痛可以描述为急性或慢性。\n'The chosen endpoint should be appropriate with regard to the pain characteristics (e.g. consistent, flaring or paroxysmal pain).'可被翻译为：所选择的终点应当适合于疼痛特征（例如，一致性、扩散性或突发性疼痛）。\n'Specific tools have been developed to evaluate pain intensity in children and should be used in clinical trials.'可被翻译为：已经开发了用于评价儿童疼痛强度的特定工具，并且应当用于临床试验。\n\n根据上述已知信息，请将'Assessments have to be adapted to the time course of pain (e.g. intermittent or paroxysmal, essentially constant with varying levels of intensity or single episode).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"评估必须适应疼痛的时间过程（例如间歇性或阵发性，随不同水平的强度或单次发作基本上是恒定的）。"
    },
    {
        "instruction":"已知信息：\n'In addition, immunophenotyping of leukocyte populations, a non-functional assay, can be conducted to identify the specific cell populations affected and might provide useful clinical biomarkers.'可被翻译为：另外，白细胞的免疫表型检测（非功能性试验）可用于鉴别受影响的细胞亚群，并可提供有用的临床生物标志物。\n'2.3 Immunophenotyping'可被翻译为：2.3 免疫表型分析\n'For immunomodulatory pharmaceuticals, additional endpoints (such as immunophenotyping by flow cytometry) might be included in the study design.'可被翻译为：对于免疫调节类药物， 试验设计可能包括附加的终点指标（如流式细胞术的免疫表型分 析）。\n'When immunophenotyping studies are used to characterize or identify alterations in specific leukocyte populations, the choice of the lymphoid organs and\/or peripheral blood to be evaluated should be based on changes observed. Immunophenotyping can be easily added to standard repeat dose toxicity studies and changes can be followed during the dosing phase and periods without drug exposure (reversal period).'可被翻译为：当采用免疫表型研究表征或鉴别特定白细胞群的改变时，应根据观察到的变化选择待评价免疫器官和\/或外周血。免疫表型研究易于结合常规重复给药毒性研究进行，在给药期和恢复期均可以检测免疫表型的变化。\n\n根据上述已知信息，请将'Immunophenotyping is the identification and\/or enumeration of leukocyte subsets using antibodies. Immunophenotyping is usually conducted by flow cytometric analysis or by immunohistochemistry.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"免疫表型分析指采用抗体进行白细胞亚型的鉴定和\/或白细胞亚型的计数。免疫表型试验通常采用流式细胞术或免疫组织化学方法。"
    },
    {
        "instruction":"已知信息：\n'Efficacy variables'可被翻译为：疗效变量\n'9.5.3 Primary Efficacy Variable(s) The primary measurements and endpoints used to determine efficacy should be clearly specified.'可被翻译为：9.5.3 主要疗效变量 应明确规定用于确定疗效的主要衡量指标和终点。\n'1. Establishing efficacy in key RA domains.'可被翻译为：1. 建立在关键RA领域的疗效。\n'2.Other domains.'可被翻译为：2. 其他方面。\n\n根据上述已知信息，请将'Efficacy variables should be specified for each of the three domains.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这三个方面都应明确疗效指标。"
    },
    {
        "instruction":"已知信息：\n'The quality system elements and management responsibilities described in ICH Q10 are intended to encourage the use of science-based and risk-based approaches at each lifecycle stage, thereby promoting continual improvement across the entire product lifecycle. Product and process knowledge should be managed from development through the commercial life of the product up to and including product discontinuation.'可被翻译为：ICH Q10所述的质量体系要素和管理职责意在鼓励在生命周期各阶段使用基于科学和基于风险的方法以促进药品在整个生命周期中持续改进。产品和工艺知识应从研发阶段开始进行管理，贯穿产品的整个商业化生命周期，直至产品退市。\n'The quality system elements and management responsibilities described in ICH Q10 are intended to encourage the use of science-based and risk-based approaches at each lifecycle stage, thereby promoting continual improvement across the entire product lifecycle.'可被翻译为：ICH Q10所述的质量体系要素和管理职责意在鼓励在生命周期各阶段使用基于科学和基于风险的方法，从而促进整个产品生命周期中的持续改进。\n'The quality systems and management responsibilities described in ICH Q10 are intended to encourage the use of science-based and risk-based approaches at each lifecycle stage, thereby promoting continual improvement across the entire product lifecycle.'可被翻译为：ICHQ10中所述的质量体系和管理职责旨在鼓励在生命周期的每个阶段都使用基于科学和风险的方法，从而促使药品整个生命周期的持续改进。\n'The quality system elements and management responsibilities described in this guideline are intended to encourage the use of science and risk based approaches at each lifecycle stage, thereby promoting continual improvement across the entire product lifecycle.'可被翻译为：本指导原则中阐述的质量体系要素和管理职责旨在鼓励在（产品）生命周期的每个阶段使用基于科学和风险的方 法，从而促进整个产品生命周期的持续改进。\n\n根据上述已知信息，请将'9.Lifecycle Management The quality system elements and management responsibilities described in ICH Q10 are intended to encourage the use of science-based and risk-based approaches at each lifecycle stage, thereby promoting continual improvement across the entire product lifecycle.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"9. 生命周期管理 ICH Q10描述的质量体系要素和管理职责，意在鼓励在 生命周期的每一个阶段使用基于科学和基于风险的方法，以 促进整个产品生命周期的持续改进。"
    },
    {
        "instruction":"已知信息：\n'In all cases it is essential to accumulate evidence to support a strong prediction of efficacy in the intended use(s) from PK\/PD analyses that are founded on a thorough documentation of in-vitro activity, non-clinical evidence of efficacy and relevant human PK data, which should include adequate PK data obtained from patients who are systemically ill with a range of types of infection in which the sponsor expects the new agent will need to be used.'可被翻译为：在所有情况下，必需要收集证据来支持从PK\/PD分析结果强烈预测用于预期用途的 疗效，PK\/PD分析结果来自于体外活性、非临床疗效证据及相关人体PK数据 等完整记录，这应该包括从患有一系列感染类型的全身疾病、申办方预期需要使用该新药的患者中获得的充分PK数据。\n'Assuming that the PK\/PD analyses strongly support an expectation of clinical efficacy against problematic MDR pathogens, the clinical programme should take into account the properties of the test antibacterial agent (e.g. spectrum of activity) and the unmet need it may be able to address.'可被翻译为：假设PK\/PD分析强烈支持对MDR病原体有临床疗效，临床开发项目应考虑试验抗菌剂的 特性（如抗菌谱）及该药可能解决的未被满足的治疗需求。\n'Following detailed PK\/PD analyses it may still be necessary to identify a suitable dose regimen and\/or duration of treatment from preliminary efficacy studies in one or more clinical indications.'可被翻译为：经过详细的 PK\/PD 分析之后，可能仍需要从一个或多个临床适应症的初步 疗效研究中找到适当的剂量方案和\/或治疗持续时间。\n'The overall assessment of the PK\/PD relationship should be sufficiently comprehensive to assess with reasonable confidence whether or not the test antibacterial agent, when used at an adequate dose regimen, would have useful clinical activity against relevant pathogens that appear to be susceptible in vitro.'可被翻译为：PK\/PD 关系的整体评估应足够全面， 以便有合理的信心评估该试验性抗菌剂 按充分的剂量方案使用时对于在体外试验中看起来敏感的相关病原体是否具有 有效的临床活性。\n\n根据上述已知信息，请将'This is considered to be essential since it is expected that in these situations the PK\/PD analyses will form a major part of the justification for the dose regimen and the expectation of clinical activity against the target pathogens.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这被认为是必需的，因为预期在这些情况下，PK\/PD分析将作为剂量方案和 针对靶病原体的临床活性的期望的合理依据之一。"
    },
    {
        "instruction":"已知信息：\n'As a result of the evaluations described above, a minimum systemic exposure ratio of 25 can be considered as a useful pharmacokinetic endpoint for high dose selection.'可被翻译为：根据上述分析结果，最小系统暴露量比值25，可用作为高剂量选择的药代动力学终点。\n'For exposure comparisons, a dose of 250 mg (10 mL) as a single dose was used for Cmax and a dose of 625 mg\/day oral solution was used for AUC since exposure was higher for the solution than for extended release capsules (FDA, United States 1986).'可被翻译为：对于暴露比较，单 次给药剂量250 mg（10 mL）被用于Cmax，口服液剂量625 mg\/day则被用于AUC，因溶液的暴露比缓释胶囊更高（美国FDA 1986）。\n'METHOTREXATE CAS No.: 59-05-2 Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAEL Dose Cmax AUC Rabbit LOAEL (Dose Cmax AUC Rabbit Findings Human Dosec Cmax AUC NOAEL Margins Notes NOAEL not identified 0.1 mg\/kg IP GD9 [Jordan, Woo] Cmax = 0.21 µg\/mLa AUC = 0.067 µg∙h\/mLa resorbed litters, malformations NOAEL not identified 0.3 mg\/kg IV GD10 [Jordan] Cmax = 1.58 µg\/mLb AUC = 0.61 µg∙h\/mLb hydrocephalus, microphthalmia, cleft lip and palate, micrognathia, dysplastic sacral and caudal vertebrate, phocomelia, hemimelia, syndactyly, and ectrodactyly; embryolethality, resorptions psoriasis: 10 – 25 mg Q7D (5.9 – 14.7 mg\/m2) oral or IVc ALL: induction – 3.3 mg\/m2 daily; maintenance – 15 mg\/m2 oral twice\/week choriocarcinoma: 15 – 30 mg oral QD 5 (8.8 – 17.6 mg\/m2) lymphoma: 10 – 25 mg QD 4-8 oral (5.9 – 14.7 mg\/m2); 0.625 – 2.5 mg\/kg (23 – 92.5 mg\/m2) mycosis fungoides: 5 – 50 mg Q7D oral (2.9 – 29 mg\/m2) RA: 7.5 mg Q7D oral (4.4 mg\/m2) Cmax = 2.14 µg\/mLd NOAEL: rat NOAEL not identified rabbit NOAEL not identified LOAEL: rat Cmax = 0.1 (0.21\/2.14) AUC = 0.02 (0.067\/3.28) rabbit Cmax = 0.7 (1.58\/2.14) AUC = 0.2 (0.61\/3.28)'可被翻译为：甲氨蝶呤 CAS号：59-05-2 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAEL 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 人剂量 Cmax AUC 暴露倍数 NOAEL\/人 LOAEL\/人 注释 未确定 NOAEL 0.1 mg\/kg IP GD9 [Jordan, Woo] Cmax=0.21 µg\/mLa AUC=0.067 µg∙h\/mLa 窝吸 收，畸 形 未确定 NOAEL 0.3 mg\/kg IV GD10 [Jordan] Cmax=1.58 µg\/mLb AUC=0.61 µg∙h\/mLb 脑积水、小 眼、唇腭 裂、小颌畸 形、尾骶尾 发育不良、 短肢畸形、 半肢、并 趾、缺趾； 胚胎致死 性，吸收胎 银屑病: 10-25 mg Q7D (5.9-14.7 mg\/m2) 口服或 IVc 急性淋巴细胞白血病 （ALL）：诱导–每天3.3 mg\/m2，维持–15 mg\/m2口 服，2次\/周 绒毛膜癌： 15–30 mg QD 口服×5 (8.8–17.6 mg\/m2) 淋巴瘤： 10–25 mg QD×4-8口服(5.9–14.7 mg\/m2)；0.625–2.5 mg\/kg (23 – 92.5 mg\/m2) 蕈样肉芽肿： 5–50 mg Q7D口服(2.9 – 29 mg\/m2) 类风湿性关节炎: 7.5 mg Q7D口服(4.4 mg\/m2) NOAEL: 大鼠 未确定 NOAEL 兔 未确定 NOAEL LOAEL: 大鼠 Cmax = 0.1 (0.21\/2.14) AUC=0.02 (0.067\/3.28) 兔 Cmax=0.7 (1.58\/2.14) AUC=0.2 (0.61\/3.28)\n'c: The dose of 500 mg\/m2 IV bolus was used for comparison although higher doses (e.g., ~1500 mg\/m2\/day CIV) are used.'可被翻译为：c：单次静脉推注给予500 mg\/m2的这个剂量被用于比较，尽管试验中也使用了更高的剂量（例如，~1500 mg\/m2\/天 CIV）。\n\n根据上述已知信息，请将'An intravenous dose of 25 mg (14.7 mg\/m2) in psoriasis was chosen for PK margin comparisons since this was the highest dose in a non-oncology indication and would also provide a higher exposure than a 50 mg (29 mg\/m2) oral dose (mycosis fungoides) since oral bioavailability is only ~40%.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"银屑病中的静脉给药剂量 25 mg（14.7 mg\/m2）被选择用 于PK倍数比较，因为这是非肿瘤适应症中的最高剂量，且也将能提供比口服给药（蕈样肉芽肿）50 mg（29 mg\/m2）更高的暴露，因为口服生物利用度 仅~40%。"
    },
    {
        "instruction":"已知信息：\n'4. Timeline history of core SmPC: The original core SmPC (CPMP\/BPWP\/859\/95) came into operation in September 1997. First revision (CPMP\/BPWP\/859\/95 rev.1) came into operation in December 2000. Second revision (CPMP\/BPWP\/859\/95 rev. 2) came into operation in November 2004. EMA\/CHMP\/BPWP\/94038\/2007 rev 3 came into operation in May 2011.'可被翻译为：核心SmPC的历史年表：最初的核心SmPC（CPMP \/ BPWP \/ 859 \/ 95）于1997 年9月开始生效。第一版（CPMP\/BPWP\/859\/95 rev.1）于2000年12月生效。第二 版（CPMP\/BPWP\/859\/95 rev. 2）于2004年11月生效。EMA\/CHMP\/BPWP\/94038\/2007 rev 3于2011年5月生效。\n'Timeline history of core SmPC: The original core SPC (CPMP\/BPWG\/1619\/99) came into operation in December 2000.'可被翻译为：核心SmPC的发展时间史：原始核心SPC（CPMP\/BPWG\/1619\/99）于2000年12 月生效。\n'Timeline history of core SmPC: The original core SPC (CPMP\/PhVWP\/BPWG\/2231\/99) came into effect in April 2001.'可被翻译为：SmPC 的历史年表：原核心 SPC（CPMP\/PhVWP\/BPWG\/2231\/99）于 2001 年 4 月生效。\n'The original core SPC (CPMP\/BPWG\/282\/00) came into operation in January 2003.'可被翻译为：最初的核心SPC（CPMP\/BPWG\/282\/00）于2003 年1月开始生效。\n\n根据上述已知信息，请将'Timeline history of core SmPC: The original core SmPC (CPMP\/BPWP\/153\/00) came into operation in January 2005.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"核心SmPC的大事年表历史：原核心SmPC（CPMP\/BPWP\/153\/00）于2005 年1月生效。"
    },
    {
        "instruction":"已知信息：\n'The perspectives of pharmacoeconomic evaluation and research mainly include the social perspective, the patient perspective, the medical institution perspective and the insurance perspective. Different research perspectives need to measure different ranges of costs and outputs.'可被翻译为：药物经济学评价和研究的视角，主要包括社会角度、患者角度、医疗机构角度和保险方角度。不同的研究角度需要测量的成本和产出范围不同。\n'pharmacoeconomic guidelines'可被翻译为：药物经济学指南\n'An international organization dedicated to research on issues related to pharmacoeconomics, health outcomes evaluation, and public policy.'可被翻译为：致力于在药物经济学、健康产出评估和公共政策相关问题的研究的国际组织。\n'Article 7 Enterprises, social organizations, education and research institutions and individuals are encouraged to participate in the formulation and revision of medical device standards and supervise their implementation.'可被翻译为：第七条 鼓励企业、社会团体、教育科研机构及个人广泛参与医疗器械标准制修订工作，并对医疗器械标准执行情况进行监督。\n\n根据上述已知信息，请将'Research standards and research reporting formats in pharmacoeconomics serve as guidelines for study design and implementation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物经济学的研究标准和研究报告格式，是研究设计和实施的指导。"
    },
    {
        "instruction":"已知信息：\n'Where a drug retailer sells drugs, it shall provide sales document indicating drug name, manufacturer, quantity, price, batch number, etc.'可被翻译为：药品零售企业销售药品时，应当开具标明药品名称、生产厂商、数量、价格、批号等内容的销售凭证。\n'Article 92 Enterprises shall take records of drug sales. Sales records shall include the adopted name, strength, dosage form, lot number, expiry date, manufacturer, purchaser, sales quantity, unit price, amount and sales date of the drug. Special sales records shall be established for the direct transfer of drugs in accordance with Article 69 herein.'可被翻译为：第九十二条 企业应当做好药品销售记录。销售记录应当包括药品的通用名称、规格、剂型、批号、有效期、生产厂商、购货单位、销售数量、单价、金额、销售日期等内容。按照本规范第六十九条规定进行药品直调的，应当建立专门的销售记录。\n'The sales records of Chinese crude drugs shall include the name of the product, strength, place of production, purchaser, sales quantity, unit price, amount and sales date; those of Prepared Slices shall include the name of product, strength, lot number, place of production, manufacturer, purchaser, sales quantity, unit price, amount and sales date, etc.'可被翻译为：中药材销售记录应当包括品名、规格、产地、购货单位、销售数量、单价、金额、销售日期等内容；中药饮片销售记录应当包括品名、规格、批号、产地、生产厂商、购货单位、销售数量、单价、金额、销售日期等内容。\n'(III) The records of dismantling sales shall be made, including the starting date of dismantling, adopted name, strength, lot number, manufacturer, and expiry date of drugs, sales quantity, sales date, dismantling and checking personnel, etc.;'可被翻译为：（三）做好拆零销售记录，内容包括拆零起始日期、药品的通用名称、规格、批号、生产厂商、有效期、销售数量、销售日期、分拆及复核人员等；\n\n根据上述已知信息，请将'Article 168 Enterprises shall issue the proof of sales for drugs, including drug name, manufacturer, quantity, price, lot number and strength, and make the sales records.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百六十八条 企业销售药品应当开具销售凭证，内容包括药品名称、生产厂商、数量、价格、批号、规格等，并做好销售记录。"
    },
    {
        "instruction":"已知信息：\n'A new method of multivariate statistical data analysis, first proposed by the Swedish econometrician H. Wolde in 1966, is the regression modeling method of multivariate variables to multi-independent variables. In metrology absorptiometry, it is a data processing method for multi-component analysis.'可被翻译为：由瑞典经济计量学家沃尔德（H.Wold）于1966年首次提出的一种新型多元统计数据分析方法，是多因变量对多自变量的回归建模方法。在计量学吸光光度法中，是一种用于多组分分析的数据处理方法。\n'A discipline developed in the middle of the 20th century, all equations and functions in the linear programming model are linear, and it is a method to solve the multi-variable optimal decision. It is a problem to solve or plan the linear objective function optimization of an object under various interrelated multi-variable constraints. In the metrology absorptiometry, it is a data processing method used for multi-component analysis.'可被翻译为：20世纪中期发展起来的学科,线性规划模式中的所有方程式及函数都是线性的，是解决多变量最优决策的方法，是在各种相互关联的多变量约束条件下，解决或规划一个对象的线性目标函数最优的问题。在计量学吸光光度法中，是用于多组分分析的一种数据处理方法。\n'A stoichiometric data processing method used in the analysis and detection of multi-component systems by metrological absorbance spectrophotometry.'可被翻译为：在计量学吸光光度法分析检测多组分体系时，采用的一种化学计量学数据处理方法。\n'Mathematical model or computational model based on the principle of biological neural network. It is a dynamic system with a topological structure of a directed graph built manually, and it processes information by responding to continuous or discontinuous input. Absorptiometry in metrology'可被翻译为：基于生物神经网络原理的数学模型或计算模型。是由人工建立的以有向图为拓扑结构的动态系统，通过对连续或断续地输入作状态响应而进行的信息处理。在计量学吸光光度法\n\n根据上述已知信息，请将'In metrology absorptiometry, a data processing method used for multi-component analysis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在计量学吸光光度法中，对多组分分析时采用的一种数据处理方法。"
    },
    {
        "instruction":"已知信息：\n'No other studies have been conducted with ZB3579.'可被翻译为：未使用ZB3579进行其他研究。\n'There have been no literature articles citing ZB3579 during the period under review.'可被翻译为：本次报告期间，未发现引用ZB3579的文献。\n'APPENDIX 7 SCIENTIFIC ABSTRACTS \nNo presentations relevant to ZB3579 were made during the period under review.'可被翻译为：附录7 文献\/论文摘要 \n无本报告周期内与ZB3579相关的科学文献。\n'Observational or epidemiological studies;'可被翻译为：观察性研究或流行病学研究；\n\n根据上述已知信息，请将'No observational or epidemiological studies of ZB3579 have been initiated, conducted, completed or reported during the period under review.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在本报告周期内，未启动、进行、完成或报告ZB3579的观察性 或流行病学研究。"
    },
    {
        "instruction":"已知信息：\n'Article 77: Lubricant and refrigerant etc. used in the equipment should not contaminate products or containers. Food grade or equivalent lubricant should be used whenever possible.'可被翻译为：第七十七条 设备所用的润滑剂、冷却剂等不得对药品或容 器造成污染，应当尽可能使用食用级或级别相当的润滑剂。\n'5.14 Any substances associated with the operation of equipment, such as lubricants, heating fluids or coolants, should not contact intermediates or APIs so as to alter their quality beyond the official or other established specifications. Any deviations from this should be evaluated to ensure that there are no detrimental effects upon the fitness for purpose of the material. Wherever possible, food grade lubricants and oils should be used.'可被翻译为：5.14 设备所需的润滑剂、加热或冷却介质等，不应当与中间产品或原料药直接接触，以免影响中间体或原料药的质量。当任何偏离上述要求的情况发生时，应当进行评估，确保不会对物料的预期用途造成不利影响。应当尽可能使用食用级润滑剂和润滑油。\n'lubricant'可被翻译为：润滑剂\n'lubricant'可被翻译为：滂沱剂\n\n根据上述已知信息，请将'Article 77 Lubricant and refrigerant etc. used in the equipment should not contaminate products or containers. Food grade or equivalent lubricant should be used whenever possible.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十七条 设备所用的润滑剂、冷却剂等不得对药品或容器造成污染，应当尽可能使用食用级或级别相当的润滑剂。"
    },
    {
        "instruction":"已知信息：\n'Class V membranous lupus nephritis,'可被翻译为：V 型为膜性狼疮性肾炎，\n'This classification is superceded by the Renal Pathology Society Working Group and the International Society of Nephrology Working Group (ISN\/RPS Criteria from 2003) classification where six classes of lupus nephritis are described:'可被翻译为：这一分类被肾脏病理学会工作组和国际肾病学会工作组（ISN\/RPS 标准，2003）的分类法替代，新的分类中狼疮性肾炎分为 6 个类型：\n'Class II mesangial proliferative lupus nephritis,'可被翻译为：II 型为系膜增生性狼疮性肾炎，\n'Class III focal lupus nephritis,'可被翻译为：III 型为局灶性狼疮性肾炎，\n\n根据上述已知信息，请将'e.g. Classes of LN, such as proliferative glomerulonephritis (ISN\/RPS 2003 Class III or IV) or membranous nephritis (ISN\/RPS 2003 Class V);'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如狼疮性肾炎的分类中的增生性肾小球肾炎（ISN\/RPS 2003 III 或 IV 类）或膜性肾病（ISN\/RPS 2003 V 类）；"
    },
    {
        "instruction":"已知信息：\n'For confirmatory trials, an acceptable primary end point is time to need for radical therapy, or proportion of patients in need for such therapy at a predefined point in time.'可被翻译为：对于验证性试验，可接受的主要终点是至需要进行放疗的时间，或是在某个预定时间需要进行放疗的患者比例。\n'The choice of alternative time-points for primary or secondary endpoints may also be acceptable if fully justified, for example if a response to treatment is expected to occur earlier during therapy Long term follow up of at least 8+ years is expected.'可被翻译为：如果有充分依据，选择其它时间点作为主要或者次要终点也是可接受的，例如如果预期治疗反应会治疗期间的更早时候出现，预期需进行至少 8 年多的随访。\n'In cases where induction is followed by consolidation and\/or maintenance therapy, confounding effects of therapies administered after the end of experimental therapy may make endpoints other than PFS or EFS more appropriate. This means that CR (and CR + PR, if specifically justified) after end of experimental therapy could be an acceptable primary endpoint when further therapy is scheduled. In these cases, the possible influence of the experimental compound on the activity of consolidation therapy should always be addressed and outcomes with respect to CR should be supported by EFS or PFS data.'可被翻译为：如果在诱导后实施巩固治疗和\/或维持治疗，在试验治疗结束后服用的疗法的混杂疗效 可能会使得终点比 PFS 或 EFS 更适合。这意味着当计划实施进一步的治疗时， 在试验疗法结束后的 CR（若已具体证实，则为 CR+PR）可作为可接受的主要终点。 在这种情况下，试验化合物对巩固治疗活性的潜在影响应适当进行处理，并且有关 CR 的结局应有 EFS 或 PFS 数据支持。\n'A major increase in CR after induction therapy associated with trends in PFS or EFS, and survival, however, might be sufficient if scheduled treatments administered after the end of the experimental therapy are likely to confound overall outcome. This is of special relevance if the target population is small.'可被翻译为：如果在试验治疗结束后施加的预期治疗有可能混淆整体结局，那么在与 PFS、EFS 和生存趋势相关的诱导疗法结束后 CR 的大量增加应已足够。如果目标人群很小时， 这特别相关。\n\n根据上述已知信息，请将'This means that CR (and CR + PR, if specifically justified) after end of experimental therapy could be an acceptable primary endpoint when further therapy is scheduled.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这意味着当计划进行进一步的治疗时， 在实验性治疗结束后的CR（和CR+PR，如果是特别合理的）可能是可接受的主要终点。"
    },
    {
        "instruction":"已知信息：\n'In accordance with the results of AD Revaluation, to further protect drug safety for the people, NMPA issued an Announcement on June 9, 2020, with decisions made to uniformly revise the [adverse reactions],[contraindications] and [precautions] in the package inserts of Chuanbei Pipa Preparations (including syrups, ointments, granules, tablets and capsules).'可被翻译为：根据药品不良反应评估结果，为进一步保障公众用药安全，国家药品监督管理局于2020年6月9日发布公告，决定对川贝枇杷制剂（包括糖浆剂、膏剂、颗粒剂、片剂、胶囊剂）说明书【不良反应】【禁忌】和【注意事项】项进行统一修订。\n'NMPA Issued the Announcement on Revising the Package Inserts of Prescription and Over-the-counter Oral Preparations such as Huoxuezhitong Capsules'可被翻译为：国家药监局关于修订活血止痛胶囊等口服制剂处方药和非处方药说明书的公告\n'NMPA Announcement on Revising the Package Inserts of Sulfasalazine Preparations'可被翻译为：国家药监局关于修订柳氮磺吡啶制剂说明书的公告\n'Announcement of NMPA on Revising the Package Inserts of Probucol'可被翻译为：国家药监局关于修订普罗布考说明书的公告\n\n根据上述已知信息，请将'NMPA Issues Announcement on Revising Package Inserts of Chuanbei Pipa Preparations'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于修订川贝枇杷制剂说明书的公告"
    },
    {
        "instruction":"已知信息：\n'c. Phase 2 trials with combination DAA regimens'可被翻译为：c. DAA联合治疗方案II期临床试验\n'In general, phase 2 trial designs should be randomized comparisons of several different DAA combinations (all investigational or approved plus investigational) at various doses and treatment durations.'可被翻译为：总的来说，II期临床试验设计应为多种不 同DAA联用方案（所有尚在研究的药物或已批准的药物加尚在研究的药物）在 不同剂量和疗程下的随机比较。\n'The following recommendations and examples are provided for potential phase 1 and phase 2 trial designs for HCV DAAs based on the current state of the field.'可被翻译为：下文提供了基于目前研究现状的HCV DAA的可能的I期和II期临床试验设计 的建议和例子。\n'Specifically, for an end-of-phase 2 meeting, SVR4 data from all enrolled patients in key supporting phase 2 trials, and all available SVR12 (or longer) data from phase 2 trials should be submitted to support progression to phase 3.'可被翻译为：具体来讲，对于II期临床试验结束会议，应提交来自关键支撑性II期 临床试验的所有入组受试者的SVR4数据和来自II期临床试验所有可用SVR12（或 更长）数据，以支持进入III期临床试验。\n\n根据上述已知信息，请将'The following information is recommended to support phase 2 trials of multiple DAAs:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"推荐以下信息来支持多种DAA的II期临床试验："
    },
    {
        "instruction":"已知信息：\n'·Is the product a variant of something already used in this environment (i.e., extended-release dosage form of immediate release product)? Do the products have characteristics that might make the variation between these products difficult to distinguish, allowing possible errors to go undetected?'可被翻译为：·在此环境下，是否有药品的不同剂型在使用（如，速释制剂的缓释剂型）？这些药品是否有一些很难区分药品差异特征，未被发现而可能引起潜在失误？\n'Are other, similar products also used within this environment (e.g., same or similar drug class, same or similar packaging design)?'可被翻译为：其他类似产品是否也在这种环境中使用（例如，相同或相似的药物类别、相 同或类似的包装设计）？\n'An extended release drug product is a dosage form that allows a reduction in dosing frequency and reduces fluctuations in plasma concentrations when compared to an immediate release dosage form. Extended release products can be formulated as capsules, tablets, granules, pellets, or suspensions. If any part of a drug product includes an extended release component, the product should be treated as a modified release dosage form for the purposes of establishing BE, as specified below.'可被翻译为：缓释制剂与常释制剂相比，给药频率低，血药浓度波动小。缓释制剂包括胶囊、片剂、颗粒剂或混悬液等。如果药物的某个部分包含一种缓释成分，则该药物应被视为非常释制剂，并据此进行如下所述的BE研究。\n'Dissolution with HPLC as product performance test for an immediate release dosage form'可被翻译为：通过HPLC测定溶出度作为速释制剂性能试验\n\n根据上述已知信息，请将'Is the product a variant of something already used in this environment (e.g., extended release dosage form of an existing immediate release product)?'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"该产品是否是在这种环境中已经使用的产品的变体（例如，现有速释产品的 缓释剂型）？"
    },
    {
        "instruction":"已知信息：\n'A method of measuring health or utility on a scale.'可被翻译为：采用刻度尺测量健康状态或效用的方法。\n'ordinal utility'可被翻译为：序数效用\n'The analysis should show the size (point estimate) of the difference between the treatments, the associated confidence interval, and where utilised, the results of hypothesis testing.'可被翻译为：分析应该显示临床治疗之间差异 的大小（点估计）、相关的置信区间以及假设检验的结果。\n'Utilities should be designed, installed, qualified, operated, maintained and monitored in a manner to ensure that the utility system functions as expected.'可被翻译为：公用设施的设计、安装、确认、操作、维护和监测方式应确保该公用设施系统按预期运行。\n\n根据上述已知信息，请将'A representation of utility in which preferences are reflected in a ranking, where the size of the difference between the ranked utilities is meaningless.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用排序来反映偏好的一种效用表示方法，排列成序的效用间的差距大小没有意义。"
    },
    {
        "instruction":"已知信息：\n'However, in practice, it is very important to choose a questionnaire which addresses the key domains of the disease and is sensitive to reflect clinically meaningful changes.'可被翻译为：但在实际操作中，选择一种涉及该疾病的关键问题并且能够灵敏地反映出临床上有意义的变化的问卷，是非常重要的。\n'The level of improvement to be met should be pre-defined, be clinically meaningful and the results should be statistically significant.).'可被翻译为：需要满足的改善水平应该是预先确定的、具有临床有意义，结果应该具有统计学意义。\n'The functional form that relates the covariates to the outcome should be pre-specified and justified in the protocol.'可被翻译为：使协变量与结果相关联的函数形式应当在方案中事先指定，并说明理由。\n'The change in pharmacokinetics that can be expected to be clinically relevant should preferably be prospectively defined and should, if possible, be justified on the basis of concentration-response relationship of the parent drug and\/or its metabolites.'可被翻译为：可以预期应当优先定义在临床上相关的药代动力学的变化，如可能，应该基于母体药物和\/或其代谢物的浓度-反应关系来证明。\n\n根据上述已知信息，请将'A clinically relevant change in pre-specified domains (dimensions) of QoL should be defined and justified in the study protocol.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究方案应对QoL预先指定的方面（纬度）的临床相关变化进行定义并证明其合理性。"
    },
    {
        "instruction":"已知信息：\n'Those most relevant instruments can be selected to best match the product in development and the patient population to be studied.'可被翻译为：可选择这些相关的量表，与开发产品和研究的患者人群进行最佳匹配。\n'This requires reliable and valid measurement tools for the studied patient population in the specific stages of the disease.'可被翻译为：对于考察的处于具体疾病阶段的患者人群，要求可靠、经过验证的测量工具。\n'Hence, the precise definition of highly active disease should be stated and justified in the study protocol.'可被翻译为：因此，高疾病活动性的确切定义应在临床方案中规定并证明合理。\n'Separate measurement tools of ADL\/IADL for early and advanced disease stages are needed, and a version of the ADSC-ADL has been already adapted for MCI.'可被翻译为：对于 期和晚期疾病阶段，需要采用单独的 ADL\/IADL 评价工具，对于 MCI，已经采用了一个ADSC-ADL 版本。\n\n根据上述已知信息，请将'As many others are under further evaluation, the choice of the instrument for assessment and its applicability for early or advanced disease stages should be justified in the study protocol.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由于很多工具正在进一步研究中，因此对方案中评价工具的选择及其工具对疾病 期或晚期的适用性，需要阐述其合理性。"
    },
    {
        "instruction":"已知信息：\n'Applicant – “Applicant” means the party who submits a marketing application to FDA for approval of a drug, device or biologic product or who submits a reclassification petition. The applicant is responsible for submitting the required certification and disclosure statements. (See 21 CFR § 54.2(g).)'可被翻译为：申请人-“ 申请人 ”是指向 FDA 提交一项关于药品、器械或生物制剂的上市 申请批准， 或者提交一份再分类请求的一方。 申请人负责提交要求的证明和披露 声明。（参见 21 CFR § 54.2（g）。）\n'Article 10 An applicant for drug registration (hereinafter referred to as applicant) refers to the institution that submits a drug registration application and assumes corresponding legal liability.'可被翻译为：第十条 药品注册申请人（以下简称申请人），是指提出药品注册申请并承担相应法律责任的机构。\n'See section 505(o)(3)(A), 505(o)(3)(B), and 505(o)(3)(E)(ii) of the FD&C Act (21 U.S.C. 355(o)(3)(A), (B), and (E)(ii)).'可被翻译为：见FD&C法案的505(o)(3)(A)、505(o)(3)(B) 和505(o)(3)(E)(ii)（21 U.S.C. 355(o)(3)(A), (B),和(E)(ii)）。\n'Section 119(a) of the Food and Drug Administration Modernization Act of 1997 (FDAMA) amended section 505(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(b)) and directed FDA to meet with sponsors who request to meet, provided certain conditions are met, to reach agreement on the design and size of the well-controlled clinical trials intended to form the primary basis for a demonstration of effectiveness in a marketing application submitted under section 505(b) of the FD&C Act or section 351 of the Public Health Service (PHS) Act (42 U.S.C. 262).'可被翻译为：1997年《食品药品管理局食品安全现代化法案（FDAMA）》第119(a)节修正 了《联邦食品、药品和化妆品法案》（FD&C法案）（21 U.S.C 355(b)）第505(b) 节，使FDA符合申办方要求，如果满足某些条件，则使FDA就旨在成为在FD&C 法案第505(b)节或《公共健康服务（PHS）法》（42 USC 262）第351节下递交 的上市申请的有效性证明的主要基础的控制良好的临床试验的设计和规模达成 同意。\n\n根据上述已知信息，请将'9 The Medication Guide regulations refer to manufacturers. For purposes of this guidance discussing Medication Guides in the context of the FD&C Act as amended by the FDAAA, we use the term applicant to include “holder of an approved covered application” in section 505-1 of the FD&C Act and “responsible person” in section 505(o)(4) of the FD&C Act (21 U.S.C. 355(o)(4)).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"9见用药指南法规指的是生产商。本指南讨论的是用药指南由FDAAA修订的FD&C法案的内容，我们使用的术语申请人包括FD&C法案505-1部分中的“已批准申请的持有人”和FD&C法 案（21 U.S.C. 355（o）（4））第505（o）（4）部分中的“责任人”。"
    },
    {
        "instruction":"已知信息：\n'2. A near UV fluorescent lamp having a spectral distribution from 320 nm to 400 nm with a maximum energy emission between 350 nm and 370 nm; a significant proportion of UV should be in both bands of 320 to 360 nm and 360 to 400 nm.'可被翻译为：2. 近紫外荧光灯应具有320～400nm的光谱范围， 并在350～370nm有最大发射能量；在320～360nm及360～ 400nm二个谱带范围的紫外光均应占有显著的比例。\n'1. A cool white fluorescent lamp designed to produce an output similar to that specified in ISO 10977(1993) ; and'可被翻译为：1. 冷白荧光灯应具有ISO10977（1993）所规定的类似输出功率。\n'D65 is the internationally recognized standard for outdoor daylight as defined in ISO 10977 (1993).'可被翻译为：D65是国际认可的室外日光标准[ISO 10977(1993)]。\n'For option 2 the same sample should be exposed to both the cool white fluorescent and near ultraviolet lamp.'可被翻译为：相同的样品应同时暴露于冷白荧光灯和近紫外灯下。\n\n根据上述已知信息，请将'Any light source that is designed to produce an output similar to the D65\/ID65 emission standard such as an artificial daylight fluorescent lamp combining visible and ultraviolet (UV) outputs, xenon, or metal halide lamp.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"采用任何输出相似于D65\/ID65发射标准的光源，如具 有可见-紫外输出的人造日光荧光灯、氙灯或金属卤化物灯。"
    },
    {
        "instruction":"已知信息：\n'Cr(3+), the most abundant environmental form, is an essential element that plays a role in glucose metabolism.'可被翻译为：Cr（3+） 是环境中存在的最广泛的形式，是参与葡萄糖代谢的一种必需元素。\n'Blood lipid levels may be affected by other clinical conditions such as diabetes mellitus, thyroid disorders or nephrotic syndrome; in such cases, the lipid levels should be reassessed once the underlying disease has been controlled or treated.'可被翻译为：血脂水平可能受其他临床病症的影响，如糖尿病、甲状腺疾病或肾病综合征；在这种情况下，一旦控制或治疗了基础疾病 应重新评估血脂水平。\n'In 2020, according to the statistics of drug categories, for chemical drugs and biological products in the National Essential Drugs List, the top 5 drugs in terms of the number of reports were antimicrobial drugs, drugs for cardiovascular diseases, antineoplastic drugs, drugs for hormone and drugs for impacting endocrine system and drugs for treating mental disorders; the top 5 involved organs and systems were gastrointestinal disorders, skin and subcutaneous tissue diseases, systemic diseases and various reactions at the site of administration, nervous system disorders and examinations.'可被翻译为：2020年国家基本药物化学药品和生物制品不良反应\/事件报告按照药品类别统计，报告数量排名前5位的分别是抗微生物药、心血管系统用药、抗肿瘤药、激素及影响内分泌药、治疗精神障碍药；累及器官系统排名前5位的是胃肠系统疾病、皮肤及皮下组织类疾病、全身性疾病及给药部位各种反应、各类神经系统疾病以及各类检查。\n'• General pharmacology (cardiovascular, including QT interval prolongation; nervous system; etc.);'可被翻译为：安全药理学（心血管，包括 QT 间期延长；神经系 统；等等）；\n\n根据上述已知信息，请将'Chromium deficiency causes changes in the metabolism of glucose and lipids and may be associated with maturity-onset diabetes, cardiovascular diseases, and nervous system disorders (Anderson, 1993, 1995).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"铬缺乏可导致葡萄糖和脂类代谢的改变，并与成年糖尿病、心血管疾病和神经系统疾病有关 [1,2]。"
    },
    {
        "instruction":"已知信息：\n'The drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government shall be responsible for organizing the sampling of products subject to lot release for production or importation within their respective administrative regions, formulating sampling management procedures in accordance with the drug sampling regulations of the NMPA, determining relatively fixed sampling institutions and personnel to file at the lot release institutions, training the sampling institutions and personnel and conducting supervision and guidance for sampling work.'可被翻译为：省、自治区、直辖市药品监督管理部门负责组织本行政区域生产或者进口的批签发产品的抽样工作，按照国家药品监督管理局药品抽样规定制定抽样管理程序，确定相对固定的抽样机构和人员并在批签发机构备案，定期对抽样机构和人员进行培训，对抽样工作进行督查指导。\n'Food and drug regulatory departments of all provinces, autonomous regions and municipalities directly under the Central Government shall be responsible for routine regulation of the applicants for lot release within their respective administrative regions, assisting the lot release institutions in conducting on-site inspection, organizing on-site sampling of products subject to lot release, disposal of products failing to pass lot release as well as investigation and handling of violations in the lot release process.'可被翻译为：省、自治区、直辖市食品药品监督管理部门负责本行政区域批签发申请人的日常监管，协助批签发机构开展现场核实，组织批签发产品的现场抽样及批签发不合格产品的处置，对批签发过程中发现的违法违规行为进行调查处理。\n'Article 14 The lot release applicant shall propose a sampling application to the food and drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government or the sampling institutions designated thereby by virtue of the Application Form for Lot Release of Biological Products; sampling personnel shall organize on-site sampling within 5 days, and seal the samples. The lot release applicant shall be responsible for delivering the sealed samples under the stipulated conditions to the lot release institution to handle registration for lot release, and shall also submit lot release application dossiers.'可被翻译为：第十四条 批签发申请人凭生物制品批签发申请表向省、自治区、直辖市食品药品监督管理部门或者其指定的抽样机构提出抽样申请，抽样人员在5日内组织现场抽样，并将所抽样品封存。批签发申请人将封存样品在规定条件下送至批签发机构办理批签发登记，同时提交批签发申请资料。\n'Article 14 The lot release applicant shall propose a sampling application to the drug regulatory departments of provinces, autonomous regions or municipalities directly under the Central Government or the sampling institutions designated thereby by virtue of the Application Form for Lot Release of Biological Products; sampling personnel shall organize on-site sampling within 5 days, and seal the samples. The lot release applicant shall be responsible for delivering the sealed samples under the stipulated conditions to the lot release institution to handle registration for lot release, and shall submit lot release application dossiers at the same time.'可被翻译为：第十四条    批签发申请人凭生物制品批签发申请表向省、自治区、直辖市药品监督管理部门或者其指定的抽样机构提出抽样申请，抽样人员在5日内组织现场抽样，并将所抽样品封存。批签发申请人将封存样品在规定条件下送至批签发机构办理批签发登记，同时提交批签发申请资料。\n\n根据上述已知信息，请将'Food and drug regulatory departments of all provinces, autonomous regions and municipalities directly under the Central Government shall be responsible for organizing the sampling of products subject to lot release for production or importation within their respective administrative regions, determining relatively fixed sampling institutions and personnel to file at the lot release institutions, training the sampling institutions and personnel and conducting supervision and guidance for sampling work.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"省、自治区、直辖市食品药品监督管理部门负责组织本行政区域生产或者进口的批签发产品的抽样工作，确定相对固定的抽样机构和人员并在批签发机构备案，定期对抽样机构和人员进行培训，对抽样工作进行督查指导。"
    },
    {
        "instruction":"已知信息：\n'The validation study should be documented.'可被翻译为：验证研究应被记录。\n'The results of the validation study should be summarised in a validation report.'可被翻译为：验证研究的结果应总结在验证报告中。\n'A brief summary of the justification of the specification(s), a summary of the analytical procedures and validation, and characterisation of impurities should be provided.'可被翻译为：应提供质量标准制定依据的简要总结，以及对分析方法及方法学验证、杂质分析的总结。\n'A tabulated summary of the batch analyses from 3.2.S.4.4, with graphical representation where appropriate, should be provided.'可被翻译为：应提供3.2.S.4.4中的批分析汇总表，必要时提供相应的图示。\n\n根据上述已知信息，请将'Where validation is still to be completed, a summary of the studies intended to be conducted should be provided.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当验证尚未完成时，应提供拟开展的研究综述。"
    },
    {
        "instruction":"已知信息：\n'With respect to diagnosis, criteria for initiation of treatment, eligibility, response criteria and choice of reference therapy, a justification based on scientific evidence and\/or generally acknowledged and updated treatment guidelines are expected. While this is true in general, it is also expected that the exploratory studies through the judicious use of biomarkers provide guidance with respect to selection of patients in order to optimise benefit – risk, whether patient selection is in need for confirmation or not, in the planned phase III trials.'可被翻译为：就诊断、起始治疗标准、合格性、缓解标准以及对照治疗而言，预期以科学证据和\/或公认的且不断更新的治疗指导原则为基础进行证明。虽然这在一般情况下都是对的，但还是预期通过判断性使用生物标记物开展探索研究，提供有关患者选择的指导内容，从而优化获益-风险，不论在计划的 III 期试验中患者选择是否需要确认。\n'It is particularly important to perform specific trials, or at least to stratify patients based on baseline characteristics such as tumour histology and expression of predictive molecular biomarkers. Such markers help delineate distinct disease entities, enriching the patient population to those with the target of interest and defining subsets of patients most likely to benefit from therapy. However, the success of such an approach depends heavily on having an accurate diagnosis.'可被翻译为：进行特定的试验或者至少进行基于基线特征（如肿瘤组织学和有预测作用的分子标志物表达）的患者分层尤其重要。这些标志物有助于描述独特的疾病本质，丰富所关注的靶标人群，并确定最有可能从治疗中获益的患者子集。但是，这种方法的成功性很大程度上依赖于准确的诊断。\n'Subsequently, the same applies to confirmatory trials which must restrict inclusion to categories of patients with clinical and molecular characteristics that increase the likeliness of response and hence clinical benefit.'可被翻译为：其次，这种方法同样适合于对临床和分子学特征的分类有严格入选标准，以提高产生治疗反应和临床获益的可能性的验证性研究。\n'Exploratory trials should clearly test hypotheses of activity in accordance with known or presumed biological roles of their intended molecular targets.'可被翻译为：探索性试验应根据预期分子学靶标的已知或假设的生物学功能，清晰地检验关于药物活性的假设。\n\n根据上述已知信息，请将'Exploratory trials should clearly test hypotheses of activity in accordance with known or presumed biological roles of their intended molecular targets. For this purpose, trial subjects must be constituted by patients with disease that is well characterized according to relevant biomarkers. Subsequently, the same applies to confirmatory trials which must restrict inclusion to categories of patients with clinical and molecular characteristics that increase the likeliness of response and hence clinical benefit.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"探索性试验应根据预期分子学靶标的已知或假设的生物学功能，清晰地检验关于药物活性的假设。由于这个目的，试验的受试者必须是已充分了解该病的相关生物标志物的患者。其次，这种方法同样适合于对临床和分子学特征的分类有严格入选标准，以提高产生治疗反应和临床获益的可能性的验证性研究。"
    },
    {
        "instruction":"已知信息：\n'The information related to the outcome of the reaction(s)\/event(s) is noted in E.i.7 - Outcome of Reaction \/ Event at the Time of Last Observation.'可被翻译为：与反应\/事件的结果相关的信息在E.i.7中-在最后一次观察时的反应\/事件的结果。\n'E.i.5 Date of End of Reaction \/ Event'可被翻译为：E.i.5反应\/事件结束日期\n'If the reaction(s)\/event(s) do not recur after reintroducing the drug, G.k.9.i.4 Did Reaction Recur on Re-administration? would be set to 2 (rechallenge was done, reaction did not recur) and E.i.7 – Outcome of Reaction \/ Event at the Time of Last Observation would be set to 1 = recovered\/resolved.'可被翻译为：如果再次用药后反应\/事件不再发生，G.k.9.i.4再次用药后反应\/事件是否再次发 生？应该为2（再次用药，反应没有发生）和E.i.7–在最后一次观察时的反应\/事 件的结果应该为1 =恢复\/解决。\n'E.i.7 Outcome of Reaction \/ Event at the Time of Last Observation User Guidance This data element captures the latest outcome of the reaction \/ event at the time of the report. In case of irreversible congenital anomalies, the choice not recovered\/not resolved\/ongoing should be used. For other irreversible medical conditions, recovered\/resolved with sequelae should be used. Fatal should be used when death is possibly related to the reaction\/event. Considering the difficulty of deciding between ‘reaction\/event caused death’ and ‘reaction\/event contributed significantly to death’, both concepts are grouped in a single category. Where the death is unrelated to the reaction\/event, according to both the reporter and the sender, ‘fatal’ should NOT be selected here; nevertheless, death should be reported under Section D.9.'可被翻译为：E.i.7末次观察时的反应\/事件的结果 用户指导原则 该数据元素获取报告时反应元素\/事件的末次结果。 在不可逆转的先天性异常的情况下，应使用未好转\/未缓解\/正在进行的选项。对于其他不可逆转疾病，应使用好转\/缓解且不伴后遗症。 当死亡可能与反应\/事件相关时，应使用致死性。考虑到在“反应\/事件导致的死亡”和“反应\/事件对死亡有显著影响”之间很难做出决定，这2个概念被分入单一类别。当死亡与反应\/事件无关时，根据报告者和发送者提供的信息，在此处不应该选择“致死性”但是，应在第D.9节报告死亡。\n\n根据上述已知信息，请将'E.i.7 Outcome of Reaction \/ Event at the Time of Last Observation'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"E.i.7末次观察时的反应\/事件的结果"
    },
    {
        "instruction":"已知信息：\n'Fab-associated functions (e.g. neutralization of a soluble ligand, receptor activation or blockade)'可被翻译为：Fab相关功能（例如可溶性配体的中和、受体激活或阻断）\n'Fc-associated functions (e.g. antibody-dependent cell-mediated cytotoxicity, ADCC; complement-dependent cytotoxicity, CDC; complement activation) Target-mediated disposition may be seen with MoAbs.'可被翻译为：Fc相关功能（例如抗体依赖细胞介导的细胞毒性作用，ADCC；补体563依赖的细 胞毒性，CDC；补体激活） 单克隆抗体的应用可观察到靶点介导的沉积。\n'A mode of receptor regulation in which a ligand acts on its specific receptor, causing a ligand to act on its own receptor, causing a change in its own receptor.'可被翻译为：配体作用于其特异性受体，使自身的受体发配体作用于其特异性受体，使自身的受体发生变化的-种受体调节方式。\n'A compound or drug that binds to a receptor of some endogenous ligand and exhibits the action of that ligand substance.'可被翻译为：能与某些内源性配体的受体结合，并呈现该配体物质作用的化合物或药物。\n\n根据上述已知信息，请将'3. Fab-associated functions (e.g. neutralization of a soluble ligand, receptor activation or blockade)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"与 Fab 相关的功能（如可溶性配体中和、受体活化或拮抗）"
    },
    {
        "instruction":"已知信息：\n'Well known examples of such interfering substances are complement components, mannose binding protein, Fc receptors, soluble target molecules, complement receptor 1 and rheumatoid factors, but other substances including the product itself can also cause problems.'可被翻译为：众所周知的干扰物质例如补体、甘露糖结合蛋白、Fc受体、可溶性靶分子、补体受体1和类风湿因子等，但是其它物质包括产品 本身也会造成问题。\n'Binding to representative isoforms of the relevant three Fc gamma receptors (FcγRI, FcγRII and FcγRIII), FcRn and complement (C1q)'可被翻译为：相关的3个Fcγ受体（FcγRI，FcγRII和FcγRIII），FcRn和补充的代表亚 型（C1q抗体）\n'Binding assays that include endocrine receptors can serve as an initial screen.'可被翻译为：包含内分泌受体在内的结合试验可作为初步筛选。\n'The binding between antigens and antibodies, ligand and receptors and other molecules is a one-to-one relationship, and this one-to-one reaction is called a specific reaction.'可被翻译为：抗原与抗体、配体与受体等分子之间的结合是一对一的关系，这种一对一的反应称特异性反应。\n\n根据上述已知信息，请将'Examples include complement components or complement receptors, mannose binding protein, Fc receptors, soluble target molecules, and rheumatoid factors.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"范例包括补体成分或补体受体、甘露糖结合蛋白、Fc 受体、可溶性靶分子和类风湿因子。"
    },
    {
        "instruction":"已知信息：\n'In view of the limited availability of patients suffering from haemophilia B, data from pre-licensing studies only are considered insufficient to estimate all aspects of therapy with factor IX products, especially with respect to immunogenicity.'可被翻译为：鉴于B型血友病患者数量有限，上市前研究的数据被认为并不足以估算因子IX制品的所有治疗作用，特别是免疫原性。\n'The availability of data on immunogenicity at time of approval might, therefore, be limited.'可被翻译为：因此，在获得批准时免疫原性数据的可用性有限。\n'Inhibitor development should be studied in previously treated patients ( exposure days>150,  suffering from severe haemophilia A with a factor VIII level < 1%);'可被翻译为：应该在接受过治疗的患者（给药天数>150，因子 VIII 水平<1%并患有严重甲型血友病）展开抑制物产生的研究；\n'Efficacy including surgery  Clinical efficacy of factor VIII should be evaluated in at least  PTPs (≥ years, > EDs), suffering  from severe haemophilia A (factor VIII <%), and who are immunocompetent (HIV patients should  have CD > \/µL).'可被翻译为：因子 VIII 的临床疗效研究应该至少包括患有严重甲型血友病（因子 VIII<1%）并且具有免疫能力（艾滋病患者的 CD4>200\/μL）的 50 名 PTP（≥12 岁，>150ED）。\n\n根据上述已知信息，请将'In view of the limited availability of patients suffering from haemophilia A, data from pre-licensing  studies only are considered insufficient to estimate all aspects of therapy with factor VIII products,  especially with respect to immunogenicity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由于甲型血友病患者数量有限，所以认为上市前研究的数据不足以评估因子 VIII 制品治疗情况的各个方面，特别是免疫原性。"
    },
    {
        "instruction":"已知信息：\n'All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register.'可被翻译为：所有 意见均应标明《联邦公报》刊登的有效性通知中列出的文件编号。\n'Submit electronic comments to http:\/\/www.regulations.gov\/. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register.'可被翻译为：以电子形式提交至下述网站http:\/\/www.regulations.gov，以书面 形式提交至下述地址：Division of Dockets Management （HFA-305），Food and Drug Administration，5630 Fishers Lane，rm.1061，Rockville，MD 20852.所有建议 均应标明《联邦公报》刊登的有效性通知中列出的文件编号。\n'Submit electronic comments to http:\/\/www.regulations.gov. \nSubmit written comments to \nthe Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. \nAll comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register.'可被翻译为：提交电子版意见至网址：http:\/\/www.regulations.gov.，\n提交书面意见请至以下地址：\nDivision of Dockets Management （HFA-305），Food and Drug Administration，5630 Fishers Lane，rm.1061，Rockville，MD 20852.\n所有建议均 应标明《联邦公报》刊登的有效性通知中列出的文件编号。\n'Submit electronic comments to http:\/\/www.regulations.gov. \nSubmit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. \nAll comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register.'可被翻译为：以电子形式提交至下述网站http:\/\/www.regulations.gov，\n以书面形式提交至下述地址：Division of Dockets Management （HFA-305），Food and Drug Administration，5630 Fishers Lane，rm.1061，Rockville，MD 20852.\n所有建议均应标明《联邦公报》刊登的有效性通知中列出的文件编号。\n\n根据上述已知信息，请将'You should identify all comments with the docket number listed in the notice of availability that publishes in the Federal Register.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"需确认所有带有记事表编号的评论都被列入到联邦登记出版的可行性声明部分中。"
    },
    {
        "instruction":"已知信息：\n'Study sponsors are encouraged to consult with FDA prior to and during clinical studies about the management of specific situations involving potential bias on the part of a clinical investigator.'可被翻译为：鼓励研究申办方在临床研究之前和期间就涉及临床研究者潜在偏倚的特殊 情形的管理咨询 FDA。\n'Nevertheless, FDA encourages IRBs, investigators, and sponsors to work together to maximize the ability of individuals to prevent their inclusion in research to which they would object.'可被翻译为：尽管如此，FDA鼓励IRB，研究者和申办方共同合作，使得个体具有最大限度 不被收录到他们会反对参与的研究中的能力。\n'The Department of Health and Human Services Guidance Document, “Financial Relationships and Interests in Research Involving Human Subjects: Guidance for Human Subject Protection,” which is applicable to FDA regulated research, recommends that consideration be given to providing potential subjects with information about the financial interests and arrangements of the parties involved in the research.'可被翻译为：卫生和人类服务部指南文件， “涉及人体受试者的研究中的财务关系和权益：人体受试者 保护指南“ ，适用于 FDA 监管的研究， 建议考虑向潜在的受试者提供研究涉及各方财务权益和安排的 信息。\n'Selection bias, related to the availability of biological samples from all subjects, or failure connected to the assay in question, should be minimized where possible.'可被翻译为：如果可能，应将与所有受试者生物学样本可用性相 关的选择偏倚或与待评价的测定法相关的失败最小化。\n\n根据上述已知信息，请将'During these consultations, FDA staff should focus on the protection of research subjects and the minimization of bias from all potential sources.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在这些咨询期间，FDA工作人员应重点放在保护研 究受试者和减少所有潜在来源的偏倚方面。"
    },
    {
        "instruction":"已知信息：\n'• Data are obtained within a study from different laboratories with the same bioanalytical method.'可被翻译为：·在一项试验中，从不同实验室使用同一生物分析方法获得数据\n'Reanalysis of a portion of the incurred samples in a separate analytical run on a different day to determine whether the original analytical results are reproducible.'可被翻译为：在不同天的另外一个分析批中，重新分析一部分已测样品，以确定原分析结果是否可以重现。\n'Incurred Sample Reanalysis (ISR): Reanalysis of a portion of the incurred samples in a separate analytical run on a different day to determine whether the original analytical results are reproducible.'可被翻译为：已测样品再分析（ISR）：在不同天的另外一个分析批中，重新分析一部分已测样品，以确定原分析结果是否可以重现。\n'All aspects of ISR evaluations should be documented to allow reconstruction of the study and any investigations. Individual samples that are quite different from the original value (e.g., > 50%, “flyers”) should not trigger reanalysis of the original sample and do not need to be investigated. ISR sample data should not replace the original study sample data.'可被翻译为：ISR评价的所有内容均应记录，以允许重构该试验和任何调查。与原始值偏差很大（例如>50%或“异常值”）的单个样品不应引发对原始样品的重新分析， 且不必调查。ISR样品数据不应取代研究样品的原始数据。\n\n根据上述已知信息，请将'ISR is conducted by repeating the analysis of a subset of samples from a given study in separate (i.e., different to the original) runs on different days using the same bioanalytical method.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过使用同样的生物分析方法，在不同天单独的（即不同于原来的）分析批重新分析给定试验的部分样品，来开展ISR。"
    },
    {
        "instruction":"已知信息：\n'Rat blood can be used for micronucleus analysis provided methods are used to ensure analysis of the newly formed reticulocytes (Hayashi et al., 2007; MacGregor et al., 2006), and the sample size is sufficiently large to provide appropriate statistical sensitivity given the lower micronucleus levels in rat blood than in bone marrow (Kissling et al., 2007).'可被翻译为：大鼠血液也可用于微核分析，只要所用方法学可确保能分析新生网织红细胞（Hayashi等,2007；MacGregor等,2006），而且与骨髓相比， 大鼠的血液样本量足够大，可提供合适的统计学灵敏度以确定更低的微核水平（Kissling等，2007）。\n'Although rats rapidly remove micronucleated erythrocytes from the circulation, it has been established that micronucleus induction by a range of clastogens and aneugens can be detected in rat blood reticulocytes (Wakata et al., 1998; Hamada et al., 2001).'可被翻译为：虽然大鼠可快速清 除循环中的含微核红细胞，但是已确定大鼠血液网织红细胞 中可检测到由一系列断裂剂和非整倍体剂诱导的微核 （Wakata等，1998；Hamada等，2001）。\n'6. There is some experience with in vivo assays for micronucleus induction in skin and colon (Hayashi et al., 2007), and DNA damage assays in these tissues can also be an appropriate substitute.'可被翻译为：（6）采用皮肤和结肠进行诱导微核的体内试验已有一 些经验（Hayashi等，2007），而且在这些组织中进行DNA 损伤试验也是一种合适的替代方法。\n'Hotchkiss CE, Bishop ME, Dertinger SD, Slikker W, Moore MM, MacGregor JT. Flow cytometric analysis of micronuclei in peripheral blood reticulocytes IV: an index of chromosomal damage in the rhesus monkey (macaca mulatta). Toxicol Sci 2008 ;102:352 8.'可被翻译为：Hotchkiss CE, Bishop ME, Dertinger SD, Slikker W, Moore MM, MacGregor JT. Flow cytometric analysis of micronuclei in peripheral blood reticulocytes IV: an index of chromosomal damage in the rhesus monkey (macaca mulatta). Toxicol Sci 2008 ;102:352-8.\n\n根据上述已知信息，请将'Hayashi M, MacGregor JT, Gatehouse DG, Blakey DH, Dertinger SD, Abramsson Zetterberg L et al. In vivo erythrocyte micronucleus assay. III. Validation and regulatory acceptance of automated scoring and the use of rat peripheral blood reticulocytes, with discussion of non-hematopoietic target cells and a single dose-level limit test. Mutat Res 2007;627:10-30.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Hayashi M, MacGregor JT, Gatehouse DG, Blakey DH, Dertinger SD, Abramsson-Zetterberg L et al. In vivo erythrocyte micronucleus assay. III. Validation and regulatory acceptance of automated scoring and the use of rat peripheral blood reticulocytes, with discussion of non-hematopoietic target cells and a single dose-level limit test. Mutat Res 2007;627:10-30."
    },
    {
        "instruction":"已知信息：\n'Manufacturers should provide information on the host cells, rDNA molecules (such as plasmids), method of transformation and of cell banking, and the results of characterisation studies.'可被翻译为：生产商应提供有关宿主细胞、重组DNA分子(如质粒)、转化及细胞建库的方法 以及鉴定结果等方面的资料。\n'Information on materials and components used for the preparation of primary cell substrates should be provided, including the identity and source of all reagents of human or animal origin. A description of testing performed on components of animal origin to certify the absence of detectable contaminants and adventitious agents should be included.'可被翻译为：应提供用于制备原代细胞基质的原材料及组成成分的资料，包括人和动物源性的所有试剂的特征、来源，以及对动物源性成分证明检测不出污染物和外源因子的检测方法和结果。\n'A complete description, including source, characteristics and testing of all materials used during manufacture should be provided.'可被翻译为：需提供生产所用所有物料的完整描述（包括来源、特征和检测）。\n'Description of batches and results of batch analyses should be provided.'可被翻译为：应提供批次信息和批分析结果。\n\n根据上述已知信息，请将'A description of any genetic manipulation or selection should be provided. All available information regarding the identification, characteristics, and results of testing of these cells for endogenous and adventitious agents should be provided.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"还应提供所有对基因操作和筛选的描述、细胞内源性和外源性因子的鉴别、特性和 检测结果等资料。"
    },
    {
        "instruction":"已知信息：\n'Stratification at the stage of randomisation and adjustment for covariates in the analysis may be seen as complementary methods of accounting for covariates.'可被翻译为：在随机化阶段分层和分析时校正协变量可以看作对协变量作出解释的补充方法。\n'Stratified randomisation is often used to reduce the likelihood of such imbalances between treatment groups within the levels of specified covariates (generally qualitative covariates or categorised quantitative covariates).'可被翻译为：分层随机化常常用于在指定的协变量（一般为定性协变量或分类定量协变量）水平内减少治疗组间这种不平衡的概率。\n'Analysis may need to be stratified according to the use of potentially confounding factors such as percutaneous endoscopic gastrostomy.'可被翻译为：可能需要根据潜在混杂因素（如经皮内镜胃造瘘）的使用情况进行分层分析。\n'It is recommended that the TOC visit should occur at a pre-defined number of days after randomisation.'可被翻译为：建议 TOC 访视在随机 后的预定天数内进行。\n\n根据上述已知信息，请将'This includes the use of covariates not stratified for in the randomisation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这包括随机化中不用于分层的协变量。"
    },
    {
        "instruction":"已知信息：\n'An add-on study is a placebo-controlled trial of a new agent conducted in people also receiving standard treatment.'可被翻译为：加载研究是对接受标准治疗的人进行的新药的安慰剂 对照试验。\n'In this case a placebo-controlled trial with add-on design (standard therapy +study drug versus standard therapy +placebo) with adequate rescue medication would be the preferred design.'可被翻译为：在这种情况下，首选设计是有适当救援药物、采用附加设计的安慰剂对照试验（标准治疗+研究药物 vs. 标准治疗+安慰剂）。\n'In placebo controlled add-on design setting the background treatment becomes of particular relevance.'可被翻译为：在安慰剂对照的附加治疗设计中，设定基础治疗尤为重要。\n'• Placebo control with appropriate design modifications1 (e.g., add-on study)'可被翻译为：进行适当修改1的安慰剂对照（例如加载 研究 ）\n\n根据上述已知信息，请将'If the new treatment is intended to be used exclusively as add-on to standard symptomatic treatment(e.g. AChEI) a simple two way placebo controlled add-on study is the appropriate design.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果新的治疗仅拟作为标准对症治疗（例如，AchEI）的辅助药物，简单的安慰剂对照加成交叉研究可作为适当的设计。"
    },
    {
        "instruction":"已知信息：\n'The star-number is unique for the presence of one or more functionally important mutations on the same allele and each *-marked allele has its phenotypic description based on the functionally important mutations present (see Human Cytochrome P450 (CYP) Allele Nomenclature website2).'可被翻译为：星号是相同等位基因上出现一个或多个功能上重要 的突变所独有的，每个被*标记的等位基因均基于其存在的具有功能学重要意义 的突变来描述其表型（参见人类细胞色素P450（CYP）等位基因命名网站2）。\n'In this gene more than 110 functionally different alleles have been identified, with their functionality assessed using specific probe drugs in vivo.'可被翻译为：在该基因中，已经鉴别出超过110个功能不同的等位基因， 采用特定探针药物，在体内对其功能性进行评价。\n'Allele specificity: Occurrence of mutations in cis and trans When two different variations with known functional implications are identified in heterozygosity within the same gene, it is important to know whether or not the two variations are on the same allele (in cis) or segregated between the two alleles (in trans).'可被翻译为：等位基因特异性：顺式突变和反式突变的发生率当通过相同基因的杂合性识别出2种功能意义已知的不同变异时，重要的是了解2种变异是否位于同一等位基因上（顺式）或位于2个等位基因上（反式）。\n'point mutations'可被翻译为：点突变\n\n根据上述已知信息，请将'The nomenclature system for the CYP star (*)allele designation takes into account mutations causing 412 functional consequences such as stop mutations or amino acid changes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"CYP星号（*）等位基因指定的命名系统考虑到引起功能不良后果的突变， 例如终止突变或氨基酸变化。"
    },
    {
        "instruction":"已知信息：\n'Specificity\/selectivity can be verified by demonstrating that the measured result of an analyte is comparable to the measured result of a second, well characterised analytical procedure that ideally applies a different measurement principle.'可被翻译为：专属性\/选择性可通过证明被分析物的测定结果与另一个经充分表征的分析方法测定结果相当来确认，理想情况下该方法应为不同测定原理的方法。\n'In some cases, specificity\/selectivity may be inherently given by the underlying scientific principles of the analytical procedure.'可被翻译为：在一些情况下，专属性\/选择性可能是分析方法基本科学原理的固有属性。\n'The specificity or selectivity of an analytical procedure can be demonstrated through absence of interference or comparison of results to an orthogonal procedure.'可被翻译为：关于分析方法的专属性或选择性，可证明无干扰，或通过对比测定结果与正交方法结果来证明。\n'Selectivity could be demonstrated when the analytical procedure is not specific.'可被翻译为：当分析方法不专属时，可证明其选择性。\n\n根据上述已知信息，请将'The specificity\/selectivity of an analytical procedure should be demonstrated to fulfil the accuracy requirements for the content or potency of an analyte in the sample.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应证明分析方法的专属性\/选择性，满足样品中被分析物含量或效价的准确度要求。"
    },
    {
        "instruction":"已知信息：\n'Depending on the purpose of the trial and the anticipated benefit-risk profile of the investigated agent, an appropriate patient population should be selected a priori.'可被翻译为：根据试验的目的和试验用药物的预期获益风险特征， 应该先验性选择适当的患者人群。\n'Some groups in the general population require additional investigation during drug development because they have unique risk\/benefit considerations, or because they can be anticipated to need modification of the dose or schedule of a drug.'可被翻译为：在药物研发中，针对一般人群中的部分群体需要开展额 外研究，因为这部分群体独特的风险\/获益考虑，或预期需要 调整药物剂量或给药方案。\n'An understanding of the clinical characteristics (manifestations and timing) of the specific population targeted by the drug (which may be a subset of the total population with a disease). An understanding of which aspects of the disease are meaningful to the patient and might also be affected by the drug’s activity.'可被翻译为：理解作为药物靶标的特定人群（可能是患有某种疾病的总人群中的一个子集）的临床特征（表现和发作时间）。理解疾病的哪些方面对于患者是有意义的，并且可能受到药物活性的影响。\n'Although clinical drug development is often described as consisting of four temporal phases (phases 1- 4), it is important to appreciate that the phase concept is a description and not a requirement, and that the phases of drug development may overlap or be combined.'可被翻译为：虽然通常临床药物研发分为四个阶 段（1期-4期），但需要明确的是，阶段的概念只是便于描 述，并非规定，并且药物研发的阶段可能重叠或合并。\n\n根据上述已知信息，请将'In the earlier phases of drug development the choice of subjects for a clinical trial may be heavily influenced by the wish to maximise the chance of observing specific clinical effects of interest, and hence they may come from a very narrow subgroup of the total patient population for which the drug may eventually be indicated.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在药物研发的早期阶段，临床试验受试者的选择在很大 程度上受到主观愿望的影响，即希望最大可能地观察到感兴 趣的特定临床疗效，因此，研究对象往往是药物最终适用的 患者总体中一个非常局限的亚组。"
    },
    {
        "instruction":"已知信息：\n'S7A Approval by the Steering Committee under Step 2 and release for public consultation. 2 March 2000 S7A'可被翻译为：S7A 指导委员会批准进入第二阶段，并发布公开征求意 见。 2000年 3月2日 S7A\n'Approval by the Steering Committee under Step 2 and release for public consultation.'可被翻译为：指导委员会批准进入第二阶段，并发布 公开征求意见。\n'S1 Approval by the Steering Committee under Step 2 and release for public consultation.'可被翻译为：S1 指导委员会批准进入第二阶段， 并发布以公开征询意见。\n'Q11 Approval by the Steering Committee under Step 2 and release for public consultation.'可被翻译为：Q11 本指导原则由指导委员会批准进入第二阶段，并发布以公开征求意见。\n\n根据上述已知信息，请将'M7 Approval by the Steering Committee under Step 2 and release for public consultation. 6 February 2013'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"M7 在第二阶段中获得执行委员会批准，并且公开征求意见。 2013年2月6 日"
    },
    {
        "instruction":"已知信息：\n'The experimental design of the validation study should reflect the number of replicates used in routine analysis to generate a reportable result.'可被翻译为：验证研究的实验设计应反映常规分析中生成一个可报告结果的重复测定次数。\n'Whether and to what extent replication should be performed will depend on the results from validation studies.'可被翻译为：稳定性研究是否需重复及重复程度取决于验证研究的结果。\n'Accuracy should be assessed using an appropriate number of determinations and concentration levels covering the reportable range (e.g., 3 concentrations\/3 replicates each of the full analytical procedure).'可被翻译为：准确度需要在可报告范围内，使用各浓度水平适当数量的平行样品进行评估（如：按完整分析方法在3个浓度各重复测定3次）。\n'Repeatability: Test at least 6 replicates using established analytical procedure parameters at target range'可被翻译为：重复性： 使用建立的分析方法参数在目标范围内进行，至少6次重复测定。\n\n根据上述已知信息，请将'If justified, it may be acceptable to perform some validation tests using a different number of replicates or to adjust the number of replicates in the analytical procedure based on data generated during validation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果证明合理，可以使用不同重复测定次数进行验证测试，也可根据验证期间生成的数据调整分析方法中的重复测定次数。"
    },
    {
        "instruction":"已知信息：\n'The computerized system that supports the eIC must be secure with restricted access and should include methods to ensure confidentiality regarding the subject’s identity, study participation, and personal information after informed consent has been obtained.'可被翻译为：在获得知情同意后，支持eIC的计算机系统必须设置使用权限，并应采取措施来确保关于受试者身份、研究参与和个人信息的保密性。\n'If documentation is handled by electronic data processing methods, only authorized persons should be able to enter or modify data in the system and there should be a record of changes and deletions; access should be restricted by passwords or other means and the entry of critical data should be independently checked.'可被翻译为：使用电子数据处理系统的，只有经授权的人员方可输入或更改数据，更改和删除情况应当有记录；应当使用密码或其他方式 来控制系统的登录；关键数据输入后，应当由他人独立进行复核。\n'Sponsors should ensure that software updates to the sponsor’s electronic system or the EHR do not affect the reliability and the integrity of EHR data entering the sponsor’s electronic system.'可被翻译为：申办人应确保对申办人电子系统或EHR的软件更新不影响EHR数据的可靠性和完整性。\n'Identification of the data originator (i.e., EHR or study personnel entering or modifying the clinical study data) and the date and time data were entered into the EHR should be available to FDA at the time of inspection (see section IV of this guidance).'可被翻译为：FDA在检 查时应该可以获得数据起源的确认（例如，EHR或研究人员进入或修改临床研究 数据）和进入EHR的日期和时间（见本指南第IV部分）。\n\n根据上述已知信息，请将'In such cases, the sponsor should ensure that the appropriate authority controls are in place to limit system access for entering and modifying data to the research component of the EHR to study personnel only.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这种情况下，申办者应该确保仅对于研究人员EHR研究组件，进行录入和修改数据的受限系统的登录具有适当的权限控制。"
    },
    {
        "instruction":"已知信息：\n'3. The manufacturer should verify those testing methods that do not need validation so as to ensure the accuracy and reliability of testing data.'可被翻译为：（三）对不需要进行验证的检验方法，企业应当对检验方法 进行确认，以确保检验数据准确、可靠；\n'(iii) Test methods are validated;'可被翻译为：（三）检验方法应经过验证；\n'3. Requirements and guidance on procedures and conditions for non-clinical safety evaluation in the planning, conduct, monitoring, recording, and reporting of studies to ensure the accuracy and reliability of experimental data.'可被翻译为：3.为保证试验数据的准确、可靠、对于非临床安全性评价在研究计划，实施，监督，记录，及报告等各项工作的过程和条件提出的要求和指导。\n'3. Reference to testing methods;'可被翻译为：3.检验方法依据；\n\n根据上述已知信息，请将'3. The manufacturer should verify those testing methods that do not need validation so as to ensure the accuracy and reliability of testing data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3.对不需要进行验证的检验方法，企业应当对检验方法进行确认，以确保检验数据准确、可靠。"
    },
    {
        "instruction":"已知信息：\n'Therefore, background therapy should be standardised and stable as far as possible without compromising optimisation.'可被翻译为：因此，背景治疗应该在标准化和稳定的前提下尽可能优化。\n'Concomitant background treatment should be kept as similar as possible during the study.'可被翻译为：研究期间应尽可能保持相似的伴随背景治疗。\n'Concomitant therapy Treatments that might modulate the perception of pain or patients’ response to pain, either directly or by interacting with the investigational products should generally be avoided during the trial.'可被翻译为：伴随治疗在试验过程中一般应避免可能调节疼痛感知或患者对疼痛反应的治疗（直接或通过与试验用药\n'Treatment for BPH should remain unchanged during the study period whenever possible.'可被翻译为：在研究期间，只要有可能，良性前列腺增生症的治疗应保持不变。\n\n根据上述已知信息，请将'Where unavoidable, concomitant treatments should be standardised and should remain stable for a defined period before and during the trial.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在不可避免的情况下，伴随治疗应标准化，并在试验之前和试验期间保持稳定一个所定义的周期。"
    },
    {
        "instruction":"已知信息：\n'In addition, the case identifier assigned by the previous sender in C.1.1 should be included here by the retransmitter.'可被翻译为：此外，在 C.1.1中由既往发送者分配的情况标识符应该包括在内。\n'However, the ‘Worldwide Unique Case Identification Number’ (C.1.8.1) used in any previous transmissions of the case should always remain the same (See the user guidance for C.1.8).'可被翻译为：但是，在任何既往病例传输中使用的“全球唯一病例识别码病例识别码” （C.1.8.1）应始终保持不变（见C.1.8的用户指导原则）。\n'In case of amendment it is important to use the same ‘Sender’s (case) Safety Report Unique Identifier’ (C1.1) and ‘Worldwide Unique Case Identification’ (C.1.8) previously submitted (See exceptions in C.1.1).'可被翻译为：在修订的情况下，使用与既往提交的相同的“发送者的（病例）安全报告唯一识别码” （C1.1）和“全球唯一病例识别码”（C.1.8）至关重要（例外情况见 C.1.1）。\n'C.1.1 Sender’s (case) Safety Report Unique Identifier'可被翻译为：C.1.1发送者（病例）安全性报告唯一的标识符\n\n根据上述已知信息，请将'When the same sender retransmits the same case (e.g. to transmit follow- up information), C.1.1 usually remains constant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当相同的发送者重新传输相同病例（例如：传输随访信息）时，C.1.1 通常保持不变。"
    },
    {
        "instruction":"已知信息：\n'The Rules Governing Medicinal Products in the European Union Volume 2C Notice to Applicants; A guideline on summary of product characteristics (SmPC) September 2009'可被翻译为：欧盟药品管理法第2C卷通知申请人；产品特征概述的指导原则（SmPC）2009年9月\n'Rules governing medicinal products in the European Union Volume 2C Notice to applicants; A guideline on summary of product characteristics (SmPC) September 2009'可被翻译为：欧盟药品管理规则第2C卷给申请人的通知；产品特性概述指南（SmPC）2009年9月\n'The Rules Governing Medicinal Products in the European Union'可被翻译为：欧盟药品管理规则\n'Eudralex Volume 9A of The Rules Governing Medicinal Products in the European Union – Guidelines on Pharmacovigilance for Medicinal Products for Human Use-to be replaced by Good Vigilance Practice after July 2012'可被翻译为：–欧盟药品监管规定Eudralex卷9A-人用药品药物警戒指南-2012年7月之后由药物警戒规范替代\n\n根据上述已知信息，请将'Rules governing medicinal products in the European Union Volume guideline on summary of product characteristics (SmPC) Septe 2C'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"欧盟药品管理规定第 2C 卷申请人须知；产品特性概要指导原则(SmPC)，2009 年 9 月"
    },
    {
        "instruction":"已知信息：\n'M4 Approval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies. 8 November 2000 M4'可被翻译为：M4 指导委员会批准进入第四阶段，并推荐给ICH三方监管机构采纳。 2000 年 11 月 8 日 M4\n'Q7A Approval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies.'可被翻译为：Q7A 指导委员会批准第四阶段版本，并推荐给ICH三方的监管机构采用。\n'M4Q Approval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies. 8 November 2000 M4Q'可被翻译为：M4Q 指导委员会批准进入第四阶段， 并推荐给ICH三方监管机构采 纳。 2000年11月8日 M4Q\n'M4S Approval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies. 8 November 2000 M4S'可被翻译为：M4S 指导委员会批准进入第四阶段，并推荐给ICH三方监管机构采纳。 2000年11月8日 M4S\n\n根据上述已知信息，请将'S7A Approval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies. 8 November 2000 S7A'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"S7A 指导委员会批准进入第四阶段，并推荐给ICH三方 的监管机构采纳。 2000年11月8日 S7A"
    },
    {
        "instruction":"已知信息：\n'Provincial drug regulatory departments shall carry out on-site inspection and technical review in accordance with the requirements in the Provisions for the Supervision and Administration of Drug Manufacture, the Provisions for Drug Registration and relevant technical guidelines for changes, and change the relevant information of their Drug Manufacturing Certificate if the requirements are met. After completing the change of Drug Manufacturing Certificate, the provincial drug regulatory department shall update the change information of the manufacturing site or manufacturer as indicated in the drug registration approval document of the MAH and its annexes in the change system for drug registration filing by virtue of the changed Drug Manufacturing Certificate. Where there is a need to submit a supplementary application to the CDE for the change of biological products, the MAH shall submit a supplementary application in accordance with the Provisions.'可被翻译为：省级药品监管部门按照《药品生产监督管理办法》《药品注册管理办法》及相关变更技术指导原则要求开展现场检查和技术审评，符合要求的，对其《药品生产许可证》相关信息予以变更。完成《药品生产许可证》变更后，省级药品监管部门凭变更后的《药品生产许可证》在药品注册备案变更系统中对持有人药品注册批准证明文件及其附件载明的生产场地或生产企业的变更信息进行更新，生物制品变更中涉及需要向药审中心提出补充申请事项的，持有人按照本办法提出补充申请。\n'Article 11 For changing the names of MAH, manufacturer, manufacturing site and so on, after the change of corresponding items in the Drug Manufacturing Certificate is completed, the change shall be filed to the local provincial drug regulatory department to change the corresponding management information of drug approval documents.'可被翻译为：第十一条 持有人名称、生产企业名称、生产地址名称等变更，应当完成药品生产许可证相应事项变更后，向所在地省级药品监管部门就药品批准证明文件相应管理信息变更进行备案。\n'To build, rebuild or expand a workshop or manufacturing line at the original site or another site, relevant regulations and technical requirements shall be met, and relevant materials regarding the change shall be submitted to the local drug regulatory department of the province, autonomous region or municipality directly under the Central Government for GMP compliance inspection. The manufacturer shall be notified of the inspection results. Products on which the inspection results comply with relevant regulations, meeting release requirements, can be sold and marketed. Related changes shall be specified in the duplicate of the Drug Manufacturing Certificate.'可被翻译为：原址或者异地新建、改建、扩建车间或者生产线的，应当符合相关规定和技术要求，提交涉及变更内容的有关材料，并报经所在地省、自治区、直辖市药品监督管理部门进行药品生产质量管理规范符合性检查，检查结果应当通知企业。检查结果符合规定，产品符合放行要求的可以上市销售。有关变更情况，应当在药品生产许可证副本中载明。\n'Article 18 If a medical device manufacturer establishes the manufacturing premises across the province, autonomous region or municipality directly under the central government, it shall apply to the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the manufacturing premises is located for Medical Device Manufacturing License.'可被翻译为：第十八条  医疗器械生产企业跨省、自治区、直辖市设立生产场地的，应当向新设生产场地所在地省、自治区、直辖市药品监督管理部门申请医疗器械生产许可。\n\n根据上述已知信息，请将'To change the address of manufacturing site or the manufacturing scope, the drug manufacturer shall, in accordance with the provisions of Article 6 of these Provisions and relevant technical requirements, submit relevant materials related to the changes to the local drug regulatory department of the province, autonomous region or municipality directly under the Central Government for review and approval.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"变更生产地址或者生产范围，药品生产企业应当按照本办法第六条的规定及相关变更技术要求，提交涉及变更内容的有关材料，并报经所在地省、自治区、直辖市药品监督管理部门审查决定。"
    },
    {
        "instruction":"已知信息：\n'6 Effects in Humans'可被翻译为：6 人体内作用\n'Adverse medical and clinical events occurring in the course of drug treatment. It does not necessarily have a clear causal relationship with the drug.'可被翻译为：药物治疗过程中出现的不良医学临床事件。它不一定与该药有明确的因果关系。\n'E.i.3.2f Other Medically Important Condition'可被翻译为：E.i.3.2f其他重要医学事件其他重要医学事件\n'This is particularly important for generalised linear or non-linear models where mis-specification could lead to incorrect estimates of the treatment effect.'可被翻译为：这一点对于广义线性模型或非线性模型尤为重要，因为模型的错误会导致治疗效果的不准确估计。\n\n根据上述已知信息，请将'6. Other medically important events that without treatment could lead to the aforementioned outcomes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"6.导致其他重要医学事件，如不进行治疗可能出现上述所列情况的。"
    },
    {
        "instruction":"已知信息：\n'Differences in responses among studies should be described.'可被翻译为：应该描述研究之间的反应差异。\n'Treatment comparison should include analyses that allow for centre differences with respect to response.'可被翻译为：治疗方法的对比应包括考虑各中心疗效差异的分析。\n'All methods of analysis rely on assumptions, and different methods may rely on different assumptions even when aligned to the same estimand.'可被翻译为：所有的分析方法都依赖于假设，而且即使对应于相同的估计 目标，不同的分析方法也可能依赖于不同的假设。\n'To be used as a main secondary endpoint, disease specific questionnaires are preferred to generic instruments.'可被翻译为：为了能用作为主要次要终点，疾病特定的问卷最好采用通用的工具。\n\n根据上述已知信息，请将'The preferred main analysis should rely on the differences in the rate of responders.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"首选的主要分析应依赖于治疗反应率的差异。"
    },
    {
        "instruction":"已知信息：\n'Pharmacokinetic studies are particularly important to assess the clearance of the drug and to anticipate possible accumulation of parent drug or metabolites, interactions with metabolic enzymes and transporters, and potential drug-drug interactions.'可被翻译为：药代 动力学研究对评估药物的清除、预测原型药物或其代谢物是 否蓄积、与代谢酶和转运体的相互作用以及潜在的药物间相 互作用等方面尤为重要。\n'Therefore, if relevant, it is recommended that assessment of biomarkers for efficacy and\/or safety is included within the specific pharmacokinetic study in subjects with decreased renal function.'可被翻译为：因此，如果相关，建议对疗效和\/或安全性生物标记物的评估包括在肾功能下降受试者 的专属药代动力学研究。\n'Factors to investigate as covariates could include age, weight, gender, renal function, S-bilirubin, liver enzymes, genotype, soluble receptors\/ligands, tumour burden, inflammatory markers etc.'可被翻译为：作为协变量而被研究的因素可包括年龄、体重、性别、肾功 能、S-胆红素、肝酶、基因型、可溶性受体\/配体、肿瘤负荷、炎症标志物等。\n'The renal function groups should preferably be comparable with respect to factors that are expected to significantly influence the pharmacokinetics of the drug.'可被翻译为：肾功能组人群在显著影响药物药代动力学的因素方面最好相当。\n\n根据上述已知信息，请将'Where other factors are believed important in assessing pharmacokinetics (e.g., soluble circulating receptors, renal or hepatic function), the timing and plans to measure these factors should also be specified.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果其它因素对评估药代动力学有重要影响（例如可溶 性循环受体、肾或肝功能），那么还应明确这些因素的测定 时间和计划。"
    },
    {
        "instruction":"已知信息：\n'For every change, the applicant will perform a risk assessment to evaluate potential impact on the performance characteristics and the link to CQA (biological activity) as defined in the respective ATP. The outcome of the risk assessment informs the extent of the bridging studies used to demonstrate adherence to the performance characteristics and associated criteria.'可被翻译为：对于每项变更，申请人将进行风险评估以确认对性能特征以及与ATP中CQA（生物活性）关联的潜在影响，将根据风险评估的结果确定所需的桥接研究的程度，用于证明符合性能指特征和相关标准。\n'The outcome of this risk assessment informs the design and extent of the studies needed to support the change including a bridging strategy to demonstrate that the revised or new procedure remains fit for the intended purpose.'可被翻译为：该风险评估的结果可为支持变更所需研究（包括桥接策略，以证明经修订或新订方法适用于预期目的）的设计和程度提供参考。\n'Adherence to performance characteristics and criteria ensured by control strategy and defined bridging strategy (see below) to assess impact of changes'可被翻译为：通过控制策略和规定的桥接策略（见下文） 确保符合性能特征和标准，以评估变更的影 响\n'The applicant should not implement the new analytical procedure using the predefined reporting category unless adherence to the performance characteristics and associated criteria defined in the ATP are demonstrated during the bridging studies.'可被翻译为：除非在桥接研究期间证明符合ATP中定义的性能特征和相关标准，申请人不得按照预先设定的报告类别实施新的分析方法。\n\n根据上述已知信息，请将'As an outcome of the risk assessment, experimental bridging studies to demonstrate adherence to the performance characteristics and associated criteria will be performed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"作为风险评估的结果，将开展实验性桥接研究，以证明符合性 能特征和相关标准。"
    },
    {
        "instruction":"已知信息：\n'This type of mutagenic carcinogen is usually detected in a bacterial reverse mutation (mutagenicity) assay.'可被翻译为：这类致突变致癌物常通过细菌 回复突变（致突变性）试验检测。\n'The focus of this guideline is on DNA reactive substances that have a potential to directly cause DNA damage when present at low levels leading to mutations and therefore, potentially causing cancer. This type of mutagenic carcinogen is usually detected in a bacterial reverse mutation (mutagenicity) assay. Other types of genotoxicants that are non-mutagenic typically have threshold mechanisms and usually do not pose carcinogenic risk in humans at the level ordinarily present as impurities. Therefore to limit a possible human cancer risk associated with the exposure to potentially mutagenic impurities, the bacterial mutagenicity assay is used to assess the mutagenic potential and the need for controls. Structure-based assessments are useful for predicting bacterial mutagenicity outcomes based upon the established knowledge. There are a variety of approaches to conduct this evaluation including a review of the available literature, and\/or computational toxicology assessment.'可被翻译为：本指导原则关注焦点为较低水平即可直接造成DNA损伤，进而导致DNA突变，因此可能引发癌症的DNA反应性物质。这类致突变性致癌物通常由细菌回复突变（致突变性）试验检测确定。其它类型的非致突变性遗传毒性物质通常有阈值机制，以一般杂质水平存在时通常不会对人造成致癌风险。因此，为限制人暴露于潜在致突变杂质相关的患癌风险，使用细菌致突变试验来评估杂质致突变的可能性及控制的必要性。根据已有知识，基于结构的评估有助于预测细菌致突变试验结果。这种评估有多种方法，包括综述已有文献和 \/或计算机毒理学评估。\n'reverse mutation'可被翻译为：回复突变\n'Extensive reviews have shown that many compounds that are mutagenic in the bacterial reverse mutation (Ames) test are rodent carcinogens.'可被翻译为：大量回顾研究显示许多在细菌回复突变（Ames）试验中检出为致突变剂的化合物是啮齿类动物致癌剂。\n\n根据上述已知信息，请将'i. Assessment of mutagenicity in a bacterial reverse gene mutation test.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（1）以一项细菌回复突变试验评价致突变性。"
    },
    {
        "instruction":"已知信息：\n'Assessing potential effects and the severity of consequences of identified potential medication errors and system failures.'可被翻译为：评估所识别的潜在用药错误和系统故障的潜在影响和后果的严重程度。\n'A. Failure Mode and Effects Analysis'可被翻译为：A 失效模式和效应分析\n'·An estimate of the probability of occurrence of each use error and failure'可被翻译为：·每个用药错误和用药失败的发生概率的一个评估\n'·Identification of the potential use errors and system failures that could occur at each step of the medication use process'可被翻译为：·潜在用药错误和系统失效的鉴定，可能发生在用药过程中每一个步骤。\n\n根据上述已知信息，请将'·Identification of the potential effects and severity of consequences of each use error and failure'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"·每个用药错误和用药失败的潜在影响和后果的严重程度的鉴定"
    },
    {
        "instruction":"已知信息：\n'Article 64 Drugs shall be imported via the ports where drug importation is permitted, and drug importers shall file a record with the local drug regulatory department at the port. The drugs shall be released by customs on the basis of the Drug Import Note issued by the said departments and shall not release drugs for which no Drug Import Note has been issued.'可被翻译为：第六十四条 药品应当从允许药品进口的口岸进口，并由进口药品的企业向口岸所在地药品监督管理部门备案。海关凭药品监督管理部门出具的进口药品通关单办理通关手续。无进口药品通关单的，海关不得放行。\n'Article 10 In any of the following cases, the importation record filing of drugs to be imported shall proceed only after they have been tested and confirmed by the drug control institute of port that they meet the prescribed standards. If they do not meet the prescribed standards based on testing, the drug regulatory department at ports of entry shall not approve the importation record filing.'可被翻译为：第十条 下列情形的进口药品，必须经口岸药品检验所检验符合标准规定后，方可办理进口备案手续。检验不符合标准规定的，口岸药品监督管理局不予进口备案：\n'Article 17 Importation record filing of drugs to be imported shall not be approved in any of the following cases, and the drug regulatory department at ports of entry shall issue the Notice of Non-Acceptance of Drug Importation record filing; in the case of narcotic drugs and psychotropic substances, the drug regulatory department at ports of entry shall not issue the Notice of Port Testing for Import Drugs:'可被翻译为：第十七条 下列情形之一的进口药品，不予进口备案，由口岸药品监督管理局发出《药品不予进口备案通知书》；对麻醉药品、精神药品，口岸药品监督管理局不予发放《进口药品口岸检验通知书》：\n'Article 18 when importation record filing of drugs to be imported is not approved, the importer shall withdraw the cargo. Drugs which cannot be withdrawn shall be handed over by the customs to the drug regulatory department at ports of entry for supervision and handling.'可被翻译为：第十八条 对不予进口备案的进口药品，进口单位应当予以退运。无法退运的，由海关移交口岸药品监督管理局监督处理。\n\n根据上述已知信息，请将'Article 40 To import drug substances which have been imported but have not yet been included in the list of imported drugs for the time being, the importer shall go through the formalities of importation record filing with the drug regulatory department at ports of entry in accordance with the regulations of the Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十条 进口暂未列入进口药品目录的原料药，应当遵照本办法的规定，到口岸药品监督管理局办理进口备案手续。"
    },
    {
        "instruction":"已知信息：\n'Control of Study Procedures'可被翻译为：研究程序的控制\n'Approaches to minimise the impact of this variation in data collection and interpretation of the trial results should be described and justified in the study protocol.'可被翻译为：应在研究方案中 说明并论证减少这一差异对数据收集和试验结果解读影响的方法。\n'Refer to 21 CFR 320.38, 320.63 and the guidances for industry Handling and Retention of BA and BE Testing Samples (May 2004) and Compliance Policy for the Quantity of Bioavailability and Bioequivalence Samples Retained Under 21 CFR 320.38(c) (August 2020), as applicable, regarding considerations for retention of study drug samples and to 21 CFR 320.36 for requirements for maintenance of records of BE testing. Retention samples should be randomly selected from the drug supplies received before dispensing during the IVRT study in which the test topical product and RS are compared. Experimental observations that may have the potential to influence the interpretation of the study results, as well as any protocol deviations, should be reported.'可被翻译为：参考21 CFR 320.38，320.63和FDA行业指南《生物利用度（BA）和生物等效性（BE）研究中试验样品的处理和保存》（2004年5月）和《21 CFR 320.38(c) BE样品留存的数量及生物利用度》（2020年8月），如适用，关于保留研究药物样品的考虑以及21 CFR 320.36关于保存BE检测记录的要求。在采用自研外用制剂和RS进行IVRT对比研究前，应从收到的药品中随机选择样品进行留样。应报告可能影响研究结果解释的试验观察，以及任何与方案发生的偏离。\n'Knowledge of interim results (whether individual or treatment group level) has the potential to introduce bias or influence the conduct of the study and interpretation of study results.'可被翻译为：获知中期结果（无论受试者水平还是治疗组水平）有可 能引入偏倚，或影响研究的实施和研究结果的解释。\n\n根据上述已知信息，请将'Study procedures that have the potential to influence the results of the study should be appropriately controlled. Also, experimental observations that may have the potential to influence the interpretation of the study results, as well as any protocol or standard operating procedure (SOP) deviations, should be reported.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应对可能影响研究结果的研究程序进行适当控制。另外，应报告可能影响研究结果解释的试验观察，以及任何与方案或标准操作规程（SOP）发生的偏离。"
    },
    {
        "instruction":"已知信息：\n'In fact, the color  coding has made it difficult for these users to differentiate between drugs within the same therapeutic class when the color code was used on the container label and carton labeling.  Because these products are typically stored near each other, the similar appearance of the  container labels and carton labeling has led to dispensing and administering the wrong strength,  wrong dose, and wrong product.'可被翻译为：事实上，当颜色编码被 应用在容器标签和纸盒标识上时，用户更难区分同一治疗类别的不同药物。因为这 些药物通常都存储在彼此附近，容器标签和纸盒标识的相似造成了错误规格，错误 剂量和错误药品的分发和配给。\n'·Ensure container closures do not look similar within a product line or across a different product line. Distinguish container closures by size, shape, color, tactile features, or some other means. Drug products packaged in container closures that have a similar appearance has led to product selection errors in which the wrong drug and wrong strength have been dispensed and administered. Examples that have contributed to product selection errors resulting in dispensing the wrong drug or wrong strength include but are not limited to:'可被翻译为：确保同一个生产线或跨生产线的产品的包装密闭容器看起来不相似。可通过大小、性状、颜色、触觉、或其它方式区分包装容器。将药品包装于相似外观的密闭容器中，会导致药品挑选错误，即分发和服用错误的药物或规格。导致药品挑选错误，即导致分发错误的药品或规格的例子，包括但不限于：\n'E. Avoid Look-alike Container Labels and Carton Labeling'可被翻译为：E.避免使用外形相似的容器标签和纸盒标识\n'Examples that have contributed to product selection errors resulting in dispensing the wrong drug or wrong strength include, but are not limited to:'可被翻译为：可导致产生错误药物或错误规格的 产品选择错误的示例包括但不限于：\n\n根据上述已知信息，请将'E. Avoid Look-alike Container Labels and Carton Labeling  Look-alike container labels and carton labeling have frequently contributed to product selection  errors leading to the dispensing and administration of the wrong drug, wrong strength and\/or  wrong dose.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"E.避免使用外形相似的容器标签和纸盒标识 。 外观相似的容器标签和纸盒标识经常导致药品选择错误，从而又导致分发和配 给了错误的药品，错误的规格和\/或错误的剂量。"
    },
    {
        "instruction":"已知信息：\n'The data and samples are then relabelled with a second code, which is linked to the first code via a second coding key.'可被翻译为：数据和样本随后接受第二代码的再 标记，后者通过第二编码索引与首次密码链接。\n'It is possible to trace the data or samples back to the individual by the use of both coding keys.'可被翻译为：通过两个编 码索引可以将数据或样本追溯到受试者本人。\n'As the samples and associated data can very indirectly be traced back to the subject via the use of both coding keys, it may be possible to undertake actions such as sample withdrawal, or the return of individual results in accordance with the subject’s request.'可被翻译为：由 于样本及相关数据能通过两个编码索引间接追溯到受试者， 因此，可根据受试者的要求撤除样本或归还个人结果。\n'Once the link has been deleted it is no longer possible to trace the data and samples back to individual subjects through the coding key(s).'可被翻译为：一旦联系被 删除，数据和样本将不可能再通过编码索引追溯到受试者本人。\n\n根据上述已知信息，请将'Access to both coding keys is needed to link any data or samples back to a subject identifier.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"只有使用两种 编码索引，才能将数据或样本结果追溯到受试者的识别信息 上。"
    },
    {
        "instruction":"已知信息：\n'Article 1 The Rules is formulated in accordance with the Regulations on the Supervision and Administration of Medical Devices to enhance the supervision and administration of medical devices and ensure that the nomenclature of medical devices is scientific and normative.'可被翻译为：第一条 为加强医疗器械监督管理，保证医疗器械通用名称命名科学、规范，根据《医疗器械监督管理条例》，制定本规则。\n'Article 1 The Rules is stipulated in accordance with the Regulations on Supervision and Administration of Medical Devices to standardize the classification of medical devices.'可被翻译为：第一条 为规范医疗器械分类，根据《医疗器械监督管理条例》，制定本规则。\n'The medical device distributors shall execute Unique Device Identification (UDI) system of medical devices in accordance with relevant regulations of the State.'可被翻译为：医疗器械经营企业应当按照国家有关规定执行医疗器械唯一标识制度。\n'Article 1 In order to strengthen monitoring and re-evaluation of medical device adverse events, promptly and effectively control post-market risks of medical devices and ensure human health and life safety, the Provisions is hereby formulated in accordance with Regulations for the Supervision and Administration of Medical Devices.'可被翻译为：第一条 为加强医疗器械不良事件监测和再评价，及时、有效控制医疗器械上市后风险，保障人体健康和生命安全，根据《医疗器械监督管理条例》，制定本办法。\n\n根据上述已知信息，请将'Article 1 The Rules are hereby formulated in accordance with the Regulations on Supervision and Administration of Medical Devices, so as to regulate the establishment of unique device identification system (UDI system) and strengthen the whole-life cycle management of medical devices.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一条 为规范医疗器械唯一标识系统建设，加强医疗器械全生命周期管理，根据《医疗器械监督管理条例》，制定本规则。"
    },
    {
        "instruction":"已知信息：\n'More detailed cumulative subject exposure in clinical trials should be presented if available, e.g., sub-grouped by age, sex, and racial\/ethnic group for the entire development programme.'可被翻译为：应提供临床试验中更详细的累积受试者暴露情况，如果有的话，例如 按照年龄、性别和人种\/种族对整个开发计划进行分组。\n'If clinical trials have been or are being performed in special populations (e.g., pregnant women; patients with renal, hepatic, or cardiac impairment; or patients with relevant genetic polymorphisms), exposure data should be provided, as appropriate.'可被翻译为：如果在特殊人群（例如孕妇，肾脏、肝脏或心脏功能受损患者或具有 相关遗传多态性的患者）已进行或正在进行临床试验，则应酌情提供 暴露数据。\n'If the summary tabulations of SAEs are presented by indication, the exposure data should also be presented by indication, when available;'可被翻译为：如果按适应症撰写SAE汇总表，在可能的情况下也应按 适应症呈现暴露量数据；\n'If the Serious Adverse Events (SAEs) from clinical trials are presented by indication in the summary tabulations, the patient exposure should also be presented by indication, where available.'可被翻译为：如果临床试验中的严重不良事件（SAE）通过总结表中的适应症来展 示，那么患者的暴露量也应按适应症提供。\n\n根据上述已知信息，请将'The data should be presented according to the following categories: 1. Post-approval (non-clinical trial) exposure: An overall estimation of patient exposure should be provided.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"数据应根据以下分类展示： 1. 批准后（非临床试验）暴露： 应提供患者暴露的总体估计。"
    },
    {
        "instruction":"已知信息：\n'The preferred approach is a randomised, controlled, parallel-group, fixed-dose design, evaluating at least 3 separate dose levels.'可被翻译为：首选的方法是随机、对照、平行组、固定剂量设计，评价至少 3 个单独的剂量水平。\n'The most common clinical trial design for confirmatory trials is the parallel group design in which subjects are randomised to one of two or more arms, each arm being allocated a different treatment.'可被翻译为：对于确证性试验，最常见的临床试验设计是平行组设计， 该设计将受试者随机分配到两组或多组中的一组，每组采用 不同的处理。\n'Within this general description there is a wide variety of designs that can be used successfully: parallel or cross-over designs (see ICH E9), single fixed dose or titration in the active drug group, several fixed doses.'可被翻译为：在本节描述中，提出了可被成功采用的多种 设计：平行或交叉设计(参阅ICH E9)、试验药物单一固定剂 量或剂量递增、以及数个固定剂量。\n'Randomization to several fixed doses of the test drug in addition to placebo allows assessment of dose-response and may be particularly useful in a comparative trial to ensure a fair comparison of treatments (see ICH E4: Dose-Response Information to Support Drug Registration).'可被翻译为：除了安慰剂之外，几个固定剂量的试验药物组之间的随 机化分配有助于评估量效关系，并特别有利于在比较试验中 确保治疗间的公平比较。(参阅ICH E4：支持药物注册的量 效信息)。\n\n根据上述已知信息，请将'The parallel group design with randomization to several fixed dose groups is the general rule for the major dose-response studies.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于多数剂量-反应研究的一般规则为随 机分配至几个固定剂量组的平行组设计。"
    },
    {
        "instruction":"已知信息：\n'NMPA Announcement on Issuing the Catalogue of Reference Preparations of Generic Drugs (Forty-three Batch)'可被翻译为：国家药监局关于发布仿制药参比制剂目录（第四十三批）的通告\n'NMPA Announcement on Issuing the Catalogue of Reference Preparations of Generic Drugs (Fiftieth Batch)'可被翻译为：国家药监局关于发布仿制药参比制剂目录（第五十批）的通告\n'NMPA Announcement on Issuing the Catalogue of Reference Preparations of Generic Drugs  (Thirty-eighth Batch)'可被翻译为：国家药监局关于发布仿制药参比制剂目录（第三十八批）的通告\n'On June 22, the Catalogue of Reference Preparations of Generic Drugs (Forty-two Batch) was issued, upon review and determination by the NMPA Experts Committee of Quality and Efficacy Consistency Evaluation of Generic Drugs.'可被翻译为：经国家药品监督管理局仿制药质量和疗效一致性评价专家委员会审核确定，现于6月22日发布仿制药参比制剂目录（第四十二批）。\n\n根据上述已知信息，请将'NMPA Announcement on Issuing the Catalogue of Reference Preparations of Generic Drugs (Forty-two Batch)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于发布仿制药参比制剂目录（第四十二批）的通告"
    },
    {
        "instruction":"已知信息：\n'1.6 Pharmacodynamic Endpoints in High Dose Selection'可被翻译为：1.6 高剂量选择的药效学终点\n'At least one of the test species should exhibit the desired pharmacodynamic response.'可被翻译为：至少一种实验动物种属应显示出预期的 药效学（PD）效应。\n'All dosed animals, except for high dose male mice, were administered p-cresidine in the diet for 104 weeks and observed for an additional period of up to 2 weeks. All high dose male mice were dead by the end of week 92. Mortality rates were dose-related for both sexes of both species. That incidences of certain tumors were higher in low dose than in high dose groups was probably due to accelerated mortality in the high dose groups.'可被翻译为：除高剂量组雄性小鼠外，所有剂量组的动物均在饮食中给予对-甲酚定104周，并额外观察最多2周。所有高剂量雄性小鼠在第92周末全部死亡。这两个种系的雌性和雄性动物的死亡率都是剂量相关的。对于某些肿瘤，低剂量组的肿瘤发生率高于高剂量组，可能是由于高剂量组加速死亡所致。\n'Such an approach would further reduce the number of animals needed, circumvent inter-animal variability and would give the possibility for multiple pharmacodynamic readouts.'可被翻译为：这种方法能进一步减少所需动物的数量，规避动物间差异，并带来多种药效读数的可能性。\n\n根据上述已知信息，请将'The high dose selected should produce a pharmacodynamic response in dosed animals of such magnitude as would preclude further dose escalation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"选择的高剂量应在给药动物中 产生足够的药效学反应，无需进一步提高剂量。"
    },
    {
        "instruction":"已知信息：\n'A: Yes, a literature report could be considered a covered clinical study if it is being relied upon by the applicant or FDA to establish that the product is effective (including showing equivalence to an effective product) or where a single investigator makes a significant contribution to the demonstration of safety.18 When an applicant relies on a literature report in this manner, clinical investigator financial disclosure is required.'可被翻译为：答：是的， 文献报告可以被认为是一项涵盖的临床研究， 如果它被申请人或 FDA依赖于确定该产品是有效的（包括显示与一种有效的产品具有等效性） 或其中单一研究者对安全性的证明具有重要贡献18 。如果申请人以这种方式 依靠文献报告， 则需要进行临床研究者财务信息的披露。\n'G. COVERED CLINICAL STUDY'可被翻译为：G. 涵盖的临床研究\n'E.9. Q: What is considered “material support” when identifying sponsors of the covered study?'可被翻译为：E.9. 问：在确定涵盖研究的申办方时，哪些被认为是“重要支持 ”？\n'G.3. Q: The definition of a covered clinical study includes “any study in which a single investigator makes a significant contribution to the demonstration of safety.”'可被翻译为：G.3. 问：一项涵盖的临床研究的定义中包括“其中单一研究者对安全性的证明具 有重要贡献的任何研究 ”。\n\n根据上述已知信息，请将'G.4. Q: Can a literature report be considered a covered clinical study?'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"G.4. 问：文献报告可以被认为是涵盖的临床研究吗？"
    },
    {
        "instruction":"已知信息：\n'Article 26 After receiving the ordered recall notice, the medical device manufacturer shall notify the medical device distributors and using units or inform the users in accordance with Article 15 and Article 16 of these Provisions, formulate and submit a recall plan, and organize its implementation.'可被翻译为：第二十六条 医疗器械生产企业收到责令召回通知书后，应当按照本办法第十五条、第十六条的规定通知医疗器械经营企业和使用单位或者告知使用者，制定、提交召回计划，并组织实施。\n'Article 26 After making the decision to order the recall, the drug regulatory department shall send the notice of ordered recall to the drug manufacturer. The notice includes the following items:'可被翻译为：第二十六条 药品监督管理部门作出责令召回决定，应当将责令召回通知书送达药品生产企业，通知书包括以下内容：\n'Article 25 When the food and drug regulatory department makes a decision on ordered recall, it shall send the notice of ordered recall to the medical device manufacturer, and the notice shall include the following items:'可被翻译为：第二十五条 食品药品监督管理部门作出责令召回决定，应当将责令召回通知书送达医疗器械生产企业，通知书包括以下内容：\n'Article 28 The drug manufacturer shall report the relevant information of the recall to the drug regulatory department according to the provisions in Article 20, Article 21, Article 22 and Article 23 of these Provisions, and engage in subsequent handling of the recalled drug.'可被翻译为：第二十八条 药品生产企业应当按照本办法第二十条、第二十一条、第二十二条、第二十三条的规定向药品监督管理部门报告药品召回的相关情况，进行召回药品的后续处理。\n\n根据上述已知信息，请将'Article 27 After receiving the notice of ordered recall, the drug manufacturer shall notify the drug distributor and user according to the provisions in Article 16 and Article 17 of these Provisions, formulate and submit the recall plan and organize its implementation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十七条 药品生产企业在收到责令召回通知书后，应当按照本办法第十六条、第十七条的规定通知药品经营企业和使用单位，制定、提交召回计划，并组织实施。"
    },
    {
        "instruction":"已知信息：\n'However, a sender should not infer dates unless there is a clear clinical rationale and this rationale should be stated in the case narrative.'可被翻译为：然而，发送者不应推断日期，除 非有明确的临床依据，而这种依据应在病例描述中进行陈述。\n'A blank field for start date or end date or both is acceptable if the information is not known to the sender.'可被翻译为：如果发送者不知道具体信息，则开始 日期或结束日期或两者都留空白是可以接受的。\n'The date specified cannot refer to a future date. If the date of birth is known to the sender but cannot be transmitted due to data privacy requirements, this data element should be left blank with nullFlavor set to ‘MSK’. Please see Section 3.3.6 for further guidance on the use of nullFlavor to describe missing or non-transmitted information.'可被翻译为：所需的最低精准度为年（即“CCYY”）。 指定日期无法查阅未来日期。 如果发送者已知出生日期，但由于数据隐私要求而无法发送，则不应填写该数据元素元素，且不完整信息设为“MSK”。 关于使用不完整信息描述缺失或未传输的信息的进一步指导原则，请参见第 3.3.6 节。\n'If the date of birth is known to the sender but cannot be transmitted due to data privacy requirements, this data element should be left blank with nullFlavor = MSK. Please see Section 3.3.6 for further guidance on the use of nullFlavor to describe missing or non-transmitted information.'可被翻译为：如果发送者已知出生日期，但由于数据隐私要求而无法发送，则不应填写该数据元素元素，且不完整信息=MSK。 关于使用不完整信息描述缺失或未传输的信息的进一步指导原则，请参见第 3.3.6节。\n\n根据上述已知信息，请将'When a precise date is not available, the decision of whether to leave blank or an inferred date for a given event should be left up to the sender’s clinical judgment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当确切的日期未知时，对于是否留 空白或一个给定事件推断日期应由发送者进行临床判断。"
    },
    {
        "instruction":"已知信息：\n'Article 42 The food and drug regulatory department shall conduct formal review after accepting an application, and handle respectively according to the following circumstances:'可被翻译为：第四十二条 食品药品监督管理部门收到申请后对申报资料进行形式审查，并根据下列情况分别作出处理：\n'Article 147 Drug regulatory departments shall conduct preliminary review on applications, and proceed according to the following circumstances respectively:'可被翻译为：第一百四十七条 药品监督管理部门收到申请后进行形式审查，并根据下列情况分别作出处理：\n'Article 85 Upon receiving a drug registration application, the drug regulatory departments shall conduct preliminary review and make a decision of acceptance or rejection according to the following circumstances respectively:'可被翻译为：第八十五条 药品监督管理部门收到药品注册申请后进行形式审查，并根据下列情况分别作出是否受理的决定：\n'Article 11 Upon receipt of application, the drug regulatory department of the province, autonomous region, or municipality directly under the central government shall handle respectively according to the following circumstances:'可被翻译为：第十一条  省、自治区、直辖市药品监督管理部门收到申请后，应当根据下列情况分别作出处理：\n\n根据上述已知信息，请将'Article 32 The food and drug regulatory department shall conduct preliminary review after accepting an application, and handle respectively according to the following circumstances:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十二条 食品药品监督管理部门收到申请后对申报资料进行形式审查，并根据下列情况分别作出处理："
    },
    {
        "instruction":"已知信息：\n'(3) fail to promptly discover systemic risks of drug safety, or fail to promptly eliminate drug safety hazards within their supervision and administration region, resulting in serious effects; or'可被翻译为：（三）未及时发现药品安全系统性风险，或者未及时消除监督管理区域内药品安全隐患，造成严重影响；\n'(1) performing responsibility insufficiently, resulting in serious negative effects or heavy losses;'可被翻译为：（一）履行职责不力，造成严重不良影响或者重大损失；\n'(3) incompetence in the performance of duties which causes serious adverse effects or serious losses.'可被翻译为：（三）履行职责不力，造成严重不良影响或者重大损失。\n'(7) having any other dereliction of duty in vaccine administration, resulting in serious negative effects or heavy losses.'可被翻译为：（七）其他未履行疫苗监督管理职责的行为，造成严重不良影响或者重大损失。\n\n根据上述已知信息，请将'(4) failing to perform drug supervision and administration duties, resulting in serious adverse impact or serious losses.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）其他不履行药品监督管理职责，造成严重不良影响或者重大损失。"
    },
    {
        "instruction":"已知信息：\n'Approaches other than those set forth in this guideline may be applicable and acceptable with appropriate science-based justification.'可被翻译为：在适当科学论证后，可接受本指导原则中未提到的其他方式进行分析方法验证。\n'This can be particularly important for small clinical trials.'可被翻译为：这对于小型临床试验而言尤其重要。\n'1. FDA May Require Applicants to Conduct Studies and Clinical Trials'可被翻译为：1．FDA可能要求申请人进行的研究和临床试验\n'D. careful design of viral clearance studies using different methods of virus inactivation or removal in the same production process in order to achieve maximum viral clearance; and'可被翻译为：D.为获得最佳病毒清除效果，对病毒清除研究应进行仔 细设计，在同一生产过程中使用不同的病毒灭活或去除方法。\n\n根据上述已知信息，请将'Scientific grounds, or reference to guidelines which do not require or specifically exclude such studies, can be an appropriate justification to conduct certain studies only at small- scale (e.g., viral removal).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"科学的根据、或参照指导原则不需要或明确排除此类研究，可以作为仅开展小规模的特定研究（例如，病毒的去除）的合理依据。"
    },
    {
        "instruction":"已知信息：\n'An assessment of the clinical meaningfulness of endpoints and their observed effect sizes.'可被翻译为：评估终点的临床意义及其观察到的效应大小。\n'The following are clinically meaningful definitions to be considered in the study design and to help in the definition of study endpoints.'可被翻译为：以下内容是研究方案设计中所涉及的有重要临床意义的定义,对研究终点的设定有辅助作用。\n'Clinical trials within a drug development program generally build upon the knowledge gained in early studies to guide the design and endpoint selection for later phases of development. A drug development program consisting of only a single trial intended to demonstrate the safety and effectiveness of a drug may fail due to insufficient exploratory evidence gained from earlier phases of study. Different endpoints have different combinations of characteristics. Ability to readily detect change may be more important than clinical meaningfulness for an early phase trial with a POC primary objective.'可被翻译为：一个药物研发计划中的临床试验通常建立在从早期研究中汲取的知识的基础上以便指导后续阶段研发的设计和终点选择。仅由旨在证明药物安全性和有效性的单项试验组成的药物研发计划可能因未能从早期阶段研究中获得充分的探索性证据而失败。不同终点可以有不同组合的特征。快捷检测变化的能力比以POC为主要目标的早期临床试验的临床意义更为重要。\n'Important secondary endpoints, particularly in the context of a study that succeeded in achieving the primary endpoint, should also be shown.'可被翻译为：特别是在成功达到主要终点的研究的上下文中，还 应当显示重要的次要终点。\n\n根据上述已知信息，请将'In contrast, clinical meaningfulness is an important endpoint characteristic in a study intended to provide evidence of effectiveness to support a marketing application. Including several endpoints with different characteristics may improve the overall interpretability of the study results. For example, a phase 3 clinical trial with a clinically meaningful but  subjective primary efficacy endpoint (i.e., one that may be prone to bias) may benefit from having secondary endpoints that are resistant to bias (such as laboratory measurements).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"相反，临床意义是旨在提供有效性证据以支持上市申请的一项研究的重要终点特征。将带有不同特征的多个终点纳入其中可提高研究结果的总体可判读性。例如，含有具有临床意义但是主观性较强的 主要疗效终点（即易于发生偏倚的终点）的III期临床试验可能从不易于发生偏倚的次要研究终点（例如实验室测定）中受益。"
    },
    {
        "instruction":"已知信息：\n'b. Circumstances under which FDA will not exercise enforcement discretion and a Medication Guide must be provided to a patient in inpatient and outpatient settings'可被翻译为：b．FDA不行使自由裁量权，必须向住院患者和门诊患者提供用药指南的各种情况\n'One goal of this guidance is to articulate the circumstances under which FDA intends to exercise enforcement discretion regarding the requirement to provide Medication Guides in certain settings, such as when a drug is dispensed to a healthcare professional for administration to a patient in an inpatient setting. We believe that this exercise of enforcement discretion will allow patients to receive important information about the drugs they will be taking without burdening the healthcare system to provide repetitive information when no material changes have been made.'可被翻译为：本指南的一个目的是明确FDA计划行使对于在某些环境中要求提供用药指南的自由裁量权的环境条件，例如在住院患者环境中药品分配至医疗保健专业人员进行患者给药。我们相信该自由裁量权的行使将使患者可以得到药品的重要信息，他们将获得没有负担的医疗保健体系，避免没有实质性改变时提供重复的信息。\n'Inpatient Must provide Medication Guide FDA intends to exercise enforcement discretion; Medication Guide need not be provided FDA intends to exercise enforcement discretion; Medication Guide need not be provided FDA intends to exercise enforcement discretion; Medication Guide need not be provided Must provide Medication Guide as specified in REMS'可被翻译为：住院患者 必须提供用药指南 FDA行使自由裁量权；不需要提供用药指南 FDA行使自由裁量权； 不需要提供用药指南 FDA行使自由裁量权； 不需要提供用药指南 按照REMS规定必须提供用药指南\n'A. Circumstances under which FDA intends to exercise enforcement discretion regarding Medication Guide distribution A Medication Guide need not be provided (i.e., FDA intends to exercise enforcement discretion concerning distribution of a Medication Guide to a patient) when a drug is dispensed under the following circumstances:'可被翻译为：A．各种环境下，FDA计划行使对于用药指南发放的自由裁量权当药品在下列环境中分配时，用药指南不需要提供（例如，FDA计划行使关于给患者发放用药指南的自由裁量权）：\n\n根据上述已知信息，请将'A Medication Guide must be provided to the patient or the patient’s agent (i.e., FDA does not intend to exercise enforcement discretion) in the following situations:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在下列情况，必须向患者或患者的代理人提供用药指南（例如，FAD不行使自由裁量权）："
    },
    {
        "instruction":"已知信息：\n'Real-time quantitative PCR (RQ-PCR)'可被翻译为：实时定量 PCR（RQ-PCR）\n'If appropriate, a PCR test or other suitable methods may be used.'可被翻译为：如适用，可使用PCR试验 或其他适当的方法。\n'o A correlation between qPCR and the infectivity assay or growth-based assay is established, and the signal noted in the qPCR assay is at or below the LOD of the infectivity or growth-based assay; or'可被翻译为：○ 确立qPCR与感染性测定或基于生长的测定间的相关性，在 qPCR检测中观察到的信号低于等于基于感染性或生长的测定法 的检测限；或\n'ASSAY Content or potency Other quantitative measurements (1)'可被翻译为：含量测定 含量或效价 其他定量测定 (1)\n\n根据上述已知信息，请将'Often an assay with a quantitative readout, like quantitative polymerase chain reaction (qPCR), is used because of the ease of performing\/standardizing the assay, high throughput format, rapid turnaround time, and assay sensitivity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通常会采用显示定量读数的测定法，例如定量聚合酶链式反应（qPCR），因为易于开展测定\/实施标准化、工作通量较高、周转时间较快以及测定灵敏度极佳。"
    },
    {
        "instruction":"已知信息：\n'However, if a particular group of patients is to be excluded from a study, the investigator should justify this approach, provide a detailed explanation of the exclusions, and discuss the resulting limitations in study interpretation. 15'可被翻译为：但是，如果需要从研究中排除一个特殊的患者组，研究者应该说明这一方 法的合理性，详细地阐明这一排除，并在研究解读中讨论产生的局限性。\n'Areas of non-compliance should be identified within the study report and their impact on study results\/data interpretation should be considered relative to the overall safety assessment.'可被翻译为：在试验报告中应注明未遵循GLP的地方，并且应考虑它们与总体安全性 评估相关的对试验结果\/数据阐释的影响。\n'Such information should be described and discussed in section 2.5.5 Overview of Safety, with appropriate cross references to section 2.7.4 Summary of Clinical Safety and any other relevant sections.'可被翻译为：这些信息应在第2.5.5节“安全性综述”进行描述和讨论，并适当交叉引用 第2.7.4节“临床安全性总结”以及任何其他相关章节。\n'As noted in section Background and Overview of Clinical Efficacy 2.7.3.1, however, any results of these studies that are pertinent to evaluation of safety should be discussed in section Summary of Clinical Safety 2.7.4.'可被翻译为：如第2.7.3.1节“背景和临床有效性综述”所述，这些与安全性评估 相关的研究的任何结果应放在第2.7.4节“临床安全性总结”中讨论。\n\n根据上述已知信息，请将'The impact of exclusions on the generalisability of the study should be discussed in section 13 of the study report, or in an overview of safety and efficacy.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应在研究报告第13章或安全 性和疗效概述中讨论排除标准对研究普适性的影响。"
    },
    {
        "instruction":"已知信息：\n'Pharmacogenomics and pharmacogenetics have the potential to improve the discovery, development and use of medicines.'可被翻译为：药物基因组学和遗传药理学能促进药物的发现、开发和 使用。\n'This guideline contains definitions of key terms in the discipline of pharmacogenomics and pharmacogenetics, namely genomic biomarkers, pharmacogenomics, pharmacogenetics and genomic data and sample coding categories.'可被翻译为：本指导原则包括药物基因组学和遗传药理学中关键术 语，即基因组生物标志物、药物基因组学、遗传药理学、基 因组数据和样本编码分类的定义。\n'An agreement on definitions will facilitate the integration of the discipline of pharmacogenomics and pharmacogenetics into global drug development and approval processes.'可被翻译为：定义的统一将 推动药物基因组学和遗传药理学整合到全球药物开发和批 准程序中去。\n'2.2 Pharmacogenomics and Pharmacogenetics'可被翻译为：2.2 药物基因组学和遗传药理学\n\n根据上述已知信息，请将'As new scientific knowledge in the discipline of pharmacogenomics and pharmacogenetics emerges, the current guideline will be reviewed and expanded if appropriate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由于药物基因组学和遗传药理学 中不断出现新的科学知识，因此必要时，本指导原则将被审核并做补充完善。"
    },
    {
        "instruction":"已知信息：\n'A vibrational form of a molecule. The regular extension and contraction of a bond along its axis. That is, the bond length changes, but the bond Angle does not change.'可被翻译为：分子的一种振动形式。是化学键沿着键轴方向做规律性的伸与缩的运动。即键长有变化，键角无变化。\n'A form of vibration in a molecule. Atoms at two chemically bonded ends of a molecule move simultaneously in opposite directions perpendicular to the plane.'可被翻译为：分子的一种振动形式。分子中两个化学键端的原子同时做反向垂直于平面方向的运动。\n'A vibrational form of a molecule. A regular change in bond Angle during vibration, resembling the \"open\" and \"closed\" of scissors.'可被翻译为：分子的一种振动形式。指在振动过程中键角规律性的变化，似剪刀的\"开”与“闭。\n'A vibrational form of a molecule. The movement of an atom in a direction perpendicular to its bond axis. There may be a change in bond Angle. The bending vibration is divided into two kinds: in-plane bending vibration and out-of-plane bending vibration.'可被翻译为：分子的一种振动形式。原子沿垂直于它的键轴方向的运动。可能有键角的变化。弯曲振动又分为面内弯曲振动及面外弯曲振动两种。\n\n根据上述已知信息，请将'A form of vibration of a molecule. The bond Angle between the two bonds does not change during vibration, but oscillates in-plane with respect to the rest of the molecule.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"分子的一种振动形式。振动过程中两键间键角无变化，但相对于分子的其余部分做面内摇摆。"
    },
    {
        "instruction":"已知信息：\n'Meanwhile, DAL will give priority to the review and approval of short supplied new drugs and pediatric drugs catering to urgent clinical needs, drugs for the prevention of major infectious diseases and rare diseases;as well as to conditioned marketing approval for drugs against diseases that are seriouslylife-threatening and have no proven effective treatment, and drugs urgently needed for public health.'可被翻译为：同时，对临床急需的短缺药品、防治重大传染病和罕见病等疾病的新药、儿童用药品优先审评审批；对治疗严重危及生命且尚无有效治疗手段的疾病以及公共卫生方面急需的药品，可以附带条件批准上市。\n'Article 96 The State encourages the research, development, and manufacture of drugs in shortage, and implements priority review and approval for drugs in shortage in urgent clinical needs or new drugs for prevention and treatment of serious infectious diseases and rare diseases.'可被翻译为：第九十六条 国家鼓励短缺药品的研制和生产，对临床急需的短缺药品、防治重大传染病和罕见病等疾病的新药予以优先审评审批。\n'(3) new drugs for the treatment of diseases such as AIDS, malignant tumors and rare diseases, etc. with significant clinical advantage; and'可被翻译为：（三）治疗艾滋病、恶性肿瘤、罕见病等疾病且具有明显临床治疗优势的新药；\n'Article 59 During clinical trials, for innovative drugs or modified new drugs used for the prevention and treatment of serious life-threatening diseases or diseases that seriously affect the quality of life but no effective means of prevention and treatment is available, or significantly clinically superior over current treatments with sufficient evidence is demonstrated, the applicant may apply for the breakthrough therapy drug procedure.'可被翻译为：第五十九条 药物临床试验期间，用于防治严重危及生命或者严重影响生存质量的疾病，且尚无有效防治手段或者与现有治疗手段相比有足够证据表明具有明显临床优势的创新药或者改良型新药等，申请人可以申请适用突破性治疗药物程序。\n\n根据上述已知信息，请将'(1) Drugs with urgent clinical needs in shortage, innovative drugs and modified new drugs for the prevention and treatment of major infectious diseases or rare diseases;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）临床急需的短缺药品、防治重大传染病和罕见病等疾病的创新药和改良型新药；"
    },
    {
        "instruction":"已知信息：\n'The FDA may communicate these  preliminary responses to the sponsor or applicant.'可被翻译为：FDA可能将这些初步回应传达给申办方或申请人。\n'Similarly, questions involving combination products usually demand significant time to solicit and consider feedback from multiple FDA centers. In all cases, FDA takes a thoughtful and measured approach to answering sponsor questions efficiently and comprehensively, particularly those questions that are likely to have an important impact on critical decision points in development programs or that represent FDA views related to the evidence that will be used to support marketing.'可被翻译为：同样地，涉及组合产品的问题通常需要大量时间来征求和考虑来自多个FDA中心的反馈。在所有情况下，FDA会采取深思熟虑和有计划的方法来有效和全面地回答申办方的问题，特别是那些可能对开发计划中的关键决策点具有重要影响或代表FDA关于用于支持上市的证据的见解。\n'The acknowledgment may include: the response itself, an estimated response time frame, notification that the question(s) have been consulted to other offices\/centers with an undetermined response time frame, a recommendation to submit the questions via a formal meeting request, or redirection to another specialized functional area in FDA (e.g., Import\/Export).'可被翻译为：该确认回执可能包括：回复本身、估计的回复时间段、已经向具有未确定回复时间段的其他办公室\/中心咨询问题的通知、对经由正式会议请求提交的问题的建议、或者重新 寄给FDA的另一个专门功能领域（例如，导入\/导出）。\n'Depending on the nature of the questions presented during the conversation, the sponsor may be referred to the formal meeting process for a fuller discussion of the issue(s) with additional review staff and management. Both FDA project managers and sponsors should provide mutual names and telephone numbers for communicating time-sensitive issues (e.g., notification of clinical hold).'可被翻译为：根据会谈期间所提出的问题的性质，可让申办方进行正式会议过程，以便与附加审评人员和管理人员更充分地讨论问题。FDA项目经理和申办方应提供相互的姓名和电话号码，用于沟通时效性问 题（例如临床试验暂停通知）。\n\n根据上述已知信息，请将'Depending on the nature and complexity of the question(s), FDA will either respond to the question(s) or redirect the sponsor to an alternative pathway for receiving a response (e.g., other FDA subject matter expert, formal meeting request process).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据问题的性质和复杂性，FDA将对问题作出回复，或重新给申办方指定可接收回复的替代途径（例如，其他FDA 学科问题专家，正式会议请求过程）。"
    },
    {
        "instruction":"已知信息：\n'(2) having the premises, facilities, equipment and hygienic environment required for drug manufacturing;'可被翻译为：（二）有与药品生产相适应的厂房、设施、设备和卫生环境；\n'(2) have the premises, facilities, and hygienic environment required for drug manufacturing;'可被翻译为：（二）有与药品生产相适应的厂房、设施和卫生环境；\n'3.2.P.3.1 Manufacturer(s) Drug Product Manufacturing sites (including those for testing, primary and secondary packaging, device assembly for drug product-device combination products 3.2.P.3.2 Batch Formula Drug Product Batch Formula (Qualitative and Quantitative) 3.2.P.3.3 Description of manufacturing process and process controls Individual unit operations and their sequence in the manufacturing process For levels\/details of ECs for inputs (process parameters and material attributes) and outputs of individual unit operations, reference is made to Chapter 3, section 3.2.3.1 3.2.P.3.4 Controls of Critical Steps and Intermediates Specifications (e.g., test, elements of analytical procedure and acceptance criteria) for critical steps and intermediates which may include storage conditions of critical intermediates.'可被翻译为：3.2.P.3.1 生产商 制剂生产场地（包括检测、初级和次级包装、药械组合产品的器械组 装的场地） 3.2.P.3.2 批处方 制剂批处方（定性和定量） 3.2.P.3.3 生产工艺和过程控制 单个单元操作及其在生产工艺中的顺序 对于单个单元操作的输入（工艺参数和物料属性）和输出的EC的水 平\/详情，请参见第3章，第3.2.3.1节 3.2.P.3.4 关键步骤和中间体的 控制 关键步骤和中间体的质量标准（例如，检测、分析方法要素和可接受 标准），可能包括关键中间体的储存条件。\n'Actual degradation products in the drug product include those observed above the ICH Q3B reporting threshold during storage of the drug product in the proposed long-term storage conditions and primary and secondary packaging, and also include those impurities that arise during the manufacture of the drug product.'可被翻译为：制剂中实际的降 解产物包括那些制剂在拟定的长期储存条件以及内包装和外包装储存期间观察 到的高于ICH Q3B 报告限度的杂质，还包括那些在制剂生产过程中产生的杂质。\n\n根据上述已知信息，请将'Drug Product Manufacturing sites (including those for testing, primary and secondary packaging, device assembly for drug product-device combination products'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"制剂生产产地（包括测试、初级和次级包装、药 械组合产品的器械组装）"
    },
    {
        "instruction":"已知信息：\n'Although the emphasis in this section is on the use of natural history studies as critical background information, such studies may be continued during clinical development to assess the suitability of new measurement tools and outcome measures for use in future treatment trials. The data for natural history studies can be collected prospectively or retrospectively, but prospective longitudinal natural history studies are likely to generate the most useful information about a disease.'可被翻译为：尽管该章节的重点强调的是将自然史研究用作关键背景信息，但是在临床研发过程中此类研究仍然继续以评价新的测量手段和结局指标在未来治疗试验中的适用性。 可以前瞻性地或回顾性地采集自然史研究的数据，但是前瞻性的纵向自然史研究更有可能生成最有用的疾病信息。\n'Understanding whether there is a continuous range of, or distinctly separable, phenotypes can greatly alter the drug development program. Natural history data should be collected for a sufficient duration to capture clinically meaningful outcomes and determine variability in the course of the disease.'可被翻译为：理解表型是否连续或明显离散会极大地改变药物研发计划。 应收集充分长时间内的自然史数据以便采集具有临床意义的结局，并且判定疾病病程的变异性。\n'While studies with historical controls have been used in clinical development programs of rare diseases, historical controls may be unsuitable for adequate and well-controlled studies in many circumstances.'可被翻译为：尽管有历史对照的研究已经应用在罕见病临床研发计划中，但是在许多情形下，历史对照不适用于充分的和良好对照的研究。\n'Sponsors can often obtain this knowledge, along with disease characteristics of patient subsets, from a natural history study of the disease (see section III, Natural History Studies).'可被翻译为：申办方通常可以从疾病的自然史研究中获得这种知识以及患者子集 的疾病特征（见第III节，自然史研究）。\n\n根据上述已知信息，请将'Longitudinal studies characterize the course of disease within individuals and better enable different phenotypes to be distinguished. The potential use of natural history data as a historical comparator for patients treated in a clinical trial is often of interest but the challenges associated with the use of historical controls are well recognized.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"纵向研究表征了个体的病程，并且能够更好地区分不同表型。 对于在临床试验中接受治疗的患者，将自然史数据用作历史对照通常是有意义的，但是使用历史对照所面临的挑战也已经为人们所熟知。"
    },
    {
        "instruction":"已知信息：\n'flowing steam sterilization'可被翻译为：流通蒸汽灭菌\n'The method of sterilization by heating the articles to be sterilized in boiling water.'可被翻译为：把待灭菌物品放入沸水中加热灭菌的方法。\n'Method of killing microorganisms by heating saturated steam with pressure greater than normal pressure.'可被翻译为：用压力大于常压的饱和水蒸气加热杀灭微生物的方法。\n'boiling sterilization'可被翻译为：煮沸灭菌\n\n根据上述已知信息，请将'Method of sterilization in saturated steam, boiling water, or circulating steam.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在饱和蒸汽、沸水或流通蒸汽中进行灭菌的方法。"
    },
    {
        "instruction":"已知信息：\n'The HL7 model-driven methodology is used to develop consensus-based standards for healthcare system interoperability and information exchange.HL7 V3 messages are based on an XML encoding syntax.'可被翻译为：HL7 模型驱动的方法可用于制定基于共识的标准，用于医疗保健系统互通性和信息交换。 HL7 V3 信息是基于 XML 编码语法。\n'The HL7 version 3 (V3) messaging standard deals with a static model of health care information as viewed within the scope of HL7 standards development activities.'可被翻译为：HL7版本3（V3）信息标准涉及在HL7标准开发活动范围内的静态卫生保健信息模型。\n'To learn more about HL7 V3, refer to ‘Understanding Version 3: A primer on the HL7 Version 3 Healthcare Interoperability Standard – Normative Edition,’ by Andrew Hinchley.'可被翻译为：欲了解更多关于 HL7 V3 的信息，请参见 Andrew Hinchley 的“了解版本 3：HL7 版本 3医疗互通性标准-规范版入门”。\n'There can be many practical challenges to the interoperability of EHRs and EDC systems.'可被翻译为：EHR和EDC系统的互操作性也存在实践挑战。\n\n根据上述已知信息，请将'HL7 V3 supports development of specifications that facilitate interoperability between systems.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"元素 HL7 V3支持开发有助于系统间互通性的规范。"
    },
    {
        "instruction":"已知信息：\n'Article 28 The registrant, filing entity or contract manufacturer of medical devices shall carry out training in aspects such as laws, regulations, provisions, standards and quality management, etc. of medical devices, establish training system, formulate training plan, strengthen the assessment and keep proper training records.'可被翻译为：第二十八条  医疗器械注册人、备案人、受托生产企业应当开展医疗器械法律、法规、规章、标准以及质量管理等方面的培训，建立培训制度，制定培训计划，加强考核并做好培训记录。\n'Article 31 The medical device distributors shall purchase medical devices from medical device registrant, filing entity and distributor with legal qualification.'可被翻译为：第三十一条  医疗器械经营企业应当从具有合法资质的医疗器械注册人、备案人、经营企业购进医疗器械。\n'Article 26 The legal representative and principal responsible person of the registrant or filing entity of medical devices shall assume full responsibility for quality and safety of the medical devices manufactured.'可被翻译为：第二十六条  医疗器械注册人、备案人的法定代表人、主要负责人对其生产的医疗器械质量安全全面负责。\n'Article 59 If the registrant, filing entity and distributor of the medical devices fail to take effective removal measures for the existing quality and safety risks of the medical devices, the drug regulatory departments may hold a liability interview with legal representative or person in charge of enterprise of the registrant, filing entity and distributor of the medical devices.'可被翻译为：第五十九条  医疗器械注册人、备案人、经营企业对存在的医疗器械质量安全风险，未采取有效措施消除的，药品监督管理部门可以对医疗器械注册人、备案人、经营企业的法定代表人或者企业负责人进行责任约谈。\n\n根据上述已知信息，请将'Article 37 The registrant, filing entity and distributor of the medical devices shall strengthen training and management of the sales personnel, and assume legal liabilities for purchase or sale of medical devices of the sales personnel in the name of the enterprise.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十七条  医疗器械注册人、备案人和经营企业应当加强对销售人员的培训和管理，对销售人员以本企业名义从事的医疗器械购销行为承担法律责任。"
    },
    {
        "instruction":"已知信息：\n'All operations involved in the production of a drug, including processing, compounding, formulating, filling, packaging, and labelling.'可被翻译为：药品生产过程中涉及的所有操作，包括加工、配制、配方、灌装、包装和标签。\n'Includes the intermediate, bulk and finished product of drug.'可被翻译为：包括药品的中间产品、待包装产品和成品。\n'A general term for a report on the testing of starting materials, intermediates, active substances, excipients, reference substances and their finished products used in the manufacture of pharmaceutical products.'可被翻译为：对用于药品生产的起始物料、中间体、活性物质、辅料、标准物质及其成品的检测报告的通称。\n'Impurities related to the active pharmaceutical ingredient in a drug. These include starting materials, intermediates, by-products, and degradation products.'可被翻译为：药品中与活性药物成分相关的杂质。包括起始物料、中间体、副产物和降解产物。\n\n根据上述已知信息，请将'All products related to pharmacy, including starting materials (active pharmaceutical ingredients and excipients), finished dosage forms, and biological and other specific products.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"所有与药学相关的产品，包括起始原料(活性药物成分和赋形剂)、成品剂型、生物制品和其他特定产品。"
    },
    {
        "instruction":"已知信息：\n'14.10 Intermediates and APIs failing to meet established specifications should be identified as such and quarantined. These intermediates or APIs can be reprocessed or reworked as described below. The final disposition of rejected materials should be recorded.'可被翻译为：14.10 不符合既定质量标准的中间体和原料药应进行标识并隔离。这些中间体或原料药可按以下要求进行返工或重新加工，不合格物料的最终处置应有记录。\n'14.51 If the conditions under which returned intermediates or APIs have been stored or shipped before or during their return or the condition of their containers casts doubt on their quality, the returned intermediates or APIs should be reprocessed, reworked, or destroyed, as appropriate.'可被翻译为：14.51 退回的中间体或原料药在其退回之前、或者运输途中的贮存条件或其包装状况使其质量值得怀疑时，应当视情形对退回的中间体或原料药进行返工、重新加工或销毁。\n'14.52 Records of returned intermediates or APIs should be maintained. For each return, documentation should include: \n− Name and address of the consignee \n− Intermediate or API, batch number, and quantity returned \n− Reason for return \n− Use or disposal of the returned intermediate or API'可被翻译为：14.52 应当保存中间体或原料药退货记录。每次的退货记录应当包括： \n- 收货方的名称和地址； \n-退回中间体或原料药的批号、数量； \n-退货原因； \n- 退回中间体或原料药的使用或处置。\n'2.14 The persons authorised to release intermediates and APIs should be specified.'可被翻译为：2.14 应当指定授权放行中间体和原料药的人员。\n\n根据上述已知信息，请将'14.50 Returned intermediates or APIs should be identified as such and quarantined.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"14.50 应当对退回的中间体或原料药进行标识并隔离。"
    },
    {
        "instruction":"已知信息：\n'6. Drug MAHs, manufacturers, distributors and user units should follow the NMPA Guiding Opinions on the Construction of Drug Information Traceability System (NMPA Department of Drug Supervision (2018) No. 35) and the NMPA-formulated unified standards and specifications, actively carry out the construction of drug information traceability system, and implement whole-process traceability by categories and stages in accordance with  the subsequent work deployment of the NMPA.'可被翻译为：6.药品上市许可持有人、生产企业、经营企业和使用单位应当根据《国家药监局关于药品信息化追溯体系建设的指导意见》（国药监药管〔2018〕35号）以及国家药监局统一制定的标准和规范，主动开展药品信息化追溯体系建设，并按照后续国家药监局的工作部署，分类别、分阶段实施全过程可追溯。\n'NMPA Issued Three Informationization Standards such as the Basic Technical Requirements for Drug Traceability System'可被翻译为：国家药监局关于发布《药品追溯系统基本技术要求》等3项信息化标准的公告\n'The drug regulatory department under the State Council shall, in collaboration with the competent health department under the State Council, formulate unified vaccine traceability norms and standards, establish a national coordination platform for vaccine electronic traceability, and integrate traceability information of the whole process throughout manufacture, distribution and immunization to realize the traceability of vaccines.'可被翻译为：国务院药品监督管理部门会同国务院卫生健康主管部门制定统一的疫苗追溯标准和规范，建立全国疫苗电子追溯协同平台，整合疫苗生产、流通和预防接种全过程追溯信息，实现疫苗可追溯。\n'Article 4 Drug MAHs and drug manufacturers shall establish and implement drug traceability systems, attach traceability labels to sales package units at each level as specified, implement drug traceability by information-based means, accurately document and retain drug traceability data in a timely manner and provide traceability information to the drug traceability coordination service platform.'可被翻译为：第四条 药品上市许可持有人、药品生产企业应当建立并实施药品追溯制度，按照规定赋予药品各级销售包装单元追溯标识，通过信息化手段实施药品追溯，及时准确记录、保存药品追溯数据，并向药品追溯协同服务平台提供追溯信息。\n\n根据上述已知信息，请将'The Information Center of NMPA is responsible for the construction and management of the drug traceability coordination service platform and drug safety credit archives, and is in charge of the unified coding of drug manufacture sites.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药品监督管理局信息中心负责药品追溯协同服务平台、药品安全信用档案建设和管理，对药品生产场地进行统一编码。"
    },
    {
        "instruction":"已知信息：\n'Article 20 Key posts should be occupied by full-time personnel, which should at least include the heads of the manufacturer, production management, quality management, and the Qualified Person.'可被翻译为：第二十条 关键人员应当为企业的全职人员，至少应当包括企业负责人、生产管理负责人、质量管理负责人和质量受权人。\n'Article 18: The manufacturer should have an adequate number of managerial and operating personnel with appropriate qualifications (with respect to, including education, training, and practical experience). The responsibilities of each department and each position should be clearly specified.'可被翻译为：第十八条 企业应当配备足够数量并具有适当资质（含学 历、培训和实践经验）的管理和操作人员，应当明确规定每个部 门和每个岗位的职责。\n'The heads of production and quality management must be independent from each other. The head of the quality management and the Qualified Person can be the same person. Procedures should be established to ensure the independence of the Qualified Person for fulfilling responsibilities, without interference from the head of the manufacturer or other personnel.'可被翻译为：质量管理负责人和生产管理负责人不得互相兼任。质量管理负责人和质量受权人可以兼任。应当制定操作规程确保质量受权人独立履行职责，不受企业负责人和其他人员的干扰。\n'(VII)  Description of the changes in the key personnel including the production management person, quality management person, and qualified person;'可被翻译为：（七）生产管理负责人、质量管理负责人、质量受权人等关键人员变动情况的说明；\n\n根据上述已知信息，请将'Article 20: Key posts should be occupied by full-time personnel, which should at least include the heads of the manufacturer, production management, quality management, and the Qualified Person.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十条 关键人员应当为企业的全职人员，至少应当包括 企业负责人、生产管理负责人、质量管理负责人和质量受权人。"
    },
    {
        "instruction":"已知信息：\n'If this is not feasible, blind evaluation of the main endpoints (efficacy and safety) by independent adjudication committees comprised of experts in the field is mandatory.'可被翻译为：如果不可行，则必需由行业专家组成的独立评估委员会对主要终点（有效性和安全性）进行盲态评估。\n'All secondary efficacy endpoints should be adjudicated by an independent and blinded committee in order to limit the introduction of any bias.'可被翻译为：应由独立且盲态的委员会判定所有次要疗效终点，以限制任何偏差的引入。\n'4.3.4.4. Selection of the primary endpoints'可被翻译为：4.3.4.4. 主要终点的选择\n'A blinded review by an independent adjudicating committee is recommended.'可被翻译为：建议由独立的裁定委员会进行盲态审查。\n\n根据上述已知信息，请将'It is recommended that the assessment of the main efficacy and safety outcomes is performed blind by an independent adjudicating committee (see section 4.3.4.4. “Selection of the primary endpoints”).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"推荐由一个独立裁定委员会进行主要有效性和安全性结局的盲态评估（见第 4.3.4.4.节“主要终点的选择”）。"
    },
    {
        "instruction":"已知信息：\n'ANNEX : Granularity Document The CTD specifies many section headings and numbers.'可被翻译为：附件：粒度文件 CTD规定了很多章节的标题和编号。\n'22 Nov. 2003 Granularity: section headings and numbers, documents location\/hierarchy, documents pagination The CTD specifies many section headings and numbers. Could guidance be provided for all modules on headings in relation to document location and the section headings within those documents? Could guidance also be provided on where in the CTD and eCTD multiple documents can be located in the hierarchy? As a consequence of this definition could guidance be given on how documents should be paginated and on what the module Table of Contents should therefore include? Please refer to the Annex of the Organisation of the Common Technical Document: \"Granularity Document\".'可被翻译为：22 2003 年 11 月 粒度文件：章节标题和编号、文档位置\/层级结构，文档分页 CTD规定了许多的章节标题和数字。 可以提供这些文档所有模块的关于文件位置标题和章节标题 的指导意见吗？ 还可以同时给出关于 CTD 和 eCTD 中多个文档可以位于层级结构中何处吗？作为这一定义的结果，可以指导如何分页文件，以及该模块目录应包括哪些内容？ 请参阅通用技术文档组织的附件：“颗粒度文件”。\n'Option 3 (using multiple 3.2.P.4 sections with 3.2.P.4.x granularity): One or multiple documents can be submitted at the appropriate 3.2.P.4.x level per excipient CTD topic.'可被翻译为：选项3（使用多个3.2.P.4章节，且3.2.P.4.X也有文件粒度）：根据CTD的 辅料问题，在相应的3.2.P.4.x层级可提交一份或多份文件。\n'Could guidance be provided for all modules on headings in relation to document location and the section headings within those documents? \nCould guidance also be provided on where in the CTD and eCTD multiple documents can be located in the hierarchy? \nAs a consequence of this definition could guidance be given on how documents should be paginated and on what the module Table of Contents should therefore include?'可被翻译为：是否可以为所有模块文件内与文件位置相关的标题及各章节的标题提供指导？\n是否也可以为CTD和eCTD文件中的哪些地方可以按层级排序提供指导？ \n根据该定义的结果，是否也能够为文件应如何编制页码提供指导，以及应纳入什么样的模块目录表？\n\n根据上述已知信息，请将'15 July 2003 Is the term, “section”, defined in the CTD? Is there a different use of the term in Module 2 and 3? Do the ICH regions define sections differently? Each section in the CTD is identified by a number and a heading Please refer to the Granularity Document Annex for a description documents to be provided in each section. The annex delineates when multiple documents per heading may be provided. Also, refer to regional guidance as to when one or multiple documents should be provided per heading.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"15 2003 年 7 月 CTD 中定义的术语“章节”是什么？ 模块 2 和 3 中的术语是否 有不同的用途？ ICH 的区域定义的章节是否是有差异的？ CTD 中的每个章节由一个数字和一个标题确定。请参阅“粒度文件附件”，查看每个章节中提供的说明文件。附件描述每个标题可能提供多个文件的情况。另外，当每个标题应提供一个或多个文件时参考章节指南。"
    },
    {
        "instruction":"已知信息：\n'(1) Records of receipt, grouping designation, administration, testing and evaluation, and disposal of test system should be retained completely and traceably, and should be consistent with those in the application dossiers. For example:'可被翻译为：（一）应完整保存实验系统可追溯的接收、分组、给药、检测、处置等记录，并确保与申报资料一致。如：\n'(2) Records of receipt, formulating, analysis (such as homogeneity, concentration, stability, etc.), use and return of the test\/control articles should be retained completely and traceably and should be consistent with those in the application dossiers. For example:'可被翻译为：（二）应完整保存可追溯的受试物和对照品的接收、配制、分析(如均一性、浓度、稳定性等)、使用、返还等记录，并与申报资料一致。如：\n'(4) Records of receipt, quarantine, use and disposal of laboratory animals should be retained completely, and the quantity shall be accountable and consistent with that specified in the application dossiers;'可被翻译为：（四）实验动物接收、检疫、使用、处理等应保存完整记录且数量吻合，并与申报资料相符；\n'(3) Records of biological samples (such as blood, urine, tissue, etc.) on collection (such as collection time, etc.), labelling, processing, transfer, testing and storage should be retained in a complete and traceable manner and should be consistent with those in the application dossiers. For example:'可被翻译为：（三）应完整保存可追溯的生物样本(血液、尿液、组织 等)采集(时间等)、标识、处理、转运、交接、检测及保存等记录，并与申报资料一致。如：\n\n根据上述已知信息，请将'(2) Records of storage, use, and passage, etc. of test system should be retained completely, and information such as time, quantity, and so forth in the records should be consistent with that specified in the application dossiers.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）实验系统的保存、取用、传代等应保存完整记录，且记录的时间、数量等信息应与申报资料相符。"
    },
    {
        "instruction":"已知信息：\n'Purge factors may be measured or predicted.'可被翻译为：清除因子可进行测定或预测。\n'The effects of this approach should be taken into account when analysing the data.'可被翻译为：分析数据时，应考虑这种方法带来的影响。\n'For Option 4 approaches where justification based on scientific principles alone is not considered sufficient, as well as for Option 3 approaches, analytical data to support the control approach is expected. This could include as appropriate information on the structural changes to the impurity caused by downstream chemistry (“fate”), analytical data on pilot scale batches, and in some cases, laboratory scale studies with intentional addition of the impurity (“spiking studies”). In these cases, it is important to demonstrate that the fate\/purge argument for the impurity is robust and will consistently assure a negligible probability of an impurity residing in the final drug substance above the acceptable limit. Where the purge factor is based on developmental data, it is important to address the expected scale-dependence or independence. In the case that the small scale model used in the development stage is considered to not represent the commercial scale, confirmation of suitable control in pilot scale and\/or initial commercial batches is generally appropriate. The need for data from pilot\/commercial batches is influenced by the magnitude of the purge factor calculated from laboratory or pilot scale data, point of entry of the impurity, and knowledge of downstream process purge points.'可被翻译为：与采用方法3时一样，采用方法4时，如仅根据科学原理来进行论述是不够充分的，需提交分析数据来支持控制方法。提交的资料可包括：在下游化学反应中导致杂质结构改变的相关信息（去向）、中试批次的分析数据，某些情况下可提供实验室规模下加样研究结果。在这些情况下，证明该杂质的去向\/清除的论据的可靠性是至关重要的，它能够自始至终地保证最终原料药中杂质残留量超过可接受限度的可能性可以忽略。如果清除因子是根据研发数据得到的，须注意评估其规模依赖性或非依赖性。如果用于研发阶段的小规模模型被认为不能代表商业规模，则需要确认中试规模和\/或初始商业批次中所用的控制是适当的。根据由实验室或中试规模数据计算所得的清除因子大小、杂质引入步骤和对下游工艺清除工艺的理解，决定是否需要中试\/商业批次数据。\n'purge factor'可被翻译为：清除因子\n\n根据上述已知信息，请将'Where the purge factor is based on developmental data, it is important to address the expected scale-dependence or independence.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果清除因子是根据研发数据得到 的，一定要处理预期的规模依赖性或非依赖性。"
    },
    {
        "instruction":"已知信息：\n'Case studies are provided to illustrate the application of the WoE approach. These cases are provided for illustrative purposes only and are not intended to be prescriptive nor to indicate the sufficiency of data to support a WoE assessment. Cases 1 and 2 are examples of pharmaceuticals for which the key WoE factors were integrated to conclude that a 2-year rat study would not add value to the assessment of human carcinogenic risk. Case 3 describes how data from the WoE factors were integrated to conclude that the carcinogenic potential for humans was uncertain, and a 2-year rat carcinogenicity study would add value to the assessment of human carcinogenic risk. Case 4 describes a pharmaceutical for which a 2-year rat carcinogenicity study was concluded to not contribute value to the assessment of human carcinogenic risk despite there being no data available for other compounds within the pharmacologic class.'可被翻译为：提供了一系列案例研究以说明WoE方法的应用。提供的这些案例仅用于说明目的，并非用作规范或表明支持WoE评估的数据充分程度。案例1和2是通过综合WoE关键因素得出2年大鼠试验不会为人体致癌性风险评估提供更多有价值的信息的结论。案例3描述了如何将WoE因素的数据进行整合，得出人体潜在致癌性尚不确定，2年大鼠致癌性试验将为人体致癌性风险评估提供更多有价值的信息的结论。案例4介绍了一个药物，尽管相同药理学类别中的其他化合物尚无可用数据，仍然得出了2年大鼠致癌性试验不会为人体致癌性风险评估贡献价值的结论。\n'This strategy could be based on a weight of evidence approach, including a review of relevant data from a variety of sources. The data sources can include published data (e.g., information from transgenic, knock-out or animal disease models, human genetic diseases), information on class effects, detailed information on target biology and mechanism of action, in vitro data, data from chronic toxicity studies and clinical data. In some cases, the available information can be sufficient to address carcinogenic potential and inform clinical risk without additional nonclinical studies.'可被翻译为：该策略可以将证据权重作为基础，包括对不同来源相关数据的审查。数据来源可以包括已发表的数据（如来自转基因、基因敲除或疾病动物模型、人遗传疾病的信息）、类别效应的信息、靶点生物学和作用机制的详细信息、体外数据、慢性毒性试验的数据以及临床数据。在某些情况下，现有数据即可以充分说明潜在的致癌性，并且告知临床风险，而无需额外的非临床试验。\n'The data that support this risk assessment can come from a number of sources that include, but are not limited to:'可被翻译为：支持该风险评估的数据来源包括但不限于：\n'A “weight of evidence” approach, that is use of scientific judgment in evaluation of the totality of the data derived from one long-term carcinogenicity study along with other appropriate experimental investigations, enhances the assessment of carcinogenic risk to humans.'可被翻译为：对来自一项长期致癌性试验和其他适当的试验研究所得到的全部数据进行科学评价和判 断的“证据权重法”，可提升对人体致癌性风险的评价。\n\n根据上述已知信息，请将'A WoE approach is based on a comprehensive assessment of the totality of data relevant to carcinogenic potential available from public sources and from relevant drug development studies. These factors include, but are not limited to:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"WoE方法是基于对公开来源和相关药物开发研究中获得的与潜在致癌性相关的全部数据的综合评估。这些因素包括但不限于："
    },
    {
        "instruction":"已知信息：\n'For a drug approved for marketing, where an indication is to be added and clinical trials are required, a new drug clinical trial application shall be filed.'可被翻译为：获准上市的药品增加适应症（或者功能主治）需要开展药物临床试验的，应当提出新的药物临床试验申请。\n'Article 31 Where suspension of a drug clinical trial has been ordered and the sponsor plans to continue the drug clinical trial, a supplementary application for resuming the drug clinical trial shall be submitted after taking rectification actions, and the drug clinical trial may be continued after the application is reviewed and approved. Where a drug clinical trial has been suspended for three years and no application has been filed and approved for resumption of the drug clinical trial, the drug clinical trial permit shall cease to be valid automatically.'可被翻译为：第三十一条 药物临床试验被责令暂停后，申办者拟继续开展药物临床试验的，应当在完成整改后提出恢复药物临床试验的补充申请，经审查同意后方可继续开展药物临床试验。药物临床试验暂停时间满三年且未申请并获准恢复药物临床试验的，该药物临床试验许可自行失效。\n'Article 32 A drug clinical trial shall be conducted within three years after approval. Where no subject has signed any informed consent form within three years since the date when the clinical trial application was approved, the drug clinical trial permit shall cease to be valid automatically. Where the sponsor plans to continue the drug clinical trial, a new drug clinical trial application shall be submitted.'可被翻译为：第三十二条 药物临床试验应当在批准后三年内实施。药物临床试验申请自获准之日起，三年内未有受试者签署知情同意书的，该药物临床试验许可自行失效。仍需实施药物临床试验的，应当重新申请。\n'Article 27 For a drug approved for clinical trials, where an indication is to be added or the drug is to be used in combination with other drug(s), the applicant shall file a new drug clinical trial application to the CDE, and after approval shall the new drug clinical trial be conducted.'可被翻译为：第二十七条 获准开展药物临床试验的药物拟增加适应症（或者功能主治）以及增加与其他药物联合用药的，申请人应当提出新的药物临床试验申请，经批准后方可开展新的药物临床试验。\n\n根据上述已知信息，请将'Where the sponsor plans to continue a drug clinical trial after it has been terminated, a new drug clinical trial application shall be submitted.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物临床试验终止后，拟继续开展药物临床试验的，应当重新提出药物临床试验申请。"
    },
    {
        "instruction":"已知信息：\n'When there is an identified concern specific to bone metabolism or structure, additional endpoints should be considered. Examples include assessments of bone mass and geometry using densitometric techniques, serum and urinary biomarkers of bone formation and resorption, and bone histomorphometry.'可被翻译为：当对骨代谢或结构具有确定的特殊担忧时，应考虑附加的终点指标。终点指标应基于已确定的担忧的大小和类型以及所涉及的试验种属。例如采用密度测量技术评估骨量和几何结构，骨形成和骨吸收的血清和尿液生物标志物，以及骨组织形态测量。\n'The evaluation of response is performed according to RECIST criteria when soft-tissue metastases are detectable. However, prostate cancer is characterised by osteblastic bone metastases not always suitable to assessment according to RECIST. Therefore the occurrence of new bone lesions as a marker for progressive disease might be considered acceptable, provided that pre-specified criteria (an example being the PCWG2 criteria) adequately addressing the possibility of a flare reaction or trauma are defined in the protocol. Indeed, subclinical lytic bone lesion successfully treated may firstly responds with an osteoblastic reaction before restitution. Specifically for bone scan it is also of importance to consider uptake caused by trauma and other benign conditions such as osteoporotic fractures. Medicinal compounds acting as inhibitors of osteoblast activity may confound the assessment of disease activity by bone scans.'可被翻译为：如果检测出软组织转移，需要根据RECIST标准评价治疗反应。但是，存在成骨细胞骨转移的前列腺癌不一定适合根据RECIST进行评估。因此，只要方案中预先定义了标准（例如PCWG2标准）来充分解决发作反应或者创伤的可能性，可以考虑将出现新的骨病灶作为疾病进展的一个标志。实际上，成功治疗的亚临床溶骨性骨病灶在恢复之前首先会出现成骨性反应。尤其是对于骨扫描，考虑到创伤和其它良性疾病（如骨质疏松性骨折）引起的骨吸收也是非常重要的。作为成骨细胞活性抑制剂的药物可能会干扰通过骨扫描评估疾病活动。\n'However, clinical trials must still establish that increases in BMD are associated with reductions in the incidences of bone fractures.'可被翻译为：然而，临床试验仍然必须确定BMD的 增加与骨折发生率的减少有关。\n'For example, it may be of clinical or regulatory importance to consider the effect of a treatment under different conditions from those of the trial that can be carried out.'可被翻译为：例如，在与可实施试验条件不同的条件下的治疗效应可能 具有临床或监管重要性。\n\n根据上述已知信息，请将'Specifically for bone scan it is also of importance to consider uptake caused by trauma and other benign conditions such as osteoporotic fractures.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"尤其是对于骨扫描，考虑到创伤和其它良性疾病（如骨质疏松性骨折）引起的骨吸收也是非常重要的。"
    },
    {
        "instruction":"已知信息：\n'Confirmation of structure based on e.g., synthetic route and spectral analyses should be provided. Information such as the potential for isomerism, the identification of stereochemistry, or the potential for forming polymorphs should also be included.'可被翻译为：应提供结合合成路线和光谱分析等方法进行的结构确证信息。如可能产生异构化，则需确证立体结构；如存在多晶型，也需要提供相关确证信息。\n'The identification of compounds by chemical methods.'可被翻译为：运用化学方法鉴别化合物。\n'A resource database of protein structure information collected from methods such as X-ray crystal diffraction and nuclear magnetic resonance analysis.'可被翻译为：收集来源于X射线晶体衍射和核磁共振解析等方法测定的蛋白质结构信息资源数据库。\n'x-ray diffraction of single crystal'可被翻译为：X 射线单晶衍射\n\n根据上述已知信息，请将'For chemical total synthesis or semi-synthesis, microbial fermentation and raw materials extracted from animals and plants, UV-visible absorption spectroscopy, infrared absorption spectroscopy, nuclear magnetic resonance spectroscopy, mass spectrometry, specific rotation, X-ray single crystal diffraction or X-ray powder diffraction, differential scanning calorimetry, thermogravimetric and other physical and chemical methods are used to confirm the process of the structure of the target compound.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于化学全合成或半合成、微生物发酵以及从动、植物中提取的原料药，使用紫外可见吸收光谱、红外吸收光谱、核磁共振谱、质谱、比旋度、X射线单晶衍射或X射线粉末衍射、差示扫描量热法、热重等物理和化学方法，确证目标化合物结构的过程。"
    },
    {
        "instruction":"已知信息：\n'4.INTERNATIONAL BIRTH DATES # Date of Approval Questions Answers 4.1 March 2014 When transitioning to the PBRER, how should the MAH handle medicinal products whose current DLP is not synchronised to the new definition of the IBD? The definition of IBD in the Guideline refers to the date of the first marketing approval for any product containing the active substance granted to any company in any country in the world.'可被翻译为：4. 国际诞生日 # 批准日期 疑问 解答 4.1 2014年3月 当过渡到PBRER时，MAH如何处理 当前DLP与IBD的新定义不同步的药 品？ 指南中IBD的定义是指任何含有活性物质的任何产品在世界任何国家\/区域任何公司 的首次上市批准的日期。\n'2.8 Periodicity and PBRER Data Lock Point 2.8.1 International Birth Date and Data Lock Point Each medicinal product should have an IBD: the IBD is the date of the first marketing approval for any product containing the active substance granted to any company in any country in the world.'可被翻译为：2.8 定期和PBRER的数据锁定点 2.8.1 国际诞生日和数据锁定点 每种药品都应具有IBD：IBD是指任何公司的任何含有活性物质的药品在 世界上任何国家\/区域被首次批准上市销售的日期。\n'The date of the first marketing authorisation for any product containing the active substance granted to any company in any country in the world.'可被翻译为：任何公司的任何含有活性物质的药品在世界上任何国家\/区域被首次批准上市销售的日期。\n'4.2 March 2014 How can the MAH determine the IBD for products based on the definition of IBD in the Guideline? The definition of IBD in the Guideline refers to the date of the first marketing approval for any product containing the active substance granted to any company in any country in the world.'可被翻译为：4.2 2014年3月 MAH如何基于指南中IBD的定义确定 产品的IBD？ 准则中IBD的定义是指任何含有活性物质的任何产品在世界任何国家\/区域任何公司 的首次营销批准的日期。\n\n根据上述已知信息，请将'International Birth Date (IBD) ICH Guideline E2C The date of the first marketing authorisation for any product containing the active substance granted to any company in any country in the world. 9.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国际诞生日(IBD) ICH指导原 则E2C 任何公司的任何含有活性物质的药品在世界上任何 国家\/区域被首次批准上市销售的日期。"
    },
    {
        "instruction":"已知信息：\n'If historical positive controls are used, then the variance of the present data should be consistent with that seen historically, which can be demonstrated by reporting minimal detectable differences with by time analysis.'可被翻译为：如果阳性对照为历史数据，那时间-效应分析中应报告最小可 检测值，以提示递呈数据的变异度与历史数据一致。\n'Statistical power calculations could also be provided from historical data and testing the effects of positive controls.'可被翻译为：还可以根据使用相同方案的同一实验室的历史数据提供统计学把握度计算。\n'Recent historical control data from the performing laboratory is preferable.'可被翻译为：首选本实验室的近期历史对照数据。\n'Limited historical control data and laboratory experience'可被翻译为：历史对照数据和实验室经验有限\n\n根据上述已知信息，请将'If historical positive control data are utilized to justify assay sensitivity or statistical power is calculated from historical control data, then the variance of the present data should be consistent with that seen historically.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果利用历史阳性对照 数据来证明试验灵敏度或根据历史对照数据计算统计学把握度，则当前数据的方 差应与历史数据保持一致。"
    },
    {
        "instruction":"已知信息：\n'Safety evaluation should include monitoring of short term and local tolerance (blood pressure, heart rate, temperature, and monitoring of other adverse events, skin reactions) at repeated intervals following the infusion of the new product.'可被翻译为：安全性评价应包括监测在重复输注新产品后的间隔内的短期和局部耐受性（血压、 心率、体温、监测其他不良事件、皮肤反应）。\n'Evaluation of efficacy and safety should be performed at regular intervals, depending on the anticipated rapidity of action of the medicinal product and the duration of the trial.'可被翻译为：根据预期的药物作用速度和试验持续时间，应定期进行阶段性的有效性和安全性评价。\n'Pharmacodynamic (PD) studies should include, apart from the evaluation of tolerability, the assessment of duration of action, the effect of the agent on haemodynamic parameters (e.g. stroke volume, Pulmonary Capillary Wedge Pressure [PCWP]), heart rate, as well as the effect on impulse formation, conduction and repolarisation (i.e., QT\/QTc intervals) and cardiac arrhythmia, neuro- hormonal parameters (e.g. sympathetic nervous system) and renal function.'可被翻译为：除了耐受性的评估之外，药效学（PD）研究还应包括作用持续时间的评估、药物对血液动力学参数（如每搏输出量、肺毛细血管楔压[PCWP]）和心率的影响以及对心脏激动、传导和复极化（即QT\/QTc 间期）和心律失常、神经激素参数（如交感神经系统）、肾功能的影响。\n'- Other laboratory tests for evaluation of safety parameters (e.g., complete blood count, serum chemistries)'可被翻译为：-用于评估安全性参数的其他实验室检查（例如全血细胞计数，血生化）\n\n根据上述已知信息，请将'Safety evaluation should include monitoring of short term tolerance (blood pressure, heart rate, temperature, and monitoring of other relevant parameters) at repeated intervals following the administration of the new product.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"安全性评价应包括对重复给予新产品后在重复时间间隔的短期耐受性监测（血压、 心率、体温和其他相关参数的监测）。"
    },
    {
        "instruction":"已知信息：\n'The ability of antibacterial agents to inhibit or kill bacteria is measured in vitro by dilution or diffusion.'可被翻译为：在体外通过稀释法或扩散法测定抗菌药物抑制或杀死细菌的能力。\n'Using the diffusion and penetration effect of antibiotics in the medium, the standard solution with known concentration and the test product solution with unknown content were added and placed in a small steel tube containing test bacteria under the same conditions, and the titer of the test product was determined by comparing the size of the antibacterial zone.'可被翻译为：利用抗生素在培养基内的扩散渗透作用，将已知浓度的标准品溶液与未知含量的供试品溶液在同样条件下分别加入放置在含有试验菌的小钢管内，通过比较抑菌圈大小，测定供试品效价的方法。\n'The degree to which antibacterial agents inhibit specific bacteria or fungi in vitro or in vivo.'可被翻译为：抗菌药物在体外或体内对特定细菌或真菌的抑杀程度。\n'The minimum concentration of the drug required to inhibit the growth of 50% of the bacteria under test.'可被翻译为：能抑制50%受试菌生长所需药物的最低浓度。\n\n根据上述已知信息，请将'The method of diluting antibiotics into different concentrations to inhibit the growth of test bacteria and determine its antibacterial effect.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将抗生素稀释成不同浓度抑制试验菌生长，测定其抗菌效果的方法。"
    },
    {
        "instruction":"已知信息：\n'amino acid composition'可被翻译为：氨基酸组成\n'Any naturally occurring or synthetic compound consisting of two or more amino acids joined by the carboxyl group of one amino acid to the amino group of another amino acid. Such compounds containing less than 50 amino acid residues are generally referred to as peptides.'可被翻译为：任何由两个或两个以上的氨基酸通过一个氨基酸的竣基与另一个氨基酸的氨基连接而成的自然界存在的或合成的化合物。一般将含50个氨基酸残基以下的这类化合物称为肽。\n'In the sequence of peptide or protein, the amino group and the carboxyl group between amino acids are dehydrated to form a bond, so the amino acid in the peptide or protein molecule is not a complete amino acid and is called residue.'可被翻译为：在肽或蛋白质的序列中，氨基酸之间的氨基和竣基脱水成键，因此肽或蛋白质分子中的氨基酸已不是完整的氨基酸，被称为残基。\n'A protein containing a complete range of essential amino acids in sufficient amounts and proportions to sustain life and promote growth and development.'可被翻译为：含有的必需氨基酸种类齐全、含量充足、比例适当因而能够维持生命和促进生长发育的一类蛋白质。\n\n根据上述已知信息，请将'The composition of a peptide or protein, expressed in terms of the relative amounts and types of amino acids of which it is composed. It is usually expressed in mole percent.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种肽或蛋白质的组成，用构成它的氨基酸的相对量和种类来表示。通常以摩尔百分数表示。"
    },
    {
        "instruction":"已知信息：\n'Identify potential sources of process variability;'可被翻译为：确认工艺变化的潜在源头；\n'A comprehensive pharmaceutical development approach will generate process and product understanding and identify sources of variability. Sources of variability that can impact product quality should be identified, appropriately understood, and subsequently controlled. Understanding sources of variability and their impact on downstream processes or processing, in-process materials, and drug product quality can provide an opportunity to shift controls upstream and minimise the need for end product testing. Product and process understanding, in combination with quality risk management (see ICH Q9), will support the control of the process such that the variability (e.g., of raw materials) can be compensated for in an adaptable manner to deliver consistent product quality.'可被翻译为：全面的药品研发策略有助于对生产工艺和产品的理解，并且可以确定波动的来源。应该确定和了解会影响产品质量的变异来源，并且随后加以控制。了解变异来源及其对下游的工艺、操作、中间体和制剂质量的影响，有助于将控制移到上游并减少成品检验的需求。将对产品和工艺的了解与质量风险管理（见ICH Q9）相结合更有利于工艺控制，使波动（如原材料的波动）以适当的方式得到调节，从而得到持续稳定的产品质量。\n'It facilitates continual improvement of process performance and product quality throughout the product lifecycle.'可被翻译为：在整个产品生命周期内，它能促进工艺性能和产品质量的持续改进。\n'Innovation, continual improvement, the outputs of process performance and product quality monitoring and CAPA drive change.'可被翻译为：创新、持续改进、工艺性能和产品质量监测结果以及CAPA会导致变更。\n\n根据上述已知信息，请将'(d) Identify sources of variation affecting process performance and product quality for potential continual improvement activities to reduce or control variation;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(d) 识别影响工艺性能和产品质量的变异的来源，以便进行潜在的持续改进活动来减少或控制变异；"
    },
    {
        "instruction":"已知信息：\n'8. The amount of product obtained at different stages of manufacture, and reconciliation when necessary;'可被翻译为：8.不同生产工序所得产量及必要时的物料平衡计算。\n'8. The amount of product obtained at different stages of manufacture, and reconciliation when necessary;'可被翻译为：（八）不同生产工序所得产量及必要时的物料平衡计算；\n'1. A cool white fluorescent lamp designed to produce an output similar to that specified in ISO 10977(1993) ; and'可被翻译为：1. 冷白荧光灯应具有ISO10977（1993）所规定的类似输出功率。\n'time interval'可被翻译为：间隔时间\n\n根据上述已知信息，请将'The time interval used to produce a quantity of output material.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"生产一定量的输出物料的时间区间。"
    },
    {
        "instruction":"已知信息：\n'With respect to clinical risk information, the investigator brochure should specifically and accurately list those adverse events that have been observed with an investigational drug and for which a causal relationship with the drug is suspected or confirmed. In addition, the investigator brochure should list adverse events that commonly occur with the class of drugs or may be predicted to occur based on the pharmacological properties of the drug, even if not yet observed with the drug under investigation, to alert the investigator to the possibility of their occurrence. Sponsors should use judgment in determining which terms accurately reflect a particular adverse event, including syndrome names if applicable. The investigator brochure should not list adverse events that are unlikely to have been caused by the drug because such lists could dilute the importance of clinically meaningful risk information.'可被翻译为：关于临床风险信息，研究者手册应该特别和准确列出那些已经观察到的与研究用药物有关的不良事件，其与药物的因果关系是可疑的或确定的。此外，研究者手册应该列出常见的与一类药物有关的或根据药物药理学性质预测可发生的不良事件，警告研究者其发生的可能性，即使还未在药物研究中实际观察到。申办者应该对使用哪个术语准确反映特殊不良事件做出判断，包括综合征的名称（如适用）。研究者手册不应该列出不太可能由药物造成的不良事件，因为这样的列表可能稀释临床上有意义的风险信息的重要性。\n'Certain serious adverse events can be anticipated to occur in the study population independent of drug exposure. Such events include known consequences of the underlying disease or condition under investigation (e.g., symptoms, disease progression) and events unlikely to be related to the underlying disease or condition under investigation but common in the study population independent of drug therapy (e.g., cardiovascular events in an elderly population). An example of the former would be a non-acute death observed in a trial in cancer patients. An example of the latter would be an acute myocardial infarction observed in a long-duration trial in an elderly population with cancer. Although these serious adverse events meet the definition of unexpected at 21 CFR 312.32(a), as they are not listed in the investigator brochure (see sections III.D and VI.B), these events do not warrant expedited reporting as individual cases because it is not possible, based on a single case, to determine that there is a reasonable possibility that the drug caused the event. As a result, they do not meet the definition of a suspected adverse reaction.'可被翻译为：可以预期某些严重不良事件发生于特定研究人群中，而非依赖于药物暴露。这些事件包括潜在疾病的已知结果或研究的条件（例如，症状，疾病进展）和不太可能与潜在疾病或研究的条件相关的事件，但在特定研究人群中常见，且不依赖于药物暴露（例如，老年人群中的心脑血管事件）。前者包括在癌症患者试验中观察到的非急性死亡。后者包括老年患癌人群长期试验中观察到的急性心肌梗死。尽管这些严重不良事件满足 21 CFR 312.32（a）“非预期”的定义，由于它们未在研究者手册中列出（见III.D 和VI.B 部分），因为作为单一事件，可能不能确定药物造成该事件的合理可能性，所以不能保证这些事件将按照个体事件快速报告。由此，这类事件不能满足可疑不良反应的定义。\n'An adverse event or suspected adverse reaction is considered “unexpected” if it is not listed in the investigator brochure or is not listed at the specificity or severity that has been observed; or, if an investigator brochure is not required or available, is not consistent with the risk information described in the general investigational plan or elsewhere in the current application, as amended. For example, under this definition, hepatic necrosis would be unexpected (by virtue of greater severity) if the investigator brochure referred only to elevated hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by virtue of greater specificity) if the investigator brochure listed only cerebral vascular accidents. \"Unexpected,\" as used in this definition, also refers to adverse events or suspected adverse reactions that are mentioned in the investigator brochure as occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug under investigation.'可被翻译为：如果事件没有在研究者手册中列出，或没有被列为观察到特异性或严重性；或者，研究者手册不需要或不可用的情况下，与修订的当前申请中的一般研究计划或其它地方所描述的风险不一致，那么这个不良事件或可疑不良反应可以认为是“非预期的”。例如，根据这个定义，如果研究者手册只提到肝酶升高或肝炎，那么肝坏死就属于非预期的（更严重的后果）。同样，如果研究者手册只列出了脑血管意外，脑血栓栓塞和大脑血管炎就是非预期的（更高的特异性）。“非预期的”，如定义中所述的，也指在研究者手册提到的，与一类药品相关的或预期来自该药品的药理作用的，但是在研究中没有伴随该药品用药而发生的不良事件或可疑不良反应。\n'This definition relies entirely on the adverse events or suspected adverse reactions listed in the investigator brochure for the particular drug under investigation (or elsewhere in the general investigational plan if an investigator brochure is not required or available) as the basis for determining whether newly acquired information generated from clinical trials or reported from other sources is unexpected.6 This means that events not listed for the particular drug under investigation in the investigator brochure are considered “unexpected” and those listed are considered “expected.” When new adverse event information is received, it is the sponsor’s responsibility to determine whether the event is “unexpected” for IND safety reporting purposes. In the clinical trial setting, there has been some confusion with the term “expected” as it has been used to mean “anticipated” for the disease being treated or population being studied rather than “listed in the investigator brochure.” For example, some adverse events can be anticipated to occur as a result of a disease or in an older population (e.g., cancer-related deaths in a cancer trial, strokes or acute myocardial infarctions in an older population). However, for reporting purposes, these anticipated events are not “expected” because they are not listed in the investigator brochure (i.e., the test drug is not suspected or known to cause them). Monitoring and reporting these types of anticipated events are further discussed in section V.A.3 of this document.'可被翻译为：该定义完全依赖于研究中该药品的研究者手册（或者研究者手册不要求提供或不可获得的情况下，在一般研究计划中）所列的不良事件或可疑不良反应作为依据，以确定从临床试验或其它来源的报告中新获得的信息是否是属于非预期 。这意味着在研药品的研究者手册中没有列出的事件认为是“非预期的”而那些列出的认为是“预期的”。当收到新的不良事件信息，申办者有责任确定该事件用于IND安全性报告的递交是否是“非预期的”。在临床试验中，术语“预期的”使用有一些混乱，对于疾病治疗或研究人群，过去常被认为指“预测的”而不是“在研究者手册中列出的”。例如，一些不良事件可以预测会作为某疾病的结果而发生或者在老年人群中发生（例如，癌症试验中癌症相关死亡、中风或老年人群中急性心肌梗死）。然而，出于报告的目的，这些预测事件不是“预期的”因为他们没有在研究者手册中列出（例如，不会怀疑或肯定该受试药物导致了某些事件）。本文件 V.A.3 部分对监测和报告这类型预期事件有进一步的讨论。\n\n根据上述已知信息，请将'Adverse events listed in the investigator brochure as occurring with members of the same class of drugs, or as anticipated from the pharmacological properties of the drug, would be considered unexpected until they have been observed with the drug under investigation. For example, although angioedema is anticipated to occur in some patients exposed to drugs in the angiotensin-converting enzyme (ACE) inhibitor class and angioedema would be described in the investigator brochure as a class effect, a case of angioedema observed with the drug under investigation should be considered unexpected for reporting purposes until it is included in the investigator brochure as occurring with the drug under investigation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究者手册中列出的不良事件伴随同类药品用药出现的，或作为预期来自药品药理作用的，将认为是“非预期的”，直到在在研药品中观察到了这些不良事件为止。例如，尽管血管性水肿预计会发生在一些暴露于血管紧张素转化酶（ACE）抑制剂类的药品的患者中，而且作为伴随同类药品出现的血管性水肿将在研究者手册中进行描述，药物研究中观察到的一例血管性水肿应该认为是“非预期的”（用于报告的），直到其伴随研究用药物发生而将其列入研究者手册中为止。"
    },
    {
        "instruction":"已知信息：\n'For identification tests, a critical aspect is to demonstrate the capability to identify the analyte of interest based on unique aspects of its molecular structure and\/or other specific properties.'可被翻译为：对于鉴别试验，一个关键点是基于其分子结构和\/或其他特性 证明其能鉴别目标分析物的能力。\n'Impurities may warrant identification and qualification, depending on the following:'可被翻译为：杂质是否必要鉴别和定量，取决以下信息：\n'A patient must fulfil 2 or more of the following criteria:'可被翻译为：患者必须满足以下标准中的至少两项：\n'A patient must fulfil 2 or more of the following 3 criteria:'可被翻译为：病人需至少满足以下三个标准中的 2 个：\n\n根据上述已知信息，请将'To qualify as a probe substance, a compound must fulfil certain criteria such as'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种化合物必须符合特定标准，才能被鉴定为探针物质，例如"
    },
    {
        "instruction":"已知信息：\n'A WCB is derived from one or more containers of the MCB.'可被翻译为：WCB来源于一支或多支MCB。\n'The manufacturer may choose to characterise the WCB instead of the MCB, if justified.'可被翻译为：如理由充分，生产商也可选择对WCB进行鉴定，而不是MCB。\n'Additional WCBs are generated from the MCB as needed.'可被翻译为：如果需要，可从MCB中生产更多的WCB。\n'The concept of a two-tiered cell bank, in which the MCB which is used to generate Working Cell Banks (WCBs), is generally accepted as the most practical approach to providing a supply of cell substrate for continued manufacture of the product.'可被翻译为：二级细胞库的概念，即主细胞库（MCB）传代产生工作细胞库(WCB)，通常被认为在连续生产产品时细胞基质供应的最实际方法。\n\n根据上述已知信息，请将'A single-tiered banking system consisting only of the MCB but no WCBs could be used in principle, for example, if relatively few containers were needed each year to produce the desired product.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如每年生产的产品仅需有限的几支细胞时，仅建有MCB而没有WCB的单级细胞库，原则上亦是允许的。"
    },
    {
        "instruction":"已知信息：\n'Guideline on the evaluation of medicinal products for the treatment of chronic constipation'可被翻译为：治疗慢性便秘用药品的评估指南\n'Guideline on the evaluation of medicinal products for the treatment of chronic constipation Draft'可被翻译为：治疗慢性便秘用药物的评估指南草案\n'This guideline is a revision and expansion of the previous “Points to Consider on the Evaluation of Medicinal Products for the treatment of Irritable Bowel Syndrome”, which has been in operation since the year 2003.'可被翻译为：本指南是对自 2003 年起开始实施的“评估治疗肠易激综合征药品的考虑要点” 的修订和扩充。\n'This Guideline is intended to assist applicants during the development of products for the treatment of Irritable Bowel Syndrome (IBS).'可被翻译为：撰写本《指南》的目的是在肠易激综合征（IBS）治疗药物开发期间帮助申办方。\n\n根据上述已知信息，请将'Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用于治疗肠易激综合征药物的评价指南"
    },
    {
        "instruction":"已知信息：\n'Our main knowledge on genetic factors influencing absorption, distribution, metabolism and excretion (ADME) is centred on drug metabolism. Genetic variations in metabolizing enzymes may lead to (i) increased or decreased clearance of the parent drug or pharmacologically active or toxic metabolites, (ii) increased or decreased production of active metabolites of the respective prodrugs, or (iii) increased or decreased formation of toxic products. These metabolising steps may involve phase I and\/or phase II enzymes.'可被翻译为：与药物吸收、分布、代谢和排泄ADME相关的遗传因素均以药物代谢为重点。同化酶基因变异可能导致以下变化(i)原药、活性或毒性代谢产物清除率的升高或降低,(ii)各前体药物活性代谢产物产量的升高或降低(iii)毒性产物形成的增加或减少。这些新陈代谢的步骤可能包含第一和\/或第二阶段生化酶的作用。\n'CYP2C9 genetic polymorphism produces poor metabolizer (PM) and extensive metabolizer phenotypes and differences in Drug A exposure.'可被翻译为：由于CYP2C9的遗传多态性产生弱代谢物（PM）和强代 谢物表型，药物A的暴露量会有差异。\n'(i)drug-metabolising enzymes (cytochrome P450 enzymes, (CYPs), phase II enzymes),'可被翻译为：（i）药物代谢酶（细胞色素P450酶、（CYP）、II相酶），\n'Human drug metabolism studies indicate that ZB3579 has no effect on cytochrome P450 enzymes, such that the clinical pharmacokinetics of ZB3579 are unlikely to be affected by P450 inducers or inhibitors.'可被翻译为：人体药物代谢研究表明，ZB3579对细胞色素P450酶无作用，因 此ZB3579的临床药代动力学不太可能受到P450诱导剂或抑制剂的影响。\n\n根据上述已知信息，请将'The normal (wild-type) situation with a certain metabolising capacity, is referred to as 'extensive metabolisers' (EM). Increased metabolism occurs in the 'ultrarapid metaboliser' (UM), and is usually the result of multiple active alleles; decreased metabolism occurs in the 'poor metaboliser' (PM), and is usually the result of mutations or gene deletions leading to reduced or abolished expression or function of the respective enzymes. 30-50% of all clinically used drugs are metabolized by functionally polymorphic enzymes 1,2, including Phase I cytochrome P450 enzymes (e.g., CYP2C9, CYP2C19 and CYP2D63), and phase II enzymes (e.g., UDP-glucuronosyltransferases, N-acetyltransferase-2 and some methyltransferases).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"有一定的新陈代谢能力的正常(野生型)情况，被称之为“广泛代谢者”(EM),而代谢的升高发生在“超速代谢者”(UM)中,通常是多个活动等位基因的结果; 低的新陈代谢发生在弱代谢者(PM)中，通常是基因突变或缺失所导致相应酶的活性降低或表达缺陷或功能丧失。30 - 50%的临床药物的代谢会受到功能多态酶的影响1,2，包括第一阶段细胞色素P450 酶(如CYP2C9、CYP2C19、CYP2D63酶)和第二阶段酶(如UDP-葡糖醛酸转移酶、N-乙酰化酶 2 和一些甲基转移酶)。"
    },
    {
        "instruction":"已知信息：\n'The first example below outlines a protocol for a single change (a manufacturing site change) to a single product.'可被翻译为：下面的第一个示例概述了单个产品的单个变更（单个产地变更）方案。\n'If the protocol describes several changes for a particular product, a justification should be added showing how the changes are related and that inclusion in a single protocol is appropriate.'可被翻译为：如果方案描述了一个特定产品的若干个变更，则应添加一个理由来说明这些变更是如何相互关联的，以及将这些变更包 含在同一个方案中是合适的。\n'If multiple changes are to be implemented, these activities should address the potential risk from the cumulative effect of multiple changes and how they are linked.'可被翻译为：如果实施多项变更，这些措施应针对来自多项变更累积影响产生的潜在风险以及多项变更之间的关系。\n'The risk of the proposed change(s) should be similar across products; additional considerations should be taken into account depending on the approach, for example: a. One or more changes to be implemented across multiple products (e.g., change in stopper across multiple products that use the same container closure system): the same risk mitigation strategy should be applicable across all impacted products; b. One or more changes to be implemented across multiple products and at multiple sites (e.g., change in analytical method across multiple sites, change in manufacturing site(s) across multiple products): the same risk mitigation strategy should be applicable across all impacted products and\/or sites (see Annex IE).'可被翻译为：拟定变更的风险对于不同产 品应相似；根据此种方法应考量其他考虑，如： a. 一个或多个变更将在多个产品上实施（例如，使用相同包装系统的多个产品的胶塞变更）：相同的风险降低 策略应适用于所有受影响的产品； b.一个或多个变更将在多个产品和多个产地实施（例如，跨多个产地的分析方法变更、跨多个产品的产地变更）：相同的风险降低策略应适用于所有受影响的产品和\/或 产地（参见附件IE）。\n\n根据上述已知信息，请将'The second example outlines a protocol for multiple changes (multiple manufacturing site changes) that could be implemented for multiple products.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二个示例概述了可以为多个产品实施的多个变更（多个产地变更）方案。"
    },
    {
        "instruction":"已知信息：\n'The development of new compounds in this area is therefore ongoing.'可被翻译为：因此，该领域的新药研发仍在进行中。\n'new neoplastic medicines'可被翻译为：新型抗肿瘤药物\n'Currently a large number of new medicinal products are under late clinical development or have recently been marketed.'可被翻译为：目前有很多新药正处于临床开发的后期或者已经在最近上市销售。\n'Multicentre trials of this nature may, in principle, be carried out at any stage of clinical development. They may have several centres with a large number of subjects per centre or, in the case of a rare disease, they may have a large number of centres with very few subjects per centre.'可被翻译为：原则上，在临床研发的任何阶段均可开展这种性质的多中心试验。多中心试验可能有几个中心，每个中心的受试者数量较大；也可能有很多中心，每个中心 只有很少的受试者，比如罕见病研究。\n\n根据上述已知信息，请将'A very large number of anti-cancer compounds have been and currently are under development.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"已经开发的和目前正在开发的抗癌化合物有很多。"
    },
    {
        "instruction":"已知信息：\n'A manufacturer’s objective intent may, for example, be shown by labeling claims, advertising matter, or oral or written statements by the manufacturer or its representatives.'可被翻译为：制造商的目标意图，例如，可以由标签声明，广告内容或者制造商或其代表口头的或书面的声明得到展示。\n'The objective intent of the manufacturer regarding the use of a product, process or service as reflected in the specifications, instructions and information provided by the manufacturer (18).'可被翻译为：制造商关于使用产品、工艺或服务的客观意图，反映在制造商提供的规格、说明书和信息中(18)。\n'It may be shown by the circumstances that the HCT\/P is, with the knowledge of the manufacturer or its representatives, offered for a purpose for which it is neither labeled nor advertised.'可被翻译为：就制造商或其代表所知，HCT\/P可根据目的可不 做标签和广告，可能由其具体情况进行展示。\n'6. What does FDA mean by “manufacturer’s objective intent” in 21 CFR 1271.10(a)(2)?'可被翻译为：6. FDA在21 CFR 1271.10(a)(2)中“制造商目标意图”的含义是什么？\n\n根据上述已知信息，请将'A manufacturer’s objective intent is determined by the expressions of the manufacturer or its representatives, or may be shown by the circumstances surrounding the distribution of the article.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"制造商的目的意图由制造商或其代表的表述决定，或可能由其相关文章分布情况 决定。"
    },
    {
        "instruction":"已知信息：\n'The choice of excipients listed in 3.2.P.1, their concentration, their characteristics that can influence the drug product performance should be discussed relative to their respective functions.'可被翻译为：应针对3.2.P.1中辅料种类的选择、用量的确定以及影响制剂性能特性的辅料性质 进行论述。\n'The compatibility of the drug substance with excipients listed in 3.2.P.1 should be discussed. Additionally, key physicochemical characteristics (e.g., water content, solubility, particle size distribution, polymorphic or solid state form) of the drug substance that can influence the performance of the drug product should be discussed.'可被翻译为：应论述3.2.P.1中列出的辅料与原料药的相容性。此外，还应说明能影响制剂性能的原料药的关键理化性质（如，水分、溶解性、粒度分布、多晶型或固体形态等）。\n'To support a biowaiver request, the quantity of excipients in the IR drug product should be consistent with the intended function (e.g., lubricant).'可被翻译为：速释制剂中的辅料用量应该与预期功能（例如润滑剂）相匹配以支持生物豁免申请。\n'Changes in the formulation, excipients, or device components may affect the  drug product delivery characteristics and clinical performance of the drug-device combination  product.'可被翻译为：配方、辅料或器械部件的改变可能会影响给药系 统的特点以及药物-器械联用产品的临床性能。\n\n根据上述已知信息，请将'The excipients chosen, their concentration, and the characteristics that can influence the drug product performance (e.g., stability, bioavailability) or manufacturability should be discussed relative to the respective function of each excipient. This should include all substances used in the manufacture of the drug product, whether they appear in the finished product or not (e.g., processing aids). Compatibility of excipients with other excipients, where relevant (for example, combination of preservatives in a dual preservative system), should be established. The ability of excipients (e.g., antioxidants, penetration enhancers, disintegrants, release controlling agents) to provide their intended functionality, and to perform throughout the intended drug product shelf life, should also be demonstrated. The information on excipient performance can be used, as appropriate, to justify the choice and quality attributes of the excipient, and to support the justification of the drug product specification (3.2.P.5.6).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"申报者应针对各种辅料的作用，详述其选择过程、配比以及可能影响制剂性能（如稳定性、生物利用度）或可生产性的特性。处方中应包括制剂生产中所用到的所有物质，不论其是否出现在成品中（如：工艺辅助剂）。必要时，应建立辅料之间的相容性（比如双重防腐系统中防腐剂的组合）。同时，应阐述辅料（如抗氧剂、渗透促进剂、崩解剂、控释剂）是否能实现预期的作用，是否能在预期的有效期内发挥作用。可能的情况下，可以利用有关辅料性能的资料，来论证辅料的选择和质量属性，并支持证明制剂质量标准的合理性 （3.2.P.5.6）。"
    },
    {
        "instruction":"已知信息：\n'Measurements of Quality of Life on generic (e.g. SF-36; SF-12) as well as disease specific instruments (e.g. PAC-QOL).'可被翻译为：使用通用的（如 SF-36；SF-12）以及疾病特异性的工具（如 PAC-QOL） 评估生活质量\n'Other scales that measure functional disability such as the Norris scale (Norris 1974), the Appel Scale (Appel 1987) and the ALS Severity Scale (ALSSS; Hillel 1989) were previously used (Brooks 2006); however, the ALSFRS-R is the preferred scale.'可被翻译为：其他功能残疾评定量表如Norris量表（Norris 1974）、Appel量表（Appel 1987）和ALS严重程度量表（ALSSS; Hillel 1989）在先前的研究中被使用过（Brooks 2006）；但ALSFRS-R应为首选量表。\n'Quality of Life (e.g. validated generic scales (SF-36), or disease specific scales (AIMS) The following secondary endpoints could also be considered:'可被翻译为：生命质量（例如验证通用量表（SF-36），或疾病特定量表（AIMS）- 也可以考虑以下次要终点：\n'- Measurements of Quality of Life on generic (e.g. SF-36; SF-12) as well as disease specific instruments (e.g. PAC-QOL)'可被翻译为：一般的生活质量（例如 SF-36;SF- 12）以及疾病特定工具（例如 PAC-QOL） 的测量。\n\n根据上述已知信息，请将'Both generic (e.g. SF-36, EQ5-D, the Health Utilities Index [HUI], Sickness Impact Profile [SIP]) (Bergner 1981) and specific scales, (e.g. ALS Assessment Questionnaires ALSAQ-40 or ALSQ5) are available which can be combined (e.g. SIP\/ALS19) (McGuire 1997; Jenkinson 1999 and 2001; Bromberg 2001).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通用量表（如SF-36、EQ5-D、健康效用指数[HUI]、疾病影 响程度测定量表[SIP]）（Bergner 1981）和特异性量表（如ALS评估问卷ALSAQ-40或ALSQ5）都是可用的，也可联合使用（如SIP\/ALS19）（McGuire 1997, Jenkinson 256 1999 and 2001, Bromberg 2001）。"
    },
    {
        "instruction":"已知信息：\n'An immune response to a therapeutic protein representing a counterpart to an endogenous protein may result in cross-reactivity, directed to the endogenous protein in cases where endogenous protein is still produced.'可被翻译为：代表着内源性蛋白对应物的治疗蛋白的免疫应答会导致出现针对内源性蛋白的交叉反应性，如果在内源性蛋白不断合成的情况下。\n'Therefore, potential cross-reactivity with pre-existing antibodies should be considered.'可被翻译为：因此， 应考虑与既存抗体间的潜在交叉反应性。\n'Immunogenicity for mAbs can be age related e.g. protein turnover is different in children compared to adults and this can result in differences in observed immunogenicity, e.g. for antibodies used in treatment of juvenile arthritis compared to rheumatoid arthritis at comparable doses. Previous exposure to similar or related monoclonal antibodies can also influence immunogenicity.'可被翻译为：单抗的免疫原性和年龄相关，如蛋白质周转在儿童和成人之间是不同的，这会导致观察到的免疫原性有所不同，例如在幼年型关节炎和类风湿性关节炎中使用相当剂量的抗体时就有这种情况。\n'Patient-related factors, which might influence the immune response to a therapeutic protein, include genetic factors, age of the patient, disease-related factors including other treatments, and pre-existing antibodies (protein therapeutic -reactive antibodies) due to previous exposure to the product or products containing substances with structural similarity; as well as sensitisation of patients due to process-and product-related impurities and excipients.'可被翻译为：可能影响治疗蛋白的免疫应答的患者相关因素包括遗传因素、患者年龄、疾病相关因素（包括其他治疗）以及因既往曾暴露于该产品或含结构相似性物质的产品而形成的既存抗体（蛋白治疗药-反应性抗体）；以及因工艺和产品相关杂质和辅料所致的患者致敏。\n\n根据上述已知信息，请将'ii. cross-reactive antibodies, e.g. due to previous therapy with related substances'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"ii.交叉反应抗体，因既往曾接受相关物质治疗所致"
    },
    {
        "instruction":"已知信息：\n'In order to implement the Regulations on the Supervision and Administration of Medical Devices, the NMPA organized to formulate the Catalogue of Distribution of Class II Medical Devices Exempted from Filing, which was issued on June 28，2021.'可被翻译为：为贯彻实施《医疗器械监督管理条例》，国家药监局组织制定了《免于经营备案的第二类医疗器械产品目录》。于2021年6月28日予以公布。\n'NMPA has drafted a Catalogue of Class II Medical Devices Exempted from Distribution and Filing, for which public comments are currently solicited. After being issued, the Catalogue shall be executed.'可被翻译为：国家药监局已起草有关免于经营备案的第二类医疗器械产品目录，目前正在公开征求意见。产品目录发布后，按目录执行。\n'NMPA Announcement on Issuing the Catalogue of Medical Devices Exempt from Clinical Trials (Revised Second Batch)'可被翻译为：国家药监局关于发布免于进行临床试验医疗器械目录（第二批修订）的通告\n'NMPA Announcement on Issuing the Working Procedures for Dynamic Adjustment of Classification Catalogue for Medical Devices'可被翻译为：国家药监局关于发布医疗器械分类目录动态调整工作程序的公告\n\n根据上述已知信息，请将'NMPA Announcement on Issuing the Catalogue of Distribution of Class II Medical Devices Exempted from Filing'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于公布《免于经营备案的第二类医疗器械产品目录》的公告"
    },
    {
        "instruction":"已知信息：\n'(5) acute relapse of underlying diseases or worsening of disease conditions in vaccine recipients who have immunization contraindications prescribed on the vaccine package insert and who or whose guardian fails to provide truthful information about his\/her health condition and the contraindication for the vaccine prior to immunization;'可被翻译为：（五）受种者有疫苗说明书规定的接种禁忌，在接种前受种者或者其监护人未如实提供受种者的健康状况和接种禁忌等情况，接种后受种者原有疾病急性复发或者病情加重；\n'Timing and number of doses will depend on the onset and duration of the immune response of the particular vaccine.'可被翻译为：给药时间和次数将取决于特定疫苗免疫应答发生和持续的 时间。\n'If any disease prevention and control institutions or immunization entities violate the work norms, immunization procedure, vaccine use guidance and immunization plan in immunization, and thus cause injury to vaccine recipients, they shall assume the compensation liability according to law.'可被翻译为：疾病预防控制机构、接种单位因违反预防接种工作规范、免疫程序、疫苗使用指导原则、接种方案，造成受种者损害的，应当依法承担赔偿责任。\n'The following circumstances are not adverse reactions of immunization:'可被翻译为：下列情形不属于预防接种异常反应：\n\n根据上述已知信息，请将'(4) coincidental events following immunization in recipients who were in the latent period or prodromal period of a certain disease at the time of immunization;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）受种者在接种时正处于某种疾病的潜伏期或者前驱期，接种后偶合发病；"
    },
    {
        "instruction":"已知信息：\n'The accuracy and precision of receptor solution sample collection at each time point should be appropriately qualified. Evidence to qualify a sampling procedure should illustrate that the sampling technique can reliably collect a consistent volume of the sample from the well-mixed volume of the receptor compartment at each sampling event, and that no artifacts are likely to be created by the sampling technique (e.g., because of carryover between samples in automated sampling systems or because of sampling from an unmixed volume in the sampling arm of a vertical diffusion cell). Information should be included describing the equipment manufacturer’s specification for the accuracy and precision of receptor solution sampling, when available.'可被翻译为：应对每个时间点接收液取样的准确性和精密度进行确认。在取样程序的确认过程中应证明，所用取样技术可以从混合良好的接收室中始终一致的收集到相同体积的接收液，且不会因取样技术的原因引起误差（例如，由于自动取样系统中样品间的相互干扰或样品的残留，或因为从混合不均一的立式扩散池采样臂中取样）。如适用，应描述设备生产商关于接收液取样准确度和精密度的规范信息。\n'Fill the reservoir dosage area with the sample under test. Ensure that the reservoir is filled to the top to minimize the possibility of air bubble formation between the surface of the sample and the membrane. A uniform surface can be obtained with the aid of a spatula. The typical quantity of sample is between 300 mg and 4 g, depending on the type of immersion cell used. Using forceps or tweezers, remove the membrane from the soaking receptor solution and place it over the top of the sample compartment by rolling it onto the surface to avoid entrapment of air. Ensure that the membrane is free of wrinkles. Assemble the immersion cell components as specified by the device manufacturer. Carefully place the completed assembly into the bottom of the dissolution vessel with the membrane facing up. The appropriate preheated receptor solution may be preloaded in the vessel or can be added after immersion of the immersion cell to start the test.'可被翻译为：用待测样品填充储层上药区。确保药物充满到顶部，以尽量减少样品表面和膜之间形成气泡的可能性。借助于刮刀可以得到一个均匀的表面。样品的典型数量在300mg至4g之间，取决于所使用的浸没池的类型。使用镊子将膜从浸泡的受体溶液中取出，并将其滚动到样品室表面，以避免空气滞留。确保薄膜无褶皱。按照设备制造商的规定组装浸没池组件。小心地将完成的组件放入溶解容器的底部，使膜面朝上。适当的预热受体溶液可以预装在容器中，或者可以在浸泡池浸泡后加入，以开始测试。\n'Receptor Solution Sampling Qualification'可被翻译为：接收液取样确认\n'The system should be appropriately equilibrated under the predefined experimental conditions prior to the beginning of the IVRT run. No air bubbles should be present in the receptor solution (under the membrane) immediately prior to, or during the experiment; if appropriate, the receptor solution can be degassed. The system temperature (including the membrane surface temperature and the circulating water bath temperature, if applicable) should be stable and well controlled. IVRT membranes can be presoaked with receptor solution prior to assembling in the diffusion cell or equilibrated with the receptor solution in situ within the diffusion cell prior to dosing (e.g., for 30 min at a membrane temperature of 32°) depending upon the method.'可被翻译为：在IVRT开始运行之前，系统应在预定的实验条件下适当地平衡。在实验前或实验过程中，受体溶液(膜下)中不应出现气泡;如果合适，受体溶液可以脱气。系统温度(包括膜表面温度和循环水浴温度，如适用)应稳定且控制良好。IVRT膜在装配于扩散池之前可以用受体溶液预浸泡，或者在给药之前用扩散池内的受体溶液原位平衡(例如，在32°的膜温度下30分钟)，具体取决于方法。\n\n根据上述已知信息，请将'Sampling is dependent upon the equipment used and should follow instructions provided by the manufacturer, when appropriate. The receptor solution used to replace the volume removed during sampling may be pre-warmed to the temperature of the receptor solution in the receptor compartment, and it is important to ensure that air bubbles are not present beneath the membrane after sampling and refilling the receptor solution at each time point.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"抽样取决于所使用的设备，在适当情况下应遵循制造商提供的说明。可以使用经过预热到与反应釜中受体温度一致的受体溶液，用于替代采样过程中去除的样品体积受体溶液，并且重要的是要确保在采样和在每个时间点重新填充受体溶液后膜下不存在气泡。"
    },
    {
        "instruction":"已知信息：\n'** PBRER sections that could be used as an information source for the DSUR. *** DSUR sections that could be used as a data source for the PBRER.'可被翻译为：** 可以用作DSUR的信息来源的PBRER章节。 *** 可以用作PBRER的数据来源的DSUR章节。\n'Alternatively, the information specific to the combination can be incorporated into a separate section(s) of the DSUR for one or all of the individual components of the combination.'可被翻译为：或者，关于联合治疗的特定信息，可以包含在针对联合治疗 的一个或全部组分的DSUR的单个或多个章节中。\n'Last Update: 31 March 2014 E2C(R2)  Table 1 - Sharing Content between PBRER and DSUR This table is intended to supplement Appendix D (List of PBRER Sections that May be Shared with Other Regulatory Documents) and sets out the sections that were proposed to be common.'可被翻译为：上一次更新：2014年3月31日 E2C（R2）疑问与解答  表1 PBRER与DSUR之间共享的内容 该表旨在补充附录D（可能与其它监管文件共享的PBRER章节列表），并列出了提出的共享章节。\n'The information to be included in these sections is intended to enable sharing of content between the PBRER and DSUR when the birth dates and DLPs are aligned.'可被翻译为：要包括在这些章节中的信息用于在诞生日与DLP一致 时，在PBRER和DSUR之间共享内容。\n\n根据上述已知信息，请将'In addition, this table identifies additional DSUR sections that can be considered information sources for corresponding sections in the PBRER, or vice versa.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"此外，该表还标识了可被视为PBRER中相应章节的信息源的其它DSUR章节，反之亦然。"
    },
    {
        "instruction":"已知信息：\n'Annex ID: PACMP Example 1 Alternative manufacturing site for a small molecule drug substance Outline for Step 1 Submission'可被翻译为：附件ID：PACMP示例1 小分子原料药新增产地 阶段1递交的提纲\n'The primary objective of this expanded PACMP is to support the mobility across drug substance manufacturing sites, i.e., the transfer of one or multiple products from one donor site to one or more recipient site(s) including CMOs (sites already licensed with appropriate inspection record) thereby reducing the number of regulatory submissions of similar content and driving consistency.'可被翻译为：该扩展的PACMP旨在支持生物技术产品原液生产场地转移的灵活性，即，将一个或多个产品从原场地转移到一个或多个新场地，包括CMO（该生产场地经检查后获得许可），进而减少相似内容的注册申报数量，并促进一致性。\n'• No change in analytical methods or specification for release and stability testing for drug substance manufactured at the alternative site'可被翻译为：未变更新产地原料药的放行和稳定性检测的质量标准和分析方法。\n'• Alternative manufacturing site to have acceptable compliance status for small molecule drug substance manufacturing; depending on the region, this may be indicated by the last GMP inspection with acceptable outcome, through a valid GMP certificate, or other appropriate documentation (e.g., Qualified Person declaration)'可被翻译为：对于小分子原料药的生产，新增产地应具有可接受的合规性状态；根据不同地区的情况，可能需要通过出具有效的GMP证书或其他适当的文件（例如质量授权人声明）证明其最近一次的GMP检查结果为可接受的。\n\n根据上述已知信息，请将'This PACMP is intended to allow for the addition of an alternative manufacturing site for the manufacture, testing, and release of the drug substance for a small molecule solid oral drug product.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"该PACMP旨在允许为一个小分子固体口服制剂增加一个可选的原料药生产、检验和放行产地。"
    },
    {
        "instruction":"已知信息：\n'The ability of the design to gracefully accept input intended for newer versions of itself. The concept can be applied to entire systems, data communications, protocols, file formats and computer programming languages. For example, if products designed for the older standard can receive, read, view or play the newer standard or format (excluding new functionality), then the product is said to be Forward Compatible.'可被翻译为：使设计具备良好地接受新版本输入信息的能力。本概念适用于整个系统、数据通信、协议、文件格式和计算机编程语言。例如，如果按照旧标准设计的产品收、阅读、查看或播放新标准或格式（不包括新功能）下的信息，则认为该产品是具备“向上兼容性”的。\n'backward (or downward) compatibility'可被翻译为：向下兼容性\n'• Image file formats (.jpeg, .jpg)'可被翻译为：• 图像文件格式（.jpeg，.jpg）\n'Other approaches and formats can be used as appropriate.'可被翻译为：适当时也可使用其他的方法和格式。\n\n根据上述已知信息，请将'The ability of the design to gracefully accept input created with older versions of itself. The concept can be applied to entire systems, data communications, protocols, file formats and computer programming languages. For example, if products designed for the new standard can receive, read, view or play older standards or formats, then the product is said to be Backward Compatible.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"使设计具备良好地接受旧版本输入信息的能力。本概念可用于整个系统、数据通信、协议、文件格式和计算机编程语言。例如，如果使用新标准设计的产品可以接收、阅读、查看或播放使用旧标准或格式设计的产品信息，那么就说该产品是向下兼容的。"
    },
    {
        "instruction":"已知信息：\n'Limit of Quantitation: The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices, and is used particularly for the determination of impurities and\/or degradation products. (ICH Q2)'可被翻译为：一种独立分析方法的定量限是样品中某待测物能以适当的精密度和准确度被定量检出的最低量。定量限是一种针对样品中低含量物质定量分析的参数，特别用于杂质和\/或降解产物的测定。（ICH Q2）\n'The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices, and is used particularly for the determination of impurities and\/or degradation products.'可被翻译为：某一分析方法的定量限度是指在合适的准确性和精密度下，能够定量测定样品中被分析物的最低量。它是样品中含量下，能够定量测定样品中被分析物的最低量。它是样品中含量低的化合物定量测定的参数，特别适用于杂质和\/或降解产物的测定。\n'The quantitation limit is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy.'可被翻译为：定量限是指在有适当的准确度和精密度，能够定量测定样本中被分析物的最低量。\n'Lower Limit of Quantification (LLOQ): The lowest amount of an analyte in a sample that can be quantitatively determined using a method with predefined precision and accuracy.'可被翻译为：定量下限（LLOQ）：使用预先定义其精密度和准确度的方法，使样品中的待测物可被定量测定的最低浓度。\n\n根据上述已知信息，请将'LoQ: Limit of Quantitation: The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"LoQ： 定量限：一种分析方法的定量限是样品中某待测物能以适当的精密度和准确 度被定量检出的最低量。"
    },
    {
        "instruction":"已知信息：\n'(1) failing to supply, receive, and purchase vaccines as required;'可被翻译为：（一）未按照规定供应、接收、采购疫苗；\n'(3) failing to establish and maintain records of vaccine reception, purchase, storage, distribution, supply, inoculation, and disposal as required;'可被翻译为：（三）未按照规定建立并保存疫苗接收、购进、储存、配送、供应、接种、处置记录；\n'(III) Failing to keep the records of adverse event monitoring or preserve the records for insufficient duration;'可被翻译为：（三）未保存不良事件监测记录或者保存年限不足的；\n'When accepting or purchasing vaccines, disease prevention and control institutions and immunization entities shall ask for the abovementioned supporting documents and keep such documents for no less than five years upon the expiration date of vaccines for reference.'可被翻译为：疾病预防控制机构、接种单位在接收或者购进疫苗时，应当索取前款规定的证明文件，并保存至疫苗有效期满后不少于五年备查。\n\n根据上述已知信息，请将'(2) failing to obtain and keep relevant certification documents and temperature monitoring records when receiving or purchasing vaccines;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）接收或者购进疫苗时未按照规定索取并保存相关证明文件、温度监测记录；"
    },
    {
        "instruction":"已知信息：\n'In individual cases this might be non-achievable due to expected good prognosis with respect to survival and availability of several active next-line regimens, including experimental therapies, at the time of disease progression and a small target population. If PFS is the selected primary endpoint for the study, this requires a thorough justification. A careful discussion at the planning stage is also needed for the assessment of possibly therapy-related fatalities. Even though only a major benefit in terms of PFS prolongation would be acceptable, whenever possible the number of patients included should be sufficient to obtain an estimate on overall survival where a trend in a favourable direction is expected.'可被翻译为：在个别情况下，由于有关生存的预后和若干下一线方案的可及性（包括在疾病进展时的试验疗法以及小目标群体），这可能无法实现。如果在研究中 PFS 被选为主要终点， 那么这需要进行彻底的证实。也需要在规划阶段开展认真讨论，以评估可能与疗法相关的死亡人数。即使可接受在 PFS 延长方面的重大获益，那么只要有可能所包含的患者 的数量应足以获得总生存期的预估值（预期出现有利方向趋势）。\n'Since progression to more severe stages of MDS and to AML is common and signals poor prognosis, any treatment that could delay or avoid progression is expected to have a positive impact on clinical outcome. Concerning the respective merits of disease progression-related endpoints and OS, all recommendations expressed in the main text of this guideline apply. Haematological or cytogenetic responses cannot be accepted a priori to assess efficacy, and response rate is more suitable for exploratory trials (detecting activity and dose-effect relationships) than for efficacy purposes (and detection of a clinical benefit).'可被翻译为：因为患者通常会进展成更为严重的MDS和AML，这是预后不良的信号，任何可能延迟或者避免进展的治疗都被认为是对临床结局有积极作用。对于疾病进展相关终点及 OS的各自优点，本指南的主体部分中表述的所有建议均适用。血液学或细胞遗传学缓解不能作为评估疗效的先验性指标，并且缓解率更适合用于探索性试验（探察活性和剂量-作用关系），而不是用于疗效目的（和探察临床获益）。\n'In principle, PFS is an acceptable primary endpoint, but survival data are needed in order to exclude with reasonable certainty detrimental effects on survival.'可被翻译为：原则上，PFS 是一个可接受的主要终点，但是需要生存期数据以便有合理的确定性来排除对生存期的不利作用。\n'The definition of progression must be based on a combination of standardised clinical and biological data and centralised blinded review is needed in order to establish progression.'可被翻译为：疾病进展的定义必须基于标准化的临床数据和生物学数据，需要进行集中的盲态审查来确认疾病进展。\n\n根据上述已知信息，请将'Confirmatory studies are expected to be randomised and well controlled using a licensed or evidence based medicinal product as reference. In principle, PFS is an acceptable primary endpoint, but survival data are needed in order to exclude with reasonable certainty detrimental effects on survival. In high risk MDS, however, survival is the preferred measure of patient benefit. In the case HSCT is a realistic treatment option in responding patients, please refer to the section “Treatment administered with curative intent”. The definition of progression must be based on a combination of standardised clinical and biological data and centralised blinded review is needed in order to establish progression.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"验证性研究预期是随机、充分对照研究，采用已上市或基于证据的药物作为参比药物。原则上，PFS是一个可接受的主要终点，但是需要生存期数据以便有合理的确定性来排除对生存期的不利作用。但是，对于高风险的 MDS，生存期是患者获益的首选测量指标。在这种情况下，HSCT对于见效患者是个更现实的治疗选择，请参考“以治愈为目的的治疗”章节。疾病进展的定义必须基于标准化的临床数据和生物学数据，需要进行集中的盲态审查来确认疾病进展。"
    },
    {
        "instruction":"已知信息：\n'Article 113: Only starting materials which have been approved to release by the quality management department and which are within their shelf life or re-test date should be used.'可被翻译为：第一百一十三条 只有经质量管理部门批准放行并在有效 期或复验期内的原辅料方可使用。\n'Article 114 The storage of starting materials should be in accordance with the expiry or re-test date. Re-test should be carried out for materials within the shelf life in case of encountering any abnormal situations that may adversely affect the quality of materials.'可被翻译为：第一百一十四条 原辅料应当按照有效期或复验期贮存。贮存期内，如发现对质量有不良影响的特殊情况，应当进行复验。\n'The date placed on the container label of a drug product designating the time prior to which a batch of the product is expected to remain within the approved shelf life specification if stored under defined conditions, and after which it must not be used.'可被翻译为：这是制剂容器标签上的一个日期，在此日期前，某一批制剂只要贮藏于规定的条件下，将保持符合其批准的货架期标准的要求，在此日期以后该药不能使用。\n'Re-test should be carried out for materials within the shelf life in case of encountering any abnormal situations that may adversely affect the quality of materials.'可被翻译为：贮 存期内，如发现对质量有不良影响的特殊情况，应当进行复验。\n\n根据上述已知信息，请将'Article 113 Only starting materials which have been approved to release by the quality management department and which are within their shelf life or re-test date should be used.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百一十三条 只有经质量管理部门批准放行并在有效期或复验期内的原辅料方可使用。"
    },
    {
        "instruction":"已知信息：\n'a gene or DNA sequence with a known location on a chromosome that  can be used to identify individuals or species; a genetic marker may be a short DNA sequence, such as a sequence surrounding a single base-0 pair change, or a long one, like mini satellites'可被翻译为：染色体上一个位置已知的基因或DNA序列，它可用于 鉴别个体或物种；一个基因标志物可以是一段短的DNA序列，例如单个碱基对变化附近的序列，或一段较长的 序列，例如微小卫星\n'dna marker'可被翻译为：DNA标记\n'restriction fragment length polymorphism'可被翻译为：限制性片段长度多态性\n'The phenomenon in which the genomic DNA of different individuals or populations is digested by the same restriction enzyme or enzymes to produce a fragment of DNA that varies in length and number. Each has its own electrophoretic map, reflecting the differences in genomic DNA sequence between individuals and populations.'可被翻译为：不同个体或种群间的基因组DNA经同样一种或几种限制性内切酶消化后所产生的DNA片段的长度数量各不相同的现象。各自有其独特的电泳图谱，反映出个体和种群间基因组DNA序列的差异。\n\n根据上述已知信息，请将'An alternative strategy would be to demonstrate the presence of unique markers, for example, by using banding cytogenetics to detect a unique marker chromosome, or DNA analysis to detect a genomic polymorphism pattern (for example, restriction fragment length polymorphism, variable number of tandem repeats, or genomic dinucleotide repeats).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"替代方法可显示其独特的标志物。例如，通过使用染色体细胞遗传学来检测独特的标记染色体，或用DNA分析来检测基因组多态性(例如，限制性片段长度多态性，串联重复数目的变化，或基因组双核 苷酸重复数目)。"
    },
    {
        "instruction":"已知信息：\n'Thus, it is necessary to perform an- other study using a batch equilibrium method (OPPTS 835.1110 or OECD 106 for 2 sludges and\/or OECD 106 with 3 soil types).'可被翻译为：因此，有必要使用批量平衡法进行另一研究（对于2 种污泥，OPPTS 835.1110或OECD 106，和\/或使用3个土壤类型，OECD 106）。\n'This value is determined from the three Koc values for soil that have been determined in the OECD 106 study.'可被翻译为：这个值是从OECD106研究中确定的土壤的三个Koc值确定的。\n'The adsorption constant is preferably determined using sludge when it is used in Phase II Tier A (OPPTS 835.1110 or OECD 106) to determine whether a Phase II Tier B assessment for soil (or groundwater) is triggered (see Q. 10iv).'可被翻译为：当吸附常数被用于II期A级（OPPTS 835.1110或OECD 106）确定是否触发土壤（或地下水）的II期B级评估时（参见Q.10iv），首选使用污泥测定吸附常数。\n'iii) Should sludge or soil be used to determine sorption?'可被翻译为：iii）应该使用污泥还是土壤来确定吸附？\n\n根据上述已知信息，请将'A study using 2 types of sludge and 3 soil types according to OECD 106 is preferred.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据OECD 106，优先考虑使用2种类型的污泥和3种土壤类型的研究。"
    },
    {
        "instruction":"已知信息：\n'The vaccination regimen should maximize maternal antibody titers and\/or immune response throughout the embryonic, fetal, and early postnatal periods.'可被翻译为：疫苗接种方案应使在整个胚胎、胎仔和出生后早期阶段尽可能提高母体抗体 滴度和\/或免疫应答。\n'The types of reproductive and\/or developmental toxicity studies used for preventative and therapeutic vaccines depend on the target population for the vaccine and the relevant reproductive risk.'可被翻译为：用于预防和治疗性疫苗的生殖和\/或发育毒性试验的类型取决于疫苗的目标 人群和相关的生殖风险。\n'Based on the rare occurrence of haemophilia A in women, experience regarding the use of factor VIII during pregnancy and breast-feeding is not available.'可被翻译为：基于女性发生血友病的情况极其罕见，所 以尚无孕期和哺乳期妇女的因子VIII使用经验。\n'When concomitant and rescue medication specific for ITP (e.g. steroids) is given during trial in addition to the experimental drug full details should be provided including time of its discontinuation.'可被翻译为：如果在临床研究期间，患者如果除受试药物以外还同时接受了特别针对ITP 的伴随治疗和急救给药，则要求提供其余给药的全部细节信息，包括停药时间。\n\n根据上述已知信息，请将'When developing vaccines to be given during pregnancy, a justification should be provided for the specific study design, based upon its intended use (e.g., protecting the mother during pregnancy or protecting the child early postnatally).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当正在开发的疫苗拟用于妊娠期间时，应基于其拟定用途（例如，在妊娠 期间保护母亲或在出生后早期保护儿童）提供该特异性试验设计的合理性。"
    },
    {
        "instruction":"已知信息：\n'area under the plasma concentration-time curve'可被翻译为：血浆浓度-时间曲线面积\n'Area under the glucose infusion rate curve from administration to end of clamp at time t;'可被翻译为：给药到钳夹结束时间 t 的葡萄糖输注速率曲线下面积；\n'Area under the plasma concentration curve extrapolated to infinite time;'可被翻译为：血浆浓度曲线外推到时间无限的线下面积；\n'AUC0-t - Area under the concentration time curve from time zero to the last measurable time point.'可被翻译为：AUC0-t– 从零时到最后一个可测量的时间点的浓度时间曲线下面积。\n\n根据上述已知信息，请将'Area under the plasma concentration curve from administration to end of clamp at time t;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"给药到钳夹结束时间 t 的血浆浓度曲线下面积；"
    },
    {
        "instruction":"已知信息：\n'Lithium is used as a human therapeutic, and extensive human data exists in the administration of lithium salts in the treatment of mania, bipolar disorder, and recurrent unipolar depression.'可被翻译为：锂可用于人类疾病治疗，大量人体数据表明，锂盐可治疗躁狂症、双相障碍和反复发作的单相抑郁。\n'LITHIUM'可被翻译为：锂\n'This means that the true surrogacy of pCR, i.e. to what extent a certain difference in pCR rate can predict a certain difference in EFS, however, has not been established. (Fisher et al, 1998, Bear et al, 2006; Wapnir et al, 2006; Mieog et al, 2007; Mazouni et al, 2007; Kong et al, 2011; Berruti et al, 2011; Mamounas et al, 2012; Esserman et al, 2012; von Minckwitz et al, 2012; Cortazar et al, 2014; Bonnefoi et al, 2014).'可被翻译为：但是，尚未建立pCR 的真实可替代性，即pCR 率的差异达到什么程度才可以预测出EFS 存在某种程度的差异（Fisher et al, 1998, Bear et al, 2006; Wapnir et al, 2006; Mieog et al, 2007; Mazouni et al, 2007; Kong et al, 2011; Berruti et al, 2011; Mamounas et al, 2012; Esserman et al, 2012; von Minckwitz et al, 2012; Cortazar et al, 2014; Bonnefoi et al, 2014）。\n'By means of adding additional items to the original ADAS-Classic its responsiveness in patients with milder cognitive impairment is increased (Skinner et al 2012).'可被翻译为：通过在 原ADAS-经典量表中增加新的项目，改善了它在轻度认知损害患者中的反应性（Skinner et al 2012）。\n\n根据上述已知信息，请将'Lithium treatment in humans is mainly associated with an increased risk of reduced urinary concentrating ability, hypothyroidism, hyperparathyroidism, and weight gain (McKnight et al, 2012).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"锂盐治疗可能会引起尿频、甲状腺功能减退、 甲状旁腺机能亢进及体重增加的风险[2]。"
    },
    {
        "instruction":"已知信息：\n'Sterility of the medicinal product cannot be   assured by testing, it needs to be assured by the use of a suitable and validated manufacturing   process.'可被翻译为：药品的无菌不能通过检测来保证，它需要由使用适当的且经过验证的生产工艺来保证。\n'1. Each batch of drugs, prior to release, should undergo quality assessment, so as to ensure that the products and manufacturing comply with the registration requirements and the Provisions, and the following activities should be confirmed:'可被翻译为：1.在批准放行前，应当对每批药品进行质量评价，保证药品及其生产应当符合注册和本规范要求，并确认以下各项内容：\n'3.1 General Principles The goal of manufacturing process development for the drug substance is to establish a commercial manufacturing process capable of consistently producing drug substance of the intended quality.'可被翻译为：3.1 总则 原料药生产工艺开发的目的是建立一个能够持续生产出预期质量原料药的商业化生产工艺。\n'Any proposed change to the manufacturing process should be evaluated for the impact on the quality of drug substance and drug product.'可被翻译为：对生产工艺有任何拟定的变更时，均应评估其对原料药和制剂质量产生的影 响。\n\n根据上述已知信息，请将'The drug substance manufacturing process should be validated before commercial distribution of resulting drug product.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"原料药的生产工艺验证应在其制剂产品上市销售前进行。"
    },
    {
        "instruction":"已知信息：\n'Dosage regimens different from the standard dosages stated in the core SmPC should be supported by clinical data.'可被翻译为：给药方案不同于核心药品特征摘要中规定的标准给药剂量时，应提供临床数据支持。\n'The use of pharmacokinetic\/pharmacodynamics data to assist dose selection is encouraged.'可被翻译为：鼓励使用药代动力学\/药效学数据来协助剂量选择。\n'In certain cases, such as drugs used chronically or drugs with fixed-dose regimens, it can be appropriate to infer dosage information from electronic healthcare data.'可被翻译为：在某些情况下，例如药物是长期使用或者是按固定剂量使用，从电子医疗保健数据中推断 剂量信息可能是适当的。\n'The sponsor- investigator should address these deficiencies in writing to the division with any requested data.'可被翻译为：申办方-研究者应该采用书面的形式向审评部门函告知这些缺陷和所有请求的数据。\n\n根据上述已知信息，请将'If other dosage regimens are requested, they should be supported by clinical data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果要求其他剂量方案，应该得到临床数据的支持。"
    },
    {
        "instruction":"已知信息：\n'Estimands for secondary trial objectives (e.g. related to secondary variables) that are likely to support regulatory decisions should also be defined and specified explicitly, each with a corresponding main estimator and a suitable sensitivity analysis.'可被翻译为：对于可能支持监管决策的次要试验目 的（例如，与次要变量相关），相应的估计目标也应当明确定义 和说明，并且每个估计目标都有相应的主估计方法和合适的敏感性分析。\n'Figure 1: Aligning target of estimation, method of estimation, and sensitivity analysis, for a given trial objective This framework enables proper trial planning that clearly distinguishes between the target of estimation (trial objective, estimand), the method of estimation (estimator), the numerical result (“estimate”, see Glossary), and a sensitivity analysis. This will assist sponsors in planning trials, regulators in their reviews, and will enhance the interactions between these parties when discussing the suitability of clinical trial designs, and the interpretation of clinical trial results.'可被翻译为：图1：协调估计的目标、估计的方法和敏感性分析，使其与给定试验目的对应 该框架有助于制定适当的试验计划，以明确区分估计的目标 （试验目的，估计目标）、估计的方法（估计方法）、数值结果 （“估计值”，见词汇表）和敏感性分析。\n'The protocol and the analysis plan should pre-specify the main estimator that is aligned with the primary estimand and leads to the primary analysis, together with a suitable sensitivity analysis to explore the robustness under deviations from its assumptions.'可被翻译为：方案和分析计划中应预先规定与主要估计目标一致并 对应主要分析的主估计方法，以及当假设偏离时用来探索结果稳 健性的合适的敏感性分析。\n'The reasons for including a covariate in the primary analysis should be explicitly stated in the protocol.'可被翻译为：应在方案中清楚地阐明主要分析中包括协变量的原因。\n\n根据上述已知信息，请将'A.6.DOCUMENTING ESTIMANDS AND SENSITIVITY ANALYSIS A trial protocol should define and specify explicitly a primary estimand that corresponds to the primary trial objective.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A.6. 估计目标和敏感性分析的记录 试验方案应当定义并明确说明与主要试验目的相对应的主要 估计目标。"
    },
    {
        "instruction":"已知信息：\n'Gently but firmly touch the RODAC agar surface against the area being sampled, exert moderate, even, vertical pressure and then carefully replace lid. Avoid using rubbing motions of the plate at the sample site as this may break the agar.'可被翻译为：将 RODAC 碟用于取样的琼脂表面轻轻但牢固地接触被取样的表面，垂直均匀按压，取下，小心地重新盖上盖子。避免碟表面与取样面摩擦，因为可能会使琼脂裂开。\n'When using Hycheck press down on the spike to bend the paddle at the hinge line gently lowering the slide and press the agar to the surface with firm and even pressure. Repeat this step using the 2nd agar surface on an area adjacent to the initial test site. Replace slide in container and close tightly.'可被翻译为：使用 Hycheck 取样条时，以尖头为着力点，手持盖按压，让取样条在折线处向下弯曲，垂直均匀地将培养基表面压在被取样表面。翻转，将反面培养基同样操作，从第一个取样点的邻近表面取样。将培养基条放回瓶中，盖紧。\n'At the microbiologist’s discretion, it may be determined that a RODAC plate should be used to sample the irregular surface. In this situation, a RODAC plate comprised of colorless agar such as tryptic soy agar would be appropriate. A colored agar such as D\/E agar should be avoided.'可被翻译为：根据微生物学家的判断，可能需要使用 RODAC 碟对不规则表面取样。在此情形下，适合使用无色琼脂 RODAC 碟如 TSA，应避免使用有颜色的琼脂如 D\/E 琼脂。\n'RODAC\/Hycheck Sterility Control: Place an unused RODAC plate and\/or Hycheck plate within a sterile Whirl-pak® bag.'可被翻译为：RODAC\/Hycheck 无菌控制：将未使用的 RODAC 碟和\/或 Hycheck 碟放入无菌Whirl- pak®袋中。\n\n根据上述已知信息，请将'Carefully remove the lid of RODAC plate or loosen the cap on the Hycheck slide tube. Take care not to touch the agar surface.Note: Examine agar for contamination and or dehydration'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"小心取下 RODAC 碟的盖子或松开 Hycheck 滑管的盖子。小心不要接触琼脂培养基表面。注：检查琼脂是否被污染或脱水"
    },
    {
        "instruction":"已知信息：\n'Specificity\/selectivity can be shown by demonstrating that the identification and\/or quantitation of an analyte is not impacted by the presence of other substances (e.g., impurities, degradation products, related substances, matrices, or other components likely to be present).'可被翻译为：专属性\/选择性可通过证明被分析物的鉴别和\/或定量不受共存的其他物质（如：杂质、降解产物、有关物质、基质或可能存在的其他组分）的影响来证明。\n'Impurities may warrant identification and qualification, depending on the following:'可被翻译为：杂质是否必要鉴别和定量，取决以下信息：\n'Antibodies present in confirmed positive samples need to be examined for specificity for the active protein and, in relevant cases, distinguished from antibodies which bind to product-related and process-related components ( e.g., host cell proteins).'可被翻译为：需要检查经确认的阳性样本中存在的抗体对于活性蛋白的特异性，在相关情境下，区分可与产品相关和工艺相关成分（例如宿主细胞蛋白）相结合的抗体。\n'Absence of interference: Demonstration of non-interference with excipients and dissolution media likely to impact the quantitation of the main analyte'可被翻译为：无干扰 证明可能影响主要被分析物定量的辅 料和溶出介质对试验结果不干扰\n\n根据上述已知信息，请将'In cases where the analyte is a process-related impurity, specificity (non-interference) must also be confirmed against the product.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果被分析物是工艺相关杂质，还必须对照产 品确认专属性（无干扰）。"
    },
    {
        "instruction":"已知信息：\n'This can be particularly important for small clinical trials.'可被翻译为：这对于小型临床试验而言尤其重要。\n'If such studies are performed they should be based on a careful consideration of the sample size needed to provide a clear answer regarding the regimen to be selected for further evaluation.'可被翻译为：如果进行这些研究，应认 真考虑能选择进入进一步评估的明确剂量方案所需的样本量。\n'Pharmacodynamic studies should include evaluation of mechanism of action, tolerability, duration of action, and relevant clinical or haemodynamic parameters.'可被翻译为：药效学研究应包括对作用机制、耐受性、作用持续时间以及相关的临床或血 流动力学参数的评估。\n'Studies should be designed to capture all such relevant safety data.'可被翻译为：应设计数项研究以采集所有此类相关的安全性数据。\n\n根据上述已知信息，请将'They have to be chosen carefully to serve a specific purpose of increasing the power of small studies and capture a number of relevant clinical parameters.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"结合须仔细挑选后确立，以增加小试验的效能和采集一些相关的临床参数。"
    },
    {
        "instruction":"已知信息：\n'Symptom scales open to deterioration are preferred to dichotomous modes of answers (e.g. like “satisfactory relief” or “adequate relief”) as the latter have not been validated nor used in GORD. 15\/26'可被翻译为：存在恶化倾向的症状量表最好采用分成两种回答的模式（如“令人满意的治 疗 ”或“充分的治疗 ”），因为 后者既没有经过验证也没有被用于 GORD。\n'A.Symptom Scores'可被翻译为：A. 症状评分\n'Clinical or symptom scores'可被翻译为：临床或症状评分\n'Other scales or scores can be used for the assessment of symptoms provided that they are validated in the populations (and in the languages) in which they are being tested.'可被翻译为：对于其他量表或评分，如果已在其拟采用的人群（和语种）中进行了验证，则可用于症状评估。\n\n根据上述已知信息，请将'Symptom scores: Assessment of symptoms is an acceptable clinical variable although there are no validated scales.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"症状评分：症状的评估是一个可接受的临床变量，尽管尚无经过验证的量表。"
    },
    {
        "instruction":"已知信息：\n'Post-approval CMC commitments: specified CMC development activities, agreed between the MAH and regulatory authority at the time of approval (e.g., specific process monitoring, additional testing) that will be performed during the commercial phase should be listed in the PLCM document.'可被翻译为：批准后CMC承诺：MAH和监管机构在批准时达成一致的将在 商业阶段实施的特定CMC开发活动（如特定的工艺监测、额外测试）应列于PLCM文件中。\n'Unless otherwise specified by regulatory requirement identifying ECs for a given product is not mandatory.'可被翻译为：除非监管要求另有规定，否则确认产品的ECs不是强制性的。\n'Changes to CMC regulatory commitments are managed according to existing regional regulations and guidance.'可被翻译为：对CMC监管承诺的变更应根据现有区域性法规和指南进行管理。\n'(1) The results of regulatory inspections and findings, audits and other assessments, and commitments made to regulatory authorities;'可被翻译为：（1）监管机构的检查和调查、审计和其他评估以及对监管机构作出的承诺；\n\n根据上述已知信息，请将'ECs should not be confused with CMC regulatory commitments (e.g., stability, post- approval CMC commitment and other commitments) made by a MAH to provide data or information to the regulatory agency in a MAA.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"EC不应与MAH在MAA中向监管机构提供数据或信息而作出 的CMC承诺（如稳定性、批准后CMC承诺和其他承诺）相混淆。"
    },
    {
        "instruction":"已知信息：\n'5. Keeping dedicated protective clothing inside areas where products with special risk of cross-contamination are processed;'可被翻译为：（五）在易产生交叉污染的生产区内，操作人员应当穿戴该 区域专用的防护服；\n'The handling of sterile product, containers or devices in a controlled environment in which the air supply, materials and personnel are regulated to prevent microbial, endotoxin\/pyrogen and particle contamination.'可被翻译为：在受控环境中处理无菌产品、容器或设备，其中空气供应、材料和人员受到调节，以防止微生物、内毒素\/热原和颗粒污染。\n'5. Special Populations'可被翻译为：5 特殊人群\n'− Assess the risk of cross-contamination between products that could result from sharing product-contacting equipment and parts'可被翻译为：- 评估各产品之间由于公用产品接触器材引起的交叉污染的风险\n\n根据上述已知信息，请将'5. Keeping dedicated protective clothing inside areas where products with special risk of cross-contamination are processed;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）在易产生交叉污染的生产区内，操作人员应当穿戴该 区域专用的防护服；"
    },
    {
        "instruction":"已知信息：\n'When the clinical effect defined by the primary objective is to be measured in more than one way, the protocol should identify one of the measurements as the primary variable on the basis of clinical relevance, importance, objectivity, and\/or other relevant characteristics, whenever such selection is feasible. Secondary variables are either supportive measurements related to the primary objective or measurements of effects related to the secondary objectives.'可被翻译为：当根据主要目的确定的临床效应存在多种测量方法 时，应根据临床相关性、重要性、客观性、和\/或其它相关特 性，在方案中选择其中一种切实可行的测量方法作为主要指 标。 次要指标是与主要目的相关的支持性指标，或与次要目 的相关的效应指标。\n'In addition, the clinical relevance of the specific primary variable selected and the validity of the associated measurement procedures will generally need to be addressed and justified in the protocol.'可被翻译为：另外，所选择的具体主要指标的临床相关性和相 关测量过程的合理性通常需要在方案中阐明。\n'category scale'可被翻译为：类别尺度法\n'When a rating scale is used as a primary variable, it is especially important to address such factors as content validity (see Glossary), inter- and intra-rater reliability (see Glossary) and responsiveness for detecting changes in the severity of disease.'可被翻译为：当量表被用作主要指标时，阐明内容效度（见词汇表）、 评价者内和评价者间信度（见词汇表）及检测疾病严重程度 变化的反应度等尤其重要。\n\n根据上述已知信息，请将'When a global assessment variable is used as a primary or secondary variable, fuller details of the scale should be included in the protocol with respect to: \n1) the relevance of the scale to the primary objective of the trial; \n2) the basis for the validity and reliability of the scale; \n3) how to utilise the data collected on an individual subject to assign him\/her to a unique category of the scale; \n4) how to assign subjects with missing data to a unique category of the scale, or otherwise evaluate them.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"使用全局评价指标作 为主要或次要指标时，应该在方案中对量表的以下方面进行 详细说明： \n1）量表与试验主要目的的相关性； \n2）量表的效度和信度基础； \n3）如何根据所收集的数据将个体受试者归类于量表中的特定类别； \n4）如何将有缺失数据的受试者归类于量表中的特定类 别，或用其他方法评价。"
    },
    {
        "instruction":"已知信息：\n'12 See the guidance for industry Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products — Content and Format.'可被翻译为：12 参见行业指南人用处方药物和生物制品的标签的临床研究部分- 内容和格式。\n'Draft guidance for industry Adaptive Design Clinical Trials for Drugs and Biologics \nDraft guidance for industry Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products \nDraft guidance for industry Non-Inferiority Clinical Trials \nGuidance for industry Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products — Content and Format Guidance for industry Guideline on Format and Content of Clinical and Statistical Sections of an Application Guidance for industry Integrated Summaries of Effectiveness and Safety: Location Within the Common Technical Document \n15 Guidances for industry can be found on the FDA Drugs guidance Web page at http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm.'可被翻译为：行业指南草案药物和生物制品的适应性临床试验设计 \n行业指南草案支持人用药物和生物制品批准的临床试验的富集策略 \n行业指南草案非劣效性临床试验 \n行业指南人用处方药物和生物制品的标签的临床研究部分- 内容和格式 行业指南申请的临床和统计学部分的格式和内容的指南 行业指南有效性和安全的综合总结：通用技术文件内的位置 \n15 行业指南可以在FDA药品指南网页 http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm上找到。\n'Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products — Content and Format'可被翻译为：人用处方药和生物制品说明书的警告和预防措施、禁忌用药、和加框警告部分—内容和格式\n'Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products — Content and Format2'可被翻译为：人用处方药和生物制品说明书的警告和预防措施、禁忌用药、和加框警告部分—内容和格式 2\n\n根据上述已知信息，请将'14 See the guidance for industry Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products — Content and Format.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"14参见行业指南人用处方药物和生物制品的标签的临床研究部分- 内容和格式。"
    },
    {
        "instruction":"已知信息：\n'If the sponsor is also conducting clinical trials with individual component(s) of the fixed combination product, separate DSUR(s) should be submitted for each component.'可被翻译为：如果申办者也同时在对固定复方制剂的各个成分进行临 床试验，应为每个成分分别递交DSUR。\n'The combination of active substances within a single pharmaceutical form of administration is a ‘fixed combination’ medicinal product.'可被翻译为：几种活性物质组合在一个单独的药物制剂中就称为“固定复方”药品。\n'This guideline covers fixed combination (also referred to as fixed dose combinations, FDCs) medicinal products containing two or more active substances within a single pharmaceutical form.'可被翻译为：本指南涵盖了包含两种及两种以上活性物质且具有一种剂型的固定复方制剂（又称固定剂量复方制剂，FDC）。\n'1.A combination of two or more actives in a fixed ratio of doses. This term is used generically to mean a particular combination of actives irrespective of the formulation or brand. It may be administered as single entity products given concurrently or as a finished pharmaceutical product.\n2.A combination of two or more active pharmaceutical ingredients in a fixed ratio of doses. This term is used generically to mean a particular combination of active pharmaceutical ingredients irrespective of the formulation or brand. It may be administered as single entity products given concurrently or as a finished pharmaceutical product.\n3.A combination of two or more APIs in a fixed ratio of doses. This term is used generically to mean a particular combination of APIs irrespective of the formulation or brand. It may be administered as singleentity products given concurrently or as a finished pharmaceutical product (FPP).'可被翻译为：1.混合剂:两种或两种以上活性物质按固定剂量比例的组合该术语一般用于指一种特定的活性组合，而不考虑其配方或品牌。它可以作为单一实体产品同时给药，也可以作为成品给药。\n2.混合剂:两种或两种以上活性药物成分按固定剂量比例的组合该术语一般用于指活性药物成分的特定组合，而不考虑其配方或品牌。它可以作为单一实体产品同时给药，也可以作为成品给药。\n3.两种或两种以上原料药按固定剂量比例的组合。该术语一般用于指原料药的特定组合，而不考虑其配方或品牌。它可以作为单一实体产品同时给药或作为成品药品(FPP)给药。\n\n根据上述已知信息，请将'In general, a single DSUR should be prepared for clinical trials involving a fixed combination product (i.e., a product consisting of at least two active ingredients in a fixed dose that is administered in a single dosage form).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通常，固定组成复方制剂（例如，复方中至少含有两种固定 剂量活性成分，并以单一剂型给药）的临床试验仅需递交一份 DSUR。"
    },
    {
        "instruction":"已知信息：\n'Process knowledge and continual improvement are drivers for change.'可被翻译为：工艺知识和持续改进是变更的驱动因素。\n'Typically, process knowledge, analytical procedure knowledge and continual improvement are drivers for change.'可被翻译为：通常工艺知识、分析方法知识和持续改进都是变 更的推动因素。\n'It facilitates continual improvement of process performance and product quality throughout the product lifecycle.'可被翻译为：在整个产品生命周期内，它能促进工艺性能和产品质量的持续改进。\n'(d) Identify sources of variation affecting process performance and product quality for potential continual improvement activities to reduce or control variation;'可被翻译为：(d) 识别影响工艺性能和产品质量的变异的来源，以便进行潜在的持续改进活动来减少或控制变异；\n\n根据上述已知信息，请将'Innovation, continual improvement, the outputs of process performance and product quality monitoring and CAPA drive change.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"创新、持续改进、工艺性能和产品质量监测结果以及CAPA会导致变更。"
    },
    {
        "instruction":"已知信息：\n'If the alternative assay does not predict MEFL, this should be confirmed in definitive in vivo EFD studies in two species.'可被翻译为：若该替代试验不能预测MEFL阳性时，则应在两种种属的正式体内EFD试验中 进行确认。\n'That is, the alternative assay should predict a negative result at some extrapolated level under the conditions for which the in vivo study yielded a negative result (no MEFL).'可被翻译为：也就是说，在体 内试验结果为阴性（无MEFL）的情况下，替代试验应该在某些外推剂量水平上 预测为阴性结果。\n'When a qualified alternative assay clearly predicts MEFL in the first species (e.g., rat) at clinically relevant extrapolated exposures, this can be considered, on a case-by-case basis, to sufficiently characterize the EFD risk.'可被翻译为：当经资格验证的替代试验在临床相关外推暴露量下对第一种种属（如大鼠） 明确预测具有MEFL时，根据具体情况具体分析原则，被认为足以表征EFD风 险。\n'2) While pEFD studies can be used, negative results from definitive in vivo EFD studies in two species are warranted to establish that alternative assay results represent a false positive.'可被翻译为：② 当使用pEFD试验时，需要两种种属的正式体内EFD试验的阴性结果，以确 定替代试验结果为假阳性。\n\n根据上述已知信息，请将'If the alternative assay for the first species predicts a negative outcome (i.e., no MEFL), a definitive in vivo EFD study in the second species should be conducted to confirm the assessment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果第一种种属的替代试验预测为阴性结果（即无MEFL），则应进行第二 种种属的正式体内EFD试验以确认该评估结果。"
    },
    {
        "instruction":"已知信息：\n'Molybdenum is an essential element with an estimated upper level intake range of 100-600 µg\/day for infants to adults, respectively (EC Scientific Committee on Food, 2000).'可被翻译为：钼是一种人体必需的元素，婴儿至成人摄入量上限约为100~600 µg\/天[1]。\n'Cobalt is essential in the human body because it is an integral component of Vitamin B12 and functions as a co-enzyme for several enzymes critical in the synthesis of hemoglobin and the prevention of pernicious anemia.'可被翻译为：钴是维生素B12的组成部分，是合成血红蛋白的多种酶的辅酶且具有预防恶性贫血的作用，因此，钴是人体必需的元素。\n'TOTAL 2.5 g - - - - - - - 1.2 µg 0.8 µg 0.7 µg 0.7 µg 4 µg 9.5 µg 12.5 µg'可被翻译为：总和 2.5g -- -- - - - - - 1.2µg 0.8µg 0.7µg 0.7µg 4µg 9.5µg 12.5µg\n'PDE = 0.1 µg\/kg\/d x 50 kg = 5.0 µg\/day'可被翻译为：PDE=0.1 µg\/kg\/天 50 kg=5.0 µg\/天\n\n根据上述已知信息，请将'The Recommended Dietary Allowance of Vitamin B12 ranges from 0.7 to 2.4 µg\/day (NAS, 2010), which corresponds to 0.03 to 0.1 µg of cobalt.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"推荐的维生素B12摄入量为0.7~2.4 μg\/天[2]，相当于0.03~0.1 μg的钴。"
    },
    {
        "instruction":"已知信息：\n'In some cases, collection of data that do not contribute to better characterizing the safety profile of a drug may have negative consequences.'可被翻译为：在一些情况下，不能有助于更好的确定药物安全性特征的数据收集可能存在 不利影响。\n'For example, the identification of CYP2D6 ultrarapid metaboliser (UM) phenotype is difficult since many individuals who are phenotypically UMs do not carry duplications of an active form of the CYP2D6 gene, which is the only available genetic biomarker for this phenotype.'可被翻译为：例如，CYP2D6超快代谢（UM）表型的鉴别非常困难，因为许多表现型为UM的个体并不复制活性形式的CYP2D6基因，但是这却是这种表型的唯一可用基因生物标志物。\n'One example is the case of codeine metabolism in CYP2D6 ultra-rapid metabolisers (UM), who will form more active metabolites such as morphine and morphine-6-glucuronide.'可被翻译为：一个例子是CYP2D6超快代谢者（UM）中的可待因 代谢的情况，其将形成更活跃的代谢物，例如吗啡和吗啡-6-葡萄糖醛酸苷。\n'In the case of genomic BM related to PK, e.g. CYP2D6, avoid the use of CYP2D6 substrates in PM (or UM) to prevent the ADRs related to increased drug (or active metabolites) exposure.'可被翻译为：若存在PK相关性基因组BM（如CYP2D6），应避免PM（或UM）患者使用CYP2D6 底物类药物从而避免药物（或活性代谢产物）暴露增加相关ADR。\n\n根据上述已知信息，请将'However, CYP2D6 is also a good example where non thorough analytics could lead to erroneous UM designation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"然而，CYP2D6也是一个很好的例子来说明不彻底的分析手段会导致错误地指定UM。"
    },
    {
        "instruction":"已知信息：\n'Where a drug manufactured overseas undergoes the aforementioned changes, they shall be reported to the CDE for filing prior to implementation.'可被翻译为：境外生产药品发生上述变更的，应当在变更实施前报药品审评中心备案。\n'Article 10 Where a drug manufactured overseas and marketed in China is to be transferred to manufacturing within the territory of China, the domestic applicant shall submit an application in accordance with the requirements and procedures for drug marketing registration application. The original registration application dossier of the drug manufactured overseas may be submitted for relevant CMC, non-clinical and clinical data (if applicable), and those meeting the requirements may be applied for becoming reference preparations. Specific requirements for application dossiers shall be separately formulated by CDE.'可被翻译为：第十条 已在境内上市的境外生产药品转移至境内生产的，应当由境内申请人按照药品上市注册申请的要求和程序提出申请，相关药学、非临床研究和临床研究资料（适用时）可提交境外生产药品的原注册申报资料，符合要求的可申请成为参比制剂。具体申报资料要求由药审中心另行制定。\n'Article 9 For the change between overseas MAHs, the new MAH shall submit a supplementary application to CDE.'可被翻译为：第九条 境外持有人之间变更的，由变更后持有人向药审中心提出补充申请。\n'Registration testing of drugs manufactured overseas shall be conducted by the port drug testing institutions organized by the NIFDC.'可被翻译为：境外生产药品的药品注册检验由中检院组织口岸药品检验机构实施。\n\n根据上述已知信息，请将'The change of the above information for drugs manufactured overseas shall be filed to the CDE.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"境外生产药品上述信息的变更向药审中心提出备案。"
    },
    {
        "instruction":"已知信息：\n'the structure or known activity of the compound indicates that the use of other test methods\/systems might be appropriate.'可被翻译为：化合物的结构或已知活性提示采用其他试验方法或系统可能更合适。\n'As several assay methods are possible, the assay used should be described.'可被翻译为：由于可以使用几种检测方法，所以需要描述所使用的方法。\n'The list of compounds in each of the training sets (data used to discover potentially predictive relationships) and test sets (data used to assess the strength and utility of a predictive relationship) for qualification of the assay and the basis for selection of these compounds.'可被翻译为：试验资格验证时每个训练集（用于探索潜在预测关系的数据）和测 试集（用于评估预测关系强度和效用的数据）的化合物清单，以及选择这 些化合物的依据。\n'Assay qualification (for regulatory use): Confirmation of the predictivity of an alternative assay(s) to identify MEFL, as observed in vivo.'可被翻译为：试验资格验证（为监管目的）（Assay qualification (for regulatory use)）： 确定一个替代试验对MEFL的预测能力，如同在体内试验中观察到的。\n\n根据上述已知信息，请将'The compounds in this list as well as others can be used to support qualification of an alternative assay or battery of assays.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"此清单中的化合物以及其它化合物，可用于支持一个或一组替代试验的资格 验证。"
    },
    {
        "instruction":"已知信息：\n'Evaluation of why and how problems have occurred with similar products can be helpful and should be conducted before finalizing the physical design features of a drug product. When identified early, error prone features can be eliminated from the design so that the same type of error does not occur with the product under development. Once a drug product reaches the final stages of development it may be difficult to change product features such as shape, strength, and dosing because such changes may require the collection of additional clinical or CMC data to support even minor modifications.'可被翻译为：很有必要在药品的物理设计完成之前评价相似药品的问题为什么以及怎么发生的。若能早期阶段识别到，可消除设计中容易出错的特性，以便相同类型的错误不会在研发过程中出现。一旦产品设计达到研发的最后阶段，是很难改变产品特征如形状、规格和剂型，因为这种变更会要求收集额外的临床试验或CMC数据，来支持即使很小的修订。\n'As drug development proceeds to later-phase studies, factors such as increasing experience with manufacture of the drug, changes in available technology, and the need for larger amounts of the drug in later phases of clinical development may lead to manufacturing changes that include manufacturing procedures, purification methods, and increased scale.'可被翻译为：随着药物研发进展至后期研究，诸如药物生产经验增加、现有技术的变更以及在临床研发后期阶段需要更大量的药品等因素均会导致生产变更，包括生产流程、纯化方法和生产规模扩大。\n'Post-Approval Changes to the Drug Product Chemistry, Manufacturing, and Controls'可被翻译为：制剂化学、生产和控制的批准后变更\n'These guidelines are valuable in the assessment of Chemistry, Manufacturing and Controls (CMC) changes across the product lifecycle.'可被翻译为：在整个产品生命周期中的化学、生产和控制（CMC）变更评估中， 这些指导原则是具有价值的。\n\n根据上述已知信息，请将'Once a drug product reaches the final stages of development, it may be difficult to change product features such as shape, size, strength, and dosing because such changes may require the collection of additional clinical or chemistry, manufacturing, and controls data to support even minor modifications.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一旦药品到达 开发的最终阶段，可能难以改变产品特征，例如形状、尺寸、规格和剂量，因为这 样的变化可能需要收集额外的临床或化学、生产和控制数据以支持甚至小修改。"
    },
    {
        "instruction":"已知信息：\n'A comparative clinical efficacy trial will usually be required as part of the comparability exercise.'可被翻译为：临床疗效的比较试验通常作为可比性工作的一部分。\n'c) suitable control drugs that may be used in comparative trials;'可被翻译为：c)可用于对照试验中的合适的对照药物；\n'A wide variety of medicinal products is currently available on the market for the treatment of constipation.'可被翻译为：目前市面上有各种各样可用于治疗便秘的药物。\n'Currently, the potency of r-hFSH-containing products is evaluated by calibration against an international standard (or an internal reference standard calibrated against the international standard; Steelman-Pohley assay).'可被翻译为：目前通过国际标准校准（或国际标准校准的内参标准品；Steelman-Pohley 检测） 来评估含有 r-hFSH 的药品的效力。\n\n根据上述已知信息，请将'As there are currently several medicinal products approved for the treatment of CML in CP a comparative trial should be undertaken against a licensed reference product.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"目前已经有几种药物被批准用于治疗慢性期的 CML，对比试验应采用已获批的药物作为对照药。"
    },
    {
        "instruction":"已知信息：\n'Preclinical safety data'可被翻译为：临床前安全性数据\n'5.3 Preclinical safety data [Product specific]'可被翻译为：5.3 临床前安全性数据 [产品特有信息]\n'Table 2 \nSummary of Prior and Ongoing Important Risks \nPotential Risk \nPreclinical data \nClinical data \nActions \nIrritability'可被翻译为：表2 \n此前和进行中的研究中的重要风险总结 \n潜在风险 \n临床前数据 \n临床数据 \n措施 \n应激性\n'Immunogenicity data (when applicable)'可被翻译为：免疫原性数据（如适用）\n\n根据上述已知信息，请将'Identified Risks \nPreclinical data \nClinical data \nActions \nNone identified \nNot applicable \nNot applicable \nNot applicable'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"已确认的风险 \n临床前数据 \n临床数据 \n措施 \n无已确认的风险 \n不适用 \n不适用 \n不适用"
    },
    {
        "instruction":"已知信息：\n'In addition, symptoms and signs (e.g. incontinence episodes, urinary frequency, urinary urgency, volumes voided etc.) should be evaluated as secondary endpoints.'可被翻译为：此外，症状和体征（如尿失禁发作，尿频，尿急，排尿量等）应作为次要终点评估。\n'They are hence recommended in addition to history and clinical examination and to micturition diaries to confirm the diagnosis of stress, urge or mixed incontinence for the purpose of registration studies where possible.'可被翻译为：因此在可能的情况下建议将其与病史和临床检查及排尿日记一起来确诊压力型、紧迫型或混合性尿失禁，用于注册研究。\n'Lower urinary tract symptoms (urgency symptoms) are less common.'可被翻译为：下尿路症状（尿急症状）较为少见。\n'Prognostically unfavourable factors are older age at time of onset of symptoms, short time from first symptoms to diagnosis, bulbar onset and worsening respiratory function.'可被翻译为：提示预后不良的因素为症状出现时年龄较大、从初次出现症状到作出诊断的时间短、延髓 起病及呼吸功能恶化。\n\n根据上述已知信息，请将'Complications or worsening of the symptoms or de novo appearance of new urinary symptoms must also be recorded and investigated.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"也须记录和研究并发症或症状恶化或新发尿失禁症状。"
    },
    {
        "instruction":"已知信息：\n'QL: The lowest spiking level with acceptable accuracy and precision'可被翻译为：QL：准确度和精密度符合要求情况下的最低加标水平。\n'The potency range is the range that meets accuracy and precision.'可被翻译为：效价范围是指符合准确度和精密度要求的范围。\n'The range of an analytical procedure is the interval between the lowest and the highest results in which the analytical procedure has a suitable level of precision, accuracy and response. (ICH Q2)'可被翻译为：分析方法的范围是最低结果和最高结果之间的区间，在此区间内分析方法具有适当水平的精密度、准确度及响应。（ICH Q2）\n'Validation of range, including lower and higher range limits: The lowest to highest relative potency levels that meet accuracy, precision, and response criteria, determined over at least 5 potency levels.'可被翻译为：范围验证，包括范围下限和上限： 在至少5个效价水平上进行测试，符合准确度、精密度和响应标准的最低到最 高相对效价水平，，。\n\n根据上述已知信息，请将'The range extends from and is inclusive of the QL to the highest spiking level with acceptable accuracy, precision and response'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"准确度、精密度和响应符合要求情况下，范围从QL（包括QL）延伸到最高加标水平"
    },
    {
        "instruction":"已知信息：\n'The heritable biological information encoded in the nucleotide sequence of DNA or RNA (some viruses).'可被翻译为：编码于DNA或RNA（一些病毒）核昔酸序列中的可遗传的生物信息。\n'A nucleotide triad sequence from start codon to stop codon. In general, the readable frame is the code sequence of a gene.'可被翻译为：自起始密码子到终止密码子之间的核昔酸三联体序列。一般情况下，可读框即指某个基因的编码序列。\n'The pattern and arrangement of amino acid residues in a polypeptide chain.'可被翻译为：多肽链中氨基酸残基的连接方式和排列。\n'A peptide consisting of more than 20 amino acid residues.'可被翻译为：由20个以上的氨基酸残基组成的肽。\n\n根据上述已知信息，请将'The genetic information carried by the nucleotide sequence. A set of 64 triplet codons that encode the start and end of 20 amino acid and polypeptide chains.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"核昔酸序列所携带的遗传信息。编码20种氨基酸和多肽链起始及终止的一套64个三联体密码子。"
    },
    {
        "instruction":"已知信息：\n'three-compartment model'可被翻译为：三室模型\n'The drug is distributed to all parts of the body after entering the systemic circulation, and achieves dynamic balance; If the distribution balance rate of drugs in plasma and tissues is different, it can be divided into central chamber and peripheral chamber, the drug first enters the central chamber and distributes evenly in the chamber, and then slowly distributes to the peripheral chamber, which is called the two-compartment model.'可被翻译为：药物进入全身循环后分布到机体各部位，并达到动态平衡；如药物在血浆中和组织中的分布平衡速度不同，可分为中央室和周边室，药物首先进入中央室并在该室均匀分布，而后才缓慢地分布到周边室，则称为二室模型。\n'The ratio of the area under the concentration-time curve of the target organ or target tissue to the non-target tissue.'可被翻译为：靶器官或靶组织与非靶组织的浓度-时间曲线下面积的比值。\n'concentration-time curve'可被翻译为：浓度-时间曲线\n\n根据上述已知信息，请将'When the drug enters bone and fat slowly, or binds to a tissue very firmly, the concentration-time curve decreases exponentially in three phases, that is, the three-compartment model.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物缓慢进入骨和脂肪时，或与某组织结合得非常牢固时，这时的浓度-时间曲线呈三相指数衰减，即为三室模型。"
    },
    {
        "instruction":"已知信息：\n'There is clinical evidence of an association between IVIg administration and thromboembolic events such as myocardial infarction, cerebral vascular accident (including stroke), pulmonary embolism and deep vein thromboses which is assumed to be related to a relative increase in blood viscosity through the high influx of immunoglobulin in at-risk patients.'可被翻译为：有临床资料证明静脉注射免疫球蛋白和血栓栓塞事件如心肌梗死、脑血管意外 （包括中风）、肺栓塞及深静脉血栓形成有关，其中深静脉血栓形成被认为与高危患 者接受高剂量免疫球蛋白输入使得血液粘度相对增加有关。\n'Patients developing thrombocytopenia are in danger of arterial and venous thromboembolic complications (heparin-induced thrombocytopenia and thrombosis, HITT).'可被翻译为：血小板减少症患者有动脉和静脉血栓栓塞并发症（肝素诱导型血小板减少症和血栓症，HITT）的危险。\n'Very rarely: Thromboembolic reactions such as myocardial infarction, stroke, pulmonary embolism, deep vein thromboses.'可被翻译为：非常罕见的不良反应：血栓栓塞反应如心肌梗死、中风、肺栓塞、深静脉血栓 形成。\n'2. Scope \nThe scope of this guideline is restricted to the development of medicinal products for the prophylaxis of acute venous thromboembolic events , i.e., deep vein thrombosis (DVT) and pulmonary embolism (PE) that involve or originate from lower limb veinsin patients undergoing surgery at high risk of VTE.'可被翻译为：2. 适用范围\n本指导原则的适用范围仅限于与急性静脉血栓栓塞的预防有关的药品开发，即累及或来自 VTE 高危手术术中患者下肢静脉的深静脉血栓（DVT）和肺栓塞（PE）。\n\n根据上述已知信息，请将'Arterial and venous thromboembolic events including myocardial infarction, stroke, deep venous thrombosis and pulmonary embolism have been associated with the use of immunoglobulins.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"已知使用免疫球蛋白会造成动脉和静脉血栓栓塞事件，包括心肌梗塞、中风、深静脉血栓和肺栓塞。"
    },
    {
        "instruction":"已知信息：\n'Here TTP on last prior therapy is compared with TTP\/PFS on the experimental therapy.'可被翻译为：在这里，将上一次治疗前的TTP与实验性治疗的TTP\/PFS进行比较。\n'In the latter case, TTP on last prior therapy is compared with time to progression or death on the experimental therapy.'可被翻译为：在后一种情况，是将最后一次既往治疗的TTP与实验性治疗 的至进展或死亡的时间进行比较。\n'In previously treated patients, a within patient comparison of TTP\/PFS might provide evidence of activity. Here TTP on last prior therapy is compared with TTP\/PFS on the experimental therapy. It should be noted, however, that the underlying assumption of at least similar growth rate over time cannot always be substantiated. For exploratory purposes this constitutes no major concern. It is advisable to recruit patients with secondary as well as primary resistance on prior therapy. This ensures at least to some extent, that the study population is relevant. It should also be noted that patients with early failure (primary resistance) on prior therapy may show some inversions in terms of TTP just due to fluctuations in tumour growth rate and variability related to imaging techniques.'可被翻译为：在先前治疗的患者中，患者自身比较 TTP\/PFS 可以提供活性证据。将在最后先前治疗的 TTP 与试验治疗的 TTP\/PFS 进行比较。但是，需注意的一点是，无法证实在整个期间 至少保持相似增长率的潜在假设。对于探索性目的而言，这并不是主要的问题。建议招募对先前治疗存在继发性耐药或原发性耐药的受试者。这至少可以保证在某种程度上研究人群具有相关性。也应注意到先前治疗中早期失败（原发性耐药）的患者可能由于随着肿瘤生长率的波动和影像技术的可变性而出现 TTP 相反的情况。\n'PTP - Previously Treated Patient (defined as >150 EDs) PUP - Previously Untreated Patient'可被翻译为：PTP-已接受治疗患者（定义为用药天数>150 天）\n\n根据上述已知信息，请将'In previously treated patients, a within patient comparison of TTP\/PFS might provide evidence of activity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在接受既往治疗的患者中，患者自身的TTP\/PFS比较可提供药物活性的证据。"
    },
    {
        "instruction":"已知信息：\n'The term “ relapsing MS (RMS)” applies to those affected patients either with a RRMS or SPMS with superimposed relapses.'可被翻译为：术语“复发性 MS（RMS）”适用于患有复发性 RRMS 或 SPMS 的患者。\n'The term relapsing MS includes 1) patients with RRMS, 2) patients with SPMS and superimposed relapses and 3) patients with a clinically isolated demyelination event and evidence of dissemination of lesions in time and space on the MRI.'可被翻译为：术语复发性MS包括1）RRMS患者，2）SPMS和合并复发患者，以及3）只有一次脱髓鞘性临床 事件并且在随后的核磁共振扫描中显示时间和空间上有病变扩散的患者。\n'Besides these main types of disease, a benign variety of MS refers to a RR form with only few relapses and no significant disability after several years of evolution.'可被翻译为：除了这些主要疾病类型以外，良性 MS 类型指的是几乎没有复发的 RRMS，这种形式的 MS 在延续很多年后也不会造成严重的失能。\n'Around 15% of patients develop a sustained deterioration of their neurological function early; i.e. primary progressive MS (PPMS).'可被翻译为：大约有 15%的患者从一开始就患上了神经功能持续性恶化；这种形式的疾病被称为是原发进展型多 发性硬化症（PPMS）。\n\n根据上述已知信息，请将'Approximately 85 % of all MS patients present relapsing-remitting (RR) MS, which is characterised by unpredictable acute episodes of neurological dysfunction named relapses, followed by variable recovery and periods of clinical stability.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"有大约 85%的患者所患的是复发缓解型 MS（RRMS），其特点是不可预测的神经功能障碍急 性发作，也称为临床发作或复发，随后是不稳定的恢复期和临床稳定期。"
    },
    {
        "instruction":"已知信息：\n'Persons who use electronic signatures based upon use of identification codes in combination with passwords shall employ controls to ensure their security and integrity. Such controls shall include:'可被翻译为：同时使用识别码和密码的电子签名应给予管理以确保其安全性和完整性，管理内容应包括：\n'The establishment of, and adherence to, written policies that hold individuals accountable and responsible for actions initiated under their electronic signatures, in order to deter record and signature falsification.'可被翻译为：为了阻止记录和签名伪造，制定并遵循源于个人电子签名行为的责任与职责的书面方针。\n'Each electronic signature shall be unique to one individual and shall not be reused by, or reassigned to, anyone else.'可被翻译为：每个电子签名应对应唯一的个体，且不应被他人重新使用或重新分配给他人。\n'(i) When an individual executes a series of signings during a single, continuous period of controlled system access, the first signing shall be executed using all electronic signature components; subsequent signings shall be executed using at least one electronic signature component that is only executable by, and designed to be used only by, the individual.'可被翻译为：（一）当一个体对单个受控系统连续访问，并进行一系列签名时，第一个签名应包含电子签名的所有组成部分；随后的签名应至少包含电子签名中只为个体设计使用的其中一种组成部分。\n\n根据上述已知信息，请将'Before an organization establishes, assigns, certifies, or otherwise sanctions an individual's electronic signature, or any element of such electronic signature, the organization shall verify the identity of the individual.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"建立、分配、证明或批准个体的电子签名或电子签名的任何要素前，应核实个人身份。"
    },
    {
        "instruction":"已知信息：\n'Whatever choice is made must be prespecified and fully justified in the protocol.'可被翻译为：无论作出那一种选择，都必须在方案中预先规定，并全面阐释其合理性。\n'The following conditions are required and any deviations should be fully justified.'可被翻译为：要求达到以下条件，任何偏离都应该有充分的合理原因。\n'The reasons and justification for the choice should be described in the protocol.'可被翻译为：方案中应当描述这一选择的原因和依据。\n'In each instance, justification that the chosen value is of clinical significance will be required.'可被翻译为：在每个实例中，需要合理说明所选数值具有临床显著性。\n\n根据上述已知信息，请将'A full justification of the choice of control(s) will be required.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"选择对照应该有充分的依据。"
    },
    {
        "instruction":"已知信息：\n'This summary with risk assessment can evolve through the lifecycle of the product and may be used to support post-authorisation applications.'可被翻译为：这份概述和风险评价在产品生命周期内会不断演变，可用于支持许可授予后的申请。\n'This risk-based approach should also have been taken into account for the Risk Management Plan (RMP),discussing how risks identified by data from the development programme, and potential risks, or missing information should be handled in a post-authorisation setting.'可被翻译为：风险管理计划（RMP）也应考虑用这种基于风险的考虑方法，讨论在产品批准以后，如何处理从开发过程的数据中识别的风险、潜在的风险或信息缺失。\n'The impact of NAbs on clinical outcomes is unlikely to be sufficiently ascertainable before 12 months of therapy and thus will need to be further evaluated post-authorisation as part of the risk management plan.'可被翻译为：12个月治疗前NAbs对于临床结果的 影响不一定足够明确，因此应在上市后作为风险管理计划的一部分进一步进行评估。\n'Immunogenicity issues should be further addressed in the Risk Management Plan (RMP).'可被翻译为：免疫原性问题应在风险管理计划（RMP）中进一步解决。\n\n根据上述已知信息，请将'Post-authorisation risk management could be a further potential area of application of such scales.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"上市后风险管理可能是这些量表进一步的潜在应用领域。"
    },
    {
        "instruction":"已知信息：\n'A primary analysis, unambiguously pre-specified in the protocol, correctly carried out and interpreted, should support the conclusions which are drawn from the trial.'可被翻译为：在研究方案中明确预先确定并且已经过正确的统计分析和解释的主要分析可为通过试验得出的结论提供支持。\n'When the full analysis set and the per protocol set lead to essentially the same conclusions, confidence in the trial results is increased, bearing in mind, however, that the need to exclude a substantial proportion of subjects from the per protocol analysis throws some doubt on the overall validity of the trial.'可被翻译为：当全分析集和符合 方案集得出实质上相同的结论时，会增加试验结果的可信度， 但应注意，对于排除了大比例受试者的符合方案分析会给试 验的整体正确性带来一些疑虑。\n'Any interim analysis that is not planned appropriately (with or without the consequences of stopping the trial early) may flaw the results of a trial and possibly weaken confidence in the conclusions drawn. Therefore, such analyses should be avoided.'可被翻译为：任何没有恰当计划的期中分析（不论有或没有提早终止 试验的影响）都可能导致试验结果的缺陷，并可能降低所得 结论的可靠性，因此，应该避免这些分析。\n'A summary of the research protocol, study design and a description of the procedures to be followed, including identification of any procedures which are experimental;'可被翻译为：研究方案摘要，研究设计，以及所用流程的描述，包括任何实验性流程的鉴 别；\n\n根据上述已知信息，请将'The extent to which the procedures in the protocol are followed and the primary analysis is planned a priori will contribute to the degree of confidence in the final results and conclusions of the trial.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对方案中步骤的遵循程度和主要分析预先计划的程 度，都将决定试验最终结果和结论的可信度。"
    },
    {
        "instruction":"已知信息：\n'16 July 2003 Does the deadline for mandatory submission of the CTD in Japan, the EU and the US (highly recommended in the US) also refer to the eCTD? Has ICH considered planning a seminar to help with CTD and eCTD submissions? The deadline does not refer to the eCTD although the regulatory authorities are accepting eCTD submissions. Please refer to regional guidance for specific guidance on eCTD submissions. Currently the ICH is not planning to conduct a CTD seminar. However, the ICH6 Conference, November 2003 in Osaka Japan, will focus on the CTD and eCTD.'可被翻译为：16 2003 年 7 月 在日本、欧盟和美国强制性提交 CTD 的最后期限（在美国强 烈推荐）也涉及 eCTD？ ICH 是否考虑计划组织一个研讨会来帮助 CTD 和 eCTD 提交 工作？ 尽管监管机构接受 eCTD 的提交，但截止日期并不涉及 eCTD。有关 eCTD 提交的具体指导，请参阅区域的指导。 目前，ICH 并不打算举办 CTD 研讨会。 然而，ICH6 会议，将于 2003 年 11 月在日本大版举行，着重于 CTD 和 eCTD。\n'In order to facilitate the implementation of the CTD Efficacy (M4E) guideline, the ICH Experts have developed a series of Q&As:'可被翻译为：为了促进CTD有效性部分（M4E）指导原则的实施，ICH专家组拟定了一系列问答：\n'21 Nov. 2003 Herbal CTD Will a Herbal Products version of the CTD be published and how much will it vary from the pharmaceutical CTD. ICH does not plan to issue any specific version of the CTD for Herbal Products.'可被翻译为：21 2003 年 11 月 草药产品CTD 将出版 CTD 的草药产品版本，以及药物 CTD 将有多少变 化？ ICH 没有发布任何特定版本草药产品 CTD 的计划。\n'In order to facilitate the implementation of the CTD General (M4) guideline, the ICH Experts have developed a series of Q&As: M4 Q&As'可被翻译为：为了促进CTD 通用指导原则(M4)的实施, ICH 专家组拟定了一系列问答: M4 问答\n\n根据上述已知信息，请将'19 Nov. 2003 CTD training Does ICH recommend any particular comprehensive training course on the implementation of the CTD? No, there are no general ICH recommendations for training on CTD implementation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"19 2003 年 11 月 CTD培训 ICH 是否有推荐的有关 CTD 实施的综合培训课程？ 没有，没有关于 CTD 实施培训的通用 ICH 建议。"
    },
    {
        "instruction":"已知信息：\n'Detailed information on this medicinal product is available on the website of the European Medicines Agency http:\/\/www.ema.europa.eu'可被翻译为：本药品详细信息可以在欧洲药品管理局的网站http:\/\/www.ema.europa.eu获得。\n'<Detailed information on this medicinal product is available on the website of the European Medicines Agency http:\/\/www.ema.europa.eu.>'可被翻译为：<有关本品的详细信息，请见欧洲药品管理局的网站 http:\/\/www.ema.europa.eu.\n'<Detailed information on this medicinal product is available on the website of the European Medicines 460 Agency http:\/\/www.ema.europa.eu.>'可被翻译为：<本药品详细信息可在欧洲药品局的网站http:\/\/www.ema.europa.eu.获得。>\n'Detailed information about ISO\/HL7 27953-2 can be obtained from ISO web site: http:\/\/www.iso.org\/iso\/home\/store.htm.'可被翻译为：有关 ISO\/HL7 27953-2 的详细信息，请登录 ISO网站http:\/\/www.iso.org\/iso\/home\/store.htm 查询。\n\n根据上述已知信息，请将'Detailed information on this medicine is available on the European Medicines Agency web site: http:\/\/www.ema.europa.eu <There are also links to other websites about rare diseases and treatments.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"该药的详细信息可见于欧洲药品管理局网站：http:\/\/www.ema.europa.eu。<还有关于罕见疾病和治疗的其他网站链接。"
    },
    {
        "instruction":"已知信息：\n'After a clinical trial is completed, the applicant shall fill the Application Form for Drug Registration, submit the clinical trial data, other altered and supplementary data in accordance with regulations, give in detail the basis and reasons, and provide relevant approved documents.'可被翻译为：临床试验结束后，申请人应当填写《药品注册申请表》，按照规定报送临床试验资料及其他变更和补充的资料，并详细说明依据和理由，提供相关证明文件。\n'(1) While applying for drug clinical trials, drug marketing registration and chemical APIs, the applicants shall carry out the study in accordance with the requirements of relevant technical guidances promulgated by NMPA, collate and submit the application dossier as per the format number and item order of the current version of M4: Common Technical Document for the Registration Application of Pharmaceuticals for Human Use (hereinafter referred to as CTD). If some items are not applicable, they can be missing, but \"not applicable\" shall be indicated and the reasons shall be specified.(Non-applicable items can be left default but \"not applicable\" shall be indicated and reasons shall be specified.)'可被翻译为：（一）申请人提出药物临床试验、药品上市注册及化学原料药申请时，应按照国家药品监管部门公布的相关技术指导原则的有关要求开展研究，并按照现行版《M4：人用药物注册申请通用技术文档（CTD）》（以下简称CTD）格式编号及项目顺序整理并提交申报资料。不适用的项目可合理缺项，但应标明不适用并说明理由。\n'Article 39 After completion of a clinical trial, the applicant shall submit a clinical trial final report, a statistical analysis report and its database to the State Food and Drug Administration.'可被翻译为：第三十九条 申请人完成临床试验后，应当向国家食品药品监督管理局提交临床试验总结报告、统计分析报告以及数据库。\n'(4) the applicant shall submit a complete clinical trial report to the State Food and Drug Administration after the completion of a clinical trial; and'可被翻译为：（四）临床试验结束后，申请人应当将完整的临床试验报告报送国家食品药品监督管理局；\n\n根据上述已知信息，请将'(2) While applying for drug marketing registration upon completion of the clinical trial, the applicant shall submit the electronic clinical trial database on the basis of CTD. For specific requirements such as database format and related documents, please refer to the relevant guidelines for clinical trial data submission.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）申请人在完成临床试验提出药品上市注册申请时，应在CTD基础上提交电子临床试验数据库。数据库格式以及相关文件等具体要求见临床试验数据递交相关指导原则。"
    },
    {
        "instruction":"已知信息：\n'The selection or adjustment of therapeutic drugs, dosage, usage, frequency of administration and course of administration according to the patient's condition and individual situation.'可被翻译为：针对患者的病情和个体化情况所选择或调整的治疗药物、剂量、用法、给药频次及给药疗程。\n'The medical (or self-medication) process of formulating or adjusting drug treatment plans scientifically and reasonably according to the individual situation of patients.'可被翻译为：针对患者的个体化情况科学合理制定或调整药物治疗方案的医疗（或自我药疗）过程。\n'In the course of medical treatment, according to the efficacy and condition, according to a certain law to increase or reduce the drug dose to achieve effective and safe medical behavior.'可被翻译为：在医疗过程中，根据疗效和病情，按照一定规律增加或减少药物剂量使达到有效和安全的医疗行为。\n'The discipline that studies the specific problems of how to rationally select drugs and drug methods and formulate drug treatment plans in the prevention and treatment of diseases. Pharmacotherapeutics is the practice of pharmacological theory in clinical use of drugs.'可被翻译为：研究在疾病防治中如何合理地选择药物和用药方法及制定药物治疗方案等具体问题的学科。药物治疗学是药理学理论在临床用药的实践。\n\n根据上述已知信息，请将'According to the patient's specific condition and individual differences to select therapeutic drugs, formulate drug delivery plan, safe and effective treatment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据患者的具体病情和个体差异选择治疗药物，制订给药方案，进行安全有效的治疗。"
    },
    {
        "instruction":"已知信息：\n'In humans and animals, the skin, especially the hair follicles, appears to be the most sensitive target of toxicity from repeated oral exposure to thallium (US EPA, 1992; US EPA, 2009).'可被翻译为：人和动物的皮肤，特别是毛囊，是铊重复口服给药最敏感的毒性靶点[2,3]。\n'high toxicity'可被翻译为：高毒性\n'Studies in animals or humans of absorption, distribution, metabolism, and excretion of the individual drugs show no potential for an unmanageable interaction (one that cannot be addressed with dose adjustments) or serious toxicity for the combination.'可被翻译为：在动物或人类中对个体药物的吸收、分布、代谢和排泄的研究显示，无难以处理的相互作用（一种不能用剂量调整来解决）或组合的严重毒性 的可能性。\n'This endpoint is based on inducing a minimal level of toxicity in the parental animals at the high dose.'可被翻译为：此终点是基于亲代动物在高剂量时产生最小毒性。\n\n根据上述已知信息，请将'The major toxicity identified in humans and animals is alopecia, and absorption and toxicity is considered high by the inhalation route (IPCS, 1996).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"脱发是人和动物的主要毒性反应，吸入途径的吸收和毒性很高[6]。"
    },
    {
        "instruction":"已知信息：\n'Population pharmacokinetic analysis could provide the requested data if a sufficient number of patients in different age ranges (including patients >65 and >75 years) are included in the clinical trials.'可被翻译为：如果临床试验中各个年龄层（包括65岁以上和75岁以上患者）都纳 入了足够数量的患者，此时的群体药代动力学分析可提供所需的数据。\n'In clinical efficacy studies of new medicinal products, there has been a clear preponderance of women aged 30-50, meaning that the composition of the study groups have not fully reflected the epidemiology of the disease (see also 7.3.), and usually only a tiny proportion of elderly people have been included.'可被翻译为：在新药临床疗效研究中，30-50岁女性具有明显优势，这说明研究组的构成并没有充分反映该疾病的流行病学特征（见7.3），仅纳入了一小部分高龄患者。\n'The investigational program should include a sufficient number of elderly patients, particularly the very elderly (>75 years old) as they represent a large target population in both acute and chronic pain. For known drug classes, subgroup analyses of the whole elderly population in the overall database are in general sufficient.'可被翻译为：研究计划应包括足够数量的老年患者，特别是高龄老年人（>75岁），因为他们代表急性和慢性疼痛中的大目标人群。对于已知的药物类别，总体数据库中的全部老年人群的亚组分析通常是足够的。\n'A reasonable number of elderly patients (>65 years, >75 and > 85 years, respectively) should be included in the therapeutic confirmatory studies.'可被翻译为：在治疗验证性研究中，需要纳入合理人数老年患者（分别>65 岁才，>75 岁和>85 岁）。\n\n根据上述已知信息，请将'Potential differences between the population(s) included in effectiveness studies and the overall patient population expected to receive the drug when it is marketed (e.g., exclusion of patients over 75 years old in studies of a drug for a disease common in the elderly).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"有效性研究中包括的人群与上市时预期接受药物的总患者人群（例如，在老年人常见疾病的药物的研究中排除75岁以上的患者）之间的潜在差异。"
    },
    {
        "instruction":"已知信息：\n'Technology Selection'可被翻译为：技术选择\n'However it is expected that knowledge from different processes and systems will be appropriately utilised.'可被翻译为：尽管如此，监管部门希望从不同生产工艺过程和系统中获得的 知识可以被恰当地利用。\n'Knowledge gained from other products, or from new innovative technologies, can also contribute to these goals.'可被翻译为：从其他产品或革新技术中获得的知识也有 助于这些目标的完成。\n'(2) Absolute expression or words, such as \"the highest technology\", \"the most scientific\", \"the most advanced\", \"the best\", etc..'可被翻译为：（二）含有“最高技术”、“最科学”、“最先进”、“最佳”等绝对化语言和表示的；\n\n根据上述已知信息，请将'Knowledge of best practices, state-of-the-art technologies and regulatory expectations contribute to the selection of the most suitable technology for a given purpose.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对最 佳做法、最先进技术以及监管预期的了解，有助于为特定目标选择 最合适的技术。"
    },
    {
        "instruction":"已知信息：\n'Medical Dictionary for Regulatory Activities (MedDRA) terminology for adverse event reporting used globally by the biopharmaceutical industry and regulators to promote consistent reporting and data analysis.'可被翻译为：用于不良事件报告的国际医学用语词典（MedDRA）术语在全球范围内由生物制药行业和监管机构使用，以促进报告和数据分析的一致性。\n'MedDRA® - the Medical Dictionary for Regulatory Activities - is a medical terminology used to classify adverse event information associated with the use of biopharmaceuticals and other medical products (e.g. medical devices and vaccines). Coding these data to a standard set of MedDRA terms allows health authorities and the biopharmaceutical industry to more readily exchange and analyze data related to the safe use of medical products11.'可被翻译为：MedDRA®-国际医学用语词典-是用于分类与使用生物药物和其他医疗产品（如医疗器械和疫苗）相关的不良事件信息的医学术语。将这些数据编码为一套标准的 MedDRA 术语，使卫生监管机构和生物制药行业能够更容易地交换和分析与医疗产品安全使用相关的数据11。\n'Preferably the reporting should apply the terminology used in the ‘Medical Dictionary for Regulatory Activities’ (MedDRA).'可被翻译为：报告最好使用“药事管理辞典”（MedDRA）中用到的术语。\n'Preferably the reporting should apply the terminology used in the Medical Dictionary for Regulatory Activities (MedDRA).'可被翻译为：报告最好使用药事管理标准医学术语集（MedDRA）中的术语。\n\n根据上述已知信息，请将'Medical Dictionary for Regulatory Activities Medical Dictionary for Regulatory Activities (MedDRA) terminology for adverse event reporting used globally by the biopharmaceutical industry and regulators to promote consistent reporting and data analysis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国际医学用语词典 用于不良事件报告的国际医学用语词典（MedDRA）术语在全球范围 内由生物制药行业和监管机构使用，以促进报告和数据分析的一致性。"
    },
    {
        "instruction":"已知信息：\n'The extent of drug product testing should be established by assessing whether or not acceptable change has occurred at the end of the light exposure testing as described in the Decision Flow Chart for Photostability Testing of Drug Products.'可被翻译为：制剂测试范围应依据“制剂光稳定性决策流程图”，通过评估光暴露试验结束时是否产生了可接受的变化来进行设计。\n'The intrinsic photostability characteristics of new drug substances and products should be evaluated to demonstrate that, as appropriate, light exposure does not result in unacceptable change.'可被翻译为：新原料药和制剂的内在光稳定特性应经过评估，以证明适当的光照不会引起不可接受的变化。\n'The sensitivity of the drug to light.'可被翻译为：药物对光线的敏感程度。\n'The determination of which tests should be included will be product-specific. The items emphasised in the following subsections are not intended to be all-inclusive, but represent product characteristics that should typically be documented to adequately demonstrate product stability.'可被翻译为：下列各节强调的内容并非稳定性研究的全部指标，而是列出了能指示制剂稳定性的代表性特征。\n\n根据上述已知信息，请将'Testing should progress until the results demonstrate that the drug product is adequately protected from exposure to light.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"试验应一直做到其结果显示该制剂可以充分抵御光照为止。"
    },
    {
        "instruction":"已知信息：\n'In case of bleeding: documentation of particulars; judgement of severity and treatment outcome by clinician and patient (consumption)'可被翻译为：在出血的情况中：由医师和患者详细记录，判断严重程度和治疗结果（消耗量）\n'Assessment of bleeding'可被翻译为：出血的评估\n'All the remaining major bleeds may be considered as non-life threatening major bleeds.'可被翻译为：所有其他严重出血事件可被视为非危及生命的严重出血事件。\n'In addition, response should be determined by the physician in a minimum of 10  patients undergoing at least 5 surgical procedures (comprising major surgeries), including efficacy of  haemostasis, loss of blood, and requirements for transfusion.'可被翻译为：医生应该对经历至少 10 次外科手术（包括大手术）的至少 5 名病人进行反应测定，包括止血效果、失血和输血需求情况。\n\n根据上述已知信息，请将'Response should be assessed as “none”, “moderate”,  “good” or “excellent” by the physician for those patients who were treated in hospital with the product  for major bleeds.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由医师将使用制品进行大出血住院治疗的患者的反应分为“无效”、“一般”、“良好”和“显著”四个等级。"
    },
    {
        "instruction":"已知信息：\n'Article 110 For the variation of the items specified in the approval document and its attachment for approved new drug development, drug production and import drug, supplementary applications shall be made.'可被翻译为：第一百一十条 变更研制新药、生产药品和进口药品已获批准证明文件及其附件中载明事项的，应当提出补充申请。\n'Article 116 Supplementary applications of import drugs shall be reviewed and approved by the State Food and Drug Administration. Those supplementary applications to change the place of production of the drug substance used for any import drug preparation, change the appearance of an import drug not resulting in specification changes, amend the insert sheet of an import drug according to the national specifications or the requirements of the State Food and Drug Administration, update the safety information in the insert sheet of an import drug, alter drug packaging label in accordance with regulations, or change the registration agent shall be filed to the State Food and Drug Administration for record.'可被翻译为：第一百一十六条 进口药品的补充申请，由国家食品药品监督管理局审批。其中改变进口药品制剂所用原料药的产地、变更进口药品外观但不改变药品标准、根据国家药品标准或国家食品药品监督管理局的要求修改进口药说明书、补充完善进口药说明书的安全性内容、按规定变更进口药品包装标签、改变注册代理机构的补充申请，由国家食品药品监督管理局备案。\n'5 In the BPCA, the term sponsor refers to an entity that has submitted an investigational new drug application or a new drug application before the new drug application is approved. The term holder of an approved application refers to a company holding an approved new drug application to market a drug product containing the drug at issue (21 U.S.C. 355a(b), (c), and (d)).'可被翻译为：5在BPCA中，“申办方”指的是在新药申请被批准之前递交了研究性新药申请或新药申请的实体。“已批准申请的持有人”指的是持有使药品（包含讨论中的药品）上市的已批准新药 申请的公司（21 U.S.C. 355a（b）、（c）和（d））。\n'Application for generic drugs refers to registration application for producing the drugs having existing national drug standard which is approved to be marketed by the State Food and Drug Administration, whereas the application for biological products shall be submitted as the process of new drug application.'可被翻译为：仿制药申请，是指生产国家食品药品监督管理局已批准上市的已有国家标准的药品的注册申请；但是生物制品按照新药申请的程序申报。\n\n根据上述已知信息，请将'Supplementary application refers to application for variation, addition, or cancellation of the items or contents approved in the original application for new drug, generic drug or import drug.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"补充申请，是指新药申请、仿制药申请或者进口药品申请经批准后，改变、增加或者取消原批准事项或者内容的注册申请。"
    },
    {
        "instruction":"已知信息：\n'The latter include both synthetic (methotrexate (MTX), sulfasalazine) and biological DMARDs.'可被翻译为：后者包括合成（氨甲喋呤（MTX）、柳氮磺胺吡啶）和生物DMARD。\n'In DMARD-naïve (or MTX-naïve) RA patients a test drug could receive a first-line therapy indication either as monotherapy or in combination with MTX or another synthetic DMARD.'可被翻译为：在 DMARD 初治（或 MTX 初治）RA 患者中，试验药物可作为一线治疗选择，单药治疗或是 与 MTX 或其他合成 DMARD 联合治疗。\n'Nonsteroidal anti-inflammatory drugs (NSAIDs) are considered a first–line treatment option in most cases of newly diagnosed JIA, followed by intra-articular glucocorticosteroids and disease modifying antirheumatic drugs (DMARDs).'可被翻译为：认为非甾体类抗炎药（NSAID）是大多数新诊断的JIA病例的一线治疗方案，其次是关节内糖皮质激素和改善病情的抗风湿药物（DMARD）。\n'The scope of this guideline is to provide a European common position on pertinent issues relating to the clinical evaluation of medicinal products (e.g. synthetic as well as biological DMARDs) for the treatment of RA diagnosed according to international classification criteria, e.g. ACR\/EULAR 2010.'可被翻译为：本指南的目的是提供对类风湿关节炎（根据国际分类标准诊断）治疗药物（如合成类及生物类 DMARDs）临床评价相关问题的欧洲共同立场，如 ACR\/EULAR 2010。\n\n根据上述已知信息，请将'Available agents include synthetic disease- modifying anti-rheumatic drugs (DMARDs), biological DMARDs and glucocorticoids.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"可用药物一般包括合成改善病情抗风湿药物、生物型改善病情抗风湿药物和糖皮质激素。"
    },
    {
        "instruction":"已知信息：\n'OQ: Operation Qualification'可被翻译为：运行确认\n'performance qualification (PQ): Documented verification that the equipment or system performs consistently and reproducibly within defined specifications and parameters in its normal operating environment (i.e. in the production environment).'可被翻译为：性能确认（PQ）：证明设备或系统性能在正常操作环境下（即生产环境下）持续重复满足既定标准和参数的文件化工作。\n'1.This condition relates to carrying out room classification tests with the normal production process with equipment in operation, and the normal staff present in the room.\n2.Documented verification that the system or subsystem performs as intended over all anticipated operating ranges.\n3.This is the documentary evidence to verify that the equipment operates in accordance with its design specifications within its normal operating range and performs as intended throughout all anticipated operating ranges.\n4.Operational qualification is the documentary evidence to verify that the equipment operates in accordance with its design specifications in its normal operating range and performs as intended throughout all anticipated operating ranges.'可被翻译为：1.这个条件涉及到在正常的生产过程中，在设备运行的情况下，在正常的工作人员在场的情况下进行房间分类试验。\n2.系统或子系统在所有预期工作范围内按预期运行的文件验证。\n3.这是证明设备在其正常工作范围内按照其设计规范运行，并在所有预期工作范围内按预期运行的文件证据。\n4.运行确认是证明设备在其正常运行范围内按照其设计规范运行，并在所有预期运行范围内按预期运行的书面证据。\n'12.30 Before starting process validation activities, appropriate qualification of critical equipment and ancillary systems should be completed. Qualification is usually carried out by conducting the following activities, individually or combined: \n− Design Qualification (DQ): documented verification that the proposed design of the facilities, equipment, or systems is suitable for the intended purpose. \n− Installation Qualification (IQ): documented verification that the equipment or systems, as installed or modified, comply with the approved design, the manufacturer’s recommendations and\/or user requirements. \n− Operational Qualification (OQ): documented verification that the equipment or systems, as installed or modified, perform as intended throughout the anticipated operating ranges. \n− Performance Qualification (PQ): documented verification that the equipment and ancillary systems, as connected together, can perform effectively and reproducibly based on the approved process method and specifications.'可被翻译为：12.30 工艺验证开始前，关键设备及辅助系统应当完成适当的确认。通常通过下列单独或联合活动来进行确认： \n— 设计确认（DQ）:确认设施、设备或系统的设计适合其预定用途，并有相应文件。 \n— 安装确认（IQ）:确认安装或调整后的设备或系统符合经批准的设计标准、制造商建议和（或）用户要求，并有相应文件。 \n— 运行确认（0Q）:确认安装或调整后的设备或系统在整个预期操作范围内能按意图正常运行，并有相应文件。 \n— 性能确认（PQ）:确认设备及辅助系统连接后，按经批准的工艺方法和标准，能重复、有效地发挥其性能，并有相应文件。\n\n根据上述已知信息，请将'operational qualification (OQ): Documented verification that the system or subsystem performs as intended over all anticipated operating ranges.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"运行确认（OQ）：证明系统或子系统按既定预期运行范围运行的文件化工作。"
    },
    {
        "instruction":"已知信息：\n'When the definition of inactive disease status is met for 6 continuous months, the patient is considered to be in clinical remission on medication.'可被翻译为：当连续6个月符合非活动性疾病状态的定义时，患者被认为通过药物治疗达到临床缓解。\n'Complete clinical remission is defined by complete absence of disease activity measured by disease activity indices in patients who do not require any ongoing lupus specific therapy.'可被翻译为：完全临床消退的定义是在当时无需狼疮特定治疗的情况下，通过疾病活动度指数测量发现疾病活动完全消失。\n'These endpoints include minimal disease activity and inactive disease based on the JADAS, and inactive disease \/ clinical remission (on and\/or off treatment) based on the ACR.'可被翻译为：这些终点包括基于JADAS的最小疾病活动度和非活动性疾病，以及基于ACR的非活动性疾病\/临床缓解（治疗和\/或不治疗）。\n'Minimal disease activity and inactive disease \/ remission (if not chosen as the primary endpoint)'可被翻译为：最小疾病活动度和非活动性疾病\/缓解（如果未选择作为主要终点）\n\n根据上述已知信息，请将'When the inactive disease status is met for 12 months in the absence of any medication, the patient is classified as being in a state of clinical remission off medication.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当在没有任何药物的情况下长达12个月符合非活动性疾病状态时，将患者分类为无药物治疗即达到临床缓解状态。"
    },
    {
        "instruction":"已知信息：\n'pharmacokinetic antagonism'可被翻译为：药动学拮抗\n'The time it takes for the plasma drug concentration to decrease by half after the distribution of the drug in the body reaches equilibrium.'可被翻译为：药物在体内分布达到平衡状态后血浆药物浓度降低一半所需的时间。\n'(2) predict whether a clinically achievable concentration of the investigational drug can reduce the enrichment of drug-resistant viral populations;'可被翻译为：（2）预测试验药的某个临床可达到的浓度是否可以减少抗药病毒的群落 富集；\n'For agonist\/antagonist products, the PK parameters for both the agonist and the antagonist, along with their active metabolites (if any), should be determined.'可被翻译为：对于激动剂\/拮抗剂产品，还应测定激动剂和拮抗剂及其活性代谢物（如果有）的PK参数。\n\n根据上述已知信息，请将'Antagonist drugs can effectively reduce the concentration of the active drug at the site of action.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"拮抗剂的药物可以有效地降低作用部位活性药物浓度的情况。"
    },
    {
        "instruction":"已知信息：\n'Viral Safety Evaluation of Biotech Products Case C: When the cells or unprocessed bulk are known to contain a virus, other than a rodent retrovirus, for which there is no evidence of capacity for infecting humans, (such as those identified by footnote 2 in Table 3, except rodent retroviruses (Case B)), virus removal and inactivation evaluation studies should use the identified virus.'可被翻译为：情况C：已知细胞或未加工品中含有除啮齿类动物逆转录病毒以外的病毒，而这些病毒又无证据证明其对人有感染性[如表3脚注2中所标明的，除啮齿类动物逆转录病毒（情况B）以外的病毒]，则病毒消除和灭活的评价研究应使用已 鉴定的病毒。\n'Case A: Where no virus, virus-like particle or retrovirus-like particle has been demonstrated in the cells or the unprocessed bulk, virus removal and inactivation studies should be performed with non-specific “model” viruses as previously stated.'可被翻译为：情况A：细胞或未加工品中未发现有病毒、病毒样颗粒或逆转录病毒样颗粒时，应使用上述非特异模型病毒进行病 毒消除和病毒灭活研究。\n'Table 4 presents an example of an action plan, in terms of process evaluation and characterisation of viral clearance as well as virus tests on purified bulk, in response to the results of virus tests on cells and\/or the unprocessed bulk.'可被翻译为：表4是举例说明对于细胞和\/或未加工品病毒检测结果 而采取的行动方案，包括工艺评价、病毒清除鉴定和纯品的病毒试验。\n'The amount of virus eliminated or inactivated by the production process should be compared to the amount of virus which may be present in unprocessed bulk.'可被翻译为：生产过程中所消除或灭活的病毒量应与收获液中可能存在的病毒量相比较。\n\n根据上述已知信息，请将'Case E: When a virus, which cannot be classified by currently available methodologies, is detected in the cells or unprocessed bulk, the product is usually considered unacceptable since the virus may prove to be pathogenic.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"情况E：在细胞或未加工品中检测到用现有方法无法分类的病毒时，由于这种病毒有可能是致病性的，因此该产品一般不予接受。"
    },
    {
        "instruction":"已知信息：\n'Safety concerns may arise from the presence of impurities or contaminants. It is preferable to rely on purification processes to remove impurities and contaminants rather than to establish a preclinical testing program for their qualification. In all cases, the product should be sufficiently characterised to allow an appropriate design of preclinical safety studies.'可被翻译为：药物中存在的杂质或污染物可能导致安全性担忧。最好依靠纯化工艺去除杂质和污染物，而不是为了限度确定建立一套临床前试验计划。在任何情况下，都应该充分明确产品的特征，以便对临床前安全性试验进行合理设计。\n'The safety of recombinant products with regard to viral contamination can only be reasonably assured by the application of virus testing within the manufacturing process and implementation of virus inactivation and removal steps during the manufacturing process, according to the relevant guidelines (e.g. ICH Q5A ‘Note for Guidance on quality of biotechnological products: viral safety evaluation of  biotechnology products derived from cell lines of human or animal origin’ (CPMP\/ICH\/295\/95)).'可被翻译为：根据相关指导原则（例如 ICH Q5A“生物技术制品质量的指南：从人源或动物 源细胞株衍生的生物技术制品的病毒安全性评价”（CPMP\/ICH\/295\/95）），重组产品在病毒污染方面的安全性只有在生产工艺中应用病毒测试并在生产过程中实施病毒 灭活和清除步骤才能得到保证。\n'ICH S6 (R1) Harmonised Tripartite Guideline on Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals'可被翻译为：生物技术衍生药品的临床前安全性评价之 ICH S6（R1）协调三方指导原则\n'PRECLINICAL SAFETY EVALUATION OF BIOTECHNOLOGY-DERIVED PHARMACEUTICALS S6(R1)'可被翻译为：生物制品的临床前安全性评价 S6(R1)\n\n根据上述已知信息，请将'Since immunogenicity concerns may arise from the presence of impurities or contaminants, it is preferable to rely on purification processes to remove impurities and contaminants rather than to establish a preclinical testing program for their qualification (refer to ICH S6 (R1) Harmonised Tripartite Guideline on Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由于免疫原性问题是由杂质或污染物的存在引起的，所以首选依赖纯化工艺来除去杂质和污染物，而非建立临床前试验计划来进行鉴别（请参考 ICH S6（R1）生物技术衍生药品的临床前安全性评价协调三方指导原则）。"
    },
    {
        "instruction":"已知信息：\n'Rat liver Unscheduled DNA Synthesis (UDS) test \n• In particular for bacterial mutagenicity positive with S9 only • Responsible liver metabolite known o to be generated in test species used o to induce bulky adducts'可被翻译为：大鼠肝脏非程序性DNA合成（UDS）试验 \n• 尤其是细菌突变试验仅在S9代谢活 化条件下结果为阳性时 • 针对下列肝脏代谢物：已知在试验所用的种属中产生能够诱导大的加合物\n'For directly acting mutagens (bacterial mutagenicity positive without S9) and compounds known to be clastogenic* Rat liver Unscheduled DNA Synthesis (UDS) test'可被翻译为：对于直接作用的致突变物（不加S9细菌突变为阳性） 和已知的致突变化合物* 大鼠肝非程序性 DNA 合成（UDS） 试验\n'Responsible liver metabolite known o to be generated in test species used o to induce bulky adducts Comet assay'可被翻译为：已知相关的肝代谢物会 o 在试验所用物种中产生 o 诱导大的加合物 彗星试验\n'The UDS assay is considered useful mainly for compounds that induce bulky DNA adducts or are positive in the Ames test.'可被翻译为：UDS试验被认为主要适用于诱导 大的DNA加合物或Ames试验为阳性结果的化合物。\n\n根据上述已知信息，请将'Rat liver Unscheduled DNA Synthesis (UDS) test \n·In particular for bacterial mutagenicity positive with S9 only \n·Responsible liver metabolite known\n o to be generated in test species used\n o to induce bulky adducts'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"大鼠肝脏非程序性DNA合成（UDS）试验 \n• 尤其是细菌突变试验仅在S9代谢活化条件下结果为阳性时 \n• 已知可产生下列变化的肝脏代谢物\no在试验所用物种中产生 \no诱导大的加合物"
    },
    {
        "instruction":"已知信息：\n'For approved indications, new information on efficacy\/effectiveness under conditions of actual use should also be described in this section, if available.'可被翻译为：对于已批准的适应症，在实际使用条件下的有效性\/疗效的新信 息（如果有）也应在本章节中描述。\n'17.2 Newly Identified information on Efficacy\/Effectiveness'可被翻译为：17.2新确定的有效性\/疗效信息\n'Summarising relevant new safety information that could have an impact on the benefit-risk profile of the medicinal product; Summarising any important new efficacy\/effectiveness information that has become available during the reporting interval;'可被翻译为：总结可能对药品的利益-风险特征有影响的相关新安全性信息； 总结在报告期内获得的任何重要的、新的有效性\/疗效信息；\n'3.16.5 Effectiveness of Risk Minimisation (if applicable) Relevant information on the effectiveness and\/or limitations of specific risk minimisation activities for important identified risks that has become available during the reporting interval should be summarised in this section.'可被翻译为：3.16.5 风险最小化措施的有效性（如果适用） 本报告应概述有关在报告期内可用的重要已确定风险的具体风险最小化措 施的有效性和\/或限制的相关信息。\n\n根据上述已知信息，请将'3.17.2 Newly Identified information on Efficacy\/Effectiveness New information on efficacy\/effectiveness in approved indications that may have become available during the reporting interval should be presented in this section.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3.17.2 关于有效性\/疗效的新确定信息 在本章节中，应介绍在报告期内可能已获得的关于已批准适应症的有效性\/ 疗效的新信息。"
    },
    {
        "instruction":"已知信息：\n'However, when complex, regulatory, or technical issues are discussed during the course of a telephone conversation between the sponsor and the FDA project manager, the caller should follow-up with a written communication (e.g., email, sponsor submission, FDA correspondence) to document the discussion and\/or respond to information requested during the conversation.'可被翻译为：然 而，当在申办方和FDA项目经理之间的电话会谈期间讨论复杂的、监管的或技 术问题时，应采用书面沟通（例如电子邮件、申办方提案、FDA信函）随访呼 叫者，以记录讨论和\/或对在会谈期间请求的信息的回复。\n'Sponsors are advised that such informal responses may not accurately or comprehensively capture FDA’s thinking. In rare cases, however, and with supervisory approval, it may be appropriate for FDA review team members to communicate directly with sponsors regarding minor issues related to their drug development program.'可被翻译为：告知申办方，这种非正式回复可能不能准确或全面地获取FDA的见解。然而，在极少数情况下，并且在监督批准下，FDA审评小组成员可以适当地与申办方就其与药物开发计划相关的小问题进行沟通。\n'‒ FDA project managers should send preliminary responses to sponsor questions before the meeting so that the meeting time can be dedicated to unresolved issues for which more discussion is needed. In the preliminary responses, FDA should provide high-level recommendations for important issues identified during the review of the meeting package, even if questions concerning those issues were not explicitly posed by the sponsor.'可被翻译为：- FDA项目经理应在会前发送对申办方所提问题的初步回复，以便将 与会时间用于需要进行更多讨论的未解决问题。在初步回复中，即 使有关这些议题的问题申办方没有明确提出，FDA也应为在审评会 议文件包期间发现的重要议题提供高级别建议。\n'Project managers should send a courtesy copy of written FDA correspondence to sponsors via secure email when such communications are time-sensitive or communicate actions (e.g., clinical hold).'可被翻译为：当此类沟通具有时效性或为沟通行动（例如临床试验暂停）时，项目经理应当通过安全电子邮件向申办方发送书面FDA信函的副本。\n\n根据上述已知信息，请将'Depending on the nature of the questions presented during the conversation, the sponsor may be referred to the formal meeting process for a fuller discussion of the issue(s) with additional review staff and management. Both FDA project managers and sponsors should provide mutual names and telephone numbers for communicating time-sensitive issues (e.g., notification of clinical hold).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据会谈期间所提出的问题的性质，可让申办方进行正式会议过程，以便与附加审评人员和管理人员更充分地讨论问题。FDA项目经理和申办方应提供相互的姓名和电话号码，用于沟通时效性问 题（例如临床试验暂停通知）。"
    },
    {
        "instruction":"已知信息：\n'18.13 Production of APIs or intermediates from cell culture or fermentation involves biological processes such as cultivation of cells or extraction and purification of material from living organisms. Note that there may be additional process steps, such as physicochemical modification, that are part of the manufacturing process. The raw materials used (media, buffer components) may provide the potential for growth of microbiological contaminants. Depending on the source, method of preparation, and the intended use of the API or intermediate, control of bioburden, viral contamination, and\/or endotoxins during manufacturing and monitoring of the process at appropriate stages may be necessary.'可被翻译为：18.13 细胞培养或发酵生产原料药或中间体涉及如细胞培养，或从活体组织提取和纯化等生物工艺。生产工艺中也可能存在某些附加工艺步骤，如物理化学修饰。所用原材料（如培养基、缓冲组分）可能导致微生物污染物的生长。根据原料药或中间体的来源、制备方法和预期用途，必要时，在生产过程中需要控制生物负荷、病毒污染和\/ 或内毒素并在工艺的适宜阶段对其进行监测。\n'18. SPECIFIC GUIDANCE FOR APIs MANUFACTURED BY CELL CULTURE\/FERMENTATION'可被翻译为：18 细胞培养\/发酵生产原料药专用指南\n'18.11 The term “biotechnological process” (biotech) refers to the use of cells or organisms that have been generated or modified by recombinant DNA, hybridoma or other technology to produce APIs. The APIs produced by biotechnological processes normally consist of high molecular weight substances, such as proteins and polypeptides, for which specific guidance is given in this Section. Certain APIs of low molecular weight, such as antibiotics, amino acids, vitamins, and carbohydrates, can also be produced by recombinant DNA technology.The level of control for these types of APIs is similar to that employed for classical fermentation.'可被翻译为：18.11 “生物技术工艺”（生物技术）指使用细胞或组织生产原料药，这些细胞或组织可通过DNA重组技术、杂交瘤技术或其它技术得到。生物技术工艺生产的原料药通常由蛋白质、多肽等高分子物质组成，本章提出了相应的具体要求。某些低分子原料药，如抗生素、氨基酸、维生素和碳水化合物也可使用DNA重组技术生产，其控制要求与传统发酵工艺生产的原料药相似。\n'This Guide covers APIs that are manufactured by chemical synthesis, extraction, cell culture\/fermentation, by recovery from natural sources, or by any combination of these processes. Specific guidance for APIs manufactured by cell culture\/fermentation is described in Section 18.'可被翻译为：本指南适用于通过化学合成、提取、细胞培养\/发酵生产，或从天然资源中获取的原料药，也包括采用上述多种方法组合生产的原料药。第18章规定了采用细胞培养\/发酵工艺生产原料药的特定要求。\n\n根据上述已知信息，请将'18.10 Section 18 is intended to address specific controls for APIs or intermediates manufactured by cell culture or fermentation using natural or recombinant organisms and that have not been covered adequately in the previous sections. It is not intended to be a stand-alone Section. In general, the GMP principles in the other sections of this document apply. Note that the principles of fermentation for “classical” processes for production of small molecules and for processes using recombinant and non-recombinant organisms for production of proteins and\/or polypeptides are the same, although the degree of control will differ. Where practical, this section will address these differences. In general, the degree of control for biotechnological processes used to produce proteins and polypeptides is greater than that for classical fermentation processes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"18.10 本章专门对采用天然或重组组织进行细胞培养或发酵生产的原料药或中间体提出了未在之前章节充分阐明的特殊控制要求。本章并非独立存在章节。总体上，本指南其它章节中的GMP原则通常也适用于本章节。需要说明是，生产小分子化合物的“传统”发酵工艺与 采用重组与非重组组织生产蛋白质和\/或多肽的发酵工艺本质相同，只是控制程度有所不同。生产蛋白质和多肽的生物技术工艺的控制要求通常要严于传统发酵工艺，本章对此作出了规定\/阐述。"
    },
    {
        "instruction":"已知信息：\n'List of excipients [Product specific] Sodium chloride 9 mg\/mL Water for injections.'可被翻译为：辅料清单 [产品特定的] 氯化钠 9 mg\/mL 注射用水\n'[If applicable taking into account the dilution with sodium chloride]: Depending on the time when you administer the injection, the content of sodium given to the patient may in some cases be greater than 1 mmol (23 mg).'可被翻译为：[如果氯化钠稀释适用]：因为患者进行药品注射的时间有所不同，在某些情况 下，患者所摄入的钠含量可能高于1mmoL。在低钠饮食患者中应考虑这一点。\n'Inactive ingredients Sodium chloride (4.5 mg\/mL), Citrate (7.2 mg\/mL) in water for injection (WFI)'可被翻译为：非活性成分 氯化钠(4.5 mg\/mL)，柠檬酸（7.2mg\/mL），溶于注射用水(WFI)\n'The solution can be directly administered by the intravenous route<, or it can also be diluted in an isotonic solution (e.g. 5 % glucose or 0.9 % sodium chloride)>.'可被翻译为：溶液可以经静脉直接给药<，它也可以用等渗溶液（例如 5％葡萄糖或 0.9％氯化钠）稀释>。\n\n根据上述已知信息，请将'The medicinal product may be diluted with sodium chloride 9 mg\/mL solution for injection.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"可用 9 mg\/mL 注射用氯化钠溶液稀释药品。"
    },
    {
        "instruction":"已知信息：\n'The manufacture of sterile products is subject to special requirements in order to minimize risks of microbial, particulate and endotoxin\/pyrogen contamination. The following key areas should be considered:'可被翻译为：无菌产品的生产应符合特殊要求，以尽量降低微生物、微粒和内毒素\/热原污染的风险。应考虑以下关键领域：\n'Facility, equipment and process should be appropriately designed, qualified and\/or validated and where applicable, subjected to ongoing verification according to the relevant sections of the Good Manufacturing Practices (GMP) guidelines. The use of appropriate technologies (e.g. Restricted Access Barriers Systems (RABS), isolators, robotic systems, rapid\/alternative methods and continuous monitoring systems) should be considered to increase the protection of the product from potential extraneous sources of endotoxin\/pyrogen, particulate and microbial contamination such as personnel, materials and the surrounding environment, and assist in the rapid detection of potential contaminants in the environment and the product.'可被翻译为：设施、设备和工艺应按照药品生产质量管理规范（GMP）指南的相关章节进行适当的设计、确认和\/或验证，并在适用的情况下进行持续确认。应考虑采用适当的技术（例如限制进入隔离系统（RABS）、隔离器、自动化系统、快速\/替代方法和连续监测系统），加强对产品的保护，使其免受潜在的外来内毒素\/热原、微粒和微生物污染源（例如人员、物料和周围环境）的影响，并帮助快速检测环境和产品中的潜在污染物。\n'The process should be shown to achieve the removal and inactivation of the selected viruses during the purification and inactivation processes.'可被翻译为：应证明在工艺纯化和病毒灭活过程中，确已达到去除 和灭活所设病毒的目的。\n'authorised products where a significant change in the manufacturing process has been made (e.g.  additional viral inactivation\/removal steps or new purification procedures).'可被翻译为：生产工艺有明显改变的已上市制品（如：增加病毒灭活\/清除步骤或新的提纯步骤）。\n\n根据上述已知信息，请将'iv. A description of extraction and purification procedures, as applicableYou should describe procedures to ensure the avoidance, removal, and\/or inactivation of animal proteins and viruses and any other infectious agents, where applicable. You should address the avoidance and\/or removal of pyrogenic material and bacterial endotoxins by establishing appropriate controls during the manufacturing process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"iv. 提取和纯化过程的描述，如适用。应描述相关过程，适用时确保避开、去除、和\/或动物蛋白、病毒及任何其它感染剂。在生产过程中，应通过确定恰当的控制方法，解决避免、和\/或去除热源物质和细菌内毒素的问题。"
    },
    {
        "instruction":"已知信息：\n'Validated prognostic models may be used to stratify the study population by predicted rates of progression (Gomeni 2014).'可被翻译为：可以使用经过验证的预后模型按预测进展率对研究人群进行分层（Gomeni 2014）。\n'Disease severity should be clearly defined using validated grading systems and sponsors should ensure that the target population is adequately reflected in the study population.'可被翻译为：疾病的严重程度应使用分级系统明确界定，申办者应确保目标人群对研究人群有充分的体现。\n'IPSS is based on the percentage of bone marrow blasts, cytogenetics and number and degree of peripheral cytopenias at diagnosis, enabling identification of four risks groups: low, intermediate-1, intermediate-2, and high risk. Recently, new clinical and laboratory variables were identified tha might add prognostic information to the IPSS (red blood cell transfusion dependency, high levels of LDH). Sponsors are therefore advised to follow closely the expected refinement of prognostic scores to be used in the design of clinical trials when sufficiently validated.'可被翻译为：IPSS基于诊断时的骨髓原始细胞百分比、细胞遗传学以及外周血细胞数量和减少程度，可以用来评判四个风险组：低、中度-1、中度-2和高风险组。最近，新发现的临床和实验室变量被认为有可能增加IPSS中的预后信息（红细胞输血依赖性、高水平LDH）。因此当这些变量被充分验证后，建议申办方紧密跟进用于临床试验设计的预后评分的改进。\n'Alternative species, including non-rodents, can also be used if indicated, and if sufficiently validated.'可被翻译为：如果需要且被充分证明合适，也可采用替代的种属（包括非啮齿类）进 行试验。\n\n根据上述已知信息，请将'Sponsors are therefore advised to follow closely the expected refinement of prognostic scores to be used in the design of clinical trials when sufficiently validated.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"因此当这些变量被充分验证后，建议申办方紧密跟进用于临床试验设计的预后评分的改进。"
    },
    {
        "instruction":"已知信息：\n'b) the total burden of disease (multimorbidity) or other clinical situations may render a subject vulnerable to adverse effects of any drug, a situation further complicated by the interactions between multiple drugs used to treat multiple diseases, and by prescription cascades (using drugs to treat adverse events of other drugs).'可被翻译为：b)总的疾病负担（多病）或其他临床情形可能使得受试者易于发生任何药物的 不良作用，这种情形因用于治疗多种疾病的多种药物间的相互作用，以及处 方级联（用药治疗其他药物的不良事件）而进一步复杂化。\n'When two treatments are used for the same disease or condition, they may differentially affect various outcomes of interest in that disease, particularly if they represent different classes or modalities of treatment.'可被翻译为：当两种治疗用于同一种疾病或病情的时候，特别当它们 是属于不同种类或不同方式的两种治疗时，它们可能对这种 疾病的结果产生不同的影响。\n'2 The term codevelopment as used in this guidance refers to the concurrent development of two or more new investigational drug products that are intended to be used in combination to treat a disease or condition.'可被翻译为：2本指南中所使用的术语“共同开发”是指并行开发两种或两种以上新试验药物联合用于治 疗某种疾病或病症。\n'Chronic obstructive pulmonary disease (COPD) and asthma have different aetiologies but may coexist in the same patient.'可被翻译为：慢性阻塞性肺病（COPD）和哮喘有不同的病因，但可能共存于同一患者。\n\n根据上述已知信息，请将'a) a drug used to treat a given disease may have an impact on other concurrent disease(s) (i.e. beta blockers used for hypertension may impair control of diabetes or asthma);'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"a) 用于治疗给定疾病的药物可能影响其他并行疾病（即，降压药beta阻滞剂可 能损害糖尿病或哮喘的控制）；"
    },
    {
        "instruction":"已知信息：\n'Note 2 To assess the mutagenic potential of impurities, a single bacterial mutagenicity assay can be carried out with a fully adequate protocol according to ICH S2(R1) and OECD 471 guidelines (Ref. 13 and 14).'可被翻译为：注 2 为了评估杂质的潜在致突变性，可以根据 ICH S2(R1)和 OECD 471 指南 （参考文献 13 和 14）制订全面充分的方案进行单一细菌的致突变试验。\n'3.2 Recommended Protocol for the Bacterial Mutation Assay Advice on the protocols is given in the OECD guideline (1997) and the IWGT report (Gatehouse et al., 1994).'可被翻译为：3.2 细菌突变试验的推荐方案OECD指导原则（1997）和IWGT报告（Gatehouse等， 1994）给出了对方案的建议。\n'3.3.2 Study Design\/Test Protocols For the cytogenetic evaluation of chromosomal damage in metaphase cells in vitro, the test protocol should include the conduct of tests with and without metabolic activation, with appropriate positive and negative controls.'可被翻译为：3.3.2 试验设计\/试验方案 对于体外中期相细胞染色体损伤的细胞遗传学评价，试验方案应包括在有和无代谢活化两种条件、设有合适的阳性和阴性对照情况下进行试验。\n'For MLA, the test protocol should include the conduct of tests with and without metabolic activation, with appropriate positive and negative controls, where the treatment with the test article is for 3 to 4 hours.'可被翻译为：对于MLA，试验方案应包括在有和无代谢活化两种条件、设有合适的阳性和阴性对照情 况下进行试验，受试物应给药处理3~4小时。\n\n根据上述已知信息，请将'One difference from the OECD and IWGT recommendations is that, based on experience with testing pharmaceuticals, a single bacterial mutation (Ames) test is considered sufficient when it is clearly negative or positive, and carried out with a fully adequate protocol including all strains with and without metabolic activation, a suitable dose range that fulfills criteria for top dose selection, and appropriate positive and negative controls.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"与OECD和IWGT报告建议的一个不同点是：基于药物检测的经验，当Ames试验结果是明确的阳性或阴性，且是在完全适当的方案下进行（包括在有和无代谢活化条件下使用所有菌株，能满足高浓度选择标准的合适的浓度范围，有合适的阳性和阴性对照）时，一个单独的Ames试验被认为 是足够的。"
    },
    {
        "instruction":"已知信息：\n'• What situations warrant a contraindication; what information to provide in those situations when the use of the product is contraindicated; and how to organize the CONTRAINDICATIONS section'可被翻译为：• 何种情况需用禁忌；当禁用产品时在这些情况下需提供哪些信息；以及如何组织禁忌部分\n'When a pediatric indication is not supported by available data, the Pediatric Use subsection must contain a statement explaining that safety and effectiveness have not been established in the relevant pediatric population(s) (21 CFR 201.57(c)(9)(iv)(F). In such cases, the pediatric information pertaining to the unapproved use (including a description of the clinical trial(s), dosing, and pharmacokinetic information) generally should appear only in USE IN SPECIFIC POPULATIONS, Pediatric Use, to avoid the impression that the drug has an approved pediatric use (see section III.B., Insufficient Evidence to Support Safety and Effectiveness for a Pediatric Indication). If a specific risk has been identified for pediatric patients, this risk information must be described in the Pediatric Use subsection and, if appropriate, placed in the CONTRAINDICATIONS section or WARNINGS AND PRECAUTIONS section. In such cases, the Pediatric Use subsection must refer to the risk information in the CONTRAINDICATIONS or WARNINGS AND PRECAUTIONS section, as required by regulation (21 CFR 201.57(c)(9)(iv)(B), (E), and (F)).'可被翻译为：当现有数据不支持儿科适应症时，儿科用药小节应包含解释安全性和有效性在相关儿科人群尚未确立的说明（21 CFR 201.57（c）（9）（iv）（F））。在这种情况下，有关未批准的用途的儿科信息（包括临床试验、给药剂量和药代动力学数据的描述）一般应仅出现在特殊人群用药的儿科用药小节中，以避免产生该药已 批准儿科用途的错觉（见第III.B.节“支持儿科适应症安全性和有效性的证据不 充足”）。如果对于儿科患者已确定具有某一特定风险，这种风险信息必须在儿科用药小节中予以描述，而且，如果合适，应置于禁忌症部分或警告和注意事项部 分。在这种情况下，按照法规要求（21 CFR 201.57（c）（9）（iv）（B）、（E）和（F）），儿科用药小节应提及禁忌症或警告和注意事项部分的风险信息。\n'·Use in a defined subset of patients (e.g., people with mild disease) where the risks of the drug are such that the drug should never be used in that subset of the larger population7'可被翻译为：·在限定患者亚群（例如，轻度疾病患者）中的应用，药物风险绝不允许药物在 更大的亚群中使用7\n'• CONTRAINDICATIONS: Any pediatric age group or setting in which the drug should not be used in pediatric patients because the risk of use outweighs any potential benefit should be described.'可被翻译为：·禁忌症：由于用药风险超过潜在的获益而使得药物不应在儿科患者使用的任何儿科年龄段或情况均应描述。\n\n根据上述已知信息，请将'7The INDICATIONS AND US AGE section must contain information about use of the drug when safety  considerations are such that the drug should be reserved for certain patients (e.g, patients with severe disease) or situations (e.g., patients refractory to other drugs) (§201.57(c)(2)(i)(B) and (E)).In rare cases, when the risks of the drug clearly outweigh any possible therapeutic benefit and the drug should never be used in a selected patient subset, a contraindication for use of the drug in that subset should also be described in the CONTRAINDICATIONS section.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"7适应症和用法部分必须包含当考虑药物安全性时的药物应用信息，即某些患者（例如，有严重疾病的患者）或某些状态下（例如，其他药物耐药的患者）应保留药物的应用（§ 201.57(c)(2)(i)(B) 和(E)）。在罕见的情况下，当某种药物的风险明显大于任何可能的治疗益处时，并且该药应该从未用在某个选定患者亚集中，在禁忌部分也应描述此患者亚集的用药禁忌。"
    },
    {
        "instruction":"已知信息：\n'A loading dose of at least 0.2 to 0.5 g\/kg ({XX} to {YY} ml\/kg) body weight may be required.'可被翻译为：可能需要的负荷剂量至少为0.2-0.5g\/kg（{XX} 至{YY}ml\/kg）体重。\n'The recommended starting dose is 0.4-0.8 g\/kg given once, followed by at least 0.2 g\/kg given every three to four weeks.'可被翻译为：推荐起始剂量为0.4-0.8g\/kg一次，随 后每三至四周给药至少0.2g\/kg。\n'The dose regimen should achieve a trough level of IgG (measured before the next infusion) of at least 5 to 6 g\/l and aim to be within the reference interval of serum IgG for age.'可被翻译为：给药方案应使IgG达到至少5-6g\/l的谷浓度（在下一次输液前测量），并且最终达到该年龄下血清IgG的参考范围内。\n'Daily dose = 0.119 µg\/L x 28800 L = 68.6 µg\/kg 50 kg PDE = 68.6 µg\/kg x 50 kg \/ (1 x 10 x 1 x 1 x 1) = 343 µg\/day'可被翻译为：日剂量= = 68.6 μg\/kg PDE=68.6 μg\/kg×50 kg\/（1×10×1×1×1）=343 μg\/天\n\n根据上述已知信息，请将'The dose required to achieve a trough level of 5-6 g\/l is of the order of 0.2-0.8 g\/kg\/month.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"要求谷浓度水平达到5-6g\/L的给药剂量为0.2-0.8g\/kg\/月。"
    },
    {
        "instruction":"已知信息：\n'50\/group female F344 rats (SPF) 2 years (Diet) 50 3: 40; 200; 1000 ppm. (1.9; 9.8;53.8 mg\/kg\/d) Pheochromo- cytoma\/Female 53.8 mg\/kg\/d 116.9**'可被翻译为：50只\/组雄性F344大鼠 （SPF） 2年（喂饲） 50只 3个：40；200； 1000 ppm（1.9： 9.8； 53.8mg\/kg\/天） 嗜铬细胞瘤\/雌 性 53.8mg\/kg\/天 116.9**\n'Ref. 8 50\/group male Fischer 344 rat 78 weeks (study duration: 102 wk) Diet 20 2: 250; 500 ppm (7.7; 15.2 mg\/kg\/d) Mesenchymal tumors (fibroma, fibrosarcoma, haemangiosarcoma, osteosarcoma, sarcoma not otherwise specified) of the spleen or splenic capsule 72'可被翻译为：参考文献8 50只\/组 雄性 Fischer 344大鼠 78周（研 究时长：102周） 喂饲法 20只 2个： 250；500ppm （7.7；15.2mg\/k g\/d） 间充质肿瘤（纤维瘤，纤维肉 瘤，血管肉瘤， 骨肉瘤，未另说明的恶性肉瘤） 脾脏或脾被膜 72\n'50\/group female Crj:BDF1 (SPF) 2 years (Diet) 50 3: 125;500; 2000 ppm. (17.6; 72.6; 275.2 mg\/kg\/d) Hepatic hemangiosarcomas 275.2 mg\/kg\/d 1919.9'可被翻译为：50只\/组雌性 Crj:BDF1 （SPF） 2年（喂饲） 50只 3个：125；500； 2000 ppm （17.6：72.6； 275.2mg\/kg\/ 天） 肝血管内皮瘤 275.2mg\/kg\/天 1919.9\n'50\/group male Crj:BDF1 (SPF) 2 years (Diet) 50 3: 125;500; 2000 ppm. (15.3; 60.1;240 .1 mg\/kg\/d) NA'可被翻译为：50只\/组雄性 Crj:BDF1 （SPF） 2年 （喂饲） 50只 3个：125；500； 2000 ppm （15.3：60.1； 240.1mg\/kg\/ 天） NA\n\n根据上述已知信息，请将'+ 50\/group male F344 rats (SPF) 2 years (Diet) 50 3: 40; 200; 1000 ppm. (1.5; 7.7; 41.2 mg\/kg\/d) Spleen hemangiosarcomas 7.7 mg\/kg\/d 173.5'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"50只\/组雄性F344大鼠（SPF） 2年（喂饲） 50只 3个：40；200；1000 ppm（1.5：7.7；41.2mg\/kg\/天） 脾脏、血管肉瘤mg\/kg\/天 173.5"
    },
    {
        "instruction":"已知信息：\n'Assessment of interaction terms based on statistical significance tests is therefore of little value.'可被翻译为：根据统计学显著性检验对交互作用项的评价价值不大。\n'This should be addressed in clinical studies, but it is accepted that formal testing with adequate statistical power of such a hypothesis cannot always be done.'可被翻译为：在临床研究中应对此进行说 明，但是，公认的事实是：并不是总能采用有足够统计学效力的正式检验进行这种假设 的检验。\n'Statistical significance need not convey a positive signal, nor lack of statistical significance impute absence of effect.'可被翻译为：统计学显著性 并不意味着阳性信号，无统计学显著性也不意味着无影响。\n'Sample Size and Statistical Power Sample size and statistical power should be estimated before initiating the study.'可被翻译为：6. 样本量及统计学把握度 在启动研究之前，研究者应估计样本量及统计学把握度。\n\n根据上述已知信息，请将'Tests for interactions often lack statistical power and the absence of statistical evidence of an interaction is not evidence that there is no clinically relevant interaction.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"交互作用的检验常常缺乏统计学把握度，一个交互作用无统计学证据并不能证明不存在有临床意义的交互作用。"
    },
    {
        "instruction":"已知信息：\n'FDA recommends applicants developing certain extended release solid oral dosage forms to conduct in vitro studies to determine the potential for dose dumping in alcohol in vivo. In vitro assessments of the drug release from the drug product using media with various alcohol concentrations may be recommended. An in vivo BE study of the drug product when administered with alcohol may be suggested in some cases. For information on specific products, we recommend that applicants consult the guidance for industry Individual Product Bioequivalence Recommendations and any available relevant product-specific guidance.25'可被翻译为：FDA建议研发缓释固体口服制剂的申请人进行体外研究，评价药物在体内酒精环境中出现药物突释的可能性。应考察药物在不同浓度的酒精溶媒中的释放情况。某些特定情况下可能需要进行体内药物与酒同服时的生物等效性研究。可参考相关行业指导原则《个别药物生物等效性要求》以及任何可用的相关的特殊药 物的指导原则以获取更多信息25\n'This guidance focuses on the general principles for developing and evaluating the abuse deterrence of generic solid oral opioid drug products formulated to incorporate physical or chemical barriers, agonist\/antagonists, aversive agents, or combinations of two or more of these technologies. It does not provide testing recommendations for generic versions of opioid drug products incorporating other technologies (i.e., delivery system, NME\/prodrug, or novel approaches), but FDA may provide testing recommendations in future product-specific guidances.'可被翻译为：本指南的重点是开发和评估防止固体口服阿片类药物仿制药（其配方结合使用物理或化学屏 障、激动剂\/拮抗剂、厌恶剂、或联合使用两种或更多种这些措施）滥用的一般原则，并不提供关于结合了其它技术（即传递系统、NME\/前体药物、或新颖方法）的阿片类药物仿制药的检测建议，但FDA可能会在以后的产品特定指南中提供检测建议。\n'Similar to comparable products or thrombin solutions, the product may be denatured after exposure to solutions containing alcohol, iodine or heavy metals (e.g. antiseptic solutions).'可被翻译为：与同类产品或凝血酶溶液相似，本品暴露于含乙醇、 碘或重金属的溶液（如：消毒液）后可能变性。\n'This guidance does not address drug products that are administered via ophthalmic, otic, nasal, inhalation, oral, or injection-based routes, or that are transdermal or topical delivery systems (including products known as patches, topical patches, or extended-release films).'可被翻译为：本指南不适用于通过眼、耳、鼻、吸入、口服或注射途径的药品，亦不适用于经皮或局部给药系统（包括贴剂、局部贴剂或缓释膜剂）。\n\n根据上述已知信息，请将'If strong opioid products are formulated as oral prolonged release products, careful evaluation of the potential for dose-dumping (e.g. in connection with alcohol) is of particular importance. Similar effects should be investigated with transdermal delivery systems (e.g. exposure to heat).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果强效阿片类药物产品配制为口服延释产品，则仔细评价剂量倾斜的可能性（例如与酒精相关）是特别重要的。应当用透皮递送系统（例如暴露于热）研究类似的效应"
    },
    {
        "instruction":"已知信息：\n'2 For the purposes of this guidance, drug includes drugs regulated under section 505 of the Federal Food, Drug, and Cosmetic Act and biological products regulated under section 351 of the Public Health Service Act.'可被翻译为：2在本指南中，药物包括《联邦食品、药品、化妆品法案》第505部分监管的药物以及《公众健康服务法案》第351部分监管的生物制品。\n'2 For the purposes of this guidance, all references to drugs or drug products include both human drugs and biological drug products regulated by the Center for Drug Evaluation and Research or the Center for Biologics Evaluation and Research unless otherwise specified.'可被翻译为：2 根据本指导原则的目的，除非另有规定，本文所有提到的药物或药品为药物审评和研究中心或生物制品 审评和研究中心规定的人用药和生物制品。\n'This guidance provides information on the implementation of new section 505(o) of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 355(o)), added by section 901 of the Food and Drug Administration Amendments Act of 2007 (FDAAA). Section 505(o)(3) authorizes FDA to require certain postmarketing studies and clinical trials2 for prescription drugs approved under section 505 of the Act and biological products approved under section 351 of the Public Health Service Act (the PHS Act) (42 U.S.C. 262).3 This guidance provides information about the requirements for postmarketing studies and clinical trials under section 505(o)(3) of the Act. The guidance also describes the types of postmarketing studies and clinical trials that:'可被翻译为：该指南提供了关于联邦食品、药品和化妆品法案（法案） （21 U.S.C. 355(o)）新的第505(o)部分的实施信息，添加了食品药品监督管理局2007 修订案 （FDAAA）的第901部分。第505(o)(3)部分授权FDA对于该法案第505部分批准 的处方药物和按照美国卫生及公共服务部第351部分（PHS法案）（42 U.S.C. 262）3批准的生物制品要求一定的上市后研究和临床试验2 该指南提供了法案 第 505(o)(3)部分实施上市后研究和临床试验有关要求的信息。该指南也描述了上市后 研究和临床试验的类型：\n'Part 312 applies, with certain exceptions, to all clinical investigations of drugs and biological products that are subject to section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or to the licensing provisions of the Public Health Service Act (58 Stat. 632, as amended (42 U.S.C. 201 et seq.)).'可被翻译为：6第 312 款适用于，除了某些例外，服从于联邦食品、药品和化妆品法（21 U.S.C355） 第 505 款或者公共保健服务法（58stat. 632，经修订（42 U.S.C 201 以及下面的 内容））许可规定药物和生物制品的所有临床研究。\n\n根据上述已知信息，请将'2 For the purposes of this guidance, references to drugs and drug and biological products include drugs approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) and biological products licensed under section 351 of the Public Health Service Act (PHSA) (42 U.S.C. 262) that are drugs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2出于本指导原则的目的，药物以及药品和生物制品指的是包括按照联邦食品、药品和化妆品法案第505节（21 U.S.C. 355）批准的药品以及按照公共保健服务法（PHSA）（42 U.S.C. 262）许可的属于药物的生物制品。"
    },
    {
        "instruction":"已知信息：\n'The treatment regimen, species and strain selection should, as far as is feasible, be determined with regard to the available pharmacokinetic and toxicokinetic information. In practice, the vast majority of these studies is conducted in the rat and mouse.'可被翻译为：给药方案和动物种属、品系的选择应尽可能根据已有的药代动力学和毒代动力学信息确定。实际上，大多数研究采用大鼠和小鼠进行。\n'Consideration should be given to the selection of relevant animal models or other test systems so that scientifically valid information can be derived. Selection factors can include the pharmacodynamic responsiveness of the model, pharmacokinetic profile, species, strain, gender and age of the experimental animals, the susceptibility, sensitivity, and reproducibility of the test system and available background data on the substance. Data from humans (e.g., in vitro metabolism), when available, should also be considered in the test system selection. The time points for the measurements should be based on pharmacodynamic and pharmacokinetic considerations. Justification should be provided for the selection of the particular animal model or test system.'可被翻译为：应考虑选择相关动物模型或其他试验系统，这样才能获得科学有效的信息。选择因素可包括模型的药效学反应性，药代动力学特征，实验动物种属、品系、性别和年龄，试验系统的易感性、敏感性和重现性以及受试物已有的背景数据，如可能，还应考虑人体获得的数据（如体外代谢）。检测时间点的选择应考虑药效学和药代动力学特征，应说明选择特定动物模型或试 验系统的理由。\n'The treatment regimen during the exposure period should be selected on the basis of the toxicological findings and on pharmacokinetic and toxicokinetic principles.'可被翻译为：暴露期间的试验方案应根据毒理学发现、药代动力学和毒代动力学原则来选择。\n'The doses should be selected following integration of rodent and human pharmacokinetic, pharmacodynamic, and toxicity data. The rationale for the selection of these doses should be provided.'可被翻译为：应综合啮齿类动物和人体 药代动力学、药效学和毒性数据选择剂量，应说明选择理由。\n\n根据上述已知信息，请将'The treatment regimen (Note 11) and species should be selected whenever possible with regard to pharmacodynamic and pharmacokinetic principles. This may not be achievable for the very first studies, at a time when neither animal nor human pharmacokinetic data are normally available.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"给药方案（注释11）和种属的选择应尽可能与药效学和药代动力学原则相符。但在既无动物也无人体药代动力学数据可借鉴的研究初期，此要求或许难以达到。"
    },
    {
        "instruction":"已知信息：\n'Screening for antagonists targeting specific receptors.'可被翻译为：以特定受体为靶位筛选具有拮抗剂作用的。\n'receptor target'可被翻译为：受体靶标\n'− Assess certain receptor affinities for any circulating or major metabolites, including conjugates, to evaluate the potential for off-target binding and resulting serious risk'可被翻译为：- 针对任何循环或主要代谢产物（包括结合物）评估其特定受体亲和力，用于评估非靶性结合的可能性以及所产生的严重风险。\n'receptor antagonist'可被翻译为：受体拮抗剂\n\n根据上述已知信息，请将'• Antagonist binding interaction identified for one off-target receptor with Ki 8-fold higher than Cmax at maximum clinical dose. Known pharmacology of off-target receptor not associated with tumorigenesis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"• 拮抗剂与一种脱靶受体有结合相互作用，其Ki值比 临床最大剂量下的Cmax 高8倍。脱靶受体的已知药 理作用与肿瘤发生无关。"
    },
    {
        "instruction":"已知信息：\n'2. Electronic data collection system passes the system verification, and retains verification record. Set user management, role management and permission management for the computerized system, different personnel or roles have the unique logon rights. With audit track function, it can display the records of modification data and modification reason.'可被翻译为：2.电子数据采集系统经过系统验证， 并保存验证记录。计算机化系统设置用户管理、角色管理和权限管理， 不同人员或角色具有唯一登录权限。具有稽查轨迹功能，能够显示修改数据与修改原因的记录。\n'Article 141 In case of recording data through the computer system, personnel at relevant posts shall, in accordance with the operating procedure, log into the computer system with authorization and password to enter the data, so as to ensure that the data are original, authentic, accurate, safe and traceable.'可被翻译为：第一百四十一条 通过计算机系统记录数据时，相关岗位人员应当按照操作规程，通过授权及密码登录计算机系统，进行数据的录入，保证数据原始、真实、准确、安全和可追溯。\n'Ensuring that post-implementation verification occurs and reviewing the results of that verification as a measure of change management effectiveness (e.g., to identify improvements to the change management system).'可被翻译为：确保进行变更实施后确认并审核结果，以衡量变更管理的有效性 （如识别变更管理系统的改进）。\n'NMPA Issued the Guidelines for the Verification of Medical Device Registration Quality Management System'可被翻译为：国家药监局关于发布医疗器械注册质量管理体系核查指南的通告\n\n根据上述已知信息，请将'(2) Electronic data collection system passes the system verification, and retains verification record. Set user management, role management and permission management for the computerized system, different personnel or roles have the unique logon rights.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）采用电子记录的计算机化系统经过系统验证， 并保存验证记录。计算机化系统设置用户管理、角色管理和权限管理，不同人员或角色具有唯一登录权限。"
    },
    {
        "instruction":"已知信息：\n'(Good trade and distribution practices are) that part of quality assurance that ensures that the quality of pharmaceutical products is maintained by means of adequate control throughout the numerous activities which occur during the trade and the distribution process.'可被翻译为：(良好的贸易和分销规范)是质量保证的一部分，通过对贸易和分销过程中发生的众多活动进行充分控制，确保药品质量得到保持。\n'good trade and distribution practices (gtdp)'可被翻译为：良好的贸易和分销惯例(GTDP)\n'10. WHO guidelines on good manufacturing practices: validation. Appendix 7. Non-sterile process validation. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: forty-ninth report. Geneva: World Health Organization; 2015: Annex 3 (WHO Technical Report Series, No. 992; https:\/\/www.who.int\/medicines\/areas\/quality_safety\/quality_assurance\/Annex3 TRS992.pdf, accessed 30 November 2020).'可被翻译为：WHOGMP指南：验证，WHO TRS992附录3附录7无菌工艺验证，2015\n'WHO good manufacturing practices: guidelines on validation. Appendix 6. Guidelines on qualification. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-third report. Geneva: World Health Organization; 2019: Annex 3 (WHO Technical Report Series, No. 1019; https:\/\/www.who.int\/medicines\/areas\/quality_safety\/quality_assurance\/WHO_TRS_1019_ An nex3.pdf?ua=1, accessed 30 November 2020).'可被翻译为：WHO GMP验证指南，WHO TRS1019附录3附录6确认指南，2019\n\n根据上述已知信息，请将'Good Trade and Distribution Practices (Annex 2, WHO Technical Report Series, No. 917).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"良好的贸易和分销做法(附件2，WHO技术报告系列，第917号)。"
    },
    {
        "instruction":"已知信息：\n'Reports should be prepared after review.'可被翻译为：回顾分析应当有报告。\n'Article 148 Qualification or validation should be implemented in accordance with a predefined and approved protocol, and be recorded. Upon completion of qualification or validation, a report should be prepared, reviewed and approved. The qualification or validation result and conclusion (including comments and suggestions) should be recorded and archived.'可被翻译为：第一百四十八条 确认或验证应当按照预先确定和批准的方案实施，并有记录。确认或验证工作完成后，应当写出报告，并经审核、批准。确认或验证的结果和结论（包括评价和建议）应当有记录并存档。\n'Article 147: The qualification or validation protocol should be prepared based on its object. The protocol should be reviewed and approved.'可被翻译为：第一百四十七条 应当根据确认或验证的对象制定确认或 验证方案，并经审核、批准。\n'Article 147 The qualification or validation protocol should be prepared based on its object. The protocol should be reviewed and approved. Responsibilities should be specified in the protocol.'可被翻译为：第一百四十七条 应当根据确认或验证的对象制定确认或验证方案，并经审核、批准。确认或验证方案应当明确职责。\n\n根据上述已知信息，请将'Upon completion of qualification or validation, a report should be prepared, reviewed and approved.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"确认或验证工作完成后，应当写出报告， 并经审核、批准。"
    },
    {
        "instruction":"已知信息：\n'It could include information that supports or refutes previously identified safety issues, as well as evidence of new safety signals.'可被翻译为：可以包括支持或否定已确认的安全性 问题的信息，以及新的安全性信号的证据。\n'It could include information that supports or refutes previously identified safety concerns, as well as evidence of new safety signals.'可被翻译为：它 可以包括支持或驳斥先前确定的安全性问题的信息，以及新的安全性信号的证 据。\n'5 It could include information that supports or refutes previously identified safety concerns, as well as evidence of new safety signals.'可被翻译为：5它 可以包括支持或驳回先前确定的安全性问题的信息，以及新的安全信号的证 据。\n'It could also provide information that either supports or refutes a signal.'可被翻译为：它还可以提供支持或驳斥信号的信息。\n\n根据上述已知信息，请将'12 It could include information that supports or refutes previously identified safety issues, as well as evidence of new safety signals.*'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"12可以包括支持或否定已确认的安全性 问题的信息，以及新的安全性信号*的证据。"
    },
    {
        "instruction":"已知信息：\n'22 See draft guidance, Applying Human Factors and Usability Engineering to Optimize Medical Device Design. When final, this guidance will represent FDA’s current thinking on this topic.'可被翻译为：22见指导原则草案，应用人为因素和使用工程学以便优化医疗器械设计，一经定稿，即代表FDA对于本课 题的当前想法。\n'14 See FDA guidances: Do it by Design, An Introduction to Human Factors in Medical Devices, December 1996; guidance for industry and FDA Premarket and Design Control Reviewers: Medical Device Use-Safety: Incorporating Human Factors Engineering into Risk Management, July 18, 2000; and draft guidance for industry and Food and Drug Administration staff - Applying Human Factors and Usability Engineering to Optimize Medical Device Design, June 22, 2011; available on FDA Medical Devices guidance Web page at http:\/\/www.fda.gov\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/default.htm (when final, this guidance will represent FDA’s current thinking on this topic).'可被翻译为：14见FDA指导原则：源于设计，医疗器械中人为因素的介绍，1996年12月；为行业和FDA上市前和设计 控制审评人员制定的指导原则：医疗器械使用-安全：把人为因素工程学整合到风险管理中，2000年7月18日；为行业和食品药品监督管理局工作人员制定的指导原则草稿-应用人为因素和使用工程学以便优化医疗器械设计，2011年6月22日；FDA医疗器械指导原则网址： http:\/\/www.fda.gov\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/default.htm（一经定稿，本指导原则将代表FDA关于这一主题的最新见解）\n'Draft guidance for industry and FDA staff Applying Human Factors and Usability Engineering  to Optimize Medical Device Design'可被翻译为：Draft guidance for industry and FDA staff Applying Human Factors and Usability Engineering to Optimize Medical Device Design\n'·CDRH guidance for industry and FDA Premarket and Design Control Reviewers, Medical Device Use-Safety: Incorporating Human Factors Engineering into Risk Management, July 18, 2000, and CDRH draft guidance for industry and Food and Drug Administration staff on Applying Human Factors and Usability Engineering to Optimize Medical Device Design, June 22, 2011.'可被翻译为：·为行业及FDA上市前和设计控制审评人员制定的CDRH指导原则，药械使用安全：将人为因素工程学整合至风险管理中，2000年7月18日，为行业及FDA工作人员制定的CDRH指导原则草案-应用人为因素和使用工程学以优化药械设计，2011年6月22日。\n\n根据上述已知信息，请将'18 FDA draft guidance, Applying Human Factors and Usability Engineering to Optimize Medical Device Design, June 22, 2011. When final, this guidance will represent FDA’s current thinking on this topic.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"18FDA指导原则草案，应用人为因素和使用工程学以便优化医疗器械设计，2011年6月22日。一经定稿，本指导原则将代表FDA关于这一主题的最新见解。"
    },
    {
        "instruction":"已知信息：\n'Article 17 CFDI shall establish an expert consultation system if needs and seek for expert opinions on major and difficult issues during the registration inspection process.'可被翻译为：第十七条 核查中心根据工作需要建立专家咨询制度，在注册核查过程中就重大疑难问题听取专家意见。\n'CFDI shall investigate or study the objections raised and inspect and review conclusion based on the investigation and study.'可被翻译为：核查中心应当对提出的异议情况进行调查或研究，并结合调查研究情况作出核查审核结论。\n'Article 11 The drug regulatory department may establish an expert consultation mechanism to listen to expert opinions on important issues in the process of technical evaluation, on-site inspection, supervision and inspection, and give play to the role of experts for technical support.'可被翻译为：第十一条 药品监督管理部门可以建立专家咨询机制，就技术审评、现场核查、监督检查等过程中的重要问题听取专家意见，发挥专家的技术支撑作用。\n'Article 17 The CDE and other specialized technical institutions shall, if necessary, establish an expert advisory system, set up an expert advisory committee, listen to experts' opinions on major issues during the process of review, inspection, testing, and adopted name approval, and bring into full play the technical support role of experts.'可被翻译为：第十七条 药品审评中心等专业技术机构根据工作需要建立专家咨询制度，成立专家咨询委员会，在审评、核查、检验、通用名称核准等过程中就重大问题听取专家意见，充分发挥专家的技术支撑作用。\n\n根据上述已知信息，请将'Article 38 For complex or controversial issues, CFDI may hold a review meeting of registration inspection experts to listen to expert opinions on inspection, evaluation, and test. CFDI shall inspect and review conclusion based on the opinions of experts.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十八条 对于复杂或者有争议的问题，核查中心可召开注册核查专家会审会，听取核查、审评、检验等方面的专家意见。核查中心应当综合专家意见作出核查审核结论。"
    },
    {
        "instruction":"已知信息：\n'Article 7 The food and drug regulatory department shall publicize relevant information on medical device registration and filing promptly in accordance with laws. The applicant can look up the approval progress and relevant results as well as the public can look up the result of approval.'可被翻译为：第七条 食品药品监督管理部门依法及时公布医疗器械注册、备案相关信息。申请人可以查询审批进度和结果，公众可以查阅审批结果。\n'All controls applied by the regulatory authority to the manufacturer and\/or authorized representative at the stage of, and as a condition of, making available an individual medical device with a view to its distribution and\/or use within the jurisdiction.'可被翻译为：监管机构对制造商和\/或授权代表实施的所有控制措施，在提供单个医疗器械的阶段，并作为其在管辖范围内分销和\/或使用的条件。\n'1.The act whereby the regulatory authority in one jurisdiction may take into account and give significant weight to – i.e. totally or partially rely upon – evaluations performed by another regulatory authority or trusted institution in reaching its own decision. The relying authority remains responsible and accountable for decisions taken, even when it relies on the decisions and information of others (25).\n2.An act whereby a regulatory authority in one jurisdiction may take into account or give significant weight to work performed by another regulator, or other trusted institution, in reaching its own decision.'可被翻译为：1.一个司法管辖区的监管机构在做出自己的决定时，可能会考虑到另一个监管机构或值得信赖的机构所进行的评估，并给予重大重视，即完全或部分依赖。依赖机构仍然对所做的决定负责，即使它依赖于他人的决定和信息(25)。\n2.一个司法管辖区的监管机构在做出自己的决定时，可能会考虑到另一个监管机构或其他受信任的机构所做的工作或给予重大重视的行为。\n'All controls applied by the regulatory authority to the manufacturer and\/or the authorized representative before the manufacturer’s medical device may be placed on the market or put into service.'可被翻译为：在制造商的医疗器械可以投放市场或投入使用之前，监管机构对制造商和\/或授权代表实施的所有控制。\n\n根据上述已知信息，请将'The process whereby a party submits information to the regulatory authority in a jurisdiction, regarding the identification of a medical device(s) that is or will be supplied to the market in that jurisdiction (20).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"缔约方向管辖区内的监管机构提交信息的过程，涉及在该管辖区内已供应或将供应给市场的医疗器械的识别(20)。"
    },
    {
        "instruction":"已知信息：\n'Carcinogenicity studies are not warranted to support marketing for therapeutics intended to treat patients with advanced cancer.'可被翻译为：拟用于治疗晚期肿瘤患者的药物上市，致癌性试验通常不是必要的。\n'A pre- and postnatal toxicology study is generally not warranted to support clinical trials or for marketing of pharmaceuticals for the treatment of patients with advanced cancer.'可被翻译为：拟用于晚期癌症患者的药物临床试验或上市，通常不必进行 围产期毒性试验。\n'Such limits are not appropriate for pharmaceuticals intended to treat patients with advanced cancer, and justifications described above should be considered to set higher limits.'可被翻译为：对于拟用于晚期肿瘤患者的药物，上述限度可能不适用，论证时应考虑设置更高的杂质限度。\n'For most pharmaceuticals intended for the treatment of patients with advanced cancer, nonclinical studies of 3 months duration are considered sufficient to support marketing.'可被翻译为：对于拟用于晚期肿瘤患者的大多数药物来说，为期3个月的非临床毒性试验足以支持上市。\n\n根据上述已知信息，请将'In general, toxicology studies investigating the safety of combinations of pharmaceuticals intended to treat patients with advanced cancer are not warranted.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通常，拟用于晚期肿瘤患者联合用药的安全性毒理学研究是没有必要的。"
    },
    {
        "instruction":"已知信息：\n'For Chemical Entities, a step involved in the synthesis of the chemical structure of the drug substance from precursor molecular fragments. Typically it involves C-X or C-C bond formation or breaking.'可被翻译为：对于化学实体药物，指从其前体分子片段合成原料药化学结构的反应步骤。典型的有 C-X 或 C-C 键的形成或断裂。\n'chemical transformation step'可被翻译为：化学转化步骤\n'It can be acceptable for a starting material that is demonstrated to be a commercially available chemical to enter late in the synthesis, e.g., in the last chemical transformation prior to the drug substance.'可被翻译为：市售化学品作为起始原料在合成的较后步骤引入是可以接受的，例如在原料药之前的最后一步化学变化。\n'The study of chemical drugs and natural active ingredients of chemical structure, physical and chemical properties, chemical synthesis, in vivo metabolism, chemical structure and efficacy of the relationship between the chemical mechanism of drug action, as well as the search for new ways and methods of a discipline. The chemical laws and methods related to the creation and development of new drugs belong to the category of pharmaceutical chemistry research.'可被翻译为：研究化学药物及天然活性成分的化学结构、理化性质、化学合成、体内代谢、化学结构与药效的相互关系，药物作用的化学机制，以及寻找新药的途径和方法的一门学科。与创制和发展新药有关的化学规律和方法均属药物化学研究的范畴。\n\n根据上述已知信息，请将'11. Glossary Chemical Transformation Step: For Chemical Entities, a step involved in the synthesis of the chemical structure of the drug substance from precursor molecular fragments.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"11. 术语 化学转化步骤（Chemical Transformation Step）：对于 化学实体药物，指从其前体分子片段合成原料药化学结构的 反应步骤。"
    },
    {
        "instruction":"已知信息：\n'An information structure that represents the requirements for a set of messages.'可被翻译为：表示信息要求的信息结构。\n'message standard'可被翻译为：消息标准\n'Prior to the message standard described in this IG, ICH electronic messaging standards were developed by the ICH M2 EWG for Electronic Standards for the Transmission of Regulatory Information(ESTRI).'可被翻译为：在本IG描述的信息标准之前，由ICH M2 EWG开发了ICH电子信息传输标准，用于监管信息电子传输标准（ESTRI）。\n'As a prerequisite to international electronic information transfer, it is proposed that a common set of standards, be agreed to ensure the integrity of information and data exchange between Pharmaceutical companies and Authorities and between Authorities.'可被翻译为：统筹建立一套统一的技术标准，是药品国际监管信息电子传输的前提，需 要以此来保证制药企业与监管部门之间以及各个监管部门之间信息和数据交换 的完整性。\n\n根据上述已知信息，请将'A defined manner of packaging information for a message that has been agreed upon by multiple parties. Messaging standards define specific messages by a combination of content requirements (key data and structures for containing it) and transactional requirements (timing and specified content at stages). Messaging standards also define the means for coding such information in a manner that allows the exchange of this information between different systems.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种指定的打包多方认同的信息的方式。消息传递标准通过内容需求（关键数据和包含关键数据的结构）和事务性要求（时间选择和指定内容）的组合来定义特定消息。消息传递标准还定义了编码信息的方式，以允许此类信息在不同系统之间进行交换。"
    },
    {
        "instruction":"已知信息：\n'50 B6C3F1 Mice (M) 2 years Gavage 50 3: 1.79;7.14; 14.3 mg\/kg\/d Forestomach 5.92+'可被翻译为：50只B6C3F1 小鼠（雄性） 2年灌胃 50只 3个：1.79；7.14； 14.3mg\/kg\/d 前胃 5.92+\n'Ref. 4 52\/sex\/group B6C3F1 mouse 2 year 3 times\/wk Gavage 52 2: 50 and 100 mg\/kg (21 and 42 mg\/kg\/d) Forestomach papilloma, carcinoma\/ Male 49.6'可被翻译为：参考文献4 52只\/性别\/组 B6C3F1 小鼠 2年\/ 3次\/周 灌胃 52只 2个： 50和 100mg\/kg （21和 42mg\/kg\/ 天） 前胃 乳头状瘤，雄性 49.6\n'Ref. 5 50\/sex\/ group B6C3F1 mice 2 years 5 days\/wk Oral gavage 50 2: 17.7; 35.4 mg\/kg\/d Harderian gland \/Female 32.9'可被翻译为：参考文献5 50只\/性别\/组 B6C3F1小鼠 2年 5天\/周 灌胃 50只 2个： 17.7； 35.4mg\/kg\/d 哈氏腺\/ 雌性 32.9\n'Ref. 6 p- chloroaniline HCl 50\/group female B6C3F1 mice 103 weeks 5 times\/ wk Gavage 50 3: 3; 10; 30 mg\/kg (2.1; 7.1; 21.4 mg\/kg\/d) Negative NA'可被翻译为：参考文献6盐酸对氯苯 胺 50只\/组 雌性 B6C3F1 小鼠 103周 5次\/周 灌胃 50只 3个： 3；10；30mg\/kg （2.1；7.1；21.4 mg\/kg\/d） 阴性 NA\n\n根据上述已知信息，请将'50 B6C3F1 Mice (F) 2 years Gavage 50 3: 1.79;7.14; 14.3 mg\/kg\/d Forestomach 6.77+'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"50只B6C3F1小鼠（雌性） 2年灌胃 50只 3个：1.79；7.14；14.3mg\/kg\/d 前胃 6.77+"
    },
    {
        "instruction":"已知信息：\n'Early engagement with regulatory authorities is encouraged, particularly when a study has novel elements considered critical to quality (e.g., defining patient populations, procedures, or endpoints).'可被翻译为：鼓励尽早与监管机构沟通，尤其是当一项研究出现可能 影响质量的新关键要素（例如：确定患者人群、程序或终点） 时。\n'For these reasons, the design features of such trials should receive special attention and their conduct needs special care. For example, it is especially important to minimise the incidence of violations of the entry criteria, non- compliance, withdrawals, losses to follow-up, missing data and other deviations from the protocol, and also to minimise their impact on the subsequent analyses.'可被翻译为：由于这些原因，这些试验的设计特点 应受到特别关注，它们的实施需要特别小心，例如，尽量减 少违反入选标准、不依从、退出、失访、数据缺失和其它偏 离方案的发生率，并使它们对后续分析的影响降至最低。\n'ICH E9 provides general statistical principles for planning and conducting statistical anal- yses of randomised clinical trials.'可被翻译为：ICH E9为计划和实施随机临床试验的统计分析提供了一般性的统计学原则。\n'Statistical Principles for Clinical Trials – CPMP\/ICH\/363\/96 (ICH E9)'可被翻译为：临床研究的统计学原则– CPMP\/ICH\/363\/96 (ICH E9)\n\n根据上述已知信息，请将'Studies with adaptive features and\/or interim decision points need specific attention during proactive planning and ongoing review of critical to quality factors, and risk management (ICH E9 Statistical Principles for Clinical Trials).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在对关键质量因素和风险管理进行前瞻性规划和持续 审查期间，需要特别关注具有适应性特征和\/或中期决策点 的研究（ICH E9临床试验的统计学原则）。"
    },
    {
        "instruction":"已知信息：\n'but the co-administration of basal insulin infusion has been shown to alter the late glucodynamic profile of NPH insulin and possibly and even more relevantly of long-acting insulin preparations, overestimating the effect of the study insulins.'可被翻译为：但同时给的基础胰岛素注射会改变 NPH 葡萄糖的葡萄糖动力学，对长效胰岛素制剂的改变甚至更大，造成高估受试胰岛素的效果。\n'The resulting levels of hyperinsulinaemia are expected to lie on the steep part of the dose-response curve of insulin and can thus be expected to be highly sensitive to detect potential differences in the time-action profiles of two insulins.'可被翻译为：高胰岛素血水平多在胰岛素剂量-效应曲线的陡部，因此在检测两种胰岛素时间-作用情况差异时高度敏感。\n'The glucose-infusion rate (GIR) over time describes the time-action profile of an insulin preparation.'可被翻译为：对应时间的葡萄糖输注速率（GIR）描述胰岛素制剂的时间-作用情况。\n'Methods for suppressing endogenous insulin or adjusting measured insulin serum concentrations for estimated endogenous insulin may be considered (see below).'可被翻译为：可以考虑采取抑制内源性胰岛素或者为其调整胰岛素血清浓度测量值的方法（见下）。\n\n根据上述已知信息，请将'lead to a rapid and pronounced worsening of insulin sensitivity, thus influencing the estimated time-action profile of the investigated insulin preparation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"导致胰岛素敏感性的迅速和明显的恶化，因此影响受试胰岛素制剂的时间-作用情况评估。"
    },
    {
        "instruction":"已知信息：\n'(2) pooled analyses of data from more than one study.'可被翻译为：（2）超过一项研究的数据的汇总分析。\n'2. Pooled Analyses of Data From More Than One Study'可被翻译为：2. 超过一项研究的数据的汇总分析\n'If the test antibacterial agent showed convincing clinical efficacy against pathogens that were resistant to one or more agents of the same (or very closely-related) drug class (e.g. a lipoglycopeptide showed efficacy against vancomycin-insusceptible enterococci) then this should be stated.'可被翻译为：. 如果试验性抗菌剂显示对于对一种或多种同类（或很接受的相关类别）药物 耐药的病原体有临床疗效（例如某个脂糖肽类药物显示对万古霉素不敏感的 肠球菌有疗效），则应该声明。\n'The products are obtained from the pooled plasma of donors with high titres of antibodies against hepatitis B virus.'可被翻译为：这些产品是从含有高滴度抗乙肝病毒抗体的捐献者的混合血浆中获得。\n\n根据上述已知信息，请将'Data on efficacy against a specific pathogen obtained from more than one study in a single indication may be pooled if these are of the same or very similar design.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"来自于针对某特定病原体、用于某个适应症的多项研究的疗效数据可以合并，只要 这些研究的设计相同或非常相似。"
    },
    {
        "instruction":"已知信息：\n'If no procedure for dealing with outliers was foreseen in the trial protocol, one analysis with the actual values and at least one other analysis eliminating or reducing the outlier effect should be performed and differences between their results discussed.'可被翻译为：如果在试验方案中未预先规定应对离群值的程序，则需要在 对实际值做一次分析的同时，至少进行一次排除或减少离群 值效应的分析，并讨论它们的结果之间的差异。\n'When the conduct of the trial is over and the data are assembled and available for preliminary inspection, it is valuable to carry out the blind review of the planned analysis also described in Section 5.'可被翻译为：当试验结束而且数据经整理可供初步检查 时，如第5章节提到的按计划进行盲态审核是有价值的。\n'If the blind review suggests changes to the principal features stated in the protocol, these should be documented in a protocol amendment.'可被翻译为：如果盲态审核建议修改方案中所述的主要特征，应记录 在修订方案中。\n'A trial may be regarded as valid, nonetheless, provided the methods of dealing with missing values are sensible, and particularly if those methods are pre-defined in the protocol.'可被翻译为：虽然如此，只要缺失数据 的处理方法合理，尤其是在方案中预先定义了这些方法，则 试验可以被认为是可靠的。\n\n根据上述已知信息，请将'Because of the unpredictability of some problems, it may sometimes be preferable to defer detailed consideration of the manner of dealing with irregularities until the blind review of the data at the end of the trial, and, if so, this should be stated in the protocol.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由于一些问题的不可预测性，有时把不规则问题应对方 法的详细考虑推迟到试验结束对数据进行盲态审核时可能 更可取，如果这样做则需要在方案中加以说明。"
    },
    {
        "instruction":"已知信息：\n'interventricular septal defects; misaligned, fused or small caudal vertebrae 4 mg per day 21 (2.4 mg\/m2\/day) Cmax = 0.079 µg\/mLc AUC(0-24h) = 0.402 µg·h\/mLd NOAEL: rat NOAEL not identified rabbit NOAEL not identified LOAEL: rat Cmax = 34 (2.7\/0.079)central and\/or neural arches) resorptions; increased post- implantation loss, decreased viable fetuses AUC = 85 (34.3\/0.402) rabbit Cmax = 0.9 (0.072\/0.079) AUC = 1.0 (0.418\/0.402)'可被翻译为：室间隔缺损；尾椎错 位、融合或小 每天4 mg×21 (2.4 mg\/m2\/天) Cmax=0.079 µg\/mLc AUC(0- 24h)=0.402 µg·h\/mLd NOAEL: 大鼠 未确定NOAEL 兔 未确定NOAEL LOAEL: 大鼠 Cmax=34 (2.7\/0.079) AUC=85 (34.3\/0.402) 兔 Cmax=0.9 (0.072\/0.079) AUC=1.0 (0.418\/0.402)\n'Cmax = 27 µg\/mLc AUC = 521 µg∙h\/mLd 75 mg\/kg oral [US Label, FDA, United States1990a] Cmax = 81 µg\/mLc AUC = 1563 µg∙h\/mLd abortions (at maternally toxic dose) 400 mg Cmax = 9.07 µg\/mLe AUC(0-24h)= 134.8 µg∙h\/mLe NOAEL: rat Cmax = 3.7 (33.8\/9.07) AUC = 2.8 (380\/134.8) rabbit Cmax = 3.0 (27\/9.07) AUC = 3.9 (521\/134.8) LOAEL: rat Cmax = 6.0 (54\/9.07) AUC = 4.5 (608\/134.8) rabbit Cmax = 8.9 (81\/9.07) AUC = 11.6 (1563\/134.8)'可被翻译为：Cmax=27 µg\/mLc AUC=521 µg∙h\/mLd 75 mg\/kg 经口 [美国说明书, 美国FDA 1990a] Cmax=81 µg\/mLc AUC=1563 µg∙h\/mLd 流产 (在 母体毒性 剂量下) 400 mg Cmax=9.07 µg\/mLe AUC(0-24h)= 134.8 µg∙h\/mLe NOAEL: 大鼠 Cmax = 3.7 (33.8\/9.07) AUC = 2.8 (380\/134.8) 兔 Cmax = 3.0 (27\/9.07) AUC = 3.9 (521\/134.8) LOAEL: 大鼠 Cmax = 6.0 (54\/9.07) AUC = 4.5 (608\/134.8) 兔 Cmax = 8.9 (81\/9.07) AUC = 11.6 (1563\/134.8)\n'Thalidomide CAS No.: 50-35-1 Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findingsa Rabbit NOAEL Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Human Dose Cmax AUC Margins NOAEL\/Human LOAEL\/Human Notes 10 mg\/kgb [Janer] Cmax = 0.97µg\/mLc AUC(0-24h) = 10.75 µg·h\/mLc 50 mg\/kgb [Newman, Schardein] Cmax = 4.87µg\/mLc AUC(0-24h) = 53.75 µg·h\/mLc decreased implanta- tion sites 20 mg\/kg oral GD7-19 [Christian] at GD19 Cmax = 0.82 µg\/mLd AUC(0-24h) = 4.18 µg·h\/mLd 60 mg\/kg oral GD7-19 [Christian] at GD19 Cmax = 2.16 µg\/mLe AUC(0-24h) = 14.4 µg.h\/mLe'可被翻译为：沙利度胺 CAS号：50-35-1 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现a 兔NOAEL 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 人剂量 Cmax AUC 暴露倍数 NOAEL\/人 LOAEL\/人 注 释 10 mg\/kgb [Janer] Cmax=0.97µg\/ mLc AUC(0-24h) =10.75 µg·h\/mLc 50 mg\/kgb [Newman, Schardein] Cmax=4.87µg\/ mLc AUC(0-24h) =53.75 µg·h\/mLc 着床点 减少 20 mg\/kg 经口 GD7-19 [Christian] 在GD19时 Cmax=0.82 µg\/mLd AUC(0- 24h)=4.18 µg·h\/mLd 60 mg\/kg 经口 GD7-19 [Christian] 在GD19时 Cmax=2.16 µg\/mLe AUC(0- 24h)=14.4 µg.h\/mLe\n'Isotretinoin (13-cis-retinoic acid) CAS No.: 4759-48-2 Rat NOAEL Dose Cmax AUC Rat LOAEL Dose Cmax AUC Rat Findings Rabbit NOAEL Dose Cmax AUC Rabbit LOAEL Dose Cmax AUC Rabbit Findings Human Dose Cmax AUC Margins NOAEL\/Human LOAEL\/Human Notes 50 mg\/kg oral dose on GD10 [Tembe] Cmax = 0.9 µg\/mLa AUC(0-10h) = 4.8 µg∙h\/mLa 100 mg\/kg oral dose on GD10 [Tembe] Cmax = 1.8 µg\/mLa AUC(0-10h) = 9.6 µg∙h\/mLa LOAEL: microtia and talipes. Higher doses: microcephaly, anotia, exopthalmos, protruding tongue, cleft lip, mandibular hypoplasia, cleft palate, overdeveloped papillae, analatresia, spina bifide,deformed tail, and acaudate; increased resorptions 3 mg\/kg oral GD8-11 [Eckhoff] Cmax = 0.95 µg\/mLb AUC = 12.2 µg∙h\/mLb 15 mg\/kg oral GD8-11 [Eckhoff] Cmax = 3.1 µg\/mLc AUC = 49.1 µg∙h\/mLc increased resorptions, malformations including eye defects, tail defects, cardiomegaly, skin tag on face 0.5 mg\/kg BID (1 mg\/kg\/day) Cmax = 0.32 µg\/mLd AUC = 7.52 µg∙h\/mLd NOAEL: rat Cmax = 2.8 (0.9\/0.32) AUC = 0.6 (4.8\/7.52) rabbit Cmax = 3.0 (0.95\/0.32) AUC = 1.6 (12.2\/7.52) LOAEL: rat Cmax = 5.6 (1.8\/0.32) AUC = 1.3 (9.6\/7.52) rabbit Cmax = 9.7 (3.1\/0.32)'可被翻译为：异维甲酸（13-顺式维甲酸） CAS 号：4759-48-2 大鼠NOAEL 剂量 Cmax AUC 大鼠LOAEL 剂量 Cmax AUC 大鼠 发现 兔NOAEL 剂量 Cmax AUC 兔LOAEL 剂量 Cmax AUC 兔 发现 人剂量 Cmax AUC 暴露倍数 NOAEL\/人 LOAEL\/人 注释 50 mg\/kg 于GD10经口 给药 [Tembe] Cmax=0.9 µg\/mLa AUC(0-10h)=4.8 µg∙h\/mLa 100 mg\/kg 于GD10经口 给药[Tembe] Cmax=1.8 µg\/mLa AUC(0-10h)=9.6 µg∙h\/mLa LOAEL：小 耳和畸形 足。 更高剂量 下： 小头、无 耳、眼球突 出、舌头突 出、唇裂、 下颌骨发育 不全、腭 裂、乳头发 育过度、肛 门闭锁、脊 柱裂、畸形 尾、无尾； 吸收胎增加 3 mg\/kg 经口 GD8-11 [Eckhoff] Cmax=0.95 µg\/mLb AUC=12.2 µg∙h\/mLb 15 mg\/kg 经口GD8-11 [Eckhoff] Cmax=3.1 µg\/mLc AUC=49.1 µg∙h\/mLc 吸收胎增 加，畸形包 括眼缺陷、 尾缺陷、心 脏扩大、面 部皮赘 0.5 mg\/kg BID (1 mg\/kg\/天) Cmax=0.32 µg\/mLd AUC=7.52 µg∙h\/mLd NOAEL: 大鼠 Cmax=2.8 (0.9\/0.32) AUC=0.6 (4.8\/7.52) 兔 Cmax=3.0 (0.95\/0.32) AUC=1.6 (12.2\/7.52) LOAEL: 大鼠 Cmax=5.6 (1.8\/0.32) AUC=1.3 (9.6\/7.52) 兔 Cmax=9.7 (3.1\/0.32)\n\n根据上述已知信息，请将'resorptions rotated or flexed limbs (4\/38 fetuses at 60 mg\/kg and 15\/25 fetuses at 180 mg\/kg) hydrocephaly (n=2\/38) increased postimplantation loss, including dead fetuses, and numerous external and visceral malformations at 180 mg\/kg 50 mg oralf Cmax = 0.62 µg\/mLg AUC(0-inf) = 4.9 µg·h\/mLg NOAEL: rat Cmax = 1.6 (0.97\/0.62) AUC = 2.2 (10.75\/4.9) rabbit Cmax = 1.3 (0.82\/0.62) AUC = 0.9 (4.18\/4.9) LOAEL: rat Cmax = 7.9 (4.87\/0.62) AUC = 11.0 (53.75\/4.9) rabbit Cmax = 3.5 (2.16\/0.62) AUC = 2.9 (14.4\/4.9)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"吸收胎 肢体旋转或弯 曲(60 mg\/kg剂量下 4\/38胎仔，180 mg\/kg 剂量下15\/25 胎仔) 脑积水 (n=2\/38) 在180 mg\/kg剂 量下：着床后丢失 增加，包括死胎， 以及大量外观和内 脏畸形 50 mg 口服f Cmax=0.62 µg\/mLg AUC(0-inf)=4.9 µg·h\/mLg NOAEL: 大鼠 Cmax = 1.6 (0.97\/0.62) AUC = 2.2 (10.75\/4.9) 兔 Cmax = 1.3 (0.82\/0.62) AUC = 0.9 (4.18\/4.9) LOAEL: 大鼠 Cmax = 7.9 (4.87\/0.62) AUC = 11.0 (53.75\/4.9) 兔 Cmax = 3.5 (2.16\/0.62) AUC = 2.9 (14.4\/4.9)"
    },
    {
        "instruction":"已知信息：\n'Where further studies are required when approval is given to a vaccine registration application, the vaccine MAH shall complete the studies within the specified period.'可被翻译为：对批准疫苗注册申请时提出进一步研究要求的，疫苗持有人应当在规定期限内完成研究。\n'Where requirements for conditional approval are met upon review, the Drug Approval License shall specify the validity period of the conditional Drug Approval License, the post-approval studies to be completed, the timeline for completing post-approval studies and other relevant details.'可被翻译为：经审评，符合附条件批准要求的，在药品注册证书中载明附条件批准药品注册证书的有效期、上市后需要继续完成的研究工作及完成时限等相关事项。\n'Article 67 For a conditionally approved drug, where the MAH fails to complete the studies as required within the specified timeline or fails to prove that the benefits outweigh risks, the NMPA shall handle the matter in accordance with the law until the Drug Approval License is revoked.'可被翻译为：第六十七条 对附条件批准的药品，持有人逾期未按照要求完成研究或者不能证明其获益大于风险的，国家药品监督管理局应当依法处理，直至注销药品注册证书。\n'Article 66 For a conditionally approved drug, the MAH shall take appropriate risk management measures after the drug is marketed and complete relevant studies including drug clinical trials as requested and submit supplementary applications within the specified timeline.'可被翻译为：第六十六条 对附条件批准的药品，持有人应当在药品上市后采取相应的风险管理措施，并在规定期限内按照要求完成药物临床试验等相关研究，以补充申请方式申报。\n\n根据上述已知信息，请将'Where the Drug Approval License and its attachments require the MAH to carry out relevant post-marketing studies, the MAH shall complete the studies within the specified timeline and submit a supplementary application, filing or report as required.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品注册证书及附件要求持有人在药品上市后开展相关研究工作的，持有人应当在规定时限内完成并按照要求提出补充申请、备案或者报告。"
    },
    {
        "instruction":"已知信息：\n'Article 120 The valid term of a drug approval number, Import Drug License or Pharmaceutical Product License issued by the State Food and Drug Administration is five years. To continue its drug production or importation, the applicant shall submit a re-registration application six months prior to the expiry date.'可被翻译为：第一百二十条 国家食品药品监督管理局核发的药品批准文号、《进口药品注册证》或者《医药产品注册证》的有效期为5年。有效期届满，需要继续生产或者进口的，申请人应当在有效期届满前6个月申请再注册。\n'Where a re-registration application has been rejected, except where the drug approval document is withdrawn due to lawfully defined reasons, the drug approval number, Dug Import License or Pharmaceutical Production Certificate shall be withdrawn on the expiry date.'可被翻译为：对不予再注册的品种，除因法定事由被撤销药品批准证明文件的外，在有效期届满时，注销其药品批准文号、《进口药品注册证》或者《医药产品注册证》。\n'5 In the BPCA, the term sponsor refers to an entity that has submitted an investigational new drug application or a new drug application before the new drug application is approved. The term holder of an approved application refers to a company holding an approved new drug application to market a drug product containing the drug at issue (21 U.S.C. 355a(b), (c), and (d)).'可被翻译为：5在BPCA中，“申办方”指的是在新药申请被批准之前递交了研究性新药申请或新药申请的实体。“已批准申请的持有人”指的是持有使药品（包含讨论中的药品）上市的已批准新药 申请的公司（21 U.S.C. 355a（b）、（c）和（d））。\n'Article 122 Where applying for drug re-registration, the holder of a drug approval number shall submit the application to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government, fill in the Application Form for Drug Re-registration, and provide relevant data.'可被翻译为：第一百二十二条 药品再注册申请由药品批准文号的持有者向省、自治区、直辖市药品监督管理部门提出，按照规定填写《药品再注册申请表》，并提供有关申报资料。\n\n根据上述已知信息，请将'Re-registration application refers to application for continued production or importation of a drug after the expiration of the valid term of the drug approval document.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"再注册申请，是指药品批准证明文件有效期满后申请人拟继续生产或者进口该药品的注册申请。"
    },
    {
        "instruction":"已知信息：\n'For marketing authorisation, data from at least 3 lots of purified bulk at pilot-plant scale or commercial scale should be provided.'可被翻译为：上市审批时，应提供至少三批试生产规模或生产规模的纯化后 产品的检定数据。\n'Data from at least 3 lots of unprocessed bulk at pilot- plant scale or commercial scale should be submitted as part of the marketing application\/registration package.'可被翻译为：在进行上市注册申请时，至少应上报三批试生产或规模化生产的未加工品的研究资料。\n'8. The absence of detectable virus should be confirmed for purified bulk by means of suitable methods having high specificity and sensitivity for the detection of the virus in question. For the purpose of marketing authorisation, data from at least 3 lots of purified bulk manufactured at pilot-plant scale or commercial scale should be provided. However, for cell lines such as CHO cells for which the endogenous particles have been extensively characterised and adequate clearance has been demonstrated, it is not usually necessary to assay for the presence of the non-infectious particles in purified bulk.'可被翻译为：8. 应对可能存在的病毒使用具有高特异性和高敏感性的方法进行检测，并确证纯化后产品中无可检测的病毒。当进行上市申请时，应至少提供三批次中试生产或商业化生产规模的原液纯化制造数据。对于像CHO这类内源性颗粒已充分鉴定且已经证明能够被有效清除的细 胞系，通常不需要再对纯化后产品进行非感染性颗粒的检测。\n'pilot-plant scale'可被翻译为：试生产规模、中试\n\n根据上述已知信息，请将'For the purpose of marketing authorisation, data from at least 3 lots of purified bulk manufactured at pilot-plant scale or commercial scale should be provided.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"申请上市时，应提供至少三批试生 产规模或生产规模纯化后产品的检定数据。"
    },
    {
        "instruction":"已知信息：\n'Article 51 Where progress in scientific research, risks monitoring on cosmetics safety and evaluation shows that there are safety risks in certain cosmetic ingredients, and such risks could be eliminated by setting the use scope and conditions of ingredients, such use restrictions and conditions of ingredients should be clarified in the inventory of existing cosmetic ingredients.'可被翻译为：第五十一条 根据科学研究的发展、化妆品安全风险监测和评价等，发现化妆品原料存在安全风险，能够通过设定原料的使用范围和条件消除安全风险的，应当在已使用的化妆品原料目录中明确原料限制使用的范围和条件。\n'Article 21 Registrants and filing persons of new cosmetic ingredients shall establish a safety risk monitoring and evaluation system after the launch of new cosmetic ingredients, conduct follow-up research on the safety of new cosmetic ingredients, and continue to monitor and evaluate the use and safety of new cosmetic ingredients.'可被翻译为：第二十一条 化妆品新原料注册人、备案人应当建立化妆品新原料上市后的安全风险监测和评价体系，对化妆品新原料的安全性进行追踪研究，对化妆品新原料的使用和安全情况进行持续监测和评价。\n'(1) In the name of the registrants and filing persons, handling the registration and filing of cosmetics and new cosmetic ingredients;'可被翻译为：（一）以注册人、备案人的名义，办理化妆品、化妆品新原料注册、备案；\n'Registrants and filing persons of cosmetics and new cosmetic ingredients shall apply for registration and filing through the information service platform of registration and filing for cosmetics and new cosmetic ingredients (hereinafter referred to as the information service platform) in accordance with regulations.'可被翻译为：化妆品、化妆品新原料注册人、备案人按照规定通过化妆品、化妆品新原料注册备案信息服务平台（以下简称信息服务平台）申请注册、进行备案。\n\n根据上述已知信息，请将'Article 50 Where progress in scientific research changes the understanding of the safety of cosmetics and cosmetic ingredients, or there is evidence to show that certain cosmetics and cosmetic ingredients may be defective, the drug regulatory departments undertaking registration and filing may order the registrants and filing persons of cosmetics and new cosmetic ingredients to carry out safety re-evaluation or may directly organize relevant ingredients and cosmetics enterprises to conduct a safety re-evaluation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十条 根据科学研究的发展，对化妆品、化妆品原料的安全性认识发生改变的，或者有证据表明化妆品、化妆品原料可能存在缺陷的，承担注册、备案管理工作的药品监督管理部门可以责令化妆品、化妆品新原料注册人、备案人开展安全再评估，或者直接组织相关原料企业和化妆品企业开展安全再评估。"
    },
    {
        "instruction":"已知信息：\n'Drugs affecting body weight, neuromuscular function, and\/or mood can also appear to affect mating and fertility.'可被翻译为：药物对体重、神经肌肉功能和\/或情绪的影响也可能影响交配和生育能力。\n'Findings that are suggestive of perturbations of the endocrine system are also a concern because endocrine disruptions may adversely affect male (and female) reproductive physiology and performance.'可被翻译为：因为内分泌失调会不利于雄性（和雌性）生殖生理学和性能，表明内分泌系统扰乱的发现也是一项问题。\n'Assessment of reproductive organs or function (e.g., estrous cyclicity, sperm count, or qualitative histologic assessment of spermatogenesis) can only be conducted in sexually mature animals. If the clinical age range includes prepubertal stages, there can be a concern whether the pharmaceutical could cause any delayed effect on sexual maturation or reproductive function in adulthood. If the clinical treatment is only during prepubertal stages, a JAS should be designed to treat only during immaturity, and then allow the animal to mature without further treatment and conduct assessments after maturation is reached.'可被翻译为：生殖器官或功能的评估（如动情周期、精子计数或精子发生的定性组织学评估）只能在性成熟动物中进行。如果临床年龄范围包括青春期前，则可能担忧药物是否会对性成熟或成年期的生殖功能造成延迟性影响。如果临床仅在青春期前阶段给药， JAS应设计为仅在未成熟阶段给药，然后让动物在不给药的情况下成熟，并在达到成熟后进行评估。\n'In rodents, for concerns relevant to females, assessment of estrous cyclicity is recommended for assessment of reproductive and endocrine function. For concerns relevant to male rodents, sperm analysis (e.g., counts, motility, morphology) and\/or testicular immunohistochemistry (e.g., apoptosis) can be considered if of value to further characterise effects.'可被翻译为：在啮齿类动物中，对于与雌性相关的担忧，推荐对动情周期进行评估，以评估生殖和内分泌功能。对于与雄性啮齿类动物相关的担忧，如果对进一步表征影响有价值，应考虑精子分析（例如计数、运动性和\/或形态学）和\/或睾丸免疫组织化学（如细胞凋亡）。\n\n根据上述已知信息，请将'For example, drug-induced alterations in endocrine function can affect testicular weight, gamete maturation and release, sperm count, and\/or fertility.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"例如，药物诱导的内分泌功能改变可影响睾丸重量、配子的成熟和释放、精子数目和\/或生育能力。"
    },
    {
        "instruction":"已知信息：\n'The pharmacopoeial texts referenced in Section 2.1 of this annex can be used as interchangeable in accordance with the conditions set out in this annex.'可被翻译为：当符合本附录规定的条件时，本附录第2.1节中各药典的文件具有同等效力。\n'4.4 MHLW consideration: The pharmacopoeial texts referenced in Section 2.1 of this annex can be used as interchangeable in accordance with the conditions set out in this annex.'可被翻译为：4.4 日本厚生劳动省（MHLW）的考虑 当符合本附录规定的条件时，本附录第2.1节中各药典的文件具有同等效力。\n'Details of implementation requirements will be provided in the notification by MHLW when this annex is implemented. 4.5 Health Canada Consideration In Canada, any of the pharmacopoeial texts cited in section 2.1 of this annex and used in accordance with the conditions set out in this annex can be considered interchangeable.'可被翻译为：当本附录在 日本实施时，MHLW将在通告中规定具体的实施要求。 4.5 加拿大卫生部的考虑 在加拿大，当符合本附录规定的条件时，本附录第2.1节所述的相关药典具有同等效力。\n'Details of implementation requirements will be provided in the notification by MHLW when this annex is implemented.'可被翻译为：当本附录在日本实施时，MHLW将在通告中规定具体的实施要求。\n\n根据上述已知信息，请将'The pharmacopoeial texts referenced in Section 2.1 of this annex can be used as interchangeable in accordance with the conditions set out in this annex. Details of implementation requirements will be provided in the notification by MHLW when this annex is implemented.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当符合本附录规定的条件时，本附录第2.1节中各药典的文件具有同等效力。当本附录在日本实施时，MHLW将在通告中规定具体的实施要求。"
    },
    {
        "instruction":"已知信息：\n'The disturbance is not better explained by cerebrovascular disease, another neurodegenerative disease, the effects of a substance, or another mental, neurological, or systemic disorder.'可被翻译为：精神障碍不能通过脑血管疾病、其他神经变性性疾病，药物效应或其他精神、神经 或系统性病症来解释。\n'however it is not realistic to accumulate sufficient information on safety in pre authorisation studies in children.'可被翻译为：但是，充分累积上市批准之前的儿科研究的安全性信息并不现实。\n'A JAS is designed to address safety concerns that cannot be adequately addressed in other nonclinical studies or paediatric clinical trials, including potential long-term safety effects.'可被翻译为：JAS旨在阐述在其他非临床试验或儿科临床试验中无法得到充分阐述的安全性问题，包括潜在的长期安全性影响。\n'Magnetic resonance imaging (MRI) is a useful tool for monitoring CNS lesions in MS.'可被翻译为：磁共振成像（MRI）是一种非常有用的监测MS中CNS病变的工具。\n\n根据上述已知信息，请将'The concern for a potential effect on the developing CNS cannot be addressed clinically by monitoring and management.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对发育中的CNS的 潜在影响的担忧无法通过临床上的监测和管理来解决。"
    },
    {
        "instruction":"已知信息：\n'Article 128: Finished products should be held in quarantine until release.'可被翻译为：第一百二十八条 成品放行前应当待验贮存。\n'Article 107: Incoming materials and finished products should be quarantined immediately after receipt or processing, until they are released for use or distribution.'可被翻译为：第一百零七条 物料接收和成品生产后应当及时按照待验 管理，直至放行。\n'Article 107 Incoming materials and finished products should be quarantined immediately after receipt or processing, until they are released for use or distribution.'可被翻译为：第一百零七条 物料接收和成品生产后应当及时按照待验管理，直至放行。\n'Article 57: Storage areas should be of sufficient capacity to allow orderly storage of the various categories of materials and products: starting and packaging materials, intermediate, bulk and finished products, products in quarantine, released, rejected, returned or recalled.'可被翻译为：第五十七条 仓储区应当有足够的空间，确保有序存放待 验、合格、不合格、退货或召回的原辅料、包装材料、中间产品、 待包装产品和成品等各类物料和产品。\n\n根据上述已知信息，请将'Article 128 Finished products should be held in quarantine until release.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百二十八条 成品放行前应当待验贮存。"
    },
    {
        "instruction":"已知信息：\n'A list of all IECs or IRBs consulted should be given in appendix 16.1.3 and, if required by the regulatory authority, the name of the committee Chair should be provided. 5.2 ETHICAL CONDUCT OF THE STUDY It should be confirmed that the study was conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki. 5.3 PATIENT INFORMATION AND CONSENT How and when informed consent was obtained in relation to patient enrolment, (e.g., at allocation, pre-screening) should be described.'可被翻译为：并应在附录16.1.3中列出所 有IEC或IRB的列表，如果监管机构要求，应提供委员会 主席的姓名。 5.2 研究的伦理行为 应确认该项研究是按照符合赫尔辛基宣言的伦理原则 进行的。 5.3 患者知情与同意 应当描述如何以及何时获得与患者入选有关的知情同 意书（例如分配时，筛选前）。\n'16.1 STUDY INFORMATION 16.1.1 Protocol and protocol amendments 16.1.2 Sample case report form (unique pages only) 16.1.3 List of IECs or IRBs (plus the name of the committee Chair if required by the regulatory authority) - Representative written information for patient and sample consent forms 16.1.4 List and description of investigators and other important participants in the study, including brief (1 page) CVs or equivalent summaries of training and experience relevant to the performance of the clinical study 16.1.5 Signatures of principal or coordinating investigator(s) or sponsor’s responsible medical officer, depending on the regulatory authority's requirement 16.1.6 Listing of patients receiving test drug(s)\/investigational product(s) from specific batches, where more than one batch was used'可被翻译为：16.1 研究信息 16.1.1 方案和方案修订案 16.1.2 病例报告表样本（仅提供唯一页面） 16.1.3 IEC或IRB列表（如果监管机构要求，加上委员会主 席姓名）-代表性患者书面信息和同意书样本 16.1.4 研究者及其他重要研究参与者的列表和描述，包括个 人简历（1页）或同等的临床研究相关培训和经验汇总 16.1.5 主要或协调研究者或申办方负责医学专员的签名，根 据监管机构的要求而定 16.1.6 如使用1批以上药物，接受特定批次试验药品\/研究性 产品的患者列表\n'Representative written information for the patient (if any) and a sample patient consent form should be provided in appendix 16.1.3.'可被翻译为：附录16.1.3应提供患者的代表性书面告知信（如有） 和患者同意书样本。\n'4.8.9 If a subject is unable to read or if a legally acceptable representative is unable to read, an impartial witness should be present during the entire informed consent discussion. After the written informed consent form and any other written information to be provided to subjects, is read and explained to the subject or the subject’s legally acceptable representative, and after the subject or the subject’s legally acceptable representative has orally consented to the subject’s participation in the trial and, if capable of doing so, has signed and personally dated the informed consent form, the witness should sign and personally date the consent form. By signing the consent form, the witness attests that the information in the consent form and any other written information was accurately explained to, and apparently understood by, the subject or the subject's legally acceptable representative, and that informed consent was freely given by the subject or the subject’s legally acceptable representative.'可被翻译为：4.8.9 如果一名受试者不能阅读，或一位合法可接受的代表不能阅读，在整个知情同意讨论期间必须有一位公正的见证人在场。在书面的知情同意书和其他文字资料交给受试者后，向受试者或受试者的合法可接受代表进行阅读并解释，在受试者或 受试者的合法可接受代表已经口头同意受试者参加试验、并且如果可能已在知情同意书上亲自签字和注明日期后，见证人应当亲自在知情同意书上签字并注明日期。见证人通过签署知情同意书证明，知情同意书和其他文字资料已被准确地向受试者或受试者的合法可接受代表作了解释，受试者或受试者的合法可接受代表显然懂得这些解释，知情同意是受试者或受试者的合法可接受代表自由地给出的。\n\n根据上述已知信息，请将'List of IECs or IRBs (plus the name of the committee Chair if required by the regulatory authority) - Representative written information for patient and sample consent forms'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"IEC或IRB列表（如果监管机构要求，加上委员会主席姓名）- 代表性患者书面信息和同意书样本"
    },
    {
        "instruction":"已知信息：\n'Article 24 No entity or individual is allowed to falsify, alter, trade in, rent or lend out the Medical Device Manufacturing License.'可被翻译为：第二十四条  任何单位或者个人不得伪造、变造、买卖、出租、出借医疗器械生产许可证。\n'Article 45 An enterprise to be engaged in distribution activities of medical devices shall not engage in distributing medical devices that have not been registered or filed, without qualification certification documents or that have been expired, invalid or obsolete.'可被翻译为：第四十五条  从事医疗器械经营活动的，不得经营未依法注册或者备案，无合格证明文件以及过期、失效、淘汰的医疗器械。\n'Article 22 No entity or individual shall forge, alter, rent, lend, or buy and sell the Drug Manufacturing Certificate.'可被翻译为：第二十二条 任何单位或者个人不得伪造、变造、出租、出借、买卖药品生产许可证。\n'Article 23 If an entity applies for Class III Medical Device Distribution License and files for Class II medical device distribution concurrently, or has obtained Class III Medical Device Distribution License when filing for Class II medical device distribution, then it may be exempted from submitting corresponding materials.'可被翻译为：第二十三条  同时申请第三类医疗器械经营许可和进行第二类医疗器械经营备案的，或者已经取得第三类医疗器械经营许可进行第二类医疗器械备案的，可以免予提交相应资料。\n\n根据上述已知信息，请将'Article 28 No entity or individual is allowed to falsify, alter, trade in, rent or lend out the Medical Device Distribution License.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十八条  任何单位和个人不得伪造、变造、买卖、出租、出借医疗器械经营许可证。"
    },
    {
        "instruction":"已知信息：\n'while patients with T1DM may be preferable for comparison of long-acting insulins.'可被翻译为：而比较长效胰岛素更宜用 I 型糖尿病患者。\n'it may be difficult to determine the duration of action of a long-acting insulin, particularly in healthy subjects with interfering endogenous insulin.'可被翻译为：确定长效胰岛素的作用时间可能有困难，特别是对有内源性胰岛素干扰的健康受试者。\n'but the co-administration of basal insulin infusion has been shown to alter the late glucodynamic profile of NPH insulin and possibly and even more relevantly of long-acting insulin preparations, overestimating the effect of the study insulins.'可被翻译为：但同时给的基础胰岛素注射会改变 NPH 葡萄糖的葡萄糖动力学，对长效胰岛素制剂的改变甚至更大，造成高估受试胰岛素的效果。\n'Besides their better availability, healthy volunteers usually exhibit lower intra-individual variability compared to patients with type 1 diabetes mellitus (T1DM)'可被翻译为：健康志愿者比起I型糖尿病（T1DM）患者，除了容易找到以外，通常表现出较少的人际差异，\n\n根据上述已知信息，请将'Therefore, patients with type 1 diabetes are generally considered more suitable to determine the time-action profile of long-acting insulins.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"因此，一般认为长效胰岛素的时间-作用数据更适于通过I型糖尿病患者来测定。"
    },
    {
        "instruction":"已知信息：\n'An internal quality control is built into each plate and tube tested. Since antibiotics have different listed dosages per label, the test antibiotic\/unknown sample is diluted to a known sample concentration ([U3]). The unknown sample [U3] has an equivalent concentration of the median reference standard ([S3]). The median reference standard ([S3]) is the median concentration (i.e. mid-point) of the five-point standard curve ([S1], [S2], [S4] and [S5]). The five- point standard functions as the testable detection range and is prepared from a traceable and within expiry USP Reference Standard (RS).'可被翻译为：内部质量控制来源于每个测试平板和试管。由于抗生素在每个标签上都标明不同剂量， 检测抗生素\/未知样品被稀释为已知样品浓度（【U3】）。未知样品【U3】与中间对照 （【S3】）的浓度相同。中值标准品（【S3】）浓度处于5点标准浓度曲线（【S1】， 【S2】，【S4】和【S5】）中间（即，中点）。5点标准的作用是建立检测范围，它们采用可追溯的在效期内的USP标准品（RS）制备。\n'Absorbance values of the media reference standard ([S3]) are predetermined per antibiotic. Refer USP<81> for testing parameters and acceptable data requirements.'可被翻译为：预先确定每种抗生素的中值标准品（【S3】）的吸光度。参考USP<81>中测试参数 和可接受数据要求\n'Test antibiotic\/unknown [U3] tubes will contain the growth broth, inoculum and the test \nantibiotic\/unknown [U3] in triplicate. The standard curve ([S1]-[S5]) tubes will contain the growth broth, inoculum and each of the respective standard curve concentrations [S1], [S2], [S3], [S4], and [S5] in triplicate. The QC tubes will contain additional median reference standard [S3], will be used to perform preliminary absorbance checks and serve as a quality check for diluents and inoculum used in test. See Diagram 6 for an example of one independent test run for the Tube Method and placement of the standard curve and unknown sample into triplicate tubes.'可被翻译为：一式三份抗生素\/未知样品【U3】试管中含有生长肉汤、接种物和受检抗生素\/未知样品【U3】。一式三份标准曲线（【S1】-【S5】）管含有生长肉汤、接种物和各代表性标准曲线浓度【S1】、【S2】、【S3】、【S4】和【S5】。QC 管含有另一份中值标准品【S3】，该管是用于进行初始吸光度检查，作为检测中所用稀释倍数和接种物的质量检\n查。参见图 6 浊度法一次独立检测，及标准曲线和知样品一式三份样品管设置示例。\n'The calculated potency of the test antibiotic\/unknown sample ([U3]) must be 80% to 125% of the median reference standard ([S3]);'可被翻译为：测试抗生素\/未知样品（【U3】）的计算效价必须为中值标准品（【S3】）的 80-125%\n\n根据上述已知信息，请将'Antibiotic Reference Standards ([S1] – [S5]) and Unknown Sample (U3]) Preparation'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"抗生素标准品（【S1】-【S5】）和未知样品（【U3】）制备"
    },
    {
        "instruction":"已知信息：\n'A pharmaceutical product type that contains a drug substance, generally, in association with excipients.'可被翻译为：含有原液并通常与辅料放在一起的一种药品类型。\n'A pharmaceutical product type, for example, tablet, capsule, solution, cream, etc., which has not previously been registered in a region or Member State, and which contains a drug ingredient generally, but not necessarily, in association with excipients.'可被翻译为：一种药物的制剂形式，如片剂、胶囊剂、溶液剂、乳膏剂，它们以前未在地区或成员国注册过。通常是一种药物成份与辅料的组合，但不一定都是。\n'1.The form of the FPP, e.g. tablet, capsule, elixir or suppository.\n2.The form of the completed pharmaceutical product, e.g. tablet, capsule, elixir, injection, suppository.\n3.The form of the completed pharmaceutical preparation, e.g. tablet, capsule, elixir, suppository.\n4.The form of the completed pharmaceutical product, e.g. tablet, capsule, elixir or suppository.\n5.The form of the finished pharmaceutical product, e.g. tablet, capsule, elixir or suppository.'可被翻译为：1.FPP的形式，如片剂、胶囊、酏剂或栓剂。\n2.药品成品的形态，如片剂、胶囊、酏剂、注射剂、栓剂。\n3.完整的药物制剂形式，如片剂、胶囊、酏剂、栓剂。\n4.制剂的形式，如片剂、胶囊、酏剂或栓剂。\n5.制成品的形式，如片剂、胶囊、酏剂或栓剂。\n'Use of blinding, specific methods of blinding, and potential weaknesses (e.g., tablet enclosed in a capsule, odor of the study drug).'可被翻译为：使用的盲法，具体的盲法和潜在的弱点（例如，片剂封闭在胶囊中，研究药物的气味）。\n\n根据上述已知信息，请将'A pharmaceutical product type (e.g., tablet, capsule, solution, cream) that contains a drug substance generally, but not necessarily, in association with excipients.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通常含有一种药物活性成分及各种辅料（但不一定必须有辅料）制成的药物制剂形式（如片剂、胶囊、溶液剂、乳膏剂）。"
    },
    {
        "instruction":"已知信息：\n'7.5.2. (Neo)adjuvant therapy In the adjuvant setting, the ultimate aim is to increase cure rate.'可被翻译为：7.5.2. （新）辅助疗法\n'(Neo)adjuvant therapy'可被翻译为：（新）辅助治疗\n'7.5.2. (Neo)adjuvant therapy'可被翻译为：（新）辅助疗法\n'As more effective treatment options become available in the metastatic setting, more trials are expected also in the (neo) adjuvant treatment.'可被翻译为：由于目前有更有效的治疗选择可用于治疗转移性疾病，预期会进行更多的关于（新）辅助治疗的临床试验。\n\n根据上述已知信息，请将'(Neo)adjuvant therapy In the adjuvant setting, the ultimate aim is to increase cure rate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（新）辅助治疗 辅助治疗的最终目的是提高治愈率。"
    },
    {
        "instruction":"已知信息：\n'Any deviation from the guideline should be explained and discussed in the application.'可被翻译为：在申请中应该对同本指南的偏差予以解释和讨论。\n'III. In case of inconsistency between the previously issued Guideline for Exemption from Human Bio equivalence Tests and the M9 Guideline, the M9 Guideline shall prevail.'可被翻译为：三、如果先前发布的《人类生物等效性试验豁免指南》与M9指南不一致，应以M9指南为准。\n'Of note, GCP requirements also apply.'可被翻译为：需要注意， GCP 要求也同样适用。\n'Data as requested in Note for Guidance “The use of Ionization Radiation in the Manufacture for Medicinal Products” should be provided, supplemented as necessary by data requirements given in ISO 195 11137 and Ph. Eur. chapter 5.1.1.'可被翻译为：应提供指导原则《电离辐射在药品生产中的使用》所要求的数据，必要时按ISO 11137和Ph. Eur. 5.1.1中给出的数据要求补充。\n\n根据上述已知信息，请将'Where any requirements in ISO 11137 are in contradiction to requirements stated in any Note for Guidance issued by the EMA, the requirements of the Note for guidance apply.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"ISO 11137中的任何要求与EMA发布的任何指导原则中载明的要求冲突的， 适用指导原则的要求。"
    },
    {
        "instruction":"已知信息：\n'Following adoption of the Note for Guidance on evaluation of medicinal products indicated for the treatment of bacterial infections (CPMP\/EWP\/558\/95 rev 1) it became apparent that some areas of the guideline would benefit from further explanation of the requirements for approval of new antibacterial agents and for significant variations to the marketing authorisation.'可被翻译为：“细菌感染的治疗药物的评估指南（CPMP\/EWP\/558\/95 rev 1）的注释”被采纳之后， 由于它对新抗菌剂的审批要求及其销售许可证的重大变更的审批要求作 了进一步的解释， 使得该指南中的部分内容更加清晰明了。\n'The guidance is relevant to the development of medicinal products that are indicated for the treatment of the different forms of urinary incontinence in adult females, adult males and in the paediatric population.'可被翻译为：该指南关系到治疗不同类型尿失禁的药品的开发，包括成年女性、成年男性和儿科人群中的用药。\n'27 June 2013 \nCPMP\/EWP\/18\/01\/Rev. 1 \nCommittee for Medicinal Products for Human Use (CHMP) \nGuideline on the clinical investigation of medicinal products for the treatment of urinary incontinence'可被翻译为：2013年06月27日 \nEMA\/CHMP\/18\/01\/修订版第1版 \n人用药品委员会 \n药物治疗尿失禁的临床研究指导原则\n'Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Urinary Incontinence'可被翻译为：药物治疗尿失禁的临床研究指导原则\n\n根据上述已知信息，请将'Executive summary \nFollowing adoption of the Note for Guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence (CPMP\/EWP\/18\/01) it became apparent that some areas of the guideline would benefit from further explanation of the requirements for approval and for significant variations to the marketing authorisation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"执行摘要 \n随着治疗尿失禁药物临床试验指导原则\/CPMP\/EWP\/18\/01的采纳， 指导方针的一些内容将因批准要求和上市批准重要变更要求得到进一步的解释而改善。"
    },
    {
        "instruction":"已知信息：\n'The use of registries is encouraged.'可被翻译为：鼓励注册使用。\n'All patients should preferably be included in registries to monitor long-term safety and efficacy.'可被翻译为：首选在登记研究中纳入所有患者以监测长期安全和有效性。\n'30.Is it possible for researchers or first responders to identify individuals who do not want to participate? Study protocols may describe situations in which emergency care personnel could reasonably infer that some incapacitated individuals would not agree to participate in a research study, even if the individuals meet the inclusion criteria.'可被翻译为：30 研究者或首个接待员有可能确定不愿意参与的个体吗？ 研究方案可以描述一些这样的情形，其中紧急治疗人员可以合理的推论某些 失能个体不会同意参与某项研究性研究，即使这些个体符合入组标准。\n'The outcome “VTE-related death” may include fatal PE documented by autopsy as well as deaths in which a fatal PE cannot be ruled out.'可被翻译为：结局“VTE 相关死亡”可包括通过验尸记录的致命 PE 以及死亡，其中不能排除致命 PE。\n\n根据上述已知信息，请将'It  is recommended to participate in registries which include standard care as well, which may allow comparisons.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"建议参与登记（包括标准护理），这允许对比。"
    },
    {
        "instruction":"已知信息：\n'Events such as discontinuation of treatment, switching between treatments, or use of an additional medication may render the later measurements of the variable irrelevant or difficult to interpret even when they can be collected. Measurements after a subject dies do not exist.'可被翻译为：诸如终止治疗、转组治疗或使用额外药物等事件可能导致 变量的后续观测值即使可以收集到数据也与估计目标不相关或难 以解释。而对于死亡的受试者，死亡后的观测值是不存在的。\n'For example, an estimand based on this strategy cannot be constructed with respect to a variable that cannot be measured due to death.'可被翻译为：例如，在死亡 之后变量是无法观测的，因此不能基于此策略构建估计目标。\n'In general, the treatment policy strategy cannot be implemented for intercurrent events that are terminal events, since values for the variable after the intercurrent event do not exist.'可被翻译为：一般情况下，对于终末事件类型的伴发事件，不能采用疗法 策略，原因是该类伴发事件后变量的值不再存在。\n'Examples of intercurrent events that would affect the existence of the measurements include terminal events such as death and leg amputation (when assessing symptoms of diabetic foot ulcers), when these events are not part of the variable itself.'可被翻译为：影响观测结果存在的伴 发事件包括终末事件，例如死亡和腿截肢（当评估糖尿病性足溃 疡的症状时），而且这些事件不是变量本身的一部分。\n\n根据上述已知信息，请将'For terminal events such as death, the variable cannot be measured after the intercurrent event, but neither should these data generally be regarded as missing.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于死亡等终末事件，变量不能在伴发事件后进行观测， 但这些数据通常都不应被视为缺失。"
    },
    {
        "instruction":"已知信息：\n'Daily weighing of pregnant females during treatment can provide useful information. Weighing an animal more frequently than twice weekly during periods other than pregnancy (premating, mating, lactation) may also be advisable for some compounds.'可被翻译为：给药期间每日对妊娠动物称体重可提供有用的信息。对某些化合物，在非妊娠期(交配前、交配期、哺乳期)则最好每周称体重 2 次以上。\n'It is appropriate to use G.k.6 to capture the earliest exposure during pregnancy, a clinical judgment should be used to choose the most appropriate value\/unit.'可被翻译为：使用G.k.6采集怀孕期间最早的暴露是适当的，应作出临床判断选择最合适的值\/单位。\n'Approximately 16 pregnant females'可被翻译为：约16只妊娠雌性\n'In addition, a number of other secondary endpoints may provide useful information.'可被翻译为：此外，其他的一些次要终点可能会提供有用的信息。\n\n根据上述已知信息，请将'e: Daily weighing of pregnant females during treatment can provide useful information.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"e：给药期间对妊娠雌性动物每天称重可以提供有用的信息。"
    },
    {
        "instruction":"已知信息：\n'The selection principle about “significant structural fragment” has frequently been misinterpreted as meaning that the proposed starting material should be structurally similar to the drug substance. However, as stated in ICH Q11, this general principle is intended to help distinguish starting materials from reagents, catalysts, solvents, or other raw materials.'可被翻译为：“重要结构片断的选择原则经常被误解为所选起始原料应该与原 料药具有相似的结构。但是，正如ICH Q11所声明的，该原则旨在帮助将试剂、催化剂、溶剂以及其他原料与起始原料区分开来。\n'The term “significant structural fragment” is not intended to dictate the selection of either a very early or a very late intermediate as the starting material. A proposed starting material may be defined downstream from a commercially available chemical, provided that there are multiple chemical transformation steps between the proposed starting material and the drug substance, and provided the justification addresses the ICH Q11 general principles. The presence of a “significant structural fragment” should not be the sole basis for starting material selection. Starting materials justified solely on the basis that they are a “significant structural fragment” probably will not be accepted by regulatory authorities, as the other general principles for the appropriate selection of a proposed starting material should also be considered.'可被翻译为：该原则无意规定选择一个非常靠前或是非常靠后的中间体作为起始原料。如果选择的起始原料到原料药有多步化学转化步骤，并且依据 ICH Q11的基本原则能给出可以接受的论证，则所选起始原料可以是市售物料经几步反应后所得的物料。具有“重要结构片断”不应作为起始原料选择的唯一依据。仅仅依据具有“重要结构片断”来论证一个起始原料不被监管机构所接受，因为恰当选择所选起始原料的其他原则也需要考虑。\n'A general term used to denote raw materials (starting materials, reagents, solvents), process aids, intermediates, APIs and packaging and labelling materials.'可被翻译为：原材料(起始物料，试剂、溶剂)、工艺辅助材料、中间体，APIs 和包装及标签材料的总称。\n'A general term used to denote raw materials (starting materials, reagents, solvents), process aids, intermediates, APIs and packaging and labelling materials.'可被翻译为：用以表示原料（起始物料，试剂、溶剂）、工艺助剂、中间体、原料药、 标签和包装材料的总称。\n\n根据上述已知信息，请将'“Significant structural fragment” in this context is intended to distinguish starting materials from reagents, solvents, or other raw materials. Commonly available chemicals used to create salts, esters or other simple derivatives should be considered reagents.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"此处所说的“重要结构片段”用于区分起始原料与试剂、溶剂及其他原材料。用来制备盐、酯或其他简单衍生物的常用化学 物质应该被视为试剂。"
    },
    {
        "instruction":"已知信息：\n'- If you have any further questions, ask your nuclear medicine doctor who will supervise the procedure.'可被翻译为：如果您有任何问题，请咨询监管此过程的核医学医生。\n'When in doubt, it is important to consult your nuclear medicine doctor who will supervise the procedure.'可被翻译为：如果您已经怀孕只有在益处大于风险时，您的核医学医生才会在怀孕期间给你使用该产品\n'Your Nuclear medicine doctor will inform you about the usual duration of the procedure.'可被翻译为：您的核医学医生会告知您的程序的常规持续时间。\n'Please talk to your Nuclear medicine doctor <if you are under 18 years old>'可被翻译为：<如果您未满 18 岁>请告知您的核医学医生。\n\n根据上述已知信息，请将'If you have any further question on the use of X, please ask your nuclear medicine doctor who supervises the procedure.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果您对使用 X 有任何进一步的问题，请咨询监管此过程的核医学医生。"
    },
    {
        "instruction":"已知信息：\n'For dose selections and pharmacodynamics studies: please refer also to guideline on the clinical development products for specific immunotherapy for the treatment of allergic diseases (Doc. Ref. CHMP\/EWP\/04\/2006).'可被翻译为：关于剂量选择和药效学研究：也请参考变态反应性疾病特异性免疫治疗药物 临床开发指导原则（Doc. Ref.CHMP\/EWP\/04\/2006）。\n'Besides aspects like the general product safety and clinical efficacy, there has to be a focus on immunogenicity, particularly on inhibitor development, anaphylactic reactions and thrombogenic effects.'可被翻译为：除了一般产品安全性和临床疗效方面外，还须关注免疫原性，特别是抑制物形成、过敏性反应和血栓形成效应。\n'For biopharmaceuticals, samples for anti-drug antibodies should be collected, and evaluated if appropriate (see ICH S6).'可被翻译为：对于生物制品，如果适当，应进行抗药抗体（ADA）采样并评价（参见ICH S6）。\n'Potential immunological adverse effects should be addressed in the risk management plan (see chapter 9).'可被翻译为：潜在免疫不良作用应在风险管理计划中阐述（见第 9 章节）。\n\n根据上述已知信息，请将'4 The treatment schedules described in this table should be modified as appropriate for molecules with extended pharmacodynamic effects, long half-lives or potential for anaphylactic reactions. In addition, the potential effects of immunogenicity should be considered (see ICH S6).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4 对于具有广泛的药理作用、长半衰期或过敏反应潜力的分子，本表中的给 药方案应进行适当调整。此外，应考虑免疫原性的潜在作用（见ICH S6）。"
    },
    {
        "instruction":"已知信息：\n'(2) a non-drug substance is substituted for a drug or one drug is substituted for another;'可被翻译为：（二）以非药品冒充药品或者以他种药品冒充此种药品；\n'A variety of drugs that can be used for treatment when the preferred drug cannot be used for some reason.'可被翻译为：由于某种原因不能选用首选药用于治疗时，可供选用的药物品种。\n'Drugs subject to special administration by the State, such as vaccines, blood products, narcotic drugs, psychotropic substances, toxic drugs for medical use, radioactive drugs, and pharmaceutical precursor chemicals, shall not be sold online.'可被翻译为：疫苗、血液制品、麻醉药品、精神药品、医疗用毒性药品、放射性药品、药品类易制毒化学品等国家实行特殊管理的药品不得在网络上销售。\n'Vaccines, blood products, narcotic drugs, psychotropic substances, toxic drugs for medical use, radioactive drugs, pharmaceutical precursor chemicals and other drugs under special control of the country cannot be sold online. The specific catalog shall be formulated by the NMPA.'可被翻译为：疫苗、血液制品、麻醉药品、精神药品、医疗用毒性药品、放射性药品、药品类易制毒化学品等国家实行特殊管理的药品不得在网络上销售，具体目录由国家药品监督管理局组织制定。\n\n根据上述已知信息，请将'(1) substitute narcotics, psychotropic substances, toxic drugs for medical use, radioactive drugs or pharmaceutical precursor chemicals for other drugs, or vice versa;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）以麻醉药品、精神药品、医疗用毒性药品、放射性药品、药品类易制毒化学品冒充其他药品，或者以其他药品冒充上述药品；"
    },
    {
        "instruction":"已知信息：\n'Minipig\/ Pig \n● Many similar developmental milestones as humans \n● Relatively large at birth \n● Relatively easy to handle \n● Breeding can be planned in advance \n● Litter size allows allocation of piglets to different endpoints \n● Amenable to fostering \n● Relatively large litters usually allow balanced sex distribution \n● Neonatal GI tract similar to human for orally administered drugs \n● All routes of administration feasible (except inhalation); best model for dermal studies (low density of adnexa and hair follicles, similar thickness of epidermis) \n● Less well-established historical control data than dog or NHP toxicology species \n● Require colostrum for passive transfer of maternal Ig in immediate perinatal period \n● Some organ systems relatively mature at birth compared to human infants (e.g., lungs, musculoskeletal) \n● Large body size requires comparably large amounts of test compound compared to rodents \n● IV and gavage administration can be challenging in very young piglets \n● Short development (~6-9 months), relatively easy transport and housing compared to other large non-rodents'可被翻译为：小型猪\/猪 \n• 很多发育里程碑与人类相似 \n• 出生时体型较大 \n• 相对容易操作 \n• 可以提前计划繁殖 \n• 窝仔数允许将仔猪分配至不同的终点指标 \n• 与犬或NHP毒理学种属相比，历史对照数据较不完善 \n• 围产期内需要初乳以被动转移母体Ig \n• 与人类婴儿相比一些器官系统出生时相对成熟（如肺、肌 肉骨骼） \n• 体型大，使得与啮齿类动物相比需要相当大量的受试物 \n• 适合于养育 \n• 窝仔数相对大，使得通常能平衡性别分布 \n• 对于口服药物，新生幼仔的胃肠道与人类相似 \n• 所有给药途径均可行（吸入除外）；皮肤试验的最佳模型（低密度的附件和毛囊，相似的表皮厚度） \n• 与其他大型非啮齿类动物相比，发育期较短（约6~9个月），运输和饲养相对容易 \n• 在非常年幼的仔猪中，静脉注射给药和灌胃给药具有挑战性\n'Guinea pigs: often lack of kinetic and toxicity data, susceptibility to some antibiotics and to disturbance of the alimentary tract, long fetal period, insufficient historical background data.'可被翻译为：豚鼠：常缺乏动力学和毒理资料，对一些抗生素和消化道功能紊乱敏感，胎仔发育期长，历史背景资料不足。\n'Dogs: seasonal breeders, inbreeding factors, insufficient historical background data.'可被翻译为：犬：季节性繁殖，多近亲繁殖，历史背景资料不足。\n'Ferrets: seasonal breeder unless special management systems used (success highly dependent on human\/animal interaction), insufficient historical background data.'可被翻译为：白鼬：如果不采用特殊的管理系统，只能季节性繁殖（其成功与否主要取决于人和动物的相互影响），历史背景资料不足。\n\n根据上述已知信息，请将'Domestic and\/or mini pigs: malformation clusters with variable background rate, large amounts of compound required, large housing necessary, insufficient historical background data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"家养猪和\/或小型猪：群体畸形的背景情况多变，所需的受试物量大，需要较大饲养空间，历史背景资料不足。"
    },
    {
        "instruction":"已知信息：\n'safety factor'可被翻译为：安全系数\n'A factor set to eliminate the uncertainties involved in determining the adverse effects of an evaluated chemical on a large population by extrapolating data from animal trials to humans, or from small-population surveys. It is used to establish standards for the control of chemicals to ensure the safety of exposed populations.'可被翻译为：在以动物试验数据外推到人，或以小范围人群调查结果判断所评价的化学品对大范围人群的有害作用时，为排除所涉及的不确定因素而设定的系数。用于制定化学品控制标准，以保证接触人群的安全。\n'benchmark dose'可被翻译为：基线剂量\n'Acceptable limit: Maximum acceptable concentration of an impurity in a drug substance or drug product derived from the acceptable intake and the daily dose of the drug.'可被翻译为：可接受限度： 从可接受摄入量和药物每日剂量推导而来的原料药或制剂中杂质的最大可 接受浓度。\n\n根据上述已知信息，请将'Safety Factor: A composite (reductive) factor applied by the risk assessment experts to the NOAEL or other reference point, such as the benchmark dose or benchmark dose lower confidence limit, to derive a reference dose that is considered safe or without appreciable risk, such as an acceptable daily intake or tolerable daily intake (the NOAEL or other reference point is divided by the safety factor to calculate the reference dose).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"安全因子： 风险评估专家针对NOAEL或其他参照点，例如基准剂量或基准剂量置信下 限，应用的一种复合（简化）因子，用以推算一个被认为安全或未见风险的参照 剂量；例如一个可接受的日摄入量或日耐受量（参照剂量通过NOAEL或其他参 照点除以安全因子计算得出）。"
    },
    {
        "instruction":"已知信息：\n'Article 18 The personnel engaged in drug distribution and quality management of an enterprise shall comply with the qualification requirements specified in relevant laws and regulations and this GSP, and shall be under no Job Forbidden by relevant laws and regulations.'可被翻译为：第十八条 企业从事药品经营和质量管理工作的人员，应当符合有关法律法规及本规范规定的资格要求，不得有相关法律法规禁止从业的情形。\n'The State encourages and guides the operation of retail drug chains. The headquarters of a retail drug chain shall establish a unified quality management system and perform management responsibilities for the business activities of the chain retailers.'可被翻译为：国家鼓励、引导药品零售连锁经营。从事药品零售连锁经营活动的企业总部，应当建立统一的质量管理制度，对所属零售企业的经营活动履行管理责任。\n'Article 124 The personnel engaged in drug distribution and quality management of an enterprise shall comply with the qualification requirements specified in relevant laws and regulations and this GSP, and shall be under no Job Forbidden by relevant laws and regulations.'可被翻译为：第一百二十四条 企业从事药品经营和质量管理工作的人员，应当符合有关法律法规及本规范规定的资格要求，不得有相关法律法规禁止从业的情形。\n'Article 180 The GSP provides basic requirements for quality management of drug distribution. Specific requirements for enterprise informatization management, automatic monitoring of temperature and humidity for drug storage and transportation, drug acceptance inspection management, drug cold chain logistics management, and retail chain management shall be separately formulated by the National Medical Products Administration (NMPA) in the form of appendixes.'可被翻译为：第一百八十条 本规范为药品经营质量管理的基本要求。对企业信息化管理、药品储运温湿度自动监测、药品验收管理、药品冷链物流管理、零售连锁管理等具体要求，由国家食品药品监督管理总局以附录方式另行制定。\n\n根据上述已知信息，请将'Article 179 The management of the headquarters of drug retail chain enterprise shall comply with the relevant provisions of the GSP for drug wholesale enterprises, and the management of its stores shall comply with the relevant provisions of the GSP for drug retail enterprises.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百七十九条 药品零售连锁企业总部的管理应当符合本规范药品批发企业相关规定，门店的管理应当符合本规范药品零售企业相关规定。"
    },
    {
        "instruction":"已知信息：\n'• All reports would be generated with the same version of MedDRA.'可被翻译为：• 所有提交报告都使用同一 MedDRA 版本。\n'• Requires re-coding of all trials to be updated to the current version of MedDRA.'可被翻译为：• 必须重新编码所有临床试验数据以更新到现行 MedDRA 版本。\n'• Project level reports would utilize the current version of MedDRA.'可被翻译为：• 项目层面的报告使用现行版本的 MedDRA。\n'• Coded trial data is coded in the most recent version of MedDRA.'可被翻译为：• 临床试验数据是用最新版 MedDRA 编码的。\n\n根据上述已知信息，请将'• All trials within the project would be coded with the same version of MedDRA.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"• 一个项目下所有的临床试验使用同一 MedDRA 版本编码。"
    },
    {
        "instruction":"已知信息：\n'ICH HARMONISED TRIPARTITE GUIDELINE DEFINITIONS FOR GENOMIC BIOMARKERS, PHARMACOGENOMICS, PHARMACOGENETICS, GENOMIC DATA AND SAMPLE CODING CATEGORIES E15 \nCurrent Step 4 version \ndated 1 November 2007 \nThis Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process.'可被翻译为：ICH E15 \n现行第四阶段版本 \n2007年11月1日 \n该指导原则由相应的ICH专家工作组制定，按照ICH进 程，已通过药品监管机构讨论。\n'INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE DEVELOPMENT AND MANUFACTURE OF DRUG SUBSTANCES (CHEMICAL ENTITIES AND BIOTECHNOLOGICAL\/BIOLOGICAL ENTITIES) Q11 Current Step 4 version dated 1 May 2012 \nThis Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process.'可被翻译为：ICH \/ Q11 ICH进程第四阶段 2012年5月1日 \n根据ICH进程，本指导原则由相应的ICH专家组制定， 并已提交给管理当局征询意见。\n'ICH HARMONISED TRIPARTITE GUIDELINE CHOICE OF CONTROL GROUP AND RELATED ISSUES IN CLINICAL TRIALS E10 \nCurrent Step 4 version \ndated 20 July 2000 \nThis Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process.'可被翻译为：ICH E10 \n现行第四阶段版本 \n2000年7月20日 \n该指导原则由相应的ICH专家工作组制定，按照ICH 进程，已通过药品监管机构讨论。\n'ICH HARMONISED TRIPARTITE GUIDELINE STATISTICAL PRINCIPLES FOR CLINICAL TRIALS E9 \nCurrent Step 4 version \ndated 5 February 1998 \nThis Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process.'可被翻译为：ICH E9 \n现行第四阶段版本 \n1998年2月5日 \n该指导原则由相应的ICH专家工作组制定，按照ICH进程，已通过药品监管机构讨论。\n\n根据上述已知信息，请将'ICH HARMONISED TRIPARTITE GUIDELINE BIOMARKERS RELATED TO DRUG OR BIOTECHNOLOGY PRODUCT DEVELOPMENT: CONTEXT, STRUCTURE AND FORMAT OF QUALIFICATION SUBMISSIONS E16 \nCurrent Step 4 version \ndated 20 August 2010 \nThis Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"ICH E16 \n现行第四阶段版本 \n2010年8月20日 \n该指导原则由相应的ICH专家工作组制定，按照ICH进 程，已通过药品监管机构讨论。"
    },
    {
        "instruction":"已知信息：\n'(4) manufacture and sale of counterfeit or inferior drugs which cause personal injuries;'可被翻译为：（四）生产、销售假药、劣药，造成人身伤害后果；\n'A drug shall be deemed a counterfeit drug in any of the following circumstances:'可被翻译为：有下列情形之一的，为假药：\n'(3) manufacture and sale of counterfeit or inferior biological products;'可被翻译为：（三）生产、销售的生物制品属于假药、劣药；\n'Article 98 The manufacture (including preparation, same hereinafter), sale, or use of counterfeit or inferior drugs is prohibited.'可被翻译为：第九十八条 禁止生产（包括配制，下同）、销售、使用假药、劣药。\n\n根据上述已知信息，请将'(5) repeated violations of manufacture and sale of counterfeit or inferior drugs; or'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）生产、销售假药、劣药，经处理后再犯；"
    },
    {
        "instruction":"已知信息：\n'In this type of trial, though, the event of interest will be focused to ensure a convenient and practical study.'可被翻译为：但是在这一类试验中，为保证研究 的方便和实用性需要集中研究目的。\n'The former represents an intercurrent event and the clinical question of interest in respect of that should be clear.'可被翻译为：前者代表伴发事件，关于该事件的临床问题 应明确。\n'Where such specific criteria are not expected to affect interpretation of the variable, they would not need to be addressed as intercurrent events. As indicated above, consideration of intercurrent events is required when constructing the estimand.'可被翻译为：如果预期这些具体 标准不会影响对变量的解释，则不需要将它们作为伴发事件处 理。如上所述，在构建估计目标时需要考虑伴发事件。\n'Where that has been defined as an intercurrent event, this can be reflected through the strategy chosen to account for that intercurrent event and not as a missing data problem.'可被翻译为：在将其定义为伴发事件的情况下，可以选择相 应策略，而不是将其作为缺失数据问题来处理。\n\n根据上述已知信息，请将'The former represents an intercurrent event, to be addressed in the precise specification of the trial objective through the estimand.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"前者代表一个伴 发事件，需通过在试验目的中对估计目标的精确说明加以解决；"
    },
    {
        "instruction":"已知信息：\n'• Contact the appropriate FDA project manager’s next level supervisor for assistance in eliciting a response from the project manager'可被翻译为：联系相应FDA项目经理的上一级主管，适用于帮助获得项目经理的回复\n'• Contact CDER’s ECT or CBER’s Ombudsman for assistance in eliciting a response from 441 the project manager'可被翻译为：联系CDER的ECT或CBER的监察专员，适用于帮助获得项目经理的回复\n'• Contact the appropriate FDA project manager, typically the review division RPM, for a status update after the expected amount of time (e.g., the timelines described in a MAPP) for FDA response has passed; Contact the appropriate FDA project manager, typically the review division RPM, for a status update after the estimated response time has passed (i.e., the estimated FDA-response date communicated to the sponsor previously)'可被翻译为：联系相应的FDA项目经理，通常是审评部门RPM，适用于FDA回复时间已过的预期时间（例如，在MAPP中描述的时间限）的状态更新；或者联系相应的FDA项目经理，通常是审评部门RPM，适用于估计回复时间已过（例如，之前估计的与申办方沟通的FDA回复日期）的状态更新\n'Applicants should contact the appropriate FDA project manager if there is a question about a specific submission. The review division will determine whether approval for a specific cardiovascular outcome claim supplement needs clinical data for approval.'可被翻译为：如果有关于特定提交资料的疑问，申请者可以联系适当的FDA项目经理。评审部将确定特定的心血管结局声明补遗的批准是否需要临床数据获得批准。\n\n根据上述已知信息，请将'• Contact the appropriate division or office management officials for assistance in eliciting 438 a response from the project manager'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"联系相应部门或办公室管理人员，适用于帮助获得项目经理的回复"
    },
    {
        "instruction":"已知信息：\n'Article 188 Operations on different products should not be carried out simultaneously in the same room unless there is no risk of mixups or cross-contamination.'可被翻译为：第一百八十八条 不得在同一生产操作间同时进行不同品种和规格药品的生产操作，除非没有发生混淆或交叉污染的可能。\n'Article 206 Appropriate segregation or other precautions to effectively prevent contamination, cross-contamination or mixups should be adopted if several packaging lines are working simultaneously.'可被翻译为：第二百零六条 有数条包装线同时进行包装时，应当采取隔离或其他有效防止污染、交叉污染或混淆的措施。\n'Article 54: Premises or areas for the packaging of drugs should be reasonably designed and laid out, so as to avoid mixups or cross-contamination.'可被翻译为：第五十四条 用于药品包装的厂房或区域应当合理设计和 布局，以避免混淆或交叉污染。\n'Article 54 Premises or areas for the packaging of drugs should be reasonably designed and laid out, so as to avoid mixups or cross-contamination. Where several packaging lines are in the same area, there should be segregation in place.'可被翻译为：第五十四条 用于药品包装的厂房或区域应当合理设计和布局，以避免混淆或交叉污染。如同一区域内有数条包装线，应当有隔离措施。\n\n根据上述已知信息，请将'Article 188: Operations on different products should not be carried out simultaneously in the same room unless there is no risk of mixups or cross-contamination.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百八十八条 不得在同一生产操作间同时进行不同品 种和规格药品的生产操作，除非没有发生混淆或交叉污染的可能。"
    },
    {
        "instruction":"已知信息：\n'The percentage of the radioactive activity of a given radionuclide in the total radioactive activity of the product being tested.'可被翻译为：某一指定放射性核素的放射活度占供试品放射性总活度的百分比例。\n'A method of using phase solubility to accurately measure the purity of a substance.'可被翻译为：利用相溶解度来精确测量测定物质纯度的方法。\n'The action of two or more drugs is equal to the sum of the separate actions of each chemical compound.'可被翻译为：两种以上药物作用等于每一种化合物质单独作用的总和。\n'A force exerted in two directions on adjacent parts of the same object so that the two parts are displaced relative to each other in their respective directions of effort.'可被翻译为：由两方向施力于同一物体的相邻部分，使两部分沿各自的着力方向发生相对位移的力。\n\n根据上述已知信息，请将'A method of determining the content of radioactive compounds by dividing a sample into two equal parts, adding different amounts of the same chemical form of a non-radioactive compound, and then measuring the specific activity of each part by antidilution.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将样品分成等量的两部分，分别加入不同量的相同化学形式的非放射性化合物，然后用反稀释测量各部分的比放射性，由此测知放射性化合物含量的方法。"
    },
    {
        "instruction":"已知信息：\n'The action of two or more drugs is equal to the sum of the separate actions of each chemical compound.'可被翻译为：两种以上药物作用等于每一种化合物质单独作用的总和。\n'Mechanism of action for each drug in the combination'可被翻译为：联合药物中的每种药物的作用机理\n'Mechanisms of action or in vitro data of potential off-target effects of the individual drugs do not suggest a potential for additive or synergistic toxicity of a serious nature.'可被翻译为：个体药物的潜在脱靶效应的作用机制或体外数据没有暗示具有严重性质 的加和或协同毒性的可能性。\n'Claims of additive or synergistic efficacy would be required to be supported by specific efficacy data using the proposed combination.'可被翻译为：加成或者协同疗效主张将需要得到使用拟定联合治疗的特定疗效数据支持。\n\n根据上述已知信息，请将'The additive or synergistic effect produced by the combination of drugs with identical properties of action.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"作用性质相同药物的联合应用，产生的相加或协同效应。"
    },
    {
        "instruction":"已知信息：\n'For the medical device with the approval for registration renewal, periodic risk evaluation report of this registration period shall be completed when the application for next registration renewal is submitted, and shall be kept by MAHs for future reference.'可被翻译为：获得延续注册的医疗器械，应当在下一次延续注册申请时完成本注册周期的定期风险评价报告，并由持有人留存备查。\n'MAHs of innovative medical devices shall, within the first registration cycle, submit analysis, evaluation and summary report of product adverse event monitoring to national monitoring agency every half a year. In case of identifying any possible serious defects of a medical device, national monitoring agency shall promptly report to National Medical Products Administration.'可被翻译为：创新医疗器械持有人应当在首个注册周期内，每半年向国家监测机构提交产品不良事件监测分析评价汇总报告。国家监测机构发现医疗器械可能存在严重缺陷的信息，应当及时报国家药品监督管理局。\n'Article 30 Local provincial monitoring agencies where MAHs locate shall complete the review of evaluation results within 10 days upon the receipt of evaluation results from MAHs, and if necessary, may carry out on-site investigation on the adverse events that cause or possibly cause severe injuries or death by entrusting or cooperating with the provincial monitoring agencies where adverse events occur. For the medical devices approved by the NMPA to be registered, national monitoring agencies shall also re-check the evaluation review results by provincial monitoring agencies, and if necessary, may organize investigation on the adverse events causing death.'可被翻译为：第三十条  持有人所在地省级监测机构应当在收到持有人评价结果10日内完成对评价结果的审核，必要时可以委托或者会同不良事件发生地省级监测机构对导致或者可能导致严重伤害或者死亡的不良事件开展现场调查。其中，对于国家药品监督管理局批准注册的医疗器械，国家监测机构还应当对省级监测机构作出的评价审核结果进行复核，必要时可以组织对导致死亡的不良事件开展调查。\n'Article 29 After reporting medical device adverse events or knowing relevant medical device adverse events through the National Medical Device Adverse Events Monitoring Information System, MAHs shall carry out subsequent investigation, analysis and evaluation as required. The evaluation results of the events causing death shall be reported to local provincial monitoring agencies where MAHs locate within 30 days and the evaluation results of the events causing severe injuries or possibly causing severe injuries or death shall be reported to local provincial monitoring agencies where MAHs locate within 45 days. If the MAH has any new identification or notification of event information and evaluation results, it shall submit a supplementary report as required.'可被翻译为：第二十九条  持有人在报告医疗器械不良事件后或者通过国家医疗器械不良事件监测信息系统获知相关医疗器械不良事件后，应当按要求开展后续调查、分析和评价，导致死亡的事件应当在30日内，导致严重伤害、可能导致严重伤害或者死亡的事件应当在45日内向持有人所在地省级监测机构报告评价结果。对于事件情况和评价结果有新的发现或者认知的，应当补充报告。\n\n根据上述已知信息，请将'MAHs shall evaluate the identified adverse events, improve the product quality based on evaluation results and report the evaluation results and measures for quality assurance to monitoring agencies; where review and approval by the original registration authority is required, application shall be submitted in accordance with the regulations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"持有人应当对发现的不良事件进行评价，根据评价结果完善产品质量，并向监测机构报告评价结果和完善质量的措施；需要原注册机关审批的，应当按规定提交申请。"
    },
    {
        "instruction":"已知信息：\n'In specific cases it may be appropriate to contact the European Medicines Agency to discuss the issue during a pharmacogenetic briefing meeting or a Scientific Advice meeting.'可被翻译为：在特殊情况下，可以通过药理遗传学会议简报或者科学意见会议联系欧洲药品管理局讨论上述情况。\n'See also the guidance for industry Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants.'可被翻译为：另见行业指南《FDA与生物类似药生物制品开 发者或申办方的正式会议》。\n'• between pharmaceutical companies and regulatory authorities;'可被翻译为：● 制药公司和监管机构之间；\n'Appropriate dose response studies might need to be carried out, unless relevant information is already available.'可被翻译为：可能需要进行适当的剂量反应研究，除非已经获得相关信息。\n\n根据上述已知信息，请将'Companies developing biosimilars are invited to contact Regulatory Authorities in the EEA to obtain further advice on their development, whenever there is a need for more detailed information than provided in the guidelines already available.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如需更多指导原则规定以外的详细信息，开发生物类似物的公司可以和EEA的监管机构联络，进一步获取有关开发的建议。"
    },
    {
        "instruction":"已知信息：\n'For example, in studies investigating the activity of a compound targeting a specific, molecularly well-defined structure assumed to be pivotal for the condition(s), it might be possible to enrol patients with formally different histological diagnosis, but expressing this target.'可被翻译为：例如，在探讨以一种特异性的、假定对疾病关键的明确分 子结构为靶点的化合物的活性研究中，可能会招入组织学诊断不同但表达该靶点的患者。\n'If not pharmacologically justified, proper analyses of biopsies from accessible tumours (primaries and\/or metastatic lesions), are expected to constitute a pivotal role in studies undertaken to identify the proper target population for confirmatory studies.'可被翻译为：如果药理学上没有合理的理由，则期望对可取组织的肿瘤（原发性和\/或转移性病 变）的正确活检分析在进行确定验证性研究的合适目标人群的研究中起到举足轻重的作用。\n'The pivotal role of the target in different histological diagnoses, however, must be demonstrated. This should be addressed in clinical studies, but it is accepted that formal testing with adequate statistical power of such a hypothesis cannot always be done. Possible consequences with respect to selection of proper reference therapy(ies) must be considered and the study should be designed so that it is possible, based on all available evidence, including non-clinical and pharmacological data, to conclude on the benefit – risk in the different subgroups of patients for which a claim is to be made. Prior to the initiation of confirmatory studies using non-conventional criteria for eligibility, EU scientific advice should be sought.'可被翻译为：但是，必须阐释目标在不同组织学诊断中的关键作用。这应在临床研究中进行处理，但是通常认为无法通过此类假设的充分统计功效来开展正式测试。要求考虑有关选择适当的参照疗法的潜在后果，并要求设计研究，以便于有可能根据所有可用数据（包括非临床数据和药理数据）在提出要求的不同患者亚组中得出有关获益-风险的结论。 在使用非常规合格标准开始确证性研究之前，应向欧盟寻求获取科学建议。\n'The dose schedule selected for pivotal studies must be justified on the basis of the results of the dose-finding studies in the target population.'可被翻译为：必须根据在目标人群中开展的剂量确定研究的结果判定关键研究中所选的剂量方案。\n\n根据上述已知信息，请将'The pivotal role of the target in different histological diagnoses, however, must be demonstrated.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"但是，必须证明靶点在不同组织学诊断中的关键作用。"
    },
    {
        "instruction":"已知信息：\n'The duration of a study intended to demonstrate a clinically meaningful effect on relapses will depend on the activity of the population studied and in cases of a prevalent population with a milder disease course may need to last 3-years.'可被翻译为：一项以证明复发的临床意义的影响的研究将取决于研究人群的活动，一个普遍轻微患患者群的研究可能至少需要三年。\n'Study duration will depend on the selected endpoints.'可被翻译为：研究时长将取决于所选择的终点。\n'Consequently, confirmatory studies with products intended to modify the course of the disease should be of a large scale and of sufficient duration to allow for the evaluation of an effect on relapses and disability.'可被翻译为：因此，产品的确证性研究的目的是修复疾病进程，这是一个庞大的规模，需要的足够的时间， 以便对复发和残疾的效果进行评价。\n'In adolescents and adults the specified reliable informant will depend on the symptom and functional severity of the individuals being studied'可被翻译为：在青少年和成年人中，特定可靠的信息提供者将取决于所研究个体的症状和功能严重程度。\n\n根据上述已知信息，请将'Study duration will depend on the population studied, and should be sufficient to show a reliable and relevant effect on disability.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究持续时间将取决于所研究的人群，并应足以显示对残疾的可靠和相关治有效性应。"
    },
    {
        "instruction":"已知信息：\n'Although study treatment duration is expected to be at least six months, a shorter duration for the placebo arm may be acceptable.'可被翻译为：虽然预期研究治疗时间应至少持续6个月，但对于安慰剂组治疗时间短一点，也是可以接受的。\n'Other study duration for efficacy studies might be possible if appropriately justified.'可被翻译为：如果理由充分，疗效研究的持续时间也可调整。\n'Long INN names may be shortened.'可被翻译为：较长的INN名称可以缩减。\n'After the initial treatment period, an additional study period of at least 4 weeks should be added evaluating withdrawal and\/or rebound, which can be best addressed with a randomised withdrawal phase.'可被翻译为：在最初的治疗阶段之后， 还应增设一个至少 4 周的研究阶段来评估撤药和\/或反弹，最好有一个随机的撤药期。\n\n根据上述已知信息，请将'In case an efficacy study has to be conducted, the randomised treatment period may need to be shortened.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果要进行疗效研究，随机治疗阶段可能需要缩短。"
    },
    {
        "instruction":"已知信息：\n'Manufacturers can present process development information in a number of different ways, but some specific recommendations are provided below for consideration.'可被翻译为：生产企业可以用多种不同的方法呈现工艺开发信 息，以下建议可供考虑。\n'Manufacturers should follow the respective guidance'可被翻译为：生产商应该遵循各自的指导文件并加以申明。\n'42. In-process control: Checks performed during production in order to monitor and if necessary to adjust the process to ensure that the product conforms to its specification.'可被翻译为：（四十二）中间控制 也称过程控制，指为确保产品符合有关标准，生产中对工艺过程加以监控，以便在必要时进行调节而做的各项检查。\n'[Product specific: Clinical study results can be briefly summarised here]'可被翻译为：[产品特性：可以在这里简要总结临床研究结果]\n\n根据上述已知信息，请将'The manufacturers should adjust the recommendations presented here to their specific product and its production process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"制造商应根据其特定产品及其生产过程调整本文推荐的方案。"
    },
    {
        "instruction":"已知信息：\n'NMPA Announcement on Issuing the Classification Rules and Classification Catalogue of Cosmetics'可被翻译为：国家药监局关于发布《化妆品分类规则和分类目录》的公告\n'In order to implement the Provisions for Registration and Notification of Cosmetics and standardize and guide the registration and notification of cosmetics, the NMPA has developed the Rules for Registration and Notification Dossiers of Cosmetics, which is hereby issued and shall take effect as of May 1, 2021.'可被翻译为：为贯彻落实《化妆品注册备案管理办法》，规范和指导化妆品注册与备案工作，国家药监局制定了《化妆品注册备案资料管理规定》，现予公布，自2021年5月1日起施行。\n'In order to fully implement the Regulations on the Supervision and Administration of Cosmetics and standardize and guide the evaluation of efficacy claims of cosmetics, the NMPA has organized to formulate the Standard for the Evaluation of Efficacy Claims Cosmetics, which was issued on April 8 and shall take effect as of May 1, 2021.'可被翻译为：为贯彻落实《化妆品监督管理条例》，规范和指导化妆品功效宣称评价工作，国家药监局组织起草了《化妆品功效宣称评价规范》，于2021年4月8日予以公布，自2021年5月1日起施行。\n'In order to fully implement the Regulations on the Supervision and Administration of Cosmetics and standardize and guide the safety evaluation of cosmetics, the NMPA has organized to formulate the Technical Guidance for the Safety Evaluation of Cosmetics (2021 Edition), which was issued on April 8 and shall take effect as of May 1,2021.'可被翻译为：为贯彻落实《化妆品监督管理条例》，规范和指导化妆品安全评估工作，国家药监局组织起草了《化妆品安全评估技术导则（2021年版）》，于4月8日发布，自2021年5月1日起施行。\n\n根据上述已知信息，请将'In order to fully implement the Regulations on the Supervision and Administration of Cosmetics and standardize and guide the classification of cosmetics, the NMPA has formulated the Classification Rules and Classification Catalogue of Cosmetics, which was issued on April 8 and shall take effect as of May 1, 2021.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为贯彻落实《化妆品监督管理条例》，规范和指导化妆品分类工作，国家药监局制定了《化妆品分类规则和分类目录》，于2021年4月8日予以公布，自2021年5月1日起施行。"
    },
    {
        "instruction":"已知信息：\n'Manufacturing data and process knowledge can be used to support a design space for existing products. Relevant information should be utilised from e.g., commercial scale manufacturing, process improvement, CAPA and development data.'可被翻译为：生产数据和对工艺的认知可用于支持现有产 品的设计空间研究，应利用来自诸如商业化规模的生产、工 艺改进、CAPA和研发数据中的相关信息。\n'A design space that spans multiple unit operations can provide more operational flexibility.'可被翻译为：一个跨多个单元操作的设计空间可以提供更大的操作灵活性。\n'10.3 Example 3: Presentation of a Design Space for a Biotechnological Drug Substance Unit Operation This example is based on a design space for a drug substance purification unit operation (Q-anion exchange column run for a monoclonal antibody in flow-through mode), determined from the common region of successful operating ranges for multiple CQAs. This figure illustrates a potential depiction of a design space based on successful operating ranges for three CQAs and the use of prior knowledge (platform manufacturing) in developing a design space.'可被翻译为：10.3 案例3：生物技术原料药单元操作的设计空间体现 本案例是基于原料药纯化单元操作（采用穿流（flow- through）方式运行的单克隆抗体的Q阴离子交换柱）的设计 空间，该设计空间的建立是根据多个关键质量属性成功操作 范围的一般区域来确定的。该图基于三个关键质量属性的成 功操作范围和在设计空间开发过程中使用以前的知识（平台 制造），描述了潜在的设计空间。\n'Inspection should verify\/assess that manufacturing operations are appropriately carried out within the Design Space.'可被翻译为：检查应核实\/评估生产操作是在设计空间范围内进行 的。\n\n根据上述已知信息，请将'For manufacturing operations run under narrow operational ranges in fixed equipment, an expanded region of operation and an understanding of multi-parameter interactions may not be achievable from existing manufacturing data alone and additional studies may be needed to develop a design space.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于工艺参数范围较窄并固定设备的生产操作，仅用现 有的生产数据可能无法论证工艺参数操作范围的放大或了 解多参数之间的相互作用，可能需要进行其他研究来开发设 计空间。"
    },
    {
        "instruction":"已知信息：\n'One of the components of the pharmacopoeia is the section or reference material related to the drug standard. It includes general rules for preparations, general testing methods, and guidelines.'可被翻译为：药典的组成部分之一，是与药品标准相关的章节或参考资料。包括制剂通则、通用检测方法和指导原则等。\n'A Quality Manual or equivalent documentation approach should be established and should contain the description of the pharmaceutical quality system.'可被翻译为：应建立质量手册或同等的文件，（其中）应包含对药品质量体系的阐述。\n'APPENDICES The following appendices contain specifications related to various components referenced throughout this document.'可被翻译为：附录 以下附录包含与整个文件中参考的各种组分相关的规范。\n'Common methods for identifying metal ions (e.g., iron salts), inorganic anions (e.g., chlorides), or organic acid salts (e.g., salicylate) under the Pharmacopoeia Quality Standard for variety identification in the Pharmacopoeia Appendix.'可被翻译为：药典附录中对药典品种质量标准鉴别项下对金属离子(比如铁盐)、无机阴离子(比如氯化物)或水杨酸盐等有机酸盐进行鉴别试验的通用方法。\n\n根据上述已知信息，请将'One of the components of the pharmacopoeia that explains and uses the pharmacopoeia's basic guidelines for proper quality verification. Specify common issues related to the main body, appendices, and quality verification to avoid repetition throughout the book.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药典的组成部分之一，解释和使用药典正确进行质量检定的基本指导原则。把与正文、附录及质量检定有关的共性问题加以规定,避免在全书中重复说明。"
    },
    {
        "instruction":"已知信息：\n'Actions Taken in the Reporting Period for Safety Reasons'可被翻译为：报告周期内因安全性原因采取的措施\n'Actions Taken in the Reporting Interval for Safety Reasons'可被翻译为：在报告期内因安全性原因而采取的行动\n'(3) To revise a document that has been approved by the ethics committee, if the change has no impact on the subjects' rights and interests, safety and health, or the change is non-substantial to the purposes or endpoints of the clinical trial, reporting in advance is not required, although the changes shall be reported in writing afterwards;'可被翻译为：（三）对伦理委员会已批准文件的任何修订，不影响受试者权益、安全和健康，或者与临床试验目的或终点不相关的非实质性改变无需事前报告，但事后应当书面告知；\n'(5) Deviation from the clinical trial protocol that has an impact on the subjects' rights and interests, safety and health or clinical trial scientificity, including the request deviation and report deviation.'可被翻译为：（五）影响受试者权益、安全和健康或者临床试验科学性的临床试验方案偏离，包括请求偏离和报告偏离。\n\n根据上述已知信息，请将'In order to protect the subjects' rights and interests, safety and health, the deviation in emergency that cannot be reported in time shall be reported in writing in accordance with the relevant regulations as soon as possible afterwards.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为保护受试者权益、安全和健康，在紧急情况下发生的偏离无法及时报告的，应当在事后以书面形式尽快按照相关规定报告。"
    },
    {
        "instruction":"已知信息：\n'(ii) Public disclosure to the communities in which the clinical investigation will be conducted and from which the subjects will be drawn, prior to initiation of the clinical investigation, of plans for the investigation and its risks and expected benefits;'可被翻译为：ii. 在开始该项临床研究之前，向将在其中开展临床研究并从中招募受 试者的社区公开披露研究计划，以及研究风险和预期收益；\n'(iii) Public disclosure of sufficient information following completion of the clinical investigation to apprise the community and researchers of the study, including the demographic characteristics of the research population, and its results;'可被翻译为：iii. 该项研究完成后，必须向该研究的社区和其他研究者披露充分的信 息，包括该研究人群的人口统计学特征及其结果；\n'(i) Consultation (including, where appropriate, consultation carried out by the IRB) with representatives of the communities in which the clinical investigation will be conducted and from which the subjects will be drawn;'可被翻译为：i. 与将在其中开展临床研究并从中招募受试者的社区代表进行咨询活 动（根据情况，包括由IRB开展的咨询）；\n'If a protocol is changed, the sponsor, IRB, and clinical investigator may subsequently need to conduct additional community consultation or public disclosure activities to ensure that the communities in which the research will be conducted and from which subjects will be drawn are aware of the changes. 33.'可被翻译为：如果方案被变更，申办方、IRB和临床研究者可能需要随后 进行额外的社区咨询或公开披露活动，以确保将在其中开展研究并从中招募受试 者的社区了解这些变更。\n\n根据上述已知信息，请将'For example, the regulations require consultation with representatives of and public disclosure to the communities in which the clinical investigation will be conducted and from which the subjects will be drawn, prior to initiation of the clinical investigation. They also require public disclosure of sufficient information following completion of the clinical investigation to apprise the community and researchers of the study.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"例如，这些法规要求，在研究开始前，需要咨询将要从事研究和选取受试者的社区代表；在研究开始和直至完成必须公开披露信息，告知该社区和该项研究的研究者。"
    },
    {
        "instruction":"已知信息：\n'The presence of double bonds or rings in a molecule makes certain atoms or groups different in the direction and direction of space, resulting in different stereostructures.'可被翻译为：分子中存在双键或环，使某些原子或基团在空间的顺反向位不同，从而导致立体结构不同。\n'Stereoisomerism in a molecule with a double bond or ring structure, due to the obstruction of the free rotation of the atoms or groups connected to the double bond or ring in the molecule, there are different spatial arrangements resulting in a stereoisomerism.'可被翻译为：在有双键或环状结构的分子中，由于分子中与双键或环相连接的原子或基团的自由旋转受阻碍，存在不同的空间排列而产生的立体异构现象。\n'double bond'可被翻译为：双键\n'Because of the rotation of the single bond, the arrangement of the atoms or atomic groups connected to the carbon changes in space, so a compound of a structure may have a variety of conformations, and they are conformational isomers of each other.'可被翻译为：由于单键的旋转，使连接在碳上的原子或原子团在空间的排布位置随之发生变化，所以一种构造式的化合物可能有多种构象，它们之间互为构象异构体。\n\n根据上述已知信息，请将'When a double bond is present in the molecule or when the single bond cannot rotate freely due to steric hindrance, the relative distance and spatial arrangement of the substituents on two adjacent atoms may result in two geometric isomers, the same substituent on the same side of the double bond or fixed single bond.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当分子中存在双键或由于空间位阻使单键不能自由旋转时，相邻两个原子上的取代基的相对距离和空间排列情况可出现两种几何异构体，相同的取代基处于双键或固定单键同一侧的构象。"
    },
    {
        "instruction":"已知信息：\n'certificate of pharmaceutical product'可被翻译为：医药产品证书\n'2. A new template for the Certificate of a Pharmaceutical Product (see annex) will be put into use in line with China's pharmaceutical export practices and the latest World Health Organization guidelines. From Dec 1, 2022, all provincial-level drug regulatory authorities shall issue the Certificate of a Pharmaceutical Product in accordance with the new template.'可被翻译为：2.根据中国药品出口工作实践和世卫组织相关的最新指南，《药品出口销售证明》新模板（见附件）将投入使用。自2022年12月1日起，各省级药品监管部门应当按照更新后的模板签发《药品出口销售证明》。\n'1. From Dec 1, 2022, the electronic certificates of the Documentation for Export of APIs to EU and Certificate of a Pharmaceutical Product will be put into use. The electronic certificate and the paper version are equally authentic.'可被翻译为：1.自2022年12月1日起，对签发的《出口欧盟原料药证明文件》和《药品出口销售证明》启用电子证明。电子证明与纸质证明具有同等效力。\n'Template for product descriptions'可被翻译为：产品说明的模板\n\n根据上述已知信息，请将'Annex: The template for Certificate of a Pharmaceutical Product (2022 Edition)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"附件：《药品出口销售证明》模板（2022年版）"
    },
    {
        "instruction":"已知信息：\n'In these cases, monitoring for the drug substance or drug product degradation product in long term primary stability studies at the proposed storage conditions (in the proposed commercial pack) is expected unless otherwise justified.'可被翻译为：这种情况下， 除另有论述外，应监控拟定存贮条件下（拟定的商业包装）长期主要稳定性试验 中原料药或制剂中的降解。\n'However, it is strongly suggested that studies be conducted on the drug substance and drug product under accelerated and stress conditions. Studies under accelerated conditions may provide useful support data for establishing the expiration date, provide product stability information for future product development (e.g., preliminary assessment of proposed manufacturing changes such as change in formulation, scale-up), assist in validation of analytical methods for the stability program, or generate information which may help elucidate the degradation profile of the drug substance or drug product.'可被翻译为：然而，强烈建议在加速和强制破坏条件下对药物原液和制剂进行研究，因为加速条件研究可能为制定有效期提供有用的支持性数据，为产品的进一步开发提供稳定性依据（如：对配方、规模放大等生产工艺改变作初步评估），亦有助于验证稳定性试验方案中的分析方法或提供可能有助于阐明原 液或制剂降解的相关信息。\n'Based on the result of these accelerated studies, if it is anticipated that the degradation product will form at levels approaching the acceptable limit under the proposed packaging and storage conditions, then efforts to control formation of the degradation product is expected. In these cases, monitoring for the drug substance or drug product degradation product in long term primary stability studies at the proposed storage conditions (in the proposed commercial pack) is expected unless otherwise justified. Whether or not a specification limit for the mutagenic degradation product is appropriate will generally depend on the results from these stability studies.'可被翻译为：根据这些加速试验的结果，如预计降解产物将在拟定包装和储藏条件下形成，且接近可接受限度水平，则应采取措施控制降解产物的形成。这种情况下，除另有论述外，应在拟定储藏条件下（采用拟定的商业包装），监测用于确定有效期的长期稳定性批次原料药或制剂中的降解产物。该致突变降解产物的质量标准限度是否合理通常取决于这些稳定性研究的结果。\n'8.4 Control of Degradation Products For a potential degradation product that has been characterized as mutagenic, it is important to understand if the degradation pathway is relevant to the drug substance and drug product manufacturing processes and\/or their proposed packaging and storage conditions.'可被翻译为：降解产物的控制（8.4） 对于已经定性为具有致突变的潜在降解杂质，一定要了解该降解途径与原料 药和制剂的生产工艺和\/或其拟定的包装和存贮条件的相关性。\n\n根据上述已知信息，请将'Studies of the exposure of the drug substance or drug product to extreme conditions may help to reveal patterns of degradation; if so, such changes should be monitored under proposed storage conditions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"原液或制剂暴露于极端条件下的稳定性研究可能有助于揭示产品的降解形式，如有降解，则应在建议的贮藏条件下监测这些变化。"
    },
    {
        "instruction":"已知信息：\n'If the applicant meets the specified conditions, its application shall be approved according to law, and the Medical Device Manufacturing License shall be issued within 10 working days; if it does not meet the specified conditions, its application shall not be approved and the reasons shall be given in writing. In the meantime, the applicant shall be notified that it is entitled to apply for administrative reconsideration or administrative litigation according to law.'可被翻译为：符合规定条件的，依法作出准予许可的书面决定，并于10个工作日内发给《医疗器械生产许可证》；不符合规定条件的，作出不予许可的书面决定，并说明理由，同时告知申请人享有依法申请行政复议或者提起行政诉讼的权利。\n'If specified conditions are met upon review, renewal shall be granted, and the number of the renewed Medical Device Distribution License shall remain the same. If specified conditions are not met, rectification within a prescribed time limit shall be ordered; if specified conditions are still not met upon rectification, renewal shall not be granted, and the reasons shall be given in writing. If no decision is made within prescribed time limit, it shall be deemed that renewal is granted.'可被翻译为：经审查符合规定条件的，准予延续，延续后的医疗器械经营许可证编号不变。不符合规定条件的，责令限期整改；整改后仍不符合规定条件的，不予延续，并书面说明理由。逾期未作出决定的，视为准予延续。\n'If specified conditions are met upon review, renewal shall be granted, and the number of the renewed Medical Device Manufacturing License shall remain the same. If specified conditions are not met, rectification within a prescribed time limit shall be ordered; if specified conditions are still not met upon rectification, renewal shall not be granted, and the reasons shall be given in writing.'可被翻译为：经审查符合规定条件的，准予延续，延续的医疗器械生产许可证编号不变。不符合规定条件的，责令限期改正；整改后仍不符合规定条件的，不予延续，并书面说明理由。\n'Article 15 In case of changes in a Medical Device Distribution License, an change application in the Medical Device Distribution License shall be made to the former license issuing department, and relevant materials involving the change contents as stipulated in Article 10 of these Provisions shall be submitted. For changes in distribution premises, distribution mode, distribution scope and warehouse address, the drug regulatory department shall make a decision on whether granting the change or not within 20 working days upon the date of acceptance. When necessary, on-site inspection shall be carried out as required by the Good Supply Practice for medical devices.'可被翻译为：第十五条  医疗器械经营许可证变更的，应当向原发证部门提出医疗器械经营许可证变更申请，并提交本办法第十条规定中涉及变更内容的有关材料。经营场所、经营方式、经营范围、库房地址变更的，药品监督管理部门自受理之日起20个工作日内作出准予变更或者不予变更的决定。必要时按照医疗器械经营质量管理规范的要求开展现场核查。\n\n根据上述已知信息，请将'If specified conditions are met, a written decision on granting license shall be made, and the Medical Device Distribution License shall be issued within 10 working days; if specified conditions are not met, a written decision on not granting license shall be made, and the reasons shall be given.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"符合规定条件的，作出准予许可的书面决定，并于10个工作日内发给医疗器械经营许可证；不符合规定条件的，作出不予许可的书面决定，并说明理由。"
    },
    {
        "instruction":"已知信息：\n'Enhanced Parameter-Based Approach: • EC:'可被翻译为：基于强化研究的参数的方法： EC：\n'- Evidence to control the CQAs through the process parameter settings'可被翻译为：- 通过工艺参数设置控制CQAs的证据；\n'Enhanced Parameter-Based Approach'可被翻译为：基于强化研究的参数的方法\n'Minimal Parameter-Based Approach: • EC:'可被翻译为：基于基础研究的参数的方法 EC：\n\n根据上述已知信息，请将'Enhanced Parameter-Based Approach: • EC: CQAs have been identified and DoE studies for selected CQAs show that:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"基于强化研究的参数的方法： EC： 已经确定了CQA，对选定的CQA的DoE研究表明："
    },
    {
        "instruction":"已知信息：\n'NMPA CDE Announcement on Issuing the Guidance for Real-World Data Used to Generate Real-World Evidences (Interim)'可被翻译为：国家药监局药审中心关于发布《用于产生真实世界证据的真实世界数据指导原则（试行）》的通告\n'Considering the actual needs in research &development and registration of pediatric drugs, to help enterprises better understand the application of the Guidance for Real World Evidences Supporting Research &Development and Evaluation of Drugs(Interim) in research & development of pediatric drugs, upon the approval by the NMPA, CDE issued the Technical Guidance for Real-World Study Supporting Research& Development and Evaluation of Pediatric Drugs (Interim) , which shall come into force as of the date of issuance.'可被翻译为：考虑到我国儿童药物研发及药品注册中的实际需要，帮助企业更好地理解《真实世界证据支持药物研发与审评的指导原则（试行）》在儿童药物研发中的应用，在国家药品监督管理局的部署下，药审中心组织制定了《真实世界研究支持儿童药物研发与审评的技术指导原则（试行）》。自发布之日起施行。\n'To further guide and standardize the use of real-world evidence in drug R&D and review, and ensure the quality and efficiency of drug R&D, NMPA has organized the formulation of the Guidelines for Real-World Evidence to Support Drug Development and Review (Interim), which has been released on January 7, 2020.'可被翻译为：为进一步指导和规范真实世界证据用于支持药物研发和审评的有关工作，保障药物研发工作质量和效率，国家药品监督管理局组织制定了《真实世界证据支持药物研发与审评的指导原则（试行）》，并于2020年1月7日发布。\n'NMPA Issued the Announcement on the Guidelines for Real-World Evidence to Support Drug Development and Review (Interim)'可被翻译为：国家药监局发布关于支持《真实世界证据支持药物研发与审评的指导原则（试行）》的公告\n\n根据上述已知信息，请将'In order to further guide and regulate sponsors to use real-world data to generate real-world evidences to support drug R&D, the CDE has organized to formulate the Guidance for Real-World Data Used to Generate Real-World Evidences (Interim),which was issued for implementation on April 13 upon review and approval by NMPA.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为进一步指导和规范申办者利用真实世界数据生成真实世界证据支持药物研发，药审中心组织制定了《用于产生真实世界证据的真实世界数据指导原则（试行）》，经国家药品监督管理局审查同意，于4月13日发布实施。"
    },
    {
        "instruction":"已知信息：\n'The level of transgene expression, associated biological activity, and all factors associated with the proposed mechanism of action of the vector\/delivery system including maintenance of the therapeutic sequence in the target cell should be analysed.'可被翻译为：需要分析和生物活性相关的转基因表达水平、载 体\/传递系统行动的预期机制相关的所有因素，包括维持靶细胞中的治疗序列。\n'In vitro and in vivo studies performed to unravel the mechanism of action relating to the proposed therapeutic use (i.e. pharmacodynamic “proof of concept” studies) shall be performed using relevant animal species and models suitable to show that the nucleic acid sequence reaches its intended target (target organ or cells) and provides its intended function (level of expression and functional activity). The duration of the transgene expression and the therapeutic effect associated with the nucleic acid sequence and the proposed dosing regimen in the clinical studies shall be described.'可被翻译为：揭示与推荐治疗方式相关的反应机制的体外和体内研究， 应在适合展现核酸序列达 到预期靶向（靶器官或细胞） 且提供预期的功能（表达和功能活性的水平） 的相关动物物种和模型中进行。转基因表达的持续时间、与临床研究中核酸序列相关的治疗作用以 及推荐剂量方案需要说明。\n'As for any other medicinal products, the effects of co-medications should be investigated on a case by case basis since it can affect infection efficacy of the vector, therapeutic gene expression, biological activity of the expressed proteins and tissue distribution of the vector.'可被翻译为：与其它任何药品联合用药的作用需逐一进行研究， 因为它可能会影响载体的感染效 力、治疗基因的表达、表达蛋白质的生物活性以及载体的组织分布。\n'For viral vectors: these include, but are not limited to, the virus backbone, therapeutic transgene, regulatory sequences and helper-virus.'可被翻译为：● 病毒载体：包括但不仅限于病毒骨架、治疗转基因、调控序列以及辅助病毒。\n\n根据上述已知信息，请将'The in vitro biological activity of all transgene(s) and any other expressed sequences  should be determined.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应确认所有转基因 和其它任何表达序列的体内生物活性。"
    },
    {
        "instruction":"已知信息：\n'A randomised controlled trial (RCT) to prove superiority in inadequate\/non-responders to single (or multiple) active components of the FDC is required to demonstrate that the FDC has greater efficacy in comparison with the respective mono-components.'可被翻译为：在疗效不足或无效患者研究中，需要开展可证明FDC相对于单个（或多个）活性成分的优效性的随机对照试验（RCT），用以证明FDC比相应的单药成份更有效。\n'If the rationale is an improved efficacy in terms of greater clinical response compared to an initial therapy with one of the monocomponent(s) by the second monocomponents(s), an RCT is required and should demonstrate:'可被翻译为：如果其基本原理为增加疗效，即初始治疗的临床疗效高于某种单药成份及第 二种单药成份，那么需要开展随机对照试验，并且应表明：\n'In addition, the clinical trial should demonstrate improved safety of the FDC, utilising explicitly defined safety events as co-primary endpoint(s).'可被翻译为：此外，临床试验应证明FDC的安全性有所提高，即利用明确定义的安全性事件作为协同主要终点。\n'The clinical efficacy\/safety studies to support an FDC application for initial treatment will depend on the rationale of the FDC.'可被翻译为：支持FDC适用于初始治疗的临床疗效\/安全性研究将取决于FDC的基本原理。\n\n根据上述已知信息，请将'If the rationale is that the initial use of an FDC results in improved safety, an RCT should be performed to demonstrate'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果基本原理是首次使用FDC可以提高安全性，应开展随机对照试验来证明："
    },
    {
        "instruction":"已知信息：\n'Article 22 For drugs with special requirements on storage, its requirements shall be marked in the notable place of the label.'可被翻译为：第二十二条 对贮藏有特殊要求的药品，应当在标签的醒目位置注明。\n'9.42 Labels used on containers of intermediates or APIs should indicate the name or identifying code, the batch number of the product, and storage conditions, when such information is critical to assure the quality of intermediate or API.'可被翻译为：9.42 中间体或原料药容器上的标签应当注明与质量有关的关键信息，如产品名称、代码、批号及贮存条件。\n'10.23 The manufacturer should ensure that the contract acceptor (contractor) for transportation of the API or intermediate knows and follows the appropriate transport and storage conditions.'可被翻译为：10.23 生产企业应当确保原料药或中间体的运输方了解运输和贮存条件要求，并遵照执行。\n'The shelf life and special storage conditions of unstable laboratory reagents, solutions and culture media should be indicated on the label.'可被翻译为：不稳定的试剂、 试液和培养基应当标注有效期及特殊贮存条件。\n\n根据上述已知信息，请将'10.22 Special transport or storage conditions for an API or intermediate should be stated on the label.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"10.22 有特殊运输或贮存条件要求的原料药或中间体应当在其标签中注明。"
    },
    {
        "instruction":"已知信息：\n'The data may show so little degradation and so little variability that it is apparent from looking at the data that the requested re-test period will be granted. Under these circumstances, it is normally unnecessary to go through the formal statistical analysis; providing a justification for the omission should be sufficient.'可被翻译为：有时数据表明降解和变异非常小，则从数据上就可以明显看出所申请的复检期是合理的，这时通常不必进行正式的统计分析，只要提供省略的理由即可。\n'However, it may not be necessary to examine specifically for certain degradation products if it has been demonstrated that they are not formed under accelerated or long term storage conditions.'可被翻译为：但是，如果已经证明强力试验条件 下的某些降解产物不会在加速或长期放置条件下形成，则可不必对 该降解产物进行专门检查。\n'Data, other than those from formal stability studies, that support the analytical procedures, the proposed re-test period or shelf life, and the label storage statements.'可被翻译为：除了正式稳定性研究资料外，其他支持分析方法、复检期或货 架期和贮藏条件的试验数据。\n'Assessment of interaction terms based on statistical significance tests is therefore of little value.'可被翻译为：根据统计学显著性检验对交互作用项的评价价值不大。\n\n根据上述已知信息，请将'Where the data show so little degradation and so little variability that it is apparent from looking at the data that the requested shelf life will be granted, it is normally unnecessary to go through the formal statistical analysis; providing a justification for the omission should be sufficient.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"有时数据表明降解和变异非常小，以至于从数据上就可以明显看出所申请的货架期是合理的，这时通常不必进行正式的统计分析，只要提供省略的理由即可。"
    },
    {
        "instruction":"已知信息：\n'As described in section V.A.3.a, there should generally be no need to report unblinded study endpoints in an IND safety report. In many cases, an independent DMC would monitor the serious events that are study endpoints (see FDA’s guidance document on Establishment and Operation of Clinical Trial Data Monitoring Committees).10 If a sponsor has concerns that unblinding of adverse events will compromise the integrity of the study, the sponsor can propose in advance an alternative reporting format or frequency to maintain the blind that must be agreed to by the director of the review division in FDA with responsibility for review of the IND (21 CFR 312.32(c)(3)) (see section VI.A).'可被翻译为：按照V.A.3.a部分的描述，通常情况下，没有必要在IND安全报告中报告揭盲的研究终点。许多情况下，独立的DMC可以监控严重事件的研究终点（见FDA的指导原则文件“临床试验数据监测委员会的建立和运作”）。 如果申办者担心不良事件的揭盲会影响研究的完整性，申办者可以提前提出一个替代的报告格式或报告频率保持盲态，但必须得到负责IND审查的FDA审查部门主任的同意（21CFR 312.32（c）（3））（见VI.A部分）。\n'In general, if the blind is broken and a subject with an adverse event that would meet the criteria for reporting as a single event was receiving placebo, the event should not be reported in an IND safety report because there is not a reasonable possibility that the drug caused the adverse event. If the blind is broken and this subject was receiving drug treatment (test drug or active comparator), it must be reported in an IND safety report (21 CFR 312.32(c)(1)(i)(A)). For those adverse events that would not be reported unless an aggregate analysis indicated that they are occurring more frequently in the drug treatment group than in the placebo group, a determination that the adverse event is a suspected adverse reaction would require analysis and reporting of the event rates in both the drug-treatment and placebo groups.'可被翻译为：通常，如果揭盲后不良事件作为单一事件满足报告标准，且该受试者接受了安慰剂，因为药物造成该不良事件不具有合理可能性，所以该事件不能在 IND 安全性报告中进行报告。如果揭盲后这个受试者是接受药物治疗的（受试药物或阳性对照药），则必须在 IND 安全性报告中进行报告（21 CFR 312.32（c）（1）（i）（A））。对于不进行报告的不良事件，如果确定它们是可疑不良反应，需要对药品治疗组和安慰剂组中该事件的发生率进行分析和报告，但汇总分析表明这些事件在药物治疗组发生的频率高于安慰剂组的情况下除外。\n'The fact that an event is not identified in the protocol does not mean that the sponsor must report a single occurrence of the event expeditiously. The sponsor should use judgment in determining whether there is a reasonable possibility that the drug caused the event. Often, a single case will be unpersuasive. For example, in the osteoporosis trial previously described, a single case of acute narrow angle glaucoma would generally not be reported in an IND safety report because such cases are seen in an untreated elderly population, but if monitoring for subsequent cases revealed additional cases in the drug treatment group, the sponsor would consider the events to meet the definition of suspected adverse reactions at 21 CFR 312.32(a) and would report them expeditiously. However, FDA will accept expedited reports for individual cases of unexpected serious adverse events that are not study endpoints and are not specified in the protocol as “anticipated” (e.g., they are known consequences of the disease being treated or common in the study population) to address concerns expressed by sponsors about not expeditiously reporting such cases.'可被翻译为：实际上未在方案中明确的事件，不代表申办者必须将其按照单一发生的事件进行快速报告。申办者应该做出判断，确定药物对造成的事件是否具有合理的可能性。单一事例常常没有说服力。例如，在之前描述的骨质疏松症试验中，急性狭角青光眼的单一事例通常不会在 IND 安全性报告中报告，因为这些事件可见于未接受治疗的老年人群中，但是如果后续的监控表明在给药组出现了更多的事件，申办者会认为该事件满足可疑不良反应的定义（21 CFR 312.32（a））并将快速报告该事件。然而，FDA 会接受非研究终点的和未在方案中指定为“预期的”（例如，不良事件指的是正在治疗或研究人群中常见疾病的已知结果）非预期严重不良事件个体事例的快速报告，以解除申办者对于未快速报告这些事例产生的担忧。\n'(4) Blind trials (if any) are set up, kept blind and unblinded according to the requirements of the trial protocol; accidental unblinding or emergency unblinding due to SAE (serious adverse events) should be unblinded according to the emergency unblinding procedure and explained in writing by the investigator.'可被翻译为：（四）盲法试验(如涉及) 按照试验方案的要求设盲、保持盲态和实施揭盲； 意外破盲或因 SAE(严重不良事件) 等需紧急揭盲时， 研究者应按照紧急揭盲规程操作并书面说明原因。\n\n根据上述已知信息，请将'The blind should ordinarily be broken for IND safety reports submitted to FDA and all participating investigators. Knowledge of the treatment received is necessary for interpreting the event, may be essential for the medical management of the subject, and may provide critical safety information about a drug that could have implications for the ongoing conduct of the trial (e.g., monitoring, informed consent). The Agency does not believe that unblinding single or small numbers of serious and unexpected adverse event cases will compromise the integrity of the study, in part because such unblinding should be infrequent. For example, because the requirement under § 312.32(c)(5) specifically describes different reporting requirements for study endpoints, in a trial evaluating death, myocardial infarctions, and strokes as endpoints, a case of liver injury, if unblinded, would have no effect on overall study integrity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"提交给 FDA 和所有参与研究者的 IND 安全性报告通常应该进行破盲。接受治疗的知识对于解释相关事件是必须的，对于受试者的医疗管理也是很重要的，也可以提供对正在进行的试验产生影响的药品关键安全性信息（例如，监控、知情同意）。机构不相信揭盲单一或小数量的严重和非预期不良事件病例会破坏研究的完整性，部分原因是这种揭盲应该是很少发生的。例如，由于依据§ 312.32（c）（5）的要求特别描述了研究终点的不同的报告要求，在一项评估死亡、心肌梗死和中风作为终点的试验中，肝损伤的病例在揭盲后，不会对整体研究的完整性有影响。"
    },
    {
        "instruction":"已知信息：\n'• assign each standardised whole litter to a single dose group'可被翻译为：· 将每个标准化的整窝分配至单个剂量组\n'This can be achieved by how the study litters are constructed and standardised in combination with how the study litters are assigned to dose groups and how the individual pups are assigned to endpoint subsets.'可被翻译为：这可以通过如何构建和标准化试验窝，并结合如何将试验窝分配至不同剂量组，以及 如何将个体幼仔分配至终点指标亚组来实现。\n'The whole litter is then assigned to the same dose group so all 10 pups in a litter will be treated with the same dose.'可被翻译为：然后整窝幼仔被分配到相同的剂量组，所以一窝的所有10只幼仔都将被给予相同的剂量。\n'When assigning individual animals to endpoints in definitive studies, it is recommended that litter mates of the same sex not be assigned to the same endpoint to avoid maternal care biases (see Appendix C).'可被翻译为：在确定性试验中，当将个体动物分配至终点指标组时，为了避免母体护理偏差，建议不要将同性别的同窝幼仔分配至同一终点指标组（参见附录C）。\n\n根据上述已知信息，请将'For assigning study animals to dose groups, it is preferred that each standardised litter be assigned to a single dose group to minimise the risk for cross-contamination and to avoid treated and control offspring competing for suckling position and time.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于将试验动物分配至剂量组，首选将每一标准化窝分配至一个剂量组，以尽可能减少交叉污染的风险和避免给药组和对照组子代竞争哺乳位置和时间。"
    },
    {
        "instruction":"已知信息：\n'The development of combination therapies may be a beneficial approach.'可被翻译为：联合治疗开发可能是一种很利的方法。\n'Such agents may be used in conjunction with other supportive measures and\/or surgical procedures or as sole treatments.'可被翻译为：这样的药物可能用于联合其他支持性治疗手段和\/或外科操作或作为单独的治疗。\n'Typically this would require a trial in which the combination is compared to the two monotherapy arms and to placebo where appropriate.'可被翻译为：一般而言，将要求通 过一项试验将联用治疗分别与两个单药治疗组进行比较，如果适用也包括安慰剂。\n'Care should therefore be taken that both study arms include comparable numbers of patients of different ethnic background.'可被翻译为：因此应注意，两个研究臂中不同种族背景的患者人数应相似。\n\n根据上述已知信息，请将'Therefore, the inclusion ofmonotherapy arms in addition to the combination arms may be helpful to address this.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"因此，除联合治疗组外纳入单药治疗组可能有助于解决这一问题。"
    },
    {
        "instruction":"已知信息：\n'in summary, the nonclinical studies should include (1) a hERG assay, following best practice considerations (see ICH S7B Q&A 2), that shows low risk as defined in ICH S7B Q&As 1.1-1.2 and (2) no evidence of QTc prolongation in an in vivo assay conducted according to ICH S7B at exposures that cover high clinical exposures (see ICH S7B Q&As 1.1 and 3; note that some recommendations only apply to decision making under ICH Q&A 6.1). Decision-making Both the intersection-union test and the concentration-response analysis can estimate the maximum effect of a drug treatment on the QTc interval, but they are not used to test the same hypothesis.'可被翻译为：1；总而言之，非临床研究应包括：（1） 遵循最佳实践考虑的hERG检测（参见ICH S7B 问答2）显示出ICH S7B 问答1.1-1.2定义的低风险，以及（2）根据ICH S7B进行的体内试验中， 在暴露覆盖高临床暴露时，没有证据表明QTc延长（参见ICH S7B 问 答1.1和3；注意，一些建议仅适用于在ICH问题6.1下做出的决策）。 决策 交叉联合检验和浓度-反应分析都可以估计药物治疗对 QTc 间期的最 大影响，但它们不用于检验相同的假设。\n'When using a concentration-response analysis as the primary basis for decisions to classify the risk of a drug, the upper bound of the two-sided 90% confidence interval for the QTc effect of a drug treatment as estimated by exposure-response analysis should be <10 ms at the highest clinically relevant exposure to conclude that an expanded ECG safety evaluation during later stages of drug development is not needed. (See ICH E14, Section 2.2.4 and Q&A #7).'可被翻译为：当使用浓度-反应分析作为决定 药物风险分类决策的主要依据时，通过暴露-反应分析估计药物治疗的 QTc 效应，在最高临床相关暴露时，双侧 90%置信区间的上限应为<10ms，则可 得出药物开发的后期阶段不需要扩展的 ECG 安全性评价的结论。（见 ICH E14，第 2.2.4 节和问答#7）。\n'If nonclinical studies do not show low risk (or are not performed), there is reluctance to conclude a lack of an effect in an absence of a positive control; however, if the upper bound of the two-sided 90% confidence interval around the estimated maximal effect on ΔQTc is less than 10 ms, the treatment is unlikely to have an actual mean effect as large as 20 ms.'可被翻译为：如果非临床研究未显示出低风险（或未开展），则在没有阳性对照的情况下较 难得出缺乏效应的结论；然而，如果估计ΔQTc最大效应的双侧90%置信区间的上限 小于10ms，则该治疗不太可能具有高达20ms的实际平均效应。\n'2.Alternative QT clinical study designs incorporating ECG assessments with as many of the usual “thorough QT\/QTc” design features as possible (see ICH E14 Section 2.2 and Q&A 5.1).'可被翻译为：2. 替代性QT临床研究设计，结合了ECG评估和尽可能多的常规“全面QT\/QTc”设 计特征（参见ICH E14第2.2节和问答5.1）。\n\n根据上述已知信息，请将'The high-quality ECG data (see ICH E14 and E14 Q&A #1) collected in the alternative QT clinical assessment do not suggest QT prolongation, generally defined under this Q&A as an upper bound of the two-sided 90% confidence interval around the estimated maximal effect on ΔQTc less than 10 ms, as computed by the concentration-response analysis or the intersection-union test.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2. 在替代性QT临床评估中采集到的高质量ECG数据（参见ICH E14和E14问答 #1）未显示QT延长，在此问答中通常定义为，通过浓度-反应分析或交叉检验 计算，对ΔQTc估计最大效应的双侧90%置信区间上限小于10ms。"
    },
    {
        "instruction":"已知信息：\n'Article 6 The generic name of a medical device is composed of a core word and generally no more than three feature words.'可被翻译为：第六条 医疗器械通用名称由一个核心词和一般不超过三个特征词组成。\n'Article 5 The same generic name shall apply to medical devices in the same category with the same or similar intended use and common technologies.'可被翻译为：第五条 具有相同或者相似的预期目的、共同技术的同品种医疗器械应当使用相同的通用名称。\n'(8) Installation and use instructions or illustrations; medical devices intended for personal use shall also be attached with special instructions for safe use.'可被翻译为：（八）安装和使用说明或者图示，由消费者个人自行使用的医疗器械还应当具有安全使用的特别说明；\n'A set of devices having the same or similar intended purposes or commonality of technology allowing them to be classified in a generic manner not reflecting specific characteristics (13).'可被翻译为：具有相同或类似预期目的或技术共性的一组器械，允许它们以通用方式分类，而不反映特定特征(13)。\n\n根据上述已知信息，请将'The core word is a generalized expression for medical devices with the same or similar technical principles, structure or intended use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"核心词是对具有相同或者相似的技术原理、结构组成或者预期目的的医疗器械的概括表述。"
    },
    {
        "instruction":"已知信息：\n'ICH: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use'可被翻译为：ICH: 国际人用药品注册技术要求协调会\n'INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE'可被翻译为：国际人用药品注册技术要求协调会（ICH）\n'INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE'可被翻译为：E6(R1) 人用药品注册技术要求 国际协调会\n'International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use'可被翻译为：国际人用药品注册技术要求协调会\n\n根据上述已知信息，请将'ICH The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human use'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国际人药技术协调委员会"
    },
    {
        "instruction":"已知信息：\n'Even when the design and conduct of a trial appear to have been quite similar to those of the trials providing the basis for determining the non-inferiority margin, outcomes with the active control treatment that are visibly atypical (e.g., cure rate in an antibiotic trial that is unusually high or low) can indicate that important differences existed.'可被翻译为：即便试验的设计和实 施似乎与确定非劣效界值的基准试验十分类似，活性对照组 结果却明显异常（如，抗生素试验的治愈率异常的高或低） 则可提示存在重要的差异。\n'The margin generally is identified based on past experience in placebo- controlled trials of adequate design under conditions similar to those planned for the new trial, but could also be supported by dose response or active control superiority studies.'可被翻译为：界值往往是根据既往在与计划的新试验相 似的条件下、经过恰当设计的安慰剂对照试验的经验来确定 的，但也可以通过剂量反应或活性对照的有效研究获得。\n'The determination of the margin in a non-inferiority trial is based on both statistical reasoning and clinical judgment, should reflect uncertainties in the evidence on which the choice is based, and should be suitably conservative.'可被翻译为：界值的确定要根据统计学推理和临床判断，要反映出使 用证据的不确定性，而且应当适当保守。\n'1.5.1.1 Historical Evidence of Sensitivity to Drugs Effects and Choosing the Non-inferiority Margin'可被翻译为：1.5.1.1 药效灵敏度的历史性证据和非劣效界值的选择\n\n根据上述已知信息，请将'The fact that the choice of the margin to be excluded is based on historical evidence gives the non-inferiority trial an element in common with a historically controlled (externally controlled) trial.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"界值的选定只有根据以往的经验这一事实，说明非劣效 性试验与历史性对照(外部对照)试验有一个共同的要素。"
    },
    {
        "instruction":"已知信息：\n'A) Premating to conception (adult male and female reproductive functions, development and maturation of gametes, mating behavior, fertilization).'可被翻译为：A）从交配前至受孕（成年雄性和雌性生殖功能、配子的发育和成熟、交配行为、受精）。\n'C) Implantation to closure of the hard palate (adult female reproductive functions, embryonic development, major organ formation).'可被翻译为：C）从着床至硬腭闭合（成年雌性生殖功能、胚胎发育、主要器官形成）。\n'The combination of studies selected should allow exposure of mature adults and all stages of development from conception to sexual maturity. To allow detection of immediate and latent effects of exposure, observations should be continued through one complete life cycle, i.e. from conception in one generation through conception in the following generation. For convenience of testing this integrated sequence can be subdivided into the following stages. \nA. Premating to conception (adult male and female reproductive functions, development and maturation of gametes, mating behavior, fertilisation). \nB. Conception to implantation (adult female reproductive functions, preimplantation development, implantation). \nC. Implantation to closure of the hard palate (adult female reproductive functions, embryonic development, major organ formation). \nD. Closure of the hard palate to the end of pregnancy (adult female reproductive functions, fetal development and growth, organ development and growth). \nE. Birth to weaning (adult female reproductive functions, neonate adaptation to extrauterine life, preweaning development and growth). \nF. Weaning to sexual maturity (postweaning development and growth, adaptation to independent life, attainment of full sexual function).'可被翻译为：联合进行所选的多项生殖毒性研究时，应注意在动物成年期和从受孕到幼仔性成熟的发育各阶段给药。为测定出给药所致的速发和迟发效应，其观察应持续一个完整的生命周期，即从某一代的受孕到其下一代受孕间的时间周期。为方便测试，可将生命周期的这一完整过程分成以下几个阶段：\nA. 从交配前到受孕（成年雄性和雌性生殖功能、配子的发育和成熟、交配行为、受精）。\nB. 从受孕到着床（成年雌性生殖功能、着床前发育、着床）。\nC. 从着床到硬腭闭合（成年雌性生殖功能、胚胎发育、主要器官形成）。\nD. 从硬腭闭合到妊娠终止（成年雌性生殖功能、胎仔发育和生长、器官发育和生长）。\nE. 从出生到离乳（成年雌性生殖功能、幼仔对宫外生活的适应性、离乳前发育和生长）。\nF. 从离乳到性成熟（离乳后发育和生长、独立生活的适应能力、达到性成熟的情况）。\n'The FEED study design in female rodents (see Annex 1) allows for the detection of effects on the estrous cycle, tubal transport, implantation, and development of preimplantation stages of the embryo.'可被翻译为：雌性啮齿类动物的FEED试验设计（见附件1）可检测给药对动情周期、输 卵管运输、着床和胚胎着床前阶段发育的影响。\n\n根据上述已知信息，请将'B) Conception to implantation (adult female reproductive functions, preimplantation development, implantation).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"B）从受孕至着床（成年雌性生殖功能、着床前发育、着床）。"
    },
    {
        "instruction":"已知信息：\n'However, an immune response against a therapeutic product is a result of many factors and thus, conclusions on potential impact of the concomitant immuno-modulating medication are not straightforward.'可被翻译为：然而，抗治疗产品的免疫应答是多种因素综合作用的结果，因此伴随免疫调节药物的潜在影响之相关结论不是直接明了的。\n'A patient’s underlying disease can be an important factor in the context of developing an unwanted immune response.'可被翻译为：在出现不良免疫应答的背景下，患者的基础疾病是一个重要因素。\n'4. Patient- and disease-related factors'可被翻译为：4. 患者和疾病相关因素\n'4.1. Patient- and disease-related factors'可被翻译为：4.1. 患者和疾病相关因素\n\n根据上述已知信息，请将'These products may induce unwanted immune responses, which can be influenced by various factors, including patient- and disease-related factors as well as product-related factors.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这些产品可能诱导不良免疫应答，并且受到多种因素的影响，包括患者和疾病相关因素以及产品 相关因素。"
    },
    {
        "instruction":"已知信息：\n'MRCTs may enable simultaneous submission of marketing authorisation applica- tions and support regulatory decision-making in multiple regions, allowing earlier access to new drugs worldwide.'可被翻译为：MRCT可在多个 区域同步递交上市许可申请，支持监管决策，使新药能够 及早在世界各地上市。\n'Although MRCTs may generally become the preferred option for investigating a new drug for which regulatory submission is planned in multiple regions, the potential for regional differences to impact the interpretability of study results should be carefully considered. 2.'可被翻译为：尽管MRCT通常可作为计划在多个区 域监管递交的新药研究首要选择，但应仔细考虑区域差异 影响研究结果可解释性的可能性。\n'Figure 1. Illustrations of clinical drug development workflow across regions for drug submission and regulatory review in independent and global strategies \n*: Marketing Authorization Application\/New Drug Application \n**: Could be parallel single region trials or MRCTs \nIt may be plausible and efficient for an MRCT to be the single pivotal trial to support regulatory submission, and if this is the case, it should be designed to provide sufficient and robust evidence to support approval.'可被翻译为：图1. 在独立和全球策略中，各区域用于药物递交和监管审查的临床药 物研发工作流程说明 \n*:上市许可申请\/新药申请 \n**:可能是平行单区域试验或MRCT \nMRCT作为支持监管递交的单个关键试验可能是合理、有效的， 此时应该设计成可以提供充分可靠证据的试验来支持获批。\n'The premise of scientific evaluation of clinical trial data is that clinical trials are carried out in accordance with the internationally accepted GCP and the clinical trial data shall be authentic, accurate, complete and traceable. The applicant can provide the drug evaluation authority with relevant documents or materials that prove the quality of clinical trial data for supporting marketing application. Verification results and conclusions of regulatory authorities of foreign countries with management practice can be taken as the references for quality evaluation of clinical trial data. China's drug regulatory authorities should conduct necessary verification of the clinical trial data for supporting marketing registration in China based on risks.'可被翻译为：科学评价临床试验数据的前提是，临床试验按照国际通行GCP开展，临床试验数据应具有真实性、准确性、完整性和可溯源性。申请人可向药品审评部门提供证明支持其上市申请的临床试验数据质量的相关文件或资料。境外管理规范国家的监管机构核查结果和结论可作为临床试验数据质量评估的参考。中国药品监管机构基于风险对用于支持在中国境内注册上市的临床试验数据进行必要的核查。\n\n根据上述已知信息，请将'With the increasing globalisation of drug development, it has become important that data from multi-regional clinical trials (MRCTs) can be accepted by regulatory authorities across regions and countries as the primary source of evidence, to support marketing ap- proval of drugs (medicinal products).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"随着药物研发日益全球化，不同区域和国家监管机构能够接 受多区域临床试验（Multi-Regional Clinical Trials, MRCT） 数据作为支持药物（医药产品）批准上市的主要证据来源已经变得 很重要。"
    },
    {
        "instruction":"已知信息：\n'The factors considered in the safety assessment for establishing the PDE are listed below in approximate order of relevance:'可被翻译为：在确定PDE值的安全性评估中所需考虑的因素，依大致相关性排序如下：\n'Where appropriate, these standards were considered in the safety assessment and establishment of the PDEs.'可被翻译为：在适当的时候，可以考虑采用这些标准来进行安全性评估和确定PDE。\n'3. Tabular Summary of Safety Signals (if not included in the body of the report);'可被翻译为：3. 安全性信号的总结表（如果没有被包括在报告正文中）；\n'Some considerations for identifying factors that are critical to the quality of a study are provided in Section 7.'可被翻译为：第7节提供了对确定研究中关键质量因 素的一些考虑事项。\n\n根据上述已知信息，请将'A summary safety assessment identifying the critical study for setting a PDE for each element is included in Appendix 3.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"附录3包含了确定各元素PDE的关键研究的安全性评估总结。"
    },
    {
        "instruction":"已知信息：\n'Certain applications of color coding are appropriate. Examples include the color coding of  certain drug product strengths such as warfarin, levothyroxine, and conjugated estrogen-  containing products.'可被翻译为：颜色编码的某些应用是恰当的，比如对特定药品规格进行颜色编码，如含华法林，甲状腺素，和共轭雌激素产品。\n'In fact, the color  coding has made it difficult for these users to differentiate between drugs within the same therapeutic class when the color code was used on the container label and carton labeling.  Because these products are typically stored near each other, the similar appearance of the  container labels and carton labeling has led to dispensing and administering the wrong strength,  wrong dose, and wrong product.'可被翻译为：事实上，当颜色编码被 应用在容器标签和纸盒标识上时，用户更难区分同一治疗类别的不同药物。因为这 些药物通常都存储在彼此附近，容器标签和纸盒标识的相似造成了错误规格，错误 剂量和错误药品的分发和配给。\n'Errors can also occur when the  color code is not meaningful to end users outside the limited environment where the color coding  has an established use (e.g., Broselow Tape in the emergency room, and user-applied, color-  coded labels in the operating room).'可被翻译为：在特定环境中，颜色编码是有着确定的用法的（如，急诊室里的Broselow 测 量带和手术室里用户适用的颜色编码标签），但颜色编码对于特定环境之外的终端 用户没有意义，此时也会造成错误。\n'b. Color Coding  Color coding is a technique that uses color to designate a specific meaning.'可被翻译为：b. 颜色编码 颜色编码是一种使用颜色来指定特定含义的技术。\n\n根据上述已知信息，请将'Color coding is reserved for special circumstances and only after human factors testing and feedback on the prototype from all end  users is received and evaluated by FDA prior to use. The use of color coding on drug labels has been limited and not without risk.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"颜色编码是留到特殊情况下才使用的，并且只有经过对所有终端用户进行对原形的人为因素测试和反馈，且结果被FDA收集到 和评价后才可使用。药品标签上颜色编码的使用已被限制，并且是有风险的。"
    },
    {
        "instruction":"已知信息：\n'However, the ERA dossier may consist of an adequate justification for the absence of specific study data.'可被翻译为：然而，ERA卷宗可能包含没有特定研究数据的充分理由。\n'Important limitations of these studies can include a lack of clinical outcome data or information of the indication for use of a product.'可被翻译为：这些研究的主要局限包括缺少临床结局数据或用药指征的资料。\n'Absence of endoscopy may thus be acceptable with justification.'可被翻译为：可能因此被证实可不进行内窥镜检查。\n'3 Is it acceptable to demonstrate the absence of analytical interference of the IS itself, any impurities or its isotopic stability based on the analytical results of the zero sample?'可被翻译为：3 是否可接受根据零浓度样品的分析结果 证明IS本身、任何杂质或其同位素稳定 性不存在分析干扰？\n\n根据上述已知信息，请将'This may reflect the absence of any data or the absence of studies of acceptable quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这可能反映没有任何数据，或者没有质量可接受的研究。"
    },
    {
        "instruction":"已知信息：\n'If the response is by telephone, CDER or CBER should follow up with a written confirmation within 14 calendar days of the verbal notification.'可被翻译为：如果回应是致电形式，那么CDER或CBER应在口头通知的14个日历日内以书面形式予以确认。\n'The deciding official should respond to the sponsor within the 30-day window in writing or by telephone (i.e., 30-day response).'可被翻译为：决策官员应在这个30天的窗口内以书面或致电形式向申办方作出回应（即，30-天回应）。\n'If the meeting is granted, the deciding official should provide an interim response or a decision on the FDRR within 30 calendar days of the meeting date.'可被翻译为：如果准予了会议要求，决策官员应在会议日期的30个日历日内就该项FDRR给出临时回应或作出决定。\n'The deciding official should provide an interim response or a decision on the appeal within 30 calendar days from receipt of the information to the sponsor’s application. In instances when the deciding official decides a meeting with the sponsor is needed before a response can be issued, a meeting request should be sent within 30 calendar days from receipt of the FDRR.'可被翻译为：决策官员应在收到申办方申请信息的30个日历日内就该项上诉给出临时回应或作出决定。如果决策官员决定需与申办方举行会议才可发布回应，则应在收到该 FDRR的30个日历日内发出这一会议要求。\n\n根据上述已知信息，请将'If the response is by telephone, the deciding official should follow up with a written confirmation within 14 calendar days of the verbal response.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果回应是致电形式，那么该决策官员应在口头回应的14个日历日内以书面形式予以确认。"
    },
    {
        "instruction":"已知信息：\n'A subdiscipline of toxicology that developed out of immunology and toxicology. The study of the harmful effects of foreign chemicals and physical factors on the body's immune system and their mechanisms.'可被翻译为：在免疫学和毒理学基础上发展起来的一个毒理学分支学科。主要研究外源化学物质和物理因素对机体免疫系统的有害作用及其机制。\n'hematotoxicology'可被翻译为：血液毒理学\n'The discipline that studies the characteristics and mechanisms of the damaging effects of foreign chemicals on the kidney by using the basic methods and techniques of toxicology.'可被翻译为：利用毒理学的基本方法和技术，研究外源化学物对肾脏的损害作用特点及其机制的学科。\n'Under the guidance of the basic theories of traditional Chinese medicine and the use of modern scientific methods, the study of the interaction and laws between traditional Chinese medicine and the body.'可被翻译为：以中医药基本理论为指导，运用现代科学方法，研究中药和机体相互作用及规律的学科。\n\n根据上述已知信息，请将'An interdisciplinary study of the toxic effects of drugs, nontherapeutic chemicals, and other environmental factors on blood and hematopoietic tissue. It is a synthesis of the basic theories of traditional hematology and toxicology.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究药物、非治疗性化学物和其他环境因素对血液和造血组织产生毒害效应的一门交叉学科。是综合了传统血液学和毒理学的基本理论而形成的。"
    },
    {
        "instruction":"已知信息：\n'NOTES Note 1 The ICH M7 Guideline recommendations provide a state-of-the-art approach for assessing the potential of impurities to induce point mutations and ensure that such impurities are controlled to safe levels so that below or above the ICH Q3A\/B qualification threshold no further qualification for mutagenic potential is required.'可被翻译为：注解 注 1 ICH M7 指南中的建议提供了一种最先进的方法来评估杂质诱发点突变 的可能性，保证这样的杂质被控制在安全水平，以至于在低于或高于 ICH Q3A\/B 质控限度时无需进一步界定致突变可能性。\n'Note 1 The ICH M7 Guideline recommendations provide a state-of-the-art approach for assessing the potential of impurities to induce point mutations and ensure that such impurities are controlled to safe levels so that below or above the ICH Q3A\/B qualification threshold no further qualification for mutagenic potential is required. This includes the initial use of (Q)SAR tools to predict bacterial mutagenicity. In cases where the amount of the impurity exceeds 1 mg daily dose for chronic administration, evaluation of genotoxic potential as recommended in ICH Q3A\/B could be considered. In cases where the amount of the impurity is less than 1 mg, no further genotoxicity testing is required regardless of other qualification thresholds.'可被翻译为：注1 ICH M7指导原则中的建议提供了一种目前最先进的方法来评估杂质诱发点突变的可能性，保证这样的杂质被 控制在安全水平，从而在低于或高于ICH Q3A\/B质控限度时无需进一步界定致突变可能性。该方法包括预先使用（Q） SAR工具来预测细菌致突变性。如果在长期给药时该杂质日 摄入量超出1mg，应按照ICH Q3A\/Q3B的建议考虑进行潜在遗传毒性评估。如果该杂质日摄入量少于1mg，无论其它质控限度如何，都无需进行进一步的遗传毒性检测。\n'Implementation of M7 is encouraged after publication; however, because of the complexity of the guideline, application of M7 is not expected prior to 18 months after ICH publication.'可被翻译为：鼓励M7公布后立即实施；但是，由于本指导原则的复杂性，因此预计M7在ICH公布18个月后予以执行。\n'ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC) IMPURITIES IN PHARMACEUTICALS TO LIMIT POTENTIAL CARCINOGENIC RISK M7'可被翻译为：M7 评估和控制药物中DNA反应性（致突变）杂质以限制潜在的致 癌风险 行业指南\n\n根据上述已知信息，请将'Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk 26 Implementation of Guideline: Implementation of M7 is encouraged after publication; however, because of the complexity of the guideline, application of M7 is not expected prior to 18 months after ICH publication.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"指南实施： 鼓励M7 公布后即行实施；但是，由于本指南的复杂性，因此预计M7在 ICH 公布18个月后予以执行。"
    },
    {
        "instruction":"已知信息：\n'For novel products requiring a PUP study, the lack of data in PUPs should be indicated through a statement in 4.2 Posology and method of administration (see core SmPC), until data from 20 PUPs investigated for efficacy and safety are available.'可被翻译为：对于需要进行 PUP 研究的新 产品，在得到 20 名 PUP 的疗效和安全性数据前，应通过 4.2 给药剂量和方法（见核心SmPC）中的声明来说明。\n'For novel factor VIII  products where a PUP study is required, the PUP study should start prior to marketing authorisation  and the lack of data in PUPs should be indicated through a statement in. Posology and method of  administration (see core SmPC), however, PUPs will be excluded from the indication until data from 4.2  investigated for efficacy and safety are available.'可被翻译为：对于需要 开展PUP临床试验的新因子VIII制品来说，PUP临床试验要在上市申请前开展然而并且在获得 50 名PUP的疗效和安全性数据前，须在 4.2节剂量学和给药方法的声明（详见核心SmPC）中指出缺少PUP数据，PUP将会从适应人群删除\n'[Product specific – see clinical guideline for further details]'可被翻译为：[产品特性—更详细内容见临床指导原则]\n'[Product specific: Clinical study results can be briefly summarised here]'可被翻译为：[产品特性：可以在这里简要总结临床研究结果]\n\n根据上述已知信息，请将'[Product specific for products where a study in PUPs is required but results are not yet available – see clinical guideline for further details:]'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"[要求进行PUP研究但仍未获得结果的产品的产品特性-更详细内容见临床指导 原则：]"
    },
    {
        "instruction":"已知信息：\n'Superiority of the combination to MTX alone has to be shown and needs to be clinically meaningful.'可被翻译为：必须证明联合疗法相对于单独MTX的优效性，并且需要 具有临床意义。\n'If the experimental agent (A) is added to an established regimen (B), superiority of AB vs. B should be demonstrated and benefit-risk should be shown to be favourable.'可被翻译为：如果向一种已经确定的治疗方案（B）中添加实验性药物（A），应证明AB对B的 优效性，而且获益-风险应显示为是有利的。\n'If patients with increased risk of efficacy failure to TKIs are identifiable at baseline, it is foreseen that add-on studies with a non-TKI that is active in patients with CML may be undertaken. Superiority should be demonstrated comparing the combination regimen with a single TKI. In studies exploring the combination of two TKI the potential of additive toxicity should be fully addressed.'可被翻译为：如果在基线时可以识别出TKI治疗失败的风险更高的患者，】能会进行在一种对CML患者有活性的非TKI的基础上附加其它药物的研究。应证明联合用药相对于单用TKI 更优。在探索两种TKI联用的研究中，应该充分阐明联用时毒性增加的可能性。\n'If one of the components is regarded as an acceptable treatment regimen in monotherapy, a randomised phase II study comparing the monotherapy regimen with the combination is informative.'可被翻译为：如果认为一个组成成分是单药治疗的可接受治疗方案，那么与联合治疗比较单药治 疗方案的随机II期研究就是有用的。\n\n根据上述已知信息，请将'Superiority should be demonstrated comparing the combination regimen with a single TKI.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应证明联合用药相对于单用 TKI 更优。"
    },
    {
        "instruction":"已知信息：\n'8. All quality-related returns, complaints, recalls and the investigations;'可被翻译为：8.所有因质量原因造成的退货、投诉、召回及调查；\n'8. All quality-related returns, complaints, recalls and the investigations;'可被翻译为：（八）所有因质量原因造成的退货、投诉、召回及调查；\n'2.50 Regular quality reviews of APIs should be conducted with the objective of verifying the consistency of the process. Such reviews should normally be conducted and documented annually and should include at least: \n− A review of critical in-process control and critical API test results; \n− A review of all batches that failed to meet established specification(s);\n− A review of all critical deviations or non-conformances and related investigations; \n− A review of any changes carried out to the processes or analytical methods; \n− A review of results of the stability monitoring program; \n− A review of all quality-related returns, complaints and recalls; and \n− A review of adequacy of corrective actions.'可被翻译为：2.50 应当对原料药定期进行质量回顾，以确认工艺稳定可靠。通常，应当每年进行一次回顾并形成文件，至少应当包括： \n- 回顾关键中间控制点及原料药关键检验结果； \n- 回顾所有不符合质量标准的批次； \n- 回顾所有重大偏差或不符合情形及其相关调查； \n- 回顾所有生产工艺或检验方法等的变更； \n- 回顾稳定性考察的结果；\n- 回顾所有质量相关的退货、投诉和召回； \n- 回顾纠正措施的充分性。\n'17.70 Agents, brokers, traders, distributors, repackers, or relabellers should maintain records of complaints and recalls, as specified in Section 15, for all complaints and recalls that come to their attention.'可被翻译为：17.70 代理商、中间商、贸易商、经销商、分包装商或重新贴签方应当按照第15章中的要求保存收到的所有投诉和召回记录。\n\n根据上述已知信息，请将'(viii) A review of all quality-related returns, complaints and recalls and the investigations performed at the time;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（七）对所有与质量相关的退货、投诉和召回以及当时进行的调查进行回顾；"
    },
    {
        "instruction":"已知信息：\n'For those who have the manufacturing conditions of children's skin care and eye care cosmetics shall be specially indicated in the manufacturing licensed items.'可被翻译为：具备儿童护肤类、眼部护肤类化妆品生产条件的，应当在生产许可项目中特别标注。\n'Article 36 Cosmetics for children shall comply with requirements for quality and safety of cosmetics for children in laws, regulations, mandatory national standards, technical specifications, and Good Manufacturing Practice for Cosmetics, etc., and shall be indicated on the product label as specified by the NMPA.'可被翻译为：第三十六条 供儿童使用的化妆品应当符合法律、法规、强制性国家标准、技术规范以及化妆品生产质量管理规范等关于儿童化妆品质量安全的要求，并按照国家药品监督管理局的规定在产品标签上进行标注。\n'Article 38 The registrant, the filing entity and the contract manufacturer of cosmetics shall take measures to avoid the product character and appearance, etc. from being confused with food, drug and other products, so as to prevent being eaten or used by mistake.'可被翻译为：第三十八条 化妆品注册人、备案人、受托生产企业应当采取措施避免产品性状、外观形态等与食品、药品等产品相混淆，防止误食、误用。\n'Article 144 Business premises shall be equipped with appropriate facilities or other effective measures shall be taken to prevent drugs from being affected by the outdoor environment, and the premises shall also be spacious, bright, clean and hygienic.'可被翻译为：第一百四十四条 营业场所应当具有相应设施或者采取其他有效措施，避免药品受室外环境的影响，并做到宽敞、明亮、整洁、卫生。\n\n根据上述已知信息，请将'In the manufacturing and sale of toys and utensils, etc. for juveniles, the precautions shall be indicated according to law, and measures shall be taken to prevent the products from being used as cosmetics for children by mistake.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"生产、销售用于未成年人的玩具、用具等，应当依法标明注意事项，并采取措施防止产品被误用为儿童化妆品。"
    },
    {
        "instruction":"已知信息：\n'Sponsors should ensure that the data submitted in support of the proposed protocol are current, complete, and accurate, because any change in the underlying data, assumptions, and information could affect the assessment of the protocol and the resulting recommendations and\/or SPA agreement. For animal carcinogenicity protocols, review staff will present their assessment to the Executive Carcinogenicity Assessment Committee (ECAC).'可被翻译为：申办方应确 保递交的支持提议方案的数据是最新的、完整的和准确的，因为基础数据、假设 和信息的任何更改都可能影响方案的评估以及由此产生的建议和\/或SPA同意。 对于动物致癌性方案，审核人员将向执行致癌性评估委员会（ECAC）提出 评估。\n'A. Animal Carcinogenicity Protocols'可被翻译为：A. 动物致癌性方案\n'Animal carcinogenicity protocols.'可被翻译为：动物致癌性方案。\n'However, the PDUFA V goals also apply to animal carcinogenicity protocols and final product stability protocols, whereas the statutory section does not.'可被翻译为：然而，PDUFA V目标也适用于动物致癌性方案和最终药品稳定性方 案，而法定部分则不适用。\n\n根据上述已知信息，请将'A. Animal Carcinogenicity Protocols The sponsor should include the background information detailed in the guidance for industry Carcinogenicity Study Protocol Submissions in addition to the complete protocol.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A. 动物致癌性方案 除了完整的方案外，申办方还应包括行业指南《致癌性研究方案递交》中详 述的背景信息。"
    },
    {
        "instruction":"已知信息：\n'Article 78 The Provisions for In-Vitro Diagnostic Reagent Registration shall be applicable to the registration and filing of in-vitro diagnostic reagents administered as medical devices.'可被翻译为：第七十八条 按医疗器械管理的体外诊断试剂的注册与备案适用《体外诊断试剂注册管理办法》。\n'Article 69 For a filed in-vitro diagnostic reagent, where the contents set forth in the filing information form for in-vitro diagnostic reagent changed, the filing entity shall submit a description of the change and related supporting documents to the original filing department and apply for change of filing. Where the filing materials meet the formal requirements, the food and drug regulatory department shall put the changes in the information of changes, and file a record.'可被翻译为：第六十九条 已备案的体外诊断试剂，备案信息表中登载内容及备案的产品技术要求发生变化的，备案人应当提交变化情况的说明及相关证明文件，向原备案部门提出变更备案信息。备案资料符合形式要求的，食品药品监督管理部门应当将变更情况登载于变更信息中，将备案资料存档。\n'Article 58 For a medical device filing, the filing entity shall submit the filing documents in accordance with Article 9 of the Regulations on Supervision and Administration of Medical Devices.'可被翻译为：第五十八条 办理医疗器械备案，备案人应当按照《医疗器械监督管理条例》第九条的规定提交备案资料。\n'Article 81 Where, in violation of the Provisions, a change of filing for a class I in-vitro diagnostic reagent is not performed, or a registration alteration of registry items for a class II or class III in-vitro diagnostic reagent is not performed according to law, punishments shall be imposed according to the situation concerning fail in filing in the Regulations on Supervision and Administration of Medical Devices.'可被翻译为：第八十一条 违反本办法规定，未依法办理第一类体外诊断试剂变更备案或者第二类、第三类体外诊断试剂注册登记事项变更的，按照《医疗器械监督管理条例》有关未备案的情形予以处罚。\n\n根据上述已知信息，请将'Article 68 For an in-vitro diagnostic reagent filing, the filing entity shall submit the filing materials in accordance with Article 9 of the Regulations on Supervision and Administration of Medical Devices.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十八条 办理体外诊断试剂备案，备案人应当按照《医疗器械监督管理条例》第九条的规定提交备案资料。"
    },
    {
        "instruction":"已知信息：\n'Cardiovascular diseases are currently the leading cause of death in industrialized countries and alsoexpected to become so in emerging countries by 2020 [3, 4].'可被翻译为：心血管疾病目前是工业化国家中的主要致死原因，预计到 2020 年在新兴国家中也会如此[3,4]。\n'Target organ damage of heart, brain, kidneys and, in particular, blood vessels is presumably and plausibly associated with morbidity and mortality.'可被翻译为：推测心脏、大脑、肾脏、尤其是血管的靶器官损伤可能与发病率和死亡率相关。\n'The choice of interventional procedures [percutaneous coronary intervention (PCI) or coronary artery bypass graft CABG)] falls outside the scope of this guideline.'可被翻译为：介入性手术[经皮冠状动脉介入术（PCI）或冠状动脉旁路移植术（CABG）]的选择不在本指导原则的范围之内。\n'2. Fludeoxyglucose F 18 Injection is indicated in PET imaging in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging, for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging.'可被翻译为：2. F 18 脱氧葡萄糖注射液适用于冠状动脉疾病和左心功能不全患者的 PET成像（与心肌灌注显像合用时），识别冠状动脉疾病和左心功能 不全患者中出现残糖代谢和收缩功能可逆性丧失的左心室心肌（与心 肌灌注显像合用时）。\n\n根据上述已知信息，请将'Among these, coronary artery disease(CAD) is the most prevalent manifestation and is associated with high mortality and morbidity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"其中，冠状动脉疾病（CAD）是最为常见的，导致了高死亡率和发病率。"
    },
    {
        "instruction":"已知信息：\n'General considerations should be applied when establishing a clinically relevant difference or a non-inferiority margin.'可被翻译为：当确立临床相关差异或一个非劣效性界值 时应用一般注意事项。\n'The suggested non-inferiority margins have been selected on the basis that they are very likely to be sufficient to differentiate the treatment effect of the test agent from no antibacterial therapy and reflect a clinically acceptable difference to an appropriate active comparative regimen.'可被翻译为：建议的非劣效性边界应该基于极有可能足以区别试验药物相较不接受抗菌剂的治疗作用并反映出相较一种适当的活性参比治疗方案具有临床可接受的差异来选择。\n'The choice of non-inferiority margin should be clinically justified (reference is made to Choice of the Non-Inferiority margin - CPMP\/EWP\/2158\/99)'可被翻译为：非劣效性界值的设定应该有临床依据(非劣效性界值的设定参考文献- CPMP\/EWP\/2158\/99)。\n'In case a non-inferiority study is conducted the choice of the non-inferiority margin should not be based on the difference of (any) active bowel cleansing medication to placebo but on a clinically acceptable difference of the endpoint used.'可被翻译为：对于非劣效性研究，非劣界值的选择不应该基于（任何）阳性清肠类药物与安慰剂的差异，而应该是所用终点的临床可接受差异。\n\n根据上述已知信息，请将'The final choice of the non-inferiority margin should take into account clinical judgement regarding how large a difference between the test and reference treatments could be considered clinically important in each type of infection.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"非劣效性边界的最终选择应考虑到在临 床上如何判断在每种类型的感染中， 试验治疗与参比治疗之间的差异幅度达到多 大可被视为有临床重要性。"
    },
    {
        "instruction":"已知信息：\n'1 Examples of HCT\/Ps include, but are not limited to, bone, ligament, skin, dura mater, heart valve, cornea, hematopoietic stem\/progenitor cells derived from peripheral and cord blood, manipulated autologous chondrocytes, epithelial cells on a synthetic matrix, and semen or other reproductive tissue.'可被翻译为：1 HCT\/Ps的例子包括，但不限于，骨、韧带、皮肤、硬脑膜、心脏瓣膜、角膜、来源于外周和脐 带血的造血干\/祖细胞，治疗脱臼的自体软骨细胞，合成基质上的上皮细胞，以及精液或其他生殖组织。\n'A biological material including, but not limited to, blood, serum, plasma and urine.'可被翻译为：一种生物材料，包括但不限于全血、血清、血浆和尿液。\n'(5) Ancillary products used in the manufacture of HCT\/P;'可被翻译为：（5）用于HCT\/P制造的配套产品；\n'3) The manufacture of the HCT\/P does not involve the combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT\/P; and'可被翻译为：3) HCT\/P的制造并不包括将细胞或组织与其他物质相混合，除了水，晶体或消毒， 保存，或存储等不会增加其临床风险的操作；以及\n\n根据上述已知信息，请将'(3) Secreted or extracted human products, such as milk, collagen, and cell factors, except that semen is considered an HCT\/P;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（3）人体分泌物或提取物，比如乳汁，胶原蛋白和细胞因子等，但不包括精 液；"
    },
    {
        "instruction":"已知信息：\n'In such cases, the need to change treatment becomes a study endpoint.'可被翻译为：在这种情况下，研 究终点变为需要改变治疗。\n'It is possible to design a study to plan for early escape from ineffective therapy.'可被翻译为：一项研究设计计划从无效治疗中及早脱离是有可能。\n'Sometimes supplemental information can be used to explore the potential impact of unmeasured confounders on the study findings.'可被翻译为：有时候，辅助信息可被用于探索未测量的变量对 研究发现可能产生的影响。\n'However, if it is not known whether under conditions of use the endocrine-related finding will be relevant to humans, additional studies sometimes can be warranted.'可被翻译为：然而，如果不知道在使用条件下，内分泌相关结果是否与人类相关，则可能有必要进行附加研究。\n\n根据上述已知信息，请将'With care, however, withdrawal for lack of effectiveness can sometimes be used as a study endpoint.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"但应注意到，有时因缺乏有效性而退出 试验可以作为研究的终点。"
    },
    {
        "instruction":"已知信息：\n'A storage statement should be established for the labeling in accordance with relevant national\/regional requirements.'可被翻译为：应按照相应的国家\/地区的要求，在标签上说明贮藏条件。\n'6) The requirements for bulk storage of the products, including the container, labeling and special storage conditions;'可被翻译为：6.待包装产品的贮存要求，包括容器、标签及特殊贮存条件；\n'The formal labeling requirements for photolabile drug substances and drug products are established by national\/regional requirements.'可被翻译为：光敏性原料药和制剂的正式标签要求是根据国家\/地区的要求制定的。\n'Such labelling should be in accordance with relevant national\/regional requirements.'可被翻译为：这种标签应符合当地有关国家\/地区的规定。\n\n根据上述已知信息，请将'2.2.10.Statements\/Labeling A storage statement should be established for the labeling in accordance with relevant national\/regional requirements.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2.2.10 说明\/标签 应按照相应的国家\/地区的要求，在标签上说明贮藏条件。"
    },
    {
        "instruction":"已知信息：\n'In order to broaden the ICH’s outreach and be able to develop a global, harmonised and implementable electronic messaging standard, the ICH Steering Committee, which is the body that governs the ICH, made a decision to align its development efforts with SDOs. The ISO, HL7, CEN, CDISC and IHTSDO, along with their respective technical committees (TCs) and stakeholders for health informatics standardisation, have collectively identified an opportunity to collaborate, coordinate, and cooperate so their efforts will support the creation of global electronic health informatics standards that can be integrated into the broader healthcare environment.'可被翻译为：为扩大ICH的推广范围，并能够制定全球统一和可实施的电子信息传输标准，ICH指导委员会（管理 ICH 的机构）决定与 SDO 共同开发此标准。ISO、HL7、CEN、CDISC 和 IHTSDO 以及各自的技术委员会（TC）和健康信息学标准化的利益相关者共同把握合作、协调和配合的机会，这样他们的努力就可以支持创建全球电子健康信息标准，进而应用到更广泛的医疗环境中。\n'In 2006, the ICH decided to pursue an alternative model for the development of the third revision of E2B that engaged SDOs. This IG describes the messaging standard for the implementation of the E2B(R3) message developed through this new process.'可被翻译为：2006年，ICH决定为制定E2B的第3个修订版（由SDO参与开发）寻求更新。该IG描述了通过此新程序制定的E2B（R3）信息传输实施的标准。\n'Prior to the message standard described in this IG, ICH electronic messaging standards were developed by the ICH M2 EWG for Electronic Standards for the Transmission of Regulatory Information(ESTRI).'可被翻译为：在本IG描述的信息标准之前，由ICH M2 EWG开发了ICH电子信息传输标准，用于监管信息电子传输标准（ESTRI）。\n'Specifically, the current message standard was developed through a collaborative relationship between the ICH and the Joint Initiative Council (JIC); the JIC is a partnership of the International Organisation for Standardisation (ISO), the Health Level Seven (HL7), the European Committee for Standardisation (CEN), the Clinical Data Interchange Standards Consortium (CDISC), the International Health Terminology Standards Development Organisation (IHTSDO), and GS12.'可被翻译为：具体而言，当前的信息标准是由 ICH 与联合行动委员会（JIC）共同制定；JIC 是国际标准化组织（ISO）、HL7、欧洲标准化委员会（CEN）、临床数据交换标准协会（CDISC）、国际医学术语标准化与研发组织（IHTSDO）和 GS1 的合营组织2。\n\n根据上述已知信息，请将'Development of the standard described in this IG represents a change of the ICH process, as the messaging standard was developed through a partnership with external Standards Development Organisations (SDOs).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"本IG中描述的标准发展代表了ICH流程的变化，因为通过与外部标准开发机构（SDO）合作开发了信息传输标准。"
    },
    {
        "instruction":"已知信息：\n'Enrichment of substitutions from mixtures at baseline should also be reported; how these data are considered in treatment-emergent resistance analyses may depend on clinical trial design and nucleotide sequencing methods.'可被翻译为：还应报告对来自基线混合物的取代的富集；在对治疗过程 中出现的耐药性进行分析时，如何对待这些数据可能取决于临床试验设计和核苷 酸测序方法。\n'It is advisable to recruit patients with secondary as well as primary resistance on prior therapy. This ensures at least to some extent, that the study population is relevant.'可被翻译为：建议招募对既往治疗出现继发性和原发性耐药的患 者。这至少在一定程度上保证了研究人群是相关的。\n'Concentration-response assessments should be done in phase 2 and phase 3 trials.'可被翻译为：浓度-效应评估应在II期和III期试验中完成。\n'Specifically, for an end-of-phase 2 meeting, SVR4 data from all enrolled patients in key supporting phase 2 trials, and all available SVR12 (or longer) data from phase 2 trials should be submitted to support progression to phase 3.'可被翻译为：具体来讲，对于II期临床试验结束会议，应提交来自关键支撑性II期 临床试验的所有入组受试者的SVR4数据和来自II期临床试验所有可用SVR12（或 更长）数据，以支持进入III期临床试验。\n\n根据上述已知信息，请将'The potential persistence of resistance-associated substitutions should be characterized for patients enrolled in phase 1 and phase 2 clinical trials so that preliminary long term follow-up data are obtained by the time of completion of phase 3 trials.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应对入组I期和II期临床试验的受试者进行耐药性相关取 代的潜在持续性表征，从而到完成III期临床试验时获得初步的长期随访数据。"
    },
    {
        "instruction":"已知信息：\n'M: ≥ 2 weeks prior to cohabitation through at least confirmation of mating'可被翻译为：雄性：合笼前≥2周至至少确认交配成功\n'F: ≥ 2 weeks prior to cohabitation through implantation (GD6)'可被翻译为：雌性：合笼前≥2周至着床（GD6）\n'Mating period b ≥ 2 weeks'可被翻译为：交配期b ≥2周\n'The FEED study design for male rodents that includes 2 to 4 weeks of treatment prior to cohabitation allows for the detection of effects on spermatogenesis and epididymal transport.'可被翻译为：对雄性啮齿类动物的FEED试验设计包括合笼前给药2~4周，以便能检测 对精子生成和附睾运输的影响。\n\n根据上述已知信息，请将'Daily, commencing 2 weeks before cohabitation and until confirmation of mating'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"每天，从合笼前2周开始，直到确认交配"
    },
    {
        "instruction":"已知信息：\n'If the % mass of fine particles (<500 µm) of T <10%, then T is deemed unsuitable for insufflation.'可被翻译为：如果T的细颗粒（<500μm）的 质量百分比<10％，则认为T不适合鼻吸入。\n'The percentage (mass, quantity, or volume) of particles within a given particle size range.'可被翻译为：一定粒度范围内粒子所占的（质量、数量或体积）百分率。\n'If the % mass of fine particles (<500 µm) of T ≥10%, testing should proceed to Tier 2.'可被翻译为：如果T的细颗粒（<500μm）的质量百分比≥10％，则应推进到层次2的检测。\n'If the % mass of fine particles (<500 µm) of R <10%, then R is deemed unsuitable for insufflation.'可被翻译为：如果R的细颗粒（<500μm）的质量百分比<10％，则认为R不适合鼻 吸入。\n\n根据上述已知信息，请将'Is % mass of fine particles of T (< 500 µm) < 10%?'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"T的细颗粒（＜500 m）的 质量百分比＜10%？"
    },
    {
        "instruction":"已知信息：\n'The activities carried out and measures taken by public authorities to ensure that products comply with the requirements set out in legislation and do not endanger health, safety or any other aspect of public interest protection (based on EU Council Directive EC No 756\/2008 of 9 July 2008 concerning the requirements for accreditation and market surveillance relating to  the marketing of products and repealing Regulation (EEC) No 339\/93) (21).'可被翻译为：公共当局为确保产品符合立法规定的要求并且不危害健康、安全或公共利益保护的任何其他方面而开展的活动和采取的措施(基于2008年7月9日欧盟理事会指令EC No 756\/2008，关于与产品营销有关的认证和市场监督要求和废止法规(EEC) No 339\/93)(21)。\n'Article 1 These Provisions are formulated in accordance with the Regulations on Supervision and Administration of Medical Devices for the purpose of strengthening the supervision and administration of medical devices, controlling defective medical device products, eliminating potential safety hazards of medical devices, ensuring the safety and effectiveness of medical devices, and safeguarding human health and the safety of people’s lives.'可被翻译为：第一条 为加强医疗器械监督管理，控制存在缺陷的医疗器械产品，消除医疗器械安全隐患，保证医疗器械的安全、有效，保障人体健康和生命安全，根据《医疗器械监督管理条例》，制定本办法。\n'1.On condom packaging, a mark certifying that the product conforms to the essential requirements of the European Commission Directive 93\/42\/EEC on medical devices (4).\n2.On medical product packaging, a mark certifying that the product conforms to the essential requirements of European Medical Device Directive 93\/42\/EEC.'可被翻译为：1.在避孕套包装上，印有证明该产品符合欧盟委员会关于医疗器械的93\/42\/EEC指令基本要求的标志(4)。\n2.在医疗产品包装上，有证明产品符合欧洲医疗器械指令93\/42\/EEC基本要求的标志。\n'Article 1 These Provisions are formulated in accordance with the Standardization Law of the People's Republic of China, the Regulations for the Implementation of the Standardization Law of the People's Republic of China and the Regulations for the Supervision and Administration of Medical Devices as well as other laws and regulations to promote progress in science and technology, ensure the safety and effectiveness of medical devices, improve health care and enhance medical device standards administration.'可被翻译为：第一条 为促进科学技术进步，保障医疗器械安全有效，提高健康保障水平，加强医疗器械标准管理，根据《中华人民共和国标准化法》《中华人民共和国标准化法实施条例》和《医疗器械监督管理条例》等法律法规，制定本办法。\n\n根据上述已知信息，请将'The activities carried out and measures taken by a regulatory authority to ensure that medical devices placed on the market comply with regulations and do not endanger health, safety or any other aspect of public health (based on EU Council Directive 93\/42\/EEC of 14 JUNE 1993 concerning medical devices) (23).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"监管机构为确保投放市场的医疗器械符合法规且不危害健康、安全或公共卫生的任何其他方面而开展的活动和采取的措施(基于欧盟理事会1993年6月14日关于医疗器械的第93\/42\/EEC号指令)(23)。"
    },
    {
        "instruction":"已知信息：\n'Response Function: A mathematical expression which adequately describes the relationship between instrument response (e.g., peak area or height ratio or signal) and the concentration (amount) of analyte in the calibration standards. Response function is defined within a given range. See also Calibration Curve.'可被翻译为：响应函数：充分描述仪器响应（例如，峰面积或高比或信号）与校正标样中待测物浓度（量）之间关系的数学表达式。响应函数是在给定浓度范围内定义的。另见校正曲线。\n'The relationship between the instrument response (e.g., peak area, height or signal) and the concentration (amount) of analyte in the calibration standards within a given range. Also referred to as Standard Curve.'可被翻译为：仪器响应（例如峰面积、峰高或信号）与给定范围内校正标样中的待测物浓度（含量）的关系。也称为“标准曲线”。\n'Standard Curve: The relationship between the instrument response (e.g., peak area, height or signal) and the concentration (amount) of analyte in the calibration standards within a given range. Also referred to as calibration Curve.'可被翻译为：标准曲线：仪器响应（例如峰面积、峰高或信号）与给定范围内校正标样中待测物浓度（量）之间的关系。也称为校准曲线。\n'Calibration Curve: The relationship between the instrument response (e.g., peak area, height or signal) and the concentration (amount) of analyte in the calibration standards within a given range. Also referred to as Standard Curve.'可被翻译为：校准曲线：仪器响应（例如峰面积、峰高或信号）与给定范围内校正标样中的待测物浓度（含量）的关系。也称为“标准曲线”。\n\n根据上述已知信息，请将'A mathematical expression which adequately describes the relationship between instrument response (e.g., peak area or height ratio or signal) and the concentration (amount) of analyte in the calibration standards. Response function is defined within a given range. See also Calibration Curve.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"充分描述仪器响应（例如，峰面积或高比或信号）与校正标样中待测物浓度（量）之间关系的数学表达式。响应函数是在给定浓度范围内定义的。另见校正曲线。"
    },
    {
        "instruction":"已知信息：\n'It could be appropriate to follow a tiered testing strategy, e.g., an in vivo screening test (OECD 229 or OECD 230) can be performed if effects on the estrogen or androgen receptor are expected (note that these tests are only suitable to detect anti-androgenic effects).'可被翻译为：遵循分层测试策略可能是恰当的，例如，如果预期对雌激素或雄激素受体有作用，可以进行体内筛选试验（OECD 229或OECD 230）（注意，这些试验 仅适用于检测抗-雄激素效应）。\n'The use of the same species and strain as in already completed toxicity studies can eliminate the need to use additional animals or conduct additional studies to characterize pharmacokinetics and metabolism, and\/or for dose range finding.'可被翻译为：使用与已完成的毒性试验中相同的种 属和品系，可以消除使用其它动物或者开展其它试验来表征药代动力学和代谢和 \/或进行剂量范围探索的必要性。\n'These tests also evaluate secondary sexual characteristics in fathead minnow or medaka (OECD 229 and 230) or gonad histopathology (OECD 229).'可被翻译为：这些试验还评估了黑头呆鱼或青鳉中的第二性 征（OECD 229和230）或性腺组织病理学（OECD 229）。\n'Increased or decreased estrogenic or androgenic activity at inappropriate times can produce transient or permanent alterations in end-organ structure and\/or function.'可被翻译为：在不恰当的时间出现雌激素或雄激素活性的增加或减少可对终末器官的结构和\/或功能产生短暂或永久改变。\n\n根据上述已知信息，请将'In case it is already known from e.g. mammalian toxicity studies that estrogenic or androgenic recep- tors are targeted, the screening assay (OECD 229 or 230) may become redundant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果从例如哺乳动物毒性研究已知雌激素或雄激素受体为靶子，筛选检测 （OECD 229或230）可能变得多余。"
    },
    {
        "instruction":"已知信息：\n'o A drug may be approved with a requirement for a registry that will collect data to be analyzed in a study required as a PMR (under section 505(o)(3)), outside of a REMS (section 505-1(f)(3)(F)). When a pharmacoepidemiologic study using registry data meets the statutory criteria for a PMR described above in section III, the registry and the study will be required as a PMR.'可被翻译为：° 一种药物按照注册要求批准，将收集数据作为PMR的一项研究进行分 析（依据第505(o)(3)部分），超出REMS范围（第505-1(f)(3)(f)部分）。当药物流行病学研究使用的注册数据符合上述第III部分中描述的PMR法定标准，该注册和研究将要求视为一项PMR。\n'The applicant is required to provide certain information to FDA with regard to required postmarketing studies and clinical trials (section 505(o)(3)(E)(ii)). Under section 505(o)(3)(E)(ii), this information must include:'可被翻译为：法规要求申请方就所要求的上市后研究和临床试验向FDA提供一定信息（第505(o)(3)(E)(ii)部分）。根据第505(o)(3)(E)(ii)部分，这些信息必须包括：\n'In addition, FDAAA requires that applicants report on each study and clinical trial “otherwise undertaken by the applicant to investigate a safety issue” (see section 505(o)(3)(E)(ii)). Reports on these studies and clinical trials would previously have been required under 21 CFR 314.81(b)(2)(viii).'可被翻译为：另外，FDAAA要求申请人报告每一项研究和临床试验“否则由申请人承担安全问题调查”（见第505(o)(3)(E)(ii)部分）。依据21 CFR 314.81(B)(2)(viii)，针对报告中这些研究和临床试验的信息已经有所要求。\n'For studies or clinical trials otherwise undertaken by the applicants to investigate a safety issue, the applicant must report to FDA under section 505(o)(3)(E)(ii) of the Act and 21 CFR 314.81(b)(2)(viii). These studies or clinical trials are neither required by FDA nor agreed upon between FDA and the applicant. They may include investigations initiated by an applicant for many reasons without prior discussion with or notification to FDA. These studies and clinical trials must be summarized in a section of the annual report (drugs) or annual status report (biologics).'可被翻译为：申请人为了调查安全性问题另行实施的研究或临床试验，申请人必须依据法案 505(o)(3)(E)(ii)部分和21 CFR 314.81(B)(2)(viii) 向FDA进行报告。这些研究或临床试验未经FDA要求也不是FDA和申请人之间协商的。它们可能包括由于某种原因申请人发起的调查，既没有与FDA提前讨论也没有通知FDA。这些研究和临床试验必须在年度报告（药品）或年度状况报告（生物制品）的一部分进行总结。\n\n根据上述已知信息，请将'For each PMR required under FDAAA, the applicant must periodically report on the status of the study or clinical trial (see section 505(o)(3)(E)(ii)). For clinical trials, the report must also include whether enrollment has begun, the number of participants enrolled, the expected completion date, whether any difficulties completing the clinical trials have been encountered, and registration information as required under section 402(j) of the PHS Act (see section 505(o)(3)(E)(ii)). We recognize that some of the information required for clinical trial reporting is also relevant to observational pharmacoepidemiologic studies, and FDA will interpret the requirement to include this information as applicable to all studies or clinical trials performed in humans. Registration information for clinical trials should include documentation that the PMR is registered in accordance with Title VIII of FDAAA.20'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于按FDAAA要求进行的每个PMR，申请人必须定期报告研究或临床试验 的状况（见第505(o)(3)(E)(ii) 部分）。对于临床试验，该报告必须包括招募是否已 经开始、参与者登记数量、预期完成日期、完成临床试验是否遇到任何困难和依据 PHS法案第402(j)部分要求的注册信息（见505(o)(3)(E)(ii)）。我们承认某些临床试验要求报告的信息还与观察性药物流行病学研究相关，FDA将对该要求进行解释包括适用于所有在人体中进行的研究或临床试验信息。临床试验的注册信息应包括根据FDAAA标题VIII注册PMR的文件20。"
    },
    {
        "instruction":"已知信息：\n'The interpretation of interim analyses conducted on a less mature data set is problematic.'可被翻译为：对一个不太成熟的数据集进行中期分析的解释是有问题的。\n'As noted, the lack of randomization and blinding, and the resultant problems with lack of assurance of comparability of test group and control group, make the possibility of substantial bias inherent in this design and impossible to quantitate.'可被翻译为：值得注意的是，缺少随机化和盲法以及试验组和对照组 之间缺乏可比性保障而导致的问题，可能使该设计本身存在实质性偏倚并且不能定量。\n'For exploratory purposes, studies without a randomised reference are therefore considered interpretable and guidance provided in the section about cytotoxic compounds is relevant. Irrespective of this, inclusion of a randomised reference arm is encouraged and might be of special interest in order to explore whether, e.g. a selected biomarker is prognostic and\/or predictive (see 7.1.2). Time to progression (TTP) and progression-free survival (PFS), however, are in principle a function of underlying tumour growth rate and the activity of the anti-tumour compound. Also, if documented progressive disease is an inclusion criterion, underlying growth rate is hard to define in most patients and historical data will be even harder to interpret. Therefore, the interpretation of TTP\/PFS data without a randomised reference is problematic. In particular in breast cancer, clinical benefit response rate (CBR), i.e. CR, PR and absence of progression at 6 months, is a well established measure of anti- tumour activity and might be used for between study comparisons, even though subject to the same principle problem as TTP\/PFS.'可被翻译为：但是在原则上，进展时间(TTP)和无进展生存期(PFS)是潜在肿瘤增长率和抗肿瘤化合物 活性的一项函数。同样地，如果已记录的恶化疾病为一项纳入标准，那么很难在大多数患者中定义潜在增长率，历史数据也将更难解释。因此，在无随机性参照的情况下解释 TTP\/PFS 数据是有问题的。特别是在乳腺癌中，临床获益率(CBR)，即 CR、PR 以及连续 6 个月无恶化，是抗肿瘤活性中已确定的指标，并可用于研究比较，即使 与TTP\/PFS 一样遇到相同的原则问题。\n'In some cases a small, randomised, reference controlled study is the best option, in other cases a within-patient TTP\/PFS analysis (or the combination) might be a better alternative.'可被翻译为：在某些情况下，一项小规模的、随机、参考对 照研究参考是最好的选择；在其它情况下，患者自身的TTP\/PFS分析（或联合应用） 可能是一个更好的选择。\n\n根据上述已知信息，请将'Therefore, the interpretation of TTP\/PFS data without a randomised reference is problematic.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"因此，对没有随机参考的TTP\/PFS数据进行解释是有问题的。"
    },
    {
        "instruction":"已知信息：\n'Previously, a variety of scoring methods have been used, which in the majority of cases have not been validated.'可被翻译为：尽管目前有很多评估量表，但多数尚未得到充分验证。\n'Other assessments, such as clinical outcome assessments and certain biomarkers used as surrogate endpoints do not directly measure these but are used to predict clinical benefit.'可被翻译为：其他评价，例如临床结局评价以及用作替代终点的特定生物标志物并未直接对受益进行测定，但是可用于预测临床受益。\n'Performance-Based Approach:'可被翻译为：基于性能的方法：\n'Self-report tools are generally preferred to observer-rated tools and should be applied based on individual’s ability to use self-report tools.'可被翻译为：自我报告工具通常优先于观察者评定工具，并且应该基于个人使用自我报告工具的能力来应用。\n\n根据上述已知信息，请将'In addition, assessment modalities  (informant-report, self-report, performance-based, clinician rated) are often not compared in validation studies.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"此外，在验证研究中，往往未对评价形式（知情人报告，自我报告，基于表现，临床医生评价）进行比较。"
    },
    {
        "instruction":"已知信息：\n'A tabulated summary of the stability results from 3.2.S.7.3, with graphical representation where appropriate, should be provided.'可被翻译为：应提供3.2.S.7.3的稳定性结果汇总表，必要时提供相应的图示。\n'3.2.S.7.1 Stability Summary and Conclusions (name, manufacturer)'可被翻译为：3.2.S.7.1 稳定性总结和结论（名称，生产商）\n'A tabulated summary of the batch analyses provided under 3.2.P.5.4, with graphical representation where appropriate should be included.'可被翻译为：应提供3.2.P.5.4中的批分析汇总表，必要时提供相应的图示。\n'A tabulated summary of the batch analyses from 3.2.S.4.4, with graphical representation where appropriate, should be provided.'可被翻译为：应提供3.2.S.4.4中的批分析汇总表，必要时提供相应的图示。\n\n根据上述已知信息，请将'A tabulated summary of the stability results from 3.2.P.8.3, with graphical representation where appropriate, should be included.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应提供3.2.P.8.3的稳定性结果汇总表，必要时提供相应的图示。"
    },
    {
        "instruction":"已知信息：\n'As noted in section Background and Overview of Clinical Efficacy 2.7.3.1, however, any results of these studies that are pertinent to evaluation of safety should be discussed in section Summary of Clinical Safety 2.7.4.'可被翻译为：如第2.7.3.1节“背景和临床有效性综述”所述，这些与安全性评估 相关的研究的任何结果应放在第2.7.4节“临床安全性总结”中讨论。\n'Each study presentation should provide enough detail to understand critical aspects of the study design and the study findings, including (as applicable) treatments compared, sample size, population studied, number and location of study sites, study drug dose and regimen, treatment duration, and results for primary and important secondary endpoints.'可被翻译为：每份研究报告应提供足够的细节，以了解研究设计和研究发现的关键方面，包括（如适用）比较的治疗、样本量、研究的人群、研究中心的数量和位置，研究药物剂量和治疗方案、治疗持续时间、以及主要终点和重要次要终点的结果。\n'[Product specific: Clinical study results can be briefly summarised here]'可被翻译为：[产品特性：可以在这里简要总结临床研究结果]\n'Important demographic, efficacy and safety data should be presented in summary figures or tables in the text of the report.'可被翻译为：应在报告正文中的汇总图或表内提供重要的人口统计 学、疗效及安全性数据。\n\n根据上述已知信息，请将'13.DISCUSSION AND OVERALL CONCLUSIONS The efficacy and safety results of the study and the relationship of risks and benefit should be briefly summarised and discussed, referring to the tables, figures, and sections above as needed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"13. 讨论和总体结论 应简要汇总并讨论研究的疗效和安全性结果以及风险 和获益关系，如需要可参考上述表格、图示和章节。"
    },
    {
        "instruction":"已知信息：\n'In this case, a specific Table of Contents for that document can be included to identify the chronology and titles of the subsections contained therein.'可被翻译为：这种情况下，可以纳入该文件的专有目录， 以便识别该文件内所含小节的排列和标题。\n'If there are several documents within a section, some differentiation can be achieved by informative naming of the documents’ titles.'可被翻译为：如果在一个章节内有数份文件，通过对文件标题进行有提示性的命名可进行一 定程度的区分。\n'Could guidance be provided for all modules on headings in relation to document location and the section headings within those documents? \nCould guidance also be provided on where in the CTD and eCTD multiple documents can be located in the hierarchy? \nAs a consequence of this definition could guidance be given on how documents should be paginated and on what the module Table of Contents should therefore include?'可被翻译为：是否可以为所有模块文件内与文件位置相关的标题及各章节的标题提供指导？\n是否也可以为CTD和eCTD文件中的哪些地方可以按层级排序提供指导？ \n根据该定义的结果，是否也能够为文件应如何编制页码提供指导，以及应纳入什么样的模块目录表？\n'22 Nov. 2003 Granularity: section headings and numbers, documents location\/hierarchy, documents pagination The CTD specifies many section headings and numbers. Could guidance be provided for all modules on headings in relation to document location and the section headings within those documents? Could guidance also be provided on where in the CTD and eCTD multiple documents can be located in the hierarchy? As a consequence of this definition could guidance be given on how documents should be paginated and on what the module Table of Contents should therefore include? Please refer to the Annex of the Organisation of the Common Technical Document: \"Granularity Document\".'可被翻译为：22 2003 年 11 月 粒度文件：章节标题和编号、文档位置\/层级结构，文档分页 CTD规定了许多的章节标题和数字。 可以提供这些文档所有模块的关于文件位置标题和章节标题 的指导意见吗？ 还可以同时给出关于 CTD 和 eCTD 中多个文档可以位于层级结构中何处吗？作为这一定义的结果，可以指导如何分页文件，以及该模块目录应包括哪些内容？ 请参阅通用技术文档组织的附件：“颗粒度文件”。\n\n根据上述已知信息，请将'At the applicant’s discretion, a Table of Contents can also be included for a particular section that contains multiple documents, in order to identify the chronology and the document subject matter.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"站在申请人的角度考虑，含有多个文件的特殊章节也可建立一个目录，以 便确定文件的次序和主题。"
    },
    {
        "instruction":"已知信息：\n'Risk Assessment: Linking Material Attributes and Process Parameters to Drug Product CQAs'可被翻译为：风险评估：联接物料特性及工艺参数与药品CQA\n'2.3 Risk Assessment: Linking Material Attributes and Process Parameters to Drug Product CQAs'可被翻译为：2.3 风险评估：联接物料特性及工艺参数与药品CQA\n'Example 1: Linking Material Attributes and Process Parameters to Drug Substance CQAs - Chemical Entity'可被翻译为：案例1：物料属性和工艺参数与原料药关键质量属性的关联-化学实体药物\n'3.1.5 Linking Material Attributes and Process Parameters to Drug Substance CQAs The manufacturing process development program should identify which material attributes (e.g., of raw materials, starting materials, reagents, solvents, process aids, intermediates) and process parameters should be controlled.'可被翻译为：3.1.5 物料属性和工艺参数与原料药关键质量属性的关联 生产工艺的开发程序应当确认哪些物料的属性（例如原 材料、起始原料、试剂、溶剂、工艺助剂、中间体的属性） 和工艺参数应该被控制。\n\n根据上述已知信息，请将'Linking Material Attributes and Process Parameters to Drug Substance CQAs .'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"物料属性和工艺参数与原料药关键质量属性的关联"
    },
    {
        "instruction":"已知信息：\n'Evaluation of multiple doses is recommended.'可被翻译为：推荐对多个剂量进行评估。\n'Several dose levels should be studied to establish the optimal dose.'可被翻译为：应研究几个剂量水平，以建立最佳剂量。\n'The dose of r-hFSH should be justified, taking into account that a dose in the linear part of the dose response curve is suitable to detect potential differences in the pharmacokinetic profiles of the biosimilar and the reference medicinal product.'可被翻译为：r-hFSH的剂量应当合理，考虑量效曲线中线性部分的一个剂量适用于检测生物类似物 和参比药品的药代动力学特征的潜在差异。\n'A comparative single or repeat dose study in the saturation part of the dose-concentration-response curve is unlikely to discriminate between different activities, should they exist, and a dose in the linear part of the dose-response curve may result in treating a patient with a too low dose. It is also acknowledged that dose-response data may not exist for the reference mAb, and that exposing patients to a relatively low dose of the mAbs, in a worst case scenario, might also sensitize them to develop anti-mAb antibodies, and, consequently, may make them treatment resistant. However, for some reference mAbs clinical conditions may exist where such studies are feasible.'可被翻译为：单一或重复剂量研究中的剂量 - 浓度 - 反应曲线的饱和部分在不同的活动之间不大可能进行区分，如果它们存在，且在剂量 - 反应曲线的线性部分的剂量可能导致用低剂量治疗患者。众所周知的是，对于参照单克隆抗体，剂量 - 反应数据可能不存在，并且将患者暴露于相对低剂量的单克隆抗体时，在最坏的情况下，也可能会使他们产生抗单抗抗体，而且，最终可能会使他们产生治疗抵抗性。然而，对于可行的此类研究中一些参考单克隆抗体的临床病症可能存在。\n\n根据上述已知信息，请将'The selected dose should be in the linear part of the dose-concentration curve; if available information on the reference product is too scarce, more than one dose should preferably be tested.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"选择的剂量应该在剂量-浓度曲线的线形部分，如果参比制剂可用的信息过少，测试不止一种剂量较为适宜。"
    },
    {
        "instruction":"已知信息：\n'In long term follow up the accrual of damage caused by the disease could be evaluated using SLICC\/ACR damage index.'可被翻译为：在疾病导致的损害情况的长期随访中，可以采用SLICC\/ACR损害指数进行评估。\n'Using a SLICC\/ACR damage index may be problematic when a new study drug is associated with toxicities not listed in the Damage Index used to.'可被翻译为：如果一种新的研究药物会发生SLICC\/ACR损害指数中未列出的毒性，则可能无法使用该损害指数来测量。\n'Laboratory indices, showing either activity of the renal disease or chronic damage:'可被翻译为：实验室指标显示肾脏疾病活动或慢性损害：\n'Measures of activity and damage (number of active joints, joints with limited motion, damage index, X-ray or another validated method)'可被翻译为：活动度和损伤指标（活动关节数量、运动受限关节数量、损伤指数、射线或其他经验证方法））\n\n根据上述已知信息，请将'Accumulated multi-system chronic organ damage as measured by the SLICC\/ACR damage index is suitable to use in studies enrolling patients particularly those with short duration of disease and without pre-existing damage,'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过SLICC\/ACR损害指数测量的累积多系统慢性器官损害适用于入组患者是发病时间较短且无既存损害的研究，"
    },
    {
        "instruction":"已知信息：\n'<The colloid-osmotic effect of human albumin 200 or 250 g\/l is approximately four times that of blood plasma. Therefore, when concentrated albumin is administered, care must be taken to assure adequate hydration of the patient. Patients should be monitored carefully to guard against circulatory overload and hyperhydration.>'可被翻译为：<200 或 250g\/l 人血白蛋白的胶体渗透压大约相当于血浆的 4 倍。因此，当给予 高浓度的白蛋白时，须小心确保患者有足够的水分。应仔细监测患者以防循环超负荷和过度水化。>\n'Physico-chemical data: <human albumin {40 to 50g\/l} is mildly hypooncotic to normal plasma.> <Human albumin 200 or 250 g\/l has a corresponding hyperoncotic effect.>'可被翻译为：<人血白蛋白{200 到 550g\/l}会产生相应的高渗作用。>\n'<dot-underlined text> for 200 - 250 g\/l albumin'可被翻译为：-<点阵下滑线的文本>表示 200-250g\/l 的白蛋白核心\n'<wave-underlined text> for 40 – 50 g\/l albumin'可被翻译为：-<波浪下滑线的文本>表示 40-50g\/l 的白蛋白\n\n根据上述已知信息，请将'200-250g\/l Human albumin solutions are relatively low in electrolytes compared to the 40-50 g\/l human albumin solutions. When albumin is given, the electrolyte status of the patient should be monitored (see section 4.2) and appropriate steps taken to restore or maintain the electrolyte balance.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"与 40-50g\/l 的人血白蛋白溶液相比，200-250g\/l 人血白蛋白溶液的电解质含量较低。 当给予白蛋白时，需要监测患者的电解质状况（见第 4.2 部分）并采取适当措施来恢复 和维持电解质平衡。"
    },
    {
        "instruction":"已知信息：\n'A technique for measuring the relationship between mass and temperature of a substance at a programmed temperature.'可被翻译为：在程序控制温度下，测量物质的质量与温度关系的一类技术。\n'A technique for measuring the relationship between the difference in energy lost to the substance to be measured and the reference substance in relation to temperature (or time) at a programmed temperature.'可被翻译为：在程序控制温度下，测量输给待测物质和参比物质之间的能量差与温度（或时间）关系的一种技术。\n'The technique of measuring the relationship between the sound emitted by a substance and its temperature under programmed temperature control.'可被翻译为：在程序控制温度下，测量物质发出的声音与温度关系的技术。\n'In a homogeneous reaction, the change in the mass of the components of the reaction system per unit time and per unit volume.'可被翻译为：在均相反应中，单位时间和单位体积内反应体系中组分物质量的改变。\n\n根据上述已知信息，请将'The amount of heat absorbed or emitted per unit mass of a substance by lowering its temperature by 1k or increasing it by 1 ° C.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"单位质量的某种物质，温度降低1k或升高1℃所吸收或放出的热量。"
    },
    {
        "instruction":"已知信息：\n'The guideline applies to chemical and biological medicinal products for human and veterinary use, but 66 is not applicable for immunological veterinary medicinal products.  Guidance is provided on the choice of the method of sterilisation, the development and manufacturing   data required to support the manufacture of the finished product.'可被翻译为：指导原则适用于人用和兽用化学和生物制剂产品，但不适用于免疫类兽用 药品。 提供了关于灭菌方法选择、支持成品生产所需的开发和生产数据的指南。\n'Submission of Documentation in Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes (draft 8\/2008)'可被翻译为：湿热工艺终端灭菌的人药和兽药参数放行申报资料中文件提交（2008 年 8 月，草案）\n'Parametric release is one type of RTR testing.'可被翻译为：参数放行是实时放行检测的一种。\n'Parametric Release of Pharmaceuticals Terminally Sterilized by Moist Heat'可被翻译为：湿热灭菌的终端灭菌药品的参数放行\n\n根据上述已知信息，请将'When parametric release of sterility is proposed, the Guideline on real time release testing (formerly  Guideline on parametric release), EMA\/CHMP\/QWP\/811210\/2009-Rev1 (human products only), the  Guideline on Parametric release, EMEA\/CVMP\/QWP\/339588\/2005 (veterinary products only) and the   text of Ph. Eur. Chapter 5.1.1 should be taken into account.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"提出无菌的参数放行的，应考虑《实时放行检验指导原则 （EMA\/CHMP\/QWP\/811210\/2009-Rev1，前《参数放行指导原则》）（仅人用 药品）、《参数放行指导原则》 (EMEA\/CVMP\/QWP\/339588\/2005)（仅兽用药 品）以及Ph. Eur.第5.1.1节内容。"
    },
    {
        "instruction":"已知信息：\n'Specific aspects of best practices for the selection of the data sources, study design, and analysis plan to be described and included in any regulatory submission are discussed in detail in sections IV, V, and VI of this guidance.'可被翻译为：将被描述并纳入到任何法规提交资料中的在数据来源、研究设计和分析计划等特定方面的选择的最佳规范在本指导原则的章节IV、V和VI中详细讨论。\n'Investigators should discuss their rationale for selecting a particular study design in the study protocol and final report.'可被翻译为：研究者应该在研究方案和最终报告中 讨论选择某种特殊的研究设计的依据。\n'Published studies submitted to FDA for safety-related regulatory decision-making should be accompanied by supplemental documentation that addresses the aspects of study design, analysis, conduct, and reporting discussed in this guidance.'可被翻译为：已提交给FDA作安全性相关法规决定的已发布研究应附上解决在本指导原则中讨论的研究设计、分析、执行和报 告的问题的补充文件。\n'4.4.2.1.General aspects of study design'可被翻译为：4.4.2.1 基本研究设计\n\n根据上述已知信息，请将'Investigators should predefine aspects of the study related to the design, analysis, conduct, and reporting of the study and articulate them in the study protocol and final reports, along with a science-based rationale for the scientific study choices pertaining to these aspects of the study; more information regarding these aspects is provided in sections IV, V, and VI of this guidance.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究者应预先定义与研究的设计、分析、执行和报告有关的方面，将其整理形成研究方案和最终报告，附上与研究的这些方面有关的科学研究选择的科学依据；关于这些方面的更多信息在本指导原则的章节IV、V和VI中提供。"
    },
    {
        "instruction":"已知信息：\n'Novel constructs, like hybrid molecules fused to physiological functional molecules, should be carefully investigated for ADAs cross-reacting with relevant endogenous (or self) proteins.'可被翻译为：应仔细研究新型构造（例如杂交分子融合以形成 具有生理学功能的分子）与相关内源性（或自体）蛋白质发生 ADA 交叉反应的可能性。\n'Autoimmunity: Cross-reactivity to an endogenous counterpart'可被翻译为：自免疫：与内源性蛋白质的交叉反应性\n'Pre-existing reactivity towards the therapeutic proteins (cross-reacting ADAs, rheumatoid factors, antibodies to non-human carbohydrate moieties etc.) at baseline may influence the production of ADAs.'可被翻译为：基线期对治疗蛋白的既存反应性（交叉反应性 ADA、类风湿因子、对非人类碳水化合物部分产生的抗体）可能影响ADA的生成。\n'The potential interference of residual endogenous proteins with the therapeutic product should be addressed.'可被翻译为：残余的内源性蛋白对治疗性产品产生的潜在干扰应加以注意。\n\n根据上述已知信息，请将'Cross- reactivity of the ADAs with relevant endogenous proteins should be investigated if emerging autoimmunity is suspected.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果疑似出现自体免疫，应研究ADA与相关内源性蛋白的交叉反应性。"
    },
    {
        "instruction":"已知信息：\n'ICH Q2(R2) provides guidance on selection and evaluation of the various validation tests for analytical procedures.'可被翻译为：ICH Q2（R2）对分析方法的各种验证试验的选择和评价提供指导和建议。\n'Analytical Procedure Performance Characteristics to be Demonstrated (2)'可被翻译为：待证明的分析方法\n'Analytical procedure development and change management approaches are described in this guideline whereas analytical procedure validation is described in ICH Q2.'可被翻译为：本指导原则描述了分析方法开发和变更管理方式，而分析方法验证 在ICH Q2中描述。\n'ANALYTICAL PROCEDURE VALIDATION STRATEGY An analytical procedure validation strategy describes the selection of analytical procedure performance characteristics for validation.'可被翻译为：分析方法验证策略（ANALYTICAL PROCEDURE VALIDATION STRATEGY） 分析方法验证策略描述用于验证的分析方法性能特征的选择。\n\n根据上述已知信息，请将'Details of the performance characteristics considered for analytical procedure validation are described in ICH Q2.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"分析方法验证中考虑的性能特征描述详见ICH Q2。"
    },
    {
        "instruction":"已知信息：\n'Article 69 The applicant shall communicate with the CDE for confirmation prior to filing the drug marketing authorization application and then, when filing the drug marketing authorization application, submit a priority review and approval application to the CDE at the same time. Applications that meet the requirements shall be included into the priority review and approval procedure by the CDE after going through the prescribed public disclosure process.'可被翻译为：第六十九条 申请人在提出药品上市许可申请前，应当与药品审评中心沟通交流，经沟通交流确认后，在提出药品上市许可申请的同时，向药品审评中心提出优先审评审批申请。符合条件的，药品审评中心按照程序公示后纳入优先审评审批程序。\n'Article 16 At critical points such as before submitting the application for drug clinical trials, during the drug clinical trials and before submitting the application for drug marketing authorization, the applicant may communicate and consult with the CDE and other specialized technical institutions about major issues. During the process of drug registration, the CDE and other specialized technical institutions may organize meetings to communicate with the applicant as needed for work.'可被翻译为：第十六条 申请人在药物临床试验申请前、药物临床试验过程中以及药品上市许可申请前等关键阶段，可以就重大问题与药品审评中心等专业技术机构进行沟通交流。药品注册过程中，药品审评中心等专业技术机构可以根据工作需要组织与申请人进行沟通交流。\n'Article 65 During review, where it is found that a drug registration application included into the conditional approval procedure does not meet the requirements for conditional approval, the CDE shall terminate the conditional approval procedure and inform the applicant to apply as per the normal review procedure.'可被翻译为：第六十五条 审评过程中，发现纳入附条件批准程序的药品注册申请不能满足附条件批准条件的，药品审评中心应当终止该品种附条件批准程序，并告知申请人按照正常程序研究申报。\n'Where requirements for conditional approval are met upon review, the Drug Approval License shall specify the validity period of the conditional Drug Approval License, the post-approval studies to be completed, the timeline for completing post-approval studies and other relevant details.'可被翻译为：经审评，符合附条件批准要求的，在药品注册证书中载明附条件批准药品注册证书的有效期、上市后需要继续完成的研究工作及完成时限等相关事项。\n\n根据上述已知信息，请将'Article 64 Where conditional approval is applied for, the applicant shall communicate with the CDE about the conditions for conditional marketing approval and the studies to be completed after marketing. Upon confirmation through consultation and communication, a drug marketing authorization application may be filed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十四条 申请附条件批准的，申请人应当就附条件批准上市的条件和上市后继续完成的研究工作等与药品审评中心沟通交流，经沟通交流确认后提出药品上市许可申请。"
    },
    {
        "instruction":"已知信息：\n'The term Asthma COPD Overlap Syndrome has recently been proposed for a patient population with a similar number of features of both asthma and COPD.'可被翻译为：近来针对存在一系列哮喘和COPD共有特征的患者人群提出了哮喘COPD重叠综合征这一术语。\n'Chronic obstructive pulmonary disease (COPD) and asthma have different aetiologies but may coexist in the same patient.'可被翻译为：慢性阻塞性肺病（COPD）和哮喘有不同的病因，但可能共存于同一患者。\n'Several clinical and inflammatory asthma phenotypes have been described recently including e.g. early-onset mild allergic asthma, later-onset asthma associated with obesity, and severe non-atopic asthma with frequent exacerbations.'可被翻译为：近来对一些临床和炎症性哮喘表型进行了描述，包括如早发性轻度过敏性哮喘、迟发性伴肥胖的哮喘、以及频繁发作的重度非过敏性哮喘。\n'Special attention should be given to the frequently associated comorbidities in the ACS population in general and older patients in particular (diabetes mellitus, COPD, renal failure, anaemia), also in relation to the possible drug-drug interactions.'可被翻译为：应特别注意一般 ACS 人群特别是老年患者中经常伴有的并存病（糖尿病、COPD、肾衰竭、贫血），还应考虑可能的药物–药物相互作用。\n\n根据上述已知信息，请将'Recently attention is given to the overlap of asthma and COPD syndrome (ACOS).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"最近对哮喘与COPD综合征（ACOS）的重叠给予了关注。"
    },
    {
        "instruction":"已知信息：\n'Patients hospitalised because of an acute episode of de-compensation who are stabilized by standard therapy and are not receiving parenteral treatments but remain hospitalised are defined as patients hospitalised for heart failure (HFH); these patients can be included in studies to assess the effect of chronic therapies that are started during the hospitalisation, at discharge or during the 30 days after hospital discharge.'可被翻译为：因心力衰竭住院（HFH）的患者是指因失代偿急性发作而住院的经标准治疗后病情稳定且但是未接受胃肠外治疗但是仍在住院的患者；可将此类患者纳入研究，以评估住院期间、出院时或出院之后 30 天内开始的长期治疗的效果。\n'A delay in time to referral for transplantation (as an indicator of stabilisation of the clinical status) and,'可被翻译为：推迟需手术移植的时间（表明疾病状态稳定）和\n'Intensive care unit'可被翻译为：特护病房\n'Symptom scores, duration of hospitalisation or ICU stay, hemodynamic measurements and echocardiographic measures of LV function could serve as secondary or supportive endpoints.'可被翻译为：症状评分、住院或ICU病房住院时间长短、血液动力学测量和左心室功能超声心动图测量结果作为次要或辅助终点。\n\n根据上述已知信息，请将'Duration of stay in intensive care unit (ICU) or duration of hospitalisation both indicate time to stabilisation (for step down care or discharge as appropriate)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"ICU病房住院时间或普通病房住院时间的长短都能指示至病情稳定（如转为二级护理或出院）的时间，"
    },
    {
        "instruction":"已知信息：\n'2.Requesting that the applicant submit further analyses of data, e.g., to evaluate the effect of the clinical investigator's data on the overall study outcome;'可被翻译为：2.要求申请人提交数据的进一步分析，例如， 评估该临床研究者数据对于 总体研究结局的影响；\n'If further studies are warranted, sponsors can consider the following additional assessments:'可被翻译为：如果有必要开展进一步研究，申办方应考虑进行以下附加评估：\n'(3.0) Conduct additional immunotoxicity studies'可被翻译为：（3.0）进行附加的免疫毒性研究\n'If it is not possible to conduct a blinded study, an independent evaluation that maintains the objectivity of the data should be put in place.'可被翻译为：如果不可能进行双盲的研究，维护数据客观性的独立评价应落实 到位。\n\n根据上述已知信息，请将'3.Requesting that the applicant conduct additional independent studies to confirm the results of the questioned study; and'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3.要求申请人开展额外的独立研究，核实疑问研究的结果；以及"
    },
    {
        "instruction":"已知信息：\n'Any of a class of volatile liquids or gases inhaled through the airway that diffuse into the blood through the alveolar capillary membranes and reach the brain tissue, blocking synaptic transmission and causing general anesthesia. Commonly used drugs are: halothane, enflurane, isoflurane, nitrous oxide, etc.'可被翻译为：一类挥发性液体或气体，经气道吸入后由肺泡毛细血管膜弥散入血而到达脑组织，阻滞其突触传递功能，引起全身麻醉作用的药物。常用药物有：氟烷、恩氟烷、异氟烷、氧化亚氮等。\n'sedative-hypnotics'可被翻译为：镇静催眠药\n'The possible risk of a too potent suppression of the immune system should be considered with respect to e.g. infectious processes in the central nervous system, inhibition of existing remyelinisation,malignancies (see section 4.2.1).'可被翻译为：应针对中枢神经系统感染过程、现有髓鞘再生抑制、肿瘤考虑过于免疫系统过强抑制的可能风 险（参见第4.2.1节）。\n'Central Nervous System'可被翻译为：中枢神经系统\n\n根据上述已知信息，请将'Drugs that can produce varying degrees of inhibition on the central nervous system, causing sedation and hypnosis. Commonly used drugs are: barbiturates (e.g. Phenobarbital), benzodiazepines (e.g. Diazepam), and others (e.g. Methalamine).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对中枢神经系统能产生不同程度的抑制作用，引起镇静和催眠的药物。常用的药物有：巴比妥类（如苯巴比妥）、苯二氮卓类（如地西泮）和其他类（如甲丙氨酯）。"
    },
    {
        "instruction":"已知信息：\n'The drug product for which a biowaiver is being requested should include a drug substance that is highly soluble (BCS class 1 and BCS class 3) and highly permeable (BCS class 1), and the drug product should be rapidly dissolving (BCS class 1) or very rapidly dissolving (BCS class 3).'可被翻译为：申请生物豁免的制剂，其药物活性成分需为高溶解性（BCS第一类和BCS第三类）和高渗透性（BCS第一类），且制剂需快速溶出（BCS第一类）或者极快速溶出（BCS第三类）。\n'When new excipients or atypically large amounts of commonly used excipients are included in an IR solid dosage form, additional information documenting the absence of an impact on BA of the drug may be requested by the Agency. Such information can be provided with a relative BA study using a simple aqueous solution as the reference product. Large quantities of certain excipients, such as surfactants (e.g., polysorbate 80) and sweeteners (e.g., mannitol or sorbitol) may be problematic, and sponsors are encouraged to contact the review division when this is a factor. BCS class 3 drug products: Unlike for BCS class 1 products, for a biowaiver to be scientifically justified, BCS class 3 test drug product must contain the same excipients as the reference product. This is due to the concern that excipients can have a greater impact on absorption of low permeability drugs. The composition of the test product must be qualitatively the same and should be quantitatively very similar to the reference product.'可被翻译为：若使用新的辅料，或者非常规的大量使用了速释制剂常用辅料，则应提交额外的资料以证明该辅料的使用对制剂的生物利用度没有影响。这些额外信息可随使用单一水溶液作为参比制剂的相对生物利用度研究提供。大量使用某些特定的辅料，例如表面活性剂（如聚山梨醇酯80）和甜味剂（例如甘露醇或山梨醇）可能会存在问题，这种情况下鼓励申办方联系审评部门。（ii）BCS第三类制剂：不同于第一类制剂，为了科学评估生物豁免的可行性，BCS第三类制剂必须包含与参比制剂相同的辅料。这是因为辅料可能会对低渗透性药物的吸收产生更大的影响。试验制剂的组分必须和参比制剂一致，且含量相近。\n'For submission of a biowaiver request, an IR product should be rapidly dissolving (BCS class 1) or very rapidly dissolving (BCS class 3).'可被翻译为：若要提交生物豁免申请，速释制剂必须是快速溶出（BCS第一类）或者极快速溶出（BCS第三类）。\n'In general, using excipients that are currently in FDA-approved IR solid oral dosage forms will not affect the rate or extent of absorption of a highly soluble and highly permeable drug substance that is formulated in a rapidly dissolving IR product.'可被翻译为：一般来说，若使用FDA 已批准的速释口服制剂的辅料，且采用快速溶出的速释处方 来生产制剂，将不会影响高溶解性、高渗透性药物活性成分的吸收速度或吸收程 度。\n\n根据上述已知信息，请将'IV. \tBIOWAIVERS BASED ON BCS \nThis guidance is applicable for BA\/BE waivers (biowaivers) based on BCS, for BCS class 1 and class 3 immediate-release solid oral dosage forms. \nFor BCS class 1 drug products, the following should be demonstrated: \n• the drug substance is highly soluble \n• the drug substance is highly permeable \n• the drug product (test and reference) is rapidly dissolving, and \nthe product does not contain any excipients that will affect the rate or extent of absorption of the drug (see section V.A.)\nFor BCS class 3 drug products, the following should be demonstrated:\nthe drug substance is highly soluble \nthe drug product (test and reference) is very rapidly dissolving (see section II.C.), and \nthe test product formulation is qualitatively the same and quantitatively very similar, e.g., falls within scale-up and post-approval changes (SUPAC) IR level 1 and 2 changes, in composition to the reference (see section V.A.)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"IV.基于BCS分类的的生物豁免 \n本指导原则适用于基于BCS分类的BA\/BE豁免（生物豁免），适用于BCS 第一类和第三类速释固体口服制剂。 \n对于BCS第一类制剂，需证明下列几点： \n• 药物活性成分具有高溶解性 \n• 药物活性成分具有高渗透性 \n• 试验和参比制剂可快速溶出，且\n• 制剂不包含任何可影响药物吸收速度和程度的辅料（参见章节V.A.） \n对于BCS第三类制剂，需证明下列几点： \n• 药物活性成分具有高溶解性 \n• 试验制剂和参比制剂均可快速溶出（参见章节II.C.），且 \n• 与参比制剂相比，试验制剂应含有相同的组分，且各组分含量应相似， 如，符合规模扩大或上市后变更（SUPAC）速释制剂的第一类和第二类变更的要求。（参见章节V.A.）"
    },
    {
        "instruction":"已知信息：\n'Created for the ICH ICSR This section contains tables of Code Sets and OIDs relevant to this IG specifically created for the ICH; these code sets are maintained by or for ICH.'可被翻译为：本节包含与本 IC相关的专门为 ICH创建的代码集和 OID表；这些代码集由 ICH维护或为 ICH服务。\n'2.4 Representation of the Electronic ICSR'可被翻译为：2.4 电子ICSR的代表\n'The external code sets and OIDs used in the message include:'可被翻译为：信息中所使用的外部代码集和OID包括：\n'The ICH ICSR message allows for the preparation of adverse event\/reaction data sets that can accurately maintain and represent the intended purpose of the E2B(R3) document. Section 3 of this IG lists the exact E2B(R3) data elements and essential components to develop usable and exchangeable ICH ICSR messages.Necessary schemas for the ICH ICSR message are listed in Appendix I (A).'可被翻译为：ICH ICSR消息允许准备不良事件\/反应数据集，可以准确维护和遵守E2B（R3）文件的预期目的。该IG的第3节列出了确切的E2B （R3）数据元素和基本组成元素，以便开发有用且和可交换的ICH ICSR消息。 ICH ICSR 消息的必要模式见附录I（A）。\n\n根据上述已知信息，请将'The following table lists the ICSR elements using these external code sets:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"下表列出了使用这些外部代码集的ICSR元素："
    },
    {
        "instruction":"已知信息：\n'In observational studies, the investigator “observes and evaluates results of ongoing medical care without 'controlling' the therapy beyond normal medical practice.”'可被翻译为：在观察性研 究中，研究者“除了正常医疗实践以外不‘控制’治疗，对正在进 行的医疗活动的结局进行观察和评价”。\n'There are various epidemiologic and statistical methods for identifying and handling confounding in pharmacoepidemiologic safety studies using electronic healthcare data, and FDA does not endorse or suggest any particular method.'可被翻译为：有多种流行病学和统计学方法可以发现和处理采用电子医疗保健数据的药物流行病学安全性研究中的混杂因素，FDA不推荐或建议任何特定方法。\n'A study where the medicinal product(s) is (are) prescribed in the usual manner in accordance with the terms of the marketing authorisation. The assignment of the patient to a particular therapeutic strategy is not decided in advance by a trial protocol but falls within current practice and the prescription of the medicine is clearly separated from the decision to include the patient in the study. No additional diagnostic or monitoring procedures are applied to the patients and epidemiological methods are used for the analysis of collected data.'可被翻译为：按照常规方式根据上市批准条件进行处方的研究。患者不依据既定的试验方案分配治疗方案，而是依照现行的临床实践进行，同 时，研究中的药品的处方与患者是否入选试验无关。对这类患者 不进行额外诊断或监测，仅用流行病学方法对收集的数据进行分析。\n'Generally, even if the applicant's proposed primary analysis is based on a reduced subset of the patients with data, there should also be for any trial intended to establish efficacy an additional analysis using all randomised (or otherwise entered) patients with any on-treatment data.'可被翻译为：一般来说， 对任何疗效分析试验，即使申请人提出的主要分析是基于样 本减少的患者子集，也应该对所有随机分组的（或所有入组 的）具有任何治疗数据的患者进行额外分析。\n\n根据上述已知信息，请将'No additional diagnostic or monitoring procedures are applied to the patients and epidemiological methods are used for the analysis of collected data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对这类患者 不进行额外诊断或监测，仅用流行病学方法对收集的数据进行分 析。"
    },
    {
        "instruction":"已知信息：\n'As described in ICH S6 Guideline, when no relevant species can be identified because the biopharmaceutical does not interact with the orthologous target in any species, use of homologous molecules or transgenic models can be considered.'可被翻译为：如ICH S6指导原则所述，如果因为生物制品与所有种属 的直系同源靶点均没有相互作用而不能确定相关种属时，则可以考虑使用同源分子或者转基因模型。\n'When no relevant animal species exists for testing the clinical candidate, the use of transgenic mice expressing the human target or homologous protein in a species expressing an ortholog of the human target can be considered, assuming that sufficient background knowledge exists for the model (e.g., historical background data) (see Part I, Note 1). For products that are directed at a foreign target such as bacteria and viruses, in general no reproductive toxicity studies would be expected (see Section 2.1).'可被翻译为：如果没有测试临床候选物的相关动物种属，假设对模型具有充分的背景知识（如历史背景数据），可以考虑使用表达人体靶点的转基因小鼠，或者使用表达人体靶点同源基因种属中的同源蛋白（参见第I部分，注释1）。对于以外源性物质（如细菌和病毒）为靶点的产品，一般不需要进行生殖毒性试验（参见第2.1部分）。\n'In cases where no relevant test species exists, consideration should be given to the use of alternative models, such as the use of an analogous drug (surrogate) against the orthologous target, or the use of a transgenic model in which the animal is made to express the human target.'可被翻译为：如果不存在相关试验种属，应考虑使用替代模型， 例如使用作用于直系同源靶标的类似药物（替代品），或使用表达人类靶标的动物的转基因模 型。\n'When the pharmaceutical does not have adequate activity against the target in the routine test species, surrogate molecules can be used to assess potential adverse effects on reproduction and development.'可被翻译为：当药物对常规实验种属的靶点没有足够的活性时，可采用替代分子评估潜在 的生殖和发育毒性。\n\n根据上述已知信息，请将'When no relevant species can be identified because the biopharmaceutical does not interact with the orthologous target in any species relevant to reproductive toxicity testing, use of surrogate molecules or transgenic models can be considered, as described in ICH S6.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如ICH S6所述，当生物制品由于不与任何生殖毒性试验相关种属的同源靶 点相互作用而确定无相关种属时，可以考虑使用替代分子或转基因模型。"
    },
    {
        "instruction":"已知信息：\n'reciprocating diaphragm pump'可被翻译为：往复隔膜泵\n'A rotary pump that depends on the working volume change and movement formed between the pump cylinder and the meshing gear to transport the liquid or pressurize it.'可被翻译为：依靠泵缸与啮合齿轮间所形成的工作容积变化和移动来输送液体或使之增压的回转泵。\n'reciprocating cylinder method'可被翻译为：往复筒法\n'reciprocating holder method'可被翻译为：往复架法\n\n根据上述已知信息，请将'Referred to as \"diaphragm pump\". A special reciprocating pump. A new generation reciprocating pump specially used for conveying high abrasive solid-liquid two-phase medium.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"简称\"隔膜泵\"。一种特殊往复泵。专用于输送高磨蚀固-液两相介质的新一代往复泵。"
    },
    {
        "instruction":"已知信息：\n'Important limitations of these studies can include a lack of clinical outcome data or information of the indication for use of a product.'可被翻译为：这些研究的主要局限包括缺少临床结局数据或用药指征的资料。\n'If there is no established therapy for the specific target population, a placebo-controlled study aiming to demonstrate superiority, might be acceptable.'可被翻译为：如果特定目标人群没有确定的治疗方法， 可采用可证明优效性的安慰剂对照研究。\n'Effects on secondary endpoints are not sufficient to support efficacy in the absence of an effect on the primary endpoint.'可被翻译为：在缺乏主要终点的影响时，对次要终点的影响不足以支持疗效。\n'A clinical effect on core symptoms of ASD should be demonstrated before efficacy on other associated symptoms can be claimed.'可被翻译为：在宣称对其他相关症状的效果之前，应该证明对 ASD 核心症状的临床效果。\n\n根据上述已知信息，请将'In the absence of adequate data to support such a link, the clinical benefit associated with the effect of treatment on carriage should be demonstrated in a placebo-controlled study with a primary clinical endpoint.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果没有足够的数据来支持两者的联系，与对携带菌的治疗作用相关的临床获益应该通过安慰剂对照研究的主要临床终点来证明。"
    },
    {
        "instruction":"已知信息：\n'Once the hydration and temperature of the skin has equilibrated (e.g., after 30 min) the skin surface temperature should be measured. The skin surface temperature should be within ±1° of the target temperature (32°) prior to applying the dosage form. The temperature of the receptor solution, or the circulating water bath, or the set point of a dry heat system, or any other component of the system should not be assumed to be the same as the skin surface temperature. Instead, the skin surface temperature should be directly measured (with an infrared thermometer or a thermocouple), and the thermoregulatory mechanism of the FDC system should be adjusted as needed to produce the target temperature of 32° at the skin surface.'可被翻译为：一旦皮肤的水合作用和温度达到平衡(例如，30分钟后)，应测量皮肤表面温度。在施用剂型之前，皮肤表面温度应在目标温度(32°)的±1°内。受体溶液的温度，或循环水浴的温度，或干热系统的设定点，或系统的任何其他组成部分的温度不应假定与皮肤表面温度相同。相反，应直接测量皮肤表面温度(使用红外温度计或热电偶)，并根据需要调整FDC系统的温度调节机制，使皮肤表面温度达到32°的目标温度。\n'Skin surface temperature should be measured using an IR thermometer. The temperature of the heating block must be set higher than the desired membrane temperature (e.g., 33° for a 32° skin surface temperature).'可被翻译为：皮肤表面温度应使用红外温度计测量。加热块的温度必须设置高于所需的膜温度(例如，对于32°的皮肤表面温度设为33°)。\n'The system should be appropriately equilibrated under the predefined experimental conditions prior to the beginning of the IVPT run. No air bubbles should be present in the receptor solution (under the membrane) immediately prior and during the experiment; if appropriate, the receptor solution can be degassed. The system temperature (including the membrane surface temperature and the circulating water bath temperature, if applicable) should be stable and well controlled. Frozen biological membranes should be thawed at ambient temperature prior to assembling on the diffusion cells. Once mounted, the skin sections should be allowed to equilibrate to a physiologically relevant state of hydration and temperature (e.g., for 30 min at a membrane surface temperature of 32°).'可被翻译为：在IVPT开始运行之前，系统应在预先确定的实验条件下进行适当的平衡。在实验之前和实验过程中，受体溶液(膜下)中不应出现气泡;如果合适，受体溶液可以脱气。系统温度(包括膜表面温度和循环水浴温度，如适用)应稳定且控制良好。冷冻的生物膜应在室温下解冻，然后组装在扩散池上。一旦安装，皮肤切片应该被允许平衡到生理上相关的水合作用和温度状态(例如，在32°的膜表面温度下30分钟)。\n'The receptor compartment of the Model A VDC should be filled with receptor solution that is equilibrated to the target temperature (typically 32° or 37°) during the preparation and dosing of the membrane in the cell top assembly. The stirrers can be run during this period to speed up temperature stabilization. The receptor solution temperature should be measured and ensured to be within ±1° of the target temperature prior to mounting the cell top assembly. The stirrers can be run to help speed up temperature stabilization.'可被翻译为：A型VDC的受体室应充满受体溶液，在池体顶部组装膜的制备和给药过程中，受体溶液应平衡到目标温度(通常为32°或37°)。在此期间可以运行搅拌子以加速温度稳定。在安装池体顶部组件之前，应测量并确保受体溶液温度在目标温度的±1°范围内。搅拌子可以运行，以帮助加快温度稳定。\n\n根据上述已知信息，请将'Once the hydration and temperature of the skin has equilibrated (i.e., after 30 min) the skin surface temperature should be measured. The skin surface temperature should be within ±1° of the target temperature (32°) prior to applying the dosage form. The temperature of the receptor solution, or the circulating water bath, or the set point of a dry heat system, or any other component of the system should not be assumed to be the same as the skin surface temperature. Instead, the skin surface temperature should be directly measured (with an infrared thermometer or a thermocouple), and the thermoregulatory mechanism of the VDC system should be adjusted as needed to produce the target temperature of 32° at the skin surface. The stirrers can be run during the duration of the equilibration to speed up temperature stabilization.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一旦皮肤的水合作用和温度达到平衡(即30分钟后)，应测量皮肤表面温度。在施用剂型之前，皮肤表面温度应在目标温度(32°)的±1°内。受体溶液的温度，或循环水浴的温度，或干热系统的设定点，或系统的任何其他组成部分的温度不应假定与皮肤表面温度相同。而是直接测量皮肤表面温度(使用红外温度计或热电偶)，并根据需要调节VDC系统的热调节机制，使皮肤表面温度达到32°的目标温度。搅拌器可以在平衡期间运行，以加速温度稳定。"
    },
    {
        "instruction":"已知信息：\n'This section is not intended to be a full benefit-risk assessment of the investigational drug.'可被翻译为：本节的目的不是对试验药的获益－风险进行全 面评估。\n'Therapeutic use of an investigational drug (e.g., expanded access programmes, compassionate use programmes, particular patient use, single patient INDs, and treatment INDs); and'可被翻译为：试验药的治疗应用（例如：扩大使用项目、同情使用项目、 特殊患者应用、单个患者IND和治疗IND）；\n'Under FDA’s current regulations, there are three categories of expanded access: Expanded access for individual patients, including for emergency use (21 CFR 312.310) Expanded access for intermediate-size patient populations (21 CFR 312.315) Expanded access for large patient populations under a treatment IND or treatment protocol (21 CFR 312.320)'可被翻译为：在FDA的现行法规下，扩展使用权有三种类型： · 扩展个体患者的使用权，包括紧急用药（21 CFR 312.310） · 扩展中等规模患者人群的使用权（21 CFR 312.315） · 在治疗IND或治疗方案下扩展大规模患者人群的使用权（21 CFR 312.320）\n'Expanded Access to Investigational Drugs For Treatment Use — Qs & As'可被翻译为：扩展治疗用研究药品的使用权——Qs & As\n\n根据上述已知信息，请将'The distinction between expanded access and the use of an investigational drug in the usual studies covered under an IND is that expanded access uses are not primarily intended to obtain information about the safety or effectiveness of a drug.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"扩展使用权与涵盖在IND研究中常规使用研究药物之间的差别在于，扩展使用权用药不以 获得药物安全性或有效性信息为主要目的。"
    },
    {
        "instruction":"已知信息：\n'Each box in the diagram represents a related section of the E2B(R3) data element structure, and all the data elements in that block are listed in the attribute list (Section 3.4).'可被翻译为：图中的每个框代表 E2B（R3）数据元素结构的相关章节，该框中的所有数据元素均列在属性列表元素元素（第 3.4 节）中。\n'Figure 1 below illustrates the relationship between the main sections defined in E2B(R3) for the ICH ICSR message and XML descriptors.'可被翻译为：图1说明了在E2B（R3）中定义的主要章节之间ICH ICSR消息和XML描述符的关系。\n'C.1 IDENTIFICATION OF THE CASE SAFETY REPORT'可被翻译为：C.1 安全性报告的识别\n'ICH E2B(R3) DATA ELEMENTS'可被翻译为：ICH E2B(R3) 数据元素\n\n根据上述已知信息，请将'For example, box C.1 in the diagram Identification of the Case Safety Report represents the complete C.1 section of the E2B(R3) data elements and the C.1 block of elements listed in the ICH E2B(R3) data element list.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"例如，病例安全性识别报告图中的框 C.1 表示 E2B（R3）数据元素对应的ICH E2B（R3）数据元素列表的C.1全章和表中所列出的元素C.1模块。"
    },
    {
        "instruction":"已知信息：\n'Article 12 The ADR monitoring institutions of municipalities with districts and of counties are responsible for the collection, verification, evaluation, feedback, and reporting of ADR reporting and monitoring data within their respective administrative regions; conduct investigation and evaluation on serious ADRs within their respective administrative regions; assist relevant departments in investigating ADE clusters; and carry out publicity and training on ADR reporting and monitoring.'可被翻译为：第十二条 设区的市级、县级药品不良反应监测机构负责本行政区域内药品不良反应报告和监测资料的收集、核实、评价、反馈和上报；开展本行政区域内严重药品不良反应的调查和评价；协助有关部门开展药品群体不良事件的调查；承担药品不良反应报告和监测的宣传、培训等工作。\n'Article 25 Provincial ADR monitoring institutions shall complete the evaluation within 7 working days after receiving the serious ADR evaluation statements submitted by the ADR monitoring institution at a lower level.'可被翻译为：第二十五条 省级药品不良反应监测机构应当在收到下一级药品不良反应监测机构提交的严重药品不良反应评价意见之日起7个工作日内完成评价工作。\n'Article 15 Drug manufacturers, distributors and medical institutions shall report through the national ADR monitoring information network any drug-related adverse reactions that they become aware of or discover; if online reporting conditions are unavailable, they shall send paper reports to local ADR monitoring institutions and the local ADR monitoring institutions shall submit online reports on their behalf.'可被翻译为：第十五条 药品生产、经营企业和医疗机构获知或者发现可能与用药有关的不良反应，应当通过国家药品不良反应监测信息网络报告；不具备在线报告条件的，应当通过纸质报表报所在地药品不良反应监测机构，由所在地药品不良反应监测机构代为在线报告。\n'ADR monitoring institutions of municipalities with districts and counties shall investigate death cases to have a detailed understanding of the basic information about the case, information of drug use, and occurrence, diagnosis and treatment of the adverse reactions, etc. The investigation report shall be completed within 15 days after receiving the case report and submitted to the drug regulatory department and health administrative department at the same level and the ADR monitoring institution at a higher level.'可被翻译为：设区的市级、县级药品不良反应监测机构应当对死亡病例进行调查，详细了解死亡病例的基本信息、药品使用情况、不良反应发生及诊治情况等，自收到报告之日起15个工作日内完成调查报告，报同级药品监督管理部门和卫生行政部门，以及上一级药品不良反应监测机构。\n\n根据上述已知信息，请将'Article 24 ADR monitoring institutions of municipalities with districts and counties shall review the authenticity, completeness and accuracy of ADR reports received. The review and evaluation of serious ADR reports shall be completed within 3 working days after receiving the reports; the review and evaluation of other reports shall be completed within 15 working days.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十四条 设区的市级、县级药品不良反应监测机构应当对收到的药品不良反应报告的真实性、完整性和准确性进行审核。严重药品不良反应报告的审核和评价应当自收到报告之日起3个工作日内完成，其他报告的审核和评价应当在15个工作日内完成。"
    },
    {
        "instruction":"已知信息：\n'adulterant'可被翻译为：掺杂物\n'Herbal Products: Medicinal products containing, exclusively, plant material and\/or vegetable drug preparations as active ingredients. In some traditions, materials of inorganic or animal origin can also be present.'可被翻译为：植物药： 特指含有植物物料和\/或植物药制剂作为活性成分的药品，还包括某些传统 的无机或动物来源的物质。\n'1.Constituents are chemically defined substances or group(s) of substances found in a herbal material or herbal preparations.\n2.Chemically defined substances or group\/group(s) of substances found in a herbal material or herbal preparation.'可被翻译为：1.成分是在草药材料或草药制剂中发现的化学定义的物质或物质群。\n2.在草药材料或草药制剂中发现的化学上定义的物质或一组\/组物质。\n'finished herbal products'可被翻译为：中草药制成品\n\n根据上述已知信息，请将'Adulterant is herbal material, a herbal constituent or other substance that is either deliberately or non-intentionally (through cross-contamination or contamination) added to a herbal material, herbal preparation, or finished herbal product.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"掺假剂是草药材料，是故意或无意(通过交叉污染或污染)添加到草药材料、草药制剂或草药成品中的草药成分或其他物质。"
    },
    {
        "instruction":"已知信息：\n'Article 49 The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall formulate annual supervision and inspection plan for manufacturing of medical devices, determine the key points of supervision and administration of medical devices, specify the inspection frequency and coverage, and make comprehensive use of multiple means such as supervision and inspection, key inspection, follow-up inspection, for-cause inspection and special inspection, etc. to strengthen supervision and administration.'可被翻译为：第四十九条  省、自治区、直辖市药品监督管理部门应当制定年度医疗器械生产监督检查计划，确定医疗器械监督管理的重点，明确检查频次和覆盖范围，综合运用监督检查、重点检查、跟踪检查、有因检查和专项检查等多种形式强化监督管理。\n'Article 48 The department in charge of drug supervision and administration at the level of a city divided into districts or at county level shall make annual inspection plan, specifying the key points of supervision and administration, inspection frequency and coverage scope, and organize the implementation.'可被翻译为：第四十八条  设区的市级、县级负责药品监督管理的部门应当制定年度检查计划，明确监管重点、检查频次和覆盖范围并组织实施。\n'Article 57 If the registrant and the contract manufacturer of medical devices are not in the same province, autonomous region or municipality directly under the central government, and the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the registrant or the contract manufacturer is located needs to carry out cross-region inspection, it could also make inspection by means of joint inspection and entrusted inspection, etc.'可被翻译为：第五十七条  医疗器械注册人和受托生产企业不在同一省、自治区、直辖市，医疗器械注册人、受托生产企业所在地省、自治区、直辖市药品监督管理部门需要跨区域开展检查的，可以采取联合检查、委托检查等方式进行。\n'Article 39 Drug MAHs shall establish an annual report system in which manufacturing and sales, post-marketing studies and risk management are reported annually to the drug regulatory department of the province, autonomous region or municipality directly under the Central Government in accordance with the provisions of NMPA.'可被翻译为：第三十九条 药品上市许可持有人应当建立年度报告制度，按照国家药品监督管理局规定每年向省、自治区、直辖市药品监督管理部门报告药品生产销售、上市后研究、风险管理等情况。\n\n根据上述已知信息，请将'Article 54 The drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall stick to the principles of risk management and whole-process management and control, and in accordance with the risk analysis and assessment, establish annual inspection plan and carry out the inspection. The annual inspection plan shall at least include: the inspection scope, content, methods, priorities, requirements, timelines, and inspection agency.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十四条 省、自治区、直辖市药品监督管理部门应当坚持风险管理、全程管控原则，根据风险研判情况，制定年度检查计划并开展监督检查。年度检查计划至少包括检查范围、内容、方式、重点、要求、时限、承担检查的机构等。"
    },
    {
        "instruction":"已知信息：\n'Protocols should make adequate provision for subject management when a pathogen that requires specific treatment is detected after enrolment and\/or there is rapid worsening (e.g. onset of blood in stool) during the study period.'可被翻译为：关于在入组后检测到需特定治疗的病原体和\/或研究期间迅速恶化 （例如出现便血）时的受试者管理，方案中应该有充分的规定。\n'4.1.2. Microbiological investigations during clinical studies'可被翻译为：4.1.2 临床研究期间的微生物学研究\n'If follow-up specimens for culture are obtained from patients, the most useful specimens are those obtained at least 72 hours after the completion of drug therapy because negative culture results obtained while on therapy may represent suppression rather than elimination of organisms. Any target pathogens isolated from follow-up specimens should be tested for susceptibility to the antimicrobial used to treat the disease.'可被翻译为：如果从患者中采集用于培养的随访样本，则最有用的样本是在完成药物治疗后至少72小时获得的样本，因为治疗期间获得的阴性培养结果可能表示微生物受到抑制而不是消除。对从随访样本中分离的任何目标病原体考察对该疾病所用抗菌药的敏感性。\n'If patients are withdrawn from therapy there should be detailed documentation of the clinical and microbiological findings on the day of withdrawal.'可被翻译为：如果患者退出研究治疗， 应详细地记录在退出当天的临床和微生物学 发现。\n\n根据上述已知信息，请将'Microbiological documentation of bacterial infections should be sought from specimens obtained before or within a strictly-observed window after the first dose of study therapy is given.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"细菌感染的微生物学证明应根据在研究治疗首次剂量之后严格观察的时间 窗之前或时间窗内获取的样本。"
    },
    {
        "instruction":"已知信息：\n'Article 98 At the time of ex-warehousing of drugs, the accompanying sheet (bill) stamped with the original special seal for drug ex-warehousing of enterprises shall be attached.'可被翻译为：第九十八条 药品出库时，应当附加盖企业药品出库专用章原印章的随货同行单（票）。\n'Article 153 Upon arrival of drugs, the receiving personnel shall, in accordance with the purchase records, check the material objects according to the accompanying sheet (bill) provided by suppliers and ensure that the bills, account and goods are consistent.'可被翻译为：第一百五十三条 药品到货时，收货人员应当按采购记录，对照供货单位的随货同行单（票）核实药品实物，做到票、账、货相符。\n'Article 95 Records shall be established for ex-warehousing check of drugs, including the purchaser, adopted name, dosage form, strength, quantity, lot number, expiry date, and manufacturer of drugs, ex-warehousing date, quality status and checker, etc.'可被翻译为：第九十五条 药品出库复核应当建立记录，包括购货单位、药品的通用名称、剂型、规格、数量、批号、有效期、生产厂商、出库日期、质量状况和复核人员等内容。\n'Article 92 Enterprises shall take records of drug sales. Sales records shall include the adopted name, strength, dosage form, lot number, expiry date, manufacturer, purchaser, sales quantity, unit price, amount and sales date of the drug. Special sales records shall be established for the direct transfer of drugs in accordance with Article 69 herein.'可被翻译为：第九十二条 企业应当做好药品销售记录。销售记录应当包括药品的通用名称、规格、剂型、批号、有效期、生产厂商、购货单位、销售数量、单价、金额、销售日期等内容。按照本规范第六十九条规定进行药品直调的，应当建立专门的销售记录。\n\n根据上述已知信息，请将'The accompanying sheet (bill) shall include the supplier, the manufacturer, the adopted name, dosage form, strength, lot number and quantity of drugs, the consignee, receiving address, shipping date and other contents, and stamped with the original special seal for drug ex-warehousing of the supplier.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"随货同行单（票）应当包括供货单位、生产厂商、药品的通用名称、剂型、规格、批号、数量、收货单位、收货地址、发货日期等内容，并加盖供货单位药品出库专用章原印章。"
    },
    {
        "instruction":"已知信息：\n'15.3 March 2014 What new information should be included in Section 17.2 (newly identified information on efficacy\/effectiveness) of the PBRER?'可被翻译为：15.3 2014年3月 章节17.2（新确定的关于有效性\/效用的信息）应包括哪些新信息？\n'The important baseline efficacy and effectiveness information summarised in Section 17.1 of the PBRER will form the basis (or “reference”) for the benefit evaluation, irrespective of the reference product information used by the MAH.'可被翻译为：无论MAH使用的参考产品信息如何，PBRER章节17.1总结的重要基线有 效性和疗效信息将构成利益评估的基础（或“参考”）。\n'The basis for the benefit evaluation should be the baseline important efficacy\/effectiveness information summarised in Section 17.1 of the PBRER.'可被翻译为：利益评估的基础 应该是PBRER章节17.1总结的基本重要有效性\/疗效信息。\n'17.1 Important Baseline Efficacy\/Effectiveness Information'可被翻译为：17.1重要的基线有效性\/疗效信息\n\n根据上述已知信息，请将'15.2 March 2014 What efficacy\/effectiveness information should be presented in Section 17.1 (Important Baseline Efficacy\/Effectiveness Information) of the PBRER? In addition to the guidance provided in Section 3.17.1 of the Guideline, the MAH may wish to consider the following points when presenting efficacy\/effectiveness information in Section 17.1 of the PBRER.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"15.2 2014年3月 PBRER章节17.1（重要的基线有效性 \/效用信息）应提供哪些有效性\/效用信 息？ 除了指南章节3.17.1所提供的指导外，在提交PBRER章节17.1提出有效性\/效用信 息时，MAH不妨考虑以下几点。"
    },
    {
        "instruction":"已知信息：\n'electronic data interchange(edi)'可被翻译为：电子数据交换\n'Unlike the information in ICSR sections C to F, the ‘wrapper’ information is intended for routing purposes only (e.g. ‘from’ –>‘to’) and is not usually stored or archived. An assumption is made that an Electronic Data Interchange (EDI) trading partnership agreement is established to define the Message number, Sender ID, Receiver ID, and Message date conventions.'可被翻译为：与 ICSR 第 C 至 F 节中的信息不同，“包装”信息仅用于传输目的（例如“从”- > “至”），通常不存储或存档。假设建立电子数据采集（EDI）交易伙伴协议、以定义信息编号、发送者ID、接收者ID和信息日期规定。\n'edi message'可被翻译为：电子数据交换信息\n'skip lot (periodic) testing'可被翻译为：跳过批次(定期)测试\n\n根据上述已知信息，请将'4‘Co-existence of Traditional EDI with XML-EDI’, Skip Stein, Management Systems Consulting, Inc., http:\/\/www.msc-inc.net\/'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4“Co-existence of Traditional EDI with XML-EDI”、Skip Stein、Management Systems Consulting, Inc.， http:\/\/www.msc-inc.net\/"
    },
    {
        "instruction":"已知信息：\n'Biological and pharmacokinetic data alone are not sufficient to support clinical efficacy.'可被翻译为：仅有生物学和药物动力学数据不足以支撑其临床疗效。\n'Important limitations of these studies can include a lack of clinical outcome data or information of the indication for use of a product.'可被翻译为：这些研究的主要局限包括缺少临床结局数据或用药指征的资料。\n'Studies conducted with the regimen in the metastatic setting may provide important safety data and important supportive evidence of efficacy; however, this may not be necessary in all cases and should be determined on a case by case basis.'可被翻译为：用于转移性疾病的治疗方案的研究或许能提供重要的安全性数据和关于疗效的重要支持性证据；但是，不是所有情况都必需这样，应该逐个确定。\n'However, separate PD data may not be required if superseded by available clinical efficacy\/safety data.'可被翻译为：然而，如果存在可用临床疗效\/安全性数据，则不需要单独的PD数据。\n\n根据上述已知信息，请将'However, it may not be possible to provide clinical efficacy data for all the enzymes that are predicted to be inhibited and the data for individual enzymes may be very limited.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"但是，可能无法提供预期会受到抑制的所有酶的临床疗效数据， 对于 单个酶的数据可能也很有限。"
    },
    {
        "instruction":"已知信息：\n'The design of RABS should ensure grade A conditions with unidirectional airflow and first air protection in thecritical zone. A positive airflow from the critical zone to the supporting background environment should be maintained.'可被翻译为：RABS 的设计应通过具有单向流和关键区域初始气流保护确保 A 级条件。应保持从关键区到支持性背景环境的正向气流。\n'Grade B: For aseptic preparation and filling, this is the background cleanroom for grade A (where it is not an isolator). Air pressure differences should be continuously monitored. Cleanrooms of lower grade than grade B can be considered where isolator technology is used (see paragraph 4.20).'可被翻译为：B 级：对于无菌制备和灌装，这是 A 级的背景洁净室（非隔离器）。应持续监测压差。在使用隔离器技术的情况下可考虑低于 B 级的洁净室（参见第 4.20 节）。\n'Airflow pattern studies should be performed at the interfaces of open isolators to demonstrate the absence of air ingress.'可被翻译为：应在开放式隔离器的接口处进行气流流型研究，以证明没有空气进入。\n'The background environment for open isolators should generally correspond to a minimum of grade C. The background for closed isolators should correspond to a minimum of grade D. The decision on the background classification should be based on risk assessment and justified in the CCS.'可被翻译为：开放式隔离器的环境通常应至少为 C 级。封闭式隔离器的背景应至少为 D 级。背景级别的决定应基于风险评估并在 CCS 中论证合理性。\n\n根据上述已知信息，请将'The background environment for RABS used for aseptic processing should correspond to a minimum of grade B and airflow pattern studies should be performed to demonstrate the absence of air ingress during interventions, including door openings if applicable.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用于无菌工艺的RABS的环境应至少为 B级，并且应进行气流流型研究以证明在干预过程中没有空气进入，包括开门（如适用）。"
    },
    {
        "instruction":"已知信息：\n'Urodynamic testing is not required for inclusion of children with OAB into phase II or III studies.'可被翻译为：II或III期研究中OAB儿童的入选不需要进行尿流动力学检查。\n'The “phase” of a trial is not the focus of this regulation and there is no requirement that a study be a Phase 1, Phase 2, or Phase 3 study in order to proceed.'可被翻译为：试验的“期”不是该项法规的重点，并且为了继续进行，没有必须是1期、2期或3期研究的要求。\n'Phase II and III studies'可被翻译为：II期和III期研究\n'6.3. Confirmatory studies (phase III)'可被翻译为：6.3.验证性研究（III期）\n\n根据上述已知信息，请将'A routine performance of manometry studies in phase III of the drug development will not be required.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"无须在 III 期药物研发中例行进行测压研究。"
    },
    {
        "instruction":"已知信息：\n'This includes foreign clinical studies not conducted under an investigational new drug application (IND) or an investigational device exemption (IDE) that are submitted to FDA in support of an application for the marketing approval of a medical product (see 21 CFR 314.106, 312.120 and 814.15).'可被翻译为：这包括未按照临床试验新药申请（IND）进行的国外临床研究或用于医疗产品上市许可向FDA提交支持申请的器械临床试验豁免 （IDE）（见21 CFR 314.106， 312.120和814.15）。\n'Internationally accepted, general guidances are available for the timing and nature of nonclinical safety studies relative to clinical trials in drug development. These guidances also describe potential areas of FDA flexibility in determining the nonclinical data necessary to support an evolving clinical development program.'可被翻译为：在药物研发中非临床安全性研究距临床试验的时间以及性质目前已经有国际公认的通用指导原则可供借鉴。这些指导原则还描述了FDA在判定用于支持不断演变的临床研发计划所必需的非临床数据时拥有的灵活抉择空间。\n'For more information, see FDA’s guidance for industry Electronic Source Data in Clinical Investigations.'可被翻译为：更多信息，见FDA的行业指南 临床研究中的电子源数据。\n'As a result, FDA is providing guidance in a question and answer (Q & A) format, addressing the most frequently asked questions.'可被翻译为：因此，FDA以问题和回答 （Q & A）的形式提供指南，阐述最经常被问到的问题。\n\n根据上述已知信息，请将'For more information, see FDA’s guidance for industry and FDA staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND; Frequently Asked Questions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"更多信息，见 FDA的行业指南和FDA工作人员FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND; Frequently Asked Questions。"
    },
    {
        "instruction":"已知信息：\n'b: At least one animal per sex per litter should be retained to conduct behavioral and other functional tests, and to assess reproductive function.'可被翻译为：b：每窝每性别应至少保留1只动物，以进行行为和其它功能检测，并评估 生殖功能。\n'These numbers refer to litters available for evaluation.'可被翻译为：这些窝数是指可用于评估的窝数量。\n'PND 21, at least 1 male and 1 female\/litter where possible to achieve 16 animals per group\/sex'可被翻译为：PND21时，至少每窝1只雄性和1只雌性，使可达到16 只动物\/组\/性别\n'Both of these options obviate the need for extra animals for the CNS assessments.'可被翻译为：这两种方法都避免了需要额外的动物进行CNS评估。\n\n根据上述已知信息，请将'There can be circumstances where more animals per litter can be retained for independent functional assessments.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"某些情况下，每窝可保留更多的动物用于单独的功能性评估。"
    },
    {
        "instruction":"已知信息：\n'Pharmacogenomics: the study of variations of DNA and RNA characteristics as related to drug response (ICH15).'可被翻译为：药物基因组学：与药物反应相关的DNA和RNA特征的差异的研究（ICH15）。\n'the study of variations in DNA sequence as related to drug response, asubset of pharmacogenomics (ICH15); the study of interindividualvariations in DNA sequence related to drug disposition(pharmacokinetics)or drug action (pharmacodynamics) that caninfluence clinical response(CIOMS VI(2005))'可被翻译为：研究 DNA序列中与药物反应相关的变异，这是药物基因组学的一个分支（ICH15）；研究 DNA 序列中与药物分布（药代动力学）或药物作用（药效学）有关的且可影响临床应答的个体间变异（CIOMS VII（2005））\n'CIOMs VII (2005): Pharmacogenomics is defined more broadly as the application of genomic technologies to elucidate disease susceptibility, drug discovery, pharmacological function, drug disposition and therapeutic response.'可被翻译为：CIOMs VII（2005）：药物基因组学被更广泛地定义为应用基因组学技术来阐明疾病易感性、药物发现、药理学功能、药物处置和治疗反应。\n'CIOMs VII (2005): Pharmacogenetics is defined as the study of inter individual variations in DNA sequence related to drug disposition (pharmacokinetics) or drug action (pharmacodynamics) that can influence clinical response.'可被翻译为：CIOMs VII（2005）：药物遗传学的定义为能够影响临 床反应的、与药物处置（药代动力学）或药物作用（药效学）相关的DNA序列中的个体间差异的研究。\n\n根据上述已知信息，请将'the study of variations of DNA and RNA characteristics as related todrug response (ICH15); the application of genomic technologies toelucidate disease susceptibility, drug discovery, pharmacologicalfunction, drug disposition and therapeutic response (CIOMS VII (2005))'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究与药物反 应有关 的 DNA 或 RNA特征变异（ICH15）；应用基因组技术来阐明疾病易感性、药物发现、药理学功能、药物分布和治疗应答（CIOMS VII（2005））"
    },
    {
        "instruction":"已知信息：\n'Risks from microbial and other contamination should also be addressed.'可被翻译为：还应该论述来源于微生物和其他污染物的风险。\n'14. Caution is appropriate if the toxicological study design includes additional blood sampling, e.g., for measurement of exposure.'可被翻译为：（14）如果毒理试验设计中包含了附加的血样采集，如 用于测定暴露水平，应引起谨慎关注。\n'The section should describe current problems with pathogens relevant to the indications that are resistant to the antibacterial agent, focussing on the risk of encountering such organisms within the EU.'可被翻译为：这一章节应描述与适应症相关的、对抗菌剂耐药的病原体的当前问题，重点 是在欧盟境内遇到该类生物体的风险。\n'Organisms inhibited only at unusually high concentrations of the test antibacterial agent should be investigated for possible mechanisms of resistance and cross-resistance within and between classes.'可被翻译为：如果生物体仅在试验抗菌剂浓度非常高的时候才被抑制，应研究耐药和交叉耐药（该药物类别内和不同类别之间的）的可能机制。\n\n根据上述已知信息，请将'The risk of encountering organisms of this and other species that are unlikely to be susceptible to the test agent at concentrations expected within the gut should be taken into account in the study design and may influence the geographical location of study sites.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在研究设计时，应考虑到在肠道内预期达到的浓度下出现对试验药物不太可能敏感的大肠杆菌和其它菌种的生物体的风险，这一风险可能会影响研究中心的地理位置。"
    },
    {
        "instruction":"已知信息：\n'Haemorrhage may be a consequence of ischaemic stroke.'可被翻译为：出血可以是缺血性卒中的后果。\n'An ischaemic stroke with haemorrhagic conversion should be considered as “primary ischaemic”.'可被翻译为：应将伴有出血性转化 的缺血性卒中视为“主要缺血性”。\n'Stroke is categorized as ischaemic or haemorrhagic or undefined\/undetermined (based on computed tomographic or magnetic resonance scanning or autopsy).'可被翻译为：卒中可分为缺血性或出血性或未定义\/未确定（基于计算机 断层扫描或磁共振扫描或尸检）。\n'A clinically relevant net clinical benefit secondary endpoint consisting of “all strokes (i.e. ischaemic, undefined and haemorrhagic stroke) and other non-central nervous system embolic events” is therefore recommended.'可被翻译为：因此建议采用由“所有卒中（即缺血性、未定义和出血性卒中） 和其他非中枢神经系统栓塞事件”组成的次要终点临床相关净临床获益。\n\n根据上述已知信息，请将'In this situation, the stroke is an ischaemic stroke with haemorrhagic transformation and not a haemorrhagic stroke.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在这种情况下，卒中是伴随出血性转换的缺 血性卒中，而不是出血性卒中。"
    },
    {
        "instruction":"已知信息：\n'Examples of potential risks include: non-clinical safety concerns that have not been observed or resolved in clinical studies; adverse events observed in clinical trials or epidemiological studies for which the magnitude of the difference, compared with the comparator group (placebo or active substance, or unexposed group), on the parameter of interest raises a suspicion of, but is not large enough to suggest, a causal relationship; an event which is known to be associated with other products of the same class or which could be expected to occur based on the properties of the medicinal product.'可被翻译为：潜在风险的示例包括： 在临床研究中尚未观察或解决的非临床安全性 问题； 在临床试验或流行病学研究中观察到的不良事 件与对照组（安慰剂或活性物质或未暴露组） 相比，在所关注的参数方面的差异程度引起怀 疑，但不足以提示因果关系； 已知与相同类别的其它产品相关的或可基于药 品的性质预期会发生的事件。\n'An untoward occurrence for which there is adequate evidence of an association with the medicinal product of interest.Examples of identified risks include:·an adverse reaction adequately demonstrated in non_x0002_clinical studies and confirmed by clinical data;·an adverse reaction observed in well designed clinical trials or epidemiological studies for which the magnitude of the difference compared with the comparator group (placebo or active substance) on a parameter of interest suggests a causal relationship; ·an adverse reaction suggested by a number of well documented spontaneous reports where causality is strongly supported by temporal relationship and biological plausibility, such as anaphylactic reactions or application site reactions.'可被翻译为：有充分证据显示与所关注的药品有关联的不良事件。已确定风险的示例包括：·非临床研究中充分显示并经临床资料确认的不良反应；·在设计良好的临床试验或流行病学研究中观察到的不良反应，与比较组（安慰剂或活性物质）相比在某个关注参数上的差异程度表明有因果关系；·由许多证据充分的自发性报告中提出的不良反应，其中时序关系和生物学合理性强烈地支持因果关系，如过敏反应或应用部位反应。\n'Adverse events observed in clinical trials or epidemiological studies for which the magnitude of the difference, compared with the comparator group (placebo or active substance, or unexposed group), on the parameter of interest raises a suspicion of, but is not large enough to suggest, a causal relationship;'可被翻译为：临床试验或流行病学研究中观察到的不良事件，且与对照组 （安慰剂或活性成分或非暴露组）相比，检测参数的差异程度可 以怀疑，但不足以提示存在因果关系；\n'an adverse reaction observed in well-designed clinical trials or epidemiological studies for which the magnitude of the difference compared with the comparator group (placebo or active substance) on a parameter of interest suggests a causal relationship;'可被翻译为：在充分设计的临床试验或流行病学研究中观察到的不良反应， 且与对照组（安慰剂或活性成分组）相比，检测参数的差异程度 足以证明因果关系的存在；\n\n根据上述已知信息，请将'An untoward occurrence for which there is some basis for suspicion of an association with the medicinal product of interest but where this association has not been confirmed. Examples of potential risks include:non-clinical safety concerns that have not been observed or resolved in clinical studies; adverse events observed in clinical trials or epidemiological studies for which the magnitude of the difference, compared with the comparator group (placebo or active substance, or unexposed group), on the parameter of interest raises a suspicion of, but is not large enough to suggest, a causal relationship; an event which is known to be associated with other products of the same class or which could be expected to occur based on the properties of the medicinal product.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"有一定的依据怀疑与所关注的药品有关但是未能确认的不利事件。潜在风险的示例包括：在临床研究中尚未观察或解决的非临床安全性问题；在临床试验或流行病学研究中观察到的不良事件与对照组（安慰剂或活性物质或未暴露组）相比，在所关注的参数方面的差异程度引起怀疑，但不足以提示因果关系；已知与相同类别的其它产品相关的或可基于药 品的性质预期会发生的事件。"
    },
    {
        "instruction":"已知信息：\n'The Code of Federal Regulations (CFR) is the codification of the general and permanent rules published in the Federal Register by the departments and agencies of the Federal government.'可被翻译为：联邦法规（CFR）是联邦政府各部门和机构在联邦公报上公布的普通和永久规则的法律汇编。\n'The CFR is the codification of the general and permanent rules published in the Federal Register by the executive departments and agencies of the Federal government. It is divided into 50 titles that represent broad areas subject to Federal regulation.'可被翻译为：CFR是一部由美国联邦政府执行部门和机构在联邦公报中发布的一般性法规和永久性法规编纂，可分成 50 个标题，体现了联邦监管的广泛领域。\n'The Office of the Federal Register updates the material in the e-CFR on a daily basis.'可被翻译为：联邦公 报办公室会每天更新e-CFR中的内容。\n'The e-CFR is an unofficial editorial compilation of CFR material and Federal Register amendments.'可被翻译为：e-CFR是CFR材料和联邦公报修正案的非官方编辑汇编。\n\n根据上述已知信息，请将'Final rules are integrated into the CFR by the Office of the Federal Register and Government Publishing Office staff.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"最终规则由联邦纪事办公室和政府出版局工作人员整合进CFR。"
    },
    {
        "instruction":"已知信息：\n'To apply for filing of import class I in-vitro diagnostic reagents, the filing entity shall submit the filing documents to China Food and Drug Administration.'可被翻译为：进口第一类体外诊断试剂备案，备案人向国家食品药品监督管理总局提交备案资料。\n'(I) The foreign-invested enterprise established by an imported medical device registrant in China shall, asthe registration applicant, submit the application for medical device registration in China to the corresponding drug regulatory authority. The content of the registration application, except the name, domicile and production address of the registrant, shall, in principle, be consistent with relevant items specified in the corresponding imported medical device registration certificate and its attachments.'可被翻译为：（一）进口医疗器械注册人在中国境内设立的外商投资企业作为注册申请人，向药品监督管理部门提交境内医疗器械注册申请。注册申请内容，除注册人名称、住所、生产地址外，原则上应当与所对应的进口医疗器械注册证及其附件载明的相关事项保持一致。\n'To apply for filing of class I domestic medical devices, the filing entity shall submit the filing documents to the food and drug regulatory department of the city consisting of districts .'可被翻译为：境内第一类医疗器械备案，备案人向设区的市级食品药品监督管理部门提交备案资料。\n'To apply for filing of class I in-vitro diagnostic reagent, the filing entity shall submit the filing documents to the food and drug regulatory department of the city consisting of districts .'可被翻译为：境内第一类体外诊断试剂备案，备案人向设区的市级食品药品监督管理部门提交备案资料。\n\n根据上述已知信息，请将'To apply for filing of import class I medical devices, the filing entity shall submit the filing documents to China Food and Drug Administration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"进口第一类医疗器械备案，备案人向国家食品药品监督管理总局提交备案资料。"
    },
    {
        "instruction":"已知信息：\n'health-related quality of life(hr-qol)'可被翻译为：健康相关生存质量\n'Reflection Paper on the regulatory guidance for the use of Health-Related Quality of Life (HRQL) measures in the evaluation of medicinal products (CHPM\/EWP\/139391\/04)'可被翻译为：关于新药评价中使用健康相关生活质量（HRQL）量表的监管指导文件的反思（CHPM\/EWP\/139391\/04）\n'6.4. Health related Quality of Life (HR-QoL)'可被翻译为：6.4. 健康相关生活质量（HR-QoL）\n'Health related quality of life: Patient perception of asthma may differ from that of clinicians and should be assessed by health related quality of life (HRQoL) questionnaires, generic or disease-specific.'可被翻译为：健康相关生活质量：患者对哮喘的感知可能不同于临床医生，应采用通用的或疾病特异性的健康相关生活质量（HRQoL）问卷进行评估。\n\n根据上述已知信息，请将'Measurement of Health Related Quality of Life is a valuable measure of therapeutic efficacy, which may be applied as a secondary endpoint in ALS trials. The choice of HR-QoL tool should be justified.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"健康相关生活质量的评估是一个有价值的疗效指标，在ALS的试验中可作为次要 终点，但HR-QoL工具的选择应当是有理有据的。"
    },
    {
        "instruction":"已知信息：\n'If this is done properly, a finding that the confidence interval for the difference between new drug and the active control excludes a suitably chosen margin provides assurance that the test drug has an effect greater than zero.'可被翻译为：假如能恰当地做到 这一点，当选定的界值不在活性对照药差异的可信限范围之 内时，就可以保证新药的有效性大于零。\n'In this situation, the effect of the positive control could be examined at times other than the peak effect to determine whether an effect close to the threshold of regulatory concern can be detected; b. To use a positive control with an effect close to 5 ms (point estimate of the maximum mean difference with placebo close to 5 ms, with a one-sided 95% CI lower bound >0).'可被翻译为：在这种情况下，应在峰值效应以外的不同时间点检测阳性对照药的效 应，以确定是否能够检出接近监管当局关注阈值的效应。b. 使用能使 QT 间期延长近 5ms 的阳性对照（与安慰剂之间的最大 平均值差异的点估计值近似 5ms，单侧检验的 95%置信区间下限＞ 0）。\n'Summary tables and figures showing absolute mean values, mean percent change from baseline, confidence intervals, and p-values for changes from baseline and vehicle control should be included.'可被翻译为：汇总表及汇总图显示绝对平均值、相较于基线的变化平均百分比、置信区间以及相较于基线和溶剂对照的变化的p值。\n'5.5 Estimation, Confidence Intervals and Hypothesis Testing'可被翻译为：5.5 估计、置信区间及假设检验\n\n根据上述已知信息，请将'i. Small increases that are statistically significant compared with the negative or solvent control values but are within the confidence intervals of the appropriate historical control values for the testing facility.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（1）与阴性或溶媒对照组的数值相比有统计学意义的轻微增加，但是在该试验机构的合适的历史背景数据范围内。"
    },
    {
        "instruction":"已知信息：\n'Reference therapy The choice of reference regimen should be justified and normally this regimen should be selected from best available, evidence-based therapeutic options.'可被翻译为：参考疗法 应合理选择参考方案，而且通常应该从最佳可用的、以证据为基础的治疗方案中进 行选择。\n'The choice of reference regimen should be justified and normally this regimen should be selected from best available, evidence-based therapeutic options. In this context, “best available, evidence-based” should be read as a widely used, but not necessarily licensed regimen with a favourable benefit-risk convincingly documented through randomised trials and considered at least as good from a benefit\/risk perspective as alternative, treatment options.'可被翻译为：应证实对照试验方案的选择，并且在一般情况下这种方案应从最好的且基于证据的治疗策略中选出。关于此点，“最好的且基于证据的”应被解读为广泛使用的但未获得许可的 方案，该方案的获益-风险已通过随机试验以令人信服的方式进行记录，并从利益\/ 风险 角度至少被视为良好的替代性治疗选择。\n'Most confirmatory studies of efficacy will aim to demonstrate non-inferiority between the test antibacterial regimen (which may consist of more than one active agent) versus an appropriate comparative regimen, which should be one of the best available treatments.'可被翻译为：大多数疗效验证性研究的目标是证明试验性抗菌治疗方案（可能由多种活性药物组成） 不劣于适当的对比治疗方案（应该是可用的最佳治疗方案之一）。\n'The clinical development programme should demonstrate the efficacy of the beta-lactam agent plus the inhibitor versus one of the best available comparative therapies.'可被翻译为：临床开发项目应证明 β- 内酰胺类药物加上 β- 内酰胺酶抑制剂对比一种最佳可用参比治疗的疗效。\n\n根据上述已知信息，请将'The regimen selected should be considered one of the best available treatments based on one or more of previous studies, medical opinion, indication- specific treatment guidelines from appropriate learned societies and the anticipated prevalence of resistance to the comparative agent at the investigative sites.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在选择治疗方案时， 应该基于一个或多个既往研究、 医学意见、适当的学术团体提出的该适应症的特定治疗指南以及在研究中心对参 比药物产生耐药性的预期发生率来考虑最佳可用治疗。"
    },
    {
        "instruction":"已知信息：\n'All components are required to have an established contribution to the desired therapeutic effect.'可被翻译为：所有成份都需要为预期疗效作出一定的贡献。\n'each component contributes to efficacy and safety and\/or enhances PK\/PD of (main) active substance(s).'可被翻译为：每种成份均对疗效和安全性有贡献和\/或能增强（主要）活性物质的PK\/PD。\n'a. Description and Characterization of Lipid Components'可被翻译为：a. 脂质成分的性状和特征\n'Molecular variants of the desired product formed during manufacture and\/or storage which are active and have no deleterious effect on the safety and efficacy of the drug product. These variants possess properties comparable to the desired product and are not considered impurities.'可被翻译为：在生产和\/或贮藏中形成的预期产品的分子变异体,它们具有活性且对成品的安全性和有效性无有害影 响。这些变异体与预期产品的属性可比,不列为杂质。\n\n根据上述已知信息，请将'a. relevant contribution of all active components to the desired therapeutic effect;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"a. 所有活性成分对所需治疗效果的相关贡献；"
    },
    {
        "instruction":"已知信息：\n'Critical reagents for LBAs include binding reagents (e.g., antibodies, binding proteins, peptides) and those containing enzymatic moieties that have a direct impact on the results of the assay.'可被翻译为：LBA的关键试剂包括（例如抗体、结合蛋白、肽）和对分析结果有直接影响的含酶组分。\n'Critical reagents, including binding reagents (e.g., binding proteins, aptamers, antibodies or conjugated antibodies) and those containing enzymatic moieties, have direct impact on the results of the assay and, therefore, their quality should be assured. Critical reagents bind the analyte and, upon interaction, lead to an instrument signal corresponding to the analyte concentration. The critical reagents should be identified and defined in the assay method.'可被翻译为：关键试剂包括结合试剂（例如结合蛋白、适配子、抗体或偶联抗体）和含酶试剂，对分析结果有直接影响，因此必须确保关键试剂的质量。关键试剂通过与待测物结合，发生相互作用以产生与待测物浓度相关的仪器响应。应在分析方法中对关键试剂进行鉴定和规定。\n'• Changes in LBA critical reagents (e.g., lot-to-lot changes)'可被翻译为：·LBA关键试剂变更（例如变更批号）\n'4.1.2 Critical Reagents'可被翻译为：4.1.2 关键试剂\n\n根据上述已知信息，请将'Critical Reagent: Critical reagents for LBAs include binding reagents (e.g., antibodies, binding proteins, peptides) and those containing enzymatic moieties that have a direct impact on the results of the assay.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"关键试剂：LBA的关键试剂包括结合试剂（例如抗体、结合蛋白、肽）和对分析结果有直接影响的含酶组分。"
    },
    {
        "instruction":"已知信息：\n'For open-label and single-blind studies, details pertaining to the primary and important secondary analyses would ideally be finalised before the first participant is randomised or allocated to study intervention.'可被翻译为：对于开放研究和单盲研究，理想情况下，将在第一例受试者 被随机分配或分配到研究干预组之前，确定有关主要和重要 次要分析的详细信息。\n'Full details of the planned statistical analysis should be specified and documented before knowledge of the study results that may reveal the drug effects, which may be accomplished using a separate statistical analysis plan.'可被翻译为：在了解可能揭示药物疗效的研究结果之前，应详细说明和记录计划的统计分析 的全部细节，可使用单独的统计分析计划完成。\n'Formal records should be kept of when the statistical analysis plan was finalised as well as when the blind was subsequently broken.'可被翻译为：最终统计分析计划的 确定及随后的揭盲应保留正式记录。\n'The statistical analysis plan should specify the planned statistical techniques and diagnostic methods before the data are reviewed.'可被翻译为：统计分析计划中应在审评数据之前说明计划的分析技术及诊断方法。\n\n根据上述已知信息，请将'For double-blind studies, the statistical analysis plan should be finalised before treatment assignments are revealed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于双盲研究，应在披露治疗分配之前确定完成统计分 析。"
    },
    {
        "instruction":"已知信息：\n'Several in vitro mammalian cell systems are widely used and can be considered sufficiently validated: The in vitro metaphase chromosome aberration assay, the in vitro micronucleus assay (Note 1) and the mouse lymphoma L5178Y cell Tk (thymidine kinase) gene mutation assay (MLA).'可被翻译为：一些体外哺乳动物细胞系统已被广泛应用，并经过充分的验证：体外中期相染色体畸变试验、体外微核试验（注释1）、小鼠淋巴瘤L5178Y细胞Tk基因突变试验（MLA）。\n'For cell lines, other methods to demonstrate cell proliferation, including cell population growth over time (PD) as described above, can be used (Kirsch-Volders et al., 2003).'可被翻译为：对于细胞系，也可用其他证明细胞增殖的方法，包括如上所述的细胞群生长的经时性改变（PD）（Kirsch-Volders等，2003）。\n'For cell-based assay procedures: cell density, effector\/target cell ratio, cell generation number'可被翻译为：对于基于细胞的方法：细胞密度、效应\/靶细胞比率、细胞传代次数\n'Absence of interference: Dose-response curve fulfils the response criteria demonstrating the similarity of the analyte and reference material, as well as non-interfering signal from the matrix (for binding assay), or no dose-response from the cell line alone (for cell-based assay) Demonstration of stability-indicating properties through appropriate forced degradation samples if necessary'可被翻译为：无干扰： 剂量-响应曲线符合响应标准，证明被分析物和参比物质的相似性，以及无来 自基质的干扰信号（对于基于结合反应的试验），或细胞系本身无剂量-响应 （对于基于细胞的试验） 必要时，通过适当的强制降解样品证明稳定性指示特性。\n\n根据上述已知信息，请将'Out of different formats of cell- based assay, the cell-based proliferation assay was chosen as it is widely used and a well characterised cell line was available.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在不同形式的基于细胞的试验中，选择了基于细胞的增殖试验，因 为广泛使用，并且具有充分表征的细胞系。"
    }
]